<SEC-DOCUMENT>0000875045-24-000025.txt : 20240801
<SEC-HEADER>0000875045-24-000025.hdr.sgml : 20240801
<ACCEPTANCE-DATETIME>20240801161125
ACCESSION NUMBER:		0000875045-24-000025
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		134
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240801
DATE AS OF CHANGE:		20240801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		241166766

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a009166-a1cb-4c50-83a7-d8b5a99052fa,g:b0d9c5b1-5cff-4c82-aab8-c75b5958a97b,d:5c4866793ceb4ece82fc7beb28126ec4-->
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20240630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">145,661,642</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>biib:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:CompletedTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:CompletedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:CurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:CurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityTerminatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:OmnibusEquityPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:OmnibusEquityPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MosunetuzumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:LenderDisputeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2024</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20240630_g1.jpg" alt="biogenlogoa11.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:47.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">MA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:35.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of July&#160;31, 2024, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">145,661,642</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended June 30, 2024</span><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_16">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_19">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_22">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Six Months Ended June 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_22">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_25">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Six Months Ended June 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_25">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_28">Condensed Consolidated Balance Sheets&#160;&#8212; As of June 30, 2024 and December&#160;31, 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_28">10</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_31">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the Six Months Ended June 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_31">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_34">Condensed Consolidated Statements of Equity &#8212; For the Three and Six Months Ended June 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_34">12</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_37">14</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_118">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_118">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_247">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_247">74</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_253">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_253">75</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_256">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_259">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_259">77</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_262">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_262">77</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_265">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_265">92</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_268">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_268">92</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_271">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_271">93</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_277">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_277">94</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; "contemplate," "continue," &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; "predict," "project", "should," "target," &#8220;will,&#8221; &#8220;would&#8221; or the negative of these words or other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our portfolio as well as implementation of our corporate strategy;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. Because some of these risks and uncertainties cannot be predicted or quantified and some are beyond our control, you should not rely on our forward-looking statements as predictions of future events and you should not place undue reliance on these statements. Moreover, we operate in a very competitive and rapidly changing environment, new risks and uncertainties may emerge from time to time and it is not possible for us to predict all risks nor identify all uncertainties. Forward-looking statements speak only as of the date of this report and are based on information and estimates available to us at this time. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. You should read this report with the understanding that our actual future results, performance, events and circumstances might be materially different from what we expect.</span></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#174;, AVONEX&#174;, BYOOVIZ&#174;, PLEGRIDY&#174;, QALSODY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SKYCLARYS&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482;, IMRALDI&#8482;, OPUVIZ&#8482; and TOFIDENCE&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACTEMRA&#174;, COLUMVI&#174;, ENBREL&#174;, EYLEA&#174;, FAMPYRA&#8482;, GAZYVA&#174;, LEQEMBI&#174;, HUMIRA&#174;, LUCENTIS&#174;, LUNSUMIO&#174;, OCREVUS&#174;, REMICADE&#174;, ZURZUVAE&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Form 10-K</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Report on Form 10-K for the year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 Share Repurchase Program</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Board of Directors authorized program to repurchase up to $5.0 billion of our common stock</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 Omnibus Equity Plan</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2024 Omnibus Equity Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2017 Omnibus Equity Plan</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2017 Omnibus Equity Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 ESPP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2024 Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2015 ESPP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2015 Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AbbVie Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acorda</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acorda Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Artificial Intelligence</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alkermes</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alkermes plc</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amyotrophic Lateral Sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">aMN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibody-positive Membranous Nephropathy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AOCI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASO</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antisense Oligonucleotide</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounting Standards Update</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ATV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibody Transport Vehicle</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biologics License Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blackstone</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blackstone Life Sciences</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CCPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">California Consumer Privacy Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CHMP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Committee for Medicinal Products for Human Use</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CISA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cybersecurity and Infrastructure Security Agency</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CJEU</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Court of Justice of the European Union</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CLE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cutaneous Lupus Erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CLL</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chronic Lymphocytic Leukemia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CLO</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Legal Officer</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODM</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Operating Decision Maker</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convergence</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convergence Pharmaceuticals Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CRL</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complete Response Letter</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CROs</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract Research Organizations</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DEA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Drug Enforcement Agency</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali Therapeutics Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Directors Plan</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2015 Non-Employee Directors Equity Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">District Court</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. District Court for the District of Massachusetts</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DOJ</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Department of Justice</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Commission</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EPO</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Patent Office</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERM</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enterprise Risk Management</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">E.U.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Friedreich's Ataxia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FCPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Corrupt Practices Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FDIC</span></td><td colspan="3" style="border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal Deposit Insurance Corporation</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS (continued)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fit for Growth</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost saving program initiated in 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FSS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal Supply Schedule</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genentech</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genentech, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Intangible Low Tax Income</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GloBE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Anti-Base Erosion</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GMP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Good Manufacturing Practices</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Human Immunology Biosciences</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Humana</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Humana Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IgAN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Immunoglobulin A Nephropathy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ionis</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ionis Pharmaceuticals Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IRA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inflation Reduction Act of 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IT</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Information Technology</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intravenous</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LRRK2</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leucine-Rich Repeat Kinase 2</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MAA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketing Authorization Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MDD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Major Depressive Disorder</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mylan Ireland</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mylan Ireland Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NCD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">National Coverage Decision</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune SubOne AG</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NMPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">National Medicinal Products Administration</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OECD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organization for Economic Co-operation and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OIE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (Income) Expense, Net</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PDUFA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prescription Drug User Fee Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PMN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Primary Membranous Nephropathy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polpharma</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polpharma Biologics S.A.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPACA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient Protection and Affordable Care Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postpartum Depression</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Primary Progressive MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PRV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsing MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RRMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsing-Remitting MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RTP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research Triangle Park</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung Bioepis</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung Bioepis Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung BioLogics</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung BioLogics Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, General and Administrative</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SLE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Systemic Lupus Erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SMA</span></td><td colspan="3" style="border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS (continued)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SMN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Survival Motor Neuron</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOD1</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Superoxide Dismutase 1</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SWISSMEDIC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss Agency for Therapeutic Products</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TBA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technical Boards of Appeal</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transition Toll Tax</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. GAAP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounting Principles Generally Accepted in the U.S.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VA</span></td><td colspan="3" style="border-bottom:1pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veterans Administration</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_19"></div><div style="text-align:center"><span><br/></span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_22"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-31">1,899.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-32">1,845.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-33">3,611.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-34">3,609.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-35">444.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-36">433.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-37">838.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-38">832.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-39">120.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-40">176.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-41">305.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-42">477.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-43">2,464.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-44">2,456.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-45">4,755.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-46">4,919.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-47">546.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-48">592.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-49">1,088.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-50">1,255.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-51">513.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-52">584.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-53">966.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-54">1,154.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-55">553.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-56">548.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-57">1,135.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-58">1,153.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-59">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-60">52.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-61">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-62">103.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-63">62.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-64">56.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-65">128.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-66">114.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-67">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-68">34.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-69">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-70">44.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="6" id="f-71">88.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="6" id="f-73">88.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-74">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-75">85.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-76">121.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-77">178.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-78">51.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-79">1,766.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-80">1,747.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-81">3,591.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-82">3,772.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-83">698.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-84">708.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-85">1,163.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-86">1,146.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-87">115.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-88">114.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-89">186.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-90">165.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-91">583.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-92">593.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-93">977.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-94">980.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-96">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-98">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-99">583.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-100">591.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-101">977.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-102">979.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-103">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-104">4.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-105">6.72</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-106">6.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-107">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-108">4.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-109">6.70</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-110">6.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-111">145.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-112">144.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-113">145.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-114">144.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-115">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-116">145.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-117">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-118">145.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-119">583.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-120">591.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-121">977.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-122">979.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="f-123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-124">4.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="f-125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-126">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-127">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-128">6.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-129">34.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-130">28.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="f-131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-132">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-133">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-134">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-135">5.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-136">3.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-137">27.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-138">18.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-139">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-140">0.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-141">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-142">7.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-143">598.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-144">590.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-145">984.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-146">971.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-148">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-150">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-151">598.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-152">592.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-153">984.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-154">973.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-155">1,908.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-156">1,049.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-157">2.5</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-158">2.4</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-159">1,627.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-160">1,664.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-161">451.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-162">435.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-163">2,506.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-164">2,527.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-165">615.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-166">1,182.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-167">7,108.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-168">6,859.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-169">3,249.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-170">3,309.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-171">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-172">420.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-173">8,232.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-174">8,363.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-175">6,227.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-176">6,219.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-177">915.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-178">928.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-179">681.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-180">745.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-181">26,804.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-182">26,844.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of term loan</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-184">150.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-185">281.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-186">257.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-187">354.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-188">403.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-189">2,472.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-190">2,623.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-191">3,108.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-192">3,434.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and term loan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-193">6,292.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-194">6,788.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-195">590.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-196">641.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-197">367.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-198">400.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-199">556.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-200">781.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-201">10,915.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-202">12,045.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments, contingencies and guarantees</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-18" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-203"/></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-19" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-204"/></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-205">0.001</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-207">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-208">0.0005</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-209">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-210">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-211">407.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-212">302.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-213">146.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-214">153.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-215">18,604.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-216">17,627.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-217">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-218">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-219">15,889.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-220">14,799.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-221">26,804.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-222">26,844.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-223">977.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-224">980.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-225">306.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-226">229.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Excess and obsolescence charges related to inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-227">44.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-228">36.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Amortization of acquired inventory step-up</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationOfInventoryStepUp" scale="6" id="f-229">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:AmortizationOfInventoryStepUp" format="ixt:fixed-zero" scale="6" id="f-230">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-231">143.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-232">147.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-233">47.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-234">170.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="f-235">61.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="f-236">26.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-237">88.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-239">65.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-240">60.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effects of business acquired:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-241">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-242">21.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-243">15.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-244">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-245">188.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-246">65.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-247">115.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-248">127.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="f-249">7.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="f-250">82.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-251">103.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-252">55.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-253">1,179.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-254">942.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-255">79.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-256">137.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="6" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-258">1,682.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-260">4,120.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of equity interest in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="f-261">406.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="f-262">788.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of priority review voucher</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-263">103.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-264">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-265">84.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-266">21.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="f-267">57.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="f-268">103.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-269">3.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-270">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-271">400.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-272">1,706.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-273">40.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-274">54.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Repayment of borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-275">650.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net (distribution) contribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="6" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="f-278">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-279">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-280">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-281">684.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-282">53.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="f-283">894.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="f-284">817.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-285">35.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-286">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-287">1,049.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-288">3,419.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-289">1,908.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-290">2,617.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2024</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-293">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-294">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-295">329.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-296">160.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-297">18,021.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-298">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-299">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-300">15,213.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-301">583.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-302">583.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-303">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-304">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-305">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-306">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-307">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-309">1.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-310">1.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-311">72.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-312">72.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-313">1.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-314">1.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2024</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-317">169.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-318">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-319">407.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-320">146.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-321">18,604.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-322">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-323">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-324">15,889.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-327">168.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-328">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-329">302.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-330">153.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-331">17,627.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-332">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-333">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-334">14,799.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-335">977.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-336">977.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-337">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-338">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-339">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-340">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-341">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-342">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-343">64.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-344">64.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-345">149.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-346">149.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-347">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-348">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2024</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-351">169.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-352">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-353">407.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-354">146.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-355">18,604.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-356">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-357">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-358">15,889.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.350%"><tr><td style="width:1.0%"/><td style="width:20.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.634%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="69" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-361">168.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-362">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-363">91.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-364">172.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-365">16,854.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-366">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-367">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-368">13,796.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-369">9.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-370">13,787.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-371">591.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-372">591.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-373">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-374">593.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-375">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-376">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-377">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-378">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-379">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:fixed-zero" scale="6" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-381">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-382">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-383">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-385">3.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-386">3.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-387">3.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-388">74.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-389">74.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-390">74.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-391">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-392">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-393">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-394">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-396">168.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-397">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-398">170.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-399">172.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-400">17,446.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-401">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-402">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-403">14,466.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-404">6.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-405">14,460.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="69" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-408">167.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-409">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-410">73.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-411">164.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-412">16,466.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-85" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-413">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-414">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-415">13,397.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-416">9.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-417">13,388.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-418">979.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-419">979.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-420">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-421">980.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-422">7.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-423">7.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-424">7.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-425">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-426">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-427">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-428">29.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-429">29.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-430">29.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-431">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-432">84.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-433">84.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-434">84.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-435">153.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-436">153.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-437">153.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-438">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-439">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-440">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-443">168.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-444">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-445">170.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-446">172.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-447">17,446.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-448">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-449">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-450">14,466.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-451">6.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-452">14,460.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_40"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 1:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Summary of Significant Accounting Policies</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-453" continuedAt="f-453-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="c-1" name="biib:BusinessOverviewPolicyTextBlock" id="f-454" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD and we have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-455" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-456">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-453-1" continuedAt="f-453-2"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-457" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="f-458">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-459" continuedAt="f-459-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div></ix:nonNumeric><div style="margin-top:6pt"><ix:continuation id="f-459-1"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.</span></ix:continuation><span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-460" continuedAt="f-460-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-460-1"><ix:continuation id="f-453-2"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023 the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div id="i5c4866793ceb4ece82fc7beb28126ec4_43"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 2:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acquisitions</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-461" continuedAt="f-461-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS (omaveloxolone), the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid Reata shareholders $<ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="1" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-462">172.50</ix:nonFraction> in cash for each issued and outstanding Reata share, which totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-463">6.6</ix:nonFraction>&#160;billion. In addition, we agreed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-464">983.9</ix:nonFraction>&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" format="ixt:num-dot-decimal" scale="6" id="f-465">590.5</ix:nonFraction>&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-466">983.9</ix:nonFraction>&#160;million paid to Reata's equity award holders, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-467">393.4</ix:nonFraction>&#160;million as compensation attributable to the post-acquisition service period, of which $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-468">196.4</ix:nonFraction>&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-469">197.0</ix:nonFraction>&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the year ended December 31, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="f-470">1.0</ix:nonFraction> billion term loan under our term loan credit agreement. For additional information on our term loan credit agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-471" continuedAt="f-471-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-472">6,602.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" scale="6" id="f-473">590.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-474">7,193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="1" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-475">172.50</ix:nonFraction> per outstanding Reata common stock based on <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="-5" name="biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-476">38.3</ix:nonFraction>&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-461-1" continuedAt="f-461-2"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Preliminary Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made year-to-date to the amounts initially recorded as of the acquisition date on <ix:continuation id="f-471-1" continuedAt="f-471-2">September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.</ix:continuation></span></div><ix:continuation id="f-471-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date<br/>(as adjusted)<br/>June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="f-477">267.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="f-478">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="f-479">1,259.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="f-480">53.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-481">4,200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-482">2,300.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-483">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-484">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" scale="6" id="f-485">121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" scale="6" id="f-486">106.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="f-487">159.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="f-488">300.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="f-489">916.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" scale="6" id="f-490">151.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" sign="-" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" scale="6" id="f-491">2.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-492">6,719.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-493">473.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-494">7,193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" format="ixt:num-dot-decimal" scale="6" id="f-495">4.9</ix:nonFraction>&#160;million, deferred tax liability by $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" sign="-" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" format="ixt:num-dot-decimal" scale="6" id="f-496">4.1</ix:nonFraction>&#160;million and goodwill by $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" sign="-" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-497">9.0</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total inventory acquired was</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="9" id="f-498">1.3</ix:nonFraction>&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be within approximately <ix:nonNumeric contextRef="c-94" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" format="ixt-sec:duryear" id="f-499">3</ix:nonNumeric> years from the acquisition date. For the three and six months ended June 30, 2024, amortization from the fair value step-up adjustment was approximately $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-500">90.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-501">134.2</ix:nonFraction>&#160;million, respectively, which includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-502">46.0</ix:nonFraction>&#160;million of inventory used for clinical purposes rather than for commercial sale during the second quarter of 2024, and therefore reflected within research and development expense within our condensed consolidated statements of income.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-461-2" continuedAt="f-461-3"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets are comprised of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-503">4.2</ix:nonFraction>&#160;billion related to SKYCLARYS commercialization rights in the U.S., $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-504">2.3</ix:nonFraction>&#160;billion of IPR&amp;D related to the omaveloxolone program outside the U.S., which had not yet received regulatory approval in the E.U. as of the acquisition date, $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-505">100.0</ix:nonFraction>&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-506">40.0</ix:nonFraction>&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="f-507">14.3</ix:nonFraction>% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-508">4.2</ix:nonFraction>&#160;billion intangible asset will be amortized over its expected economic life. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon SKYCLARYS </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receiving E.U. regulatory approval in February 2024, we began selling the product in certain countries in Europe, and began amortizing the $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-509">2.3</ix:nonFraction>&#160;billion I</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PR&amp;D asset related to the program outside the U.S. over its expected economic life using an economic consumption model. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-94" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-510">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-94" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-511">16</ix:nonNumeric> years. We recorded a lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-512">151.8</ix:nonFraction>&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately <ix:nonNumeric contextRef="c-94" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-513">15</ix:nonNumeric> years, with a corresponding right-of-use asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="6" id="f-514">121.2</ix:nonFraction>&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-515">473.5</ix:nonFraction>&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expenses:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expense, primarily comprised of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" format="ixt:num-dot-decimal" scale="6" id="f-516">28.4</ix:nonFraction>&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the year ended December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Assumptions in the Allocations of Purchase Price</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of Reata, along with the estimated fair values of the assets acquired and liabilities assumed in the Reata acquisition, have been included in our condensed consolidated financial statements since the closing of the Reata acquisition on September 26, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of income taxes. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-461-3"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Human Immunology Biosciences</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, aMR, PMN and IgAN. Felzartamab has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for development in the treatment of PMN and has received ODD in the treatment of antibody-mediated rejection in kidney transplant recipients. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we made an upfront payment to HI-Bio of approximately $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-7" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="f-517">1.15</ix:nonFraction>&#160;billion which was funded through available cash on hand. Additionally, we may pay up to $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-518">650.0</ix:nonFraction>&#160;million in potential milestone payments to the former shareholders of HI-Bio. We expect this transaction to be accounted for as an acquisition of a business and recognized within our condensed consolidated financial statements during the third quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to lead program felzartamab, the HI-Bio pipeline acquired includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial, and the potential for continued development in a range of complement-mediated diseases.</span></div></ix:continuation><div id="i5c4866793ceb4ece82fc7beb28126ec4_46"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 3:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispositions</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-519" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-520">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="f-521">2.3</ix:nonFraction>&#160;billion. Under the terms of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="f-522">1.0</ix:nonFraction>&#160;billion in cash at closing, with approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="f-523">1.3</ix:nonFraction>&#160;billion in cash to be deferred over two payments. The first deferred payment of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="f-524">812.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2023 and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second deferred payment of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="f-525">437.5</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2024, we recognized</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> gains</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-526">1.4</ix:nonFraction>&#160;million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-527">7.5</ix:nonFraction>&#160;million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to reflect the changes in fair value associated with the passage of time related to the second deferred payment </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">due to us, which was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2023, we recognized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-528">2.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-529">13.7</ix:nonFraction>&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the first deferred payment due to us. Additionally, for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2023, we recognized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-530">3.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-531">9.8</ix:nonFraction>&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the second deferred payment due to us. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-532">103.0</ix:nonFraction>&#160;million upon the closing of the PRV purchase, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-533">14.4</ix:nonFraction>&#160;million is payable to Ionis. Our net portion of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-534"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-535">88.6</ix:nonFraction></ix:nonFraction>&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2024.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_49"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 4:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restructuring</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-536" continuedAt="f-536-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Fit for Growth Restructuring Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-8" name="biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" format="ixt:num-dot-decimal" scale="9" id="f-537">1.0</ix:nonFraction>&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately <ix:nonFraction unitRef="employee" contextRef="c-129" decimals="INF" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" format="ixt:num-dot-decimal" scale="0" id="f-538">1,000</ix:nonFraction> employees and we expect to incur restructuring charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-539">260.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-540">280.0</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-541" continuedAt="f-541-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-543">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-544">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-545">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-546">11.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-547">11.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-549">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-550">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-552">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-553">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-554">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-556">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-557">17.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-558">16.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-559">34.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-560">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-561">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-562">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-563">17.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-564">28.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-565">46.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-567">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-568">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-570">11.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-571">11.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-573">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-574">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-576">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-577">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-578">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-580">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-581">24.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-582">16.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-583">41.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-584">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-585">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-586">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-587">24.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-588">28.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-589">53.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimate we will incur total integration charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-590">35.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-591">40.0</ix:nonFraction>&#160;million, related to severance and employment costs, which are expected to be paid by the end of 2024. These amounts were substantially incurred during 2023.</span></div><ix:continuation id="f-541-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-593">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-594">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-596">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-597">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-599">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-600">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-602">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-603">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-604">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-606">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-607">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-609">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-610">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-611">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-612">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-613">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-614">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-615">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-536-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-94" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-616">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-94" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-617">16</ix:nonNumeric> years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-618" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions from our 2023 Fit for Growth program and Reata Integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-619">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-620">35.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-621">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-622">7.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-623">42.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-624">15.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-625">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-626">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-627">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-628">28.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-629">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-630">17.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-631">11.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-632">13.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" format="ixt:fixed-zero" scale="6" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-634">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-635">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-636">32.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_52"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 5:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Revenue</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-637" continuedAt="f-637-1" escape="true"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-638" continuedAt="f-638-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-639">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-640">208.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-641">252.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-642">66.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-643">187.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-644">254.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-645">144.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-646">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-647">165.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-648">130.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-649">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-650">146.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-651">188.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-652">229.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-653">418.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-654">196.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-655">203.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-656">400.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-657">117.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-658">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-659">182.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-660">145.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-661">74.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-662">220.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-663">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-664">39.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-665">68.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-666">34.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-667">48.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-668">82.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-669">145.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-670">105.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-671">250.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-672">180.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-673">122.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-674">302.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-675">248.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-676">213.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-677">462.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-678">259.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-679">223.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-680">483.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-682">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-683">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-685">23.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-686">23.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-687">582.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-688">567.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-689">1,149.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-690">636.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-691">572.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-692">1,209.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-693">157.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-694">271.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-695">429.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-696">155.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-697">281.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-698">437.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-699">75.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-700">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-701">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-702">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-705">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-706">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-707">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-708">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-709">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-710">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-711">237.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-712">296.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-713">534.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-714">156.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-715">281.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-716">438.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-718">117.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-719">117.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-720">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-721">109.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-722">109.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-724">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-725">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-727">58.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-728">58.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-730">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-731">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-732">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-733">20.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-734">20.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-735">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-736">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-737">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-738">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-740">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-741">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-743">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-744">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-745">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-746">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-747">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-748">187.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-749">198.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-750">7.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-751">188.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-752">195.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-753">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-755">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-756">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-757">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-758">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-759">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-760">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-761">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-762">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-763">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-764">3.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-765">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-766">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-767">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-768">0.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-769">2.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-770">3.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-771">846.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-772">1,052.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-773">1,899.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-774">801.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-775">1,044.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-776">1,845.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-637-1" continuedAt="f-637-2"><ix:continuation id="f-638-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-777">87.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-778">418.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-779">506.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-780">141.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-781">387.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-782">528.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-783">250.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-784">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-785">293.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-786">223.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-787">30.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-788">254.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-789">337.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-790">461.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-791">799.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-792">365.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-793">418.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-794">783.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-795">228.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-796">132.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-797">361.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-798">248.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-799">144.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-800">392.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-801">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-802">76.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-803">133.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-804">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-805">91.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-806">155.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-807">285.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-808">209.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-809">494.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-810">312.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-811">235.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-812">548.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-813">462.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-814">431.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-815">893.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-816">505.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-817">450.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-818">955.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-820">37.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-821">37.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-822">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-823">47.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-824">47.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-825">1,085.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-826">1,140.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-827">2,225.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-828">1,182.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-829">1,151.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-830">2,334.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-831">305.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-832">464.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-833">770.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-834">302.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-835">577.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-836">880.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-837">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-838">29.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-839">178.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-840">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-843">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-844">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-845">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-846">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-847">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-848">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-849">463.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-850">494.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-851">958.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-852">303.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-853">577.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-854">881.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-856">236.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-857">236.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-858">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-859">218.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-860">218.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-862">108.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-863">108.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-864">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-865">113.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-866">113.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-868">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-869">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-870">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-871">40.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-872">40.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-873">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-874">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-875">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-876">15.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-877">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-878">15.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-879">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-881">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-882">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-883">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-885">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-886">380.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-887">395.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-888">15.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-889">372.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-890">387.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-891">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-893">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-894">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-895">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-897">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-898">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-899">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-900">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-901">4.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-902">5.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-903">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-904">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-905">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-906">1.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-907">4.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-908">5.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-909">1,592.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-910">2,018.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-911">3,611.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-912">1,502.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-913">2,106.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-914">3,609.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-915"><ix:nonFraction unitRef="wholesaler" contextRef="c-15" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-916"><ix:nonFraction unitRef="wholesaler" contextRef="c-16" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-917"><ix:nonFraction unitRef="wholesaler" contextRef="c-17" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-918">two</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="c-433" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-919">25.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-434" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-920">12.3</ix:nonFraction>% of gross product revenue for the three months ended June 30, 2024, and <ix:nonFraction unitRef="number" contextRef="c-435" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-921">25.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-436" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-922">12.0</ix:nonFraction>% of gross product revenue for the six months ended June 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-923"><ix:nonFraction unitRef="wholesaler" contextRef="c-15" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-924"><ix:nonFraction unitRef="wholesaler" contextRef="c-16" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-925"><ix:nonFraction unitRef="wholesaler" contextRef="c-17" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-926">two</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="c-437" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-927">27.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-438" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-928">9.3</ix:nonFraction>% of gross product revenue for the three months ended June 30, 2023, and <ix:nonFraction unitRef="number" contextRef="c-439" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-929">27.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-440" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-930">8.4</ix:nonFraction>% of gross product revenue for the six months ended June 30, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-637-2" continuedAt="f-637-3"><ix:nonNumeric contextRef="c-1" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="f-931" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-932">173.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-933">857.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-934">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-935">1,062.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="f-936">399.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-937">1,355.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="f-938">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-939">1,765.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-940">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-941">27.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-942">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-943">9.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-944">260.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-945">797.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-946">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-947">1,058.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-948">155.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-949">477.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-950">11.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-951">643.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-952">162.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-953">910.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-954">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-955">1,116.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="f-956" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:67.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-957">151.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-958">135.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-959">964.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-960">926.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-961">1,116.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-962">1,062.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="c-1" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="f-963" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-964">336.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-965">325.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-966">639.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-967">609.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-968">103.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-969">103.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-970">190.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-971">216.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-972">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-973">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-974">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-975">7.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-976">444.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-977">433.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-978">838.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-979">832.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Manufacturing, Royalty and Other Revenue</span></div><ix:nonNumeric contextRef="c-1" name="biib:OtherrevenuesTableTextBlock" id="f-980" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.832%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.890%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-981">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-982">183.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-983">252.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-984">490.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-985">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-986">6.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-987">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-988">13.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-989">120.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-990">176.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-991">305.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-992">477.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, our share of contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated statements of income.</span></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our <ix:nonFraction unitRef="number" contextRef="c-470" decimals="2" name="biib:ShareOfNonControlingInterestRecognized" scale="-2" id="f-993">50.0</ix:nonFraction>% share of LEQEMBI product revenue, net and cost of sales, including royalties, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-637-3"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we are not the principal, as well as royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div id="i5c4866793ceb4ece82fc7beb28126ec4_55"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 6:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventory</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-994" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-995" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-996">401.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-997">426.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-998">1,821.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-999">1,926.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-1000">395.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-1001">255.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1002">2,617.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1003">2,609.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1004">2,506.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1005">2,527.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNoncurrent" scale="6" id="f-1006">111.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNoncurrent" scale="6" id="f-1007">81.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1008">2,617.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1009">2,609.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recorded approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="9" id="f-1010">1.3</ix:nonFraction>&#160;billion of acquired inventory, which includes measurement period adjustments, related to SKYCLARYS as a result of our acquisition of Reata in September 2023. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income when the inventory is sold, which is expected to be within approximately <ix:nonNumeric contextRef="c-94" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" format="ixt-sec:duryear" id="f-1011">3</ix:nonNumeric> years from the acquisition date. For the three and six months ended June 30, 2024, amortization from the fair value step-up adjustment was approximately $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-1012">90.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-1013">134.2</ix:nonFraction>&#160;million, respectively, which includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-1014">46.0</ix:nonFraction>&#160;million of inventory used for clinical purposes rather than for commercial sale during the second quarter of 2024, and therefore reflected within research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div id="i5c4866793ceb4ece82fc7beb28126ec4_58"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 7:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Intangible Assets and Goodwill</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-1015" continuedAt="f-1015-1" escape="true"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="f-1016" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired and in-licensed rights and patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-471" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1017">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-472" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1018">22</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1019">10,515.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1020">2,595.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1021">7,919.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1022">8,180.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1023">2,440.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1024">5,739.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-475" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1025">13</ix:nonNumeric>-<ix:nonNumeric contextRef="c-476" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1026">31</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1027">3,548.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1028">3,439.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1029">109.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1030">3,548.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1031">3,429.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1032">119.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1033">14,063.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1034">6,035.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1035">8,028.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1036">11,728.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1037">5,869.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1038">5,859.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1039">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1040">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1041">2,340.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1042">2,340.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1043">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1044">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1045">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1046">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1047">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1048">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1049">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1050">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1051">14,267.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1052">6,035.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1053">8,232.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1054">14,232.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1055">5,869.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1056">8,363.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1015-1" continuedAt="f-1015-2"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, amortization and impairment of acquired intangible assets totale</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1057">86.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1058">165.2</ix:nonFraction> million, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1059">52.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1060">103.1</ix:nonFraction> million, respectively, in the prior year comparative periods. The increases were primarily due to amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS. For the three and six months ended June 30, 2024 and 2023, we had <ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt-sec:numwordsen" scale="0" id="f-1061"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt-sec:numwordsen" scale="0" id="f-1062"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt-sec:numwordsen" scale="0" id="f-1063"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt-sec:numwordsen" scale="0" id="f-1064">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between <ix:nonNumeric contextRef="c-485" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1065">2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-486" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1066">31</ix:nonNumeric> years, with a remaining weighted average useful life of <ix:nonNumeric contextRef="c-473" name="biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" format="ixt-sec:duryear" id="f-1067">12</ix:nonNumeric> years for acquired and in-licensed rights and patents and <ix:nonNumeric contextRef="c-477" name="biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" format="ixt-sec:duryear" id="f-1068">10</ix:nonNumeric> years for developed technology and other. In connection with our acquisition of Reata in September 2023 we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1069">4.2</ix:nonFraction>&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset, with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1070">2.3</ix:nonFraction>&#160;billion, from IPR&amp;D to completed technology.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. The carrying value associated with our IPR&amp;D assets as of December 31, 2023, related to the IPR&amp;D programs we acquired in connection with our acquisition of Reata in September 2023, with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1071">2.3</ix:nonFraction>&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset from IPR&amp;D to completed technology.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease priority review voucher that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-1072">100.0</ix:nonFraction>&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1073" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="f-1074">185.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-1075">565.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-1076">660.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-1077">680.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-1078">710.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-1079">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1015-2"><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1080" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1081">6,219.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1082">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-1083">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1084">6,227.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1085">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_61"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 8:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fair Value Measurements</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1087" continuedAt="f-1087-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1086" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1088">1,449.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1090">1,449.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1092">302.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1093">302.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1096">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1098">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1100">38.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1102">38.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-1104">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-1106">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1108">1,816.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1109">302.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1110">1,513.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1112">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1114">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1116">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1118">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-1120">610.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1121">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-1122">610.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1123">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1124">416.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1125">416.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1126">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="f-1128">430.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-496" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1129">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1130">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="f-1131">430.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1132">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1133">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1134">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1135">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1136">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1138">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1139">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1140">1,506.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1141">416.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1142">660.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1143">430.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1144">31.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1145">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1146">31.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1147">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1148">31.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1149">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1150">31.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1151">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our <ix:nonFraction unitRef="number" contextRef="c-499" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1152">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1087-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-1153"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-1154">no</ix:nonFraction></ix:nonFraction> material impairments of our assets measured and carried at fair value as of June 30, 2024 and December 31, 2023. In addition, there have been no changes to our valuation techniques as of June 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of June 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-1155" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan 364-day tranche</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-1157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1158">150.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-1159">150.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-1161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1162">150.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-1163">150.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan three-year tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="f-1165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1166">500.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1167">500.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1168">1,718.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1169">1,747.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1170">1,721.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1171">1,746.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1172">1,275.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1173">1,494.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1174">1,279.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1175">1,493.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1176">1,018.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1177">1,100.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1178">1,089.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1179">1,100.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1180">969.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1181">1,474.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1182">1,049.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1183">1,474.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1184">466.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1185">474.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1186">498.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1187">472.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1188">5,448.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1189">6,292.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1190">6,137.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1191">6,788.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1192">5,448.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1193">6,292.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1194">6,287.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1195">6,938.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we drew $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="f-1196">1.0</ix:nonFraction> billion from our 2023 Term Loan, comprised of a $<ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1197">500.0</ix:nonFraction> million floating rate 364-day tranche and a $<ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1198">500.0</ix:nonFraction> million floating rate three-year tranche. As of June 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of June 30, 2024, compared to December 31, 2023, are primarily related to increases in U.S. treasury yields partially offset by a decrease in credit spreads used to value our Senior Notes since December 31, 2023. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_67"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 9:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Financial Instruments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-1199" continuedAt="f-1199-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-1200" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1201">1,449.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1202">610.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1203">1,449.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1204">610.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our money market funds approximates fair value due to their short-term maturities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-1205" continuedAt="f-1205-1" escape="true">The following tables summarize our marketable equity securities, classified as available-for-sale:</ix:nonNumeric></span></div><ix:continuation id="f-1205-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1206">800.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1208">497.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1209">302.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1210">800.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1212">497.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1213">302.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1214">31.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1215">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1216">21.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1217">10.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1218">948.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1219">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1220">542.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1221">406.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1222">979.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1223">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1224">563.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1225">416.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="f-1226" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.747%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.394%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1227">1,275.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1228">1,682.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-1229">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-1230">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-1231">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-1232">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of December 31, 2023, we have sold all of our marketable debt securities. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three and six months ended June 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="biib:StrategicInvestmentPortfolio" scale="6" id="f-1233">352.3</ix:nonFraction> million which are included in investments and other assets in our condensed consolidated balance sheets. As of December 31, </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1199-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="biib:StrategicInvestmentPortfolio" scale="6" id="f-1234">460.7</ix:nonFraction> million which are included in other current assets and investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of June 30, 2024, was primarily due to the decrease in the fair value of our investment in Sage common stock as well as the sale of a portion of our Denali and Sangamo common stock during 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div></ix:continuation><div id="i5c4866793ceb4ece82fc7beb28126ec4_73"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 10:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Derivative Instruments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-1235" continuedAt="f-1235-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of June 30, 2024 and December 31, 2023, had durations of <ix:nonNumeric contextRef="c-532" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1236">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-533" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1237">15</ix:nonNumeric> months and <ix:nonNumeric contextRef="c-534" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1238">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-535" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1239">12</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="f-1240" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1241">1,420.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1242">1,169.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1243">69.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-1244">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1245">142.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-1246">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1247">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-1248">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1249">1,658.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1250">1,169.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock" id="f-1251" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="f-1252">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:UnrealizedGainOnDerivatives" format="ixt:fixed-zero" scale="6" id="f-1253">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="f-1254">9.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="f-1255">34.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="f-1256">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="f-1257">34.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" format="ixt:num-dot-decimal" scale="6" id="f-1258">3.4</ix:nonFraction>&#160;million to be settled over the next 15 months, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="f-1259">1.9</ix:nonFraction>&#160;million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2024 and December 31, 2023, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1235-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1260" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1261">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1262">2.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1263">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1264">1.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1265">4.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1266">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1267">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1268">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1269">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1270">20.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1271">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1272">0.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1273">7.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1274">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1275">1.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1276">2.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1277">1,199.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1278">1,301.5</ix:nonFraction> million as of June 30, 2024 and December 31, 2023, respectively. Net losses of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1279">5.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1280">30.0</ix:nonFraction> million related to these contracts were recorded as a component of other (income) expense, net for the three and six months ended June 30, 2024, respectively, compared to net losses of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1281">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1282">5.4</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-1283" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1284">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1285">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1286">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="f-1287">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1288">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1289">26.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1290">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1291">11.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1292">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1293">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_76"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 11:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-1294" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1295">2,537.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1296">2,402.5</ix:nonFraction> million as of June 30, 2024 and December 31, 2023, respectively. For the three and six months ended June 30, 2024, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1297">71.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1298">141.2</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1299">64.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1300">126.6</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we built a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility includes <ix:nonFraction unitRef="sqft" contextRef="c-574" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1301">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="c-575" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1302">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="c-576" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1303">51,000</ix:nonFraction> square feet of administrative space. As of December 31, 2023, we had approximately $<ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-5" name="us-gaap:ConstructionInProgressGross" scale="6" id="f-1304">728.8</ix:nonFraction> million capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of this facility (the first manufacturing suite) received a GMP multi-product license from the SWISSMEDIC and was placed into service. The second manufacturing suite, which was also licensed to operate by the SWISSMEDIC, became operational in the first quarter of 2024, resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="f-1305">717.3</ix:nonFraction>&#160;million of fixed assets being placed into service. Solothurn has been approved for the manufacture of LEQEMBI by the FDA.</span></div></ix:nonNumeric><div id="i5c4866793ceb4ece82fc7beb28126ec4_79"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 12:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Leases</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1306" escape="true"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6100 Legacy Drive Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-94" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-1307">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-94" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1308">16</ix:nonNumeric> years. We recorded a lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1309">151.8</ix:nonFraction>&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately <ix:nonNumeric contextRef="c-94" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1310">15</ix:nonNumeric> years, with a corresponding right-of-use asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1311">121.2</ix:nonFraction>&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div id="i5c4866793ceb4ece82fc7beb28126ec4_85"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 13:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indebtedness</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Term Loan <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1312" continuedAt="f-1312-1" escape="true">Credit Agreement</ix:nonNumeric></span></div><ix:continuation id="f-1312-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $<ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1313">1.5</ix:nonFraction>&#160;billion term loan credit agreement (2023 Term Loan). On the closing date of the Reata acquisition we drew $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="f-1314">1.0</ix:nonFraction> billion from the 2023 Term Loan, comprised of a $<ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1315">500.0</ix:nonFraction>&#160;million floating rate 364-day tranche and a $<ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1316">500.0</ix:nonFraction>&#160;million floating rate three-year tranche. The remaining unused commitment of $<ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1317">500.0</ix:nonFraction>&#160;million was terminated. As of December 31, 2023, we repaid $<ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" format="ixt:num-dot-decimal" scale="6" id="f-1318">350.0</ix:nonFraction>&#160;million of the 364--day tranche. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1319">150.0</ix:nonFraction>&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $<ix:nonFraction unitRef="usd" contextRef="c-583" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1320">250.0</ix:nonFraction>&#160;million of the three-year tranche, with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1321">250.0</ix:nonFraction>&#160;million portion of the three-year tranche being subsequently repaid during the second quarter of 2024. As of June 30, 2024, the 2023 Term Loan was paid in full. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_88"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 14:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1322" continuedAt="f-1322-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-585" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1323">5.0</ix:nonFraction> billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and six months ended June 30, 2024 and 2023. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="f-1324">2.1</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of June 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1325" continuedAt="f-1325-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1326">10.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1327">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1328">147.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1329">160.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1330">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1332">5.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1333">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1334">2.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1337">2.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1338">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1340">5.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1341">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1342">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1343">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1344">153.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1345">146.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1346">25.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1347">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1348">126.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1349">153.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1350">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1351">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1352">27.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1353">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1354">2.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1357">2.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1358">34.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1359">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1360">27.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1361">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1362">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1363">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1364">153.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1365">146.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1322-1"><ix:continuation id="f-1325-1"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1366">10.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1367">20.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1368">0.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1369">141.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1370">172.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1371">5.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1372">10.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1373">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1374">3.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1375">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1376">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1377">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1378">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1379">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1380">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1381">4.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1382">6.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1383">0.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1384">3.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1385">0.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1386">14.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1387">13.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1388">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1389">144.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1390">172.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1391">15.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1392">15.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1393">1.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1394">163.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1395">164.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1396">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1397">10.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1398">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1399">18.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1400">9.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1401">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1402">18.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1403">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1404">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1405">17.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1406">1.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1407">28.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1408">0.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1409">18.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1410">7.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1411">14.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1412">13.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1413">0.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1414">144.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1415">172.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="f-1416" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.372%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1418">1.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-625" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1420">1.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1422">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-625" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1424">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1425">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1426">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1427">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1428">20.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1429">4.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="f-1430">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1431">7.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="f-1432">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1433">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1434">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1435">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1436">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1437">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1438">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1439">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1440">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1441">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1442">2.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1443">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1444">17.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_91"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 15:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per Share</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1445" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1446" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1447">583.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1448">591.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1449">977.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1450">979.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1451">145.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1452">144.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1453">145.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1454">144.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-634" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1455">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-635" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1456">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-636" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1457">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-637" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1458">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-638" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1459">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-639" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1460">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-640" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1461">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-641" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1462">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1463">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1464">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1465">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1466">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1467">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1468">145.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1469">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1470">145.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div id="i5c4866793ceb4ece82fc7beb28126ec4_94"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 16:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share-Based Payments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1471" continuedAt="f-1471-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1472" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:42.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1473">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1474">27.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1475">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1476">59.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1477">45.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1478">48.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1479">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1480">98.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1481">72.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1482">76.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1483">144.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1484">157.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1485">2.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1486">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1487">5.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1488">5.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1489">70.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1490">73.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1491">138.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1492">151.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1493">13.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1494">13.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1495">26.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1496">28.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1497">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1498">60.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1499">112.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1500">123.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1471-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-1501" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1502">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1503">59.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1504">115.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1505">121.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1506">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1507">9.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1508">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1509">19.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1510">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1511">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1512">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1513">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1514">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1515">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1516">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1517">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1518">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1519">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1520">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1521">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1522">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1523">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1524">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1525">3.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1526">72.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1527">76.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1528">144.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1529">157.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1530">2.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1531">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1532">5.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1533">5.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1534">70.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1535">73.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1536">138.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1537">151.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Omnibus Equity Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 our shareholders approved the 2024 Omnibus Equity Plan for share-based awards to our prospective and current employees, non-employee directors, officers or consultants. Awards granted from the 2024 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2024 Omnibus Equity Plan consist of <ix:nonFraction unitRef="shares" contextRef="c-678" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-1538">3.7</ix:nonFraction> million shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) on the date that our shareholders approved the 2024 Omnibus Equity Plan, plus shares that were subject to awards under the 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) that remain unissued upon the cancellation, surrender, exchange, termination or forfeiture of such awards. The 2024 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a <ix:nonFraction unitRef="number" contextRef="c-679" decimals="1" name="biib:RatioOfNumberOfSharesReservedUnderPlan" scale="0" id="f-1539">1.5</ix:nonFraction>-to-1 ratio.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not made any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan since our shareholders approved the 2024 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan in the future, except that unused shares under the 2017 Omnibus Equity Plan have been carried over for use under the 2024 Omnibus Equity Plan. Awards outstanding under the 2017 Omnibus Equity Plan and the Directors Plan as of the date our shareholders approved the 2024 Omnibus Equity Plan will remain outstanding and subject to the terms and conditions of the 2017 Omnibus Equity Plan and the Directors Plan, as applicable, and the relevant award agreements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 our shareholders approved the 2024 ESPP. The 2024 ESPP, which became effective on July 1, 2024, replaced the 2015 ESPP, which expired on June 30, 2024. The maximum number of shares of our common stock that may be purchased under the 2024 ESPP is <ix:nonFraction unitRef="shares" contextRef="c-680" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-1540">2.5</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_97"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 17:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Income Taxes</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1541" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Tax Rate</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1542" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.354%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1543">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1544">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1545">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1546">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1547">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1548">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1549">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1550">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1551">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1552">4.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1553">5.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1554">5.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1555">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1556">2.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1557">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1558">3.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1559">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1560">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1561">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1562">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1563">0.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1564">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1565">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1566">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1567">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1568">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1569">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1570">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1571">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1572">16.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1573">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1574">14.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the changes in our effective tax rates include the impact of changes in jurisdictional profit mix, including non-cash tax effects of changes in the value of our equity investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our effective tax rate for the six months ended June 30, 2024, also reflects the resolution of an uncertain tax matter during the first quarter of 2023 related to tax credits.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="f-1575">25.0</ix:nonFraction>&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_100"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 18:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Other Consolidated Financial Statement Detail</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-1576" continuedAt="f-1576-1" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="f-1577" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1578">20.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1579">75.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1580">37.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1581">156.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1582">61.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1583">49.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1584">130.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1585">111.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1586">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1587">105.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1588">61.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1589">27.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1590">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1591">8.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1592">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1593">19.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1594">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1595">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1596">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1597">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1598">85.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1599">121.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1600">178.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1601">51.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-1602" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1603">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1604">106.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1605">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1606">28.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1607">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1608">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1609">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1610">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1611">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1612">105.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1613">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1614">29.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1615">51.4</ix:nonFraction>&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-682" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1616">27.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1617">117.7</ix:nonFraction>&#160;million, partially offset by a decrease in the fair value of Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-684" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1618">10.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the six months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1619">68.3</ix:nonFraction>&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1620">17.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the six months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1621">78.0</ix:nonFraction>&#160;million, partially offset by a decrease in the fair value of Sangamo and Ionis common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-688" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1622">47.4</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-1623" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1624">964.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1625">926.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1626">228.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1627">335.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="f-1628">319.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="f-1629">214.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-1630">193.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-1631">191.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata related accrued expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" scale="6" id="f-1632">77.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" scale="6" id="f-1633">117.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-1634">689.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-1635">838.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1636">2,472.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1637">2,623.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1576-1"><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-1638">556.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-1639">781.1</ix:nonFraction> million as of June 30, 2024 and December 31, 2023, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-1640">191.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-1641">403.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i5c4866793ceb4ece82fc7beb28126ec4_103"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-1642" continuedAt="f-1642-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 19:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative and Other Relationships</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">U.S.:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">Canada:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from <ix:nonFraction unitRef="number" contextRef="c-689" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1643">13.5</ix:nonFraction>% and increasing up to <ix:nonFraction unitRef="number" contextRef="c-690" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1644">24.0</ix:nonFraction>% if annual net sales exceed $<ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-5" name="biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" format="ixt:num-dot-decimal" scale="6" id="f-1645">900.0</ix:nonFraction>&#160;million. There will be a <ix:nonFraction unitRef="number" contextRef="c-691" decimals="INF" name="biib:Reductioninroyaltyrate" scale="-2" id="f-1646">50.0</ix:nonFraction>% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross <ix:nonFraction unitRef="number" contextRef="c-692" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1647">3.0</ix:nonFraction>% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting <ix:nonNumeric contextRef="c-691" name="biib:PeriodOfCollaborationAgreement" format="ixt-sec:duryear" id="f-1648">11</ix:nonNumeric> years from the first commercial sale of OCREVUS on a country-by-country basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUNSUMIO (mosunetuzumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for <ix:nonFraction unitRef="number" contextRef="c-693" decimals="INF" name="biib:PercentageOfFutureDevelopmentCosts" scale="-2" id="f-1649">30.0</ix:nonFraction>% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1642-1" continuedAt="f-1642-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COLUMVI (glofitamab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 Roche announced that COLUMVI, in combination with chemotherapy GemOx (glofitamab-gxbm), demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma</span><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN and LUNSUMIO Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a <ix:nonFraction unitRef="number" contextRef="c-694" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" scale="-2" id="f-1650">30.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1651"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1652">50.0</ix:nonFraction></ix:nonFraction>&#160;million of combined co-promotion operating profits earned each calendar year. <ix:nonNumeric contextRef="c-1" name="biib:CoPromotionProfitSharingFormulaTableTextBlock" id="f-1653" continuedAt="f-1653-1" escape="true">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $<ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1654"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1655">50.0</ix:nonFraction></ix:nonFraction>&#160;million varies upon the following events, as summarized in the table below:</ix:nonNumeric></span></div><ix:continuation id="f-1653-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-694" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="f-1656">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-694" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1657">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-694" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" scale="-2" id="f-1658">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1659">500.0</ix:nonFraction>&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1660">150.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:SalesTriggerGrossSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="f-1661">350.0</ix:nonFraction>&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was <ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1662">35.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a <ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1663">35.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1664"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1665">50.0</ix:nonFraction></ix:nonFraction>&#160;million of operating profits earned each calendar year. <ix:nonNumeric contextRef="c-1" name="biib:PretaxProfitSharingFormulaTableTextBlock" id="f-1666" continuedAt="f-1666-1" escape="true">Our share of annual co-promotion profits in excess of $<ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1667"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1668">50.0</ix:nonFraction></ix:nonFraction>&#160;million varies upon the following events, as summarized in the table below:</ix:nonNumeric></span></div><ix:continuation id="f-1666-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="f-1669">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1670">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1671">500.0</ix:nonFraction>&#160;million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was <ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1672">35.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1642-2" continuedAt="f-1642-3"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023 we accrued a $<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-5" name="biib:AccruedPaymentToTerminationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1673">31.0</ix:nonFraction>&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. As of December 31, 2023, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-5" name="biib:PaymentsMadeToTerminationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1674">16.0</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-5" name="biib:AccruedPaymentToTerminationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1675">31.0</ix:nonFraction>&#160;million payable. The remaining portion was subsequently paid in January 2024. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the six months ended June 30, 2023.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEQEMBI (lecanemab) Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in Japan (September 2023), China (January 2024), South Korea (May 2024), Hong Kong (July 2024) and Israel (July 2024).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of LEQEMBI in the U.S., we began recognizing our <ix:nonFraction unitRef="number" contextRef="c-470" decimals="2" name="biib:ShareOfNonControlingInterestRecognized" scale="-2" id="f-1676">50.0</ix:nonFraction>% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated statements of income, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="f-1677" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1678">90.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1679">86.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1680">177.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1681">194.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1682">45.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1683">43.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1684">89.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1685">97.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1686">137.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1687">17.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1688">311.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1689">27.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1690">68.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1691">8.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1692">155.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1693">13.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s discussed above were approximately $<ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-5" name="biib:AccountsReceivableFromCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1694">10.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-5" name="biib:AccountsReceivableFromCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1695">1.4</ix:nonFraction>&#160;million as of June 30, 2024 and December 31, 2023, respectively. Amounts payable to Eisai related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-5" name="biib:AccountsPayableToCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1696">171.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-5" name="biib:AccountsPayableToCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1697">118.4</ix:nonFraction>&#160;million as of June 30, 2024 and December 31, 2023, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1642-3" continuedAt="f-1642-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" id="f-1698" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1699">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1700">14.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1701">33.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1702">32.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1703">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1704">7.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1705">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1706">16.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD and potential treatment of MDD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. In July 2024 we and Sage announced that the Phase 2 KINETIC 2 dose-range study of BIIB124 did not meet its endpoints. Based on these results, we discontinued our further development of BIIB124 for the potential treatment in essential tremor.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. ZURZUVAE for PPD became commercially available in the U.S. during the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. The CRL stated that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies would be needed. We and Sage are continuing to seek feedback from the FDA and evaluating next steps.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. During the fourth quarter of 2023 we accrued a milestone payment due to Sage of $<ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="f-1707">75.0</ix:nonFraction>&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, we recognized net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-713" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1708">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1709">11.5</ix:nonFraction> million, respectively, to reflect Sage's <ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="biib:ShareOfNetProfitFromSageTherapeuticsPercent" scale="-2" id="f-1710">50.0</ix:nonFraction>% share of net collaboration results in the U.S. for ZURZUVAE for PPD, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" id="f-1711" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1712">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1713">52.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1714">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1715">86.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1716">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1717">26.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1718">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1719">43.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1720">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1721">60.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1722">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1723">98.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1724">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1725">30.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1726">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1727">49.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease (LRRK2 Collaboration) and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1642-4" continuedAt="f-1642-5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transport Vehicle technology. In July 2024 we terminated our license with Denali for the ATV-enabled anti-amyloid beta program. This termination also results in the termination of the exclusive option agreement, as discussed above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="f-1728" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1729">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1730">22.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1731">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1732">38.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1733">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1734">13.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1735">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1736">23.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, we recorded approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1737">8.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1738">16.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1739">2.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1740">2.8</ix:nonFraction> million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="c-731" decimals="INF" name="biib:ContingentCommercializedRightsNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-1741">two</ix:nonFraction> potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately <ix:nonFraction unitRef="number" contextRef="c-731" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1742">45.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2024 we accrued a $<ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-5" name="biib:AccruedMilestonePayments" scale="6" id="f-1743">15.0</ix:nonFraction> million milestone upon the FDA approval of OPUVIZ in the U.S., which was recognized in intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="f-1744">165.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones. The timing of the commercial launch of OPUVIZ in the U.S. is subject to ongoing litigation involving our collaborator, Samsung Bioepis, in which the court has entered a preliminary injunction against us and Samsung Bioepis restraining the offer for sale or sale of OPUVIZ in the U.S.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="c-733" name="biib:CollaborativeArrangementTermExtension" format="ixt-sec:durwordsen" id="f-1745">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-5" name="biib:ContractOptionExerciseFee" scale="6" id="f-1746">60.0</ix:nonFraction> million by August 2024, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024 we exercised our option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="c-733" name="biib:CollaborativeArrangementTermExtension" format="ixt-sec:durwordsen" id="f-1747">five years</ix:nonNumeric>. In connection with this exercise, we paid Samsung Bioepis an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-5" name="biib:CollaborativeArrangementContractOptionExerciseFeePaid" format="ixt:num-dot-decimal" scale="6" id="f-1748">60.0</ix:nonFraction>&#160;million in July 2024.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="c-733" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1749">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1642-5" continuedAt="f-1642-6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June 30, 2024, we recognized net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1750">55.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1751">116.5</ix:nonFraction>&#160;million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="c-733" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1752">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to a net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1753">56.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1754">114.0</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufacturing, royalty and other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements di</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1755">19.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1756">9.9</ix:nonFraction>&#160;million as of June 30, 2024 and December 31, 2023, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1757">93.6</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1758">73.7</ix:nonFraction>&#160;million as of June 30, 2024 and December 31, 2023, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><ix:continuation id="f-1642-6" continuedAt="f-1642-7"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1642-7"> to our consolidated financial statements included in our 2023 Form 10-K.</ix:continuation> </span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_109"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 20:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investments in Variable Interest Entities</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-1759" continuedAt="f-1759-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2007 we consolidated the results of Neurimmune as we determined we were the primary beneficiary because we had the power through the collaboration to direct the activities that most significantly impacted the entity's economic performance and we were required to fund <ix:nonFraction unitRef="number" contextRef="c-740" decimals="INF" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="f-1760">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. The collaboration and license agreement with Neurimmune was for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023 we notified Neurimmune of our decision to terminate the Neurimmune Agreement. Subsequent to the termination, we reconsidered our relationship with Neurimmune and determined that we were no longer the primary beneficiary of the variable interest entity. As a result, we recorded a net gain on the deconsolidation of Neurimmune of approximately $<ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-5" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="f-1761">3.0</ix:nonFraction>&#160;million, which was recorded in other (income) expense, net within our consolidated statements of income for the year ended December 31, 2023, included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024 and December 31, 2023, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="f-1762">22.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="f-1763">16.4</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1759-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div></ix:continuation><div id="i5c4866793ceb4ece82fc7beb28126ec4_112"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 21:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Litigation</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-1764" continuedAt="f-1764-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. If an estimate of the possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are defendants in three securities actions, one filed by Nadia Shash and Amjad Khan in November 2020 in the District Court and related to ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022 in the District Court and related to ADUHELM and one filed by Thomas Allen Gray in the U.S. District Court for the District of Colorado related to statements about our compliance controls, 2023 earnings guidance and other matters. All allege violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and members of the Board of Directors are named as defendants in three derivative actions, one filed by The Booth Family Trust in February 2022 in the District Court, one filed by Elaine Wang in July 2022 in the District Court and one filed by Jonathan Blaufarb in July 2024 in the U.S. District Court for the District of Colorado. The Booth and Wang actions relate to ADUHELM and other matters, and the Blaufarb action relates to statements about our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#167;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. The Booth and Wang actions are stayed.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Technical Boards of Appeal of the European Patent Office upheld the validity of Fresenius Kabi Deutschland GmbH's (Fresenius Kabi's) European Patent 3 145 488 (the EP '488 Patent), which expires in May 2035. In June 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of the EP &#8216;488 Patent. In March 2024 the D&#252;sseldorf Regional Court dismissed Fresenius Kabi's claim of infringement of the German counterpart of the EP '488 Patent and Fresenius Kabi has appealed to the Higher Regional Court of D&#252;sseldorf.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1764-1"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Former Convergence Shareholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $<ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="f-1765">200.0</ix:nonFraction> million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed suit against us in the High Court of Justice of England and Wales on one of the previously asserted claims, seeking payment of $<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-1766">49.9</ix:nonFraction>&#160;million, interest and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the District Court dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had alleged violations of the federal RICO Act and state laws. In December 2023 Humana appealed to the United States Court of Appeals for the First Circuit and the appeal is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California, alleging that it is owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs. We estimate that the royalties claimed total approximately $<ix:nonFraction unitRef="usd" contextRef="c-743" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-1767">88.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lender Dispute</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2024, BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP filed suit against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement with Reata and seeking payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-1768">23.2</ix:nonFraction>&#160;million, plus interest, costs and attorneys' fees.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received subpoenas from the SEC seeking information relating to ADUHELM and its launch. We have also received subpoenas from the DOJ and SEC seeking information relating to our business operations in several foreign countries. The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TYSABRI Biosimilar Patent Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 Mylan Ireland filed an action in the General Court of the European Union to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;8 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of Reata, along with the estimated fair values of the assets acquired and liabilities assumed in the Reata acquisition, have been included in our condensed consolidated financial statements since the closing of the Reata acquisition on September 26, 2023.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_121"></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">EXECUTIVE SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INTRODUCTION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD and we have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we expanded our large molecule production capacity and built a large-scale biologics manufacturing facility in Solothurn, Switzerland. In the second quarter of 2021 a portion of this facility (the first manufacturing suite) received a GMP multi-product license from the SWISSMEDIC and was placed into service. The second manufacturing suite, which was also licensed to operate by the SWISSMEDIC, became operational in the first quarter of 2024. Solothurn has been approved for the manufacture of LEQEMBI by the FDA. We believe that the Solothurn facility will support our anticipated near to mid-term needs for the manufacturing of biologic assets. The plant represents a significant increase in our overall manufacturing capacity and is not yet being fully utilized, resulting in our recording of excess capacity charges. If we are unable to fully utilize our manufacturing facilities, we will incur additional excess capacity charges which would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS ENVIRONMENT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed, for example the IRA has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and/or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics on employees, the global economy and the delivery of healthcare treatments, geopolitical events, supply chain disruptions, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion on our business environment, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our 2023 Form 10-K. For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in North America, Brazil and certain E.U. countries and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a favorable March 2023 decision of the CJEU affirming TECFIDERA's right to regulatory data and marketing protection and the EC determination in May 2023 that TECFIDERA is entitled to an additional year of market protection for its pediatric indication, we believe that TECFIDERA is entitled to regulatory marketing protection in the E.U. until at least February 2, 2025, and are seeking to enforce this protection. As of June 30, 2024, some of the TECFIDERA generics have not yet fully exited some E.U. markets. We are closely monitoring this situation and working to enforce our legal right to market protection. In addition, we will continue to defend and enforce our EP 2 653 873 patent related to TECFIDERA, which expires in 2028.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS UPDATE REGARDING MACROECONOMIC CONDITIONS AND OTHER DISRUPTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant portions of our business are conducted in Europe, Asia and other international geographies. Factors such as global health outbreaks, adverse weather events, geopolitical events, inflation, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays or increased costs in manufacturing our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT ECONOMIC CONDITIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions remain vulnerable as markets continue to be impacted in part by elevated inflation, higher interest rates, global supply chain uncertainties and risks associated with geopolitical conflicts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GEOPOLITICAL TENSIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global disputes and interruptions in international relationships, including tariffs, trade protection measures, import or export licensing requirements and the imposition of trade sanctions or similar restrictions by the U.S. or other governments, affect our ability to do business. For example, tensions between the U.S. and China have led to a series of tariffs and sanctions being imposed by the U.S. on imports from China mainland, as well as other business restrictions, with additional restrictive measures being proposed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and the pharmaceutical industry, utilize China-based partners for certain raw materials, ingredients and components for our pharmaceutical products and their delivery devices. Engaging alternative suppliers may involve seeking additional regulatory approvals and be costly in terms of time and resources needed. For example, certain early processes related to our acquired SKYCLARYS product rely on a single supplier based in China. We are continuing to evaluate SKYCLARYS' supply chain and prioritizing actions to mitigate risks associated with its manufacturing and our ability to supply patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing geopolitical tensions related to Russia's invasion of Ukraine and the military conflict in the Middle East have resulted in global business disruptions and economic volatility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, sanctions and other restrictions have been levied on the government and businesses in Russia. Although we do not have affiliates or employees, in either Russia or Ukraine, we do provide various therapies to patients in Russia through a distributor. In addition, new government sanctions on the export of certain manufacturing materials to Russia may delay or limit our ability to get new products approved. The impact of the conflict on our operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflict between Russia and Ukraine, its impact on regional and global economic conditions and whether the conflict spreads or has effects on countries outside Ukraine and Russia.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the ongoing conflict between Russia and Ukraine as well as the military conflict in the Middle East and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations. Revenue generated from sales in Russia and Ukraine represent less than 2.0% of total revenue for the three and six months ended June 30, 2024 and 2023. Additionally, revenue generated from sales in the broader Middle East region represents less than 2.0% of total revenue for the three and six months ended June 30, 2024 and 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CLIMATE-RELATED DISCLOSURES</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 the SEC adopted final rules designed to enhance disclosures related to the impacts of climate-related matters. The final rules require disclosures of material climate-related risks, activities to mitigate or adapt to such risks, information about our board of directors' oversight of climate-related risks and management&#8217;s role in managing material climate-related risks and information on any climate-related targets or goals that are material to our business, results of operations or financial condition. In addition, the E.U. and California have enacted similar legislation and regulations. The E.U.'s Corporate Sustainability Reporting Directive will require expansive disclosures on various ESG matters for companies whose business and assets exceed certain thresholds within E.U. countries. California's new environmental disclosure laws will impose additional climate-related reporting requirements on large companies conducting business in the state of California.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that these new rules and laws will have on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL HIGHLIGHTS</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended June 30, 2024, compared to the three months ended June 30, 2023, reflects the following:</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_127"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL REVENUE</span></td></tr></table></div><div><img src="biib-20240630_g2.jpg" alt="6" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8.9 million or 0.4%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DILUTED EARNINGS (LOSS) PER SHARE</span></td></tr></table></div><div><img src="biib-20240630_g3.jpg" alt="22" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.07 or 1.7%</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_130"></div></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRODUCT REVENUE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20240630_g4.jpg" alt="6" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$53.8 million or 2.9%</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">MS revenue decreased $59.5 million, or 4.9%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Rare disease revenue increased $96.1 million, or 21.9%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The decrease in MS product revenue was primarily due to a decrease in Interferon demand due to competition as patients transition to higher efficacy therapies and a decrease in global TYSABRI revenue driven by increased competition in the U.S., as well as a decrease in pricing in certain international markets.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The increase in rare disease revenue was due to global SKYCLARYS revenue of $100.0 million in the second quarter of 2024. The increase was partially offset by a decrease in rest of world SPINRAZA revenue resulting primarily from the unfavorable impact of foreign currency exchange and the timing of shipments, offset in part by an increase in pricing.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_133"></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL COST AND EXPENSE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20240630_g5.jpg" alt="6" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$18.3 million or 1.0%</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Cost of sales decreased $46.7 million, or 7.9%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">R&amp;D expense decreased $70.3 million, or 12.0%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">SG&amp;A expense increased $5.8 million, or 1.1%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.34pt">The decrease in cost of sales was primarily due to favorable product mix from decreased contract manufacturing revenue and lower idle capacity charges, offset in part by $44.1&#160;million in amortization costs associated with the acquired SKYCLARYS inventory fair value step-up adjustment.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.34pt">The decrease in research and development expense was primarily driven by cost-reduction measures realized in 2024 in connection with our portfolio prioritization initiatives and our Fit for Growth program, as well as higher spend on clinical trials and close out costs incurred during 2023, partially offset by approximately $46.0&#160;million of step-up amortization related to SKYCLARYS inventory.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.34pt">The increase in selling, general and administrative expense was primarily due to an increase in operational spending on sales and marketing activities in support of LEQEMBI and SKYCLARYS as we continue to expand our U.S. and international product launches, offset in part by cost-reduction measures realized in 2024 in connection with our Fit for Growth program. </span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_136"></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">Cash and cash equivalents totaled approximately $1.9 billion as of June 30, 2024, compared to approximately $1.0 billion as of December 31, 2023.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">We generated $1,179.0 million of net cash flow from operations for the six months ended June 30, 2024.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">We received a cash payment of $103.0&#160;million from the sale of one of our two PRV's during the second quarter of 2024, of which we recognized a net portion of approximately $88.6&#160;million.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">In April 2024 we received $437.5&#160;million from Samsung BioLogics related to the sale of our equity interest in Samsung Bioepis.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">In July 2024 we completed the acquisition of HI-Bio for $1.15&#160;billion, which was funded through available cash on hand.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ACQUISITIONS AND DIVESTITURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HUMAN IMMUNOLOGY BIOSCIENCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, aMR, PMN and IgAN. Felzartamab has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for development in the treatment of PMN and has received ODD in the treatment of antibody-mediated rejection in kidney transplant recipients. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we made an upfront payment to HI-Bio of approximately $1.15&#160;billion which was funded through available cash on hand. Additionally, we may pay up to $650.0&#160;million in potential milestone payments to the former shareholders of HI-Bio. We expect this transaction to be accounted for as an acquisition of a business and recognized within our condensed consolidated financial statements during the third quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to lead program felzartamab, the HI-Bio pipeline acquired includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial, and the potential for continued development in a range of complement-mediated diseases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SALE OF PRIORITY REVIEW VOUCHER</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $103.0&#160;million upon the closing of the PRV purchase, of which approximately $14.4&#160;million is payable to Ionis. Our net portion of approximately $88.6&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2024.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEVELOPMENTS IN KEY COLLABORATIVE RELATIONSHIPS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LEQEMBI (lecanemab)</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2024 Eisai presented new clinical data from the CLARITY AD study open-label extension of LEQEMBI, demonstrating that three years of continuous LEQEMBI treatment reduced clinical decline, resulting in a clinically meaningful benefit for early Alzheimer's disease patients.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2024 the FDA accepted for review the supplemental BLA for LEQEMBI monthly IV maintenance dosing for the treatment of early Alzheimer's disease, with a PDUFA action date set for January 25, 2025.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2024 Eisai initiated the rolling submission of a BLA to the FDA for LEQEMBI subcutaneous autoinjector for weekly maintenance dosing after being granted Fast Track designation by the FDA in May 2024.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2024 the CHMP of the EMA adopted a negative opinion on the MAA for LEQEMBI. Eisai will seek re-examination of the CHMP opinion.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2024 LEQEMBI was approved in Hong Kong and Israel.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2024 we and Eisai announced the launch of LEQEMBI in China, which had been approved by the NMPA in China in January 2024.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2024 the Ministry of Food and Drug Safety approved LEQEMBI in South Korea.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">OTHER KEY DEVELOPMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">QALSODY (tofersen)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024 the EC approved QALSODY in the E.U. for the treatment of adults with ALS associated with a mutation in the SOD1 gene and became the first treatment approved in the E.U. to target a genetic cause of ALS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SKYCLARYS (omaveloxolone)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024 the EC approved SKYCLARYS in the E.U. for the treatment of FA in adults and adolescents aged 16 years and older. SKYCLARYS is the first treatment approved within the E.U. for this rare, genetic, progressive neurodegenerative disease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TOFIDENCE (referencing ACTEMRA)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 the EC approved TOFIDENCE, a biosimilar monoclonal antibody referencing ROACTEMRA. The IV formulation of TOFIDENCE has been granted marketing authorization by the EC for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">DISCONTINUED PROGRAMS AND STUDIES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ACORDA COLLABORATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2024 we notified Acorda of our decision to terminate our collaboration and license agreement, effective January 1, 2025. As a result of this termination, Acorda will regain global commercialization rights to FAMPYRA. On April 1, 2024, Acorda filed for bankruptcy protection and announced its intention to sell substantially all its assets to a third party. On July 10, 2024, Merz Therapeutics announced that it had completed the acquisition of FAMPYRA, and related assets from Acorda. We are now working with Merz Therapeutics on the transition of global commercialization rights of FAMPYRA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">BIIB105</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024 we and Ionis announced that the Phase 1/2 ALSpire study of BIIB105, an investigational ASO for the potential treatment of ALS, did not meet its endpoints. Based on these results, we discontinued our further development of BIIB105.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">BIIB121</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024 we announced that we have elected not to exercise our option to license and lead development of BIIB121, an ASO for the potential treatment of Angelman syndrome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">BIIB124</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024 we and Sage announced that the Phase 2 KINETIC 2 dose-range study of BIIB124, for the potential treatment in essential tremor, did not meet its endpoints. Based on these results, we discontinued our further development of BIIB124 for the potential treatment in essential tremor. We and Sage are evaluating next steps, if any, for other potential indications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#00587f;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following revenue discussion should be read in conjunction with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Revenue</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,845.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,464.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,456.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,592.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,502.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,018.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,106.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,611.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,609.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,755.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,919.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PRODUCT REVENUE</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,149.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,209.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,845.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,140.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,225.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,182.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,334.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">958.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,592.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,018.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,611.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,502.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,106.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,609.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and ZURZUVAE, which became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MULTIPLE SCLEROSIS</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20240630_g6.jpg" alt="6" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TYSABRI revenue decreased $20.9 million, from $483.1 million in 2023 to $462.2 million in 2024, or 4.3%, primarily due to a decrease in U.S. TYSABRI revenue driven by increased competition, as well as a decrease in pricing in rest of world TYSABRI, partially offset by favorable channel dynamics in certain emerging markets.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global TECFIDERA revenue decreased $2.0 million, from $254.2 million in 2023 to $252.2 million in 2024, or 0.8%, driven by a decrease in demand as a result of multiple TECFIDERA generic entrants in North America, Brazil and certain E.U. countries.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global Interferon revenue decreased $51.5 million, from $302.4 million in 2023 to $250.9 million in 2024, or 17.0%, driven by a decrease in demand as patients transition to higher efficacy therapies.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global VUMERITY revenue increased $19.6 million, from $146.2 million in 2023 to $165.8 million in 2024, or 13.4%, primarily due to an increase in global demand, favorable channel dynamics and an increase in pricing in rest of world VUMERITY.</span></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.5pt solid #679acb;padding:0 1pt"/></tr></table></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_154"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20240630_g7.jpg" alt="4" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global TYSABRI revenue decreased $62.4 million, from $955.9 million in 2023 to $893.5 million in 2024, or 6.5%, primarily due to a decrease in U.S. TYSABRI revenue driven by increased competition and higher discounts and allowances, as well as a decrease in pricing in rest of world TYSABRI, partially offset by favorable channel dynamics in certain emerging markets.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global TECFIDERA revenue decreased $22.2 million, from $528.7 million in 2023 to $506.5 million in 2024, or 4.2%, driven by a decrease in demand as a result of multiple TECFIDERA generic entrants in North America, Brazil and certain E.U. countries.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global Interferon revenue decreased $53.5 million, from $548.0 million in 2023 to $494.5 million in 2024, or 9.8%, driven by driven by a decrease in demand as patients transition to higher efficacy therapies.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global VUMERITY revenue increased $38.9 million, from $254.4 million in 2023 to $293.3 million in 2024, or 15.3%, primarily due to  primarily due to an increase in global demand, favorable channel dynamics and an increase in pricing.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_157"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MS revenue includes sales from TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024 we expect total MS revenue will continue to decline as a result of increasing competition for many of our MS products in both the U.S. and rest of world markets. Additionally, a biosimilar entrant of TYSABRI was approved in the U.S. and the E.U. in 2023. We believe that future sales of TYSABRI may be adversely affected by the entrance of this biosimilar.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RARE DISEASE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><img src="biib-20240630_g8.jpg" alt="6" style="height:355px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.6pt">U.S. SPINRAZA revenue increased $1.5 million, from $155.8 million in 2023 to $157.3 million in 2024, or 1.0%, primarily due to favorable net pricing, offset by a decrease in demand.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Rest of world SPINRAZA revenue decreased $9.5 million, from $281.3 million in 2023 to $271.8 million in 2024, or 3.4%, primarily due to the unfavorable impact of foreign currency exchange and the timing of shipments, offset in part by an increase in pricing.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Global SKYCLARYS revenue was $100.0 million in 2024, including $75.6 million of U.S. SKYCLARYS revenue, which we began recognizing during the fourth quarter of 2023, subsequent to our acquisition of Reata, and $24.4 million of rest of world SKYCLARYS revenue, which was approved in the E.U. and became commercially available during the first quarter of 2024. </span></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_163"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20240630_g9.jpg" alt="4" style="height:355px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.6pt">U.S. SPINRAZA revenue increased $3.3 million, from $302.5 million in 2023 to $305.8 million in 2024, or 1.1%, primarily due to favorable net pricing, offset by a decrease in demand.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Rest of world SPINRAZA revenue decreased $113.3 million, from $577.9 million in 2023 to $464.6 million in 2024, or 19.6%, primarily due to the timing of shipments, which we expect to largely normalize throughout the remainder of 2024. Rest of world patient numbers have generally remained stable through the second quarter of 2024. We also saw a modest negative impact from increased competition and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Global SKYCLARYS revenue was $178.0 million in 2024, including $148.6 million of U.S. SKYCLARYS revenue, which we began recognizing during the fourth quarter of 2023, subsequent to our acquisition of Reata, and $29.4 million of rest of world SKYCLARYS revenue, which was approved in the E.U. and became commercially available during the first quarter of 2024. </span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_166"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare disease revenue includes sales from SPINRAZA, QALSODY, which became commercially available in the U.S. during the second quarter of 2023, and SKYCLARYS, which was obtained as part of our acquisition of Reata in September 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition of Reata. In February 2024 the EC approved SKYCLARYS in the E.U. for the treatment of FA in adults and adolescents aged 16 years and older, which became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024 we expect growth in rare disease revenue as we continue to launch SKYCLARYS in the U.S. and E.U. We expect global SPINRAZA revenue to decrease by low single digits.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BIOSIMILARS</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20240630_g10.jpg" alt="6" style="height:384px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12pt">For the three months ended June 30, 2024, compared to the same period of 2023, the increase in biosimilar revenue was primarily due to an increase in sales volumes related to the continued growth of BYOOVIZ in the U.S., partially offset by a decrease in pricing due to competitive pressures.</span></div><div style="margin-top:6pt"><span><br/></span></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_172"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt;margin-top:3pt"><img src="biib-20240630_g11.jpg" alt="4" style="height:384px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:15pt;margin-top:3pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12pt">For the six months ended June 30, 2024, compared to the same period in 2023, the increase in biosimilar revenue was primarily due to an increase in sales volumes related to the continued growth of BYOOVIZ in the U.S. and channel dynamics, offset in part by a decrease in pricing due to competitive pressures.</span></div><div style="margin-bottom:15pt;margin-top:3pt"><span><br/></span></div><div><span><br/></span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_175"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilars revenue includes sales from BENEPALI, IMRALDI, FLIXABI, BYOOVIZ and TOFIDENCE. In 2023 BYOOVIZ became commercially available in certain international markets. During the third quarter of 2023 the FDA approved TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which became commercially available in the U.S. during the second quarter of 2024. TOFIDENCE was also approved in the E.U. during the second quarter of 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work with our third-party contract manufacturers for IMRALDI and BENEPALI to address supply constraints. If not resolved these supply constraints could have an adverse impact on 2024 sales. In addition, one of our contract manufacturers for IMRALDI and BENEPALI entered into a proposed acquisition by a third party, which is expected to close at the end of 2024. We are currently evaluating the impact this will have on our biosimilars business and working to implement mitigation activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating our strategic options, we have made the decision to retain our biosimilars business.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_178"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REVENUE FROM ANTI-CD20 THERAPEUTIC PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, GAZYVA and LUNSUMIO collaboration operating profits in the U.S., royalty revenue on sales of OCREVUS and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ROYALTY REVENUE ON SALES OF OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the increases in royalty revenue on sales of OCREVUS were primarily due to sales growth of OCREVUS in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BIOGEN'S SHARE OF PRE-TAX PROFITS IN THE U.S. FOR RITUXAN, GAZYVA AND LUNSUMIO</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the decreases in our share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO were primarily due to decreases in sales of RITUXAN in the U.S. resulting from competition from multiple biosimilar products, partially offset by increases in sales of GAZYVA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER REVENUE FROM ANTI-CD20 THERAPEUTIC PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits from RITUXAN in Canada, royalty revenue on sales of LUNSUMIO outside the U.S. and royalty revenue on net sales of COLUMVI in the U.S., which became commercially available during the second quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTRACT MANUFACTURING, ROYALTY AND OTHER REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTRACT MANUFACTURING REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the decreases in contract manufacturing revenue were primarily driven by higher volumes in 2023 due to the timing of batch production, which includes batches related to LEQEMBI that we began recognizing in the first quarter of 2023 upon the accelerated approval of LEQEMBI in the U.S.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, as part of the 2020 sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we provided FUJIFILM with certain minimum batch production commitment guarantees, including batches related to our contract manufacturing arrangements. As of December 31, 2023, these batch commitments have been satisfied and we expect that our contract manufacturing revenue will be lower in 2024, compared to 2023, as we are no longer supplying contract manufacturing customers using Hiller&#248;d in this manner.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROYALTY AND OTHER REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal, as well as royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_184"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESERVES FOR DISCOUNTS AND ALLOWANCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,327.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,305.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">886.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,701.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, reserves for discounts and allowances as a percentage of gross product revenue were 31.6% and 32.4%, respectively, compared to 32.1% and 31.8%, respectively, in the prior year comparative periods. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTRACTUAL ADJUSTMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, VA, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2024, compared to the same period in 2023, the decrease in contractual adjustments was primarily due to lower government rebates in rest of world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2024, compared to the same period in 2023, the increase in contractual adjustments was primarily due to higher government rebates in the U.S. and higher other rebates in biosimilars, partially offset by lower government rebates in rest of world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DISCOUNTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts, wholesaler incentives and volume related discounts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the increases in discounts were primarily driven by higher purchase and volume discounts for biosimilars, partially offset by lower purchase discounts in rest of world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RETURNS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for estimated product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the increases in returns were primarily driven by higher return rates in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">COST AND EXPENSE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">553.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(170.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,766.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,747.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,088.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,255.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(167.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,154.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(188.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,153.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,591.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,772.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(180.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COST OF SALES, EXCLUDING AMORTIZATION AND IMPAIRMENT OF ACQUIRED INTANGIBLE ASSETS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">736.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">884.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,088.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,255.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the decreases in product cost of sales were primarily due to lower cost of sales associated with contract manufacturing revenue and lower idle capacity charges, offset in part by $44.1&#160;million and $88.2&#160;million, respectively, in SKYCLARYS amortization costs. Contract manufacturing revenue includes LEQEMBI inventory produced for Eisai, beginning in the first quarter of 2023 upon the accelerated approval of LEQEMBI in the U.S. Cost of sales as a percentage of revenue was adversely affected by LEQEMBI batches due to minimal margins.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Reata in September 2023 we recorded a fair value step-up adjustment related to the acquired inventory of SKYCLARYS of approximately $1.3&#160;billion. This fair value step-up adjustment will be amortized to cost of sales within our condensed consolidated statements of income when the inventory is sold, which is expected to be within approximately 3 years from the acquisition date. For the three and six months ended June 30, 2024, amortization from the fair value step-up adjustment, associated with SKYCLARYS, as a result of inventory sold was approximately $44.1&#160;million and $88.2&#160;million, respectively. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Write Downs and Other Charges</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2023, we recorded approximately $33.5&#160;million and $78.3&#160;million, respectively, of aggregate gross idle capacity charges. We had no gross idle capacity charges for the three and six months ended June 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESEARCH AND DEVELOPMENT</span></div><div><img src="biib-20240630_g12.jpg" alt="29" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Research and development expense, as a percentage of total revenue, was 20.8% and 23.8% for the three months ended June 30, 2024 and 2023, respectively. For the three months ended June 30, 2024, compared to the same period in 2023, the decrease in research and development was primarily driven by</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">cost-reduction measures realized in 2024 in connection with our portfolio prioritization initiatives and our Fit for Growth program, as well as higher spend on clinical trials and close out costs incurred during 2023. The decrease was partially offset by approximately $46.0&#160;million of step-up amortization related to SKYCLARYS inventory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">EARLY STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q2 2024 vs. Q2 2023</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in early stage programs was driven by a decrease in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of BIIB059 for the treatment of CLE into late stage; and</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">discontinuation of BIIB093 for the treatment of TBI.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of BIIB080 for the treatment of Alzheimer's disease; and</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of cemdomespib for the treatment of diabetic neuropathic pain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">LATE STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q2 2024 vs. Q2 2023</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in late stage programs was driven by a decrease in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of ZURZUVAE from late stage to marketed upon the approval of ZURZUVAE for PPD in the U.S.;</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of QALSODY from late stage to marketed upon the accelerated approval of QALSODY in the U.S.;</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">discontinuation of BIIB093 for large hemispheric infarction; and</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, from late stage to marketed upon the approval of TOFIDENCE in the U.S.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of BIIB059 for the treatment of CLE into late stage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">MARKETED PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q2 2024 vs. Q2 2023</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase in marketed programs was driven by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">increased spend in SKYCLARYS as a result of our acquisition of Reata in September 2023, which includes approximately $46.0&#160;million related to the SKYCLARYS inventory step-up amortization;</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of QALSODY from late stage to marketed upon the accelerated approval of QALSODY in the U.S.; and</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, from late stage to marketed upon the approval of TOFIDENCE in the U.S.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase was partially offset by a decrease in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">discontinuation of ADUHELM for the treatment of Alzheimer's disease.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.581%"><div><img src="biib-20240630_g13.jpg" alt="4" style="height:864px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span><br/></span></div></div><div style="display:inline-block;max-width:6.837%;min-width:5.837%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.582%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Research and development expense, as a percentage of total revenue, was 20.3% and 23.5% for the six months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024, compared to the same period in 2023, the decrease in research and development was primarily driven by cost-reduction measures realized in 2024 in connection with our portfolio prioritization initiatives and our Fit for Growth program, as well as higher spend on clinical trials and close out costs incurred during 2023, partially offset by approximately $46.0&#160;million of step-up amortization related to SKYCLARYS inventory.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">EARLY STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2024 vs. YTD 2023</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in early stage programs was driven by a decrease in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of BIIB059 for the treatment of CLE into late stage;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB131 for the treatment of acute ischemic stroke;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB093 for the treatment of TBI; and</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB135 for the treatment of MS.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of cemdomespib for the treatment of diabetic neuropathic pain; and</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of BIIB080 for the treatment of Alzheimer's disease.</span></div><div style="margin-top:1.5pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">LATE STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2024 vs. YTD 2023</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in late stage programs was driven by a decrease in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of ZURZUVAE from late stage to marketed upon the approval of ZURZUVAE for PPD in the U.S.;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of QALSODY from late stage to marketed upon the accelerated approval of QALSODY in the U.S.;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB093 for large hemispheric infarction; and</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, from late stage to marketed upon the approval of TOFIDENCE in the U.S.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of BIIB059 for the treatment of CLE into late stage.</span></div><div style="margin-top:1.5pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">MARKETED PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2024 vs. YTD 2023</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in marketed programs was driven by a decrease in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of ADUHELM for the treatment of Alzheimer's disease; and </span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">decreased spend in LEQEMBI due to the timing of clinical spend.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">increased spend in SKYCLARYS as a result of our acquisition of Reata in September 2023, which includes approximately $46.0&#160;million related to the SKYCLARYS inventory step-up amortization;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of QALSODY from late stage to marketed upon the accelerated approval of QALSODY in the U.S.;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, from late stage to marketed upon the approval of TOFIDENCE in the U.S.; and</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of ZURZUVAE from late stage to marketed upon the approval of ZURZUVAE for PPD in the U.S.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense is reported above based on the following classifications. The development stage reported is based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Research and discovery:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents costs incurred to support our discovery research and translational science efforts. </span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Early stage programs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are programs in Phase 1 or Phase 2 development.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Late stage programs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are programs in Phase 3 development or in registration stage.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Marketed products:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Other research and development costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding any milestone and upfront payments, we expect our core research and development expense to decrease in 2024, while continuing to invest in our pipeline, such as our acquisition of HI-Bio in July 2024. This is primarily due to the continued realization of our cost savings initiatives. We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_205"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SELLING, GENERAL AND ADMINISTRATIVE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2024, compared to the same period in 2023, selling, general and administrative expense increased by approximately 1.1% primarily due to an increase in operational spending on sales and marketing activities in support of LEQEMBI and SKYCLARYS as we continue to expand our U.S. and international product launches, offset in part by cost-reduction measures realized in 2024 in connection with our Fit for Growth program. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2024, compared to the same period in 2023, selling, general and administrative expense decreased by approximately 1.5% primarily due to cost-reduction measures realized in 2024 in connection with our Fit for Growth program, offset by an increase in operational spending on sales and marketing activities in support of LEQEMBI and SKYCLARYS as we continue to expand our U.S. and international product launches. For the six months ended June 30, 2023, selling, general and administrative expense included a $31.0&#160;million obligation to Eisai related to the termination of the co-promotion agreement for our MS products in Japan during the first quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GENERAL AND ADMINISTRATIVE EXPENSE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2024, general and administrative expense increased by approximately $3.6&#160;million, or 2.2%, compared to the same period in 2023, due to integration and other acquisition-related expenses. For the six months ended June 30, 2024, general and administrative expense decreased by approximately $5.2&#160;million, or 1.6%, compared to the same period in 2023, due to cost-reduction measures. Excluding exit-related costs and acquisition-related expenses incurred during the three and six months ended June 30, 2024, general and administrative expense decreased by approximately $1.9&#160;million, or 1.2%, and $21.3&#160;million, or 6.5%, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMORTIZATION AND IMPAIRMENT OF ACQUIRED INTANGIBLE ASSETS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to TYSABRI, AVONEX, SPINRAZA, VUMERITY and SKYCLARYS, which was obtained as part of our acquisition of Reata in September 2023. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the increases in amortization and impairment of acquired intangible assets were primarily due to amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS. For the three and six months ended June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we h</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ad no i</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mpairment charges.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Intangible Assets and Goodwill</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_211"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COLLABORATION PROFIT SHARING/(LOSS REIMBURSEMENT)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit sharing/(loss reimbursement) primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars 2013 commercial agreement with Samsung Bioepis. In the third quarter of 2023 we began recognizing collaboration profit sharing/(loss reimbursement) related to Sage's 50.0% share of income and expense in the U.S. related to ZURZUVAE for PPD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, we recognized net profit-sharing expense of approximately $55.9 million and $116.5 million, respectively, to reflect Samsung Bioepis' 50.0% share of the net collaboration profits, compared to a net profit-sharing expense of $56.9 million and $114.0 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and six months ended June 30, 2024, we recognized net profit-sharing expense of approximately $6.5 million and $11.5 million, respectively, to reflect Sage's 50.0% share of net collaboration results in the U.S. for ZURZUVAE for PPD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration and license arrangements with Samsung Bioepis and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_214"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESTRUCTURING CHARGES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 FIT FOR GROWTH RESTRUCTURING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,000 employees and we expect to incur restructuring charges ranging from approximately $260.0&#160;million to $280.0&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">REATA INTEGRATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimate we will incur total integration charges ranging from approximately $35.0&#160;million to $40.0&#160;million, related to severance and employment costs, which are expected to be paid by the end of 2024. These amounts were substantially incurred during 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our cost saving initiatives, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Restructuring,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_217"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER (INCOME) EXPENSE, NET</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the changes in other (income) expense, net primarily reflect lower interest income driven by lower cash balances in 2024, compared to the same periods in 2023, as well as net losses on our holdings in equity securities in 2024 as compared to net gains in 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NET (GAINS) LOSSES IN EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2024, net unrealized and realized losses on our holdings in equity securities were approximately $29.8 million and $0.6 million, respectively, compared to net unrealized and realized gains of approximately $105.8 million and $0.7 million, respectively, in the prior year comparative period. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the three months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $51.4&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $27.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized gains recognized during the three months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $117.7&#160;million, partially offset by a decrease in the fair value of Sangamo common stock of approximately $10.9&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2024, net unrealized and realized losses on our holdings in equity securities were approximately $55.5 million and $5.5 million, respectively, compared to net unrealized gains and realized losses of approximately $29.3 million and $0.9 million, respectively, in the prior year comparative period.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the six months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $68.3&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $17.6&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized gains recognized during the six months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $78.0&#160;million, partially offset by a decrease in the fair value of Sangamo and Ionis common stock of approximately $47.4&#160;million.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_220"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INCOME TAX PROVISION</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income tax (benefit) expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">698.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">708.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,163.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the changes in our effective tax rate include the impact of changes in jurisdictional profit mix, including non-cash tax effects of changes in the value of our equity investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our effective tax rate for the six months ended June 30, 2024, also reflects the resolution of an uncertain tax matter during the first quarter of 2023 related to tax credits.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:112%">PILLAR TWO</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OECD has issued model rules, which generally provide for a jurisdictional minimum effective tax rate of 15.0%. Various countries have or are in the process of enacting legislation intended to implement the principles effective January 1, 2024. Our income tax provision for the three and six months ended June 30, 2024, reflects currently enacted legislation and guidance related to the OECD model rules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our income taxes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#00587f;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,908.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">859.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,908.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">859.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of term loan</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable and term loan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,292.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,788.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(496.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,292.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,938.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(646.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,108.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,859.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,108.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,434.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,425.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_229"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed and expect to continue to fund our operating and capital expenditures primarily through cash flow earned through our operations, as well as our existing cash resources. We believe that generic and biosimilar competition for many of our key products, the continued overall decline of our MS business and our investments in the launch of key new products and the development of our pipeline will have a significant adverse impact on our future cash flow from operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2024 we completed the acquisition of all of the issued and outstanding shares of HI-Bio for $1.15&#160;billion, which was funded through available cash on hand.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:115%">LIQUIDITY</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:115%">WORKING CAPITAL</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Our working capital was $4.0 billion and $3.4 billion as of June 30, 2024 and December 31, 2023, respectively. The change in working capital reflects an increase in total current assets of approximately $249.2 million and a decrease in total current liabilities of approximately $326.1 million. The changes in total current assets and total current liabilities were primarily driven by the following:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT ASSETS</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$859.0 million increase in cash and cash equivalents</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$37.0 million decrease in accounts receivable, net related to our ongoing operations; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$566.7 million decrease in other current assets primarily due to the receipt of $437.5&#160;million from Samsung BioLogics related to the sale of our 49.9% equity interest in Samsung Bioepis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT LIABILITIES</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$151.5 million decrease in accrued expense and other primarily due to the timing of our annual incentive compensation payment and other benefits-related payments; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$150.0 million decrease in current portion of debt due to the repayment of our 2023 Term Loan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis and the sale of our PRV, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, we had cash, cash equivalents and marketable securities totaling approximately $1.9 billion compared to approximately $1.0 billion as of December 31, 2023. The increase in the balance was primarily due to cash flows from operations, the receipt of $437.5&#160;million from Samsung BioLogics related to the sale of our 49.9% equity interest in Samsung Bioepis and the receipt of $103.0&#160;million from the sale of one of our two PRV's, partially offset by $650.0&#160;million of cash used for the repayment of our 2023 Term Loan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. We have experienced no significant limitations in our liquidity resulting from uncertainties in the banking sector.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our significant common stock investments in our strategic investment portfolio:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_232"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CASH FLOW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,179.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,706.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(684.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">OPERATING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized (gain) loss on strategic investments and share-based compensation;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">(gains) losses on the disposal of assets, deferred income taxes, changes in the fair value of contingent payments associated with our acquisitions of businesses and acquired IPR&amp;D.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2024, compared to the same period in 2023, the increase in net cash flow provided by operating activities was primarily due to lower employee-benefit payments made during the first quarter of 2024, as compared to the same period in 2023, timing of payments and changes in non-cash adjustments to net income. The increase was partially offset by an increase in inventory levels, primarily associated with our contract manufacturing for LEQEMBI.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">INVESTING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2024, compared to the same period in 2023, the change in net cash flow in investing activities was primarily due to the receipt of $437.5&#160;million from Samsung BioLogics related to the sale of our 49.9% equity interest in Samsung Bioepis, the receipt of $103.0&#160;million from the sale of one of our two PRV's and lower net purchases of marketable securities in 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FINANCING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2024, compared to the same period in 2023, the increase in net cash flow used in financing activities was primarily due to the repayment of our 2023 Term Loan for $650.0&#160;million during 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis and the sale of our PRV, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_235"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CAPITAL RESOURCES</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEBT AND CREDIT FACILITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LONG-TERM DEBT AND TERM LOAN CREDIT AGREEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term obligations primarily consist of long-term debt related to our Senior Notes with final maturity dates ranging between 2025 and 2051. As of June 30, 2024, our outstanding balance related to long-term debt was $6,292.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement (2023 Term Loan). On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid $350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion of the three-year tranche being subsequently repaid during the second quarter of 2024. As of June 30, 2024, the 2023 Term Loan was paid in full.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020 REVOLVING CREDIT FACILITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of June 30, 2024 and December 31, 2023, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of June 30, 2024 and December 31, 2023, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Senior Notes and credit facility please read, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SHARE REPURCHASE PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share repurchases of our common stock during the three and six months ended June 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of June 30, 2024.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_238"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS AND OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments and contingent payments, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our collaboration and licensing arrangements include royalty payment obligations. For additional information on our royalty payments please read, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 22, Commitments and Contingencies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our contractual obligations since December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTINGENT DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of June 30, 2024, we could trigger potential future milestone payments to third parties of up to approximately $5.1 billion, including approximately $0.9 billion in development milestones, approximately $0.4 billion in regulatory milestones and approximately $3.8 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of June 30, 2024, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to approximately $26.7&#160;million in milestones in 2024 under our current agreements, excluding opt-in payments.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER FUNDING COMMITMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $40.3 million in our condensed consolidated balance sheets for expenditures incurred by CROs as of June 30, 2024. We have approximately $573.6 million in cancellable future commitments based on existing CRO contracts as of June 30, 2024.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TAX RELATED OBLIGATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of June 30, 2024, we have approximately $161.9 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024 and December 31, 2023, we have accrued income tax liabilities of approximately $234.0&#160;million and $419.5&#160;million, respectively, under the Transition Toll Tax. The amount accrued as of June 30, 2024, is expected to be paid within one year. The Transition Toll Tax is being paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_241"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_244"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting estimates since our 2023 Form&#160;10-K. For a discussion of our other critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Form&#160;10-K. </span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_247"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and equity price exposure as well as changes in economic conditions in the markets in which we operate as a result of the conflict between Russia and Ukraine and the military conflict in the Middle East. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, foreign currency options, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOREIGN CURRENCY EXCHANGE RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar and Swiss franc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of June 30, 2024, and is not expected to have a material impact on our results of operations or financial position in the future. In December 2023 the Argentinian Peso experienced a substantial devaluation following a presidential election. The devaluation resulted in a $16.0&#160;million charge recorded during the fourth quarter of 2023 in other (income) expense, net within our consolidated statements of income for the year ended December 31, 2023, included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REVENUE AND OPERATING EXPENSE HEDGING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts and foreign currency options to manage foreign currency risk, with the majority of our forward contracts and options used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 15 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BALANCE SHEET RISK MANAGEMENT HEDGING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of June 30, 2024 and December 31, 2023, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $256.2 million and $249.4 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CREDIT RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate in certain countries where weakness in economic conditions, including the effects of the conflict between Russia and Ukraine and the military conflict in the Middle East, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of June 30, 2024 and December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EQUITY PRICE RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. We may sell such equity securities based on our business considerations, which may include limiting our price risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. The potential change in fair value for equity price sensitive instruments has been assessed on a hypothetical 10.0% adverse movement. As of June 30, 2024 and December 31, 2023, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $30.3&#160;million and $41.7&#160;million, respectively.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_253"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of June 30, 2024. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II OTHER INFORMATION</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_259"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of June 30, 2024, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_262"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction, greater acceptance or more favorable reimbursement of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those relating to inflation and those resulting from governmental or regulatory requirements, including those relating to any future potential drug price negotiation under the IRA; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third-parties;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, geopolitical events, regulatory or legislative developments; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEQEMBI is in the early stages of commercial launch in the U.S. and certain international markets and SKYCLARYS is in the early stages of commercial launch in the U.S. and certain European markets. In addition to risks associated with new product launches and the other factors described in these Risk Factors, Biogen&#8217;s and Eisai&#8217;s ability to successfully commercialize LEQEMBI and our ability to successfully commercialize SKYCLARYS may be adversely affected due to:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Eisai&#8217;s ability to obtain and maintain adequate reimbursement for LEQEMBI;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the effectiveness of Eisai's and Biogen&#8217;s commercial strategy for marketing LEQEMBI;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">requirements such as participation in a registry and the use of imaging or other diagnostics for LEQEMBI;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">our ability to obtain approval in other markets;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the approval of other new products for the same or similar indications;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Eisai&#8217;s and Biogen&#8217;s ability to maintain a positive reputation among patients, healthcare providers and others in the Alzheimer&#8217;s disease community, which may be impacted by pricing and reimbursement decisions relating to LEQEMBI, which are made by Eisai and/or third parties;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Biogen's ability to obtain and maintain adequate reimbursement for SKYCLARYS; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the effectiveness of Biogen's commercial strategy for marketing SKYCLARYS.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products from our research and development activities or our licenses or acquisitions from third parties, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies. For example, we are currently seeking approval of LEQEMBI in Europe and Eisai will be seeking reexamination of the CHMP opinion, and the approval of a subcutaneous formulation of LEQEMBI in the U.S. and any delays or challenges may impact our ability to realize the anticipated benefits from LEQEMBI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early-stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce or delay the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prioritize other opportunities in our pipeline. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may not meet investor expectations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market in 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may also be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain and maintain appropriate pricing and adequate reimbursement for our products compared to our competitors in key markets; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies, companies, the entry into strategic alliances and collaborations or our Fit for Growth program, as well as our ability to execute on strategic decisions and initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement to make any such acquisition if suitable candidates are identified.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as a result of disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions or strategic decisions, such as the decision to retain the biosimilars business, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations. For example, we recently acquired Reata and HI-Bio and are in the process of integrating Reata and HI-Bio into our Company. The ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies, depends on, among other things, how effective we are in integrating the Biogen, Reata and HI-Bio operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face risks associated with our Fit for Growth program that may impair our ability to achieve anticipated savings and operational efficiencies or that may otherwise harm our business. These risks include delays in implementation of cost optimization actions, loss of workforce capabilities, higher than anticipated separation expenses, litigation and the failure to meet financial and operational targets. In addition, the calculation of the anticipated cost savings and other benefits resulting from our Fit for Growth program are subject to many estimates and assumptions. These estimates and assumptions are subject to significant business, economic, competitive and other uncertainties and contingencies, many of which are beyond our control. if these estimates and assumptions are incorrect or if we experience delays or unforeseen events, our business and financial results could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product, diagnosis of the condition it treats and the cost to administer it may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to receive reimbursement for our products or our ability to receive comparable reimbursement to that of competing products; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth and result in reductions in revenue. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue. Additionally, in certain jurisdictions governmental health agencies may adjust, retroactively and/or prospectively, reimbursement rates for our products. Reimbursement for our products by governments, including the timing of any reimbursements, may also be affected by budgetary or political constraints, particularly in challenging economic environments. Government agencies often do not set their own budgets and therefore, have limited control over the amount of money they can spend. In addition, these agencies experience political pressure that may dictate the manner in which they spend money. There can be no assurance that the economic, budgeting or political issues will not worsen and adversely impact sales or reimbursements of our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators and other third-parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third-parties. Reliance on third-parties subjects us to a number of risks, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators or third-parties devote to our programs, products or product candidates, which may affect our ability to achieve development goals or milestones;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones, payment of development or commercial costs, ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators or third-parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators or third-parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators or third-parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue or reputation as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators or third-parties could subject us to civil or criminal investigations and monetary and injunctive penalties, require management attention, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs (including those contained in the IRA) and increasing pressure from social sources could significantly influence the manner in which our products are prescribed, purchased and reimbursed. For example, provisions of the PPACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is substantial public attention on the costs of prescription drugs and we expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. In addition, there have been (including elements of the IRA), and are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are requesting manufacturers to pay supplemental </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expense may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third-Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of collaboration partners and other third-parties over whom we have limited or no control in the development and manufacturing of biosimilars products. For example, a recently announced potential acquisition of a contract development and manufacturing organization by a third party may impact its operational, strategic or financial risk. If these third-parties fail to perform successfully, or reduce their third party manufacturing production, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet demand. We are dependent on a third-party for the manufacture of our biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive intellectual property clearances and infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies that may receive greater acceptance or more favorable reimbursement. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success in this business area.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain, defend or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of exclusivity and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third-parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third-parties to be pertinent to the manufacture, use or sale of our products.&#160;Legal proceedings may also be necessary to determine the rights, obligations and payments claimed during and after the expiration of intellectual property license agreements we have entered with third parties. Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain could reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies, disagree with our trial design or endpoints or not approve adequate reimbursement. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements, requiring confirmatory trials and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third-parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third-parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected, including adversely affecting our expenses associated with such trials. We may need to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our information systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information systems and data to operate our business. Changes in how we operate have caused us to modify our business practices in ways that heighten this dependence, including changing the requirement that most of our office-based employees in the U.S. and our other key markets work from the office, with many of our employees now working in hybrid or full-remote positions. As a result, we are increasingly dependent upon our information systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our information systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). Breakdowns, invasions, corruptions, destructions and/or breaches, which impact may include, but not limited to, comprising the capacity, reliability or security of our information systems or those of our business partners, including our cloud technologies, and/or unauthorized access to our data and information could subject us to significant liability, negatively impact our business operations, and/or require replacement of technology and/or sizeable ransom payments. Our information systems, including our cloud technologies, continue to increase in multitude and complexity, increasing our vulnerability when breakdowns, malicious intrusions and random attacks occur.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity threats and incidents are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect, particularly when they impact vendors, customers or suppliers, and other companies in our supply chain. Cybersecurity threats and incidents are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and may include or target employees or contractors acting with careless or malicious intent. Recent developments in the threat landscape include use of AI and machine learning, as well as an increased number of cyber extortion attacks, with higher financial ransom demand amounts and increasing sophistication and variety of ransomware techniques and methodology. Geopolitical instability, including that related to Russia's invasion of Ukraine or the conflict in the Middle East, may increase the risk of cybersecurity threats. Cybersecurity threats or incidents may include deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our information systems and data. Cybersecurity threats and incidents also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or products produced for contract manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent cybersecurity threats or incidents in our systems and any such incidents could materially adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in material financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Regulations continue to change as regulators worldwide consider new rules. For example, the SEC has adopted additional disclosure rules regarding cyber security risk management, strategy, governance and incident reporting by public companies. These new regulations or other regulations being considered in Europe and around the world may impact the manner in which we operate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the CCPA, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Risks of Reliance on Third-Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third-parties are independent entities subject to their own unique operational, strategic and financial risks that are outside of our control. For example, a recently announced potential acquisition of a contract development and manufacturing organization by a third party may impact its operational, strategic or financial risk. These third-parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor or raw material shortages, geopolitical instability, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are required to maintain compliance with cGMP and other stringent requirements, as applicable, and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third-parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, factors such as geopolitical events, global health outbreaks, weather events, labor or raw material shortages and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results in operations or result in product shortages. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management, personnel and other organizational changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management, other personnel and our overall retention rate may disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and other personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract or retain them. We may face difficulty in attracting and retaining talent for a number of reasons, including management changes, integration related to the Reata acquisition, the underperformance or discontinuation of one or more marketed, pre-clinical or clinical programs, recruitment by competitors or changes in the overall labor market. In addition, changes in our organizational structure or in our flexible working arrangements could impact employees' productivity and morale as well as our ability to attract, retain and motivate employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other health care providers that prescribe or purchase our products are also subject to laws and government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of laws and government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including testing, insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these or other patient assistance programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents or distributors and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing, reimbursement or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increased cost of goods due to factors such as inflation and supply chain disruptions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">additional complexity in manufacturing or conducting clinical research internationally, including materials manufactured in China or working with CROs in China;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine and the military conflict in the Middle East;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. FCPA prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We built a large-scale biologics manufacturing facility and are building a gene therapy manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we have expanded our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Solothurn facility was approved by the FDA for LEQEMBI, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we are building a new gene therapy manufacturing facility in RTP, North Carolina with no assurance that this investment will be fully utilized. If we are unable to fully utilize this gene therapy manufacturing facility, charges from excess capacity may occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity may continue to occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third-parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms and artificial intelligence based software presents new risks and challenges.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business. Additionally, the use of AI based software is increasingly being used in the biopharmaceutical industry. Use of AI based software may lead to the release of confidential proprietary information which may impact our ability to realize the benefit of our intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expense that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the costs associated with decisions to terminate research and development programs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, charges for excess capacity, charges for excess or obsolete inventory and charges for inventory write-downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expense, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms which could significantly increase our financing costs. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, negative company-specific news, biotechnology market sentiment, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. Additionally, the recently enacted IRA includes an excise tax on share repurchases, which will increase the cost of share repurchases. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third-party from attempting to acquire us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively and the effects of the integration of Reata and HI-Bio. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the OECD&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates. Many countries have or are in the process of enacting legislation intended to implement the OECD GloBE Model Rules effective on January 1, 2024. The impact on the Company will depend on the timing of implementation, the exact nature of each country's GloBE legislation, guidance and regulations thereon and their application by tax authorities either prospectively or retrospectively.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental and operational risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds which make us subject to changing and evolving rules and interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business. Additionally, regulators have passed new environmental disclosure rules. For example, the SEC, the E.U. and California have implemented new climate disclosure rules that will generally require additional disclosure. Additionally, other regulators are considering environmental disclosure rules. These new rules collectively will impose additional disclosure requirements elating to climate-related risks and emissions disclosures. We expect to be subject to these new laws, which impose extensive reporting obligations about greenhouse gas emissions and climate-related financial risks. These recently enacted and proposed regulations may require us to incur compliance and disclosure costs and will likely require substantial management attention.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the second quarter of 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:21.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2024 - April 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1, 2024 - May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 1, 2024 - June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There were no share repurchases during the second quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and six months ended June 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of June 30, 2024.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_268"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TRADING ARRANGEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no trading arrangements for the purchase or sale of our securities <ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1769"><ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1770">entered</ix:nonNumeric></ix:nonNumeric> into or <ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1771"><ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1772">terminated</ix:nonNumeric></ix:nonNumeric> by our Directors or Officers during the second quarter of 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_274"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.024%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on March 27, 2015.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment of Biogen Inc.&#8217;s Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on June 8, 2021.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment of Biogen Inc.&#8217;s Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Registration Statement on Form S-8 filed on June 20, 2024.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fifth Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 12, 2023.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen Inc. 2024 Omnibus Equity Plan. Filed as Appendix C to Biogen&#8217;s Definitive Proxy Statement on Schedule 14A filed on April 26, 2024.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen Inc. 2024 Employee Stock Purchase Plan. Filed as Appendix D to Biogen&#8217;s Definitive Proxy Statement on Schedule 14A filed on April 26, 2024.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103-formofpsuawarda.htm">Form of performance share award agreement under the Biogen Inc. 2024 Omnibus Equity Plan.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit104-formofrsuawarda.htm">Form of restricted stock unit award agreement under the Biogen Inc. 2024 Omnibus Equity Plan.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105-formofrsuawarda.htm">Form of restricted stock unit award agreement for non-employee Director's under the Biogen Inc. 2024 Omnibus Equity Plan.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2024630xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2024630xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2024630xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2024, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in Inline XBRL.</span></div></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i5c4866793ceb4ece82fc7beb28126ec4_277"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5c4866793ceb4ece82fc7beb28126ec4_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;1, 2024 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>exhibit103-formofpsuawarda.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib0e10815debe42089e3dfaa60200f462_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PERFORMANCE STOCK UNITS AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GRANTED UNDER </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BIOGEN INC. 2024 OMNIBUS EQUITY PLAN</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Grant of Performance Stock Units</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the Biogen Inc. 2024 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee or service provider of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;Grant Date&#8221;), the number of performance stock units (the &#8220;Granted PSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan.  No Granted PSUs shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the Granted PSUs are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law.  All capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Vesting  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion.  Except as provided in Section 2.C. or 2.D. below, no portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by or in the service of the Company or any Affiliate.  If the Participant ceases to be employed by or in the service of the Company and its Affiliates for any reason, any then-outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;The Award will become eligible to vest upon achievement of the Granted PSUs goals (&#8220;Performance Goals&#8221;), as adopted by the Committee in the first calendar quarter of the year in which the Award is granted and communicated.  The calculation of the number of Granted PSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (&#8220;LTI Overview&#8221;), which is also found on your Fidelity stock plan account.  Granted PSUs that become eligible to vest upon the achievement of the Performance Goals are referred to as the &#8220;Eligible PSUs.&#8221;  In the event and to the extent that the Performance Goals are not satisfied, such Granted PSUs shall not become eligible to vest and shall be immediately forfeited upon the Committee&#8217;s determination that such Performance Goals have not been satisfied (or deemed satisfied).  As specified in the Performance Goals, in the event and to the extent that the Performance Goals are exceeded, an additional number of Granted PSUs will become eligible to vest.  In no event shall the number of Eligible PSUs exceed 200% of the number of Granted PSUs.  All Eligible PSUs shall vest on (i) the later of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the third anniversary of the Grant Date or the date of the Committee&#8217;s determination of the degree to which the Annual Performance Goals have been satisfied (which shall occur not later than March 1 immediately following the end of the year to which the Annual Performance Goals relate), (ii) in the event of a Corporate Change in Control, the date or dates described in Section 2.C. below,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or (iii) in the event of a termination of the Participant&#8217;s employment or service with the Company and its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398816v4&#58;7&#47;1&#47;2024 12&#58;08&#58;25 PM</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Affiliates on account of death, Disability or Retirement, the date or dates described in Section 2.D below (the &#8220;Vesting Date&#8221;). </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;In the event of a Corporate Change in Control, subject to the Participant&#8217;s continued employment or service with the Company and its Affiliates through the date of such Corporate Change in Control&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;if the applicable performance period relating to the Performance Goals has ended prior to the date of such Corporate Change in Control, the Committee shall determine the extent to which the Performance Goals were achieved, if not yet determined, and the Granted PSUs that are eligible to vest based on the achievement of such Performance Goals shall become Eligible PSUs as of immediately prior to such Corporate Change in Control based on the level of achievement so determined&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;if the applicable performance period relating to the Performance Goals has not ended prior to the date of such Corporate Change in Control, any outstanding Granted PSUs shall become Eligible PSUs as of immediately prior to such Corporate Change in Control assuming that the Performance Goals are achieved at target (or such greater level determined by the Committee)&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;to the extent the acquiring or surviving entity assumes, continues or substitutes for Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) in connection with the Corporate Change in Control, the Eligible PSUs shall remain outstanding and, subject to the Participant&#8217;s continued employment or service with the acquiring or surviving entity, shall vest in full upon the third anniversary of the Grant Date or, if earlier, upon an Involuntary Employment Action as described in Section 10.B. of the Plan or the Participant&#8217;s termination of employment or service on account of death or Disability&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(iv) &#160;&#160;&#160;&#160;to the extent the acquiring or surviving entity does not assume, continue or substitute for the Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) in connection with the Corporate Change in Control, the Eligible PSUs shall vest in full as of immediately prior to the Corporate Change in Control&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(v)&#160;&#160;&#160;&#160;notwithstanding clause (iii) or (iv) above, with respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the latest Vesting Date described in Section 2.B.(i) above, to the extent required to avoid adverse tax results under Section 409A, the Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) shall vest in full as of immediately prior to the Corporate Change in Control.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;D.&#160;&#160;&#160;&#160;Except as otherwise provided in the Plan or Section 2.C. above, upon termination of the Participant&#8217;s employment or service with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment or service on account of death or Disability will, to the extent not vested previously, become fully vested upon the later of (a) the date of death or Disability of the Participant or (b) the date of the determination of the Eligible PSUs based on the achievement of the Performance Goals and the Committee&#8217;s determination thereof (including under Section 2.C. above, in which case the Eligible </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">378411_1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398816v4&#58;7&#47;1&#47;2024 12&#58;08&#58;25 PM</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PSUs (determined after giving effect to Section 2.C. above) will vest as of immediately prior to the Corporate Change in Control), even if such determination occurs following the date of death or Disability of the Participant&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested upon the later of (a) the date of Retirement or (b) the date of the determination of the Eligible PSUs based on the achievement of the Performance Goals and the Committee&#8217;s determination thereof (including under Section 2.C. above, and with the Eligible PSUs determined after giving effect to Section 2.C. above), and in either case, with respect to fifty percent (50%) of the number of Eligible PSUs covered by such unvested portion and as to an additional ten percent (10%) of the number of Eligible PSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Eligible PSUs of the Award&#59; provided that, notwithstanding the foregoing and Section 9.G.(2) of the Plan, in the event that the Participant&#8217;s Retirement occurs in the same calendar year as the Grant Date this Section 2.D.(ii) shall apply only to one-third (1&#47;3) of the number of Eligible PSUs covered by such unvested portion.  For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;E.&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Delivery of Award </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.31pt">With respect to a Participant who is not and does not prior to the latest Vesting Date described in Section 2.B.(i) above become eligible for Retirement, within 30 days following the date on which Eligible PSUs become vested, with respect to, and in satisfaction of, such vested Eligible PSUs (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan), the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested Eligible PSU (or, in the case of an assumption or substitution described in Section 2.C.(iii) above, of the common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award).  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.92pt">With respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the latest Vesting Date described in Section 2.B.(i) above, to the extent required to avoid adverse tax results under Section 409A, the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock (or, in the case of an assumption or substitution described in Section 2.C.(iii) above, of the common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award) in satisfaction of each vested Eligible PSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the Eligible PSU otherwise would have vested under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">378411_1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398816v4&#58;7&#47;1&#47;2024 12&#58;08&#58;25 PM</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.B.(i) of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A) and&#47;or the date the Eligible PSU vests under Section 2.B.(iii) of this Agreement, subject to Section 3.C. of this Agreement or (iii) the date on which a Corporate Change in Control occurs.  </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.92pt">If you are a &#8220;specified employee&#8221; (as defined in Section 409A), to the extent required to avoid adverse tax results under Section 409A, you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability.  The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A.  For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six-month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Cancellation and Rescission of Awards</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">No Voting, Dividend or Other Rights as a Stockholder</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares.  Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">prior to the date on which the Company delivers to the Participant shares of Common Stock.  Furthermore, the Participant is not entitled to vote any Common Stock or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Unfunded Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company or its Affiliates.  The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Withholding </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and&#47;or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant an amount of cash equal in value to the statutory minimum amount required to be withheld.  A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities.  The amount of cash to be withheld will be calculated using the closing sales price of a share of Common Stock (or, in the case of an assumption or substitution described in Section 2.C.(iii) above, of the common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award) on the applicable vesting date.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">378411_1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398816v4&#58;7&#47;1&#47;2024 12&#58;08&#58;25 PM</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and&#47;or social insurance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In certain cases, local law may require that an award be subject to tax earlier than the date of payment.  If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Provisions of the Plan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control.  A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;No Right to Employment</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his&#47;her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Governing Law</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Biogen Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Chris Viehbacher&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Executive Officer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">378411_1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398816v4&#58;7&#47;1&#47;2024 12&#58;08&#58;25 PM</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>exhibit104-formofrsuawarda.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia0bd950363524b469bcbc3b1cf81c0ab_1"></div><div style="min-height:84.96pt;width:100%"><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRANTED UNDER </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. 2024 OMNIBUS EQUITY PLAN</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Grant of Restricted Stock Units</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Biogen Inc. 2024 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee or service provider of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account (the &#8220;Grant Date&#8221;), the number of restricted stock units (the &#8220;RSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan.  No RSU shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the RSUs granted pursuant to this Agreement are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law.  All capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Vesting  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion.  No portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by or in the service of the Company or any Affiliate.  If the Participant ceases to be employed by or in the service of the Company and its Affiliates for any reason, any then-outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;The Award will become vested in three equal installments on each of the first, second and third anniversaries of the Grant Date (the &#8220;Vesting Period&#8221;).</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Except as otherwise provided in the Plan, upon termination of the Participant&#8217;s employment or service with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will promptly terminate, except as follows&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment or service on account of death or Disability will, to the extent not vested previously, become fully vested upon the Participant&#8217;s death or Disability&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested upon the Participant&#8217;s Retirement as to fifty percent (50%) of the number of shares covered by such unvested portion and as to an additional ten percent (10%) of the number of shares covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested portion of the Award&#59; provided that, notwithstanding the foregoing and Section 9.G.(2) of the Plan, in the event that the Participant&#8217;s Retirement occurs in the same calendar year as the Grant Date, this Section 2.C.(ii) shall apply only to the unvested portion of the Award that would have vested on the first anniversary of the Grant Date had the Participant remained employed by the Company or an Affiliate through such date.  For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280317_2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398817v4&#58;07&#47;01&#47;2024--12&#58;10 PM&#93;&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.647%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;D.&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment or service For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Delivery of Award </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.28pt">With respect to a Participant who is not eligible for Retirement and has a minimum grant of at least six RSUs, within 30 days following the date on which an RSU becomes vested, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested RSU.  Grants of five RSUs or less to a Participant may be settled in an equivalent value of cash instead of Common Stock at the discretion of the Committee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.84pt">With respect to a Participant who is or becomes eligible for Retirement at any time during the Vesting Period and has a minimum award of at least six RSUs, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock in satisfaction of each vested RSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the RSU otherwise would have vested under Section 2.B. of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A), subject to Section 3.C. of this Agreement or (iii) the date on which a Corporate Change in Control that satisfies the definition of a &#8220;change in control event&#8221; under Section 409A occurs.  Grants of five RSUs or less to a Participant may be settled in an equivalent value of cash instead of Common Stock at the discretion of the Committee.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.84pt">If you are a &#8220;specified employee&#8221; (as defined in Section 409A), you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii)&#160;the date of your death or Disability.  The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A.  For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six-month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Cancellation and Rescission of Awards</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">No Voting, Dividend or Other Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares.  Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate prior to the date on which the Company delivers to the Participant shares of Common Stock.  Furthermore, the Participant is not entitled to vote any Common Stock by reason of the granting of the Award or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Unfunded Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company and its Affiliates.  The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280317_2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398817v4&#58;07&#47;01&#47;2024--12&#58;10 PM&#93;&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.647%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Withholding </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and&#47;or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant a number of shares of Common Stock equal in value to the statutory minimum amount required to be withheld.  A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities.  The number of shares to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable vesting date.  Shares (net of the number withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan.  The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and&#47;or social insurance.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, local law may require that an award be subject to tax earlier than the date of payment.  If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Provisions of the Plan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control.  A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;No Right to Employment</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his&#47;her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Governing Law</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biogen Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Chris Viehbacher &#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Executive Officer </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280317_2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398817v4&#58;07&#47;01&#47;2024--12&#58;10 PM&#93;&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>exhibit105-formofrsuawarda.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2564391e56de47e09eed549591ae7931_1"></div><div style="min-height:84.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.5</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-EMPLOYEE DIRECTOR</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRANTED UNDER </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. 2024 OMNIBUS EQUITY PLAN</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Grant of Restricted Stock Units</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Biogen Inc. 2024 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, a non-employee director of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account (the &#8220;Grant Date&#8221;), the number of restricted stock units (the &#8220;RSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan.  No RSU shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the RSUs granted pursuant to this Agreement are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law.  All capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Vesting  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion.  No portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, in service with the Company or any Affiliate.  If the Participant ceases to be in the service with the Company and its Affiliates for any reason, any then-outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;The Award will become vested on the earlier of the (i)&#160;20&#91;&#9679;&#93; annual stockholders meeting and (ii)&#160;one-year anniversary of the Grant Date (as applicable, the &#8220;Vesting Period&#8221;).</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Except as otherwise provided in the Plan, upon termination of the Participant&#8217;s service with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will promptly terminate, except as follows&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of service on account of Retirement (as defined below), death or Disability will, to the extent not vested previously, become fully vested upon the Participant&#8217;s Retirement, death or Disability.  &#91;&#8220;Retirement&#8221; for the purposes of this Agreement as to any Participant shall mean such person's leaving the Board under the following circumstances&#58; (i) as of the annual stockholders meeting that occurs in the year in which such Participant reaches age 75, or (ii) upon the completion of such person's current term provided he or she has provided the Board with at least six months prior written notice of retirement, but not including such Participant's termination For Cause, as determined by the Committee.  Notwithstanding the foregoing, a Participant elected to the Board other than at an annual stockholders meeting shall not be eligible for Retirement pursuant this clause (i) of this Section 2.C until the completion of a term for which such Participant is elected to serve by the stockholders at an annual stockholders meeting&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;upon the occurrence of a Corporate Change in Control, the RSUs, to the extent unvested, shall vest in full.  Such vested RSUs shall be settled within thirty (30) days following such Corporate Change in Control.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note to Biogen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  Please confirm.</font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280317_2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398818v3&#58;07&#47;01&#47;2024--12&#58;23 PM&#93;&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.647%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;D.&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s service For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Delivery of Award </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.28pt">With respect to a Participant who is not eligible for Retirement and has a minimum grant of at least six RSUs, within 30 days following the date on which an RSU becomes vested, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested RSU.  Grants of five RSUs or less to a Participant may be settled in an equivalent value of cash instead of Common Stock at the discretion of the Committee.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.84pt">With respect to a Participant who is or becomes eligible for Retirement at any time during the Vesting Period and has a minimum award of at least six RSUs, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock in satisfaction of each vested RSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the RSU otherwise would have vested under Section 2.B. of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A), or (iii) the date on which a Corporate Change in Control that satisfies the definition of a &#8220;change in control event&#8221; under Section 409A occurs.  Grants of five RSUs or less to a Participant may be settled in an equivalent value of cash instead of Common Stock at the discretion of the Committee.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Cancellation and Rescission of Awards</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">No Voting, Dividend or Other Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares.  Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate prior to the date on which the Company delivers to the Participant shares of Common Stock.  Furthermore, the Participant is not entitled to vote any Common Stock by reason of the granting of the Award or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Unfunded Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company and its Affiliates.  The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Withholding </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and&#47;or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant a number of shares of Common Stock equal in value to the statutory minimum amount </font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280317_2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398818v3&#58;07&#47;01&#47;2024--12&#58;23 PM&#93;&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.647%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required to be withheld.  A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities.  The number of shares to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable vesting date.  Shares (net of the number withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan.  The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and&#47;or social insurance.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, local law may require that an award be subject to tax earlier than the date of payment.  If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Provisions of the Plan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control.  A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;No Rights to Continued Service</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his&#47;her service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Governing Law</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biogen Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Christopher Viehbacher &#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Executive Officer </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280317_2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;&#91;DMS&#58;6398818v3&#58;07&#47;01&#47;2024--12&#58;23 PM&#93;&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>biib-2024630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia1c527d469c1481b8e7350d2ceb3af7b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher A. Viehbacher, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 1, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>biib-2024630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic6134b5b714b4a4c96ef073074b03215_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 1, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>biib-2024630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8939e7df56884e4683087ba0b8fbf2f4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 1, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 1, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>biib-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a009166-a1cb-4c50-83a7-d8b5a99052fa,g:b0d9c5b1-5cff-4c82-aab8-c75b5958a97b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>9952156 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>9952158 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Dispositions" roleURI="http://www.biogenidec.com/role/Dispositions">
        <link:definition>9952159 - Disclosure - Dispositions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiatives" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives">
        <link:definition>9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>9952161 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>9952162 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>9952163 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>9952164 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>9952165 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>9952166 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>9952167 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biogenidec.com/role/Leases">
        <link:definition>9952168 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>9952169 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>9952170 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>9952171 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>9952172 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>9952173 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>9952174 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>9952175 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>9952176 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>9952177 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.biogenidec.com/role/AcquisitionsTables">
        <link:definition>9954472 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables">
        <link:definition>9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>9954474 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>9954475 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>9954476 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>9954477 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>9954478 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>9954479 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>9954481 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>9954482 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>9954483 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>9954485 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails">
        <link:definition>9954487 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPurchasePriceConsiderationDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails">
        <link:definition>9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPreliminatyPurchasePriceAllocationDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails">
        <link:definition>9954489 - Disclosure - Acquisitions Preliminaty Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DispositionsDetailsTextual" roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual">
        <link:definition>9954490 - Disclosure - Dispositions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails">
        <link:definition>9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
        <link:definition>9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails">
        <link:definition>9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
        <link:definition>9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyproductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails">
        <link:definition>9954495 - Disclosure - Revenues - Revenues by product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1">
        <link:definition>9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2">
        <link:definition>9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>9954499 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>9954500 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>9954501 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails">
        <link:definition>9954502 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails">
        <link:definition>9954503 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1">
        <link:definition>9954503 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>9954504 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails">
        <link:definition>9954505 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillChangesinGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails">
        <link:definition>9954506 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>9954507 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>9954508 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>9954509 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>9954510 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>9954511 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>9954512 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>9954513 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>9954514 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>9954515 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetailsTextual" roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual">
        <link:definition>9954516 - Disclosure - Leases (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>9954517 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>9954518 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9954519 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9954520 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>9954521 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails">
        <link:definition>9954522 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails">
        <link:definition>9954523 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPaymentsNarrativeDetails" roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails">
        <link:definition>9954524 - Disclosure - Share-based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>9954525 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>9954526 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>9954527 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>9954528 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOCREVUSDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails">
        <link:definition>9954529 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsProfitSharingDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails">
        <link:definition>9954530 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEisaiDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails">
        <link:definition>9954531 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails">
        <link:definition>9954532 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails">
        <link:definition>9954533 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails">
        <link:definition>9954534 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails">
        <link:definition>9954535 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails">
        <link:definition>9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails">
        <link:definition>9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails">
        <link:definition>9954538 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sangamo Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOtherArrangementsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails">
        <link:definition>9954539 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSamsungBioepisDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails">
        <link:definition>9954540 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>9954541 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>9954542 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_GenentechMember" abstract="true" name="GenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AcquiredAndInLicensedRightsAndPatentsMember" abstract="true" name="AcquiredAndInLicensedRightsAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UnrealizedGainOnDerivatives" abstract="false" name="UnrealizedGainOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GAZYVAMember" abstract="true" name="GAZYVAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ZURZUVAEMember" abstract="true" name="ZURZUVAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RatioOfNumberOfSharesReservedUnderPlan" abstract="false" name="RatioOfNumberOfSharesReservedUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_OtherClinicalProgramsMember" abstract="true" name="OtherClinicalProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" abstract="false" name="RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccruedMilestonePayments" abstract="false" name="AccruedMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ContingentCommercializedRightsNumberOfProducts" abstract="false" name="ContingentCommercializedRightsNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_SeniorNotes3.250DueFebruary152051Member" abstract="true" name="SeniorNotes3.250DueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_UnrealizedLossOnDerivatives" abstract="false" name="UnrealizedLossOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" abstract="false" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareOfNonControlingInterestRecognized" abstract="false" name="ShareOfNonControlingInterestRecognized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FUMADERMAndADUHELMMember" abstract="true" name="FUMADERMAndADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" abstract="false" name="DerivativeInstrumentsUnrealizedGainLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccountsPayableToCollaborator" abstract="false" name="AccountsPayableToCollaborator" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_QALSODYMember" abstract="true" name="QALSODYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentsMadeToTerminationAgreement" abstract="false" name="PaymentsMadeToTerminationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVenture" abstract="false" name="PayablesToDivestitureOfInterestInJointVenture" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CurrentPortionOfNotesPayableAndTermLoanMember" abstract="true" name="CurrentPortionOfNotesPayableAndTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OperatingLeaseArea" abstract="false" name="OperatingLeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" abstract="false" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_OtherAssetsCurrentFairValueDisclosure" abstract="false" name="OtherAssetsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" abstract="false" name="BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InventoryNetCurrentAndNoncurrent" abstract="false" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CompletedTechnologyMember" abstract="true" name="CompletedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SalesTriggerGrossSalesThreshold" abstract="false" name="SalesTriggerGrossSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OCREVUSMember" abstract="true" name="OCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_SKYCLARYSMember" abstract="true" name="SKYCLARYSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TheCreditFacilityMember" abstract="true" name="TheCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfFutureDevelopmentCosts" abstract="false" name="PercentageOfFutureDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_AccountsReceivableFromCollaborator" abstract="false" name="AccountsReceivableFromCollaborator" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" abstract="true" name="TheCreditFacilityFloatingRateThreeYearTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CollaborativeArrangementTermExtension" abstract="false" name="CollaborativeArrangementTermExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_HumanImmunologyBiosciencesMember" abstract="true" name="HumanImmunologyBiosciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A2020ShareRepurchaseProgramMember" abstract="true" name="A2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_OmnibusEquityPlan2024Member" abstract="true" name="OmnibusEquityPlan2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" abstract="false" name="PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PLEGRIDYMember" abstract="true" name="PLEGRIDYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Reductioninroyaltyrate" abstract="false" name="Reductioninroyaltyrate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_LenderDisputeMember" abstract="true" name="LenderDisputeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_ReataIntegrationMember" abstract="true" name="ReataIntegrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TOFIDENCEMember" abstract="true" name="TOFIDENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentsExpectedProfitShare" abstract="false" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" abstract="false" name="Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RituxanMember" abstract="true" name="RituxanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ShareOfNetProfitFromSageTherapeuticsPercent" abstract="false" name="ShareOfNetProfitFromSageTherapeuticsPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_AVONEXMember" abstract="true" name="AVONEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_LEQEMBICollaborationMember" abstract="true" name="LEQEMBICollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_IonisPharmaceuticalsInc.Member" abstract="true" name="IonisPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PretaxProfitSharingFormulaTableTextBlock" abstract="false" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PeriodOfCollaborationAgreement" abstract="false" name="PeriodOfCollaborationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_MosunetuzumabMember" abstract="true" name="MosunetuzumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" abstract="false" name="ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborativeArrangementContractOptionExerciseFeePaid" abstract="false" name="CollaborativeArrangementContractOptionExerciseFeePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_DivestituresAbstract" abstract="true" name="DivestituresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_PriorityReviewVoucherMember" abstract="true" name="PriorityReviewVoucherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AccruedPaymentToTerminationAgreement" abstract="false" name="AccruedPaymentToTerminationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BYOOVIZMember" abstract="true" name="BYOOVIZMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_ContractManufacturingAndOtherRevenueMember" abstract="true" name="ContractManufacturingAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_VUMERITYMember" abstract="true" name="VUMERITYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" abstract="false" name="FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FloatingRate364DayTrancheMember" abstract="true" name="FloatingRate364DayTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RoyaltyAttributedToOCREVUSMember" abstract="true" name="RoyaltyAttributedToOCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ClinicalInventoryMember" abstract="true" name="ClinicalInventoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SangamoMember" abstract="true" name="SangamoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" abstract="false" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TermLoan2023ThreeYearTrancheMember" abstract="true" name="TermLoan2023ThreeYearTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" abstract="false" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" abstract="true" name="NonCurrentPortionOfNotesPayableAndTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AmortizationOfInventoryStepUp" abstract="false" name="AmortizationOfInventoryStepUp" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentDueAtFirstAnniversaryMember" abstract="true" name="PaymentDueAtFirstAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_RareDiseaseProductRevenueMember" abstract="true" name="RareDiseaseProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_A2023TermLoanMember" abstract="true" name="A2023TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" abstract="false" name="BusinessAcquisitionNumberOfCommonStockSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PaymentDueAtSecondAnniversaryMember" abstract="true" name="PaymentDueAtSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityFloatingRate364DayTrancheMember" abstract="true" name="TheCreditFacilityFloatingRate364DayTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReataPharmaceuticalsIncMember" abstract="true" name="ReataPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityTerminatedMember" abstract="true" name="TheCreditFacilityTerminatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2023CostSavingInitiativesMember" abstract="true" name="A2023CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_A2023And2022CostSavingInitiativesMember" abstract="true" name="A2023And2022CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" abstract="false" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NoncontrollingInterestCapitalContribution" abstract="false" name="NoncontrollingInterestCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>biib-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a009166-a1cb-4c50-83a7-d8b5a99052fa,g:b0d9c5b1-5cff-4c82-aab8-c75b5958a97b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_89f44bd9-27ff-4b7b-b10b-2b923283b7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5df5270b-75c2-44b6-a98a-15d1205086cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_89f44bd9-27ff-4b7b-b10b-2b923283b7d8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5df5270b-75c2-44b6-a98a-15d1205086cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2a614f4d-70ce-49f8-91eb-d89bf473861a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_89f44bd9-27ff-4b7b-b10b-2b923283b7d8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2a614f4d-70ce-49f8-91eb-d89bf473861a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8885eb4b-0a8c-460c-91c6-530bbd0232d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7176518b-27c6-437e-94df-7ad413ed6f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8885eb4b-0a8c-460c-91c6-530bbd0232d3" xlink:to="loc_us-gaap_ProfitLoss_7176518b-27c6-437e-94df-7ad413ed6f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_23872bf4-63c6-4cae-809a-22202a0dfd87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8885eb4b-0a8c-460c-91c6-530bbd0232d3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_23872bf4-63c6-4cae-809a-22202a0dfd87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_9e2dcfa0-f5ce-425d-88bd-bd05a8aedce4" xlink:href="biib-20240630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:to="loc_biib_Collaborationprofitlosssharing_9e2dcfa0-f5ce-425d-88bd-bd05a8aedce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_056509a5-e184-48cd-82de-b65bef33dfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_056509a5-e184-48cd-82de-b65bef33dfa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_00aa5b4f-354a-435b-bc32-bcdb7d8d180c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_00aa5b4f-354a-435b-bc32-bcdb7d8d180c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c4806729-8fb0-4b97-aa43-513f94b60256" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c4806729-8fb0-4b97-aa43-513f94b60256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_f9f0ff79-3240-4c4d-90e9-7ef65ff7e8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_f9f0ff79-3240-4c4d-90e9-7ef65ff7e8e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_8b1d4dbc-45b9-49a4-93e1-4b38d53db134" xlink:href="biib-20240630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_8b1d4dbc-45b9-49a4-93e1-4b38d53db134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_44349d6f-0ad2-4a59-91e0-3b0294acee32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:to="loc_us-gaap_RestructuringCharges_44349d6f-0ad2-4a59-91e0-3b0294acee32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_68446123-4626-4322-afc0-51fa96519410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ed55251-007f-4cc4-a1db-fd5c231a0abb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_68446123-4626-4322-afc0-51fa96519410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23300fc1-4f98-4f31-ae3d-00fc380bcc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5366be80-58b3-4eaf-a284-8b6d2146001e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23300fc1-4f98-4f31-ae3d-00fc380bcc9f" xlink:to="loc_us-gaap_Revenues_5366be80-58b3-4eaf-a284-8b6d2146001e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a5dc9a3c-b441-4078-a725-c094fb2859ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23300fc1-4f98-4f31-ae3d-00fc380bcc9f" xlink:to="loc_us-gaap_CostsAndExpenses_a5dc9a3c-b441-4078-a725-c094fb2859ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_84819e1c-dc6e-4ff3-b9a6-31bd4cd5997d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4ab6cd26-e0d2-4d1b-9baa-8080d5a37f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_84819e1c-dc6e-4ff3-b9a6-31bd4cd5997d" xlink:to="loc_us-gaap_NetIncomeLoss_4ab6cd26-e0d2-4d1b-9baa-8080d5a37f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_134f673f-1e30-4bf2-8736-44e374de271d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_84819e1c-dc6e-4ff3-b9a6-31bd4cd5997d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_134f673f-1e30-4bf2-8736-44e374de271d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_606e1ad5-0c54-4b00-a5fc-3d6060619aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ec826888-d76f-4215-9559-6207ed79981a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_606e1ad5-0c54-4b00-a5fc-3d6060619aaf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ec826888-d76f-4215-9559-6207ed79981a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ca4dc26a-1d7b-4305-82a4-f559ae76b170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_606e1ad5-0c54-4b00-a5fc-3d6060619aaf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ca4dc26a-1d7b-4305-82a4-f559ae76b170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_04931171-e96d-4ff3-a787-ab7490231bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_606e1ad5-0c54-4b00-a5fc-3d6060619aaf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_04931171-e96d-4ff3-a787-ab7490231bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e707ad2b-e4c3-4fe2-9d20-ac73729c2b08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_606e1ad5-0c54-4b00-a5fc-3d6060619aaf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e707ad2b-e4c3-4fe2-9d20-ac73729c2b08" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f7309a4a-b0e3-48db-aee0-0a8975a27bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6c7eaaa6-397a-4b4d-bc33-7cfdc6b12da6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f7309a4a-b0e3-48db-aee0-0a8975a27bd8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6c7eaaa6-397a-4b4d-bc33-7cfdc6b12da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8d587ad6-3981-40a0-aa80-f55b6cc59084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f7309a4a-b0e3-48db-aee0-0a8975a27bd8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8d587ad6-3981-40a0-aa80-f55b6cc59084" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eaddd28d-7b11-42b2-9f1e-46e50fbf64e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_90eee8f9-59c9-4860-bbaf-f58e0ac33f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eaddd28d-7b11-42b2-9f1e-46e50fbf64e9" xlink:to="loc_us-gaap_AssetsCurrent_90eee8f9-59c9-4860-bbaf-f58e0ac33f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_643820a5-c26d-4dcf-9204-416a31c55a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eaddd28d-7b11-42b2-9f1e-46e50fbf64e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_643820a5-c26d-4dcf-9204-416a31c55a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_53f0aded-8bc6-4505-9409-a5925e12735f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eaddd28d-7b11-42b2-9f1e-46e50fbf64e9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_53f0aded-8bc6-4505-9409-a5925e12735f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d3c2aa0b-5736-4e26-b158-fce224d27089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eaddd28d-7b11-42b2-9f1e-46e50fbf64e9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d3c2aa0b-5736-4e26-b158-fce224d27089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5913f8f7-c1c9-4673-ae16-b9eb3c038dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eaddd28d-7b11-42b2-9f1e-46e50fbf64e9" xlink:to="loc_us-gaap_Goodwill_5913f8f7-c1c9-4673-ae16-b9eb3c038dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_02f2e392-ccb2-456e-9448-1c4911d71911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eaddd28d-7b11-42b2-9f1e-46e50fbf64e9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_02f2e392-ccb2-456e-9448-1c4911d71911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c37b606e-ed9e-47dd-a43a-fe98c6008242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eaddd28d-7b11-42b2-9f1e-46e50fbf64e9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c37b606e-ed9e-47dd-a43a-fe98c6008242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_632bf9c6-80f6-4c0d-9c3b-db8c1ef7f197" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_30d35c8b-2659-4a5e-8e4c-84a645c90985" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_632bf9c6-80f6-4c0d-9c3b-db8c1ef7f197" xlink:to="loc_us-gaap_LiabilitiesCurrent_30d35c8b-2659-4a5e-8e4c-84a645c90985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8cabf833-5478-4b79-85bc-48dd9ac736b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_632bf9c6-80f6-4c0d-9c3b-db8c1ef7f197" xlink:to="loc_us-gaap_LongTermDebt_8cabf833-5478-4b79-85bc-48dd9ac736b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3d7d63ab-e2b5-47da-b1a9-23abad297cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_632bf9c6-80f6-4c0d-9c3b-db8c1ef7f197" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3d7d63ab-e2b5-47da-b1a9-23abad297cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b5576f8-19c2-4ebb-b074-f6554d18e04a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_632bf9c6-80f6-4c0d-9c3b-db8c1ef7f197" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b5576f8-19c2-4ebb-b074-f6554d18e04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ba89ad25-c610-4fa8-b35f-be86b5ef4dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_632bf9c6-80f6-4c0d-9c3b-db8c1ef7f197" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ba89ad25-c610-4fa8-b35f-be86b5ef4dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b82ef64d-7679-4886-9bb3-987afc7f3050" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_88b613e3-d59f-4790-90db-cf794622b041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b82ef64d-7679-4886-9bb3-987afc7f3050" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_88b613e3-d59f-4790-90db-cf794622b041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_78bd6e6c-ca9a-4978-a804-44b7410491c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b82ef64d-7679-4886-9bb3-987afc7f3050" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_78bd6e6c-ca9a-4978-a804-44b7410491c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ad9ecfb0-4fd1-4d75-9439-9fed2730d7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b82ef64d-7679-4886-9bb3-987afc7f3050" xlink:to="loc_us-gaap_InventoryNet_ad9ecfb0-4fd1-4d75-9439-9fed2730d7b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_47b5cd71-46d8-4dac-bba5-9cd56ce0824a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b82ef64d-7679-4886-9bb3-987afc7f3050" xlink:to="loc_us-gaap_OtherAssetsCurrent_47b5cd71-46d8-4dac-bba5-9cd56ce0824a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f795d7e9-4e12-4b9c-a997-3875b09ca5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d46abda-4995-433b-85af-9362203ddbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f795d7e9-4e12-4b9c-a997-3875b09ca5d8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d46abda-4995-433b-85af-9362203ddbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_22a74352-5fb6-4922-ae1c-a96e6f646757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f795d7e9-4e12-4b9c-a997-3875b09ca5d8" xlink:to="loc_us-gaap_Liabilities_22a74352-5fb6-4922-ae1c-a96e6f646757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f630f9e1-e4ef-4f2e-8ccf-a4f50577d100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f795d7e9-4e12-4b9c-a997-3875b09ca5d8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f630f9e1-e4ef-4f2e-8ccf-a4f50577d100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_64f867dd-5524-4b6b-bfe9-ac8d511d36ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_fd676bd5-8142-46b1-a319-5182d974c3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_64f867dd-5524-4b6b-bfe9-ac8d511d36ca" xlink:to="loc_us-gaap_NotesPayableCurrent_fd676bd5-8142-46b1-a319-5182d974c3d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e6c755ea-2282-421c-aaf1-b96106c18fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_64f867dd-5524-4b6b-bfe9-ac8d511d36ca" xlink:to="loc_us-gaap_AccountsPayableCurrent_e6c755ea-2282-421c-aaf1-b96106c18fb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_aaecb903-9531-4e50-ae5d-c1c368827364" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_64f867dd-5524-4b6b-bfe9-ac8d511d36ca" xlink:to="loc_us-gaap_TaxesPayableCurrent_aaecb903-9531-4e50-ae5d-c1c368827364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e878b5bb-cdd2-4169-8a49-5bfbef11501b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_64f867dd-5524-4b6b-bfe9-ac8d511d36ca" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e878b5bb-cdd2-4169-8a49-5bfbef11501b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7fa88b1-36c0-42fd-9fa7-5b505e24d843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_056d6627-28cc-4cb3-a3b4-afc6604aeffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7fa88b1-36c0-42fd-9fa7-5b505e24d843" xlink:to="loc_us-gaap_TreasuryStockValue_056d6627-28cc-4cb3-a3b4-afc6604aeffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4b38b53d-7f5e-43b1-ad42-d67de4b27857" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7fa88b1-36c0-42fd-9fa7-5b505e24d843" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4b38b53d-7f5e-43b1-ad42-d67de4b27857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_222f386e-6a84-452f-a2e5-81c2fa235c38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7fa88b1-36c0-42fd-9fa7-5b505e24d843" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_222f386e-6a84-452f-a2e5-81c2fa235c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ef16415b-bda1-4b56-ab70-0d251a5c9614" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7fa88b1-36c0-42fd-9fa7-5b505e24d843" xlink:to="loc_us-gaap_PreferredStockValue_ef16415b-bda1-4b56-ab70-0d251a5c9614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c1083546-c831-4e2d-ad8e-fd75d328e270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7fa88b1-36c0-42fd-9fa7-5b505e24d843" xlink:to="loc_us-gaap_CommonStockValue_c1083546-c831-4e2d-ad8e-fd75d328e270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e0db10f3-edc0-4c76-86c4-5a71a027f93c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7fa88b1-36c0-42fd-9fa7-5b505e24d843" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e0db10f3-edc0-4c76-86c4-5a71a027f93c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4a56637f-a467-47a5-a4e9-1c0cfb5e5631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4a56637f-a467-47a5-a4e9-1c0cfb5e5631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_ea0f43ac-2769-4c16-913b-6d01c86be97b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_ea0f43ac-2769-4c16-913b-6d01c86be97b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_94ffce10-7420-465b-829c-a38bd362b8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_94ffce10-7420-465b-829c-a38bd362b8a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_af97f12c-2fac-4085-93c4-221b50cbf01e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_af97f12c-2fac-4085-93c4-221b50cbf01e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_28ac6366-3ce7-4197-b680-8ff0cbbc6178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_28ac6366-3ce7-4197-b680-8ff0cbbc6178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_92552358-53ad-4037-a37e-e495dde25dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_92552358-53ad-4037-a37e-e495dde25dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f30c206f-8f6b-4458-a786-f3dbd632f25b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f30c206f-8f6b-4458-a786-f3dbd632f25b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7047cfb-7eee-441e-8227-7de2bf49b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f315cc2-b645-47dc-9f7e-58a98623c7b2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7047cfb-7eee-441e-8227-7de2bf49b34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dfce63dc-512a-4a5f-a91c-c85ef51609f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_658b02be-f198-4abf-a7eb-780978e8f0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dfce63dc-512a-4a5f-a91c-c85ef51609f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_658b02be-f198-4abf-a7eb-780978e8f0f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcb04360-e633-474a-82a7-968f4cec606f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dfce63dc-512a-4a5f-a91c-c85ef51609f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcb04360-e633-474a-82a7-968f4cec606f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be705e1a-b521-49b5-81f5-6a214814277b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dfce63dc-512a-4a5f-a91c-c85ef51609f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be705e1a-b521-49b5-81f5-6a214814277b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_266818a9-aaf0-4c84-8726-b598ff6c6250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_59a8829a-0b2d-41fb-8824-463e33487240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_266818a9-aaf0-4c84-8726-b598ff6c6250" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_59a8829a-0b2d-41fb-8824-463e33487240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_277b0c36-723d-4380-89c3-6045e5ac92b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_266818a9-aaf0-4c84-8726-b598ff6c6250" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_277b0c36-723d-4380-89c3-6045e5ac92b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bf1401d3-4bf9-4bc3-8d72-eabef88be771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_266818a9-aaf0-4c84-8726-b598ff6c6250" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bf1401d3-4bf9-4bc3-8d72-eabef88be771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_0db1aa72-5b81-4753-83a1-0bfb832b7b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_266818a9-aaf0-4c84-8726-b598ff6c6250" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_0db1aa72-5b81-4753-83a1-0bfb832b7b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3930f037-2bf4-4ce0-8a7e-c4a29a292db8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3930f037-2bf4-4ce0-8a7e-c4a29a292db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e99d11b9-ae6f-4b1a-8565-40c4eb984f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e99d11b9-ae6f-4b1a-8565-40c4eb984f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_da68cd2d-da46-4076-81e7-1025772ac630" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_da68cd2d-da46-4076-81e7-1025772ac630" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f2956071-250d-4982-a192-ff7eff7e1aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_InventoryWriteDown_f2956071-250d-4982-a192-ff7eff7e1aeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_7c53b844-56ff-420e-8bdf-f99cfcc8418d" xlink:href="biib-20240630.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_biib_AmortizationOfInventoryStepUp_7c53b844-56ff-420e-8bdf-f99cfcc8418d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_de427041-50b3-4ee2-8210-4b6df60dac02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_de427041-50b3-4ee2-8210-4b6df60dac02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8081aa47-ded2-4eca-b1e3-495e9cae4bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8081aa47-ded2-4eca-b1e3-495e9cae4bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c7fb6d53-8faf-45db-8b4d-55cfbfbbec77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_ShareBasedCompensation_c7fb6d53-8faf-45db-8b4d-55cfbfbbec77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6772b90b-1684-43c0-9563-a8a9a5511033" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6772b90b-1684-43c0-9563-a8a9a5511033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f245e4ff-e9e3-4465-8441-cae844defa85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_ProfitLoss_f245e4ff-e9e3-4465-8441-cae844defa85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1bcb0dea-3c1b-4d34-bc82-a5e6006bab40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1bcb0dea-3c1b-4d34-bc82-a5e6006bab40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d0a4f1b7-a589-4d43-8fee-024965f09eab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d0a4f1b7-a589-4d43-8fee-024965f09eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_dbc64045-2721-452a-85e1-e6b65b9f1b57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_dbc64045-2721-452a-85e1-e6b65b9f1b57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c0cd1cb0-c88b-491b-85e9-c7e3bf727ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b87e67ea-34d6-44b7-83c8-1b425a1b1c5c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c0cd1cb0-c88b-491b-85e9-c7e3bf727ecb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_10111343-9a77-4a9f-ae34-7c1146977e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c2661674-6eaa-463c-9943-fad8571b12d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_10111343-9a77-4a9f-ae34-7c1146977e8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c2661674-6eaa-463c-9943-fad8571b12d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_10fe36ef-b126-4579-a1c6-e943d9445e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_10111343-9a77-4a9f-ae34-7c1146977e8e" xlink:to="loc_us-gaap_Goodwill_10fe36ef-b126-4579-a1c6-e943d9445e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b381edfd-2c2c-453a-bb73-bd879d24f38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b381edfd-2c2c-453a-bb73-bd879d24f38e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ada55ee0-294c-43eb-b236-12f21976e0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ada55ee0-294c-43eb-b236-12f21976e0d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f1413032-7f69-4009-83ab-617e3681dfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f1413032-7f69-4009-83ab-617e3681dfc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_f69f0ff4-a17f-47b4-83cc-252abc69bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_f69f0ff4-a17f-47b4-83cc-252abc69bcb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_096314d1-05b8-479f-b85e-cf5b212a8309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_096314d1-05b8-479f-b85e-cf5b212a8309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_8264100a-64ee-42de-ae1d-05cd3eb0c3f7" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_8264100a-64ee-42de-ae1d-05cd3eb0c3f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_474df825-94c9-485b-86ee-44aab27b46ce" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_474df825-94c9-485b-86ee-44aab27b46ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_0907a9ad-69ea-47aa-a824-215592c66881" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_0907a9ad-69ea-47aa-a824-215592c66881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_f390ab88-3df0-4b0e-94ac-5e2065b8de18" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_f390ab88-3df0-4b0e-94ac-5e2065b8de18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_455ac1ed-62a0-4df7-9771-aa8afdd19d18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_455ac1ed-62a0-4df7-9771-aa8afdd19d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_50aa0690-9388-4a41-8d77-072445484c16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_50aa0690-9388-4a41-8d77-072445484c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_59027b8a-a64a-4368-9a1f-4dd08ef26428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e5ca1f0e-9789-46b3-96f2-6bbdae6a2c4c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_59027b8a-a64a-4368-9a1f-4dd08ef26428" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1a301803-934f-4245-a3d0-79de606f40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_4a7b02e5-2e1a-4427-8d0c-8d515a222daa" xlink:href="biib-20240630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_1a301803-934f-4245-a3d0-79de606f40cc" xlink:to="loc_biib_ShareOfCoPromotionProfits_4a7b02e5-2e1a-4427-8d0c-8d515a222daa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_bbe38c07-ef77-4a8b-9c4f-4ed35fee9c17" xlink:href="biib-20240630.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7fdafc1e-26e5-4f41-8916-3ebca35971a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_bbe38c07-ef77-4a8b-9c4f-4ed35fee9c17" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7fdafc1e-26e5-4f41-8916-3ebca35971a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e21ea023-c498-4e5b-947b-ab6ff562628a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_bbe38c07-ef77-4a8b-9c4f-4ed35fee9c17" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e21ea023-c498-4e5b-947b-ab6ff562628a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_57264432-ac4a-4091-9e20-94b5aadcfee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_bbe38c07-ef77-4a8b-9c4f-4ed35fee9c17" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_57264432-ac4a-4091-9e20-94b5aadcfee0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d897533d-efa4-4f9e-9025-48627a1f12d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_202f3860-1383-4687-90a8-725fdfecf9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d897533d-efa4-4f9e-9025-48627a1f12d0" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_202f3860-1383-4687-90a8-725fdfecf9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24796a7e-6c8a-4f25-95de-2c2d1c924d43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d897533d-efa4-4f9e-9025-48627a1f12d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24796a7e-6c8a-4f25-95de-2c2d1c924d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4f830765-ddbc-47fc-8a2d-822f1425bb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8ae1c60e-e415-44c3-beef-99a0bf0a93cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4f830765-ddbc-47fc-8a2d-822f1425bb1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8ae1c60e-e415-44c3-beef-99a0bf0a93cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_59535bdd-46b4-44a4-965c-21c32c50bda1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4f830765-ddbc-47fc-8a2d-822f1425bb1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_59535bdd-46b4-44a4-965c-21c32c50bda1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5839a4b9-8bac-4ffa-9551-f7363aa19c67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5eae5582-9b6f-46f2-8cfd-3cd010615691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5839a4b9-8bac-4ffa-9551-f7363aa19c67" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5eae5582-9b6f-46f2-8cfd-3cd010615691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd17db95-419b-43e2-b9a8-e22ebad05349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5839a4b9-8bac-4ffa-9551-f7363aa19c67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd17db95-419b-43e2-b9a8-e22ebad05349" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_836c3cf0-318c-412a-8a6c-eb176675b5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_776b9500-7459-4dc9-ae99-140eab47ccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_836c3cf0-318c-412a-8a6c-eb176675b5eb" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_776b9500-7459-4dc9-ae99-140eab47ccaa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_7b3cd69e-6502-44ae-9089-0a2aef22095f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d143b927-0c86-478e-8660-e20e9ed57e32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_7b3cd69e-6502-44ae-9089-0a2aef22095f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d143b927-0c86-478e-8660-e20e9ed57e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_82b12081-39c6-452e-a6ac-3c81ce316977" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_7b3cd69e-6502-44ae-9089-0a2aef22095f" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_82b12081-39c6-452e-a6ac-3c81ce316977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_beb2ade5-eccb-4eeb-96ec-ea04077f87e9" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_7b3cd69e-6502-44ae-9089-0a2aef22095f" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_beb2ade5-eccb-4eeb-96ec-ea04077f87e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f81fbf19-8a9f-4d2e-a4c5-18159e3711d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9a373fcf-d07d-484d-91ef-533b0a11c6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f81fbf19-8a9f-4d2e-a4c5-18159e3711d2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9a373fcf-d07d-484d-91ef-533b0a11c6c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89714f0a-62db-4c70-90f0-6b51fad2144e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9adf251-2cf3-49cf-81f8-e26b56cfd55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89714f0a-62db-4c70-90f0-6b51fad2144e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9adf251-2cf3-49cf-81f8-e26b56cfd55a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e7a29b0d-f09a-4231-9874-d34c97ccf6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89714f0a-62db-4c70-90f0-6b51fad2144e" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e7a29b0d-f09a-4231-9874-d34c97ccf6e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_cb678249-ead2-46c1-9707-aa0ad7ee7286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_98f72c7d-30c8-4e25-a685-3570008cad68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_cb678249-ead2-46c1-9707-aa0ad7ee7286" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_98f72c7d-30c8-4e25-a685-3570008cad68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_a3e62def-22b6-4d8f-aaa7-52437a19c6a5" xlink:href="biib-20240630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_cb678249-ead2-46c1-9707-aa0ad7ee7286" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_a3e62def-22b6-4d8f-aaa7-52437a19c6a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b41b05b-cc6e-48a5-8fa9-f5e287e9529a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f43af9a1-5fb5-44bd-ba8a-c421a992bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b41b05b-cc6e-48a5-8fa9-f5e287e9529a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f43af9a1-5fb5-44bd-ba8a-c421a992bf2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5599d1c2-b0ea-42f6-8ac5-157ff40f601f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b41b05b-cc6e-48a5-8fa9-f5e287e9529a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5599d1c2-b0ea-42f6-8ac5-157ff40f601f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d692e3f7-626b-4256-88f3-8587cb006dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b41b05b-cc6e-48a5-8fa9-f5e287e9529a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d692e3f7-626b-4256-88f3-8587cb006dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_74a9be38-7d8a-40b2-a3f5-4366cba68b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b41b05b-cc6e-48a5-8fa9-f5e287e9529a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_74a9be38-7d8a-40b2-a3f5-4366cba68b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_de7bb97a-990d-4619-9fee-af6f092c30f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b41b05b-cc6e-48a5-8fa9-f5e287e9529a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_de7bb97a-990d-4619-9fee-af6f092c30f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2af742ee-0e0f-4783-97de-79ae7497aa45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b41b05b-cc6e-48a5-8fa9-f5e287e9529a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2af742ee-0e0f-4783-97de-79ae7497aa45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_a13b297e-b55d-441b-804c-9a8cce18a97a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b41b05b-cc6e-48a5-8fa9-f5e287e9529a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_a13b297e-b55d-441b-804c-9a8cce18a97a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_136f1e98-88a7-45e7-9564-74c152d79730" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0cd92615-8102-4abd-8420-7ea6a013ba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_136f1e98-88a7-45e7-9564-74c152d79730" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0cd92615-8102-4abd-8420-7ea6a013ba0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e4b6c6ed-ed1d-4b1a-afa6-677256fa250c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_136f1e98-88a7-45e7-9564-74c152d79730" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e4b6c6ed-ed1d-4b1a-afa6-677256fa250c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>biib-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a009166-a1cb-4c50-83a7-d8b5a99052fa,g:b0d9c5b1-5cff-4c82-aab8-c75b5958a97b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_63643870-cf51-44d9-96b3-a8454ab030c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_StatementTable_63643870-cf51-44d9-96b3-a8454ab030c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29e2e546-c976-47e1-b4a5-c40718ff7f1b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_63643870-cf51-44d9-96b3-a8454ab030c4" xlink:to="loc_srt_ProductOrServiceAxis_29e2e546-c976-47e1-b4a5-c40718ff7f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29e2e546-c976-47e1-b4a5-c40718ff7f1b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_29e2e546-c976-47e1-b4a5-c40718ff7f1b" xlink:to="loc_srt_ProductsAndServicesDomain_29e2e546-c976-47e1-b4a5-c40718ff7f1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_29e2e546-c976-47e1-b4a5-c40718ff7f1b" xlink:to="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9e16fb94-1aee-4bdb-840a-f28b48617e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:to="loc_us-gaap_ProductMember_9e16fb94-1aee-4bdb-840a-f28b48617e6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_26e895ad-e0ef-4036-81c4-40e1e3f243b7" xlink:href="biib-20240630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_26e895ad-e0ef-4036-81c4-40e1e3f243b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_31475113-c010-4e9a-ace1-c8193f978611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_31475113-c010-4e9a-ace1-c8193f978611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a253119f-4903-4819-b968-d98a3ef137b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_Revenues_a253119f-4903-4819-b968-d98a3ef137b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9dfab1b7-17b0-41f2-a2c3-5838ed8d5771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9dfab1b7-17b0-41f2-a2c3-5838ed8d5771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3e944d24-dd2c-4dc3-8d29-4909d8768e03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3e944d24-dd2c-4dc3-8d29-4909d8768e03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b423cd16-ff1b-4b87-804c-6ae363c107fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b423cd16-ff1b-4b87-804c-6ae363c107fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_1a1cb782-656f-4661-947e-6b97fe919539" xlink:href="biib-20240630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_1a1cb782-656f-4661-947e-6b97fe919539" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_bc017be6-b3ab-48d5-ad10-7711d1c5a58c" xlink:href="biib-20240630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_biib_Collaborationprofitlosssharing_bc017be6-b3ab-48d5-ad10-7711d1c5a58c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1eadff86-1b0d-45d5-bd21-69746ef947e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_RestructuringCharges_1eadff86-1b0d-45d5-bd21-69746ef947e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_16e4bc10-a4f4-47d3-8558-b6657ac8f9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_16e4bc10-a4f4-47d3-8558-b6657ac8f9c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2907d3cc-094b-4111-bfb9-02e35d71de24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2907d3cc-094b-4111-bfb9-02e35d71de24" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1da77d4b-4fe0-426a-bae7-f736a165a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_CostsAndExpenses_1da77d4b-4fe0-426a-bae7-f736a165a0a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d74a3f0-2d10-47bf-b3c7-1df9443f2101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d74a3f0-2d10-47bf-b3c7-1df9443f2101" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3b2187e6-aafe-45ad-b5d7-f8eec018b972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3b2187e6-aafe-45ad-b5d7-f8eec018b972" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_98237283-389e-453e-8ec5-59d185847655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_ProfitLoss_98237283-389e-453e-8ec5-59d185847655" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c0c94594-1abc-45e9-ae4c-a575479c75d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c0c94594-1abc-45e9-ae4c-a575479c75d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f18c4947-922e-410b-b720-b52a0ddee4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_NetIncomeLoss_f18c4947-922e-410b-b720-b52a0ddee4c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3e7dd31b-9cd2-45a0-a330-a2a20d20af57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_EarningsPerShareAbstract_3e7dd31b-9cd2-45a0-a330-a2a20d20af57" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_49d3a54a-91c8-4885-90b4-2843d3b2fe16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3e7dd31b-9cd2-45a0-a330-a2a20d20af57" xlink:to="loc_us-gaap_EarningsPerShareBasic_49d3a54a-91c8-4885-90b4-2843d3b2fe16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1f8220d9-7f3c-44f7-968f-c7c5955123a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3e7dd31b-9cd2-45a0-a330-a2a20d20af57" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1f8220d9-7f3c-44f7-968f-c7c5955123a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cf5f0a42-25ce-4fdb-adfa-853f0fc1b685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cf5f0a42-25ce-4fdb-adfa-853f0fc1b685" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a0e066e-5935-41ad-a4ae-9ded91f7d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cf5f0a42-25ce-4fdb-adfa-853f0fc1b685" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a0e066e-5935-41ad-a4ae-9ded91f7d3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7397b5a3-67be-40c2-8677-81ae3539289a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cf5f0a42-25ce-4fdb-adfa-853f0fc1b685" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7397b5a3-67be-40c2-8677-81ae3539289a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7f9faf13-78c3-4366-b443-8983a332dd29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1727db48-2874-4053-b76f-f8900ba5225e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7f9faf13-78c3-4366-b443-8983a332dd29" xlink:to="loc_us-gaap_StatementTable_1727db48-2874-4053-b76f-f8900ba5225e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d18aa5db-cb65-4a58-a3f3-437d52570abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1727db48-2874-4053-b76f-f8900ba5225e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d18aa5db-cb65-4a58-a3f3-437d52570abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d18aa5db-cb65-4a58-a3f3-437d52570abb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d18aa5db-cb65-4a58-a3f3-437d52570abb" xlink:to="loc_us-gaap_RelatedPartyDomain_d18aa5db-cb65-4a58-a3f3-437d52570abb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8988395a-916c-4e5e-8c05-9d3a49ef25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d18aa5db-cb65-4a58-a3f3-437d52570abb" xlink:to="loc_us-gaap_RelatedPartyDomain_8988395a-916c-4e5e-8c05-9d3a49ef25ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_47cdcad2-c35a-4109-81b7-8b1c92b52920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8988395a-916c-4e5e-8c05-9d3a49ef25ac" xlink:to="loc_us-gaap_NonrelatedPartyMember_47cdcad2-c35a-4109-81b7-8b1c92b52920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_867aac4f-f548-487c-b2a2-79958d4aaca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8988395a-916c-4e5e-8c05-9d3a49ef25ac" xlink:to="loc_us-gaap_RelatedPartyMember_867aac4f-f548-487c-b2a2-79958d4aaca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f9faf13-78c3-4366-b443-8983a332dd29" xlink:to="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8b12f70-3fe8-4385-8b14-78acf4a2bab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8b12f70-3fe8-4385-8b14-78acf4a2bab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fd3c8cde-72b5-45d1-9f4e-7a68f9d7385c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fd3c8cde-72b5-45d1-9f4e-7a68f9d7385c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ddd5ab6d-0364-40ac-bab3-8ba018c781a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_InventoryNet_ddd5ab6d-0364-40ac-bab3-8ba018c781a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f7bd38f0-cc94-4621-a732-1aae1d77978e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_OtherAssetsCurrent_f7bd38f0-cc94-4621-a732-1aae1d77978e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_647c2b6c-4e27-44de-84cd-606ae98cb0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_AssetsCurrent_647c2b6c-4e27-44de-84cd-606ae98cb0e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_440b3c25-b1fc-45a5-9285-962252b58603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_440b3c25-b1fc-45a5-9285-962252b58603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ef7d333-6ca5-4c8e-a6dc-64ca3731f60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ef7d333-6ca5-4c8e-a6dc-64ca3731f60c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c36abf9d-b69c-4d4b-9c99-858bb010e129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c36abf9d-b69c-4d4b-9c99-858bb010e129" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_384cd340-586b-46ac-b94d-e53e5dfdf32d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_Goodwill_384cd340-586b-46ac-b94d-e53e5dfdf32d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_64b4f283-4edd-4f68-b611-ccb6630a740c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_64b4f283-4edd-4f68-b611-ccb6630a740c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_85fe3987-389e-4c0c-a380-a2529f3b783e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_85fe3987-389e-4c0c-a380-a2529f3b783e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_790f4e08-0823-4395-a459-f18be613b451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_Assets_790f4e08-0823-4395-a459-f18be613b451" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f9faf13-78c3-4366-b443-8983a332dd29" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_85cc6cf9-c8e2-42d2-a64a-1be376215878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_NotesPayableCurrent_85cc6cf9-c8e2-42d2-a64a-1be376215878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_4a2135d3-b68a-4fc6-bb18-7a9fb5248af2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_TaxesPayableCurrent_4a2135d3-b68a-4fc6-bb18-7a9fb5248af2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_db05bc38-90a3-4357-b24a-c1385704dac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_AccountsPayableCurrent_db05bc38-90a3-4357-b24a-c1385704dac4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a71b6387-995e-4175-99b3-0492f2835c93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a71b6387-995e-4175-99b3-0492f2835c93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f730c24a-1dea-45e5-9b31-bae663c3c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_LiabilitiesCurrent_f730c24a-1dea-45e5-9b31-bae663c3c7d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_89950d71-6c49-485d-887e-d93ed11068a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_LongTermDebt_89950d71-6c49-485d-887e-d93ed11068a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a0352039-a5d0-4535-8405-a21686f76de4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a0352039-a5d0-4535-8405-a21686f76de4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf39b496-1a50-40e9-a629-ad77e1b482a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf39b496-1a50-40e9-a629-ad77e1b482a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8babe843-6690-4e6f-9661-30560bbd5c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8babe843-6690-4e6f-9661-30560bbd5c50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9905b405-c6cd-4e37-a106-d88cf859b29c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_Liabilities_9905b405-c6cd-4e37-a106-d88cf859b29c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_781a3933-cdcc-4905-8cd8-0f4a3cbd252a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_CommitmentsAndContingencies_781a3933-cdcc-4905-8cd8-0f4a3cbd252a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66a04ba0-c2fe-497e-8884-bbd9c963ef59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66a04ba0-c2fe-497e-8884-bbd9c963ef59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66a04ba0-c2fe-497e-8884-bbd9c963ef59" xlink:to="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_81e8cd1a-e0af-4636-b135-d817ebc0f4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_PreferredStockValue_81e8cd1a-e0af-4636-b135-d817ebc0f4b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0c6d0a49-559b-40d5-91d1-c1a0eb102de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_CommonStockValue_0c6d0a49-559b-40d5-91d1-c1a0eb102de2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_71a4a35a-e564-4bc0-9d46-7d29d6083002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_71a4a35a-e564-4bc0-9d46-7d29d6083002" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86bcbe5c-e9fc-4f59-970f-397b2503f1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86bcbe5c-e9fc-4f59-970f-397b2503f1ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac319efa-c0fe-4569-b453-bc076ea818d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac319efa-c0fe-4569-b453-bc076ea818d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_aeebefae-30d2-486c-a91d-e7c62dc09b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_TreasuryStockValue_aeebefae-30d2-486c-a91d-e7c62dc09b11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc2bd8b8-521c-4212-a659-52e176df4c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66a04ba0-c2fe-497e-8884-bbd9c963ef59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc2bd8b8-521c-4212-a659-52e176df4c45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_152adb42-715c-4f04-bc5f-30f79e0b06b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_152adb42-715c-4f04-bc5f-30f79e0b06b2" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7a115a8-1a46-45e3-9d90-d4f5d0ce3288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_StatementTable_f7a115a8-1a46-45e3-9d90-d4f5d0ce3288" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2bece41-c978-4b65-adf4-da687c567f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f7a115a8-1a46-45e3-9d90-d4f5d0ce3288" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2bece41-c978-4b65-adf4-da687c567f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e2bece41-c978-4b65-adf4-da687c567f5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2bece41-c978-4b65-adf4-da687c567f5e" xlink:to="loc_us-gaap_RelatedPartyDomain_e2bece41-c978-4b65-adf4-da687c567f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_25351c20-df1e-42db-8f4d-ce8ff5308cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2bece41-c978-4b65-adf4-da687c567f5e" xlink:to="loc_us-gaap_RelatedPartyDomain_25351c20-df1e-42db-8f4d-ce8ff5308cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_a57b2f3e-e6f6-47da-9804-b45c8ba6c766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_25351c20-df1e-42db-8f4d-ce8ff5308cb1" xlink:to="loc_us-gaap_NonrelatedPartyMember_a57b2f3e-e6f6-47da-9804-b45c8ba6c766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_7b879909-d5b0-4d36-a5d3-ae1588c40edb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_25351c20-df1e-42db-8f4d-ce8ff5308cb1" xlink:to="loc_us-gaap_RelatedPartyMember_7b879909-d5b0-4d36-a5d3-ae1588c40edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_861d0b9f-2620-4696-9c50-37d0c118a3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_861d0b9f-2620-4696-9c50-37d0c118a3a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b202fb84-1e08-4425-8249-1dd7e1f7e16c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_861d0b9f-2620-4696-9c50-37d0c118a3a9" xlink:to="loc_us-gaap_ProfitLoss_b202fb84-1e08-4425-8249-1dd7e1f7e16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_861d0b9f-2620-4696-9c50-37d0c118a3a9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8a060cb4-fb65-4f96-bf65-ff3a6c89cc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8a060cb4-fb65-4f96-bf65-ff3a6c89cc9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b9aa5d1b-05a2-4cd0-9eb3-7c297b51e1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_InventoryWriteDown_b9aa5d1b-05a2-4cd0-9eb3-7c297b51e1f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_bf71ebcf-bccf-47d1-b1fe-ec438cd51395" xlink:href="biib-20240630.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_biib_AmortizationOfInventoryStepUp_bf71ebcf-bccf-47d1-b1fe-ec438cd51395" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_340dac82-7a7a-4ee7-97ad-daef55b5bf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_ShareBasedCompensation_340dac82-7a7a-4ee7-97ad-daef55b5bf8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a4d5fe0-afc1-407e-b825-3b44ec3f31a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a4d5fe0-afc1-407e-b825-3b44ec3f31a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_6627a795-d7e8-4192-b822-f20876713d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_6627a795-d7e8-4192-b822-f20876713d6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_20563ad3-7421-4278-afdc-7ae4a4726bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_20563ad3-7421-4278-afdc-7ae4a4726bf4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a28ecf94-367a-412c-957c-dd21d4c017ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a28ecf94-367a-412c-957c-dd21d4c017ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f292414a-0dba-497c-8f36-c240ae201185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f292414a-0dba-497c-8f36-c240ae201185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fef8c234-46f7-4bec-a305-374402700d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fef8c234-46f7-4bec-a305-374402700d98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0dcd45e6-e102-4628-a09a-8eceab6e5fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0dcd45e6-e102-4628-a09a-8eceab6e5fb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0a9627bc-88d9-4a1f-bfaf-e1c5cad0c8be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0a9627bc-88d9-4a1f-bfaf-e1c5cad0c8be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6f7f2e3f-e7a0-4bc7-b556-52d0a636e1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6f7f2e3f-e7a0-4bc7-b556-52d0a636e1b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97258c5b-aec2-4526-9c7e-b2a687ef1ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97258c5b-aec2-4526-9c7e-b2a687ef1ccd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a88fc3d9-104d-46a1-9b5d-89c01b2fdfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a88fc3d9-104d-46a1-9b5d-89c01b2fdfe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1c2060d7-6cc0-4f8c-9458-e36cc2175930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1c2060d7-6cc0-4f8c-9458-e36cc2175930" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3e6079cf-86f0-4bce-af8e-2b1156879c05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3e6079cf-86f0-4bce-af8e-2b1156879c05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_943f517e-7f67-41d9-82ef-5ea2c02aab22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_943f517e-7f67-41d9-82ef-5ea2c02aab22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d4f41f68-e7c8-4540-ac0b-92dea4fca076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d4f41f68-e7c8-4540-ac0b-92dea4fca076" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a684f23d-5418-4503-b4b6-796b3caf3676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a684f23d-5418-4503-b4b6-796b3caf3676" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_1093de43-e4c6-42a5-831f-245aa11002a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_1093de43-e4c6-42a5-831f-245aa11002a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_09245e1b-78f9-492c-9ee2-05b481bd10f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_09245e1b-78f9-492c-9ee2-05b481bd10f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5753dc5-bfa3-40df-8f6c-be71265879d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5753dc5-bfa3-40df-8f6c-be71265879d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d47f5930-9e77-490c-a075-a09dd60bb60a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d47f5930-9e77-490c-a075-a09dd60bb60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7bdb09cc-f230-4efb-a96c-716ba1b37eec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7bdb09cc-f230-4efb-a96c-716ba1b37eec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_3de9893a-2b35-4b82-ad41-858b00de9ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_3de9893a-2b35-4b82-ad41-858b00de9ab9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2115476b-0500-45bf-896c-add88888ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2115476b-0500-45bf-896c-add88888ac5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e0526e57-2929-4c09-8923-d936024d21de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e0526e57-2929-4c09-8923-d936024d21de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5382817b-78d7-4500-a09a-794684977e69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5382817b-78d7-4500-a09a-794684977e69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_603a0204-d02f-477e-bb31-ea09420855f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_603a0204-d02f-477e-bb31-ea09420855f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e764437a-99ea-4b83-8dc9-0f5ef294b044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e764437a-99ea-4b83-8dc9-0f5ef294b044" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c2a987f-9d0b-4b4c-9228-fcc11b64f894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d16a90e-7fcd-43a4-a5c5-b8279f4137ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StatementTable_8d16a90e-7fcd-43a4-a5c5-b8279f4137ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8d16a90e-7fcd-43a4-a5c5-b8279f4137ed" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc" xlink:to="loc_us-gaap_EquityComponentDomain_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc" xlink:to="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1b2ac6b5-2167-4ab1-aea5-77e063a488d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_PreferredStockMember_1b2ac6b5-2167-4ab1-aea5-77e063a488d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89162a4f-b1cc-44b5-ad85-e4bb56cefc86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_CommonStockMember_89162a4f-b1cc-44b5-ad85-e4bb56cefc86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_07085798-16c6-446b-853f-fda52795b4be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_07085798-16c6-446b-853f-fda52795b4be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1cdba126-a217-480e-8b8a-f3aabcec8248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1cdba126-a217-480e-8b8a-f3aabcec8248" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dd174f21-abd7-4cf1-b7c4-a124ab620ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_RetainedEarningsMember_dd174f21-abd7-4cf1-b7c4-a124ab620ad5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_930d3bec-6273-4f33-8a7a-c1edacae5255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_930d3bec-6273-4f33-8a7a-c1edacae5255" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_469bf20c-3043-481d-ac50-08bdadb2209b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_ParentMember_469bf20c-3043-481d-ac50-08bdadb2209b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e2d71f75-bcf0-4e2e-b375-e4055464dfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e2d71f75-bcf0-4e2e-b375-e4055464dfbe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2607b003-a9f6-4c57-9f95-68fcf2143d19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2607b003-a9f6-4c57-9f95-68fcf2143d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d0f8263-f2bf-4ff5-82be-107aa1146186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d0f8263-f2bf-4ff5-82be-107aa1146186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_487a46d4-9d88-4dd7-8ea4-0984615e6265" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_487a46d4-9d88-4dd7-8ea4-0984615e6265" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4883f4d6-a858-4ab4-853c-5482ed7c603a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_ProfitLoss_4883f4d6-a858-4ab4-853c-5482ed7c603a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1c13273f-6091-478c-a3ee-38dcde9a97f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1c13273f-6091-478c-a3ee-38dcde9a97f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_690d6104-3140-43dd-b123-a61c6c9fb079" xlink:href="biib-20240630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_690d6104-3140-43dd-b123-a61c6c9fb079" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c47f550e-f994-43b9-9380-bf3496a1079e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c47f550e-f994-43b9-9380-bf3496a1079e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_ef1652ad-3675-4a68-9e84-871b330bd686" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_ef1652ad-3675-4a68-9e84-871b330bd686" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf56648b-85cd-4e7e-bb09-44c1b5d8d957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf56648b-85cd-4e7e-bb09-44c1b5d8d957" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_40532459-ef55-4955-ac9d-ffe207a5fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_40532459-ef55-4955-ac9d-ffe207a5fdc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2b53c6a-615c-4461-a29b-182cddb99169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2b53c6a-615c-4461-a29b-182cddb99169" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_d0ac2b50-9477-4bbb-b23e-5801f0aa203e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockholdersEquityOther_d0ac2b50-9477-4bbb-b23e-5801f0aa203e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_12a38a33-5648-4f38-859e-631ccdd7b6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_47d16602-2e7b-419c-b322-0862057f3036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a994a01c-0c62-4ce5-8832-ca5e4a098734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6890d5d1-4d30-4fe8-97a7-10f310984412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6890d5d1-4d30-4fe8-97a7-10f310984412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6890d5d1-4d30-4fe8-97a7-10f310984412_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6890d5d1-4d30-4fe8-97a7-10f310984412" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6890d5d1-4d30-4fe8-97a7-10f310984412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc5ac492-710e-428e-907c-f3c736e6f8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6890d5d1-4d30-4fe8-97a7-10f310984412" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc5ac492-710e-428e-907c-f3c736e6f8c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_9e01eb75-c06d-4f21-8ca1-a9b6fa54c303" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc5ac492-710e-428e-907c-f3c736e6f8c7" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_9e01eb75-c06d-4f21-8ca1-a9b6fa54c303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_acaa0459-2594-4dd0-af20-b72358571fe3" xlink:href="biib-20240630.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc5ac492-710e-428e-907c-f3c736e6f8c7" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_acaa0459-2594-4dd0-af20-b72358571fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2345984a-1021-41c5-af77-c67559df3978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2345984a-1021-41c5-af77-c67559df3978" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2345984a-1021-41c5-af77-c67559df3978_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2345984a-1021-41c5-af77-c67559df3978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2345984a-1021-41c5-af77-c67559df3978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2345984a-1021-41c5-af77-c67559df3978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_65e26f0f-6fc9-47e9-880d-56fa3f01c564" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:to="loc_biib_SKYCLARYSMember_65e26f0f-6fc9-47e9-880d-56fa3f01c564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_aff030cb-6847-4cc7-ace7-cd4c29c64ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_aff030cb-6847-4cc7-ace7-cd4c29c64ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_2f46771e-d986-4a9d-8587-6b054fb04cd7" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:to="loc_biib_PriorityReviewVoucherMember_2f46771e-d986-4a9d-8587-6b054fb04cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_6aecb9d2-2564-41cd-82de-3f81f5490312" xlink:href="biib-20240630.xsd#biib_OtherClinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:to="loc_biib_OtherClinicalProgramsMember_6aecb9d2-2564-41cd-82de-3f81f5490312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d82ba74-926e-46f4-b568-6e6fc7dad9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d82ba74-926e-46f4-b568-6e6fc7dad9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3ae73974-e4a9-4127-924b-574c96d1f299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d82ba74-926e-46f4-b568-6e6fc7dad9e3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3ae73974-e4a9-4127-924b-574c96d1f299" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_838db120-4d78-462a-ac15-efaab6c5d54f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_srt_StatementScenarioAxis_838db120-4d78-462a-ac15-efaab6c5d54f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_838db120-4d78-462a-ac15-efaab6c5d54f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_838db120-4d78-462a-ac15-efaab6c5d54f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_838db120-4d78-462a-ac15-efaab6c5d54f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_aa57a7e8-ad4a-43fb-ba2c-24b1cce01b6b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_838db120-4d78-462a-ac15-efaab6c5d54f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_aa57a7e8-ad4a-43fb-ba2c-24b1cce01b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3198bfeb-1113-4e76-bf44-30b6b120057b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_aa57a7e8-ad4a-43fb-ba2c-24b1cce01b6b" xlink:to="loc_srt_ScenarioForecastMember_3198bfeb-1113-4e76-bf44-30b6b120057b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a1715487-b9a1-4cd7-8dcc-11048af01107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_CreditFacilityAxis_a1715487-b9a1-4cd7-8dcc-11048af01107" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a1715487-b9a1-4cd7-8dcc-11048af01107_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a1715487-b9a1-4cd7-8dcc-11048af01107" xlink:to="loc_us-gaap_CreditFacilityDomain_a1715487-b9a1-4cd7-8dcc-11048af01107_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a74a577a-b87d-4a06-b5aa-28c656cbc5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a1715487-b9a1-4cd7-8dcc-11048af01107" xlink:to="loc_us-gaap_CreditFacilityDomain_a74a577a-b87d-4a06-b5aa-28c656cbc5d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e53a3431-4e71-48ad-82c5-a83ff87a42f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a74a577a-b87d-4a06-b5aa-28c656cbc5d1" xlink:to="loc_us-gaap_SecuredDebtMember_e53a3431-4e71-48ad-82c5-a83ff87a42f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7d03b119-54ab-433b-8ec4-e95ed03a525a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_DebtInstrumentAxis_7d03b119-54ab-433b-8ec4-e95ed03a525a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d03b119-54ab-433b-8ec4-e95ed03a525a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d03b119-54ab-433b-8ec4-e95ed03a525a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d03b119-54ab-433b-8ec4-e95ed03a525a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c2584a1-f288-4205-84a1-1b7174c7a8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d03b119-54ab-433b-8ec4-e95ed03a525a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c2584a1-f288-4205-84a1-1b7174c7a8b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_6a041304-55f9-46c2-a65f-3cbd7d73deed" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c2584a1-f288-4205-84a1-1b7174c7a8b4" xlink:to="loc_biib_TheCreditFacilityMember_6a041304-55f9-46c2-a65f-3cbd7d73deed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5d9ca805-18be-4035-8e54-90410b793528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5d9ca805-18be-4035-8e54-90410b793528" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5d9ca805-18be-4035-8e54-90410b793528_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d9ca805-18be-4035-8e54-90410b793528" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5d9ca805-18be-4035-8e54-90410b793528_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1068daf-6e5b-4948-a217-5af61326da9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d9ca805-18be-4035-8e54-90410b793528" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1068daf-6e5b-4948-a217-5af61326da9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_985a0313-12b0-44df-bf9c-c1abc1ab76bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1068daf-6e5b-4948-a217-5af61326da9e" xlink:to="loc_us-gaap_LineOfCreditMember_985a0313-12b0-44df-bf9c-c1abc1ab76bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_426adf51-409a-4577-9434-2d4f2f34e784" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_srt_ProductOrServiceAxis_426adf51-409a-4577-9434-2d4f2f34e784" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_426adf51-409a-4577-9434-2d4f2f34e784_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_426adf51-409a-4577-9434-2d4f2f34e784" xlink:to="loc_srt_ProductsAndServicesDomain_426adf51-409a-4577-9434-2d4f2f34e784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_142de6fa-7861-40b4-a9c8-378219f75701" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_426adf51-409a-4577-9434-2d4f2f34e784" xlink:to="loc_srt_ProductsAndServicesDomain_142de6fa-7861-40b4-a9c8-378219f75701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember_139e571d-8e15-4b39-ac31-480baac29f79" xlink:href="biib-20240630.xsd#biib_ClinicalInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_142de6fa-7861-40b4-a9c8-378219f75701" xlink:to="loc_biib_ClinicalInventoryMember_139e571d-8e15-4b39-ac31-480baac29f79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_794e48a1-5b69-4187-a2a7-f4bc820f256f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_794e48a1-5b69-4187-a2a7-f4bc820f256f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_794e48a1-5b69-4187-a2a7-f4bc820f256f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_794e48a1-5b69-4187-a2a7-f4bc820f256f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_794e48a1-5b69-4187-a2a7-f4bc820f256f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69f1f588-bde8-43c0-b7f7-828d7cae7bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_794e48a1-5b69-4187-a2a7-f4bc820f256f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69f1f588-bde8-43c0-b7f7-828d7cae7bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_57b7a98a-85b0-40c8-8f80-e002c75fdf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_69f1f588-bde8-43c0-b7f7-828d7cae7bc5" xlink:to="loc_us-gaap_SubsequentEventMember_57b7a98a-85b0-40c8-8f80-e002c75fdf6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_65045850-af46-4f13-8028-004f1f8ba70c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_65045850-af46-4f13-8028-004f1f8ba70c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_65045850-af46-4f13-8028-004f1f8ba70c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_65045850-af46-4f13-8028-004f1f8ba70c" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_65045850-af46-4f13-8028-004f1f8ba70c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_97aa8010-da86-468a-9e59-dd4a99927db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_65045850-af46-4f13-8028-004f1f8ba70c" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_97aa8010-da86-468a-9e59-dd4a99927db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_100c8d6b-1000-43f9-a9d2-67bfcb59ed1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_97aa8010-da86-468a-9e59-dd4a99927db7" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_100c8d6b-1000-43f9-a9d2-67bfcb59ed1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_17e39b1a-decb-4253-884c-eaaefcd24584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_17e39b1a-decb-4253-884c-eaaefcd24584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2db1fd8f-d010-4b42-af22-cbace89fdbee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2db1fd8f-d010-4b42-af22-cbace89fdbee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_231684a9-37ed-4266-8e4a-6c3fa79839dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_231684a9-37ed-4266-8e4a-6c3fa79839dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4080a6ad-a4d6-47fe-9b49-0c62f8f64dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4080a6ad-a4d6-47fe-9b49-0c62f8f64dae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_44fb6d1c-6833-41f0-a6c3-b82209dc0960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_44fb6d1c-6833-41f0-a6c3-b82209dc0960" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3083cd54-f31e-4984-9390-70c83c55db4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3083cd54-f31e-4984-9390-70c83c55db4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_142a565e-5c25-49fd-aa7c-066295d29ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_OperatingExpenses_142a565e-5c25-49fd-aa7c-066295d29ddc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_db34c3a0-1abc-48b1-8c45-bc95f8b4e837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_db34c3a0-1abc-48b1-8c45-bc95f8b4e837" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_92af1d32-3c81-4928-a440-dc656ef1ff9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_92af1d32-3c81-4928-a440-dc656ef1ff9a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_eace3d85-597d-46e2-9492-ee7ba6fbd996" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_eace3d85-597d-46e2-9492-ee7ba6fbd996" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_96aeb541-e103-45b5-adda-dc105255344b" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_96aeb541-e103-45b5-adda-dc105255344b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c60a6210-6455-45e9-a1a4-b397e2cc4e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c60a6210-6455-45e9-a1a4-b397e2cc4e6d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_ca3a0216-84b9-48aa-96f4-e86f776b499b" xlink:href="biib-20240630.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_OperatingLeaseArea_ca3a0216-84b9-48aa-96f4-e86f776b499b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_192ec17c-c01a-408c-9d45-481619539c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_192ec17c-c01a-408c-9d45-481619539c49" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_7ba8c196-a435-4f08-8caf-a2d3930a1010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_7ba8c196-a435-4f08-8caf-a2d3930a1010" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_9f79a818-a384-48ff-822c-f303bcb0e013" xlink:href="biib-20240630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_9f79a818-a384-48ff-822c-f303bcb0e013" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2c218dec-289a-404c-85ae-d56ef62a90f2" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2c218dec-289a-404c-85ae-d56ef62a90f2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b999c355-4408-4e24-84e3-2258e8c43bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_Goodwill_b999c355-4408-4e24-84e3-2258e8c43bc8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_363c7bed-9184-4bec-8c71-30cade2eef4c" xlink:href="biib-20240630.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_363c7bed-9184-4bec-8c71-30cade2eef4c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_2f0b161b-e7fa-48b6-86f5-7e5f74847c72" xlink:href="biib-20240630.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_2f0b161b-e7fa-48b6-86f5-7e5f74847c72" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8b6bf558-36e5-44aa-9cb5-0b713bdf1c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8b6bf558-36e5-44aa-9cb5-0b713bdf1c0b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9c3f75c5-37bb-4a8f-a512-851c87667b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_ProfitLoss_9c3f75c5-37bb-4a8f-a512-851c87667b7a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7464c030-ba70-423d-9a27-119c528bb59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7464c030-ba70-423d-9a27-119c528bb59c" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_446fb6a0-7a7e-48e4-b21c-70c5e26947eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_446fb6a0-7a7e-48e4-b21c-70c5e26947eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c9b4ee9f-97c7-44df-b249-a3a450d7c85a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_446fb6a0-7a7e-48e4-b21c-70c5e26947eb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c9b4ee9f-97c7-44df-b249-a3a450d7c85a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b4ee9f-97c7-44df-b249-a3a450d7c85a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9b4ee9f-97c7-44df-b249-a3a450d7c85a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b4ee9f-97c7-44df-b249-a3a450d7c85a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e518689-4405-4b94-8f74-5a8deccefdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9b4ee9f-97c7-44df-b249-a3a450d7c85a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e518689-4405-4b94-8f74-5a8deccefdb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_0e18fe66-3ac1-4093-b843-d3212537308b" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e518689-4405-4b94-8f74-5a8deccefdb1" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_0e18fe66-3ac1-4093-b843-d3212537308b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_305a3e8d-431e-4b18-b46b-24844591d62e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_305a3e8d-431e-4b18-b46b-24844591d62e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_29c91fc8-f7b4-4d80-8879-5b180480a906" xlink:href="biib-20240630.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_29c91fc8-f7b4-4d80-8879-5b180480a906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_232cfd16-40cf-4d9c-bfb1-5b4c6cc703f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_232cfd16-40cf-4d9c-bfb1-5b4c6cc703f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_ba422091-eaaa-4b18-8c8f-269d23aa4938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_ba422091-eaaa-4b18-8c8f-269d23aa4938" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_18c110a0-2ee6-403b-b513-78dda5fb6ad9" xlink:href="biib-20240630.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_18c110a0-2ee6-403b-b513-78dda5fb6ad9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_da429919-3716-41ca-8565-9153ecc44c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_da429919-3716-41ca-8565-9153ecc44c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da429919-3716-41ca-8565-9153ecc44c02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da429919-3716-41ca-8565-9153ecc44c02" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da429919-3716-41ca-8565-9153ecc44c02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64e397e9-cd18-48c1-a459-ad6a31cd82f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da429919-3716-41ca-8565-9153ecc44c02" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64e397e9-cd18-48c1-a459-ad6a31cd82f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_00730652-24bf-49ee-8966-69009026fdcc" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64e397e9-cd18-48c1-a459-ad6a31cd82f8" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_00730652-24bf-49ee-8966-69009026fdcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e6ba1c6-d300-41de-a328-ebd06b9440b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e6ba1c6-d300-41de-a328-ebd06b9440b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6ba1c6-d300-41de-a328-ebd06b9440b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e6ba1c6-d300-41de-a328-ebd06b9440b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6ba1c6-d300-41de-a328-ebd06b9440b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e6ba1c6-d300-41de-a328-ebd06b9440b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_4c7edeb2-3592-4237-a936-6490f593d2a9" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:to="loc_biib_SKYCLARYSMember_4c7edeb2-3592-4237-a936-6490f593d2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_339114e0-e5ed-4013-937f-3bd1dc73ac93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_339114e0-e5ed-4013-937f-3bd1dc73ac93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_3f96099a-977a-45df-8504-f5ded71faf3d" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:to="loc_biib_PriorityReviewVoucherMember_3f96099a-977a-45df-8504-f5ded71faf3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_98f80578-b89a-4270-9ae9-1344d3fea941" xlink:href="biib-20240630.xsd#biib_OtherClinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:to="loc_biib_OtherClinicalProgramsMember_98f80578-b89a-4270-9ae9-1344d3fea941" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a2a36280-3f37-4159-a324-79de0ecd6ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a2a36280-3f37-4159-a324-79de0ecd6ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_119cbb02-2e74-403c-a754-788eb615e7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_119cbb02-2e74-403c-a754-788eb615e7aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3cf4d04e-1bcf-4164-a466-bbd7717f2be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3cf4d04e-1bcf-4164-a466-bbd7717f2be4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8cf4f8be-b7c9-4ed3-ac4a-2fd03361241f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8cf4f8be-b7c9-4ed3-ac4a-2fd03361241f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_cf5004ed-8c89-4145-a898-1011ea468a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_cf5004ed-8c89-4145-a898-1011ea468a16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_1e5d2c89-8a4a-4337-a136-072d96292bfa" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_1e5d2c89-8a4a-4337-a136-072d96292bfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_ef024344-2db8-4e5c-a9b0-2871da7802f6" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_ef024344-2db8-4e5c-a9b0-2871da7802f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_090fdf6e-9214-4d58-834d-d1950c8f28c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_090fdf6e-9214-4d58-834d-d1950c8f28c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_cc46297f-2eed-4f9b-a8e3-c1e86866e9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_cc46297f-2eed-4f9b-a8e3-c1e86866e9ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c521b9ff-e616-47bd-9f79-9ff17942ae66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c521b9ff-e616-47bd-9f79-9ff17942ae66" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_f1c8effb-f55b-423a-a25c-c989cdfe8b91" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_f1c8effb-f55b-423a-a25c-c989cdfe8b91" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_3543b972-b3a5-4be3-97c9-94f14eb57681" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_3543b972-b3a5-4be3-97c9-94f14eb57681" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3c6637e2-ca4a-400a-a20a-2df72a0ca98a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3c6637e2-ca4a-400a-a20a-2df72a0ca98a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e6a8c683-96d1-4b0c-9a52-a22aa23ce09f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_Goodwill_e6a8c683-96d1-4b0c-9a52-a22aa23ce09f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5ff6dc06-a767-4b45-a3c0-a1e1d4b68c54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5ff6dc06-a767-4b45-a3c0-a1e1d4b68c54" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_29d494e3-5864-41ab-ba64-ccd2e2d6c269" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_29d494e3-5864-41ab-ba64-ccd2e2d6c269" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_5c85468f-4937-4e03-a9f3-1a0c45f7dd52" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_5c85468f-4937-4e03-a9f3-1a0c45f7dd52" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_0b5f7c35-38d3-4d52-816b-6cf4502a2db7" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_0b5f7c35-38d3-4d52-816b-6cf4502a2db7" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#DispositionsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_272d2d8f-a1e6-464e-a88a-b8e2c1483416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_us-gaap_TypeOfArrangementAxis_272d2d8f-a1e6-464e-a88a-b8e2c1483416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_272d2d8f-a1e6-464e-a88a-b8e2c1483416_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_272d2d8f-a1e6-464e-a88a-b8e2c1483416" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_272d2d8f-a1e6-464e-a88a-b8e2c1483416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7c22fc4-3ff9-4392-b75b-6f51cec1601a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_272d2d8f-a1e6-464e-a88a-b8e2c1483416" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7c22fc4-3ff9-4392-b75b-6f51cec1601a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_4a020fb9-6026-4b4b-acd9-5c8821b94984" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7c22fc4-3ff9-4392-b75b-6f51cec1601a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_4a020fb9-6026-4b4b-acd9-5c8821b94984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36cb7a60-4416-4a7a-b650-1b949fc794e4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36cb7a60-4416-4a7a-b650-1b949fc794e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_36cb7a60-4416-4a7a-b650-1b949fc794e4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36cb7a60-4416-4a7a-b650-1b949fc794e4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_36cb7a60-4416-4a7a-b650-1b949fc794e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c9ff349a-f75e-4bdf-ac2b-c580df16d073" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36cb7a60-4416-4a7a-b650-1b949fc794e4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c9ff349a-f75e-4bdf-ac2b-c580df16d073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5fc194ba-8d54-4490-9c06-812d33550a19" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9ff349a-f75e-4bdf-ac2b-c580df16d073" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5fc194ba-8d54-4490-9c06-812d33550a19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82" xlink:href="biib-20240630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82_default" xlink:href="biib-20240630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_7752923c-a0aa-4b70-a6d6-201c8844f338" xlink:href="biib-20240630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_7752923c-a0aa-4b70-a6d6-201c8844f338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_0104add0-1b58-4a3b-865c-255163a2192e" xlink:href="biib-20240630.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_7752923c-a0aa-4b70-a6d6-201c8844f338" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_0104add0-1b58-4a3b-865c-255163a2192e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_e3442064-31bc-4f3d-8d09-1c2248d92e6a" xlink:href="biib-20240630.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_7752923c-a0aa-4b70-a6d6-201c8844f338" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_e3442064-31bc-4f3d-8d09-1c2248d92e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dd9827b4-4175-4851-9ccd-bf74ee15b45e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_srt_CounterpartyNameAxis_dd9827b4-4175-4851-9ccd-bf74ee15b45e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd9827b4-4175-4851-9ccd-bf74ee15b45e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_dd9827b4-4175-4851-9ccd-bf74ee15b45e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd9827b4-4175-4851-9ccd-bf74ee15b45e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7e742f4-9dc9-448c-899f-122b4997c085" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_dd9827b4-4175-4851-9ccd-bf74ee15b45e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7e742f4-9dc9-448c-899f-122b4997c085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_fcbee49f-19ec-4a4c-a862-cd9a5f5db3f0" xlink:href="biib-20240630.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7e742f4-9dc9-448c-899f-122b4997c085" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_fcbee49f-19ec-4a4c-a862-cd9a5f5db3f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f9950cb0-a9cb-4f1c-accd-cb6523ef577a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f9950cb0-a9cb-4f1c-accd-cb6523ef577a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_cc1209ea-f9ab-46d1-8f35-b88643e229c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_cc1209ea-f9ab-46d1-8f35-b88643e229c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_3ab91561-2a88-4007-a331-7270b166c0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_3ab91561-2a88-4007-a331-7270b166c0cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_ceb1131b-866b-4595-a077-6b09d69649ad" xlink:href="biib-20240630.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_ceb1131b-866b-4595-a077-6b09d69649ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3ddc8878-e546-4f9f-a112-2de80d9e933e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3ddc8878-e546-4f9f-a112-2de80d9e933e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_7b200922-2af1-4566-bed2-fb482ff76eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_7b200922-2af1-4566-bed2-fb482ff76eef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_58f1b9c2-ef18-4e1e-93fe-88d405d32076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_AccountsPayableCurrent_58f1b9c2-ef18-4e1e-93fe-88d405d32076" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_2649b6c2-4d40-4a74-98ed-6ae331537cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_2649b6c2-4d40-4a74-98ed-6ae331537cc9" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_165d7c40-70d5-4cef-bb22-f094c7699843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_165d7c40-70d5-4cef-bb22-f094c7699843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_165d7c40-70d5-4cef-bb22-f094c7699843_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_165d7c40-70d5-4cef-bb22-f094c7699843" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_165d7c40-70d5-4cef-bb22-f094c7699843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_165d7c40-70d5-4cef-bb22-f094c7699843" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cfe1fe92-9164-4633-9ed1-be3993bfc4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cfe1fe92-9164-4633-9ed1-be3993bfc4d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_157e29a9-df89-44e5-9b2e-3f93e6a520ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_157e29a9-df89-44e5-9b2e-3f93e6a520ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_e6ec5c40-7064-4dc1-a6ec-55482d6ae732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:to="loc_us-gaap_RestructuringChargesMember_e6ec5c40-7064-4dc1-a6ec-55482d6ae732" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e6eac045-618b-43a4-806f-8d3bcc25f26f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:to="loc_us-gaap_RestructuringPlanAxis_e6eac045-618b-43a4-806f-8d3bcc25f26f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e6eac045-618b-43a4-806f-8d3bcc25f26f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_e6eac045-618b-43a4-806f-8d3bcc25f26f" xlink:to="loc_us-gaap_RestructuringPlanDomain_e6eac045-618b-43a4-806f-8d3bcc25f26f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_af31e4a9-e666-4de1-b8c3-7abf94f619ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_e6eac045-618b-43a4-806f-8d3bcc25f26f" xlink:to="loc_us-gaap_RestructuringPlanDomain_af31e4a9-e666-4de1-b8c3-7abf94f619ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_007e4038-385c-4eac-aff1-6453f0cb22ab" xlink:href="biib-20240630.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_af31e4a9-e666-4de1-b8c3-7abf94f619ed" xlink:to="loc_biib_A2023CostSavingInitiativesMember_007e4038-385c-4eac-aff1-6453f0cb22ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_023b1d29-5e63-4d1f-9b66-95fa81e84502" xlink:href="biib-20240630.xsd#biib_ReataIntegrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_af31e4a9-e666-4de1-b8c3-7abf94f619ed" xlink:to="loc_biib_ReataIntegrationMember_023b1d29-5e63-4d1f-9b66-95fa81e84502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_3e2ed694-851e-4eb4-abb8-ae6a089bb4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:to="loc_us-gaap_SeveranceCosts1_3e2ed694-851e-4eb4-abb8-ae6a089bb4e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_9b4b1a7c-3709-4f20-a4ad-5bcace6045c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:to="loc_us-gaap_OtherRestructuringCosts_9b4b1a7c-3709-4f20-a4ad-5bcace6045c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0f000f82-f26f-40f6-b87b-d8576339ed5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:to="loc_us-gaap_RestructuringCharges_0f000f82-f26f-40f6-b87b-d8576339ed5d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6dac8868-4ef7-4968-8cc1-a1c338037467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:to="loc_us-gaap_RestructuringPlanAxis_6dac8868-4ef7-4968-8cc1-a1c338037467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6dac8868-4ef7-4968-8cc1-a1c338037467_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_6dac8868-4ef7-4968-8cc1-a1c338037467" xlink:to="loc_us-gaap_RestructuringPlanDomain_6dac8868-4ef7-4968-8cc1-a1c338037467_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3aaa8e8e-462d-48d4-b4dd-28b90ce685bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_6dac8868-4ef7-4968-8cc1-a1c338037467" xlink:to="loc_us-gaap_RestructuringPlanDomain_3aaa8e8e-462d-48d4-b4dd-28b90ce685bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_25fe2556-eba4-48e4-82ae-57b19c970fa6" xlink:href="biib-20240630.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3aaa8e8e-462d-48d4-b4dd-28b90ce685bd" xlink:to="loc_biib_A2023CostSavingInitiativesMember_25fe2556-eba4-48e4-82ae-57b19c970fa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_a40034df-6c7d-4beb-b0cf-1b0214ae7ed5" xlink:href="biib-20240630.xsd#biib_ReataIntegrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3aaa8e8e-462d-48d4-b4dd-28b90ce685bd" xlink:to="loc_biib_ReataIntegrationMember_a40034df-6c7d-4beb-b0cf-1b0214ae7ed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef4462fc-18e2-4f49-9981-006becbd69d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef4462fc-18e2-4f49-9981-006becbd69d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ef4462fc-18e2-4f49-9981-006becbd69d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef4462fc-18e2-4f49-9981-006becbd69d0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ef4462fc-18e2-4f49-9981-006becbd69d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e40901c6-8a75-4f02-b99b-808bf115ee58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef4462fc-18e2-4f49-9981-006becbd69d0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e40901c6-8a75-4f02-b99b-808bf115ee58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_133e0715-38be-493f-93d3-0dc4ee836bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e40901c6-8a75-4f02-b99b-808bf115ee58" xlink:to="loc_us-gaap_RestructuringChargesMember_133e0715-38be-493f-93d3-0dc4ee836bc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:to="loc_srt_RangeAxis_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315" xlink:to="loc_srt_RangeMember_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0100ebb7-4648-45a1-a8c8-714effb9691d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315" xlink:to="loc_srt_RangeMember_0100ebb7-4648-45a1-a8c8-714effb9691d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c06b50e3-ac47-4d82-8ee1-dc0bf19a94f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0100ebb7-4648-45a1-a8c8-714effb9691d" xlink:to="loc_srt_MinimumMember_c06b50e3-ac47-4d82-8ee1-dc0bf19a94f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b86db1e-d55f-4bfd-bab0-7e7c91572407" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0100ebb7-4648-45a1-a8c8-714effb9691d" xlink:to="loc_srt_MaximumMember_0b86db1e-d55f-4bfd-bab0-7e7c91572407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_ec6bd15a-43db-4f5d-8899-5378554779c6" xlink:href="biib-20240630.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_ec6bd15a-43db-4f5d-8899-5378554779c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_64ba5783-8d55-4a53-b54a-488626ba4aab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_64ba5783-8d55-4a53-b54a-488626ba4aab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_0dddfb2b-fdaf-43b6-b0a3-ca6152bb14d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_SeveranceCosts1_0dddfb2b-fdaf-43b6-b0a3-ca6152bb14d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_f69ae352-7aec-4ae9-a54d-5c45ab278eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_f69ae352-7aec-4ae9-a54d-5c45ab278eaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5f8d095b-9552-47e8-af25-262e50bae212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5f8d095b-9552-47e8-af25-262e50bae212" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_0ec7ec07-3d42-4125-8084-f2eff32de09d" xlink:href="biib-20240630.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_biib_OperatingLeaseArea_0ec7ec07-3d42-4125-8084-f2eff32de09d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_28fa2ca2-825f-4d47-a290-9d1ab21dc1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_28fa2ca2-825f-4d47-a290-9d1ab21dc1bb" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_66c65946-53c0-4dbc-8f9d-e02fc1b76e37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_66c65946-53c0-4dbc-8f9d-e02fc1b76e37" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7195ac82-6cb0-444d-b237-68798cf92e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7195ac82-6cb0-444d-b237-68798cf92e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7195ac82-6cb0-444d-b237-68798cf92e64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7195ac82-6cb0-444d-b237-68798cf92e64" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7195ac82-6cb0-444d-b237-68798cf92e64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ec2f883d-76e1-47c2-acab-59fa290f2da5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7195ac82-6cb0-444d-b237-68798cf92e64" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ec2f883d-76e1-47c2-acab-59fa290f2da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_adc25826-9e54-4d5a-ba1e-50e2a44b42b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ec2f883d-76e1-47c2-acab-59fa290f2da5" xlink:to="loc_us-gaap_EmployeeSeveranceMember_adc25826-9e54-4d5a-ba1e-50e2a44b42b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_32dc58e7-5b25-45a2-bae7-01116f708448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_32dc58e7-5b25-45a2-bae7-01116f708448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_32dc58e7-5b25-45a2-bae7-01116f708448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32dc58e7-5b25-45a2-bae7-01116f708448" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_32dc58e7-5b25-45a2-bae7-01116f708448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ea600882-647b-41fa-9fc3-241002fa200b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32dc58e7-5b25-45a2-bae7-01116f708448" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ea600882-647b-41fa-9fc3-241002fa200b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_4d2423ae-6d6d-45f5-8574-f087c1718d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea600882-647b-41fa-9fc3-241002fa200b" xlink:to="loc_us-gaap_RestructuringChargesMember_4d2423ae-6d6d-45f5-8574-f087c1718d1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2fec62ed-f8a6-4d4e-ae0c-84d07315150b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_66c65946-53c0-4dbc-8f9d-e02fc1b76e37" xlink:to="loc_us-gaap_RestructuringCharges_2fec62ed-f8a6-4d4e-ae0c-84d07315150b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_afc80bd7-730a-4710-a67c-1f55320bba02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_afc80bd7-730a-4710-a67c-1f55320bba02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_afc80bd7-730a-4710-a67c-1f55320bba02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_afc80bd7-730a-4710-a67c-1f55320bba02" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_afc80bd7-730a-4710-a67c-1f55320bba02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_136e877c-d856-4c46-815b-d20d44ede9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_afc80bd7-730a-4710-a67c-1f55320bba02" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_136e877c-d856-4c46-815b-d20d44ede9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_87bc495c-e6d2-46bd-8f3b-db60b3269811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_136e877c-d856-4c46-815b-d20d44ede9b2" xlink:to="loc_us-gaap_EmployeeSeveranceMember_87bc495c-e6d2-46bd-8f3b-db60b3269811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e9030ba1-73af-40ff-828e-bbd9c46383ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:to="loc_us-gaap_RestructuringPlanAxis_e9030ba1-73af-40ff-828e-bbd9c46383ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e9030ba1-73af-40ff-828e-bbd9c46383ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_e9030ba1-73af-40ff-828e-bbd9c46383ad" xlink:to="loc_us-gaap_RestructuringPlanDomain_e9030ba1-73af-40ff-828e-bbd9c46383ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_982cb5bc-9a82-4423-9ddf-d49d3c5b41ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_e9030ba1-73af-40ff-828e-bbd9c46383ad" xlink:to="loc_us-gaap_RestructuringPlanDomain_982cb5bc-9a82-4423-9ddf-d49d3c5b41ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_85927d38-b754-4345-a69f-1cd5bc2c59c3" xlink:href="biib-20240630.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_982cb5bc-9a82-4423-9ddf-d49d3c5b41ff" xlink:to="loc_biib_A2023CostSavingInitiativesMember_85927d38-b754-4345-a69f-1cd5bc2c59c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember_bf2f6b38-c684-4164-b42c-f60ab80db301" xlink:href="biib-20240630.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_982cb5bc-9a82-4423-9ddf-d49d3c5b41ff" xlink:to="loc_biib_A2023And2022CostSavingInitiativesMember_bf2f6b38-c684-4164-b42c-f60ab80db301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_a7d9f706-e99c-4702-b0c7-79cf9f23b9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_RestructuringReserve_a7d9f706-e99c-4702-b0c7-79cf9f23b9f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bd67f534-47f6-4d3e-bf60-077d4d9ffe42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_RestructuringCharges_bd67f534-47f6-4d3e-bf60-077d4d9ffe42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_a4dd4bd5-c39a-4184-993c-723d202ed115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_PaymentsForRestructuring_a4dd4bd5-c39a-4184-993c-723d202ed115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_0d7fd796-cd70-416d-9e66-b915cb6620e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_0d7fd796-cd70-416d-9e66-b915cb6620e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_229e0026-2aea-43e7-a82e-bcf46171a7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_586d53f7-dd5d-42f0-9049-de96989bd252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_586d53f7-dd5d-42f0-9049-de96989bd252" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6a9f542-74b3-4596-8de7-3f7b6faf189b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:to="loc_srt_ProductOrServiceAxis_f6a9f542-74b3-4596-8de7-3f7b6faf189b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6a9f542-74b3-4596-8de7-3f7b6faf189b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f6a9f542-74b3-4596-8de7-3f7b6faf189b" xlink:to="loc_srt_ProductsAndServicesDomain_f6a9f542-74b3-4596-8de7-3f7b6faf189b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25d28e47-8124-48ce-b706-19101870d226" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f6a9f542-74b3-4596-8de7-3f7b6faf189b" xlink:to="loc_srt_ProductsAndServicesDomain_25d28e47-8124-48ce-b706-19101870d226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_25d28e47-8124-48ce-b706-19101870d226" xlink:to="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_e2fb568e-536c-4c84-9735-e3c2915767a2" xlink:href="biib-20240630.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_MSProductRevenuesMember_e2fb568e-536c-4c84-9735-e3c2915767a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_8fbf30cd-2c12-4d03-a47f-f9a391dc4d5c" xlink:href="biib-20240630.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_e2fb568e-536c-4c84-9735-e3c2915767a2" xlink:to="loc_biib_FumarateMember_8fbf30cd-2c12-4d03-a47f-f9a391dc4d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_f98d317d-9c8c-40ca-a62a-2eb37829c042" xlink:href="biib-20240630.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_8fbf30cd-2c12-4d03-a47f-f9a391dc4d5c" xlink:to="loc_biib_TECFIDERAMember_f98d317d-9c8c-40ca-a62a-2eb37829c042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_9defe4e5-bcba-4aa6-9cc3-e59c714826a9" xlink:href="biib-20240630.xsd#biib_VUMERITYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_8fbf30cd-2c12-4d03-a47f-f9a391dc4d5c" xlink:to="loc_biib_VUMERITYMember_9defe4e5-bcba-4aa6-9cc3-e59c714826a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_7b951388-12bc-4ad7-b460-69e274f78f40" xlink:href="biib-20240630.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_e2fb568e-536c-4c84-9735-e3c2915767a2" xlink:to="loc_biib_InterferonMember_7b951388-12bc-4ad7-b460-69e274f78f40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_3af04440-6cda-4f27-9fae-62aaa88237b9" xlink:href="biib-20240630.xsd#biib_AVONEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_7b951388-12bc-4ad7-b460-69e274f78f40" xlink:to="loc_biib_AVONEXMember_3af04440-6cda-4f27-9fae-62aaa88237b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_300055c6-96f8-4026-b15d-a9f551094a32" xlink:href="biib-20240630.xsd#biib_PLEGRIDYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_7b951388-12bc-4ad7-b460-69e274f78f40" xlink:to="loc_biib_PLEGRIDYMember_300055c6-96f8-4026-b15d-a9f551094a32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_43a4ffc4-b1fa-4ad4-a8f8-17583db65bfd" xlink:href="biib-20240630.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_TysabriProductMember_43a4ffc4-b1fa-4ad4-a8f8-17583db65bfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_052be3e2-b18f-4a87-a18b-f8c8e075bd56" xlink:href="biib-20240630.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_FAMPYRAMember_052be3e2-b18f-4a87-a18b-f8c8e075bd56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:href="biib-20240630.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember_9530ac5a-54de-4660-93bd-78eff6dc6d87" xlink:href="biib-20240630.xsd#biib_QALSODYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:to="loc_biib_QALSODYMember_9530ac5a-54de-4660-93bd-78eff6dc6d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_c2acebae-77e1-4df0-a4cd-4ade5734ec36" xlink:href="biib-20240630.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:to="loc_biib_SPINRAZAMember_c2acebae-77e1-4df0-a4cd-4ade5734ec36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_a5670481-33b7-4e9a-9fc2-119b51fdf379" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:to="loc_biib_SKYCLARYSMember_a5670481-33b7-4e9a-9fc2-119b51fdf379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:href="biib-20240630.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_99454f73-93ce-4da3-ad56-d7325f79d97c" xlink:href="biib-20240630.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_BENEPALIMember_99454f73-93ce-4da3-ad56-d7325f79d97c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_8c10a8bd-0ff7-476a-b557-4005d85a410c" xlink:href="biib-20240630.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_IMRALDIMember_8c10a8bd-0ff7-476a-b557-4005d85a410c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_35830a36-29b2-4e44-a9ac-501da76e5fab" xlink:href="biib-20240630.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_FLIXABIMember_35830a36-29b2-4e44-a9ac-501da76e5fab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_089c40d6-efcb-4609-bdc5-c81b63ef861a" xlink:href="biib-20240630.xsd#biib_BYOOVIZMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_BYOOVIZMember_089c40d6-efcb-4609-bdc5-c81b63ef861a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember_88ad67c8-2979-4a3c-bec3-5727486fee06" xlink:href="biib-20240630.xsd#biib_TOFIDENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_TOFIDENCEMember_88ad67c8-2979-4a3c-bec3-5727486fee06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember_cf353e6f-72e7-48ac-9ca3-c37c5c755dd8" xlink:href="biib-20240630.xsd#biib_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_OtherProductsMember_cf353e6f-72e7-48ac-9ca3-c37c5c755dd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember_bc924543-4782-46b1-908d-6becaf748713" xlink:href="biib-20240630.xsd#biib_ZURZUVAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_OtherProductsMember_cf353e6f-72e7-48ac-9ca3-c37c5c755dd8" xlink:to="loc_biib_ZURZUVAEMember_bc924543-4782-46b1-908d-6becaf748713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember_73992970-792e-4dac-b690-46bce7276e4f" xlink:href="biib-20240630.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_OtherProductsMember_cf353e6f-72e7-48ac-9ca3-c37c5c755dd8" xlink:to="loc_biib_FUMADERMAndADUHELMMember_73992970-792e-4dac-b690-46bce7276e4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6ade0631-d0c0-4d6d-b827-5087fe249ef0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:to="loc_srt_StatementGeographicalAxis_6ade0631-d0c0-4d6d-b827-5087fe249ef0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6ade0631-d0c0-4d6d-b827-5087fe249ef0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6ade0631-d0c0-4d6d-b827-5087fe249ef0" xlink:to="loc_srt_SegmentGeographicalDomain_6ade0631-d0c0-4d6d-b827-5087fe249ef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5f796566-ef70-4bcc-9dd6-db05f3415025" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6ade0631-d0c0-4d6d-b827-5087fe249ef0" xlink:to="loc_srt_SegmentGeographicalDomain_5f796566-ef70-4bcc-9dd6-db05f3415025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1ac2b51f-bea3-488d-9c2d-e574d79442e2" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5f796566-ef70-4bcc-9dd6-db05f3415025" xlink:to="loc_country_US_1ac2b51f-bea3-488d-9c2d-e574d79442e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2dcc17df-0fe7-49da-86f3-f419f7a0b5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5f796566-ef70-4bcc-9dd6-db05f3415025" xlink:to="loc_us-gaap_NonUsMember_2dcc17df-0fe7-49da-86f3-f419f7a0b5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a87b278e-b7be-4e3d-ac32-d134b270154e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_586d53f7-dd5d-42f0-9049-de96989bd252" xlink:to="loc_us-gaap_Revenues_a87b278e-b7be-4e3d-ac32-d134b270154e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_366b7ebe-199a-4639-ac7a-703cf703740d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_366b7ebe-199a-4639-ac7a-703cf703740d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_528fc509-ea53-4dc5-b996-5b3738765cba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_366b7ebe-199a-4639-ac7a-703cf703740d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_528fc509-ea53-4dc5-b996-5b3738765cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_528fc509-ea53-4dc5-b996-5b3738765cba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_528fc509-ea53-4dc5-b996-5b3738765cba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_528fc509-ea53-4dc5-b996-5b3738765cba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_528fc509-ea53-4dc5-b996-5b3738765cba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_4ecd2774-7af2-45df-90a8-0efd9af7b0df" xlink:href="biib-20240630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:to="loc_biib_ReserveforCashDiscountsMember_4ecd2774-7af2-45df-90a8-0efd9af7b0df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_7678a9e1-1b4b-43ef-a12e-b3b1a209e48c" xlink:href="biib-20240630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:to="loc_biib_ContractualAdjustmentsMember_7678a9e1-1b4b-43ef-a12e-b3b1a209e48c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_d4e5b9d7-1e37-4b78-b48a-00aed9c8620f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_d4e5b9d7-1e37-4b78-b48a-00aed9c8620f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d6a5c2a-5745-458c-b397-0f92a374b36d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d6a5c2a-5745-458c-b397-0f92a374b36d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9a7c20e4-29d6-4180-9815-e4fbe388ea91" xlink:href="biib-20240630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9a7c20e4-29d6-4180-9815-e4fbe388ea91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_d1b8627f-e4c2-4eff-a1d1-41d1a7046139" xlink:href="biib-20240630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_d1b8627f-e4c2-4eff-a1d1-41d1a7046139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_39f888c7-ec10-4fbb-ba73-2285dd6e6f5c" xlink:href="biib-20240630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_39f888c7-ec10-4fbb-ba73-2285dd6e6f5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_4a2efa21-2292-4d30-b9f9-4712bc2f20a6" xlink:href="biib-20240630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_4a2efa21-2292-4d30-b9f9-4712bc2f20a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d928353d-905a-494c-9216-1bcbab811146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d6ad605c-3f2b-4039-8ebb-a0dfeef67987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b783ceda-b239-410c-b0c1-6594543747c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d6ad605c-3f2b-4039-8ebb-a0dfeef67987" xlink:to="loc_us-gaap_StatementTable_b783ceda-b239-410c-b0c1-6594543747c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e7b04ffb-a326-42bd-86a1-66f8b9736309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b783ceda-b239-410c-b0c1-6594543747c6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e7b04ffb-a326-42bd-86a1-66f8b9736309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e7b04ffb-a326-42bd-86a1-66f8b9736309_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e7b04ffb-a326-42bd-86a1-66f8b9736309" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e7b04ffb-a326-42bd-86a1-66f8b9736309_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_de5596ab-8599-4987-8fb9-561bf3f95994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e7b04ffb-a326-42bd-86a1-66f8b9736309" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_de5596ab-8599-4987-8fb9-561bf3f95994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e6d03bfe-ee05-45e4-8547-7da5cc85cd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_de5596ab-8599-4987-8fb9-561bf3f95994" xlink:to="loc_us-gaap_AccountsReceivableMember_e6d03bfe-ee05-45e4-8547-7da5cc85cd6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9af6b48a-9c7e-4b22-957a-cc466a128b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_de5596ab-8599-4987-8fb9-561bf3f95994" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9af6b48a-9c7e-4b22-957a-cc466a128b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e2a880c9-ad8d-44af-928b-cc9df4ff66ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6ad605c-3f2b-4039-8ebb-a0dfeef67987" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e2a880c9-ad8d-44af-928b-cc9df4ff66ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b50460b1-7ff5-41ad-879b-43e0ee4b20e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:to="loc_srt_ProductOrServiceAxis_b50460b1-7ff5-41ad-879b-43e0ee4b20e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b50460b1-7ff5-41ad-879b-43e0ee4b20e0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b50460b1-7ff5-41ad-879b-43e0ee4b20e0" xlink:to="loc_srt_ProductsAndServicesDomain_b50460b1-7ff5-41ad-879b-43e0ee4b20e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d999477-4808-4f3d-82da-198bb5399e10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b50460b1-7ff5-41ad-879b-43e0ee4b20e0" xlink:to="loc_srt_ProductsAndServicesDomain_9d999477-4808-4f3d-82da-198bb5399e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_e79510bf-8490-4fe4-904b-7829ab02fb6e" xlink:href="biib-20240630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9d999477-4808-4f3d-82da-198bb5399e10" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_e79510bf-8490-4fe4-904b-7829ab02fb6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember_a892677c-f48a-4bed-bf00-dfac52a27939" xlink:href="biib-20240630.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9d999477-4808-4f3d-82da-198bb5399e10" xlink:to="loc_biib_RoyaltyAttributedToOCREVUSMember_a892677c-f48a-4bed-bf00-dfac52a27939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1457d871-7a1e-42bc-8824-19d22c18b681" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:to="loc_srt_MajorCustomersAxis_1457d871-7a1e-42bc-8824-19d22c18b681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1457d871-7a1e-42bc-8824-19d22c18b681_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1457d871-7a1e-42bc-8824-19d22c18b681" xlink:to="loc_srt_NameOfMajorCustomerDomain_1457d871-7a1e-42bc-8824-19d22c18b681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_457a9abe-bff2-4568-be60-a400304d0915" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1457d871-7a1e-42bc-8824-19d22c18b681" xlink:to="loc_srt_NameOfMajorCustomerDomain_457a9abe-bff2-4568-be60-a400304d0915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_5c5e8896-ec10-43b9-9641-4856ba0b9a0b" xlink:href="biib-20240630.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_457a9abe-bff2-4568-be60-a400304d0915" xlink:to="loc_biib_RocheGroupGenentechMember_5c5e8896-ec10-43b9-9641-4856ba0b9a0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_9edb0ba0-bcd8-4321-a464-2e4444073c39" xlink:href="biib-20240630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:to="loc_biib_ShareOfCoPromotionProfits_9edb0ba0-bcd8-4321-a464-2e4444073c39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_101887b9-998f-471c-8303-6ceb345ea274" xlink:href="biib-20240630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_101887b9-998f-471c-8303-6ceb345ea274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b09fb101-018e-428d-8a7e-bb0f41551f10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:to="loc_us-gaap_Revenues_b09fb101-018e-428d-8a7e-bb0f41551f10" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b3a5f05b-c500-42e2-b2df-e98235c66221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6e730cdb-4f78-436a-a510-364fc590235a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b3a5f05b-c500-42e2-b2df-e98235c66221" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6e730cdb-4f78-436a-a510-364fc590235a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e368f97a-8307-4562-b782-3cbb32072f47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6e730cdb-4f78-436a-a510-364fc590235a" xlink:to="loc_srt_ProductOrServiceAxis_e368f97a-8307-4562-b782-3cbb32072f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e368f97a-8307-4562-b782-3cbb32072f47_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e368f97a-8307-4562-b782-3cbb32072f47" xlink:to="loc_srt_ProductsAndServicesDomain_e368f97a-8307-4562-b782-3cbb32072f47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e368f97a-8307-4562-b782-3cbb32072f47" xlink:to="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember_0804fa51-b29b-42e1-8ba2-8a932774fb91" xlink:href="biib-20240630.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:to="loc_biib_ContractManufacturingAndOtherRevenueMember_0804fa51-b29b-42e1-8ba2-8a932774fb91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_d0bfa191-6de0-4523-9578-8fa92d192640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:to="loc_us-gaap_RoyaltyMember_d0bfa191-6de0-4523-9578-8fa92d192640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_bed54a7d-a295-4158-9524-29da9951d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_bed54a7d-a295-4158-9524-29da9951d5f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_099b3320-1b07-4403-b9a0-25d9eae21c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b3a5f05b-c500-42e2-b2df-e98235c66221" xlink:to="loc_us-gaap_Revenues_099b3320-1b07-4403-b9a0-25d9eae21c0c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b6b6682e-22aa-4e86-9ba6-bce8ed19effd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:to="loc_srt_ProductOrServiceAxis_b6b6682e-22aa-4e86-9ba6-bce8ed19effd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b6b6682e-22aa-4e86-9ba6-bce8ed19effd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b6b6682e-22aa-4e86-9ba6-bce8ed19effd" xlink:to="loc_srt_ProductsAndServicesDomain_b6b6682e-22aa-4e86-9ba6-bce8ed19effd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c50ae59f-b818-4e56-a397-88487ffda567" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b6b6682e-22aa-4e86-9ba6-bce8ed19effd" xlink:to="loc_srt_ProductsAndServicesDomain_c50ae59f-b818-4e56-a397-88487ffda567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_232d2e50-a622-4046-b23b-e3c4ec1ec1db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c50ae59f-b818-4e56-a397-88487ffda567" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_232d2e50-a622-4046-b23b-e3c4ec1ec1db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_ba3dae93-1b5b-44eb-984b-61f4c0f4813b" xlink:href="biib-20240630.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c50ae59f-b818-4e56-a397-88487ffda567" xlink:to="loc_biib_LEQEMBICollaborationMember_ba3dae93-1b5b-44eb-984b-61f4c0f4813b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c5fb4e00-6e91-4ac0-860c-c1c6f9245786" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:to="loc_srt_MajorCustomersAxis_c5fb4e00-6e91-4ac0-860c-c1c6f9245786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c5fb4e00-6e91-4ac0-860c-c1c6f9245786_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c5fb4e00-6e91-4ac0-860c-c1c6f9245786" xlink:to="loc_srt_NameOfMajorCustomerDomain_c5fb4e00-6e91-4ac0-860c-c1c6f9245786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6d72aae1-0c21-4611-9d9d-15bae73bf9ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c5fb4e00-6e91-4ac0-860c-c1c6f9245786" xlink:to="loc_srt_NameOfMajorCustomerDomain_6d72aae1-0c21-4611-9d9d-15bae73bf9ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_0a04ed35-da42-4de5-9ec3-de1b766cf489" xlink:href="biib-20240630.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6d72aae1-0c21-4611-9d9d-15bae73bf9ae" xlink:to="loc_biib_DistributorOneMember_0a04ed35-da42-4de5-9ec3-de1b766cf489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_7d89b212-14fd-4432-94ce-93d0fff93d9a" xlink:href="biib-20240630.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6d72aae1-0c21-4611-9d9d-15bae73bf9ae" xlink:to="loc_biib_DistributorTwoMember_7d89b212-14fd-4432-94ce-93d0fff93d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7c7c4822-d909-4c3b-8c3c-95e0338b7975" xlink:href="biib-20240630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7c7c4822-d909-4c3b-8c3c-95e0338b7975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_93c96789-b2a4-4cd2-94d4-980b2742efe3" xlink:href="biib-20240630.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_biib_NumberOfWholesalers_93c96789-b2a4-4cd2-94d4-980b2742efe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c726fe14-b74b-495a-829e-ea6d9b2a95bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_us-gaap_Revenues_c726fe14-b74b-495a-829e-ea6d9b2a95bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_444476f4-c015-4d1a-927f-4af35b06c55c" xlink:href="biib-20240630.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_444476f4-c015-4d1a-927f-4af35b06c55c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_052e284f-0823-48d2-ac10-03238ca4bbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_052e284f-0823-48d2-ac10-03238ca4bbfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_052e284f-0823-48d2-ac10-03238ca4bbfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_052e284f-0823-48d2-ac10-03238ca4bbfa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_052e284f-0823-48d2-ac10-03238ca4bbfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34f4046e-099a-4d03-8d24-838e162bb6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_052e284f-0823-48d2-ac10-03238ca4bbfa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34f4046e-099a-4d03-8d24-838e162bb6c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_72710344-e118-4318-9b69-beaf601a30ab" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34f4046e-099a-4d03-8d24-838e162bb6c0" xlink:to="loc_biib_EisaiMember_72710344-e118-4318-9b69-beaf601a30ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e881f6f2-fbf5-4d66-80b7-3f418e15708a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e881f6f2-fbf5-4d66-80b7-3f418e15708a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e881f6f2-fbf5-4d66-80b7-3f418e15708a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e881f6f2-fbf5-4d66-80b7-3f418e15708a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e881f6f2-fbf5-4d66-80b7-3f418e15708a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55c0b196-c4db-4fa4-85af-918803941e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e881f6f2-fbf5-4d66-80b7-3f418e15708a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55c0b196-c4db-4fa4-85af-918803941e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_2f0348f1-90d2-458f-84e2-03f5ef595642" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55c0b196-c4db-4fa4-85af-918803941e0f" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_2f0348f1-90d2-458f-84e2-03f5ef595642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_2829897b-5bd5-4aa4-bfd7-4a5b842ccb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_2829897b-5bd5-4aa4-bfd7-4a5b842ccb2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_75b6f8d7-1959-4d5f-a4c9-20e6e3b20ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_2829897b-5bd5-4aa4-bfd7-4a5b842ccb2f" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_75b6f8d7-1959-4d5f-a4c9-20e6e3b20ebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_afc1b068-6a39-4475-9787-81df5ab29029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_afc1b068-6a39-4475-9787-81df5ab29029" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2a922474-ed73-424d-9342-f433c94ff47d" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2a922474-ed73-424d-9342-f433c94ff47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5904dbb6-4f90-4735-a78e-039af07842c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_us-gaap_ProfitLoss_5904dbb6-4f90-4735-a78e-039af07842c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_380e41de-16df-48c0-bb76-f1fe2e22d056" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_380e41de-16df-48c0-bb76-f1fe2e22d056" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8d106640-cf50-43e9-9586-0bb0773aa76b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8d106640-cf50-43e9-9586-0bb0773aa76b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac7a1601-0349-4102-bd1c-d2b553b71015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac7a1601-0349-4102-bd1c-d2b553b71015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_d4d448d7-5a2f-4507-84f4-4d37ee5a308d" xlink:href="biib-20240630.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac7a1601-0349-4102-bd1c-d2b553b71015" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_d4d448d7-5a2f-4507-84f4-4d37ee5a308d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_447ac14b-9df9-4fca-8a2a-ab2753765ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac7a1601-0349-4102-bd1c-d2b553b71015" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_447ac14b-9df9-4fca-8a2a-ab2753765ca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89a9a179-e969-4586-9c57-916f4e696e8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:to="loc_srt_RangeAxis_89a9a179-e969-4586-9c57-916f4e696e8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89a9a179-e969-4586-9c57-916f4e696e8c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_89a9a179-e969-4586-9c57-916f4e696e8c" xlink:to="loc_srt_RangeMember_89a9a179-e969-4586-9c57-916f4e696e8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0cb9247e-4c80-4715-ab4b-58b4fbef7442" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_89a9a179-e969-4586-9c57-916f4e696e8c" xlink:to="loc_srt_RangeMember_0cb9247e-4c80-4715-ab4b-58b4fbef7442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05ad731c-6c2c-40af-ae8c-263c6d806843" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0cb9247e-4c80-4715-ab4b-58b4fbef7442" xlink:to="loc_srt_MinimumMember_05ad731c-6c2c-40af-ae8c-263c6d806843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3ad51d2b-6020-4207-96b9-2e0042f4942d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0cb9247e-4c80-4715-ab4b-58b4fbef7442" xlink:to="loc_srt_MaximumMember_3ad51d2b-6020-4207-96b9-2e0042f4942d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0f0a621d-826f-458c-b8fd-6123839bb022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8d106640-cf50-43e9-9586-0bb0773aa76b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0f0a621d-826f-458c-b8fd-6123839bb022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8d106640-cf50-43e9-9586-0bb0773aa76b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2cf9bbfc-f022-48fb-aae3-1d1f390296a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2cf9bbfc-f022-48fb-aae3-1d1f390296a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_76980326-1486-4f95-a68e-c4b87146203d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_76980326-1486-4f95-a68e-c4b87146203d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_584fcf14-267a-4456-88a4-d9c2ea34c67d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_584fcf14-267a-4456-88a4-d9c2ea34c67d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8bece34-9729-45cf-bf62-82b961750a27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f248205f-bd38-46c6-9350-3710d00a7af6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8bece34-9729-45cf-bf62-82b961750a27" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f248205f-bd38-46c6-9350-3710d00a7af6" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_715e6466-07ed-44f1-bf50-7cee02d2917b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f248205f-bd38-46c6-9350-3710d00a7af6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_715e6466-07ed-44f1-bf50-7cee02d2917b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_715e6466-07ed-44f1-bf50-7cee02d2917b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_715e6466-07ed-44f1-bf50-7cee02d2917b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_715e6466-07ed-44f1-bf50-7cee02d2917b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_715e6466-07ed-44f1-bf50-7cee02d2917b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e3b8645b-3b7e-42b6-9257-e918ebfcfa53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e3b8645b-3b7e-42b6-9257-e918ebfcfa53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_2278831b-1510-4d01-8d49-03b21b53fb5a" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:to="loc_biib_PriorityReviewVoucherMember_2278831b-1510-4d01-8d49-03b21b53fb5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_c890b0aa-f698-49e2-8af5-41c0a103afd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_c890b0aa-f698-49e2-8af5-41c0a103afd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14b5e32e-42d1-4a15-87fb-ff0f2ac87d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8bece34-9729-45cf-bf62-82b961750a27" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14b5e32e-42d1-4a15-87fb-ff0f2ac87d75" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_92134afd-4980-41ec-aa30-2610d08b1a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_92134afd-4980-41ec-aa30-2610d08b1a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92134afd-4980-41ec-aa30-2610d08b1a9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_92134afd-4980-41ec-aa30-2610d08b1a9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92134afd-4980-41ec-aa30-2610d08b1a9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4793c0c0-cb48-4c3a-9c8a-3321584ba175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_92134afd-4980-41ec-aa30-2610d08b1a9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4793c0c0-cb48-4c3a-9c8a-3321584ba175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_a65719a9-84fb-40cb-8fe2-1098ce6b2830" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4793c0c0-cb48-4c3a-9c8a-3321584ba175" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_a65719a9-84fb-40cb-8fe2-1098ce6b2830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0685590c-b851-4165-bf6a-a1ecede6d839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0685590c-b851-4165-bf6a-a1ecede6d839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685590c-b851-4165-bf6a-a1ecede6d839_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0685590c-b851-4165-bf6a-a1ecede6d839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685590c-b851-4165-bf6a-a1ecede6d839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0685590c-b851-4165-bf6a-a1ecede6d839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_55a51abc-ec5a-4687-b360-f8e1dabbb44b" xlink:href="biib-20240630.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_55a51abc-ec5a-4687-b360-f8e1dabbb44b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_33e981c8-9677-4f77-a725-29c588ea96aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_33e981c8-9677-4f77-a725-29c588ea96aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bbacd757-a38e-47e6-9aee-742ca17c126d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bbacd757-a38e-47e6-9aee-742ca17c126d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_2aae53f0-2f9e-42c0-a44b-b550d0db021d" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_biib_SKYCLARYSMember_2aae53f0-2f9e-42c0-a44b-b550d0db021d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_caab8ad5-e657-47a0-8d9a-03b13711629c" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_biib_PriorityReviewVoucherMember_caab8ad5-e657-47a0-8d9a-03b13711629c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CompletedTechnologyMember_22a6e6b1-6f9f-4f7e-a41f-db89fc5fecaf" xlink:href="biib-20240630.xsd#biib_CompletedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_biib_CompletedTechnologyMember_22a6e6b1-6f9f-4f7e-a41f-db89fc5fecaf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f64a55e-b61e-47c7-b4d0-d006695abcc9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_srt_RangeAxis_3f64a55e-b61e-47c7-b4d0-d006695abcc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f64a55e-b61e-47c7-b4d0-d006695abcc9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3f64a55e-b61e-47c7-b4d0-d006695abcc9" xlink:to="loc_srt_RangeMember_3f64a55e-b61e-47c7-b4d0-d006695abcc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bba12694-5155-4ebe-ad9e-65f77ba65ae4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3f64a55e-b61e-47c7-b4d0-d006695abcc9" xlink:to="loc_srt_RangeMember_bba12694-5155-4ebe-ad9e-65f77ba65ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fb5887d6-a53b-4699-bcd5-50a50835475c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bba12694-5155-4ebe-ad9e-65f77ba65ae4" xlink:to="loc_srt_MinimumMember_fb5887d6-a53b-4699-bcd5-50a50835475c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a6a38b42-bbcc-4318-be1b-ac63368f9fc1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bba12694-5155-4ebe-ad9e-65f77ba65ae4" xlink:to="loc_srt_MaximumMember_a6a38b42-bbcc-4318-be1b-ac63368f9fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca1bc9d6-375e-49d0-a4c4-95a466ffd397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca1bc9d6-375e-49d0-a4c4-95a466ffd397" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ca1bc9d6-375e-49d0-a4c4-95a466ffd397_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca1bc9d6-375e-49d0-a4c4-95a466ffd397" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ca1bc9d6-375e-49d0-a4c4-95a466ffd397_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca1bc9d6-375e-49d0-a4c4-95a466ffd397" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b2d553b1-464c-4176-907d-5a566294b3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b2d553b1-464c-4176-907d-5a566294b3a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_36f06b9c-8e40-42c1-a471-a5fa47d37995" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:to="loc_biib_PriorityReviewVoucherMember_36f06b9c-8e40-42c1-a471-a5fa47d37995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_9dcc44d8-0dba-48b3-89b3-5a0f28090b57" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:to="loc_biib_SKYCLARYSMember_9dcc44d8-0dba-48b3-89b3-5a0f28090b57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9c1532e3-5b69-4969-83b1-44e39bbe026c" xlink:href="biib-20240630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9c1532e3-5b69-4969-83b1-44e39bbe026c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f3e70127-30a1-426d-87fd-5b3b7addc284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f3e70127-30a1-426d-87fd-5b3b7addc284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b1fefd17-468c-415a-b8bc-17ce4dbdc53e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b1fefd17-468c-415a-b8bc-17ce4dbdc53e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_8ef35768-2a3c-400e-86fe-c76aa695f903" xlink:href="biib-20240630.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_8ef35768-2a3c-400e-86fe-c76aa695f903" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_908df63d-126f-4f9d-925a-518c5eb2ffda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_908df63d-126f-4f9d-925a-518c5eb2ffda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_84c1a91f-57b3-4193-a7d7-da8803d4f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_84c1a91f-57b3-4193-a7d7-da8803d4f9e8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d38e9ab-5088-464e-9d17-e79cf2daff45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d38e9ab-5088-464e-9d17-e79cf2daff45" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1974e03-4f6b-4eb1-9425-07a1f351f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1974e03-4f6b-4eb1-9425-07a1f351f65c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c1974e03-4f6b-4eb1-9425-07a1f351f65c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1974e03-4f6b-4eb1-9425-07a1f351f65c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c1974e03-4f6b-4eb1-9425-07a1f351f65c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1974e03-4f6b-4eb1-9425-07a1f351f65c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c460cb6c-f578-449f-8eb8-ac4569807514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c460cb6c-f578-449f-8eb8-ac4569807514" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bdc77bca-6593-4526-8d97-6354341593ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bdc77bca-6593-4526-8d97-6354341593ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0ba3f6a4-e5cb-49de-9563-c8d9b206c298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0ba3f6a4-e5cb-49de-9563-c8d9b206c298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebc4758c-7283-442b-8adb-c228aed38ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebc4758c-7283-442b-8adb-c228aed38ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a06449c6-0bc9-444f-8e74-789e40326dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebc4758c-7283-442b-8adb-c228aed38ead" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a06449c6-0bc9-444f-8e74-789e40326dc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7052f701-b92f-4e06-b9d2-325cde728f15" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7052f701-b92f-4e06-b9d2-325cde728f15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7052f701-b92f-4e06-b9d2-325cde728f15_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7052f701-b92f-4e06-b9d2-325cde728f15" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7052f701-b92f-4e06-b9d2-325cde728f15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f48072eb-fe70-47a6-a299-f1ddef6ecfe9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7052f701-b92f-4e06-b9d2-325cde728f15" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f48072eb-fe70-47a6-a299-f1ddef6ecfe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_f018566d-34e7-4a23-8fbf-42238d7f1e77" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f48072eb-fe70-47a6-a299-f1ddef6ecfe9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_f018566d-34e7-4a23-8fbf-42238d7f1e77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b3f7228-3c94-43d2-b944-ce89ac27320f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d38e9ab-5088-464e-9d17-e79cf2daff45" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b3f7228-3c94-43d2-b944-ce89ac27320f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b3f7228-3c94-43d2-b944-ce89ac27320f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_49493ace-df66-435a-a03c-dc674c1d01dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_49493ace-df66-435a-a03c-dc674c1d01dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4028c241-8b4a-4b65-9808-1acbfef5f705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4028c241-8b4a-4b65-9808-1acbfef5f705" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_f79b1177-8e6f-493f-b4cb-ce9a5da14583" xlink:href="biib-20240630.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_f79b1177-8e6f-493f-b4cb-ce9a5da14583" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_7e09f83d-1652-4760-acab-d0681f0c9732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_7e09f83d-1652-4760-acab-d0681f0c9732" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_75341c0a-12ce-4b41-99a4-f8b714acc2b4" xlink:href="biib-20240630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_75341c0a-12ce-4b41-99a4-f8b714acc2b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_eeda8739-ad69-46ac-87eb-5b6913621428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_DerivativeAssets_eeda8739-ad69-46ac-87eb-5b6913621428" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_98f47ec0-13b7-4d8c-8922-fd84526ab6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_98f47ec0-13b7-4d8c-8922-fd84526ab6d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b3f7228-3c94-43d2-b944-ce89ac27320f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_275207bc-a600-43e4-8543-bdf0a0d0b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_275207bc-a600-43e4-8543-bdf0a0d0b2b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_3ddeed52-65a2-45d2-8489-df2025ecf9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_3ddeed52-65a2-45d2-8489-df2025ecf9eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3a417b02-2881-4b3f-a64a-f6192f38b596" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3a417b02-2881-4b3f-a64a-f6192f38b596" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_94d17cb9-0b4a-4856-94b7-14d85a902868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94d17cb9-0b4a-4856-94b7-14d85a902868" xlink:to="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_16664e0a-9a0a-4569-91f7-e5f130b6d98b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:to="loc_us-gaap_CreditFacilityAxis_16664e0a-9a0a-4569-91f7-e5f130b6d98b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_16664e0a-9a0a-4569-91f7-e5f130b6d98b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_16664e0a-9a0a-4569-91f7-e5f130b6d98b" xlink:to="loc_us-gaap_CreditFacilityDomain_16664e0a-9a0a-4569-91f7-e5f130b6d98b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_47304b4e-adf6-4fc0-86b4-5cfe6ec8343f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_16664e0a-9a0a-4569-91f7-e5f130b6d98b" xlink:to="loc_us-gaap_CreditFacilityDomain_47304b4e-adf6-4fc0-86b4-5cfe6ec8343f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e89bde2a-7c55-4461-b63e-583babb96662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_47304b4e-adf6-4fc0-86b4-5cfe6ec8343f" xlink:to="loc_us-gaap_SecuredDebtMember_e89bde2a-7c55-4461-b63e-583babb96662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8aaba9e1-66d8-4e51-9419-a72d23751234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:to="loc_us-gaap_DebtInstrumentAxis_8aaba9e1-66d8-4e51-9419-a72d23751234" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8aaba9e1-66d8-4e51-9419-a72d23751234_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aaba9e1-66d8-4e51-9419-a72d23751234" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8aaba9e1-66d8-4e51-9419-a72d23751234_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94ba2027-56e7-4aa6-9799-9d70024f7270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aaba9e1-66d8-4e51-9419-a72d23751234" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94ba2027-56e7-4aa6-9799-9d70024f7270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_a88d8fc9-f267-4e9f-87d4-6e4f095b9018" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_94ba2027-56e7-4aa6-9799-9d70024f7270" xlink:to="loc_biib_TheCreditFacilityMember_a88d8fc9-f267-4e9f-87d4-6e4f095b9018" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ea3d5933-4b24-4033-ac16-e0d15171db90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ea3d5933-4b24-4033-ac16-e0d15171db90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ea3d5933-4b24-4033-ac16-e0d15171db90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea3d5933-4b24-4033-ac16-e0d15171db90" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ea3d5933-4b24-4033-ac16-e0d15171db90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_093e2739-1247-43af-98ab-930010e40fda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea3d5933-4b24-4033-ac16-e0d15171db90" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_093e2739-1247-43af-98ab-930010e40fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a7540d79-d440-48e9-bd1b-1b00bbb90a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_093e2739-1247-43af-98ab-930010e40fda" xlink:to="loc_us-gaap_LineOfCreditMember_a7540d79-d440-48e9-bd1b-1b00bbb90a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8cad79e8-b35b-4569-8006-bccd626470ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94d17cb9-0b4a-4856-94b7-14d85a902868" xlink:to="loc_us-gaap_AssetImpairmentCharges_8cad79e8-b35b-4569-8006-bccd626470ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ab6e2bb8-4dde-42b0-8230-17ffcfae214e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94d17cb9-0b4a-4856-94b7-14d85a902868" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ab6e2bb8-4dde-42b0-8230-17ffcfae214e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aa534a93-fe36-4981-b5ae-9539f8edca69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_DebtInstrumentAxis_aa534a93-fe36-4981-b5ae-9539f8edca69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa534a93-fe36-4981-b5ae-9539f8edca69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa534a93-fe36-4981-b5ae-9539f8edca69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa534a93-fe36-4981-b5ae-9539f8edca69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa534a93-fe36-4981-b5ae-9539f8edca69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_90486ac2-ae06-4c43-a404-689169dbf78d" xlink:href="biib-20240630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_90486ac2-ae06-4c43-a404-689169dbf78d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_6c7cba07-1baa-4e98-9a73-eb4dd709c78a" xlink:href="biib-20240630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_6c7cba07-1baa-4e98-9a73-eb4dd709c78a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_2b75d08d-c74c-4fe9-b178-b5a188f99625" xlink:href="biib-20240630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_2b75d08d-c74c-4fe9-b178-b5a188f99625" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member_067df86d-71c6-4bb4-a159-c2e3c6a592ea" xlink:href="biib-20240630.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_SeniorNotes3.250DueFebruary152051Member_067df86d-71c6-4bb4-a159-c2e3c6a592ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_7b56f1f9-84e8-45e9-8c67-2668760fb33f" xlink:href="biib-20240630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_7b56f1f9-84e8-45e9-8c67-2668760fb33f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_80c35542-920b-4ff1-aeb8-0a23e64f11ac" xlink:href="biib-20240630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_80c35542-920b-4ff1-aeb8-0a23e64f11ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentPortionOfNotesPayableAndTermLoanMember_06d9050a-81a6-4565-806e-f8423aa4c584" xlink:href="biib-20240630.xsd#biib_CurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_CurrentPortionOfNotesPayableAndTermLoanMember_06d9050a-81a6-4565-806e-f8423aa4c584" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_341bc596-fff5-4580-901c-e853ba7bc53c" xlink:href="biib-20240630.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_341bc596-fff5-4580-901c-e853ba7bc53c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_ba0b31a4-b6be-46de-8fe4-ddbbc7799796" xlink:href="biib-20240630.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_ba0b31a4-b6be-46de-8fe4-ddbbc7799796" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_5249bf19-9ce5-40c8-8893-cd41b4e3f39b" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_TheCreditFacilityMember_5249bf19-9ce5-40c8-8893-cd41b4e3f39b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_298f3d32-f3da-48fd-a38d-a65338cfcc40" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_298f3d32-f3da-48fd-a38d-a65338cfcc40" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_9bda28c0-37c4-4ac4-bca1-bb96c23ce5d4" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_9bda28c0-37c4-4ac4-bca1-bb96c23ce5d4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_21ae4853-6b09-46b9-a127-9b3c59801c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_21ae4853-6b09-46b9-a127-9b3c59801c8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21ae4853-6b09-46b9-a127-9b3c59801c8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21ae4853-6b09-46b9-a127-9b3c59801c8b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21ae4853-6b09-46b9-a127-9b3c59801c8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584f33b5-41e5-4219-b4bd-711ca26ae658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21ae4853-6b09-46b9-a127-9b3c59801c8b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584f33b5-41e5-4219-b4bd-711ca26ae658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_423fff63-d692-4095-9fc6-f0ac0d0271a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584f33b5-41e5-4219-b4bd-711ca26ae658" xlink:to="loc_us-gaap_SeniorNotesMember_423fff63-d692-4095-9fc6-f0ac0d0271a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_dd849585-bc5f-42df-a37a-d4aaf060b975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584f33b5-41e5-4219-b4bd-711ca26ae658" xlink:to="loc_us-gaap_LineOfCreditMember_dd849585-bc5f-42df-a37a-d4aaf060b975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0731c56f-c859-40df-83bd-0602c017669b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0731c56f-c859-40df-83bd-0602c017669b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_5e9ec909-049e-4929-8590-40c292fcdb8c" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0731c56f-c859-40df-83bd-0602c017669b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_5e9ec909-049e-4929-8590-40c292fcdb8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0cf3dcc8-d80a-4c75-9f5c-681be4de3362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_CreditFacilityAxis_0cf3dcc8-d80a-4c75-9f5c-681be4de3362" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0cf3dcc8-d80a-4c75-9f5c-681be4de3362_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_0cf3dcc8-d80a-4c75-9f5c-681be4de3362" xlink:to="loc_us-gaap_CreditFacilityDomain_0cf3dcc8-d80a-4c75-9f5c-681be4de3362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_06569e6d-0546-4a1a-8a0e-b9dfd901a8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_0cf3dcc8-d80a-4c75-9f5c-681be4de3362" xlink:to="loc_us-gaap_CreditFacilityDomain_06569e6d-0546-4a1a-8a0e-b9dfd901a8a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_6826b876-5cd3-41f7-b27e-6793f50d1ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_06569e6d-0546-4a1a-8a0e-b9dfd901a8a2" xlink:to="loc_us-gaap_SecuredDebtMember_6826b876-5cd3-41f7-b27e-6793f50d1ef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_f4638461-83fa-41c6-bcce-a6c5e7a8263f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_f4638461-83fa-41c6-bcce-a6c5e7a8263f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_fd1d76b3-ed40-4986-aebe-ddc73681b1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_NotesPayableCurrent_fd1d76b3-ed40-4986-aebe-ddc73681b1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_11156e68-f951-48c1-af81-fdde896a64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_NotesPayable_11156e68-f951-48c1-af81-fdde896a64b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8d0b75f8-afaf-4d57-aff6-ae4a4d10ac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8d0b75f8-afaf-4d57-aff6-ae4a4d10ac3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_886e3e66-fe3a-432a-933e-4d23f916e478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_886e3e66-fe3a-432a-933e-4d23f916e478" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_9bd701ea-376c-4366-af9b-3154eeae4828" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fb5b54c7-c99c-401f-81d0-c6b5076fe3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9bd701ea-376c-4366-af9b-3154eeae4828" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fb5b54c7-c99c-401f-81d0-c6b5076fe3cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0d486899-b694-46e9-a399-df29a67259a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fb5b54c7-c99c-401f-81d0-c6b5076fe3cb" xlink:to="loc_us-gaap_InvestmentTypeAxis_0d486899-b694-46e9-a399-df29a67259a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0d486899-b694-46e9-a399-df29a67259a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0d486899-b694-46e9-a399-df29a67259a4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0d486899-b694-46e9-a399-df29a67259a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_930b5ee5-97dc-4a88-962d-02201d07982b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0d486899-b694-46e9-a399-df29a67259a4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_930b5ee5-97dc-4a88-962d-02201d07982b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05197a08-c69d-4196-9ddd-56fa45cc2caa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_930b5ee5-97dc-4a88-962d-02201d07982b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_05197a08-c69d-4196-9ddd-56fa45cc2caa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_0f812659-7483-4466-8c22-95d4e06b894a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9bd701ea-376c-4366-af9b-3154eeae4828" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_0f812659-7483-4466-8c22-95d4e06b894a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_6a4325b1-9289-4ce8-aabf-21846da45862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_0f812659-7483-4466-8c22-95d4e06b894a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_6a4325b1-9289-4ce8-aabf-21846da45862" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76efcc2a-1af8-481d-bd73-e366613310f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_051c46d9-288b-48ff-a9fc-e65189db1d65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76efcc2a-1af8-481d-bd73-e366613310f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_051c46d9-288b-48ff-a9fc-e65189db1d65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_83370384-d345-4a02-9b28-3705949caa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_051c46d9-288b-48ff-a9fc-e65189db1d65" xlink:to="loc_us-gaap_FinancialInstrumentAxis_83370384-d345-4a02-9b28-3705949caa5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83370384-d345-4a02-9b28-3705949caa5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_83370384-d345-4a02-9b28-3705949caa5d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83370384-d345-4a02-9b28-3705949caa5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cf3afd0-dad5-4417-b6b0-486cf4ebe648" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_83370384-d345-4a02-9b28-3705949caa5d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cf3afd0-dad5-4417-b6b0-486cf4ebe648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_18110c2e-2192-42e7-88d1-34237c7a21fb" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cf3afd0-dad5-4417-b6b0-486cf4ebe648" xlink:to="loc_biib_EquitySecuritiesCurrentMember_18110c2e-2192-42e7-88d1-34237c7a21fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_e55204d6-62ae-4a23-83d6-4d86f5817adb" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cf3afd0-dad5-4417-b6b0-486cf4ebe648" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_e55204d6-62ae-4a23-83d6-4d86f5817adb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76efcc2a-1af8-481d-bd73-e366613310f3" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_6ceaffac-2f0e-44e1-9ac0-72b9d0491fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_6ceaffac-2f0e-44e1-9ac0-72b9d0491fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_2ba00e49-8399-4f6e-8f10-e2d4c0539dd3" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_2ba00e49-8399-4f6e-8f10-e2d4c0539dd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e316b857-b7a6-40fe-aaa1-eeae6de0883a" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e316b857-b7a6-40fe-aaa1-eeae6de0883a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_14b0c799-242c-414b-a90a-74d4cb565889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_14b0c799-242c-414b-a90a-74d4cb565889" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_14b5b2fb-f01a-431d-9474-2a059b6ce870" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14b5b2fb-f01a-431d-9474-2a059b6ce870" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_66e064b2-7468-4418-88bc-22361771a23b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_66e064b2-7468-4418-88bc-22361771a23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_66e064b2-7468-4418-88bc-22361771a23b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_66e064b2-7468-4418-88bc-22361771a23b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_66e064b2-7468-4418-88bc-22361771a23b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c0fee6a-a883-4061-8ff5-9733c6378e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_66e064b2-7468-4418-88bc-22361771a23b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c0fee6a-a883-4061-8ff5-9733c6378e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_de0ca5ca-2582-49f9-bf2e-47a4309d2fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c0fee6a-a883-4061-8ff5-9733c6378e2b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_de0ca5ca-2582-49f9-bf2e-47a4309d2fa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16d671ba-4868-4ec3-b257-64342a979d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16d671ba-4868-4ec3-b257-64342a979d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_8dcdd957-5dd6-4548-b410-0814205d11bb" xlink:href="biib-20240630.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16d671ba-4868-4ec3-b257-64342a979d72" xlink:to="loc_biib_StrategicInvestmentsMember_8dcdd957-5dd6-4548-b410-0814205d11bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_b8c06480-ca99-4283-9e1a-e2a4d6d41175" xlink:href="biib-20240630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14b5b2fb-f01a-431d-9474-2a059b6ce870" xlink:to="loc_biib_StrategicInvestmentPortfolio_b8c06480-ca99-4283-9e1a-e2a4d6d41175" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_44a703a7-7747-4035-bee5-458dd5cbc406" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_44a703a7-7747-4035-bee5-458dd5cbc406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_44a703a7-7747-4035-bee5-458dd5cbc406_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_44a703a7-7747-4035-bee5-458dd5cbc406" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_44a703a7-7747-4035-bee5-458dd5cbc406_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_aa92232f-6bf4-4163-88aa-23fcbb79ae1d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_44a703a7-7747-4035-bee5-458dd5cbc406" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_aa92232f-6bf4-4163-88aa-23fcbb79ae1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_8adbe842-da4d-4653-bb19-61bd6d35a54f" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_aa92232f-6bf4-4163-88aa-23fcbb79ae1d" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_8adbe842-da4d-4653-bb19-61bd6d35a54f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_srt_CurrencyAxis_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e_default" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e" xlink:to="loc_currency_AllCurrenciesDomain_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e" xlink:to="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_e2e63a09-191a-4ec0-a453-80d39d723748" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:to="loc_currency_EUR_e2e63a09-191a-4ec0-a453-80d39d723748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_49ab5714-4914-497b-8c08-0427d48f79b9" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:to="loc_currency_CHF_49ab5714-4914-497b-8c08-0427d48f79b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_00bec304-69aa-4a47-bed9-43b7a52c6284" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:to="loc_currency_JPY_00bec304-69aa-4a47-bed9-43b7a52c6284" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_e06b41b2-708a-4514-b274-95dc258ba1c6" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:to="loc_currency_CAD_e06b41b2-708a-4514-b274-95dc258ba1c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_12f280d8-4185-461a-936e-b83b6c3f59ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_12f280d8-4185-461a-936e-b83b6c3f59ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_12f280d8-4185-461a-936e-b83b6c3f59ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12f280d8-4185-461a-936e-b83b6c3f59ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_12f280d8-4185-461a-936e-b83b6c3f59ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_22b41e97-cb0a-4313-8614-e811bad7a2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12f280d8-4185-461a-936e-b83b6c3f59ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_22b41e97-cb0a-4313-8614-e811bad7a2ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_16188b8a-adc0-4d5e-9f34-897fe6d4a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_22b41e97-cb0a-4313-8614-e811bad7a2ab" xlink:to="loc_us-gaap_SalesMember_16188b8a-adc0-4d5e-9f34-897fe6d4a5bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_c024f92f-3b9f-4f9f-a667-da56148556c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_22b41e97-cb0a-4313-8614-e811bad7a2ab" xlink:to="loc_us-gaap_OperatingExpenseMember_c024f92f-3b9f-4f9f-a667-da56148556c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ffe90b21-2874-4226-b7b0-bc21618e0198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ffe90b21-2874-4226-b7b0-bc21618e0198" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ffe90b21-2874-4226-b7b0-bc21618e0198_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ffe90b21-2874-4226-b7b0-bc21618e0198" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ffe90b21-2874-4226-b7b0-bc21618e0198_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_66bf05a6-824c-45f3-b41b-33ecbb98bae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ffe90b21-2874-4226-b7b0-bc21618e0198" xlink:to="loc_us-gaap_HedgingRelationshipDomain_66bf05a6-824c-45f3-b41b-33ecbb98bae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_6c2f95bf-3c9a-4d10-bfd4-661446224cf4" xlink:href="biib-20240630.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_66bf05a6-824c-45f3-b41b-33ecbb98bae7" xlink:to="loc_biib_CashflowsrevenueMember_6c2f95bf-3c9a-4d10-bfd4-661446224cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_6643457a-7dbd-4655-a972-9ea200307111" xlink:href="biib-20240630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_66bf05a6-824c-45f3-b41b-33ecbb98bae7" xlink:to="loc_biib_CashflowsoperatingexpensesMember_6643457a-7dbd-4655-a972-9ea200307111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d9320598-b855-402b-bf03-d4dd975d0ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d9320598-b855-402b-bf03-d4dd975d0ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_698cf0d7-44b9-48cb-8550-767f701cdb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d9320598-b855-402b-bf03-d4dd975d0ecb" xlink:to="loc_us-gaap_ForeignExchangeContractMember_698cf0d7-44b9-48cb-8550-767f701cdb3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8e81e94a-e70b-4c02-be34-e63a05aad166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8e81e94a-e70b-4c02-be34-e63a05aad166" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8e81e94a-e70b-4c02-be34-e63a05aad166_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8e81e94a-e70b-4c02-be34-e63a05aad166" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8e81e94a-e70b-4c02-be34-e63a05aad166_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8e81e94a-e70b-4c02-be34-e63a05aad166" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_ce6cfded-b96f-4678-a502-c1f547c49c32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_ce6cfded-b96f-4678-a502-c1f547c49c32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_49e1cfdc-b23e-40f3-8a07-775570c8787d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_49e1cfdc-b23e-40f3-8a07-775570c8787d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_a6935378-e890-464f-ac07-267108e32171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_a6935378-e890-464f-ac07-267108e32171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_22f2e354-0cd2-4e8f-b613-945029c702cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_HedgingDesignationAxis_22f2e354-0cd2-4e8f-b613-945029c702cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_22f2e354-0cd2-4e8f-b613-945029c702cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_22f2e354-0cd2-4e8f-b613-945029c702cf" xlink:to="loc_us-gaap_HedgingDesignationDomain_22f2e354-0cd2-4e8f-b613-945029c702cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_40acfd7d-e8ed-4bbc-8c9c-4fae0e6be636" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_22f2e354-0cd2-4e8f-b613-945029c702cf" xlink:to="loc_us-gaap_HedgingDesignationDomain_40acfd7d-e8ed-4bbc-8c9c-4fae0e6be636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d2db6812-3f58-4d9f-952d-382dca52c82d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_40acfd7d-e8ed-4bbc-8c9c-4fae0e6be636" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d2db6812-3f58-4d9f-952d-382dca52c82d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2686c8f6-a646-4ed5-b1c9-4fb6832f7658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_40acfd7d-e8ed-4bbc-8c9c-4fae0e6be636" xlink:to="loc_us-gaap_NondesignatedMember_2686c8f6-a646-4ed5-b1c9-4fb6832f7658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f322ca5-7014-4020-bcad-4160442045c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_srt_RangeAxis_0f322ca5-7014-4020-bcad-4160442045c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f322ca5-7014-4020-bcad-4160442045c8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0f322ca5-7014-4020-bcad-4160442045c8" xlink:to="loc_srt_RangeMember_0f322ca5-7014-4020-bcad-4160442045c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6edbd062-7e34-4f80-b5b2-fcc4dac88b3b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0f322ca5-7014-4020-bcad-4160442045c8" xlink:to="loc_srt_RangeMember_6edbd062-7e34-4f80-b5b2-fcc4dac88b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_378de9e6-057b-4c51-a77f-f7448df7a6dc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6edbd062-7e34-4f80-b5b2-fcc4dac88b3b" xlink:to="loc_srt_MinimumMember_378de9e6-057b-4c51-a77f-f7448df7a6dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7099c10-6925-438a-af8a-95b88e67bca9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6edbd062-7e34-4f80-b5b2-fcc4dac88b3b" xlink:to="loc_srt_MaximumMember_a7099c10-6925-438a-af8a-95b88e67bca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_302b4d11-983f-451b-b8d2-58ce5c23ef08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_TypeOfArrangementAxis_302b4d11-983f-451b-b8d2-58ce5c23ef08" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_302b4d11-983f-451b-b8d2-58ce5c23ef08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_302b4d11-983f-451b-b8d2-58ce5c23ef08" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_302b4d11-983f-451b-b8d2-58ce5c23ef08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2df77776-2e47-4480-ab63-d889537d9772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_302b4d11-983f-451b-b8d2-58ce5c23ef08" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2df77776-2e47-4480-ab63-d889537d9772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_2c140ddf-f15e-490d-89c7-7faaacf1c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_2c140ddf-f15e-490d-89c7-7faaacf1c6ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_e305a5f6-5410-4121-88b9-7a716155d20c" xlink:href="biib-20240630.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_biib_UnrealizedGainOnDerivatives_e305a5f6-5410-4121-88b9-7a716155d20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_d990322c-3846-4f29-bf38-11e897b475f9" xlink:href="biib-20240630.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_biib_UnrealizedLossOnDerivatives_d990322c-3846-4f29-bf38-11e897b475f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_f9cff309-9c7f-4891-91bc-69b5533aff70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_f9cff309-9c7f-4891-91bc-69b5533aff70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_1de9d5ee-75ab-4e0d-91dc-cba8ab2ca058" xlink:href="biib-20240630.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_1de9d5ee-75ab-4e0d-91dc-cba8ab2ca058" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_eba3cf84-e439-4219-a6c6-684b8f99dd89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_eba3cf84-e439-4219-a6c6-684b8f99dd89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_e7876ca8-e3a2-46e8-8b4c-cc401cc67c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_e7876ca8-e3a2-46e8-8b4c-cc401cc67c99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_6427852f-7e2a-429e-9d9f-20b97e1c8689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_DerivativeNotionalAmount_6427852f-7e2a-429e-9d9f-20b97e1c8689" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_60358d95-00d6-4027-9572-298df0088b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_60358d95-00d6-4027-9572-298df0088b67" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bf6a1df4-8790-4dfd-8b4a-6000a39c128b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bf6a1df4-8790-4dfd-8b4a-6000a39c128b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_66e0cf86-e326-4db1-94a1-c4b457530ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_66e0cf86-e326-4db1-94a1-c4b457530ad2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_ad1d6f04-5ab6-4c3e-964a-09294dc83a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_ad1d6f04-5ab6-4c3e-964a-09294dc83a70" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1f502bbf-529d-477d-a7e3-5635715d0302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1f502bbf-529d-477d-a7e3-5635715d0302" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_4e67a5d1-5d6b-4141-a9f2-643246a573a8" xlink:href="biib-20240630.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:to="loc_biib_FacilityLocationAxis_4e67a5d1-5d6b-4141-a9f2-643246a573a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_4e67a5d1-5d6b-4141-a9f2-643246a573a8_default" xlink:href="biib-20240630.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_4e67a5d1-5d6b-4141-a9f2-643246a573a8" xlink:to="loc_biib_FacilityLocationDomain_4e67a5d1-5d6b-4141-a9f2-643246a573a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_5c68f425-d9c8-4095-ab52-dae34847c768" xlink:href="biib-20240630.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_4e67a5d1-5d6b-4141-a9f2-643246a573a8" xlink:to="loc_biib_FacilityLocationDomain_5c68f425-d9c8-4095-ab52-dae34847c768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_bc43b17e-ec67-4044-84a5-a37c35378e95" xlink:href="biib-20240630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_5c68f425-d9c8-4095-ab52-dae34847c768" xlink:to="loc_biib_SolothurnSwitzerlandMember_bc43b17e-ec67-4044-84a5-a37c35378e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_acbdc68c-175a-4fb5-812d-6ae386d3c73f" xlink:href="biib-20240630.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:to="loc_biib_FacilityTypeAxis_acbdc68c-175a-4fb5-812d-6ae386d3c73f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_acbdc68c-175a-4fb5-812d-6ae386d3c73f_default" xlink:href="biib-20240630.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_acbdc68c-175a-4fb5-812d-6ae386d3c73f" xlink:to="loc_biib_FacilityTypeDomain_acbdc68c-175a-4fb5-812d-6ae386d3c73f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:href="biib-20240630.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_acbdc68c-175a-4fb5-812d-6ae386d3c73f" xlink:to="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_dccdd32f-6e4a-4892-a71b-0c74c65b150f" xlink:href="biib-20240630.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:to="loc_biib_BiologicsManufacturingMember_dccdd32f-6e4a-4892-a71b-0c74c65b150f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_df18b395-5e85-4c4e-8676-0a0d6115e164" xlink:href="biib-20240630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_df18b395-5e85-4c4e-8676-0a0d6115e164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_9137663c-d361-437c-8589-28e19a2adacc" xlink:href="biib-20240630.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:to="loc_biib_AdministrativeSpaceMember_9137663c-d361-437c-8589-28e19a2adacc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d19ac12-80e3-4f0a-a62c-cb6e2b605613" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d19ac12-80e3-4f0a-a62c-cb6e2b605613" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ec7eab0f-145b-4f27-937c-1d712ef8cae9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_Depreciation_ec7eab0f-145b-4f27-937c-1d712ef8cae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_8d7a98da-1ff5-4d76-b9c0-f1990ef40078" xlink:href="biib-20240630.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_biib_NumberOfSquareFeet_8d7a98da-1ff5-4d76-b9c0-f1990ef40078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_9da3aedb-a52d-4cc1-8fb6-81d79bddc958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_ConstructionInProgressGross_9da3aedb-a52d-4cc1-8fb6-81d79bddc958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_07a05ab6-1d43-4cc4-b040-885893962c06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_07a05ab6-1d43-4cc4-b040-885893962c06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_cee5d6c8-4f9e-4b72-96c1-f46165a9b3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_cee5d6c8-4f9e-4b72-96c1-f46165a9b3a9" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#LeasesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1ea8de92-b222-4963-9818-0711879aa748" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1ea8de92-b222-4963-9818-0711879aa748" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_908a6432-b516-4b76-8672-64e5e9444195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1ea8de92-b222-4963-9818-0711879aa748" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_908a6432-b516-4b76-8672-64e5e9444195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_908a6432-b516-4b76-8672-64e5e9444195_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_908a6432-b516-4b76-8672-64e5e9444195" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_908a6432-b516-4b76-8672-64e5e9444195_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23cd5a17-7379-4031-860a-ee1d3daf84b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_908a6432-b516-4b76-8672-64e5e9444195" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23cd5a17-7379-4031-860a-ee1d3daf84b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_65440dc1-4ede-4da4-92e1-20077389df06" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23cd5a17-7379-4031-860a-ee1d3daf84b4" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_65440dc1-4ede-4da4-92e1-20077389df06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_293ad221-3c1b-417e-bf57-9b57ca808ca8" xlink:href="biib-20240630.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_biib_OperatingLeaseArea_293ad221-3c1b-417e-bf57-9b57ca808ca8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0c7f7976-40e5-4b4b-a4f5-3da6716d812f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0c7f7976-40e5-4b4b-a4f5-3da6716d812f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_2e38304d-6f45-465e-8d98-a224b395cabb" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_2e38304d-6f45-465e-8d98-a224b395cabb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_985475cb-628d-4f57-b77d-6546a2eda662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_985475cb-628d-4f57-b77d-6546a2eda662" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_b371efbf-955c-4dfd-aa66-33a36eda77fe" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_b371efbf-955c-4dfd-aa66-33a36eda77fe" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:to="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_73b3e507-977b-4351-8ee5-fce3c56648ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_DebtInstrumentAxis_73b3e507-977b-4351-8ee5-fce3c56648ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_73b3e507-977b-4351-8ee5-fce3c56648ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_73b3e507-977b-4351-8ee5-fce3c56648ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_73b3e507-977b-4351-8ee5-fce3c56648ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_73b3e507-977b-4351-8ee5-fce3c56648ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_2691e95c-7a24-4ae9-af58-435bab5a8c9a" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_2691e95c-7a24-4ae9-af58-435bab5a8c9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_41b314e0-3a70-42b3-81ae-f9d8b0008c2e" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_41b314e0-3a70-42b3-81ae-f9d8b0008c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember_1ebb1948-0450-415a-b10e-bdd14e6f5c4e" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_TheCreditFacilityTerminatedMember_1ebb1948-0450-415a-b10e-bdd14e6f5c4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_20b38601-6144-4006-bb26-34ff07e88913" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_TheCreditFacilityMember_20b38601-6144-4006-bb26-34ff07e88913" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember_1137be18-055f-45cd-b05c-a54d7cc62b60" xlink:href="biib-20240630.xsd#biib_A2023TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_A2023TermLoanMember_1137be18-055f-45cd-b05c-a54d7cc62b60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e374d48c-b9a7-47f4-a09b-8671c48e75d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e374d48c-b9a7-47f4-a09b-8671c48e75d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e374d48c-b9a7-47f4-a09b-8671c48e75d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e374d48c-b9a7-47f4-a09b-8671c48e75d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e374d48c-b9a7-47f4-a09b-8671c48e75d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_39c52fbf-8537-44ca-8342-8383edf11147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e374d48c-b9a7-47f4-a09b-8671c48e75d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_39c52fbf-8537-44ca-8342-8383edf11147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b842d679-8a53-4cc1-82c8-47f9118900db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_39c52fbf-8537-44ca-8342-8383edf11147" xlink:to="loc_us-gaap_LineOfCreditMember_b842d679-8a53-4cc1-82c8-47f9118900db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_621a10f4-90fc-4018-9426-6c3f69449c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_CreditFacilityAxis_621a10f4-90fc-4018-9426-6c3f69449c50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_621a10f4-90fc-4018-9426-6c3f69449c50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_621a10f4-90fc-4018-9426-6c3f69449c50" xlink:to="loc_us-gaap_CreditFacilityDomain_621a10f4-90fc-4018-9426-6c3f69449c50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_621a10f4-90fc-4018-9426-6c3f69449c50" xlink:to="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_bbc36097-f39e-464d-8905-2e55979e341f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:to="loc_us-gaap_SecuredDebtMember_bbc36097-f39e-464d-8905-2e55979e341f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember_7ea45a70-6196-4f14-a592-6068c365045a" xlink:href="biib-20240630.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:to="loc_biib_FloatingRate364DayTrancheMember_7ea45a70-6196-4f14-a592-6068c365045a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_81662cc1-afbd-4144-9833-47f2b5189b5e" xlink:href="biib-20240630.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_81662cc1-afbd-4144-9833-47f2b5189b5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f374b718-7fa7-4297-b190-ea98d1882136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f374b718-7fa7-4297-b190-ea98d1882136" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f374b718-7fa7-4297-b190-ea98d1882136_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f374b718-7fa7-4297-b190-ea98d1882136" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f374b718-7fa7-4297-b190-ea98d1882136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967940ec-2330-43c7-8d66-b389ca0a40f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f374b718-7fa7-4297-b190-ea98d1882136" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967940ec-2330-43c7-8d66-b389ca0a40f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_0cf82075-eb39-45c3-8a73-54ebb0371c93" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967940ec-2330-43c7-8d66-b389ca0a40f3" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_0cf82075-eb39-45c3-8a73-54ebb0371c93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4ba14944-6ca1-4b68-8db6-4f845228b4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4ba14944-6ca1-4b68-8db6-4f845228b4ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_de5d530c-b09e-42cf-abeb-cffaf142821c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_de5d530c-b09e-42cf-abeb-cffaf142821c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_6f74b9bc-7d0a-47c9-9f74-b2c07072ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_6f74b9bc-7d0a-47c9-9f74-b2c07072ee98" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b78e7698-07d9-489e-9492-7ead5af3c7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_95ebbd94-687f-4825-abdd-50968351c88a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b78e7698-07d9-489e-9492-7ead5af3c7c7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_95ebbd94-687f-4825-abdd-50968351c88a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_bd75bb69-e30c-497a-9f09-180e2249a697" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_95ebbd94-687f-4825-abdd-50968351c88a" xlink:to="loc_srt_ShareRepurchaseProgramAxis_bd75bb69-e30c-497a-9f09-180e2249a697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_bd75bb69-e30c-497a-9f09-180e2249a697_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_bd75bb69-e30c-497a-9f09-180e2249a697" xlink:to="loc_srt_ShareRepurchaseProgramDomain_bd75bb69-e30c-497a-9f09-180e2249a697_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_b8815dd7-440f-43da-97ca-b1319f49e90a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_bd75bb69-e30c-497a-9f09-180e2249a697" xlink:to="loc_srt_ShareRepurchaseProgramDomain_b8815dd7-440f-43da-97ca-b1319f49e90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_57e00fb5-1253-417b-b48e-f2f0ab874e03" xlink:href="biib-20240630.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_b8815dd7-440f-43da-97ca-b1319f49e90a" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_57e00fb5-1253-417b-b48e-f2f0ab874e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_71ea88be-c70c-425d-821d-0a378a77e8f0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b78e7698-07d9-489e-9492-7ead5af3c7c7" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_71ea88be-c70c-425d-821d-0a378a77e8f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_3d57d284-2d10-40c0-a9e4-20c6bca40bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b78e7698-07d9-489e-9492-7ead5af3c7c7" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_3d57d284-2d10-40c0-a9e4-20c6bca40bfa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_33f585f1-91d8-4f55-9082-59d026ef1d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_33f585f1-91d8-4f55-9082-59d026ef1d1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37c329a8-2a3a-40c1-b93a-5e70ea6d8769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_33f585f1-91d8-4f55-9082-59d026ef1d1e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37c329a8-2a3a-40c1-b93a-5e70ea6d8769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_37c329a8-2a3a-40c1-b93a-5e70ea6d8769_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37c329a8-2a3a-40c1-b93a-5e70ea6d8769" xlink:to="loc_us-gaap_EquityComponentDomain_37c329a8-2a3a-40c1-b93a-5e70ea6d8769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37c329a8-2a3a-40c1-b93a-5e70ea6d8769" xlink:to="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a5770077-9209-4499-9847-e3c0efd2d5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a5770077-9209-4499-9847-e3c0efd2d5a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_94f5acc3-293e-4fc8-b96c-b18f03f19c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_94f5acc3-293e-4fc8-b96c-b18f03f19c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_fbe02460-8117-4eb3-8b36-67f08e44b201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_fbe02460-8117-4eb3-8b36-67f08e44b201" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ea8c2e81-4c76-432c-b518-f2bc86a312d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ea8c2e81-4c76-432c-b518-f2bc86a312d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e6bc31a9-6cd4-46c4-850d-4406e8dd3a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e6bc31a9-6cd4-46c4-850d-4406e8dd3a43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_230b7c23-b68c-40cd-89cf-f71a9c89791c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a81a3303-8f2c-4d90-bb31-71038f3c1afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a81a3303-8f2c-4d90-bb31-71038f3c1afa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1e8d8932-abdb-4fa4-b978-6c75e3eff719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1e8d8932-abdb-4fa4-b978-6c75e3eff719" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a9fdce9-ac7e-4c47-8dfd-5c4478e24db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a9fdce9-ac7e-4c47-8dfd-5c4478e24db7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8984995b-3772-4081-8736-a36019175f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2481af88-ca88-4aec-a10e-2bb874aae6af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2481af88-ca88-4aec-a10e-2bb874aae6af" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e79f582c-3b76-4b56-a33f-941bf3d2de2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e79f582c-3b76-4b56-a33f-941bf3d2de2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e79f582c-3b76-4b56-a33f-941bf3d2de2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e79f582c-3b76-4b56-a33f-941bf3d2de2c" xlink:to="loc_us-gaap_EquityComponentDomain_e79f582c-3b76-4b56-a33f-941bf3d2de2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0026cf25-ad5b-4771-86c0-c20a677831ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e79f582c-3b76-4b56-a33f-941bf3d2de2c" xlink:to="loc_us-gaap_EquityComponentDomain_0026cf25-ad5b-4771-86c0-c20a677831ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e665190f-6c71-4994-945b-1f5f4755a3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0026cf25-ad5b-4771-86c0-c20a677831ee" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e665190f-6c71-4994-945b-1f5f4755a3ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_577643f4-52bc-4818-969d-91891a8649f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0026cf25-ad5b-4771-86c0-c20a677831ee" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_577643f4-52bc-4818-969d-91891a8649f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6b5d32a6-db85-4a81-b867-b7714adae9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6b5d32a6-db85-4a81-b867-b7714adae9c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6b5d32a6-db85-4a81-b867-b7714adae9c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6b5d32a6-db85-4a81-b867-b7714adae9c2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6b5d32a6-db85-4a81-b867-b7714adae9c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cdf9dbaf-c37c-472b-a880-80ee8d8d47ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6b5d32a6-db85-4a81-b867-b7714adae9c2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cdf9dbaf-c37c-472b-a880-80ee8d8d47ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_edff8cf6-7f76-4bee-893d-282508428828" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cdf9dbaf-c37c-472b-a880-80ee8d8d47ad" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_edff8cf6-7f76-4bee-893d-282508428828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d55393cd-c12c-4401-a72d-15cbed59a1bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d55393cd-c12c-4401-a72d-15cbed59a1bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d55393cd-c12c-4401-a72d-15cbed59a1bd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d55393cd-c12c-4401-a72d-15cbed59a1bd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d55393cd-c12c-4401-a72d-15cbed59a1bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b6575378-3520-46ec-894f-da53a9d0f1b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d55393cd-c12c-4401-a72d-15cbed59a1bd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b6575378-3520-46ec-894f-da53a9d0f1b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_16740855-2215-430f-b3f5-0d4eae340480" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b6575378-3520-46ec-894f-da53a9d0f1b9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_16740855-2215-430f-b3f5-0d4eae340480" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_235986fa-e630-4951-8b90-6db014f3ec28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_235986fa-e630-4951-8b90-6db014f3ec28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fcd188c3-4df1-4f31-bcc7-99bc5af28268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fcd188c3-4df1-4f31-bcc7-99bc5af28268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2e667ae9-8458-45d2-a806-8ae666888e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_Revenues_2e667ae9-8458-45d2-a806-8ae666888e4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_91ba29ad-b020-49cb-b8f8-0190ed8156ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_OperatingExpenses_91ba29ad-b020-49cb-b8f8-0190ed8156ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb0c5db9-4fd4-4ce1-b0c3-ca1f8d9c46e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_NetIncomeLoss_eb0c5db9-4fd4-4ce1-b0c3-ca1f8d9c46e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fcbe0b1a-10df-4106-8560-4c4e7b5941ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fcbe0b1a-10df-4106-8560-4c4e7b5941ec" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57ba6632-06bc-4ca1-9765-8fb128330b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_457237d8-f076-4e80-9661-475a78b3f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57ba6632-06bc-4ca1-9765-8fb128330b6b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_457237d8-f076-4e80-9661-475a78b3f09d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf561f01-4713-43b7-a24c-4ef343347ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_457237d8-f076-4e80-9661-475a78b3f09d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf561f01-4713-43b7-a24c-4ef343347ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf561f01-4713-43b7-a24c-4ef343347ed4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf561f01-4713-43b7-a24c-4ef343347ed4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf561f01-4713-43b7-a24c-4ef343347ed4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf561f01-4713-43b7-a24c-4ef343347ed4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_2df161d2-c28e-4752-8f7d-dcbba642aebc" xlink:href="biib-20240630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_2df161d2-c28e-4752-8f7d-dcbba642aebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_5b3ae2c3-18bf-4220-9b22-e66770adc63d" xlink:href="biib-20240630.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:to="loc_biib_MarketStockUnitsMember_5b3ae2c3-18bf-4220-9b22-e66770adc63d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_15848b74-9c7c-4873-b7aa-d09b51d8c7c6" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_15848b74-9c7c-4873-b7aa-d09b51d8c7c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d532eed1-8d1d-461a-93e0-e3e028799cf4" xlink:href="biib-20240630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57ba6632-06bc-4ca1-9765-8fb128330b6b" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d532eed1-8d1d-461a-93e0-e3e028799cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_271050b9-cbaf-4ce6-925a-cbb603d4dcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d532eed1-8d1d-461a-93e0-e3e028799cf4" xlink:to="loc_us-gaap_NetIncomeLossAbstract_271050b9-cbaf-4ce6-925a-cbb603d4dcd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f25ba3c4-cd00-4b2a-82c8-3d8e637441dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_271050b9-cbaf-4ce6-925a-cbb603d4dcd9" xlink:to="loc_us-gaap_NetIncomeLoss_f25ba3c4-cd00-4b2a-82c8-3d8e637441dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d532eed1-8d1d-461a-93e0-e3e028799cf4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_743317ac-ab02-4ba3-8e93-5f2b53e66310" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_743317ac-ab02-4ba3-8e93-5f2b53e66310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_ae26bfa0-d102-459d-883e-5745ed4c7e77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_ae26bfa0-d102-459d-883e-5745ed4c7e77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_901ff6bc-3435-438a-a3c7-3f4dd1bf781b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_ae26bfa0-d102-459d-883e-5745ed4c7e77" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_901ff6bc-3435-438a-a3c7-3f4dd1bf781b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ddacecbb-f341-4e6c-82e9-021a86ca592d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_ae26bfa0-d102-459d-883e-5745ed4c7e77" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ddacecbb-f341-4e6c-82e9-021a86ca592d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5933716-230d-47dc-94b8-e8d8e32d205a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5933716-230d-47dc-94b8-e8d8e32d205a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_67075d1a-62f2-430c-8d21-8c06edb693df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_67075d1a-62f2-430c-8d21-8c06edb693df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67075d1a-62f2-430c-8d21-8c06edb693df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_67075d1a-62f2-430c-8d21-8c06edb693df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67075d1a-62f2-430c-8d21-8c06edb693df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_67075d1a-62f2-430c-8d21-8c06edb693df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c202c0a6-784e-4239-b41e-2761ba348207" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c202c0a6-784e-4239-b41e-2761ba348207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_39d750f3-dde2-4308-8635-0bd9269000fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_39d750f3-dde2-4308-8635-0bd9269000fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_b1087ce0-5108-4701-927e-2e8f3987c438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:to="loc_us-gaap_ParentMember_b1087ce0-5108-4701-927e-2e8f3987c438" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dbd676b2-6989-43b1-8c9e-16844c0e1709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dbd676b2-6989-43b1-8c9e-16844c0e1709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbd676b2-6989-43b1-8c9e-16844c0e1709_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dbd676b2-6989-43b1-8c9e-16844c0e1709" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbd676b2-6989-43b1-8c9e-16844c0e1709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04384318-d017-43b9-9cd1-00dc269bec2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dbd676b2-6989-43b1-8c9e-16844c0e1709" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04384318-d017-43b9-9cd1-00dc269bec2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_3b82fbd6-f92c-4e3a-8534-9babadafac94" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04384318-d017-43b9-9cd1-00dc269bec2d" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_3b82fbd6-f92c-4e3a-8534-9babadafac94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24120813-557c-4b76-9aa5-15392d0b963b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24120813-557c-4b76-9aa5-15392d0b963b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_047e25c9-70fb-480c-b0a7-2bd373be5200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_047e25c9-70fb-480c-b0a7-2bd373be5200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_25c970c3-6073-4d57-ac5b-b9c5ae15f755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_25c970c3-6073-4d57-ac5b-b9c5ae15f755" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2a03fbd5-012e-4aa4-8913-f71ebb554b5a" xlink:href="biib-20240630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2a03fbd5-012e-4aa4-8913-f71ebb554b5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d12512bb-64a9-41b5-ab78-ccf1f94f8036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d12512bb-64a9-41b5-ab78-ccf1f94f8036" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b8d7cab8-1a4d-4da6-a961-802482cc491e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_OperatingExpenses_b8d7cab8-1a4d-4da6-a961-802482cc491e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_515c0182-8397-463f-9a4c-3a6b9c82bbee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_515c0182-8397-463f-9a4c-3a6b9c82bbee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_99a74d73-4f32-4722-b1ca-92d177091d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_99a74d73-4f32-4722-b1ca-92d177091d31" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_240ca4fb-079a-4867-b574-f88654a5de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_240ca4fb-079a-4867-b574-f88654a5de4a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83e3f55b-f641-424a-af92-acf2292ffb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:to="loc_us-gaap_AwardTypeAxis_83e3f55b-f641-424a-af92-acf2292ffb5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83e3f55b-f641-424a-af92-acf2292ffb5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_83e3f55b-f641-424a-af92-acf2292ffb5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83e3f55b-f641-424a-af92-acf2292ffb5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_83e3f55b-f641-424a-af92-acf2292ffb5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_350c0c4a-fa50-4b93-80b5-16b1e35fb3f1" xlink:href="biib-20240630.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_MarketStockUnitsMember_350c0c4a-fa50-4b93-80b5-16b1e35fb3f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_1627daac-c450-4303-a8e9-3dfb47df9c6c" xlink:href="biib-20240630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_1627daac-c450-4303-a8e9-3dfb47df9c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_1b47f5b4-31f9-4263-94d3-75d1c1e8c4b7" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_1b47f5b4-31f9-4263-94d3-75d1c1e8c4b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_805d74f3-c84f-4843-b5cb-cf43e0fc1c43" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_805d74f3-c84f-4843-b5cb-cf43e0fc1c43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_670ca511-3ee8-4b32-b90d-b08ffc8dbf9c" xlink:href="biib-20240630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_670ca511-3ee8-4b32-b90d-b08ffc8dbf9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b25c7b55-d8a8-4b2e-a3bd-03dd23a7fc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b25c7b55-d8a8-4b2e-a3bd-03dd23a7fc8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6573ece0-ffe0-47ea-81ba-0ba78939982c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6573ece0-ffe0-47ea-81ba-0ba78939982c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6573ece0-ffe0-47ea-81ba-0ba78939982c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6573ece0-ffe0-47ea-81ba-0ba78939982c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6573ece0-ffe0-47ea-81ba-0ba78939982c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e1b98c8-44fb-4fc4-a2be-1a24a5f22d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6573ece0-ffe0-47ea-81ba-0ba78939982c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e1b98c8-44fb-4fc4-a2be-1a24a5f22d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_9c13ea6d-cd86-4464-8cb5-efe0359cc7f6" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e1b98c8-44fb-4fc4-a2be-1a24a5f22d4b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_9c13ea6d-cd86-4464-8cb5-efe0359cc7f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:href="biib-20240630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_240ca4fb-079a-4867-b574-f88654a5de4a" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ed46ff72-a5e8-4d96-a3fe-e17ff9c53c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ed46ff72-a5e8-4d96-a3fe-e17ff9c53c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55b43710-7724-4619-8a0f-26074c738e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55b43710-7724-4619-8a0f-26074c738e4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cdc5cc1f-cf43-4813-a17d-31be145c0f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cdc5cc1f-cf43-4813-a17d-31be145c0f25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_715d1512-8deb-4d8b-99ba-7e17adf3cc23" xlink:href="biib-20240630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_715d1512-8deb-4d8b-99ba-7e17adf3cc23" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#SharebasedPaymentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f6573c11-c69d-4047-9885-d796c748f128" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f6573c11-c69d-4047-9885-d796c748f128" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_670cbdb5-1686-47e9-b131-7c6501f0392b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f6573c11-c69d-4047-9885-d796c748f128" xlink:to="loc_us-gaap_PlanNameAxis_670cbdb5-1686-47e9-b131-7c6501f0392b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_670cbdb5-1686-47e9-b131-7c6501f0392b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_670cbdb5-1686-47e9-b131-7c6501f0392b" xlink:to="loc_us-gaap_PlanNameDomain_670cbdb5-1686-47e9-b131-7c6501f0392b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b888b8bb-e93e-4302-af11-3c84b7138059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_670cbdb5-1686-47e9-b131-7c6501f0392b" xlink:to="loc_us-gaap_PlanNameDomain_b888b8bb-e93e-4302-af11-3c84b7138059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OmnibusEquityPlan2024Member_4b26ddd9-229d-4275-8b52-2c7ae5f75d2f" xlink:href="biib-20240630.xsd#biib_OmnibusEquityPlan2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b888b8bb-e93e-4302-af11-3c84b7138059" xlink:to="loc_biib_OmnibusEquityPlan2024Member_4b26ddd9-229d-4275-8b52-2c7ae5f75d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28173464-23fd-4a35-97c8-0a76e5c6edc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28173464-23fd-4a35-97c8-0a76e5c6edc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_7a801d2d-42e4-468f-b8a9-8db1a9526754" xlink:href="biib-20240630.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_7a801d2d-42e4-468f-b8a9-8db1a9526754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e078422-66d5-41f8-a79a-d09f5fe5f35b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e078422-66d5-41f8-a79a-d09f5fe5f35b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_65df1d95-a5ff-4c37-9db4-f7adcd3cda1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_65df1d95-a5ff-4c37-9db4-f7adcd3cda1f" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b003fdf0-7dad-411e-87e0-2655e1eed613" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:to="loc_srt_StatementScenarioAxis_b003fdf0-7dad-411e-87e0-2655e1eed613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b003fdf0-7dad-411e-87e0-2655e1eed613_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b003fdf0-7dad-411e-87e0-2655e1eed613" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b003fdf0-7dad-411e-87e0-2655e1eed613_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_caa5079d-0671-4110-b27c-d94f7855c277" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b003fdf0-7dad-411e-87e0-2655e1eed613" xlink:to="loc_srt_ScenarioUnspecifiedDomain_caa5079d-0671-4110-b27c-d94f7855c277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5f4d63a7-3683-4571-b367-a4848b53d7ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_caa5079d-0671-4110-b27c-d94f7855c277" xlink:to="loc_srt_ScenarioForecastMember_5f4d63a7-3683-4571-b367-a4848b53d7ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_104661ff-27ae-4aba-adb3-7feba8695694" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_104661ff-27ae-4aba-adb3-7feba8695694" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_104661ff-27ae-4aba-adb3-7feba8695694_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_104661ff-27ae-4aba-adb3-7feba8695694" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_104661ff-27ae-4aba-adb3-7feba8695694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b3c4d4cd-1fa2-4147-85f2-85b14ffc2260" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_104661ff-27ae-4aba-adb3-7feba8695694" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b3c4d4cd-1fa2-4147-85f2-85b14ffc2260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_373692a5-e5e3-4ad0-b051-fcaca2445286" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b3c4d4cd-1fa2-4147-85f2-85b14ffc2260" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_373692a5-e5e3-4ad0-b051-fcaca2445286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_a483159b-ad59-4a19-bcf0-5b113dc67141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_65df1d95-a5ff-4c37-9db4-f7adcd3cda1f" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_a483159b-ad59-4a19-bcf0-5b113dc67141" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:to="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a8c09f48-5d3f-47a5-9ce3-794ce4fef573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a8c09f48-5d3f-47a5-9ce3-794ce4fef573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a8c09f48-5d3f-47a5-9ce3-794ce4fef573_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a8c09f48-5d3f-47a5-9ce3-794ce4fef573" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a8c09f48-5d3f-47a5-9ce3-794ce4fef573_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2d98f2a0-bafe-4b60-b061-05645144dd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a8c09f48-5d3f-47a5-9ce3-794ce4fef573" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2d98f2a0-bafe-4b60-b061-05645144dd3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_c4d9ee6c-1025-4542-817c-55c1cf25f63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2d98f2a0-bafe-4b60-b061-05645144dd3f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_c4d9ee6c-1025-4542-817c-55c1cf25f63a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_55bb62e5-a364-4684-a67d-744e7efb5f98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:to="loc_dei_LegalEntityAxis_55bb62e5-a364-4684-a67d-744e7efb5f98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_55bb62e5-a364-4684-a67d-744e7efb5f98_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_55bb62e5-a364-4684-a67d-744e7efb5f98" xlink:to="loc_dei_EntityDomain_55bb62e5-a364-4684-a67d-744e7efb5f98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c9394315-a6a9-423a-a904-a5b99a6ef0ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_55bb62e5-a364-4684-a67d-744e7efb5f98" xlink:to="loc_dei_EntityDomain_c9394315-a6a9-423a-a904-a5b99a6ef0ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_665b10cf-30ca-4555-8dbc-3ae067e489d9" xlink:href="biib-20240630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c9394315-a6a9-423a-a904-a5b99a6ef0ba" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_665b10cf-30ca-4555-8dbc-3ae067e489d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8904aa17-111d-4c16-a723-561edfc3335d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8904aa17-111d-4c16-a723-561edfc3335d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8904aa17-111d-4c16-a723-561edfc3335d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8904aa17-111d-4c16-a723-561edfc3335d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8904aa17-111d-4c16-a723-561edfc3335d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3f024896-90de-4416-91e5-1ab9988e68d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8904aa17-111d-4c16-a723-561edfc3335d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3f024896-90de-4416-91e5-1ab9988e68d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_79741fa7-a909-47b9-bb50-e04a8d7e592d" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3f024896-90de-4416-91e5-1ab9988e68d4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_79741fa7-a909-47b9-bb50-e04a8d7e592d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_528530bf-4b84-4b49-90a6-f38d5dd5a829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_528530bf-4b84-4b49-90a6-f38d5dd5a829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9efbf3d2-daa7-43ab-8cf1-5db021eec108" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_InterestExpense_9efbf3d2-daa7-43ab-8cf1-5db021eec108" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_338af6b4-daf8-4723-bfaa-31ed88554df0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_338af6b4-daf8-4723-bfaa-31ed88554df0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_23154b04-fb55-424a-ab03-c51b6a1ad3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_23154b04-fb55-424a-ab03-c51b6a1ad3ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d2fd122d-6404-43c0-b105-44887d51be12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d2fd122d-6404-43c0-b105-44887d51be12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1966c744-d54e-4b47-a8af-db582d69bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1966c744-d54e-4b47-a8af-db582d69bed4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_782d09a1-c33d-4eb6-aa00-b6b63a0db8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_782d09a1-c33d-4eb6-aa00-b6b63a0db8f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_6db93fa0-5291-415a-91cb-a9d5fce3352b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_6db93fa0-5291-415a-91cb-a9d5fce3352b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_da3acff9-3820-4276-a88d-11192dea5f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_da3acff9-3820-4276-a88d-11192dea5f29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_993fe9f4-75e6-4698-98f5-5ae14fd4c490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_993fe9f4-75e6-4698-98f5-5ae14fd4c490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_aa79d243-1378-461c-96e2-ba8d344655d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_aa79d243-1378-461c-96e2-ba8d344655d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_056eb2ef-934c-40b7-a9af-4ac6d2a54d32" xlink:href="biib-20240630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_biib_Collaborationexpensesaccrual_056eb2ef-934c-40b7-a9af-4ac6d2a54d32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_f9c3c14a-426d-4394-990a-d5695cf148ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_f9c3c14a-426d-4394-990a-d5695cf148ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_e3d7b154-d00e-46a6-84fb-35bf6ebe45fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_e3d7b154-d00e-46a6-84fb-35bf6ebe45fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2767cab3-621e-4098-b883-d8c1ab7adbed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2767cab3-621e-4098-b883-d8c1ab7adbed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f6154b10-9c74-44ab-9547-30758d4a0236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f6154b10-9c74-44ab-9547-30758d4a0236" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_331be4d3-a38e-4c00-9629-b5a590aa8994" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:to="loc_dei_LegalEntityAxis_331be4d3-a38e-4c00-9629-b5a590aa8994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_331be4d3-a38e-4c00-9629-b5a590aa8994_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_331be4d3-a38e-4c00-9629-b5a590aa8994" xlink:to="loc_dei_EntityDomain_331be4d3-a38e-4c00-9629-b5a590aa8994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_331be4d3-a38e-4c00-9629-b5a590aa8994" xlink:to="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_a6f2d130-eba9-49a2-ade2-5ef6be0462c2" xlink:href="biib-20240630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_a6f2d130-eba9-49a2-ade2-5ef6be0462c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoMember_66787e5d-fbb3-4d54-ade2-74c40b6603d8" xlink:href="biib-20240630.xsd#biib_SangamoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:to="loc_biib_SangamoMember_66787e5d-fbb3-4d54-ade2-74c40b6603d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_96a1bdad-d978-42f5-a70b-0194357669ad" xlink:href="biib-20240630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:to="loc_biib_SageTherapeuticsIncMember_96a1bdad-d978-42f5-a70b-0194357669ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47330f29-3e93-43cb-90e5-1ad8f50d815b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47330f29-3e93-43cb-90e5-1ad8f50d815b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_6326a7a5-89a2-4d04-a7b1-f39d3dc6528b" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47330f29-3e93-43cb-90e5-1ad8f50d815b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_6326a7a5-89a2-4d04-a7b1-f39d3dc6528b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0e73c09-cdfb-4a21-90ed-136034ffa52f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0e73c09-cdfb-4a21-90ed-136034ffa52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_bf0b71df-4f66-4bd0-9865-0199f21bd516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_bf0b71df-4f66-4bd0-9865-0199f21bd516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5135f447-232c-4d94-bdb6-c973c8d0ebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5135f447-232c-4d94-bdb6-c973c8d0ebe4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_235b6a6a-11f2-433c-bcdc-b094926c160e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_235b6a6a-11f2-433c-bcdc-b094926c160e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_07ad7f0a-d406-4dad-b141-e7b43f01c009" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_07ad7f0a-d406-4dad-b141-e7b43f01c009" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38ab3009-810a-4b42-8aba-744d7488a0b1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:to="loc_srt_ProductOrServiceAxis_38ab3009-810a-4b42-8aba-744d7488a0b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_38ab3009-810a-4b42-8aba-744d7488a0b1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_38ab3009-810a-4b42-8aba-744d7488a0b1" xlink:to="loc_srt_ProductsAndServicesDomain_38ab3009-810a-4b42-8aba-744d7488a0b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91a2a042-a8f1-4e7c-98ef-1019d4d3f1fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_38ab3009-810a-4b42-8aba-744d7488a0b1" xlink:to="loc_srt_ProductsAndServicesDomain_91a2a042-a8f1-4e7c-98ef-1019d4d3f1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_81f3e2cf-b62b-4eb7-b45f-2cc824d9fe8e" xlink:href="biib-20240630.xsd#biib_OCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_91a2a042-a8f1-4e7c-98ef-1019d4d3f1fd" xlink:to="loc_biib_OCREVUSMember_81f3e2cf-b62b-4eb7-b45f-2cc824d9fe8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember_0c2e01f8-2369-42e8-8a8b-3a41f168641a" xlink:href="biib-20240630.xsd#biib_MosunetuzumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_91a2a042-a8f1-4e7c-98ef-1019d4d3f1fd" xlink:to="loc_biib_MosunetuzumabMember_0c2e01f8-2369-42e8-8a8b-3a41f168641a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5135de98-3c58-4957-b171-60c771e67d29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:to="loc_srt_RangeAxis_5135de98-3c58-4957-b171-60c771e67d29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5135de98-3c58-4957-b171-60c771e67d29_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5135de98-3c58-4957-b171-60c771e67d29" xlink:to="loc_srt_RangeMember_5135de98-3c58-4957-b171-60c771e67d29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d004e96f-53fc-4426-92bb-a44f6a00afbd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5135de98-3c58-4957-b171-60c771e67d29" xlink:to="loc_srt_RangeMember_d004e96f-53fc-4426-92bb-a44f6a00afbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e444a5af-2e85-4182-8c01-4c7a2a5c4277" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d004e96f-53fc-4426-92bb-a44f6a00afbd" xlink:to="loc_srt_MinimumMember_e444a5af-2e85-4182-8c01-4c7a2a5c4277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_23b21987-a547-4aed-84a2-fb6254bd88e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d004e96f-53fc-4426-92bb-a44f6a00afbd" xlink:to="loc_srt_MaximumMember_23b21987-a547-4aed-84a2-fb6254bd88e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_87c54be2-2a39-4d8d-b127-b251c64cd8a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:to="loc_srt_StatementGeographicalAxis_87c54be2-2a39-4d8d-b127-b251c64cd8a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_87c54be2-2a39-4d8d-b127-b251c64cd8a8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_87c54be2-2a39-4d8d-b127-b251c64cd8a8" xlink:to="loc_srt_SegmentGeographicalDomain_87c54be2-2a39-4d8d-b127-b251c64cd8a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_81746452-9c01-42f6-8fbb-d1b2c019ec5e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_87c54be2-2a39-4d8d-b127-b251c64cd8a8" xlink:to="loc_srt_SegmentGeographicalDomain_81746452-9c01-42f6-8fbb-d1b2c019ec5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_248bcfb6-36be-467f-a69d-10025d747b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_81746452-9c01-42f6-8fbb-d1b2c019ec5e" xlink:to="loc_us-gaap_ForeignCountryMember_248bcfb6-36be-467f-a69d-10025d747b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_92b319aa-3565-44ea-be36-36cb08c289e6" xlink:href="biib-20240630.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_92b319aa-3565-44ea-be36-36cb08c289e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_0a7941ea-cb0f-45b7-bb28-29f53dee49bb" xlink:href="biib-20240630.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_0a7941ea-cb0f-45b7-bb28-29f53dee49bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_5126839f-6846-4b03-b9f7-8b29a4615e84" xlink:href="biib-20240630.xsd#biib_Reductioninroyaltyrate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_Reductioninroyaltyrate_5126839f-6846-4b03-b9f7-8b29a4615e84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_eaa81581-5b11-4798-8ad1-133be6ad7aef" xlink:href="biib-20240630.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_PeriodOfCollaborationAgreement_eaa81581-5b11-4798-8ad1-133be6ad7aef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts_c6dfe22b-7a1c-411c-be54-1a1f963767cc" xlink:href="biib-20240630.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_PercentageOfFutureDevelopmentCosts_c6dfe22b-7a1c-411c-be54-1a1f963767cc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bfb33cf-fbb7-4a9c-8067-c5b07c7d6d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bfb33cf-fbb7-4a9c-8067-c5b07c7d6d83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b0471a0e-6701-43cb-8479-525a6ac64e4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bfb33cf-fbb7-4a9c-8067-c5b07c7d6d83" xlink:to="loc_srt_ProductOrServiceAxis_b0471a0e-6701-43cb-8479-525a6ac64e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b0471a0e-6701-43cb-8479-525a6ac64e4a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b0471a0e-6701-43cb-8479-525a6ac64e4a" xlink:to="loc_srt_ProductsAndServicesDomain_b0471a0e-6701-43cb-8479-525a6ac64e4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1de777ff-bb42-40ad-88ba-02dbf53a3c85" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b0471a0e-6701-43cb-8479-525a6ac64e4a" xlink:to="loc_srt_ProductsAndServicesDomain_1de777ff-bb42-40ad-88ba-02dbf53a3c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_62be4653-e46e-47df-b34b-849536147463" xlink:href="biib-20240630.xsd#biib_RituxanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1de777ff-bb42-40ad-88ba-02dbf53a3c85" xlink:to="loc_biib_RituxanMember_62be4653-e46e-47df-b34b-849536147463" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_c538b7f2-dca1-41fe-abe9-38725566967b" xlink:href="biib-20240630.xsd#biib_GAZYVAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1de777ff-bb42-40ad-88ba-02dbf53a3c85" xlink:to="loc_biib_GAZYVAMember_c538b7f2-dca1-41fe-abe9-38725566967b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_fa91eaf8-a064-41e5-a66f-824330ddc6e0" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_fa91eaf8-a064-41e5-a66f-824330ddc6e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_5f94a738-db19-4f24-b5e9-cdfdbcdea938" xlink:href="biib-20240630.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_5f94a738-db19-4f24-b5e9-cdfdbcdea938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_5da8701a-48fd-4157-9b81-fb5027066d60" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_5da8701a-48fd-4157-9b81-fb5027066d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_d0dcc2d3-cf30-431f-aec8-075eb3d305e4" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_d0dcc2d3-cf30-431f-aec8-075eb3d305e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_17d30a7e-fd00-4467-b669-0dd6431ae594" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_17d30a7e-fd00-4467-b669-0dd6431ae594" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_e27cc73c-015c-4fd0-8044-527209ef9d65" xlink:href="biib-20240630.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_e27cc73c-015c-4fd0-8044-527209ef9d65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_d7be0cc7-c0b7-43b3-865b-9aa401b3071e" xlink:href="biib-20240630.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_d7be0cc7-c0b7-43b3-865b-9aa401b3071e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_009c3f03-54ae-4f3a-8e8f-0aab2c5ec360" xlink:href="biib-20240630.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_009c3f03-54ae-4f3a-8e8f-0aab2c5ec360" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24f718a7-6269-4187-839e-a79d136d4b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24f718a7-6269-4187-839e-a79d136d4b3d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca45aa4b-9037-478e-a9ef-8f6532bf85f2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:to="loc_srt_ProductOrServiceAxis_ca45aa4b-9037-478e-a9ef-8f6532bf85f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca45aa4b-9037-478e-a9ef-8f6532bf85f2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ca45aa4b-9037-478e-a9ef-8f6532bf85f2" xlink:to="loc_srt_ProductsAndServicesDomain_ca45aa4b-9037-478e-a9ef-8f6532bf85f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab4b13f4-4b26-4f42-8b4d-0716c92d32f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ca45aa4b-9037-478e-a9ef-8f6532bf85f2" xlink:to="loc_srt_ProductsAndServicesDomain_ab4b13f4-4b26-4f42-8b4d-0716c92d32f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_2ea2ce3a-1271-44ec-aee2-9d25b71fe306" xlink:href="biib-20240630.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab4b13f4-4b26-4f42-8b4d-0716c92d32f1" xlink:to="loc_biib_LEQEMBICollaborationMember_2ea2ce3a-1271-44ec-aee2-9d25b71fe306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_afc39522-db09-4a17-b5a7-71cd1e7fb48e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_afc39522-db09-4a17-b5a7-71cd1e7fb48e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afc39522-db09-4a17-b5a7-71cd1e7fb48e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afc39522-db09-4a17-b5a7-71cd1e7fb48e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afc39522-db09-4a17-b5a7-71cd1e7fb48e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5568bde7-c17e-4e49-8f17-a4753011e714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afc39522-db09-4a17-b5a7-71cd1e7fb48e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5568bde7-c17e-4e49-8f17-a4753011e714" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_b8887eaf-2817-41f5-98e2-0c26951a2507" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5568bde7-c17e-4e49-8f17-a4753011e714" xlink:to="loc_biib_EisaiMember_b8887eaf-2817-41f5-98e2-0c26951a2507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement_15017746-73b1-4392-8f55-316c3daf640c" xlink:href="biib-20240630.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24f718a7-6269-4187-839e-a79d136d4b3d" xlink:to="loc_biib_AccruedPaymentToTerminationAgreement_15017746-73b1-4392-8f55-316c3daf640c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsMadeToTerminationAgreement_aa2f214b-9fba-4a14-9c79-f705ad5eaa13" xlink:href="biib-20240630.xsd#biib_PaymentsMadeToTerminationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24f718a7-6269-4187-839e-a79d136d4b3d" xlink:to="loc_biib_PaymentsMadeToTerminationAgreement_aa2f214b-9fba-4a14-9c79-f705ad5eaa13" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_32ce83c7-6e72-4d27-8a27-ddbe76248a36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_32ce83c7-6e72-4d27-8a27-ddbe76248a36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b57d4b3a-2ae7-4d29-9492-4b2f6c74cc13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_32ce83c7-6e72-4d27-8a27-ddbe76248a36" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b57d4b3a-2ae7-4d29-9492-4b2f6c74cc13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8237a7e-24da-4fb2-933b-598082578ef7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:to="loc_srt_ProductOrServiceAxis_b8237a7e-24da-4fb2-933b-598082578ef7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8237a7e-24da-4fb2-933b-598082578ef7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8237a7e-24da-4fb2-933b-598082578ef7" xlink:to="loc_srt_ProductsAndServicesDomain_b8237a7e-24da-4fb2-933b-598082578ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d786a0b8-a8ec-49e4-b11e-c419b6dd452c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8237a7e-24da-4fb2-933b-598082578ef7" xlink:to="loc_srt_ProductsAndServicesDomain_d786a0b8-a8ec-49e4-b11e-c419b6dd452c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_2f2afe3b-dabc-403a-9a4a-aa6ba8cbd0a7" xlink:href="biib-20240630.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d786a0b8-a8ec-49e4-b11e-c419b6dd452c" xlink:to="loc_biib_E2609andBAN2401Member_2f2afe3b-dabc-403a-9a4a-aa6ba8cbd0a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c99e06a4-0209-4ba4-bc2f-ce8e055775f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c99e06a4-0209-4ba4-bc2f-ce8e055775f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c99e06a4-0209-4ba4-bc2f-ce8e055775f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c99e06a4-0209-4ba4-bc2f-ce8e055775f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c99e06a4-0209-4ba4-bc2f-ce8e055775f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cfc5934-7251-43b8-b1db-4daf952bcdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c99e06a4-0209-4ba4-bc2f-ce8e055775f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cfc5934-7251-43b8-b1db-4daf952bcdfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_9c55526f-1085-4b95-a298-2a032d116e53" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cfc5934-7251-43b8-b1db-4daf952bcdfa" xlink:to="loc_biib_EisaiMember_9c55526f-1085-4b95-a298-2a032d116e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_2be90489-a67a-4405-a587-89920b2e671e" xlink:href="biib-20240630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:to="loc_biib_ExpenseIncurredByCollaboration_2be90489-a67a-4405-a587-89920b2e671e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_c548371c-cc09-4ff4-b233-52cff8f33dfb" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_c548371c-cc09-4ff4-b233-52cff8f33dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_0913376c-8198-4ca3-9965-ac5ca000264b" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:to="loc_biib_Expenseincurredbythecollaboration_0913376c-8198-4ca3-9965-ac5ca000264b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad352321-374b-4328-8d76-64231f40c160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad352321-374b-4328-8d76-64231f40c160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_23e2b9f1-b5d7-47e3-a930-cfcd62202306" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad352321-374b-4328-8d76-64231f40c160" xlink:to="loc_biib_EisaiMember_23e2b9f1-b5d7-47e3-a930-cfcd62202306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_30178907-ee54-4902-80e0-98345c0be4b3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:to="loc_srt_RangeAxis_30178907-ee54-4902-80e0-98345c0be4b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30178907-ee54-4902-80e0-98345c0be4b3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_30178907-ee54-4902-80e0-98345c0be4b3" xlink:to="loc_srt_RangeMember_30178907-ee54-4902-80e0-98345c0be4b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0447c47f-68a1-4a98-81b6-f8ea69ec9546" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_30178907-ee54-4902-80e0-98345c0be4b3" xlink:to="loc_srt_RangeMember_0447c47f-68a1-4a98-81b6-f8ea69ec9546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af7ddb69-d5ce-4c2b-9672-62a602314553" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0447c47f-68a1-4a98-81b6-f8ea69ec9546" xlink:to="loc_srt_MaximumMember_af7ddb69-d5ce-4c2b-9672-62a602314553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_999eca34-8b16-49ba-a128-e8647c6d8577" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:to="loc_srt_StatementScenarioAxis_999eca34-8b16-49ba-a128-e8647c6d8577" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_999eca34-8b16-49ba-a128-e8647c6d8577_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_999eca34-8b16-49ba-a128-e8647c6d8577" xlink:to="loc_srt_ScenarioUnspecifiedDomain_999eca34-8b16-49ba-a128-e8647c6d8577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_667157b2-aa0f-495e-93c3-7a6f40778b28" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_999eca34-8b16-49ba-a128-e8647c6d8577" xlink:to="loc_srt_ScenarioUnspecifiedDomain_667157b2-aa0f-495e-93c3-7a6f40778b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_dd573579-edbf-4cf1-bfce-4c34eaf199fe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_667157b2-aa0f-495e-93c3-7a6f40778b28" xlink:to="loc_srt_ScenarioForecastMember_dd573579-edbf-4cf1-bfce-4c34eaf199fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d99b6e43-6b85-420a-8f41-0fae69344297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d99b6e43-6b85-420a-8f41-0fae69344297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ff57b691-2ef6-4ba6-98d9-c3193731a934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_us-gaap_InventoryWriteDown_ff57b691-2ef6-4ba6-98d9-c3193731a934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator_22a4fe6b-d1f1-4998-a568-b183f83b4e31" xlink:href="biib-20240630.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_biib_AccountsReceivableFromCollaborator_22a4fe6b-d1f1-4998-a568-b183f83b4e31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator_8c54ce12-1296-40c1-ba6d-7065d74ac2c3" xlink:href="biib-20240630.xsd#biib_AccountsPayableToCollaborator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_biib_AccountsPayableToCollaborator_8c54ce12-1296-40c1-ba6d-7065d74ac2c3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19200724-c6f3-4a43-a7c4-f852b524a496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19200724-c6f3-4a43-a7c4-f852b524a496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19200724-c6f3-4a43-a7c4-f852b524a496_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19200724-c6f3-4a43-a7c4-f852b524a496" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19200724-c6f3-4a43-a7c4-f852b524a496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_89411526-ae45-4b02-944b-e34ab183311c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19200724-c6f3-4a43-a7c4-f852b524a496" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_89411526-ae45-4b02-944b-e34ab183311c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eae9aa73-a132-420a-9837-62b6360b11da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_89411526-ae45-4b02-944b-e34ab183311c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eae9aa73-a132-420a-9837-62b6360b11da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3a91711-4d25-416c-ba8d-01182f51da8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_89411526-ae45-4b02-944b-e34ab183311c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3a91711-4d25-416c-ba8d-01182f51da8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d58ef02a-7173-4d22-b7ee-f85061e6d9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d58ef02a-7173-4d22-b7ee-f85061e6d9ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d58ef02a-7173-4d22-b7ee-f85061e6d9ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d58ef02a-7173-4d22-b7ee-f85061e6d9ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d58ef02a-7173-4d22-b7ee-f85061e6d9ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7145057-a907-4908-8c19-ccb3e375bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d58ef02a-7173-4d22-b7ee-f85061e6d9ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7145057-a907-4908-8c19-ccb3e375bed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_51e2043a-fb9d-4797-bc72-6aee7718c012" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7145057-a907-4908-8c19-ccb3e375bed3" xlink:to="loc_biib_EisaiMember_51e2043a-fb9d-4797-bc72-6aee7718c012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_506b80c6-0c81-4617-a35d-1978971e8fdd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:to="loc_srt_ProductOrServiceAxis_506b80c6-0c81-4617-a35d-1978971e8fdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_506b80c6-0c81-4617-a35d-1978971e8fdd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_506b80c6-0c81-4617-a35d-1978971e8fdd" xlink:to="loc_srt_ProductsAndServicesDomain_506b80c6-0c81-4617-a35d-1978971e8fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59036f12-56dd-4b16-9c92-16cd4aec8c7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_506b80c6-0c81-4617-a35d-1978971e8fdd" xlink:to="loc_srt_ProductsAndServicesDomain_59036f12-56dd-4b16-9c92-16cd4aec8c7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_6247390d-c05b-4493-a6de-2b62ad6d7322" xlink:href="biib-20240630.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_59036f12-56dd-4b16-9c92-16cd4aec8c7c" xlink:to="loc_biib_LEQEMBICollaborationMember_6247390d-c05b-4493-a6de-2b62ad6d7322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_95fb7304-4cf9-4a52-8a09-b91721921544" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_biib_Expenseincurredbythecollaboration_95fb7304-4cf9-4a52-8a09-b91721921544" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9aa157b2-7792-4efc-9a84-ba3d81f25c23" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9aa157b2-7792-4efc-9a84-ba3d81f25c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_b5de06ee-597c-4ef7-81b0-074774c9ef21" xlink:href="biib-20240630.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_b5de06ee-597c-4ef7-81b0-074774c9ef21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c98fc958-f926-4da8-a47b-1c41faa52968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c98fc958-f926-4da8-a47b-1c41faa52968" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de728f49-ea9c-4bbc-a2d2-6421f440c4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de728f49-ea9c-4bbc-a2d2-6421f440c4e2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ba7e5c0b-e623-4947-ae85-b18a05ebbad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ba7e5c0b-e623-4947-ae85-b18a05ebbad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ba7e5c0b-e623-4947-ae85-b18a05ebbad6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba7e5c0b-e623-4947-ae85-b18a05ebbad6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ba7e5c0b-e623-4947-ae85-b18a05ebbad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0887ce46-4ee4-4d6d-8e2b-1c76060f9edb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba7e5c0b-e623-4947-ae85-b18a05ebbad6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0887ce46-4ee4-4d6d-8e2b-1c76060f9edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_67700d65-a091-4f80-ab96-e32cd6ddee63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0887ce46-4ee4-4d6d-8e2b-1c76060f9edb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_67700d65-a091-4f80-ab96-e32cd6ddee63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_08e826c5-b645-4079-9604-c99213d48238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_08e826c5-b645-4079-9604-c99213d48238" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_08e826c5-b645-4079-9604-c99213d48238_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_08e826c5-b645-4079-9604-c99213d48238" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_08e826c5-b645-4079-9604-c99213d48238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40ba7f13-6b6d-426a-8308-b2b1bf21c405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_08e826c5-b645-4079-9604-c99213d48238" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40ba7f13-6b6d-426a-8308-b2b1bf21c405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_a2ee7e1c-bfbd-4149-80c2-5cc7617f725d" xlink:href="biib-20240630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40ba7f13-6b6d-426a-8308-b2b1bf21c405" xlink:to="loc_biib_UCBPharmaS.A.Member_a2ee7e1c-bfbd-4149-80c2-5cc7617f725d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_675c85b3-1ca4-4a18-8f19-c5a1281771a8" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de728f49-ea9c-4bbc-a2d2-6421f440c4e2" xlink:to="loc_biib_Expenseincurredbythecollaboration_675c85b3-1ca4-4a18-8f19-c5a1281771a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9ded1850-390b-4368-a473-a0afe1daccb0" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de728f49-ea9c-4bbc-a2d2-6421f440c4e2" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9ded1850-390b-4368-a473-a0afe1daccb0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c5eadb6-07ef-47c8-a465-8293ebbe72f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c5eadb6-07ef-47c8-a465-8293ebbe72f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fed9a078-0736-471f-a8ac-f2295ca540f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c5eadb6-07ef-47c8-a465-8293ebbe72f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fed9a078-0736-471f-a8ac-f2295ca540f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_78a94e5f-e7b0-4f42-be20-22e8ff4397e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c5eadb6-07ef-47c8-a465-8293ebbe72f2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_78a94e5f-e7b0-4f42-be20-22e8ff4397e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d5f133b8-986b-45ec-8c13-964e9a4e1690" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d5f133b8-986b-45ec-8c13-964e9a4e1690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5f133b8-986b-45ec-8c13-964e9a4e1690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5f133b8-986b-45ec-8c13-964e9a4e1690" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5f133b8-986b-45ec-8c13-964e9a4e1690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df691c2e-cb88-4efa-b28b-a771d6345034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5f133b8-986b-45ec-8c13-964e9a4e1690" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df691c2e-cb88-4efa-b28b-a771d6345034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_8b80afe4-e62c-4442-b655-65c82ffa5c5b" xlink:href="biib-20240630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df691c2e-cb88-4efa-b28b-a771d6345034" xlink:to="loc_biib_SageTherapeuticsIncMember_8b80afe4-e62c-4442-b655-65c82ffa5c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:to="loc_srt_StatementScenarioAxis_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dfee4ca0-fbff-4f74-91db-71acad3a61cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_dfee4ca0-fbff-4f74-91db-71acad3a61cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_67c2821f-7013-4351-9f02-c0d89e55b01a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_dfee4ca0-fbff-4f74-91db-71acad3a61cf" xlink:to="loc_srt_ScenarioForecastMember_67c2821f-7013-4351-9f02-c0d89e55b01a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_392f5c1d-070d-483d-9d3e-a27c1970d141" xlink:href="biib-20240630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_392f5c1d-070d-483d-9d3e-a27c1970d141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_4ec69178-babe-4026-a148-41b5bf77c116" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_Expenseincurredbythecollaboration_4ec69178-babe-4026-a148-41b5bf77c116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_0ed29e9d-9493-4e11-bab1-440ec9c31f64" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_0ed29e9d-9493-4e11-bab1-440ec9c31f64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_4ed6565f-d64a-4fec-a41e-de8bd99d69be" xlink:href="biib-20240630.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_4ed6565f-d64a-4fec-a41e-de8bd99d69be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_b5b01c65-77a8-40e2-b2e9-58e31af36a9f" xlink:href="biib-20240630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_Collaborationprofitlosssharing_b5b01c65-77a8-40e2-b2e9-58e31af36a9f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d820b1e-71ad-4d40-a910-00e6d942477c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d820b1e-71ad-4d40-a910-00e6d942477c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5dc419df-7a6d-4715-a523-8bccdb1fdb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5dc419df-7a6d-4715-a523-8bccdb1fdb1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5dc419df-7a6d-4715-a523-8bccdb1fdb1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5dc419df-7a6d-4715-a523-8bccdb1fdb1a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5dc419df-7a6d-4715-a523-8bccdb1fdb1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c5527093-e5fc-4808-a368-379264f029fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5dc419df-7a6d-4715-a523-8bccdb1fdb1a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c5527093-e5fc-4808-a368-379264f029fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4c5b26de-86d3-450e-891d-e9963536dc97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c5527093-e5fc-4808-a368-379264f029fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4c5b26de-86d3-450e-891d-e9963536dc97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b36be539-e346-45e5-9176-58756ab25b00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b36be539-e346-45e5-9176-58756ab25b00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b36be539-e346-45e5-9176-58756ab25b00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b36be539-e346-45e5-9176-58756ab25b00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b36be539-e346-45e5-9176-58756ab25b00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb53db1d-5dc1-44ad-a7a9-d418da4f7914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b36be539-e346-45e5-9176-58756ab25b00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb53db1d-5dc1-44ad-a7a9-d418da4f7914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_e62a73df-4d08-43b9-8c4a-6c4b3b009c5d" xlink:href="biib-20240630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb53db1d-5dc1-44ad-a7a9-d418da4f7914" xlink:to="loc_biib_DenaliTherapeuticsIncMember_e62a73df-4d08-43b9-8c4a-6c4b3b009c5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_edfa13b8-4e51-4110-bb91-6df23faf6464" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d820b1e-71ad-4d40-a910-00e6d942477c" xlink:to="loc_biib_Expenseincurredbythecollaboration_edfa13b8-4e51-4110-bb91-6df23faf6464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_668c5d48-ac6b-4c6f-b6c2-ea018cdefaeb" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d820b1e-71ad-4d40-a910-00e6d942477c" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_668c5d48-ac6b-4c6f-b6c2-ea018cdefaeb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8589f60-e83b-4871-bfb5-7b6aaeb6ac94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_855852b5-fb00-4a17-aff1-712e65940af9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8589f60-e83b-4871-bfb5-7b6aaeb6ac94" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_855852b5-fb00-4a17-aff1-712e65940af9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_947f3753-d42f-4bf3-9a9d-8befd69f4b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_855852b5-fb00-4a17-aff1-712e65940af9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_947f3753-d42f-4bf3-9a9d-8befd69f4b42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_947f3753-d42f-4bf3-9a9d-8befd69f4b42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_947f3753-d42f-4bf3-9a9d-8befd69f4b42" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_947f3753-d42f-4bf3-9a9d-8befd69f4b42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc249c0d-68ef-4848-937c-a96358471ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_947f3753-d42f-4bf3-9a9d-8befd69f4b42" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc249c0d-68ef-4848-937c-a96358471ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e59b1f7-736f-4a38-9a3a-a634ef87d619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc249c0d-68ef-4848-937c-a96358471ae4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e59b1f7-736f-4a38-9a3a-a634ef87d619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_f246ce05-dad3-4e26-98a3-d29da1ff99a6" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8589f60-e83b-4871-bfb5-7b6aaeb6ac94" xlink:to="loc_biib_Expenseincurredbythecollaboration_f246ce05-dad3-4e26-98a3-d29da1ff99a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_6497db64-983d-484f-a38a-0fb464de9d6e" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8589f60-e83b-4871-bfb5-7b6aaeb6ac94" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_6497db64-983d-484f-a38a-0fb464de9d6e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c92dcbe6-7365-47dd-af89-7e57f84c6bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d21a7246-da80-4ac7-b82d-c3f3bd77dad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c92dcbe6-7365-47dd-af89-7e57f84c6bd9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d21a7246-da80-4ac7-b82d-c3f3bd77dad9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5b7db595-5b8f-49ed-bb70-4c8999b30c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d21a7246-da80-4ac7-b82d-c3f3bd77dad9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5b7db595-5b8f-49ed-bb70-4c8999b30c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b7db595-5b8f-49ed-bb70-4c8999b30c8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b7db595-5b8f-49ed-bb70-4c8999b30c8b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b7db595-5b8f-49ed-bb70-4c8999b30c8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d13e8b2b-a4bd-4f42-94bd-c94ef5427f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b7db595-5b8f-49ed-bb70-4c8999b30c8b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d13e8b2b-a4bd-4f42-94bd-c94ef5427f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_1f0772e1-2870-4ec5-b5af-b77ad35a8621" xlink:href="biib-20240630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d13e8b2b-a4bd-4f42-94bd-c94ef5427f5c" xlink:to="loc_biib_OtherresearchanddiscoveryMember_1f0772e1-2870-4ec5-b5af-b77ad35a8621" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f5721227-31a9-4f78-91d4-e03696cfb5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c92dcbe6-7365-47dd-af89-7e57f84c6bd9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f5721227-31a9-4f78-91d4-e03696cfb5b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e4b54172-a9d6-4fdb-bc06-80012bdae85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e4b54172-a9d6-4fdb-bc06-80012bdae85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4b54172-a9d6-4fdb-bc06-80012bdae85c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e4b54172-a9d6-4fdb-bc06-80012bdae85c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4b54172-a9d6-4fdb-bc06-80012bdae85c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_890cbdbd-9918-455f-b9bf-719e9d3ab7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e4b54172-a9d6-4fdb-bc06-80012bdae85c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_890cbdbd-9918-455f-b9bf-719e9d3ab7dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_205f0bab-a597-40c4-b731-67219b37544e" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_890cbdbd-9918-455f-b9bf-719e9d3ab7dd" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_205f0bab-a597-40c4-b731-67219b37544e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_675a93b9-2e69-44a7-b6d2-b309e8446d35" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_675a93b9-2e69-44a7-b6d2-b309e8446d35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_675a93b9-2e69-44a7-b6d2-b309e8446d35_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_675a93b9-2e69-44a7-b6d2-b309e8446d35" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_675a93b9-2e69-44a7-b6d2-b309e8446d35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e05753f9-c12a-45cd-8b5f-6ba6926488cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_675a93b9-2e69-44a7-b6d2-b309e8446d35" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e05753f9-c12a-45cd-8b5f-6ba6926488cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_007c45f2-6263-44e8-a0ca-282580c2faf2" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e05753f9-c12a-45cd-8b5f-6ba6926488cd" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_007c45f2-6263-44e8-a0ca-282580c2faf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc667fd-85f6-424d-b971-d4ab600d2388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc667fd-85f6-424d-b971-d4ab600d2388" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5fc667fd-85f6-424d-b971-d4ab600d2388_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc667fd-85f6-424d-b971-d4ab600d2388" xlink:to="loc_us-gaap_RelatedPartyDomain_5fc667fd-85f6-424d-b971-d4ab600d2388_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9b75fa00-e97f-4514-9be7-ce30b5b2a5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc667fd-85f6-424d-b971-d4ab600d2388" xlink:to="loc_us-gaap_RelatedPartyDomain_9b75fa00-e97f-4514-9be7-ce30b5b2a5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_7d366009-6536-49b1-b799-3b067f46bf01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9b75fa00-e97f-4514-9be7-ce30b5b2a5b2" xlink:to="loc_us-gaap_RelatedPartyMember_7d366009-6536-49b1-b799-3b067f46bf01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_a6f4f55a-a0de-436b-9931-58d097084da4" xlink:href="biib-20240630.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_a6f4f55a-a0de-436b-9931-58d097084da4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_6650dfd7-fc14-4d56-a913-f2eb167e85ba" xlink:href="biib-20240630.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_6650dfd7-fc14-4d56-a913-f2eb167e85ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_58651e5b-2c5a-4870-8af1-ef4565477cc5" xlink:href="biib-20240630.xsd#biib_AccruedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_AccruedMilestonePayments_58651e5b-2c5a-4870-8af1-ef4565477cc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_48d71d5c-f56f-48ca-89cc-b5d37de0615e" xlink:href="biib-20240630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_48d71d5c-f56f-48ca-89cc-b5d37de0615e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension_e35ef01c-f21a-492d-82f1-91024653861f" xlink:href="biib-20240630.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_CollaborativeArrangementTermExtension_e35ef01c-f21a-492d-82f1-91024653861f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_76503be7-8c73-47c7-8496-1c61fbc1a958" xlink:href="biib-20240630.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_ContractOptionExerciseFee_76503be7-8c73-47c7-8496-1c61fbc1a958" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementContractOptionExerciseFeePaid_61b9fdb4-b132-407d-a1c0-6563d280f8f0" xlink:href="biib-20240630.xsd#biib_CollaborativeArrangementContractOptionExerciseFeePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_CollaborativeArrangementContractOptionExerciseFeePaid_61b9fdb4-b132-407d-a1c0-6563d280f8f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_95a34780-e95b-40e7-86b3-eeb222fbd201" xlink:href="biib-20240630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_Collaborationprofitlosssharing_95a34780-e95b-40e7-86b3-eeb222fbd201" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_f8e5a758-f659-45be-a662-cdba67cd4c39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_us-gaap_AccountsReceivableNet_f8e5a758-f659-45be-a662-cdba67cd4c39" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_5e401a0d-7acd-43b4-ab4e-b7ffeac54b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_5e401a0d-7acd-43b4-ab4e-b7ffeac54b1d" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_102664ef-86e5-4105-b726-c7addfffee44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_102664ef-86e5-4105-b726-c7addfffee44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4ceb5db3-02b2-458a-b576-ca06d627d8a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_102664ef-86e5-4105-b726-c7addfffee44" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4ceb5db3-02b2-458a-b576-ca06d627d8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4ceb5db3-02b2-458a-b576-ca06d627d8a1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4ceb5db3-02b2-458a-b576-ca06d627d8a1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4ceb5db3-02b2-458a-b576-ca06d627d8a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0fdaa736-8342-4083-b973-3bea91d6c7d0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4ceb5db3-02b2-458a-b576-ca06d627d8a1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0fdaa736-8342-4083-b973-3bea91d6c7d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_ab3f67bc-16fc-4c81-8792-9d135f9dc74a" xlink:href="biib-20240630.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0fdaa736-8342-4083-b973-3bea91d6c7d0" xlink:to="loc_biib_NeurimmuneMember_ab3f67bc-16fc-4c81-8792-9d135f9dc74a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_f2e5809a-4516-4d6b-a1ad-a80209d42e67" xlink:href="biib-20240630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_f2e5809a-4516-4d6b-a1ad-a80209d42e67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_eb31db10-469e-4a2c-ac80-1e2028e71edb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_eb31db10-469e-4a2c-ac80-1e2028e71edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_152a5314-8e2d-4bb9-95a5-8361fe4b5ec9" xlink:href="biib-20240630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_152a5314-8e2d-4bb9-95a5-8361fe4b5ec9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#LitigationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_847e936c-1f68-44c6-94e3-ff2fe03fb715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_210ce860-c68b-4f86-b98d-c420a27828de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_847e936c-1f68-44c6-94e3-ff2fe03fb715" xlink:to="loc_us-gaap_LossContingenciesTable_210ce860-c68b-4f86-b98d-c420a27828de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e6e33b0c-9584-4f61-8f01-c236d5c84152" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_210ce860-c68b-4f86-b98d-c420a27828de" xlink:to="loc_srt_LitigationCaseAxis_e6e33b0c-9584-4f61-8f01-c236d5c84152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e6e33b0c-9584-4f61-8f01-c236d5c84152_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_e6e33b0c-9584-4f61-8f01-c236d5c84152" xlink:to="loc_srt_LitigationCaseTypeDomain_e6e33b0c-9584-4f61-8f01-c236d5c84152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_09149326-84f3-4ca2-b123-f55fc3eeeaf6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_e6e33b0c-9584-4f61-8f01-c236d5c84152" xlink:to="loc_srt_LitigationCaseTypeDomain_09149326-84f3-4ca2-b123-f55fc3eeeaf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_3676005c-3c82-4988-9a94-77a24ed4577d" xlink:href="biib-20240630.xsd#biib_GenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_09149326-84f3-4ca2-b123-f55fc3eeeaf6" xlink:to="loc_biib_GenentechMember_3676005c-3c82-4988-9a94-77a24ed4577d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember_5ed2294d-2ee8-40cc-a694-e0e3aa486121" xlink:href="biib-20240630.xsd#biib_LenderDisputeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_09149326-84f3-4ca2-b123-f55fc3eeeaf6" xlink:to="loc_biib_LenderDisputeMember_5ed2294d-2ee8-40cc-a694-e0e3aa486121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_ad3c8925-093f-43d7-a5ec-12ce317b12eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_847e936c-1f68-44c6-94e3-ff2fe03fb715" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_ad3c8925-093f-43d7-a5ec-12ce317b12eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_e5904096-0a59-4a41-ae1e-382dcf747124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_847e936c-1f68-44c6-94e3-ff2fe03fb715" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_e5904096-0a59-4a41-ae1e-382dcf747124" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_c4813733-1ae4-4714-84e0-344e48ee16ab" xlink:href="biib-20240630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_c4813733-1ae4-4714-84e0-344e48ee16ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_d98cb4a3-bad0-449c-8eeb-8ec568534bda" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_d98cb4a3-bad0-449c-8eeb-8ec568534bda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_2ef34f63-6833-4675-9fda-9f670fa33b35" xlink:href="biib-20240630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_2ef34f63-6833-4675-9fda-9f670fa33b35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_ff26eb4f-6329-4b66-910b-9f811f7a88a0" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_ff26eb4f-6329-4b66-910b-9f811f7a88a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_3be5a86e-d566-4929-9a1d-022cb7ea8bd1" xlink:href="biib-20240630.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_MarketStockUnitsMember_3be5a86e-d566-4929-9a1d-022cb7ea8bd1" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>biib-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a009166-a1cb-4c50-83a7-d8b5a99052fa,g:b0d9c5b1-5cff-4c82-aab8-c75b5958a97b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_af4fa404-9c7e-4a49-978c-fd29a2bdd04a_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20240630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_016fd162-bb70-4ba7-bb98-4c7315210480_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_03c5d032-c5c2-4d9a-9589-7b939b44ce87_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b43eaaa7-0c98-4a3a-ab91-99ede9087278_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_da81893c-1989-477d-9be3-2e97be9188ec_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9de5a043-c402-446d-a807-cd91e39cfe23_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_dbcf2bdb-19e4-4b73-8c94-cefbbadf5b96_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_23505fb5-86e5-4182-bfb2-faadddd8f1f6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_45f657ef-6d97-46db-ab5e-cab9a97087e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0005e67b-90e3-49a7-899f-06bd0c8c07a6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_596ab03d-c1f0-4f51-b126-79113e9a2913_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_6a39c582-cd69-41fa-b0f5-9bc0aae11fbf_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: Net (gains) losses realized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_9e625ba4-8f98-4fc0-a850-b8f1c13bd654_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_26b67e25-414d-4ac8-b3b5-ac0963a47ce5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_7ffb243c-e81b-443d-a846-92cea8a28398_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_754cf146-f60e-4738-98d6-d6dbe00d6763_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_57c36975-d0ac-4378-9714-ebc19c03d128_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_66873912-fc24-4e75-aa82-d6c929b51d12_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_d541d54b-8cef-4832-a8d3-9875e41f1c51_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20240630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_14cca614-64d6-4567-8b31-5264a74edc39_terseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty percentage to be received</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:href="biib-20240630.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_ac9950a4-a721-406b-a73e-966d9fb503ae_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20240630.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0314e911-1d36-467e-98b3-e831305bb24b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_baa2aa63-7a2c-4211-bd57-9487752f7b11_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_3340c541-40ed-4835-9ef8-7280573f897c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_76ab24a0-e2ad-49bb-8a7a-a703eed103ad_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e1a842fc-fcce-4e7b-bc3d-7b987ea696e2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_2d4c92e3-42b9-42b2-b860-ea1e9d310391_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023TermLoanMember_2bcbbb2b-094d-4df2-ac0b-54dde256db71_terseLabel_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Term Loan</link:label>
    <link:label id="lab_biib_A2023TermLoanMember_label_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Term Loan [Member]</link:label>
    <link:label id="lab_biib_A2023TermLoanMember_documentation_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember" xlink:href="biib-20240630.xsd#biib_A2023TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023TermLoanMember" xlink:to="lab_biib_A2023TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_b9f77e2e-dca8-4cc3-93d6-7885b8ea9878_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of priority review voucher, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b4680799-ef9a-404c-a3b7-55826db433e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_966c7cf3-90df-4706-ab6f-ad65465bea4d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_edec4995-f0c0-437b-b393-bc4ca61a3930_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_55e144b2-5c77-4494-be34-181843f68bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7c7b2f59-2596-49bb-9d5a-cf7b0b013a61_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_e426ae11-3bcb-411a-bd63-b035f77e571d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_fdf64253-4a4f-447c-9cf7-b2f4b284125a_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fd7732ea-d7a1-454b-9e34-858bb4498f41_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5247340d-d4a8-4dcd-b271-3224dd3ddc3d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_2aec17d4-fd02-4593-a1c2-ac54c9984dc1_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_40c0dbd0-91e9-47d6-9e60-0ea778280dc2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_0514a3a0-a859-4777-ba91-f3c029d869bd_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3654c0df-8b47-460b-8b67-7a041675f3d9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_afde14bb-6065-4aae-b5d3-a32316f074ca_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6419ff8d-c434-4417-aa3a-0e88564e0049_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ba59ae86-758c-42dc-a0c6-5824e5231983_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_93eb2e3c-6c2b-4695-9704-c531feb7491d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6075c69c-6cda-43e3-888e-fee509c68b5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TOFIDENCEMember_537eba08-6fd3-478f-a866-59ab41bb0fa8_terseLabel_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TOFIDENCE</link:label>
    <link:label id="lab_biib_TOFIDENCEMember_label_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TOFIDENCE [Member]</link:label>
    <link:label id="lab_biib_TOFIDENCEMember_documentation_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TOFIDENCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember" xlink:href="biib-20240630.xsd#biib_TOFIDENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TOFIDENCEMember" xlink:to="lab_biib_TOFIDENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_562dfc52-bbbe-4413-8fba-401b7927ba92_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_61cb3824-1133-4894-81f8-285e124c637f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_fe0f540e-2f96-4f42-9862-abd34312b4d5_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20240630.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_533d3a50-f96d-444f-a1c2-2e3fca72372c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eadf464-417f-49af-afa0-61afecb847a3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_33f3d92e-7a5e-415e-832e-e7e591741d8b_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20240630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_3f8f52dc-e2c4-47e3-bd9d-d79d40d381b5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f9db49d2-83da-4424-9e30-146be164fc4a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ddb9eb6e-a02d-4d82-9e06-8730752cba09_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_8bca1fc3-00cb-458e-9228-e1887a673f10_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20240630.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_359e8529-2aab-481d-8503-1987b4c3bded_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_9e9cfeef-2458-486d-94a0-1cc4c9078727_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20240630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d700aec9-981c-4960-9484-d1aebd08aea3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_b8f111e5-8b40-44c0-84a1-bf40da1e8158_terseLabel_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_label_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_documentation_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:href="biib-20240630.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:to="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f413e268-7555-4e25-86be-475d3d0e7084_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_a316e08b-349e-4da7-a83b-a97b9f7358bf_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementContractOptionExerciseFeePaid_991b5265-6edc-4054-98e6-1b2e3a77fa10_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementContractOptionExerciseFeePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee paid</link:label>
    <link:label id="lab_biib_CollaborativeArrangementContractOptionExerciseFeePaid_label_en-US" xlink:label="lab_biib_CollaborativeArrangementContractOptionExerciseFeePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contract Option Exercise Fee Paid</link:label>
    <link:label id="lab_biib_CollaborativeArrangementContractOptionExerciseFeePaid_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementContractOptionExerciseFeePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contract Option Exercise Fee Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementContractOptionExerciseFeePaid" xlink:href="biib-20240630.xsd#biib_CollaborativeArrangementContractOptionExerciseFeePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementContractOptionExerciseFeePaid" xlink:to="lab_biib_CollaborativeArrangementContractOptionExerciseFeePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_6355b98c-5f57-4470-bb11-4e544ae36817_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20240630.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_e88fe6eb-1cc1-4495-b152-8d7f532a717e_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20240630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1c85868d-6a4a-4de3-ac67-020504d89048_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_75690706-512e-46bc-ae99-393af0911b02_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_5f323eaa-edd4-468d-8324-8a13f4414bc0_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20240630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_527b7c3c-a62c-4488-a067-1fdb65ff7d0f_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_dbac4dde-6709-4052-bb2a-1b059955c233_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4d092a69-a1ca-4d47-93f2-a580aa9c9261_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_65b2faf9-49b5-4b88-b6f3-a9a918df99fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_1364427e-7c17-4ed3-91be-eb7ab4f4c72d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_76784593-19fb-4d08-b6ef-7cb771066fb4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_2bddeac0-6365-4a91-abf8-d5a79fc8f584_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_d1ac9c38-016f-45b8-84fd-fbc6a2651be5_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20240630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_269ad1d0-3d98-42a2-89a3-b5d354512afd_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c8556114-ac8d-46b0-9e56-bbdfa57607c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_eddcffcb-bc8e-4a33-b0c4-a0f0d07d377d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b21c7cc8-1516-42a1-b075-a61fa33091e8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_acbf08c1-5c3c-48ed-a19c-3a42a6b5363c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_fbdbf463-2235-48ab-bf4f-8292fd2b3548_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f88b2bb-c0f0-4bf9-bfdb-94049b04f7d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3cf6591f-34f0-486c-9d61-b1314c210baa_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_34071474-efbb-46ca-9603-7c8288c42ea3_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20240630.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_30854b39-f616-45b3-84b5-652bdcf0c931_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_870f40f1-3ef4-46ba-a0f9-33dcabfc8c11_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_2b2d8399-83ce-4f93-9fd9-32cde226e694_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20240630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BYOOVIZMember_ea9572d7-d273-480a-be53-de60803731bb_terseLabel_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BYOOVIZ</link:label>
    <link:label id="lab_biib_BYOOVIZMember_label_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BYOOVIZ [Member]</link:label>
    <link:label id="lab_biib_BYOOVIZMember_documentation_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BYOOVIZ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember" xlink:href="biib-20240630.xsd#biib_BYOOVIZMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BYOOVIZMember" xlink:to="lab_biib_BYOOVIZMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_9e3b2820-43ab-4585-bd93-188038bb70fb_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_715cd5d0-a3eb-481a-85a2-79592804f944_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0c91fa2a-747f-44cc-ae12-c42d07970dda_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_364bdf53-0f16-41c5-924d-9afefbb76c7d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_52eb0ac0-36a7-4bbc-88fd-3649b0d2acde_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_f4eb4c23-ed87-4d8c-aac6-11cd8fb3647c_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20240630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6e7ea585-6d90-4fda-9fbe-a52a4ecdd402_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eb143828-05ae-4148-bed5-c00526771e6a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fe051427-f6c2-4933-bc41-0ff700cb860b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_1edb97b9-dfd6-47c2-9c08-e61ff08ef3a6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_45521af6-9939-4eb2-8591-2311c8038a06_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_12f9da3b-ba04-44f5-8332-e780b75478d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_7f6d50f7-ce00-4cec-aae8-631825c73b43_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20240630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_48c6c36a-af78-40e0-9fe9-54d4fa889cf1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_38abf5d8-2556-440c-afd7-e4b83b3d6792_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_11274acf-636f-46ea-971b-811ebc4f80ca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_302995bc-52fd-42a0-9ccb-2e40876733c4_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PriorityReviewVoucherMember_39262ad1-88f5-43b1-985c-89fcc1f61b44_terseLabel_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Priority review voucher</link:label>
    <link:label id="lab_biib_PriorityReviewVoucherMember_label_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Priority Review Voucher [Member]</link:label>
    <link:label id="lab_biib_PriorityReviewVoucherMember_documentation_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Priority Review Voucher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PriorityReviewVoucherMember" xlink:to="lab_biib_PriorityReviewVoucherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3d2ec386-f2c9-47d3-bd5d-a150aaadb307_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_705c3bb3-fbce-4fcd-9575-fb2703802302_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (distribution) contribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_806f0343-86b1-4255-b6a8-2b5ab85188e9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef43df6f-ffb0-4b1d-b549-3619b825f476_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58d6e8d2-5cd2-4b99-87e4-dffcff5b7c24_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_aae9a66f-0577-4fa7-bb42-bc126ce771aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_6ff197bd-ded1-4dd7-96c5-a3636c0a930d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_b5951292-845d-4657-a409-835733c476f3_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20240630.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_460a6431-dbb1-4a8e-9e80-d3943abf6561_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2bcd00af-f43b-49ac-9f4f-ddecdeca7deb_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_acaea441-f4dd-40f4-8c20-76d7f47d3bcc_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_5bd0f087-734e-4b84-b1eb-cd7cf32e6fb9_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_434feed0-87f1-4bce-a912-9d219710e39b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_ce79f5f0-0cdd-40aa-b543-01ed23482c80_terseLabel_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_label_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_documentation_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:href="biib-20240630.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:to="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_4ec7902e-e7eb-42d9-b615-fd0ab7722716_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_16a72603-8890-4f3a-b3dc-47f4c56ebc66_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3f34fb5e-f6c9-4f9d-8e77-c731aa1b3731_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_75447c33-4901-4acc-bbf9-36e8809921bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_e4ef5951-0f69-4b40-b32d-3f87d2f0d49e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e260017f-88b4-45ea-a7ce-4033541b337d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_44288f90-f51e-4435-8e8c-e1b576871b4e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6519e2c2-c57a-4c0a-b4a1-088fe2ff21d7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_c4959fd0-2c93-4aca-8e5b-8fed913273a4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_79bf8f6b-22b6-4c48-bf33-2a08bac72b96_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_5ee4bb3d-070c-439f-ae3f-a24e627c2890_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_04415866-3c8e-4d53-a263-dc5df5388c56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a4dad30e-9231-4ad4-92ab-b1f15e8912fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_62d7ebe5-ea16-494e-b640-fba59e29cd62_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f43259ed-d6c2-4c08-910f-73e805fff17f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_8d139adc-ce22-4ad8-8f42-80df499ac1c5_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20240630.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3242ee72-9a10-443c-aadb-afa658e4144b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_eba1af9a-9c92-42a6-88c8-c965abfa777e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_cbdc8e0b-caf5-4bb0-9fb1-f60458c17e6a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_875944fc-2b1c-40b4-ae1f-d5546ab19585_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20240630.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_7ecd9aac-8f4e-4d06-b43b-7550feeec06c_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityMember_63435090-b1d6-4596-964e-6bacd0eae493_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility</link:label>
    <link:label id="lab_biib_TheCreditFacilityMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityMember" xlink:to="lab_biib_TheCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_0e8eed3a-a8ff-47bb-a45d-56e0567539ad_terseLabel_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current Portion Of Notes Payable And Term Loan</link:label>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_label_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Portion Of Notes Payable And Term Loan [Member]</link:label>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_documentation_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Portion Of Notes Payable And Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:href="biib-20240630.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:to="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_fd3e25f8-d96a-477b-bc19-61be187a6ba1_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_021e8d6d-31bf-4dd0-a2f8-b6cca02bc3f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_1e52a3f0-b8cd-411e-94fd-90d602e099c3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_6f5f3968-a347-4e09-aea0-86c3e35dd7f2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_8360bc05-2dff-483d-96bb-a0fe64e18a3a_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20240630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7759d946-9217-4490-8846-b3089aa008fb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_ca9c3a72-ced0-422b-9547-887422ff4aa1_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_d89e08d6-2837-401a-8988-f15952176eb8_totalLabel_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_label_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:href="biib-20240630.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:to="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_63a3b1f0-9a89-4a2a-bf6c-890f09d1f1f4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_41500f01-e502-4df1-8f91-d57dd6d1fb60_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_cd96453c-273f-46d5-80ca-9375a41031b2_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a6cd909a-4830-4133-82db-2df2c3dedb7e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b28714e9-b32c-4b4c-9ad6-62e2ef316806_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_5d6437f4-b57a-4804-8d46-b1b6bf276b71_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_2f517cb6-228a-4e0b-ba00-bcaec07c74cb_terseLabel_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock shares acquired</link:label>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_label_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Number of Common Stock Shares Acquired</link:label>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_documentation_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Number of Common Stock Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:href="biib-20240630.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:to="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_5110fd1e-9b21-411a-bee7-17380192fcfa_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20240630.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_f8d2c066-4afb-43ff-af3e-9f6cdcacf0c0_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables to divestiture of interest in joint venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:href="biib-20240630.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_ce86857a-a6d8-4a18-b0b3-3596d59d1486_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20240630.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5dbba521-602c-4773-9ade-779c5a3ec046_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8146b022-834d-45c5-b205-072e55eea890_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_ae78268d-54ae-4e1f-94c4-da886bb9bf6f_terseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:href="biib-20240630.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:to="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_7214e8bc-70d1-4f3d-a050-afec9df68ff0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_231ed469-e561-42f2-acbb-49b8e2e0e3f7_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0ed08a10-c493-4bc0-86bc-7506d8c5fb5c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_cad8a9ee-6d0f-4d87-87a2-56c8fb4fcdd3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_03a7a553-bca5-4403-9294-f352de5fbce3_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:href="biib-20240630.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:to="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_04453cd9-7df9-49f7-b1cf-f8557fdb8525_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_2958cf93-e058-43bf-9dac-fd373c1c51ee_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20240630.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_2ef21f5d-1260-4847-88e5-74c3a9d53381_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e420c5c5-504a-41ed-b297-614954c55066_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_77f7c07d-6331-4c51-8eb6-cb1739a6afb1_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_fbfef467-244f-4fbd-ae2c-a6ddbca70cfe_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to the UCB collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:href="biib-20240630.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CompletedTechnologyMember_89910207-7102-46cc-8e45-b58ee0535407_terseLabel_en-US" xlink:label="lab_biib_CompletedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Completed Technology</link:label>
    <link:label id="lab_biib_CompletedTechnologyMember_label_en-US" xlink:label="lab_biib_CompletedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Completed Technology [Member]</link:label>
    <link:label id="lab_biib_CompletedTechnologyMember_documentation_en-US" xlink:label="lab_biib_CompletedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Completed Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CompletedTechnologyMember" xlink:href="biib-20240630.xsd#biib_CompletedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CompletedTechnologyMember" xlink:to="lab_biib_CompletedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_f807e8e3-4453-4722-af2b-63a41195fcb6_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_d37a5e35-65cf-4fd5-8dd0-a274c9f0f539_terseLabel_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_label_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_documentation_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:href="biib-20240630.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:to="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0dc4ec55-88a6-4aac-91df-74138b5fbb35_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange (gains) losses, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_cda513ff-e880-45d6-bcf7-f10c4196fd35_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_98ad1d58-7d32-4c23-a28b-fe4c7f060629_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20240630.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_52a4481d-67d3-40a3-8e7d-000b7459c031_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_5af59190-2ced-4ebd-b4bd-de72f4cb5e38_terseLabel_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM</link:label>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_label_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember" xlink:href="biib-20240630.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMAndADUHELMMember" xlink:to="lab_biib_FUMADERMAndADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_cdca2ebd-df6a-46b1-8199-1f9a4442a3e8_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3a83f494-4c9c-4614-be81-43cdf1df6d3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_6d2f2b86-7f42-4fae-adf0-6dfb3c7f4ef8_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e27ee2fa-7d2b-422d-baa9-e8460b607bec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_95418f1e-43bc-4e5d-b69e-0eae90a52f9f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of priority review voucher</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_b66d7c0b-bf4a-4876-b234-9ed8819d9766_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_9d9d051e-fff7-4b1f-98c6-defdf65f283c_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20240630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8c033bf8-410a-432e-b786-79c2b18df63a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_890450de-5b44-4ef4-8184-90fc970e92cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_8bc4d44d-cef8-4cf9-965e-adb4f455d014_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_28937b96-33c7-4954-8051-2d95d4a0cdb5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2a47efcd-0b2a-4285-9bdf-17f53c594750_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c5ce7dc8-2a09-4202-9d8f-09638bb49966_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_6264be0b-eae3-4692-9a3f-ba3cf40fbf74_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_ac649517-4797-42da-ba02-7847c05eadc2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess and obsolescence charges related to inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc08e4ae-4ee1-4ee3-9361-f75fa7966b60_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b8b9a8e0-099f-48c5-b032-8a8c4bc17849_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReataIntegrationMember_1970d2e2-c355-4a3c-80bc-0ee4af8543ee_terseLabel_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reata Integration</link:label>
    <link:label id="lab_biib_ReataIntegrationMember_label_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reata Integration [Member]</link:label>
    <link:label id="lab_biib_ReataIntegrationMember_documentation_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reata Integration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember" xlink:href="biib-20240630.xsd#biib_ReataIntegrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReataIntegrationMember" xlink:to="lab_biib_ReataIntegrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4b62369e-91cc-4e1c-86ca-a6ebe2fb9f71_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_66f448c9-aa60-47c2-943b-4d7103a5213d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_661f28d7-c6d3-4b54-b52e-2cb9240f0355_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from divestiture of interest in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_73120db0-394a-4271-8158-5acb4bf2e742_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6a104f44-546a-4e55-9dc5-9ccc16f68d05_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d6f3a726-da4f-45c3-b7cd-468c829c422d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_48fea2c8-cb7e-4657-9c1f-83d38d5abddc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_f9607d86-4583-4154-af75-bf25bf016f97_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ed13c2b0-5bc2-4e39-a7b2-577c92f30e0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_6fbfc4a1-03f4-456d-aa9e-33675c510b47_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20240630.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_fcffb9b9-e2f7-471b-bcea-fffb36e5d6ab_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_2f987fdb-3502-4e1b-9dce-bbc631607aa6_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:to="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_2a3699a7-e7b8-4e5b-9dc1-6bbff1bf584c_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20240630.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_634c3fe3-6e4d-439f-9b9c-5dd8098d7770_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20240630.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b12f1243-8de1-4d5c-a32c-787ebf2dd428_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_4d5c6678-d0cc-40a5-ac25-216848588dbc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5aa0cf78-8f29-4f3a-8376-c0dc77534526_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f6df10cd-49da-48b6-ba91-3d23a74c69a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0daaf237-ad0f-4c4a-9f2f-b7581f817092_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_872ef812-483f-4492-8863-ff6dc3c429ca_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20240630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adc1d6e6-73b5-492a-8745-844c9fd2b7de_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_640e195d-2346-48fc-ae54-4dd9647abe0b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_a009a611-8357-4ff8-98e6-bcc65f1c3c4d_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20240630.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_22ac87c3-b8e2-4d3b-ab0d-98fe30bb9e6c_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20240630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_daebd877-62a5-40b1-bfa2-5711c4bcb0fd_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_eba79f7d-2bda-4a5d-a61d-c8a3a0f319f2_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20240630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1eeb9603-117b-4ecc-b844-6008481cba16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_edbe7486-2a37-4989-8a42-4bb29693eaf1_terseLabel_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_label_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_documentation_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:href="biib-20240630.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:to="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_165cf27e-921b-4f3d-8789-b6123f10c293_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccountsPayableToCollaborator_e425495a-ec45-4dd7-bca1-cbeb77121cf6_terseLabel_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts payable</link:label>
    <link:label id="lab_biib_AccountsPayableToCollaborator_label_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, To Collaborator</link:label>
    <link:label id="lab_biib_AccountsPayableToCollaborator_documentation_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, To Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator" xlink:href="biib-20240630.xsd#biib_AccountsPayableToCollaborator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountsPayableToCollaborator" xlink:to="lab_biib_AccountsPayableToCollaborator" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_e44202f3-8d21-4ca5-a71e-8ff338f953f7_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_f253d7f0-c02c-431a-917d-6249dbe2fa3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_960ac961-3533-40c6-8eb8-a402cc852cb2_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_f1ae1221-3b8d-4938-aff0-f593f3ddfc09_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A.</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20240630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_07e67c59-e658-4669-abe0-e118ce4ff084_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_36870b50-5d28-4cd1-bb0b-e5a5ca12e3ac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b14a40f-af7d-422c-9c8c-a15300ed8167_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ff55e3fd-3632-4c1d-8922-24e0f6cb398a_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_f8171150-d177-4c90-adc0-fe148aecae90_terseLabel_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets, receivable</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:href="biib-20240630.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:to="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_b2b7ffb5-4b34-4502-9668-9398140c58b2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_cdee2644-e5dd-4485-aa22-d2821c1e89f9_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b209b0f7-7c29-48fb-86e3-7b2f0687f7a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b09a0f4d-4901-42ca-9477-22578c5744cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_eaa5d251-6896-447e-9509-1ab713903b8b_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_9fd95217-b8e3-42bb-b5fa-916ba3bfed4b_terseLabel_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives</link:label>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember" xlink:href="biib-20240630.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023And2022CostSavingInitiativesMember" xlink:to="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_e9277936-ce4e-4802-abd5-4662f70439ef_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_c1cdf7f2-cabe-41d2-8b57-bf7a6007b711_terseLabel_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche</link:label>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_label_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche [Member]</link:label>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_documentation_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember" xlink:href="biib-20240630.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FloatingRate364DayTrancheMember" xlink:to="lab_biib_FloatingRate364DayTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54d41f45-805e-450e-8429-d7c35628f436_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_574b4a32-2982-433d-bc98-fcf580328400_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_59519f9a-110f-4d5c-87d5-d865ddaab470_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5c8bbc02-aebc-402e-95cd-c46657aa8296_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fb98b3bd-ceda-49b0-b158-ddbb539d04b1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_1c617fbf-7313-4c14-b30a-6342d5fc70a8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_a35473c8-75a5-4756-87e0-916f7941bfa2_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20240630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_80fddcca-05b8-4660-b739-31cfccfaa992_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_b2b1e7e3-08ea-4b4e-a9f2-e0aa5814442c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_da2f324e-3175-415f-a6b1-190ce7feadbd_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20240630.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55f3b492-b294-42b0-97f0-635ed80042c2_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_98361f4b-fd67-4e51-9deb-3ae49db23cc1_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, goodwill</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6871b68-ae1f-4555-9144-398b3d21fb38_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net of effects of business acquired:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_ae7beb09-abc7-4300-9ef4-9de7bd19203a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_c4670c20-7b5f-40e5-b996-cbf1efe617ef_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2c81aa0a-6086-4ac6-88e0-4aa842c4c36c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b2bc2449-ff60-4a37-b481-c59af782ca4c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c59c8541-66b0-42b7-ba73-1f8339889a44_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_f9acf3c6-5f53-40d0-9bb0-98dd977e6072_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing/(loss reimbursement)</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20240630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GAZYVAMember_82bd8dda-8bf8-4691-a455-f125024e2425_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_label_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_documentation_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember" xlink:href="biib-20240630.xsd#biib_GAZYVAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember" xlink:to="lab_biib_GAZYVAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_7c2bc76e-1432-4bcd-a223-5f3480e1fd08_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bb464f98-bc9c-4e1b-9ba9-f05559b29a17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_62af5fd3-4ab7-4b60-a6aa-0ecef9122ba6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_b60924d9-6d5d-4458-a8f7-f63aec5adce2_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherProductsMember_1d6c30cc-bda7-42be-ab12-c46f358109e1_terseLabel_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_OtherProductsMember_label_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_biib_OtherProductsMember_documentation_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember" xlink:href="biib-20240630.xsd#biib_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherProductsMember" xlink:to="lab_biib_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_35db879e-5a0a-4044-b908-772bef39541b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_f1612b8d-8283-4d6a-b51c-74d523ed3c22_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_5452b72f-8884-4aab-8485-2e29ef7dfc1a_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:href="biib-20240630.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:to="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_b7e94804-e67a-4dc4-8014-ea645e1d7b43_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1e6c1743-c196-434f-9c4a-34c3bd0df33c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_2170f3f2-5e24-45d5-9a7d-33af7cadb838_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_de801d3d-54fc-4b5b-9e4e-e774773c798a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_053a9bfb-9568-417e-8847-7e3cb210549e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated Depreciation and Other Costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3eeb97e0-d851-464e-8c32-08ed813f8bd3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8d22ccea-b568-44bb-89cf-3ed799b0d1d3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_9f893f6b-b432-40cb-8d0c-9cfc045d723f_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20240630.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_13bbff74-255e-4c56-9c5f-22c63a32789a_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_ddb4713d-0c60-4316-8a9b-b209a989ff48_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20240630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91edd43d-3bb9-4f42-9e9f-02a6e0b05f23_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_0e9460f9-ede2-48f5-a28e-ebdcb277e4a6_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_d8973cea-aef0-4b5d-9dc8-b2bb3e9a5b01_terseLabel_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember" xlink:href="biib-20240630.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2020ShareRepurchaseProgramMember" xlink:to="lab_biib_A2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_04b0b92d-990d-4065-aba8-3d455f902565_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_185c5421-3f33-417a-80ba-9b59e4e1cfa4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_204f60dc-b367-42c7-8322-3938ac626ec0_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_8f96f0af-e7fb-4202-a665-2a04da4bbf66_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_ee0dde10-0a23-43b0-8335-15ddc44398d2_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsMadeToTerminationAgreement_ae970c80-5701-431e-8413-950cd3de80f5_terseLabel_en-US" xlink:label="lab_biib_PaymentsMadeToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments Made To Termination Agreement</link:label>
    <link:label id="lab_biib_PaymentsMadeToTerminationAgreement_label_en-US" xlink:label="lab_biib_PaymentsMadeToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Made To Termination Agreement</link:label>
    <link:label id="lab_biib_PaymentsMadeToTerminationAgreement_documentation_en-US" xlink:label="lab_biib_PaymentsMadeToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Made To Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsMadeToTerminationAgreement" xlink:href="biib-20240630.xsd#biib_PaymentsMadeToTerminationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsMadeToTerminationAgreement" xlink:to="lab_biib_PaymentsMadeToTerminationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_e86fc29e-8406-4cb4-be8d-df8d926dc4c8_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:href="biib-20240630.xsd#biib_PretaxProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_27b00fd3-9124-4f95-b48b-85c2e4f0967c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentPortionOfNotesPayableAndTermLoanMember_243a7bfb-0e15-4931-bd7e-7bf3d9f5879b_terseLabel_en-US" xlink:label="lab_biib_CurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Portion Of Notes Payable And Term Loan</link:label>
    <link:label id="lab_biib_CurrentPortionOfNotesPayableAndTermLoanMember_label_en-US" xlink:label="lab_biib_CurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Portion Of Notes Payable And Term Loan [Member]</link:label>
    <link:label id="lab_biib_CurrentPortionOfNotesPayableAndTermLoanMember_documentation_en-US" xlink:label="lab_biib_CurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Portion Of Notes Payable And Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentPortionOfNotesPayableAndTermLoanMember" xlink:href="biib-20240630.xsd#biib_CurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentPortionOfNotesPayableAndTermLoanMember" xlink:to="lab_biib_CurrentPortionOfNotesPayableAndTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_08e930cc-0297-4766-84d4-cfd792d518be_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RituxanMember_562abf0e-2fa0-4109-88cc-1bf72f5ebbf7_terseLabel_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_label_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_documentation_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember" xlink:href="biib-20240630.xsd#biib_RituxanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember" xlink:to="lab_biib_RituxanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_53084753-3203-42df-99f7-26852d059b8b_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20240630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_3412d886-2423-42d5-8c13-09649811846d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_c92272bc-fe24-408c-9db1-02dc23973a57_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6e7e1f6c-2f91-4f1d-9988-6e90254dea8e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e6496652-9fca-4d9c-b363-8e3557b2fac4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4bd81d90-5039-4638-aeb8-42e3eefb2848_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a4e89a1c-527a-45bd-bd39-a9ec880aa228_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_21731a35-7828-43ad-a08b-0d0ebe872479_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2221d69a-1437-4028-a43a-52b7306d1c40_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_214b6d5b-d6c3-4192-9022-1dc4b53404e4_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_d7643423-f958-4c53-bef8-c87792e0b368_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_18ce4227-4b46-4c59-bd38-0bb6c63b35d0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b5ae8bea-abc1-4a5c-8615-3f766a63b1f2_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dc64be50-65d3-412e-92e8-36dc3189d23e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2128b226-6651-4094-a2f2-2911688775f5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_26da935e-f6f5-4c48-9f82-6e62b3cfe5b0_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_101e423b-7e12-4f45-a083-5d51d82b3207_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20240630.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_299d62e1-22df-4c2e-8c8e-f26d12fcc3f7_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of priority review voucher, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0b1b6ebd-8521-44fd-8360-46ea59a0cfaf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_92eed795-2311-4975-8533-332c8bda8ce4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d109e00a-af4c-4cf8-bb45-92252da36432_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_858c0c21-005b-4b99-95cd-ffbd10fe20ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d0ba0f6a-b691-4c03-8fa9-f29f77846c57_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedMilestonePayments_edb0b973-ef51-4a7e-a8a7-2a2983466685_terseLabel_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued milestone payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_label_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_documentation_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments" xlink:href="biib-20240630.xsd#biib_AccruedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedMilestonePayments" xlink:to="lab_biib_AccruedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_fccf9453-c547-431d-8cfe-dea2262d5b55_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20240630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ebba3622-f529-4c75-9659-79c8b67b8abe_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_594c68eb-cbc8-4206-9c02-25da80839f87_terseLabel_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_label_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired And In Licensed Rights And Patents [Member]</link:label>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_documentation_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired And In Licensed Rights And Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:href="biib-20240630.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:to="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_2f0e4fde-f5b4-4180-b793-e38ae11881c6_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Operating [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_9d6025fe-e513-4234-b808-32a208a9d7fa_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8c5f50fb-588c-4e42-a918-89d5fe8b9f7b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_95c5b329-35f8-4885-b726-396561733760_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_39a7e330-ee72-4297-b0bd-d74118e45bb8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_7db56840-9c1b-4c15-835d-b383f0733a94_terseLabel_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reata related accrued expense</link:label>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:to="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_0fc93b09-682e-4117-a484-0eef5fa3ec97_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_eedc233b-5032-4df1-afa4-2daad0c77202_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_7df74753-b4f2-4946-ad78-57a954c1f9b6_terseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement" xlink:href="biib-20240630.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement" xlink:to="lab_biib_PeriodOfCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_9803eb09-cc00-4b63-b634-a622498278ee_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold" xlink:href="biib-20240630.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_9549aba1-1679-4c0d-821d-5eddde8f94ec_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20240630.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b124b374-ecdf-4241-9e46-0eff02ba52e1_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4f38ac0c-0eea-4dde-b9d0-afed41f99c35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_01544b82-608d-4688-a634-0ad5b8cba4fc_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c4c5ab36-2d4e-42e9-aeb5-d046980980e8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_82ce838d-7d7a-408c-a839-3fb553310ba9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b44dc95e-c6ab-4327-8122-b9c01f91970a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2ba6e09a-9c02-4b70-9b9d-1da78a18da13_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_cdd5c937-b385-47ee-90b6-5c845bdf8cef_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments, contingencies and guarantees</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_363e36bc-f514-4f7b-b945-5aa53a1ac3f2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6d77fe1b-acac-48b0-9ec1-3ec2a2c53461_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85143908-ce66-4d44-b788-5e3e6f00f484_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_bbbe79d7-3ceb-4c70-a948-0d776cf8452d_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20240630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_04409bc1-54e0-4c0e-ae26-c458eec83cdf_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_833eb627-0be4-41e4-b14e-c1347c38a33a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6b3fcc4b-42cf-4e2c-982c-8ef4700e30a1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_daf21dc8-50ef-4836-832b-4ca3c8b40f4c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_96a2fa3d-8bdf-4ad3-96fb-127fb46beb76_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_3e7b585a-4ee4-4444-baa9-9f82a914c873_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_323ec5b0-b923-4617-be18-35d47e9257f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_4e4e1aa9-e94a-4d77-ac3e-1e2e63ba5194_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20240630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_892a8f50-dd3e-4e4d-a5fd-b52dbaa76d43_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20240630.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OmnibusEquityPlan2024Member_6540073e-31db-403f-adeb-97bd5e2ce125_terseLabel_en-US" xlink:label="lab_biib_OmnibusEquityPlan2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omnibus Equity Plan 2024</link:label>
    <link:label id="lab_biib_OmnibusEquityPlan2024Member_label_en-US" xlink:label="lab_biib_OmnibusEquityPlan2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omnibus Equity Plan 2024 [Member]</link:label>
    <link:label id="lab_biib_OmnibusEquityPlan2024Member_documentation_en-US" xlink:label="lab_biib_OmnibusEquityPlan2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omnibus Equity Plan 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OmnibusEquityPlan2024Member" xlink:href="biib-20240630.xsd#biib_OmnibusEquityPlan2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OmnibusEquityPlan2024Member" xlink:to="lab_biib_OmnibusEquityPlan2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_b086651d-a619-42ea-b28a-99232c92b6c9_terseLabel_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing revenue</link:label>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_label_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract manufacturing and other revenue [Member]</link:label>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_documentation_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember" xlink:href="biib-20240630.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractManufacturingAndOtherRevenueMember" xlink:to="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8c4b092e-0e37-4095-91c4-e0d78b4f8880_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_8ac1b71c-2916-4c05-b174-e1316ac2b2f1_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_5e10a32d-0794-4dea-8575-906eaaca12fe_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_6309a1c8-6697-46e2-bf02-43eeb878ac9b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_69c756bc-66d0-418b-99dd-ba5835333804_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_713b9bbc-0c67-4f21-be89-93dae0f2b786_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_508e0d83-39e6-4d87-9d04-881abd7bab95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency and other adjustments</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:to="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a402a0b-4f81-4d0f-8030-834831186bc5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_dd6e7bfa-254a-4514-9147-76f61c906ea4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_7abeb4ab-f782-4982-a5e9-4842ec5b531d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_aecd94c7-96d1-433a-8ac1-05798d53875f_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:to="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_aa8f0662-ebb0-4f07-8df9-49ed8cc6244e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_f1aa941e-99e5-4481-aa43-9ae8e1c9b3bb_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_b87aff0b-0ba3-41cd-89ed-99c7e3b0f150_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_3599a5f3-09a3-46f0-a42d-8fe0f7c16a79_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation, gain (loss), amount</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9cfa6d85-ae85-4a34-a7c3-f727e3e2aea4_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:href="biib-20240630.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_8eb39f16-15b9-49f5-b89c-ba4985cf9a72_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_ff8bb728-523a-40b2-93b6-350733928181_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20240630.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_30974e2a-6023-4832-b070-83e1ea6fddb6_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_a94ad991-e3e5-4179-a070-912c2f436eb3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0e2d0b05-5434-4dca-9270-c9ed0a51e82d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f432474e-12d2-4191-8370-0e62804e38ab_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_cf692f39-3088-437c-bfbc-6af64add9896_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5cfa6bc6-6bf8-4e59-aa84-4355a6d7a8ea_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a3365760-7065-4a5d-ac90-ac6eb3506a3b_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20acec0e-de38-4b82-96ac-a564d799cbd3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6c97ea3e-7cf8-4cf8-9a32-420a6a06c7fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0106fac9-c0f1-48a0-bcab-5b059770d11d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d34372aa-91a4-49d7-b852-d2d2d5861d40_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6feaa2fa-ab54-4326-9e39-0980f871d29a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_6bb737f5-ca7d-487b-b5a8-6247b9fe5ae5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_94e20586-f800-460c-ac2e-e82d76e5209d_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:href="biib-20240630.xsd#biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_cfc907c9-d77a-4ad4-8dd6-dc42dbe80ae9_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f8fa78ed-d3cb-4d96-b0cf-d42ba27351b4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee6660c7-b22b-452a-8362-6220f7470a50_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4937e433-d3b5-4f90-b1d3-96c31fc31ea9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_82854656-8231-4697-af92-7a78d2fefdaa_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_78c56443-9870-430a-8afa-ff39fcf24118_terseLabel_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc</link:label>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_label_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReataPharmaceuticalsIncMember" xlink:to="lab_biib_ReataPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_4f22d3cc-a40f-4da2-94ca-7c603c8d6ea0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_23aa53ba-f914-431c-88a5-e9d1abee57e5_verboseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_cf3970b6-39ab-4819-bf8d-af1596eb05e2_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_d8da6d4a-8cf5-4775-8279-05634310c561_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill resulting from Reata acquisition</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_753770ce-dfea-46e0-957d-2732a46167ca_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ac6bd796-9f42-4299-a25a-a03361942cb4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_24954e3e-1f39-44cf-8ca1-350bdce2b500_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated</link:label>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityTerminatedMember" xlink:to="lab_biib_TheCreditFacilityTerminatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_ee32e207-67f3-4a99-b222-f6fb30ef6e99_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of term loan</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8b3e915f-94e2-4a23-87f2-47951d918e9a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_f0fcc88f-732c-48ed-9601-6560459644bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZURZUVAEMember_b7afdace-61d5-4e5c-b1c6-47b05e938e10_terseLabel_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZURZUVAE</link:label>
    <link:label id="lab_biib_ZURZUVAEMember_label_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZURZUVAE [Member]</link:label>
    <link:label id="lab_biib_ZURZUVAEMember_documentation_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZURZUVAE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember" xlink:href="biib-20240630.xsd#biib_ZURZUVAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZURZUVAEMember" xlink:to="lab_biib_ZURZUVAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9782f7dd-6b7e-4665-b69e-34dbc815c17c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_3c790395-9196-4e26-9d6e-76356a8fd8a4_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20240630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_90b2d59f-fb53-4620-a5b8-4f331669cc8d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c507be4e-25ba-4b1d-a6ad-7eb3059d1826_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_76acb62e-331d-47ba-a606-e83b573b97de_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_cfb3d723-9bfd-4779-8aca-4f44a0c95606_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_39bd278f-d22f-4c8c-b951-d42008e91799_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other(1)</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_d2bf3719-2068-45f4-bd68-edb2cc7ec990_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_ec14f79e-4320-4bdf-bf9a-0996f75258c4_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20240630.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_a2d6aadc-6d6d-456f-9e6b-7bc56a5d66fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_cbf2d93a-41a1-4a96-9034-e7b66423796c_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20240630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_cdc4a012-22ba-44d8-ab74-f8560f843223_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_b36960ad-f25e-41c2-b74b-0c060e324a79_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d1a8596f-bde6-454c-9362-a3fcb160355f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1c84691d-f17c-4b49-a042-77b90e5335a5_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_95fbfbbd-0014-49dd-b454-99e1f003053b_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_a19fda98-3b3a-49eb-a12e-77c6358eb957_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_32a10290-827f-4e91-83a0-ff571a2d22ad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_19e03ae1-c068-46c3-a847-d254e8376611_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b4f97069-cdf7-45e4-b8e5-e81f60aafa82_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_16669623-16bc-44ac-8e07-06c6f4289640_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_e88f8173-4246-41bd-bd5b-8d165deb0821_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing, royalty and other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_ad9b9638-ba5e-4816-8ed6-2015007c992c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_e0e4c64a-849c-4847-82b0-9ebdfd0c4211_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_2cc57171-02b6-4d4c-9758-ca9b81c19041_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:to="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f62fc635-47f6-4b9c-a7ed-770514658f28_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_85e10d0e-2090-41f9-b0c5-c88417ec045f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_76ae7065-79f5-4157-ad32-b032308064ee_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_4d92f930-6aa0-42af-9c7d-71f027c2ae99_terseLabel_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average remaining useful life</link:label>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_label_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</link:label>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_documentation_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:href="biib-20240630.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:to="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e58cf75b-02e7-46c0-99ce-1016054cdeae_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_70f739a8-6cf0-4561-91d8-c6e3f60baed5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_73527c98-a908-4378-8c52-409ce039c36a_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_b8e17500-05fe-4a7c-8108-0c01e5913ad9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_cd703796-159f-49df-b4ca-83af52d14cb3_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20240630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_aa2e17fe-9e97-4f93-baae-dbb016e2c9f6_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1cb834c1-4a73-416f-b2c0-e410b0e12ee6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_99c4ec36-ab34-442b-b348-cc47402595bd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_4ff8b3bb-7c60-4d97-8ae8-055ad189d8ad_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6a208cbf-2040-46dd-b17a-7f85b50efffb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_41f0ddcf-385f-4df6-a323-8e49dffe47a4_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b12ceaa0-6c78-4004-9c2a-d3796e67c953_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_71ea6fe4-1807-4629-b920-beecf63daf33_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SKYCLARYSMember_841839ed-4ca7-4a75-9e67-7306b22ed72b_terseLabel_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Completed technology for SKYCLARYS (U.S.)</link:label>
    <link:label id="lab_biib_SKYCLARYSMember_label_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SKYCLARYS [Member]</link:label>
    <link:label id="lab_biib_SKYCLARYSMember_documentation_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SKYCLARYS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SKYCLARYSMember" xlink:to="lab_biib_SKYCLARYSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_720d893e-727d-4b4c-be2f-b9bdfd4cfdb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_fba8acf5-6ecd-4539-9c33-6b84caee0354_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_933848df-1618-46f7-bb90-78137debeab5_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_dc17ad93-6540-4a17-bf7b-73595fe4e689_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyrate_d52acef4-d85c-487b-97ff-8eafce66bbf5_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate" xlink:href="biib-20240630.xsd#biib_Reductioninroyaltyrate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate" xlink:to="lab_biib_Reductioninroyaltyrate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_37449975-87b4-4032-b6f1-efb1b0bc1f42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_22ea1797-208f-454b-a460-0bd350405385_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20240630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_189854a5-5706-4b5c-b3ec-c96ede4c418c_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_e0149ef3-9583-44cc-ad74-f636b2494137_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2085c421-13c4-47fd-8ab0-a8bc4da1b160_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_04b4cca5-9f15-498e-b2a4-bf4c038d2aff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LenderDisputeMember_5f8d3dc1-ed19-432e-8915-9d0e1572938f_terseLabel_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Dispute</link:label>
    <link:label id="lab_biib_LenderDisputeMember_label_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Dispute [Member]</link:label>
    <link:label id="lab_biib_LenderDisputeMember_documentation_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lender Dispute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember" xlink:href="biib-20240630.xsd#biib_LenderDisputeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LenderDisputeMember" xlink:to="lab_biib_LenderDisputeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_8e93c7fa-9fda-4639-b00d-675c6aa2fdbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_baa82039-ab71-481b-9996-2dafc04609eb_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2b5155d-392d-4aae-b06f-7727078f2a4b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb7cb137-a4fa-4d46-abd2-71e34fd1a77b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03df5d91-9f77-4460-87af-79f84dadb0fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_35cf2cb9-a8c5-4173-a9b4-646d1a30df5f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a62fa41c-ead6-49fd-a529-1b7e4e5ee3a8_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c826e4ca-340f-4d02-a66a-016189c6b598_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_2013be56-1446-4efc-81b4-e417ce11a9a5_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_9200c889-7cfc-4efd-b620-5f8a2f6a91b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e41fd105-4690-4e47-9462-d62ecc3a8c44_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_6e225ea2-a874-4214-91ad-952e0f83d80d_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20240630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_101f5bea-ed6e-4788-8865-038ab060a894_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7043aef5-8e60-43d7-bc88-9a245f192a8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_b0808d6e-c922-4482-82a6-51a5577ffd5e_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20240630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8e102aff-e2d7-4fe8-bf8d-44f1e66016d8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_8f96b65a-3e3a-4028-a869-5bb570101970_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_70ec19bd-76ec-4126-9d0d-3147b1323d25_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20240630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_300589f2-46ed-4dc9-9105-05060d953cb3_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20240630.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_14e9673c-136b-4220-a794-76f21c839819_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_23c80ba5-0636-42f8-b155-30c5c5d56b91_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Indefinite Lived Intangible Assets Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Indefinite Lived Intangible Assets Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Indefinite Lived Intangible Assets Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:href="biib-20240630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_91e13f4c-8936-49b9-af79-8259dd3e867d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense asset acquired</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_da8691d4-6d38-4ef5-839a-a2f92e5a1953_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_9f1128a2-f782-4b75-b727-acba5742752d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gains) losses on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_b6d18d45-9c27-4501-9d3e-90655e0ab359_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected profit share percentage</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:href="biib-20240630.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_470b3922-9c8c-4867-ac56-eea9bf9124b8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6534f83d-4103-4180-86f9-3a85af328c36_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_c1dc598a-72b4-4093-b745-87186949bce5_terseLabel_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable Due To Termination Agreement</link:label>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_label_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payment To Termination Agreement</link:label>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_documentation_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Payment To Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement" xlink:href="biib-20240630.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedPaymentToTerminationAgreement" xlink:to="lab_biib_AccruedPaymentToTerminationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c2c43fb3-0db7-444e-ad0c-5eb125d5e188_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_68537b3b-154c-4c29-b10e-e64f8ffffc5e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7cb02a90-a090-45aa-a520-9f076ec8dbb9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ec77f17c-590c-4e06-ba50-4b2692ed794e_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20240630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DivestituresAbstract_a638c9ea-534b-46c9-9778-391669ce84d5_terseLabel_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_label_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract" xlink:href="biib-20240630.xsd#biib_DivestituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract" xlink:to="lab_biib_DivestituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ce9b4016-db3e-4e7e-b8dc-075d5244e5e8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_e3bcfd63-9d56-466f-bfe2-c98f610a1e86_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentToInventoryMember_26543d10-980b-41af-9023-bd5e53e7b86f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment to Inventory</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentToInventoryMember_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment to Inventory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentToInventoryMember" xlink:to="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_2149baa9-4a91-463c-b3b4-1dd29e685e3f_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8e16fbd2-540f-453e-8543-b0da9f06a3f6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3bca310b-7a2f-4f1a-bb21-e3051c82ca6d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_33cced36-e9d0-45b3-bebf-8416a567837f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_a7c92c31-f65a-4716-b6a6-345c252dbcef_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20240630.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_0624d0e3-755d-4317-bcb2-5dddb4327dda_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_3a89e6be-db25-4283-8bc9-c4d4dbc25d64_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_7d4ca865-23a1-469f-ba61-957e4982796c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d2a49092-1b6d-4b49-bd92-51c93a8018b0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4aac0f81-c3e0-4dc6-85a3-46ceb4294bb8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_39a9366c-2da5-44ae-9caf-65f9f5117fff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ec645024-7494-4543-b6ee-6f3c9f3a91f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_c79790c3-b4cb-4172-a9cc-7c3a3412fbd8_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:href="biib-20240630.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a220c85-0b78-4ad6-946e-fdf483cf432f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e873f1b2-5cec-4c3f-8477-07b6859e83ec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_fe76ed70-4378-4903-afc3-6c19b69b58a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b67f3db9-bf19-4f8c-be49-5eefcd2d3ab5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1b3ad8bb-db79-4679-ac25-b4c83f00d619_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $2.5 and $2.4, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_165f5e03-27c0-4539-b476-ddea33f58dd9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_9728905a-b45e-4d1b-9bb8-c39da413d90c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_f12b4579-39e5-4a76-ab2d-e3248c6ec546_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingLeaseArea_15d7d085-b1c6-487f-aa41-1cb060dc69ff_terseLabel_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Area</link:label>
    <link:label id="lab_biib_OperatingLeaseArea_label_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Area</link:label>
    <link:label id="lab_biib_OperatingLeaseArea_documentation_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea" xlink:href="biib-20240630.xsd#biib_OperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingLeaseArea" xlink:to="lab_biib_OperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_22628db9-13ef-4fca-8c4e-e0a963c2c845_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20240630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_a1f27ad5-e46a-4b03-816e-66c5e23f470c_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_6d35f16f-5f60-41d5-90f2-cc4695646333_terseLabel_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_label_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences [Member]</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_documentation_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember" xlink:href="biib-20240630.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HumanImmunologyBiosciencesMember" xlink:to="lab_biib_HumanImmunologyBiosciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_910e14ef-14b9-4d8d-91c3-2d3bb18ec45f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_c0504860-9e39-411c-a2cd-d008b0338372_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility Floating Rate 364-Day Tranche</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate 364-Day Tranche [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility Floating Rate 364-Day Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:to="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_6de65083-1947-426b-b044-31f1a88f5a1c_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20240630.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_4fd01b15-e795-43ce-b3ed-3efc835a6171_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_b671be77-0f08-4af1-951e-531eedc159da_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2d1d85da-a48a-4688-8519-285b742ea805_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_f46a3548-322b-472c-a4f2-22657d673e15_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_fad1fd69-723b-4eb9-8b21-18f704eb3b59_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20240630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6eb54609-3972-46d2-80b1-da74edc35779_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0d9782a2-b6ea-4f04-825c-74de620b4944_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b92acd3e-3256-4e6a-9b11-e9b6c69eb077_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_baebf0b5-c062-4916-bc4b-b18242541416_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_50a064c2-98d9-4aca-8e91-5d680c52157c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0efe6778-a68b-4d66-86c6-3d7bbbb0f6a4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0ec349a4-1f67-41c8-a2f5-de023219696b_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_299809be-8dd6-4e36-a327-06ebcb6171ad_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20240630.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea0cdd28-9ac6-4678-a496-83e4246d4ba2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_526c17ab-9aab-4882-ac66-8c99e9d724e8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_83c2d74b-9422-4788-a319-de209d89446b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c78c471e-7bb3-4a3b-a5d9-e0edf48f8b00_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_1f4fe0ef-9aba-4227-855b-0c58ebbbef7a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1623f56a-bb49-4995-b92b-c9b8a72c712a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_98410c65-4ded-4cab-a1ff-f44d4539330b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_c5c896e0-b0f8-4b6a-a57c-0fe8d16877ef_terseLabel_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs</link:label>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_label_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Future Development Costs</link:label>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_documentation_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Future Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts" xlink:href="biib-20240630.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfFutureDevelopmentCosts" xlink:to="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OCREVUSMember_6389b7ad-f89c-4b09-8ac6-9825b93fca35_terseLabel_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:label id="lab_biib_OCREVUSMember_label_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCREVUS [Member]</link:label>
    <link:label id="lab_biib_OCREVUSMember_documentation_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember" xlink:href="biib-20240630.xsd#biib_OCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OCREVUSMember" xlink:to="lab_biib_OCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_383ab4ed-e227-4fc2-ac27-5e7930129c4c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b8e222e3-df3f-424b-9e50-4b3d334ea7dc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_aba7b08d-d3be-4908-8744-4813310dfd58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7e20cdfc-ba14-4d09-990b-a802e724126f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_371ec068-c581-4a75-84b5-df43c8f7ab57_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_05afe727-acb5-44aa-bf9c-68b9ead32f43_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e4c4e005-5204-4f7f-bd9d-4851b3747948_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a309450f-b27e-4902-9f7b-dd6b6d7133b5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_29ad3a62-d955-4040-ad49-e4e27015f02f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_9bd9afd0-6338-477a-86d2-067ae05b7fa1_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_47106e24-3773-406a-8ae3-56fa7e47fd61_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20240630.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8e64a196-7fc1-4e36-b784-e16353a87c7e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_284952ff-3a40-46ac-a660-08dcf29ec8d5_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_4f9944cf-2f28-47aa-a735-0ba09c424edd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_8f158e27-e066-4fd8-8a6a-0faff37e1cf5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_c0117874-418e-466c-9fd2-9d5281bb8ddb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring, Business Transformation and Other Cost Saving Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_cfd21979-7480-4d89-91c6-dc106ec5c3b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_48db2460-d8ee-4290-b7cc-08e07ba1549a_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_898c3820-847f-46e9-b9be-5b5835f58b85_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_f284a6c5-6fdc-471e-9e42-2a7dde2e7212_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoMember_3aa66a00-ebbd-480c-96dd-4932a514c53c_terseLabel_en-US" xlink:label="lab_biib_SangamoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sangamo</link:label>
    <link:label id="lab_biib_SangamoMember_label_en-US" xlink:label="lab_biib_SangamoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sangamo [Member]</link:label>
    <link:label id="lab_biib_SangamoMember_documentation_en-US" xlink:label="lab_biib_SangamoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sangamo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoMember" xlink:href="biib-20240630.xsd#biib_SangamoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoMember" xlink:to="lab_biib_SangamoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_ef096d18-13c0-4939-b4c3-e895c6ed6435_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives" xlink:href="biib-20240630.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainOnDerivatives" xlink:to="lab_biib_UnrealizedGainOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_8de96e78-ca3a-48ab-b6ab-c2d1ff6aad32_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_4bc94757-551a-47dc-ba37-f6869a2e6e93_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ade0e5a2-7c6a-4e30-a303-ad6bf1dae2cb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_a2b60fec-b2db-416c-9ed3-0c51f4dc4234_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GenentechMember_8f591e0e-208b-40ed-8ca4-436a27af35ca_terseLabel_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_GenentechMember_label_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech [Member]</link:label>
    <link:label id="lab_biib_GenentechMember_documentation_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember" xlink:href="biib-20240630.xsd#biib_GenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GenentechMember" xlink:to="lab_biib_GenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_516d7834-ea50-4894-bcd5-ce3b6aaa5f79_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_01e58715-7d7f-473c-b30c-dad2f2ff035b_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_a52f44ac-8a14-4360-beb7-b4c27023d19a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5406cf52-5ead-4ba0-8955-ccf1ab681088_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5efe1524-f9a0-407c-a722-ed2b9e4ed7fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_017b2a66-25ba-46f3-8d20-24b0da473c63_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_5689b89b-4941-4029-8f5c-6273c13962b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ClinicalInventoryMember_282db052-1945-4996-b5e5-6acf17a16352_terseLabel_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Inventory</link:label>
    <link:label id="lab_biib_ClinicalInventoryMember_label_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Inventory [Member]</link:label>
    <link:label id="lab_biib_ClinicalInventoryMember_documentation_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember" xlink:href="biib-20240630.xsd#biib_ClinicalInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ClinicalInventoryMember" xlink:to="lab_biib_ClinicalInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4cda1a64-329f-4562-bea2-b0dd6af89c8b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_2e3b1095-a607-4ece-8a0c-a2eca690ebd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b415555e-e9cb-4736-a82b-6b1decca0af1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_f0edf579-1d72-4143-891d-c062e9e50ea9_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20240630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa594ade-c724-4890-b34f-8fe48dd977dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e5479392-4aea-4b59-a2ad-9ecb76d5461d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2cfc109f-6fec-4634-bf0c-d30a06e96c74_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0339ec9d-e01c-481b-bb23-4af8abf09d66_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f7c943f5-710b-42c6-a2c9-c267cb1306a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d34d7ae2-6708-4af7-b1c6-ad6a84fd753a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4e4c7c71-e61c-4cb2-a551-69ee19997c14_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_a0a85c61-b53d-4c26-9f6e-e1fdf02dd820_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_88af7022-c37c-414a-8b0e-c2cd87b5ddb6_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_label_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution" xlink:href="biib-20240630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestCapitalContribution" xlink:to="lab_biib_NoncontrollingInterestCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_be5cf9f1-7bf5-4be3-a8ad-34b218d8e586_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20240630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_df2586f4-c793-4a71-9801-564a8f06385f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2176c862-9894-4e3e-a726-27d914796978_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_724a2e32-e770-4220-a1f2-5e2967800a16_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_decd41fa-7ff0-4dd2-9d6c-87b13140be23_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_255885f4-2bc9-4b90-ab19-721641be2c67_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_ea621509-ae32-4929-99ca-32aedd52abf7_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_label_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Extension</link:label>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension" xlink:href="biib-20240630.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementTermExtension" xlink:to="lab_biib_CollaborativeArrangementTermExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_813fc4b8-bf62-4514-a3c3-95ea1f94383b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_ef610f0d-9b1d-4055-8c91-6ae7b2304d63_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20240630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e9f68e07-9857-472e-be45-f90dc6c6e0e9_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_670f954f-71e6-4a62-acad-142532dcd6e8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_034c535b-61fe-4007-9f94-aa1a499ecfb3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_409211b0-5ed1-496e-8cf2-1315b095f80e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8086b382-d681-4e81-a36a-df74db83507b_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_ac9d0d16-adf0-49b2-9526-3cc84c92dfaa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_618b651b-d3f5-4d2f-9435-a7fa8802ddcb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Inc. shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_17df0688-8b66-4802-94b9-98f6b1a83d29_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS</link:label>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_label_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS [Member]</link:label>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_documentation_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember" xlink:href="biib-20240630.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAttributedToOCREVUSMember" xlink:to="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_29930041-98b2-444f-b171-5d8908e43fd8_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20240630.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_5c6fd1e7-41f7-45fe-aa3d-635af00c626b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent payable to Blackstone</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7b601f23-6f01-4806-9c26-135519335e41_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5afa8ba5-50bc-4504-81c6-f889256eda41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6991d5e6-abd3-481d-9917-3344eb35f929_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_bc0aa0dc-526f-4d53-ba2d-107319b66f7c_negatedTerseLabel_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives" xlink:href="biib-20240630.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedLossOnDerivatives" xlink:to="lab_biib_UnrealizedLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f45b3476-3e2a-4d41-b7cb-41ad36913f7b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e2194e06-3f44-42e8-8a79-567f22444906_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_148d6b55-098b-466e-87dc-f8da82c69f2c_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_4816528b-f65a-4ab8-bc1e-525439ca76de_terseLabel_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of net profit from sage therapeutics, Percent</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_label_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Percent</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_documentation_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:href="biib-20240630.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:to="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherClinicalProgramsMember_9a830690-55ad-4db6-b6ec-e232221deea7_terseLabel_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other clinical programs</link:label>
    <link:label id="lab_biib_OtherClinicalProgramsMember_label_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Clinical Programs [Member]</link:label>
    <link:label id="lab_biib_OtherClinicalProgramsMember_documentation_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Clinical Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember" xlink:href="biib-20240630.xsd#biib_OtherClinicalProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherClinicalProgramsMember" xlink:to="lab_biib_OtherClinicalProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_a6a38597-8861-4d4b-b347-8c1156805470_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_89a66585-129a-402b-b945-90a06d2ef5c6_terseLabel_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Term Loan Three-Year Tranche</link:label>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_label_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan 2023 Three-Year Tranche [Member]</link:label>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_documentation_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan 2023 Three-Year Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember" xlink:href="biib-20240630.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermLoan2023ThreeYearTrancheMember" xlink:to="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3dbcf1d1-dc53-415b-8649-a0028e3058bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_7cab9321-3c60-4c3a-a67c-02dcc7db8509_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20240630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_QALSODYMember_8e8f82c6-fb7c-411c-9924-f780eec020e0_terseLabel_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">QALSODY</link:label>
    <link:label id="lab_biib_QALSODYMember_label_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">QALSODY [Member]</link:label>
    <link:label id="lab_biib_QALSODYMember_documentation_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">QALSODY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember" xlink:href="biib-20240630.xsd#biib_QALSODYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_QALSODYMember" xlink:to="lab_biib_QALSODYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ca1043e7-3826-4432-8e61-aed7b64b7a76_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6414c6ac-d82b-4136-9021-e485bff9c465_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9cc3d99c-3228-4391-aec1-ac050f4f7b60_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_07badcaf-604b-4734-b8c6-c2744f808f35_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20240630.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0befd7e2-2b3c-4a77-a1f3-0cc3dea086c6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_148054b7-147a-4406-b934-481995ddbedc_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20240630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_bf94f9ed-171f-4b17-bef6-c5456a0defa4_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20240630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_4f2ca44e-95f3-40b1-a2b1-57c12a0db016_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f459df0b-2cd5-4fd7-8d99-c786da1268d2_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_d4ab052b-f687-4646-8a06-3440ad510def_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, accrued expense and other</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5f36557b-cb0a-4b17-9902-23075c588ae8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2e0a22c9-a74b-4647-bad5-e924acff21a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4c735dc2-9bed-4f0b-a291-760816a496ab_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_6446a4bb-547e-4208-9f15-81207bb2924e_terseLabel_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected operating expense reduction</link:label>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_label_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring And Related Activities, Expected Operating Expense Reduction</link:label>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_documentation_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring And Related Activities, Expected Operating Expense Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:href="biib-20240630.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:to="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_b34ffa90-e497-45b1-b83c-c357924f0fb0_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20240630.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f8c8754-e3f2-4a2e-b5b7-ec30aa407ebb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e780979b-fdd9-45d5-b4e2-b883643fbf0b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d95de149-e678-499b-abe5-dc6eddce9a60_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_c28e9f91-d4f5-4a54-a358-1ab1024ec998_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7d6d7656-0531-4c86-bea4-fd5b40df9f09_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1b730a0a-5e02-41fc-9836-50f1a3ea6011_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LEQEMBICollaborationMember_b5f3afc7-3576-4ce1-81e0-eb7617b3e9d5_terseLabel_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEQEMBI Collaboration</link:label>
    <link:label id="lab_biib_LEQEMBICollaborationMember_label_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LEQEMBI Collaboration [Member]</link:label>
    <link:label id="lab_biib_LEQEMBICollaborationMember_documentation_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LEQEMBI Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember" xlink:href="biib-20240630.xsd#biib_LEQEMBICollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LEQEMBICollaborationMember" xlink:to="lab_biib_LEQEMBICollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AVONEXMember_32997d99-0201-40a6-8bde-02f77a2e92af_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_label_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_documentation_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember" xlink:href="biib-20240630.xsd#biib_AVONEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember" xlink:to="lab_biib_AVONEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VUMERITYMember_2b887a49-3ae8-4414-96c0-9247ea347657_terseLabel_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VUMERITY</link:label>
    <link:label id="lab_biib_VUMERITYMember_label_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:label id="lab_biib_VUMERITYMember_documentation_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VUMERITY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember" xlink:href="biib-20240630.xsd#biib_VUMERITYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VUMERITYMember" xlink:to="lab_biib_VUMERITYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_845e3f27-9c41-4b58-a082-3e7ad887cf83_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c444e1ce-c675-41e3-8850-7c4f4f63e73d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_7924ec3b-a6dd-4567-a464-4aba6888da0e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PLEGRIDYMember_21c5e07f-8e7c-44a7-b4b0-dbb238cc87b7_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_label_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember" xlink:href="biib-20240630.xsd#biib_PLEGRIDYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember" xlink:to="lab_biib_PLEGRIDYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_017f9886-b1ff-42c0-80ba-1901621c7d35_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_91d056de-193f-4cb7-b8bc-8b483985130d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_553e7be4-78d9-4379-a602-c14c2de452aa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_d6f90d2b-4db0-4150-90e7-006cf5656544_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20240630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_681c799a-1c7b-48c3-8401-2ad60cd9ac1c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e8a1f9f0-7878-49e1-b183-ab7c98c3f583_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c4b07353-0b1d-4095-b233-2a680a134d8f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_94b8a0e2-b44b-44a9-a81a-fff14939b0d5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_bcff04cb-4a3a-43aa-a785-a8a44ae01e61_terseLabel_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives</link:label>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember" xlink:href="biib-20240630.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023CostSavingInitiativesMember" xlink:to="lab_biib_A2023CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_58759d63-13e0-4d47-bc13-2c1e37cf4f72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_f9be3fee-fd29-4bb3-bb15-0d5bb43f03da_terseLabel_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_label_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, From Collaborator</link:label>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_documentation_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, From Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator" xlink:href="biib-20240630.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountsReceivableFromCollaborator" xlink:to="lab_biib_AccountsReceivableFromCollaborator" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9b4e24f3-7ce3-4417-aed7-14fc04e90dca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f7337f07-19a1-49eb-98ca-d29431a631ce_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1502a2e9-b065-4a01-8764-8537efd45c0c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_1c97e4ff-2caf-433a-bd3e-8071fca08e2a_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20240630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_d538f5b8-60fc-4a16-9130-518807a19a40_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_1cf74b9b-d6a4-4886-b775-8df3f9f53497_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e08daf67-0211-4af2-8d29-b35fc1c7748d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bd9856f5-c74a-4399-b5ec-814b005b424b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f8fc3d7e-9d99-4b8a-8da5-92a5848493a1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7a62832f-758e-481e-bdcd-3e381af9e023_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_ee88ec85-7ece-42d1-ad91-c11e46bcfb01_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e968bdb7-17a8-4a61-a296-2ff52ee414c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_fbeb0f1f-c32a-49b8-bdbf-a9561d982c6d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2afc5bd4-6479-4898-877a-0f54a569a54f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_1b62dc76-f36f-4f76-947d-c0979d3f201d_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20240630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_eda96b5d-11a7-458f-aa47-36fecd24f20d_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b867d14b-cc10-4080-8189-b7c0394194e5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_e72b9e60-6869-4241-b716-7599e62b6e9c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_c2cdedfb-1438-457f-b3af-628fd37ceebe_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member" xlink:href="biib-20240630.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsInc.Member" xlink:to="lab_biib_IonisPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc4085d9-d3bf-44fe-b8d0-f8e4cb0691a5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_28348136-b24e-4f63-b06a-87db66e12eff_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_def1b331-3473-41da-a814-e64ee1aa30f6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_bd16aeea-52a4-4131-9dc4-9089fc42d3c9_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e120af6c-02d0-4014-b3ca-66bd03c93e2f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_79c9de77-b7ca-4ba2-8141-d0d0f59b1a1d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_4fefd3b2-9c2c-44bc-9279-a4f7f59d56ad_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_f378831e-5d59-4d1d-8f27-b23a9ec73fc8_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20240630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b3ef9997-c377-4424-b724-c184ba9af756_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_2be3d453-a0cb-4e08-ba95-aea6703f2ce1_terseLabel_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of non-controling interest recognized</link:label>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_label_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Non-Controling Interest Recognized</link:label>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_documentation_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Of Non-Controling Interest Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized" xlink:href="biib-20240630.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNonControlingInterestRecognized" xlink:to="lab_biib_ShareOfNonControlingInterestRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_35b458f2-b49e-4550-8182-c0494a8d05f4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_496abc18-6d34-429b-8bb1-0acc94cfaeca_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d041dfeb-7d40-4657-b0b2-ac0d5f28b455_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_62cf67a9-f67b-48bb-ba70-5e0efe223a90_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_41b195c0-e57e-48f7-808f-a4eaec1a1e07_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_acbca2cb-b4cb-420e-9194-3e83ffb5ce1f_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_label_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_documentation_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:href="biib-20240630.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:to="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_66c34fd1-5d0a-4103-88a3-a0d31fde8569_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_83bf5d13-5e46-417d-ad95-9d8c0ba4f2d5_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0d078d76-6f22-4f7f-ad52-2bf4fdb854f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3935e2dc-bd22-445b-bc3b-6980a34d42c5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a1cfc0df-d0ac-4f99-a2f7-23f03968b70d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_18e2d128-ae4c-4bea-9158-d9ed3b3b754c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $&#8212; per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb999bd2-e612-4dae-885c-08c3706acfdc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3cf5b483-3697-45d8-ad6b-914ec4910003_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_0f072e70-c744-4f6e-b296-ce474d2a1f2d_terseLabel_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</link:label>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_label_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</link:label>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_documentation_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:href="biib-20240630.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:to="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5819c3bd-4464-4ea3-84bb-232fd9782f23_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_c06a6bba-39a6-4724-ba21-9a67bd7810af_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_82956af6-ee4f-47b2-85a6-def9487e252d_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_60a840ef-f790-4324-86aa-7a204e0a3f81_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f619a804-4820-4f17-b174-82128b13c8a3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d6d792af-565a-463c-a907-91100c0ff5a2_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.000 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_88b18147-3c98-4a48-bf49-c053a2d4efce_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_1865725b-5835-41fd-80c1-53da0fb0c6e8_terseLabel_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_label_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 3.250%, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 3.250%, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member" xlink:href="biib-20240630.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotes3.250DueFebruary152051Member" xlink:to="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_711898f2-fc8a-44b6-a93d-8f3c5b85b972_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20240630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_19ca8b59-cbd5-414a-a25b-e05ac3736881_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ae3a3bb8-a5e1-4d6a-9a4c-2ec8c9043ada_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_286198ee-ea63-4b45-a375-8633d4f8c6e7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_c3353ed9-be68-4430-94c4-a75de7ee9c5d_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a7117c07-c327-4ccd-b3de-eef071bfb32f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_1d9d87e9-1bfd-4d5b-b10f-ab5620724755_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20240630.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_e9c1ecbf-b6a5-43e4-a3eb-42a3a1f98ea8_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_783237de-6afc-4807-9c82-aaa044b37f8f_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_982ccb2e-dc82-4cdc-ad36-7858efa432a7_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_68ffb338-fbd2-4787-9722-036e180cd02a_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_5ef41cca-2e11-4760-8900-f9c3fa09682b_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sage Therapeutics</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20240630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_028c96fe-5599-4f80-960e-e42d580caaeb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e97d3a85-4fc1-4bdc-bab6-32327db5bd10_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9d5feae2-6718-4796-a7c6-ae1872cc44f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dispositions</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bc8bc612-cbec-4e26-a7e9-56f848b56142_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_72f9c736-09cf-4e9c-85f4-864e9144f9fa_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bea07e61-ffb4-40bb-9506-f035eef06819_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_97b1c9ea-1bc5-48ba-825e-02b7395cd7e7_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20240630.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_4cef83ea-ea55-49ca-8403-698012182c71_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5f325549-fea2-4eab-81b4-5ee004ca1dd4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_1a6848d1-d459-4a3b-b4ef-f51d570778f2_terseLabel_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired inventory step-up</link:label>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_label_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Inventory Step-Up</link:label>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_documentation_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Inventory Step-Up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp" xlink:href="biib-20240630.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationOfInventoryStepUp" xlink:to="lab_biib_AmortizationOfInventoryStepUp" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_ea417d9c-2e05-4053-929e-a124ec262ea6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_a2a33165-0736-4b19-89f8-b5b3ce0d3ed6_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ab2755cd-9bdd-43f5-9f9c-1d4af1e60838_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_87946be8-ed2d-4eb2-9293-3cd32be548cd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d83baa64-db81-4afe-ae49-e18ca359997d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_aa5df1db-3e35-4d78-84a7-7209c78c5da0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_d4ca9b84-2e05-4581-8199-9ba4de43ac8b_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_af012125-32f9-4e20-874f-dd06d92cd25f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1e1f8824-07c0-40db-9076-3815e7557cef_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_663e7ff2-13ed-4910-8e97-d1b6e313eb13_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_1907c2dc-ef6e-4fe3-be5e-72c40a0c5e63_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20240630.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c12c28d9-bd7a-441d-aa77-8aab42f6e04b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_6ddd3b6b-e655-4ea0-bb7b-92989b665d92_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_21b08eda-ad25-4fe1-a5e5-5505ecf61c5a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt, Maturing in More than Three Months</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt, Maturing in More than Three Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_7e7c9a57-e112-4226-a1a4-bb55f0a9daad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_b5b93ca3-8131-44d7-a35d-c6de79eca685_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MosunetuzumabMember_45c5a621-b516-4d1a-ae3b-2e610c4ad518_terseLabel_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mosunetuzumab</link:label>
    <link:label id="lab_biib_MosunetuzumabMember_label_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mosunetuzumab [Member]</link:label>
    <link:label id="lab_biib_MosunetuzumabMember_documentation_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mosunetuzumab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember" xlink:href="biib-20240630.xsd#biib_MosunetuzumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MosunetuzumabMember" xlink:to="lab_biib_MosunetuzumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_02ca71ec-e864-4842-b638-d443d1244178_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1b36b5cc-089a-41cb-a08b-fd624018f5f1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_aa5c8cf0-07ae-47c7-82db-482f0246552c_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20240630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_ce808ce6-6372-4b53-9940-8e03ed7e12b8_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0532269b-22c4-4339-9988-277b96bc36ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8eb8cb2f-a538-4f98-a550-3cdd3b636e8e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_aa11d0e8-2b97-4039-91ae-4e9fd60d48f8_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20240630.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_aac84ea5-548e-493f-9369-2aa955627f7a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_9a916219-edf0-4470-a88e-8a4acc994fb4_terseLabel_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue</link:label>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_label_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue [Member]</link:label>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_documentation_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember" xlink:href="biib-20240630.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RareDiseaseProductRevenueMember" xlink:to="lab_biib_RareDiseaseProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_9132e616-4c94-46a7-b718-8541a3954315_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_050978f5-66aa-4b46-836a-ad25defba6e2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_ecbca3a1-7374-4930-adf1-468cf3998b7b_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_e538b9da-dc77-45d7-bea9-037da0b5d9db_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e5eeeb8a-7dfa-46f2-8ba9-de69de8477af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3d9fb4ba-1de2-4663-9c8d-a497b8c31c7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_7d7fc755-6c4a-4862-b92b-9db25bdd50e4_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20240630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>biib-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a009166-a1cb-4c50-83a7-d8b5a99052fa,g:b0d9c5b1-5cff-4c82-aab8-c75b5958a97b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20240630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_637c85ad-7f42-480c-89fa-b3f4fa25c0e4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_DocumentType_637c85ad-7f42-480c-89fa-b3f4fa25c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ae101aaf-fd5d-4338-b431-1e560df9b538" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_DocumentQuarterlyReport_ae101aaf-fd5d-4338-b431-1e560df9b538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9e0c5c11-a4f7-4315-9cc6-014f03e419bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_DocumentPeriodEndDate_9e0c5c11-a4f7-4315-9cc6-014f03e419bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1302284b-0956-4a74-be10-4de66b41c5dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_DocumentTransitionReport_1302284b-0956-4a74-be10-4de66b41c5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_88d84443-046e-4456-8992-6a977fd40a06" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityFileNumber_88d84443-046e-4456-8992-6a977fd40a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_76b1f03a-9cea-47b9-a783-62b09de6b3ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityRegistrantName_76b1f03a-9cea-47b9-a783-62b09de6b3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1ec9dedc-60b5-4add-8a34-59135c6c41d2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityCentralIndexKey_1ec9dedc-60b5-4add-8a34-59135c6c41d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1fc07990-b134-4192-b8d1-057119cf3b76" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_CurrentFiscalYearEndDate_1fc07990-b134-4192-b8d1-057119cf3b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_86d5a292-87cd-4d44-92df-2c35440b344e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_DocumentFiscalYearFocus_86d5a292-87cd-4d44-92df-2c35440b344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9d157c32-1754-4f87-bf01-55d7181aeead" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9d157c32-1754-4f87-bf01-55d7181aeead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0ca6f49b-7f03-4b15-a54b-cec3797a5661" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_AmendmentFlag_0ca6f49b-7f03-4b15-a54b-cec3797a5661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3757d9d7-eac4-494f-ac7b-a28115e0f00a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3757d9d7-eac4-494f-ac7b-a28115e0f00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f09763a5-e0fa-45d1-b2f6-94d035c3f831" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityTaxIdentificationNumber_f09763a5-e0fa-45d1-b2f6-94d035c3f831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_09502b4d-5e60-40af-855a-5c88cb5ed61e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityAddressAddressLine1_09502b4d-5e60-40af-855a-5c88cb5ed61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3b358b71-bc12-4841-8481-2102714a6bd2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityAddressCityOrTown_3b358b71-bc12-4841-8481-2102714a6bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1f92d36c-2953-44f5-a450-d22f79298f52" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityAddressStateOrProvince_1f92d36c-2953-44f5-a450-d22f79298f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7d8b2db6-2d46-494d-bb3e-b45314621cf2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityAddressPostalZipCode_7d8b2db6-2d46-494d-bb3e-b45314621cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a8b2a349-eee8-40fb-bebd-44fd907801b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_CityAreaCode_a8b2a349-eee8-40fb-bebd-44fd907801b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9136f034-9107-4792-8876-63dade37d62c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_LocalPhoneNumber_9136f034-9107-4792-8876-63dade37d62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_578d750e-7f4e-4688-89c7-cff290d05f1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_Security12bTitle_578d750e-7f4e-4688-89c7-cff290d05f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_57a117fc-3932-49b1-a613-2b846772a3e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_TradingSymbol_57a117fc-3932-49b1-a613-2b846772a3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b8dac79a-0f5a-4447-82d0-b3cd70772549" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_SecurityExchangeName_b8dac79a-0f5a-4447-82d0-b3cd70772549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_972c1cb3-721a-45a9-9570-4cb221092efa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityCurrentReportingStatus_972c1cb3-721a-45a9-9570-4cb221092efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0c127629-c83c-4afc-b876-34d7989707fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityInteractiveDataCurrent_0c127629-c83c-4afc-b876-34d7989707fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bab285d9-038f-4f82-8dff-d03c288ed209" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityFilerCategory_bab285d9-038f-4f82-8dff-d03c288ed209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a667694f-51ee-4ffa-b337-336858c54145" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntitySmallBusiness_a667694f-51ee-4ffa-b337-336858c54145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a2d53e1b-b1ea-41c5-86c6-8baa39a5fadc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityEmergingGrowthCompany_a2d53e1b-b1ea-41c5-86c6-8baa39a5fadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_16578107-0c73-463f-909c-8c45d8ad51e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityShellCompany_16578107-0c73-463f-909c-8c45d8ad51e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1449d832-836d-4aa7-9006-83563932822c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2cf95be1-dc1f-4de6-887a-704af1bf2d33" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1449d832-836d-4aa7-9006-83563932822c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a48f5597-cc2d-413e-9a1a-50eefa7e5ace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_63643870-cf51-44d9-96b3-a8454ab030c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a48f5597-cc2d-413e-9a1a-50eefa7e5ace" xlink:to="loc_us-gaap_StatementTable_63643870-cf51-44d9-96b3-a8454ab030c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29e2e546-c976-47e1-b4a5-c40718ff7f1b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_63643870-cf51-44d9-96b3-a8454ab030c4" xlink:to="loc_srt_ProductOrServiceAxis_29e2e546-c976-47e1-b4a5-c40718ff7f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_29e2e546-c976-47e1-b4a5-c40718ff7f1b" xlink:to="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9e16fb94-1aee-4bdb-840a-f28b48617e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:to="loc_us-gaap_ProductMember_9e16fb94-1aee-4bdb-840a-f28b48617e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_26e895ad-e0ef-4036-81c4-40e1e3f243b7" xlink:href="biib-20240630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_26e895ad-e0ef-4036-81c4-40e1e3f243b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_31475113-c010-4e9a-ace1-c8193f978611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82081980-35fd-4d3a-af1b-813f75378037" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_31475113-c010-4e9a-ace1-c8193f978611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_63643870-cf51-44d9-96b3-a8454ab030c4" xlink:to="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a253119f-4903-4819-b968-d98a3ef137b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_Revenues_a253119f-4903-4819-b968-d98a3ef137b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9dfab1b7-17b0-41f2-a2c3-5838ed8d5771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9dfab1b7-17b0-41f2-a2c3-5838ed8d5771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3e944d24-dd2c-4dc3-8d29-4909d8768e03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3e944d24-dd2c-4dc3-8d29-4909d8768e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b423cd16-ff1b-4b87-804c-6ae363c107fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b423cd16-ff1b-4b87-804c-6ae363c107fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_1a1cb782-656f-4661-947e-6b97fe919539" xlink:href="biib-20240630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_1a1cb782-656f-4661-947e-6b97fe919539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_bc017be6-b3ab-48d5-ad10-7711d1c5a58c" xlink:href="biib-20240630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_biib_Collaborationprofitlosssharing_bc017be6-b3ab-48d5-ad10-7711d1c5a58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1eadff86-1b0d-45d5-bd21-69746ef947e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_RestructuringCharges_1eadff86-1b0d-45d5-bd21-69746ef947e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_16e4bc10-a4f4-47d3-8558-b6657ac8f9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_16e4bc10-a4f4-47d3-8558-b6657ac8f9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2907d3cc-094b-4111-bfb9-02e35d71de24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2907d3cc-094b-4111-bfb9-02e35d71de24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1da77d4b-4fe0-426a-bae7-f736a165a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e586fd3d-4d4f-4e4e-a642-98829f71ba60" xlink:to="loc_us-gaap_CostsAndExpenses_1da77d4b-4fe0-426a-bae7-f736a165a0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d74a3f0-2d10-47bf-b3c7-1df9443f2101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d74a3f0-2d10-47bf-b3c7-1df9443f2101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3b2187e6-aafe-45ad-b5d7-f8eec018b972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3b2187e6-aafe-45ad-b5d7-f8eec018b972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_98237283-389e-453e-8ec5-59d185847655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_ProfitLoss_98237283-389e-453e-8ec5-59d185847655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c0c94594-1abc-45e9-ae4c-a575479c75d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c0c94594-1abc-45e9-ae4c-a575479c75d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f18c4947-922e-410b-b720-b52a0ddee4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_NetIncomeLoss_f18c4947-922e-410b-b720-b52a0ddee4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3e7dd31b-9cd2-45a0-a330-a2a20d20af57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_EarningsPerShareAbstract_3e7dd31b-9cd2-45a0-a330-a2a20d20af57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_49d3a54a-91c8-4885-90b4-2843d3b2fe16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3e7dd31b-9cd2-45a0-a330-a2a20d20af57" xlink:to="loc_us-gaap_EarningsPerShareBasic_49d3a54a-91c8-4885-90b4-2843d3b2fe16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1f8220d9-7f3c-44f7-968f-c7c5955123a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3e7dd31b-9cd2-45a0-a330-a2a20d20af57" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1f8220d9-7f3c-44f7-968f-c7c5955123a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cf5f0a42-25ce-4fdb-adfa-853f0fc1b685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9ba5345-3274-478f-b4cc-d5046c774ad2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cf5f0a42-25ce-4fdb-adfa-853f0fc1b685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a0e066e-5935-41ad-a4ae-9ded91f7d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cf5f0a42-25ce-4fdb-adfa-853f0fc1b685" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a0e066e-5935-41ad-a4ae-9ded91f7d3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7397b5a3-67be-40c2-8677-81ae3539289a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cf5f0a42-25ce-4fdb-adfa-853f0fc1b685" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7397b5a3-67be-40c2-8677-81ae3539289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7460dca9-cd1b-48e5-9537-b74655773da0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_03b4cdb6-3fba-45b8-907f-c5d899283a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7460dca9-cd1b-48e5-9537-b74655773da0" xlink:to="loc_us-gaap_NetIncomeLoss_03b4cdb6-3fba-45b8-907f-c5d899283a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7460dca9-cd1b-48e5-9537-b74655773da0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_01619ccb-0410-4ad1-a534-989001cde401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_01619ccb-0410-4ad1-a534-989001cde401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_352ff20b-5e79-4557-8e5e-be3277c5e2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_352ff20b-5e79-4557-8e5e-be3277c5e2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_409ff54d-8127-4ba0-ba59-db6ea0263313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_409ff54d-8127-4ba0-ba59-db6ea0263313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b5b2aca4-e78c-4542-8979-cc0ae87a127a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b5b2aca4-e78c-4542-8979-cc0ae87a127a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fd3f6b1b-35b3-426f-bbd4-0c3cfbcc0915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fd3f6b1b-35b3-426f-bbd4-0c3cfbcc0915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bd446be4-306d-4942-9e8f-dc7bb42300d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bd446be4-306d-4942-9e8f-dc7bb42300d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_dd6680ce-8171-48e8-b638-1546ccb73337" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_dd6680ce-8171-48e8-b638-1546ccb73337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d5c2e064-474c-475c-9828-b0a45cb82058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42b693fd-e648-4b15-8f1d-b41d583eb6c7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d5c2e064-474c-475c-9828-b0a45cb82058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_59f6c0cf-9a1b-4d3e-99bd-375feb029701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1727db48-2874-4053-b76f-f8900ba5225e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59f6c0cf-9a1b-4d3e-99bd-375feb029701" xlink:to="loc_us-gaap_StatementTable_1727db48-2874-4053-b76f-f8900ba5225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d18aa5db-cb65-4a58-a3f3-437d52570abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1727db48-2874-4053-b76f-f8900ba5225e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d18aa5db-cb65-4a58-a3f3-437d52570abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8988395a-916c-4e5e-8c05-9d3a49ef25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d18aa5db-cb65-4a58-a3f3-437d52570abb" xlink:to="loc_us-gaap_RelatedPartyDomain_8988395a-916c-4e5e-8c05-9d3a49ef25ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_47cdcad2-c35a-4109-81b7-8b1c92b52920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8988395a-916c-4e5e-8c05-9d3a49ef25ac" xlink:to="loc_us-gaap_NonrelatedPartyMember_47cdcad2-c35a-4109-81b7-8b1c92b52920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_867aac4f-f548-487c-b2a2-79958d4aaca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8988395a-916c-4e5e-8c05-9d3a49ef25ac" xlink:to="loc_us-gaap_RelatedPartyMember_867aac4f-f548-487c-b2a2-79958d4aaca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7f9faf13-78c3-4366-b443-8983a332dd29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1727db48-2874-4053-b76f-f8900ba5225e" xlink:to="loc_us-gaap_StatementLineItems_7f9faf13-78c3-4366-b443-8983a332dd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f9faf13-78c3-4366-b443-8983a332dd29" xlink:to="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8b12f70-3fe8-4385-8b14-78acf4a2bab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8b12f70-3fe8-4385-8b14-78acf4a2bab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fd3c8cde-72b5-45d1-9f4e-7a68f9d7385c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fd3c8cde-72b5-45d1-9f4e-7a68f9d7385c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ddd5ab6d-0364-40ac-bab3-8ba018c781a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_InventoryNet_ddd5ab6d-0364-40ac-bab3-8ba018c781a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f7bd38f0-cc94-4621-a732-1aae1d77978e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_OtherAssetsCurrent_f7bd38f0-cc94-4621-a732-1aae1d77978e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_647c2b6c-4e27-44de-84cd-606ae98cb0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_29e3049d-faf5-49d4-9e1f-ed4d5fd7bac0" xlink:to="loc_us-gaap_AssetsCurrent_647c2b6c-4e27-44de-84cd-606ae98cb0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_440b3c25-b1fc-45a5-9285-962252b58603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_440b3c25-b1fc-45a5-9285-962252b58603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ef7d333-6ca5-4c8e-a6dc-64ca3731f60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ef7d333-6ca5-4c8e-a6dc-64ca3731f60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c36abf9d-b69c-4d4b-9c99-858bb010e129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c36abf9d-b69c-4d4b-9c99-858bb010e129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_384cd340-586b-46ac-b94d-e53e5dfdf32d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_Goodwill_384cd340-586b-46ac-b94d-e53e5dfdf32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_64b4f283-4edd-4f68-b611-ccb6630a740c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_64b4f283-4edd-4f68-b611-ccb6630a740c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_85fe3987-389e-4c0c-a380-a2529f3b783e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_85fe3987-389e-4c0c-a380-a2529f3b783e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_790f4e08-0823-4395-a459-f18be613b451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36708b60-796c-4d34-9d35-4915ddfeab55" xlink:to="loc_us-gaap_Assets_790f4e08-0823-4395-a459-f18be613b451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f9faf13-78c3-4366-b443-8983a332dd29" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_85cc6cf9-c8e2-42d2-a64a-1be376215878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_NotesPayableCurrent_85cc6cf9-c8e2-42d2-a64a-1be376215878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_4a2135d3-b68a-4fc6-bb18-7a9fb5248af2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_TaxesPayableCurrent_4a2135d3-b68a-4fc6-bb18-7a9fb5248af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_db05bc38-90a3-4357-b24a-c1385704dac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_AccountsPayableCurrent_db05bc38-90a3-4357-b24a-c1385704dac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a71b6387-995e-4175-99b3-0492f2835c93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a71b6387-995e-4175-99b3-0492f2835c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f730c24a-1dea-45e5-9b31-bae663c3c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9c382628-f6a6-4696-a29e-d3891874921f" xlink:to="loc_us-gaap_LiabilitiesCurrent_f730c24a-1dea-45e5-9b31-bae663c3c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_89950d71-6c49-485d-887e-d93ed11068a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_LongTermDebt_89950d71-6c49-485d-887e-d93ed11068a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a0352039-a5d0-4535-8405-a21686f76de4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a0352039-a5d0-4535-8405-a21686f76de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf39b496-1a50-40e9-a629-ad77e1b482a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf39b496-1a50-40e9-a629-ad77e1b482a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8babe843-6690-4e6f-9661-30560bbd5c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8babe843-6690-4e6f-9661-30560bbd5c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9905b405-c6cd-4e37-a106-d88cf859b29c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_Liabilities_9905b405-c6cd-4e37-a106-d88cf859b29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_781a3933-cdcc-4905-8cd8-0f4a3cbd252a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_CommitmentsAndContingencies_781a3933-cdcc-4905-8cd8-0f4a3cbd252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66a04ba0-c2fe-497e-8884-bbd9c963ef59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66a04ba0-c2fe-497e-8884-bbd9c963ef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66a04ba0-c2fe-497e-8884-bbd9c963ef59" xlink:to="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_81e8cd1a-e0af-4636-b135-d817ebc0f4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_PreferredStockValue_81e8cd1a-e0af-4636-b135-d817ebc0f4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0c6d0a49-559b-40d5-91d1-c1a0eb102de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_CommonStockValue_0c6d0a49-559b-40d5-91d1-c1a0eb102de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_71a4a35a-e564-4bc0-9d46-7d29d6083002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_71a4a35a-e564-4bc0-9d46-7d29d6083002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86bcbe5c-e9fc-4f59-970f-397b2503f1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86bcbe5c-e9fc-4f59-970f-397b2503f1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac319efa-c0fe-4569-b453-bc076ea818d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac319efa-c0fe-4569-b453-bc076ea818d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_aeebefae-30d2-486c-a91d-e7c62dc09b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_74ea41a2-9a36-4a12-9f6d-129ba0fbf7c2" xlink:to="loc_us-gaap_TreasuryStockValue_aeebefae-30d2-486c-a91d-e7c62dc09b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc2bd8b8-521c-4212-a659-52e176df4c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66a04ba0-c2fe-497e-8884-bbd9c963ef59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc2bd8b8-521c-4212-a659-52e176df4c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_152adb42-715c-4f04-bc5f-30f79e0b06b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c0f4dbdb-6c8d-4c0a-ae6f-1140540e4f00" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_152adb42-715c-4f04-bc5f-30f79e0b06b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="biib-20240630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7cad97e9-6d7e-4cc7-b73c-96cb0307bdef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3a41d664-f79d-4a0b-9305-1fbf3b312e24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cad97e9-6d7e-4cc7-b73c-96cb0307bdef" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3a41d664-f79d-4a0b-9305-1fbf3b312e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9a34d783-333d-42cf-9673-c79d4ba7ec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cad97e9-6d7e-4cc7-b73c-96cb0307bdef" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9a34d783-333d-42cf-9673-c79d4ba7ec5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_456c5102-4e0f-4c96-9fb8-6749bad0031b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cad97e9-6d7e-4cc7-b73c-96cb0307bdef" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_456c5102-4e0f-4c96-9fb8-6749bad0031b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ddb61b8e-aafa-43a0-a819-39c782bf9812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7a115a8-1a46-45e3-9d90-d4f5d0ce3288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ddb61b8e-aafa-43a0-a819-39c782bf9812" xlink:to="loc_us-gaap_StatementTable_f7a115a8-1a46-45e3-9d90-d4f5d0ce3288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2bece41-c978-4b65-adf4-da687c567f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7a115a8-1a46-45e3-9d90-d4f5d0ce3288" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2bece41-c978-4b65-adf4-da687c567f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_25351c20-df1e-42db-8f4d-ce8ff5308cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2bece41-c978-4b65-adf4-da687c567f5e" xlink:to="loc_us-gaap_RelatedPartyDomain_25351c20-df1e-42db-8f4d-ce8ff5308cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_a57b2f3e-e6f6-47da-9804-b45c8ba6c766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_25351c20-df1e-42db-8f4d-ce8ff5308cb1" xlink:to="loc_us-gaap_NonrelatedPartyMember_a57b2f3e-e6f6-47da-9804-b45c8ba6c766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_7b879909-d5b0-4d36-a5d3-ae1588c40edb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_25351c20-df1e-42db-8f4d-ce8ff5308cb1" xlink:to="loc_us-gaap_RelatedPartyMember_7b879909-d5b0-4d36-a5d3-ae1588c40edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7a115a8-1a46-45e3-9d90-d4f5d0ce3288" xlink:to="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_861d0b9f-2620-4696-9c50-37d0c118a3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_861d0b9f-2620-4696-9c50-37d0c118a3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b202fb84-1e08-4425-8249-1dd7e1f7e16c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_861d0b9f-2620-4696-9c50-37d0c118a3a9" xlink:to="loc_us-gaap_ProfitLoss_b202fb84-1e08-4425-8249-1dd7e1f7e16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_861d0b9f-2620-4696-9c50-37d0c118a3a9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8a060cb4-fb65-4f96-bf65-ff3a6c89cc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8a060cb4-fb65-4f96-bf65-ff3a6c89cc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b9aa5d1b-05a2-4cd0-9eb3-7c297b51e1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_InventoryWriteDown_b9aa5d1b-05a2-4cd0-9eb3-7c297b51e1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_bf71ebcf-bccf-47d1-b1fe-ec438cd51395" xlink:href="biib-20240630.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_biib_AmortizationOfInventoryStepUp_bf71ebcf-bccf-47d1-b1fe-ec438cd51395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_340dac82-7a7a-4ee7-97ad-daef55b5bf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_ShareBasedCompensation_340dac82-7a7a-4ee7-97ad-daef55b5bf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a4d5fe0-afc1-407e-b825-3b44ec3f31a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a4d5fe0-afc1-407e-b825-3b44ec3f31a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_6627a795-d7e8-4192-b822-f20876713d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_6627a795-d7e8-4192-b822-f20876713d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_20563ad3-7421-4278-afdc-7ae4a4726bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_20563ad3-7421-4278-afdc-7ae4a4726bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a28ecf94-367a-412c-957c-dd21d4c017ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a28ecf94-367a-412c-957c-dd21d4c017ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f292414a-0dba-497c-8f36-c240ae201185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f292414a-0dba-497c-8f36-c240ae201185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fef8c234-46f7-4bec-a305-374402700d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fef8c234-46f7-4bec-a305-374402700d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0dcd45e6-e102-4628-a09a-8eceab6e5fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0dcd45e6-e102-4628-a09a-8eceab6e5fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0a9627bc-88d9-4a1f-bfaf-e1c5cad0c8be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0a9627bc-88d9-4a1f-bfaf-e1c5cad0c8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6f7f2e3f-e7a0-4bc7-b556-52d0a636e1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_820f8a6b-aa77-4529-95e4-09eed910d886" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6f7f2e3f-e7a0-4bc7-b556-52d0a636e1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97258c5b-aec2-4526-9c7e-b2a687ef1ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f96f4585-67f3-43fa-bef6-6e93c126b510" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97258c5b-aec2-4526-9c7e-b2a687ef1ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a88fc3d9-104d-46a1-9b5d-89c01b2fdfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a88fc3d9-104d-46a1-9b5d-89c01b2fdfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1c2060d7-6cc0-4f8c-9458-e36cc2175930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1c2060d7-6cc0-4f8c-9458-e36cc2175930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3e6079cf-86f0-4bce-af8e-2b1156879c05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3e6079cf-86f0-4bce-af8e-2b1156879c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_943f517e-7f67-41d9-82ef-5ea2c02aab22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_943f517e-7f67-41d9-82ef-5ea2c02aab22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d4f41f68-e7c8-4540-ac0b-92dea4fca076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d4f41f68-e7c8-4540-ac0b-92dea4fca076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a684f23d-5418-4503-b4b6-796b3caf3676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a684f23d-5418-4503-b4b6-796b3caf3676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_1093de43-e4c6-42a5-831f-245aa11002a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_1093de43-e4c6-42a5-831f-245aa11002a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_09245e1b-78f9-492c-9ee2-05b481bd10f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_09245e1b-78f9-492c-9ee2-05b481bd10f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5753dc5-bfa3-40df-8f6c-be71265879d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34cc3f0-3d6c-4233-a40e-8fcc78c3d0a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5753dc5-bfa3-40df-8f6c-be71265879d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d47f5930-9e77-490c-a075-a09dd60bb60a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d47f5930-9e77-490c-a075-a09dd60bb60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7bdb09cc-f230-4efb-a96c-716ba1b37eec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7bdb09cc-f230-4efb-a96c-716ba1b37eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_3de9893a-2b35-4b82-ad41-858b00de9ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_3de9893a-2b35-4b82-ad41-858b00de9ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2115476b-0500-45bf-896c-add88888ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2115476b-0500-45bf-896c-add88888ac5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e0526e57-2929-4c09-8923-d936024d21de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e3b5405-887e-4961-a070-3e4bd4497db2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e0526e57-2929-4c09-8923-d936024d21de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5382817b-78d7-4500-a09a-794684977e69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5382817b-78d7-4500-a09a-794684977e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_603a0204-d02f-477e-bb31-ea09420855f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_603a0204-d02f-477e-bb31-ea09420855f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e764437a-99ea-4b83-8dc9-0f5ef294b044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e764437a-99ea-4b83-8dc9-0f5ef294b044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c2a987f-9d0b-4b4c-9228-fcc11b64f894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7f47859-2529-43ce-a9f1-77bd8ee3fc24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c2a987f-9d0b-4b4c-9228-fcc11b64f894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20240630.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_44760018-1378-41fc-93bd-83039255935a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d16a90e-7fcd-43a4-a5c5-b8279f4137ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_44760018-1378-41fc-93bd-83039255935a" xlink:to="loc_us-gaap_StatementTable_8d16a90e-7fcd-43a4-a5c5-b8279f4137ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d16a90e-7fcd-43a4-a5c5-b8279f4137ed" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d7c77217-7e3b-4a4e-9c1b-8d348b371cbc" xlink:to="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1b2ac6b5-2167-4ab1-aea5-77e063a488d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_PreferredStockMember_1b2ac6b5-2167-4ab1-aea5-77e063a488d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89162a4f-b1cc-44b5-ad85-e4bb56cefc86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_CommonStockMember_89162a4f-b1cc-44b5-ad85-e4bb56cefc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_07085798-16c6-446b-853f-fda52795b4be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_07085798-16c6-446b-853f-fda52795b4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1cdba126-a217-480e-8b8a-f3aabcec8248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1cdba126-a217-480e-8b8a-f3aabcec8248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dd174f21-abd7-4cf1-b7c4-a124ab620ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_RetainedEarningsMember_dd174f21-abd7-4cf1-b7c4-a124ab620ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_930d3bec-6273-4f33-8a7a-c1edacae5255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_930d3bec-6273-4f33-8a7a-c1edacae5255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_469bf20c-3043-481d-ac50-08bdadb2209b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_ParentMember_469bf20c-3043-481d-ac50-08bdadb2209b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e2d71f75-bcf0-4e2e-b375-e4055464dfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8ad9be0-e954-4990-8890-0a816f60814c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e2d71f75-bcf0-4e2e-b375-e4055464dfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d16a90e-7fcd-43a4-a5c5-b8279f4137ed" xlink:to="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2607b003-a9f6-4c57-9f95-68fcf2143d19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2607b003-a9f6-4c57-9f95-68fcf2143d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d0f8263-f2bf-4ff5-82be-107aa1146186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d0f8263-f2bf-4ff5-82be-107aa1146186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_487a46d4-9d88-4dd7-8ea4-0984615e6265" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_487a46d4-9d88-4dd7-8ea4-0984615e6265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4883f4d6-a858-4ab4-853c-5482ed7c603a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_ProfitLoss_4883f4d6-a858-4ab4-853c-5482ed7c603a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1c13273f-6091-478c-a3ee-38dcde9a97f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1c13273f-6091-478c-a3ee-38dcde9a97f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_690d6104-3140-43dd-b123-a61c6c9fb079" xlink:href="biib-20240630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_690d6104-3140-43dd-b123-a61c6c9fb079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c47f550e-f994-43b9-9380-bf3496a1079e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c47f550e-f994-43b9-9380-bf3496a1079e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_ef1652ad-3675-4a68-9e84-871b330bd686" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_ef1652ad-3675-4a68-9e84-871b330bd686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf56648b-85cd-4e7e-bb09-44c1b5d8d957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf56648b-85cd-4e7e-bb09-44c1b5d8d957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_40532459-ef55-4955-ac9d-ffe207a5fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_40532459-ef55-4955-ac9d-ffe207a5fdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2b53c6a-615c-4461-a29b-182cddb99169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2b53c6a-615c-4461-a29b-182cddb99169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_d0ac2b50-9477-4bbb-b23e-5801f0aa203e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockholdersEquityOther_d0ac2b50-9477-4bbb-b23e-5801f0aa203e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_12a38a33-5648-4f38-859e-631ccdd7b6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_12a38a33-5648-4f38-859e-631ccdd7b6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_47d16602-2e7b-419c-b322-0862057f3036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_47d16602-2e7b-419c-b322-0862057f3036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a994a01c-0c62-4ce5-8832-ca5e4a098734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb76abd8-0330-408a-82e7-22b2a5e05bb5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_a994a01c-0c62-4ce5-8832-ca5e4a098734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20240630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8c537ddd-283d-43bf-a1aa-16ceee26a558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_290130b0-1d77-4e7f-a1ee-40c48bb0d86f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c537ddd-283d-43bf-a1aa-16ceee26a558" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_290130b0-1d77-4e7f-a1ee-40c48bb0d86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20240630.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_51687156-aa7f-4152-ac91-794baaf44b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_10c81892-c93d-4cc7-8599-639efce0b952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_51687156-aa7f-4152-ac91-794baaf44b29" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_10c81892-c93d-4cc7-8599-639efce0b952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Dispositions" xlink:type="simple" xlink:href="biib-20240630.xsd#Dispositions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Dispositions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_5cb96593-bfb9-4886-98a8-370cdbc45048" xlink:href="biib-20240630.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e733fdd3-2b6a-40c5-bbc0-ab5c2dd3d1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_5cb96593-bfb9-4886-98a8-370cdbc45048" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e733fdd3-2b6a-40c5-bbc0-ab5c2dd3d1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiatives"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c86e581-ac79-4f1c-9da4-0c7e27d09c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_d07e2974-239a-4ce5-90b1-de1b392d9bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c86e581-ac79-4f1c-9da4-0c7e27d09c9f" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_d07e2974-239a-4ce5-90b1-de1b392d9bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20240630.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b59f54f-3c62-413c-b56a-917f049e08fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_90d54204-f9b0-4686-b5c5-7e64a2d252e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b59f54f-3c62-413c-b56a-917f049e08fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_90d54204-f9b0-4686-b5c5-7e64a2d252e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20240630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2ba96720-8a0e-4e93-bc15-a40561ba2fff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_d1b38573-7fae-480a-b504-eaf475639d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2ba96720-8a0e-4e93-bc15-a40561ba2fff" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_d1b38573-7fae-480a-b504-eaf475639d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_93c1f362-82d6-43ec-89c1-f7ff33891141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_7eae29a0-bdef-4207-b4c5-b866b5b35820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_93c1f362-82d6-43ec-89c1-f7ff33891141" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_7eae29a0-bdef-4207-b4c5-b866b5b35820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eed29983-d2b7-4c98-a92b-7294fa22e11a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e4445726-8f49-4afa-b022-cd4a8e21ec41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eed29983-d2b7-4c98-a92b-7294fa22e11a" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e4445726-8f49-4afa-b022-cd4a8e21ec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9888721c-ba78-4465-9208-1270fbe88d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_56bf96bc-4364-4256-9338-b8363d8d782b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9888721c-ba78-4465-9208-1270fbe88d5f" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_56bf96bc-4364-4256-9338-b8363d8d782b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20240630.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9955ba5-b7cc-4072-b5ee-cfed25668c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_48a3f04b-82e4-43ff-8a6f-cf7ac98d9a82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9955ba5-b7cc-4072-b5ee-cfed25668c59" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_48a3f04b-82e4-43ff-8a6f-cf7ac98d9a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20240630.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca66a0b3-707c-436d-acaf-476c7d7c6e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_001c8206-06e5-4f7d-8f13-d862a7935b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca66a0b3-707c-436d-acaf-476c7d7c6e2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_001c8206-06e5-4f7d-8f13-d862a7935b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:type="simple" xlink:href="biib-20240630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_45097bdf-a425-443b-8b1b-0d429e5e20fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0be5ecc8-eba6-43e6-9757-d723e5186ace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45097bdf-a425-443b-8b1b-0d429e5e20fd" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0be5ecc8-eba6-43e6-9757-d723e5186ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20240630.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_39b0fbe4-48ae-4f46-8ac0-d5278dafba79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3e89358e-05d7-4a61-8879-4b4ce33828fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_39b0fbe4-48ae-4f46-8ac0-d5278dafba79" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3e89358e-05d7-4a61-8879-4b4ce33828fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20240630.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bb6e3220-fecf-40cd-9100-6287d2840c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a8703e54-3ac3-43d6-9b13-cc85d9484719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb6e3220-fecf-40cd-9100-6287d2840c8b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a8703e54-3ac3-43d6-9b13-cc85d9484719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20240630.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_27779aa3-b19c-442a-89c5-ec3228707617" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_030f8ca7-eb5b-460e-beb3-8ba8b2f80ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27779aa3-b19c-442a-89c5-ec3228707617" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_030f8ca7-eb5b-460e-beb3-8ba8b2f80ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20240630.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6b24b91-fba5-4505-9b0b-8f3038c788ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_def244b4-9d0d-4f87-a10d-4471ae706f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6b24b91-fba5-4505-9b0b-8f3038c788ba" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_def244b4-9d0d-4f87-a10d-4471ae706f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20240630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1996764a-9265-4452-985a-77d91e5a60d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1fbd4fda-c304-4436-b7dc-5eabf23de464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1996764a-9265-4452-985a-77d91e5a60d3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1fbd4fda-c304-4436-b7dc-5eabf23de464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20240630.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed536724-8b24-464e-8852-5c625e725ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_806b332a-a9af-46c6-920c-cdd045aba5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed536724-8b24-464e-8852-5c625e725ed3" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_806b332a-a9af-46c6-920c-cdd045aba5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d400b9a-abaa-4358-a184-1604cbcec808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c13dbd03-a6da-49fe-b023-f9ad978bedd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d400b9a-abaa-4358-a184-1604cbcec808" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c13dbd03-a6da-49fe-b023-f9ad978bedd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20240630.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_5e59a2ce-1a66-4c1b-91e8-9b1e79317c30" xlink:href="biib-20240630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_b7d465dd-5b2e-4376-9c90-7d52a0a83df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_5e59a2ce-1a66-4c1b-91e8-9b1e79317c30" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_b7d465dd-5b2e-4376-9c90-7d52a0a83df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20240630.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_d83a2e69-3685-43a1-8f83-7ef898d33d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_db01c1b6-7fb8-43ee-99a6-a17e1ebdfb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_d83a2e69-3685-43a1-8f83-7ef898d33d9b" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_db01c1b6-7fb8-43ee-99a6-a17e1ebdfb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20240630.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aeda8cd3-fdbd-4016-8832-549d9a39a3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_d5189bc8-c1f9-4ca8-a1d0-9f1656c13013" xlink:href="biib-20240630.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeda8cd3-fdbd-4016-8832-549d9a39a3c7" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_d5189bc8-c1f9-4ca8-a1d0-9f1656c13013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_cdc5b4e5-5b85-446b-885b-907fec2846b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeda8cd3-fdbd-4016-8832-549d9a39a3c7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_cdc5b4e5-5b85-446b-885b-907fec2846b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_fd5e1318-1c7d-4ab9-a095-e8f972fcdf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeda8cd3-fdbd-4016-8832-549d9a39a3c7" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_fd5e1318-1c7d-4ab9-a095-e8f972fcdf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_22189bbb-eb56-4565-8ca4-50f7c8c900b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeda8cd3-fdbd-4016-8832-549d9a39a3c7" xlink:to="loc_us-gaap_UseOfEstimates_22189bbb-eb56-4565-8ca4-50f7c8c900b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0a1cf564-a5d3-4c91-9507-a578b014d792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeda8cd3-fdbd-4016-8832-549d9a39a3c7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0a1cf564-a5d3-4c91-9507-a578b014d792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="biib-20240630.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f06d8f99-e0d5-40ef-8277-606f77d6de5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_04cf8888-735f-46aa-94ad-0d6563ad3e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f06d8f99-e0d5-40ef-8277-606f77d6de5a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_04cf8888-735f-46aa-94ad-0d6563ad3e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3d5d3e28-7f5f-4a3d-a06c-3702543b15ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_02d125a9-88e0-4350-b7a8-245a5a0bb190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3d5d3e28-7f5f-4a3d-a06c-3702543b15ed" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_02d125a9-88e0-4350-b7a8-245a5a0bb190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ea9eceed-1631-4f45-846c-b414d7cfa414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3d5d3e28-7f5f-4a3d-a06c-3702543b15ed" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ea9eceed-1631-4f45-846c-b414d7cfa414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa8a03a-2d9a-4b0d-8be4-f7af18ae9a36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e4297cb7-5891-4605-9c22-f9506f5065ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa8a03a-2d9a-4b0d-8be4-f7af18ae9a36" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e4297cb7-5891-4605-9c22-f9506f5065ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9b6f525c-7dd8-40a0-be20-6382a54ee508" xlink:href="biib-20240630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa8a03a-2d9a-4b0d-8be4-f7af18ae9a36" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9b6f525c-7dd8-40a0-be20-6382a54ee508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_a1a4079e-a350-4fdb-be54-5997c416de60" xlink:href="biib-20240630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa8a03a-2d9a-4b0d-8be4-f7af18ae9a36" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_a1a4079e-a350-4fdb-be54-5997c416de60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_364c455f-1a3c-40ab-bdfb-6ff83a322a1e" xlink:href="biib-20240630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa8a03a-2d9a-4b0d-8be4-f7af18ae9a36" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_364c455f-1a3c-40ab-bdfb-6ff83a322a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_379c63d4-fc72-4475-a5d5-822f4c3766a9" xlink:href="biib-20240630.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa8a03a-2d9a-4b0d-8be4-f7af18ae9a36" xlink:to="loc_biib_OtherrevenuesTableTextBlock_379c63d4-fc72-4475-a5d5-822f4c3766a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20240630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f6922f0d-0ae6-4c08-bb54-76830a0e38fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b67eb5f5-166c-46f3-8a4c-747681c5cac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f6922f0d-0ae6-4c08-bb54-76830a0e38fb" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b67eb5f5-166c-46f3-8a4c-747681c5cac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_95993e3a-1de0-4447-b524-eb4b8b8466b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_d2a37a79-8b83-4ec0-b25d-98da2a149369" xlink:href="biib-20240630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_95993e3a-1de0-4447-b524-eb4b8b8466b3" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_d2a37a79-8b83-4ec0-b25d-98da2a149369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7ff8c7b5-7456-4af2-ad41-ba25c218a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_95993e3a-1de0-4447-b524-eb4b8b8466b3" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7ff8c7b5-7456-4af2-ad41-ba25c218a5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_4215a4ad-3f73-40ac-a516-cba5ab24b878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_95993e3a-1de0-4447-b524-eb4b8b8466b3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_4215a4ad-3f73-40ac-a516-cba5ab24b878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fa917dc3-22ce-4e19-987b-bcae7c0f6807" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e1d241aa-cd49-4010-8f0b-a0572821bea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fa917dc3-22ce-4e19-987b-bcae7c0f6807" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e1d241aa-cd49-4010-8f0b-a0572821bea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_a2566953-4f3a-4c78-bc97-a7f08db220fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fa917dc3-22ce-4e19-987b-bcae7c0f6807" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_a2566953-4f3a-4c78-bc97-a7f08db220fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc33f185-26b0-408a-bf97-5cb46f5da0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0aa7fc39-8ea1-4598-a836-5076c1408262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc33f185-26b0-408a-bf97-5cb46f5da0f8" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0aa7fc39-8ea1-4598-a836-5076c1408262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1bc7e3ec-1662-4b75-915d-0b0052605742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc33f185-26b0-408a-bf97-5cb46f5da0f8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1bc7e3ec-1662-4b75-915d-0b0052605742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2d765c6d-6c7e-4b0b-9ffb-748b338e2c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc33f185-26b0-408a-bf97-5cb46f5da0f8" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2d765c6d-6c7e-4b0b-9ffb-748b338e2c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20240630.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eec55c3-ca00-47c9-b851-a3e85bb1fb63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_4815d04d-3fb6-48a5-81d0-0fc7580db84b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eec55c3-ca00-47c9-b851-a3e85bb1fb63" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_4815d04d-3fb6-48a5-81d0-0fc7580db84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e325d64b-df40-4c82-bfe7-804200c237fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eec55c3-ca00-47c9-b851-a3e85bb1fb63" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e325d64b-df40-4c82-bfe7-804200c237fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_c597f23b-930e-4000-886a-aad27dac2ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eec55c3-ca00-47c9-b851-a3e85bb1fb63" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_c597f23b-930e-4000-886a-aad27dac2ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_df8b7737-8b77-49de-bdfb-38f044d9427c" xlink:href="biib-20240630.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eec55c3-ca00-47c9-b851-a3e85bb1fb63" xlink:to="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_df8b7737-8b77-49de-bdfb-38f044d9427c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20240630.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_09025c68-e458-4c2a-ba63-9b33004dd2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c5ebc8ff-6e10-409a-92df-8b11eb7579de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_09025c68-e458-4c2a-ba63-9b33004dd2e9" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c5ebc8ff-6e10-409a-92df-8b11eb7579de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5e082f81-8235-4861-a804-52813ad33874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_09025c68-e458-4c2a-ba63-9b33004dd2e9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5e082f81-8235-4861-a804-52813ad33874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20240630.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_449ec903-5df7-48d2-bb96-c9b28a63e835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6c3b2e2e-3595-422a-af99-4e9b83e942c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_449ec903-5df7-48d2-bb96-c9b28a63e835" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6c3b2e2e-3595-422a-af99-4e9b83e942c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20240630.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_869f50bf-7080-4a35-905d-1370991a17bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3760a3d9-e383-4157-b022-2a756c182eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_869f50bf-7080-4a35-905d-1370991a17bd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3760a3d9-e383-4157-b022-2a756c182eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_a30e86bf-4d8e-48d3-bcee-ffdaf16382db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_869f50bf-7080-4a35-905d-1370991a17bd" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_a30e86bf-4d8e-48d3-bcee-ffdaf16382db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20240630.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b076e00f-a993-46f5-b0e9-f0018b9e8411" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a61a68b8-0bb5-4f61-bec5-9ed837841e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b076e00f-a993-46f5-b0e9-f0018b9e8411" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a61a68b8-0bb5-4f61-bec5-9ed837841e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20240630.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d55487b-4a83-4029-9fb4-d79aa6ef492e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_373dc644-e8ac-4947-a4f5-3d9f9d66d1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d55487b-4a83-4029-9fb4-d79aa6ef492e" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_373dc644-e8ac-4947-a4f5-3d9f9d66d1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_c3973725-d8f3-4cb5-8884-e2bf16042aff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d55487b-4a83-4029-9fb4-d79aa6ef492e" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_c3973725-d8f3-4cb5-8884-e2bf16042aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2cda753b-cf0d-4803-8dcd-311a439d7925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d55487b-4a83-4029-9fb4-d79aa6ef492e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2cda753b-cf0d-4803-8dcd-311a439d7925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267402be-5b74-4e92-95d8-9c6c3b4e2368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_8d822d33-4dbf-4394-95d8-3e4bf406b247" xlink:href="biib-20240630.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267402be-5b74-4e92-95d8-9c6c3b4e2368" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_8d822d33-4dbf-4394-95d8-3e4bf406b247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_7c6b67f1-6c52-4861-a113-1af56c355463" xlink:href="biib-20240630.xsd#biib_PretaxProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267402be-5b74-4e92-95d8-9c6c3b4e2368" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_7c6b67f1-6c52-4861-a113-1af56c355463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_b6ceef4f-de69-4416-86a5-762dfea65deb" xlink:href="biib-20240630.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267402be-5b74-4e92-95d8-9c6c3b4e2368" xlink:to="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_b6ceef4f-de69-4416-86a5-762dfea65deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_4bf55af7-2931-4a35-9a33-b9a7cf3989d0" xlink:href="biib-20240630.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267402be-5b74-4e92-95d8-9c6c3b4e2368" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_4bf55af7-2931-4a35-9a33-b9a7cf3989d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_c32fe1f4-ba3e-4241-86d7-b2459dc90bd9" xlink:href="biib-20240630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267402be-5b74-4e92-95d8-9c6c3b4e2368" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_c32fe1f4-ba3e-4241-86d7-b2459dc90bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_3b4471e8-933d-4562-bc42-997ace6f39b2" xlink:href="biib-20240630.xsd#biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267402be-5b74-4e92-95d8-9c6c3b4e2368" xlink:to="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_3b4471e8-933d-4562-bc42-997ace6f39b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1cc0493c-ab74-4b47-ad1d-e2c4f83d39b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e4e16e1b-4bbf-405c-a73b-86525c6ec642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cc0493c-ab74-4b47-ad1d-e2c4f83d39b9" xlink:to="loc_us-gaap_NumberOfReportableSegments_e4e16e1b-4bbf-405c-a73b-86525c6ec642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_32244b5e-1ac1-46a5-96ab-efc0b1e3da7f" xlink:href="biib-20240630.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cc0493c-ab74-4b47-ad1d-e2c4f83d39b9" xlink:to="loc_biib_InterestInSubsidiary_32244b5e-1ac1-46a5-96ab-efc0b1e3da7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_eb6e61d3-6947-4370-b514-3236188435f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_eb6e61d3-6947-4370-b514-3236188435f9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6890d5d1-4d30-4fe8-97a7-10f310984412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6890d5d1-4d30-4fe8-97a7-10f310984412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc5ac492-710e-428e-907c-f3c736e6f8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6890d5d1-4d30-4fe8-97a7-10f310984412" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc5ac492-710e-428e-907c-f3c736e6f8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_9e01eb75-c06d-4f21-8ca1-a9b6fa54c303" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc5ac492-710e-428e-907c-f3c736e6f8c7" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_9e01eb75-c06d-4f21-8ca1-a9b6fa54c303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_acaa0459-2594-4dd0-af20-b72358571fe3" xlink:href="biib-20240630.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc5ac492-710e-428e-907c-f3c736e6f8c7" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_acaa0459-2594-4dd0-af20-b72358571fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2345984a-1021-41c5-af77-c67559df3978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2345984a-1021-41c5-af77-c67559df3978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2345984a-1021-41c5-af77-c67559df3978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_65e26f0f-6fc9-47e9-880d-56fa3f01c564" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:to="loc_biib_SKYCLARYSMember_65e26f0f-6fc9-47e9-880d-56fa3f01c564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_aff030cb-6847-4cc7-ace7-cd4c29c64ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_aff030cb-6847-4cc7-ace7-cd4c29c64ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_2f46771e-d986-4a9d-8587-6b054fb04cd7" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:to="loc_biib_PriorityReviewVoucherMember_2f46771e-d986-4a9d-8587-6b054fb04cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_6aecb9d2-2564-41cd-82de-3f81f5490312" xlink:href="biib-20240630.xsd#biib_OtherClinicalProgramsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6ba442e-f9a8-47a7-b310-80eb9c7c662a" xlink:to="loc_biib_OtherClinicalProgramsMember_6aecb9d2-2564-41cd-82de-3f81f5490312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d82ba74-926e-46f4-b568-6e6fc7dad9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_52f9cfc0-7d1e-4a44-94d6-01dac3f588a8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d82ba74-926e-46f4-b568-6e6fc7dad9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3ae73974-e4a9-4127-924b-574c96d1f299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d82ba74-926e-46f4-b568-6e6fc7dad9e3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3ae73974-e4a9-4127-924b-574c96d1f299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_838db120-4d78-462a-ac15-efaab6c5d54f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_srt_StatementScenarioAxis_838db120-4d78-462a-ac15-efaab6c5d54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_aa57a7e8-ad4a-43fb-ba2c-24b1cce01b6b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_838db120-4d78-462a-ac15-efaab6c5d54f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_aa57a7e8-ad4a-43fb-ba2c-24b1cce01b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3198bfeb-1113-4e76-bf44-30b6b120057b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_aa57a7e8-ad4a-43fb-ba2c-24b1cce01b6b" xlink:to="loc_srt_ScenarioForecastMember_3198bfeb-1113-4e76-bf44-30b6b120057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a1715487-b9a1-4cd7-8dcc-11048af01107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_CreditFacilityAxis_a1715487-b9a1-4cd7-8dcc-11048af01107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a74a577a-b87d-4a06-b5aa-28c656cbc5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a1715487-b9a1-4cd7-8dcc-11048af01107" xlink:to="loc_us-gaap_CreditFacilityDomain_a74a577a-b87d-4a06-b5aa-28c656cbc5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e53a3431-4e71-48ad-82c5-a83ff87a42f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a74a577a-b87d-4a06-b5aa-28c656cbc5d1" xlink:to="loc_us-gaap_SecuredDebtMember_e53a3431-4e71-48ad-82c5-a83ff87a42f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7d03b119-54ab-433b-8ec4-e95ed03a525a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_DebtInstrumentAxis_7d03b119-54ab-433b-8ec4-e95ed03a525a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c2584a1-f288-4205-84a1-1b7174c7a8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d03b119-54ab-433b-8ec4-e95ed03a525a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c2584a1-f288-4205-84a1-1b7174c7a8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_6a041304-55f9-46c2-a65f-3cbd7d73deed" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c2584a1-f288-4205-84a1-1b7174c7a8b4" xlink:to="loc_biib_TheCreditFacilityMember_6a041304-55f9-46c2-a65f-3cbd7d73deed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5d9ca805-18be-4035-8e54-90410b793528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5d9ca805-18be-4035-8e54-90410b793528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1068daf-6e5b-4948-a217-5af61326da9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d9ca805-18be-4035-8e54-90410b793528" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1068daf-6e5b-4948-a217-5af61326da9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_985a0313-12b0-44df-bf9c-c1abc1ab76bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1068daf-6e5b-4948-a217-5af61326da9e" xlink:to="loc_us-gaap_LineOfCreditMember_985a0313-12b0-44df-bf9c-c1abc1ab76bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_426adf51-409a-4577-9434-2d4f2f34e784" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_srt_ProductOrServiceAxis_426adf51-409a-4577-9434-2d4f2f34e784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_142de6fa-7861-40b4-a9c8-378219f75701" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_426adf51-409a-4577-9434-2d4f2f34e784" xlink:to="loc_srt_ProductsAndServicesDomain_142de6fa-7861-40b4-a9c8-378219f75701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember_139e571d-8e15-4b39-ac31-480baac29f79" xlink:href="biib-20240630.xsd#biib_ClinicalInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_142de6fa-7861-40b4-a9c8-378219f75701" xlink:to="loc_biib_ClinicalInventoryMember_139e571d-8e15-4b39-ac31-480baac29f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_794e48a1-5b69-4187-a2a7-f4bc820f256f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_794e48a1-5b69-4187-a2a7-f4bc820f256f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69f1f588-bde8-43c0-b7f7-828d7cae7bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_794e48a1-5b69-4187-a2a7-f4bc820f256f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69f1f588-bde8-43c0-b7f7-828d7cae7bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_57b7a98a-85b0-40c8-8f80-e002c75fdf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_69f1f588-bde8-43c0-b7f7-828d7cae7bc5" xlink:to="loc_us-gaap_SubsequentEventMember_57b7a98a-85b0-40c8-8f80-e002c75fdf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_65045850-af46-4f13-8028-004f1f8ba70c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_65045850-af46-4f13-8028-004f1f8ba70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_97aa8010-da86-468a-9e59-dd4a99927db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_65045850-af46-4f13-8028-004f1f8ba70c" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_97aa8010-da86-468a-9e59-dd4a99927db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_100c8d6b-1000-43f9-a9d2-67bfcb59ed1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_97aa8010-da86-468a-9e59-dd4a99927db7" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_100c8d6b-1000-43f9-a9d2-67bfcb59ed1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_627065a7-ae91-4cf4-8c2d-c4de27dda3d3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_17e39b1a-decb-4253-884c-eaaefcd24584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_17e39b1a-decb-4253-884c-eaaefcd24584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2db1fd8f-d010-4b42-af22-cbace89fdbee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2db1fd8f-d010-4b42-af22-cbace89fdbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_231684a9-37ed-4266-8e4a-6c3fa79839dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_231684a9-37ed-4266-8e4a-6c3fa79839dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4080a6ad-a4d6-47fe-9b49-0c62f8f64dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4080a6ad-a4d6-47fe-9b49-0c62f8f64dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_44fb6d1c-6833-41f0-a6c3-b82209dc0960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_44fb6d1c-6833-41f0-a6c3-b82209dc0960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3083cd54-f31e-4984-9390-70c83c55db4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3083cd54-f31e-4984-9390-70c83c55db4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_142a565e-5c25-49fd-aa7c-066295d29ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_OperatingExpenses_142a565e-5c25-49fd-aa7c-066295d29ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_db34c3a0-1abc-48b1-8c45-bc95f8b4e837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_db34c3a0-1abc-48b1-8c45-bc95f8b4e837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_92af1d32-3c81-4928-a440-dc656ef1ff9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_92af1d32-3c81-4928-a440-dc656ef1ff9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_eace3d85-597d-46e2-9492-ee7ba6fbd996" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_eace3d85-597d-46e2-9492-ee7ba6fbd996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_96aeb541-e103-45b5-adda-dc105255344b" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_96aeb541-e103-45b5-adda-dc105255344b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c60a6210-6455-45e9-a1a4-b397e2cc4e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c60a6210-6455-45e9-a1a4-b397e2cc4e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_ca3a0216-84b9-48aa-96f4-e86f776b499b" xlink:href="biib-20240630.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_OperatingLeaseArea_ca3a0216-84b9-48aa-96f4-e86f776b499b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_192ec17c-c01a-408c-9d45-481619539c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_192ec17c-c01a-408c-9d45-481619539c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_7ba8c196-a435-4f08-8caf-a2d3930a1010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_7ba8c196-a435-4f08-8caf-a2d3930a1010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_9f79a818-a384-48ff-822c-f303bcb0e013" xlink:href="biib-20240630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_9f79a818-a384-48ff-822c-f303bcb0e013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2c218dec-289a-404c-85ae-d56ef62a90f2" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2c218dec-289a-404c-85ae-d56ef62a90f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b999c355-4408-4e24-84e3-2258e8c43bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_Goodwill_b999c355-4408-4e24-84e3-2258e8c43bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_363c7bed-9184-4bec-8c71-30cade2eef4c" xlink:href="biib-20240630.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_363c7bed-9184-4bec-8c71-30cade2eef4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_2f0b161b-e7fa-48b6-86f5-7e5f74847c72" xlink:href="biib-20240630.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_2f0b161b-e7fa-48b6-86f5-7e5f74847c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8b6bf558-36e5-44aa-9cb5-0b713bdf1c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8b6bf558-36e5-44aa-9cb5-0b713bdf1c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9c3f75c5-37bb-4a8f-a512-851c87667b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_ProfitLoss_9c3f75c5-37bb-4a8f-a512-851c87667b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7464c030-ba70-423d-9a27-119c528bb59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14e37e72-e6a7-4886-ba91-9819a96e9585" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7464c030-ba70-423d-9a27-119c528bb59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6b77756e-c5a7-4d92-9b59-691d902db93b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_446fb6a0-7a7e-48e4-b21c-70c5e26947eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6b77756e-c5a7-4d92-9b59-691d902db93b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_446fb6a0-7a7e-48e4-b21c-70c5e26947eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c9b4ee9f-97c7-44df-b249-a3a450d7c85a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_446fb6a0-7a7e-48e4-b21c-70c5e26947eb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c9b4ee9f-97c7-44df-b249-a3a450d7c85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e518689-4405-4b94-8f74-5a8deccefdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9b4ee9f-97c7-44df-b249-a3a450d7c85a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e518689-4405-4b94-8f74-5a8deccefdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_0e18fe66-3ac1-4093-b843-d3212537308b" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e518689-4405-4b94-8f74-5a8deccefdb1" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_0e18fe66-3ac1-4093-b843-d3212537308b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_446fb6a0-7a7e-48e4-b21c-70c5e26947eb" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_305a3e8d-431e-4b18-b46b-24844591d62e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_305a3e8d-431e-4b18-b46b-24844591d62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_29c91fc8-f7b4-4d80-8879-5b180480a906" xlink:href="biib-20240630.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_29c91fc8-f7b4-4d80-8879-5b180480a906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_232cfd16-40cf-4d9c-bfb1-5b4c6cc703f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_232cfd16-40cf-4d9c-bfb1-5b4c6cc703f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_ba422091-eaaa-4b18-8c8f-269d23aa4938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_ba422091-eaaa-4b18-8c8f-269d23aa4938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_18c110a0-2ee6-403b-b513-78dda5fb6ad9" xlink:href="biib-20240630.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fc23e60-0de3-4c6b-93fa-83553dc73ba2" xlink:to="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_18c110a0-2ee6-403b-b513-78dda5fb6ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f24d6aac-48bc-45f5-9a73-f804a9cd6482" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f24d6aac-48bc-45f5-9a73-f804a9cd6482" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_da429919-3716-41ca-8565-9153ecc44c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_da429919-3716-41ca-8565-9153ecc44c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64e397e9-cd18-48c1-a459-ad6a31cd82f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da429919-3716-41ca-8565-9153ecc44c02" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64e397e9-cd18-48c1-a459-ad6a31cd82f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_00730652-24bf-49ee-8966-69009026fdcc" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64e397e9-cd18-48c1-a459-ad6a31cd82f8" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_00730652-24bf-49ee-8966-69009026fdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e6ba1c6-d300-41de-a328-ebd06b9440b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e6ba1c6-d300-41de-a328-ebd06b9440b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e6ba1c6-d300-41de-a328-ebd06b9440b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_4c7edeb2-3592-4237-a936-6490f593d2a9" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:to="loc_biib_SKYCLARYSMember_4c7edeb2-3592-4237-a936-6490f593d2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_339114e0-e5ed-4013-937f-3bd1dc73ac93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_339114e0-e5ed-4013-937f-3bd1dc73ac93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_3f96099a-977a-45df-8504-f5ded71faf3d" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:to="loc_biib_PriorityReviewVoucherMember_3f96099a-977a-45df-8504-f5ded71faf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_98f80578-b89a-4270-9ae9-1344d3fea941" xlink:href="biib-20240630.xsd#biib_OtherClinicalProgramsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75d81172-85d5-4572-805d-ddc876c2978d" xlink:to="loc_biib_OtherClinicalProgramsMember_98f80578-b89a-4270-9ae9-1344d3fea941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0354b317-bd87-4159-b0d4-f486477364aa" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a2a36280-3f37-4159-a324-79de0ecd6ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a2a36280-3f37-4159-a324-79de0ecd6ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_119cbb02-2e74-403c-a754-788eb615e7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_119cbb02-2e74-403c-a754-788eb615e7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3cf4d04e-1bcf-4164-a466-bbd7717f2be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3cf4d04e-1bcf-4164-a466-bbd7717f2be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8cf4f8be-b7c9-4ed3-ac4a-2fd03361241f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8cf4f8be-b7c9-4ed3-ac4a-2fd03361241f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_cf5004ed-8c89-4145-a898-1011ea468a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_cf5004ed-8c89-4145-a898-1011ea468a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_1e5d2c89-8a4a-4337-a136-072d96292bfa" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_1e5d2c89-8a4a-4337-a136-072d96292bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_ef024344-2db8-4e5c-a9b0-2871da7802f6" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_ef024344-2db8-4e5c-a9b0-2871da7802f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_090fdf6e-9214-4d58-834d-d1950c8f28c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_090fdf6e-9214-4d58-834d-d1950c8f28c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_cc46297f-2eed-4f9b-a8e3-c1e86866e9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_cc46297f-2eed-4f9b-a8e3-c1e86866e9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c521b9ff-e616-47bd-9f79-9ff17942ae66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c521b9ff-e616-47bd-9f79-9ff17942ae66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_f1c8effb-f55b-423a-a25c-c989cdfe8b91" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_f1c8effb-f55b-423a-a25c-c989cdfe8b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_3543b972-b3a5-4be3-97c9-94f14eb57681" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_3543b972-b3a5-4be3-97c9-94f14eb57681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3c6637e2-ca4a-400a-a20a-2df72a0ca98a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3c6637e2-ca4a-400a-a20a-2df72a0ca98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e6a8c683-96d1-4b0c-9a52-a22aa23ce09f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_Goodwill_e6a8c683-96d1-4b0c-9a52-a22aa23ce09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5ff6dc06-a767-4b45-a3c0-a1e1d4b68c54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5ff6dc06-a767-4b45-a3c0-a1e1d4b68c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_29d494e3-5864-41ab-ba64-ccd2e2d6c269" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_29d494e3-5864-41ab-ba64-ccd2e2d6c269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_5c85468f-4937-4e03-a9f3-1a0c45f7dd52" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_5c85468f-4937-4e03-a9f3-1a0c45f7dd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_0b5f7c35-38d3-4d52-816b-6cf4502a2db7" xlink:href="biib-20240630.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dbbe0f4-f8d1-4851-8a7c-8e9ab4641d37" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_0b5f7c35-38d3-4d52-816b-6cf4502a2db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#DispositionsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_320f8a5d-b595-41b3-9908-4bccc48e029b" xlink:href="biib-20240630.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_320f8a5d-b595-41b3-9908-4bccc48e029b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_272d2d8f-a1e6-464e-a88a-b8e2c1483416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_us-gaap_TypeOfArrangementAxis_272d2d8f-a1e6-464e-a88a-b8e2c1483416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7c22fc4-3ff9-4392-b75b-6f51cec1601a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_272d2d8f-a1e6-464e-a88a-b8e2c1483416" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7c22fc4-3ff9-4392-b75b-6f51cec1601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_4a020fb9-6026-4b4b-acd9-5c8821b94984" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7c22fc4-3ff9-4392-b75b-6f51cec1601a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_4a020fb9-6026-4b4b-acd9-5c8821b94984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36cb7a60-4416-4a7a-b650-1b949fc794e4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36cb7a60-4416-4a7a-b650-1b949fc794e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c9ff349a-f75e-4bdf-ac2b-c580df16d073" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36cb7a60-4416-4a7a-b650-1b949fc794e4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c9ff349a-f75e-4bdf-ac2b-c580df16d073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5fc194ba-8d54-4490-9c06-812d33550a19" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9ff349a-f75e-4bdf-ac2b-c580df16d073" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5fc194ba-8d54-4490-9c06-812d33550a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82" xlink:href="biib-20240630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_7752923c-a0aa-4b70-a6d6-201c8844f338" xlink:href="biib-20240630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_c9e3fbec-c5d6-4f4c-8367-ff74fed89f82" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_7752923c-a0aa-4b70-a6d6-201c8844f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_0104add0-1b58-4a3b-865c-255163a2192e" xlink:href="biib-20240630.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_7752923c-a0aa-4b70-a6d6-201c8844f338" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_0104add0-1b58-4a3b-865c-255163a2192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_e3442064-31bc-4f3d-8d09-1c2248d92e6a" xlink:href="biib-20240630.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_7752923c-a0aa-4b70-a6d6-201c8844f338" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_e3442064-31bc-4f3d-8d09-1c2248d92e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dd9827b4-4175-4851-9ccd-bf74ee15b45e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_srt_CounterpartyNameAxis_dd9827b4-4175-4851-9ccd-bf74ee15b45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7e742f4-9dc9-448c-899f-122b4997c085" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_dd9827b4-4175-4851-9ccd-bf74ee15b45e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7e742f4-9dc9-448c-899f-122b4997c085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_fcbee49f-19ec-4a4c-a862-cd9a5f5db3f0" xlink:href="biib-20240630.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7e742f4-9dc9-448c-899f-122b4997c085" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_fcbee49f-19ec-4a4c-a862-cd9a5f5db3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9561d85c-b6fa-4b60-98ed-0844f58d83af" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f9950cb0-a9cb-4f1c-accd-cb6523ef577a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f9950cb0-a9cb-4f1c-accd-cb6523ef577a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_cc1209ea-f9ab-46d1-8f35-b88643e229c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_cc1209ea-f9ab-46d1-8f35-b88643e229c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_3ab91561-2a88-4007-a331-7270b166c0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_3ab91561-2a88-4007-a331-7270b166c0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_ceb1131b-866b-4595-a077-6b09d69649ad" xlink:href="biib-20240630.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_ceb1131b-866b-4595-a077-6b09d69649ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3ddc8878-e546-4f9f-a112-2de80d9e933e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3ddc8878-e546-4f9f-a112-2de80d9e933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_7b200922-2af1-4566-bed2-fb482ff76eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_7b200922-2af1-4566-bed2-fb482ff76eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_58f1b9c2-ef18-4e1e-93fe-88d405d32076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_AccountsPayableCurrent_58f1b9c2-ef18-4e1e-93fe-88d405d32076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_2649b6c2-4d40-4a74-98ed-6ae331537cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c4168423-a3f4-4901-bbbc-547a509c8795" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_2649b6c2-4d40-4a74-98ed-6ae331537cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_35479205-ec3e-4f2c-878c-66eb0f220792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_35479205-ec3e-4f2c-878c-66eb0f220792" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_165d7c40-70d5-4cef-bb22-f094c7699843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_165d7c40-70d5-4cef-bb22-f094c7699843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_165d7c40-70d5-4cef-bb22-f094c7699843" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cfe1fe92-9164-4633-9ed1-be3993bfc4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cfe1fe92-9164-4633-9ed1-be3993bfc4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_157e29a9-df89-44e5-9b2e-3f93e6a520ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_157e29a9-df89-44e5-9b2e-3f93e6a520ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_e6ec5c40-7064-4dc1-a6ec-55482d6ae732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d34be973-4222-4b8e-9fad-331b6d53a9a0" xlink:to="loc_us-gaap_RestructuringChargesMember_e6ec5c40-7064-4dc1-a6ec-55482d6ae732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e6eac045-618b-43a4-806f-8d3bcc25f26f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:to="loc_us-gaap_RestructuringPlanAxis_e6eac045-618b-43a4-806f-8d3bcc25f26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_af31e4a9-e666-4de1-b8c3-7abf94f619ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_e6eac045-618b-43a4-806f-8d3bcc25f26f" xlink:to="loc_us-gaap_RestructuringPlanDomain_af31e4a9-e666-4de1-b8c3-7abf94f619ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_007e4038-385c-4eac-aff1-6453f0cb22ab" xlink:href="biib-20240630.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_af31e4a9-e666-4de1-b8c3-7abf94f619ed" xlink:to="loc_biib_A2023CostSavingInitiativesMember_007e4038-385c-4eac-aff1-6453f0cb22ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_023b1d29-5e63-4d1f-9b66-95fa81e84502" xlink:href="biib-20240630.xsd#biib_ReataIntegrationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_af31e4a9-e666-4de1-b8c3-7abf94f619ed" xlink:to="loc_biib_ReataIntegrationMember_023b1d29-5e63-4d1f-9b66-95fa81e84502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3f504980-d2eb-4099-afb2-c91613469b14" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_3e2ed694-851e-4eb4-abb8-ae6a089bb4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:to="loc_us-gaap_SeveranceCosts1_3e2ed694-851e-4eb4-abb8-ae6a089bb4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_9b4b1a7c-3709-4f20-a4ad-5bcace6045c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:to="loc_us-gaap_OtherRestructuringCosts_9b4b1a7c-3709-4f20-a4ad-5bcace6045c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0f000f82-f26f-40f6-b87b-d8576339ed5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_563774b8-f4f2-45e2-ad0c-8125d481af6a" xlink:to="loc_us-gaap_RestructuringCharges_0f000f82-f26f-40f6-b87b-d8576339ed5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a36593ed-f42c-4a88-bd35-6190e4db60c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_35479205-ec3e-4f2c-878c-66eb0f220792" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a36593ed-f42c-4a88-bd35-6190e4db60c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6890fe50-31b7-4f7d-97da-8104e8517ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6890fe50-31b7-4f7d-97da-8104e8517ddc" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6dac8868-4ef7-4968-8cc1-a1c338037467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:to="loc_us-gaap_RestructuringPlanAxis_6dac8868-4ef7-4968-8cc1-a1c338037467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3aaa8e8e-462d-48d4-b4dd-28b90ce685bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_6dac8868-4ef7-4968-8cc1-a1c338037467" xlink:to="loc_us-gaap_RestructuringPlanDomain_3aaa8e8e-462d-48d4-b4dd-28b90ce685bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_25fe2556-eba4-48e4-82ae-57b19c970fa6" xlink:href="biib-20240630.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3aaa8e8e-462d-48d4-b4dd-28b90ce685bd" xlink:to="loc_biib_A2023CostSavingInitiativesMember_25fe2556-eba4-48e4-82ae-57b19c970fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_a40034df-6c7d-4beb-b0cf-1b0214ae7ed5" xlink:href="biib-20240630.xsd#biib_ReataIntegrationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3aaa8e8e-462d-48d4-b4dd-28b90ce685bd" xlink:to="loc_biib_ReataIntegrationMember_a40034df-6c7d-4beb-b0cf-1b0214ae7ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef4462fc-18e2-4f49-9981-006becbd69d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef4462fc-18e2-4f49-9981-006becbd69d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e40901c6-8a75-4f02-b99b-808bf115ee58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef4462fc-18e2-4f49-9981-006becbd69d0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e40901c6-8a75-4f02-b99b-808bf115ee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_133e0715-38be-493f-93d3-0dc4ee836bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e40901c6-8a75-4f02-b99b-808bf115ee58" xlink:to="loc_us-gaap_RestructuringChargesMember_133e0715-38be-493f-93d3-0dc4ee836bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:to="loc_srt_RangeAxis_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0100ebb7-4648-45a1-a8c8-714effb9691d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d6c2b91-7bce-4b81-ac6d-a4d461ae7315" xlink:to="loc_srt_RangeMember_0100ebb7-4648-45a1-a8c8-714effb9691d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c06b50e3-ac47-4d82-8ee1-dc0bf19a94f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0100ebb7-4648-45a1-a8c8-714effb9691d" xlink:to="loc_srt_MinimumMember_c06b50e3-ac47-4d82-8ee1-dc0bf19a94f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b86db1e-d55f-4bfd-bab0-7e7c91572407" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0100ebb7-4648-45a1-a8c8-714effb9691d" xlink:to="loc_srt_MaximumMember_0b86db1e-d55f-4bfd-bab0-7e7c91572407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_241c7fa3-3ffc-4769-bbfb-729746052a76" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_ec6bd15a-43db-4f5d-8899-5378554779c6" xlink:href="biib-20240630.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_ec6bd15a-43db-4f5d-8899-5378554779c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_64ba5783-8d55-4a53-b54a-488626ba4aab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_64ba5783-8d55-4a53-b54a-488626ba4aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_0dddfb2b-fdaf-43b6-b0a3-ca6152bb14d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_SeveranceCosts1_0dddfb2b-fdaf-43b6-b0a3-ca6152bb14d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_f69ae352-7aec-4ae9-a54d-5c45ab278eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_f69ae352-7aec-4ae9-a54d-5c45ab278eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5f8d095b-9552-47e8-af25-262e50bae212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_5f8d095b-9552-47e8-af25-262e50bae212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_0ec7ec07-3d42-4125-8084-f2eff32de09d" xlink:href="biib-20240630.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_biib_OperatingLeaseArea_0ec7ec07-3d42-4125-8084-f2eff32de09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_28fa2ca2-825f-4d47-a290-9d1ab21dc1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e50a33d9-5e4e-430e-b394-08ac85bc1181" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_28fa2ca2-825f-4d47-a290-9d1ab21dc1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_77a64c2f-c314-4b4a-8725-107aae11d883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_77a64c2f-c314-4b4a-8725-107aae11d883" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7195ac82-6cb0-444d-b237-68798cf92e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7195ac82-6cb0-444d-b237-68798cf92e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ec2f883d-76e1-47c2-acab-59fa290f2da5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7195ac82-6cb0-444d-b237-68798cf92e64" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ec2f883d-76e1-47c2-acab-59fa290f2da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_adc25826-9e54-4d5a-ba1e-50e2a44b42b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ec2f883d-76e1-47c2-acab-59fa290f2da5" xlink:to="loc_us-gaap_EmployeeSeveranceMember_adc25826-9e54-4d5a-ba1e-50e2a44b42b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_32dc58e7-5b25-45a2-bae7-01116f708448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_32dc58e7-5b25-45a2-bae7-01116f708448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ea600882-647b-41fa-9fc3-241002fa200b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32dc58e7-5b25-45a2-bae7-01116f708448" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ea600882-647b-41fa-9fc3-241002fa200b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_4d2423ae-6d6d-45f5-8574-f087c1718d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea600882-647b-41fa-9fc3-241002fa200b" xlink:to="loc_us-gaap_RestructuringChargesMember_4d2423ae-6d6d-45f5-8574-f087c1718d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_66c65946-53c0-4dbc-8f9d-e02fc1b76e37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_87dab8ae-d18b-44cf-a3e2-d6087a5a6953" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_66c65946-53c0-4dbc-8f9d-e02fc1b76e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2fec62ed-f8a6-4d4e-ae0c-84d07315150b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_66c65946-53c0-4dbc-8f9d-e02fc1b76e37" xlink:to="loc_us-gaap_RestructuringCharges_2fec62ed-f8a6-4d4e-ae0c-84d07315150b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b006a169-87c0-49a5-95e6-941fec3fd362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b006a169-87c0-49a5-95e6-941fec3fd362" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_afc80bd7-730a-4710-a67c-1f55320bba02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_afc80bd7-730a-4710-a67c-1f55320bba02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_136e877c-d856-4c46-815b-d20d44ede9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_afc80bd7-730a-4710-a67c-1f55320bba02" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_136e877c-d856-4c46-815b-d20d44ede9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_87bc495c-e6d2-46bd-8f3b-db60b3269811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_136e877c-d856-4c46-815b-d20d44ede9b2" xlink:to="loc_us-gaap_EmployeeSeveranceMember_87bc495c-e6d2-46bd-8f3b-db60b3269811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e9030ba1-73af-40ff-828e-bbd9c46383ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:to="loc_us-gaap_RestructuringPlanAxis_e9030ba1-73af-40ff-828e-bbd9c46383ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_982cb5bc-9a82-4423-9ddf-d49d3c5b41ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_e9030ba1-73af-40ff-828e-bbd9c46383ad" xlink:to="loc_us-gaap_RestructuringPlanDomain_982cb5bc-9a82-4423-9ddf-d49d3c5b41ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_85927d38-b754-4345-a69f-1cd5bc2c59c3" xlink:href="biib-20240630.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_982cb5bc-9a82-4423-9ddf-d49d3c5b41ff" xlink:to="loc_biib_A2023CostSavingInitiativesMember_85927d38-b754-4345-a69f-1cd5bc2c59c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember_bf2f6b38-c684-4164-b42c-f60ab80db301" xlink:href="biib-20240630.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_982cb5bc-9a82-4423-9ddf-d49d3c5b41ff" xlink:to="loc_biib_A2023And2022CostSavingInitiativesMember_bf2f6b38-c684-4164-b42c-f60ab80db301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_608973c7-8a66-444a-ae38-be00a38e8cee" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_a7d9f706-e99c-4702-b0c7-79cf9f23b9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_RestructuringReserve_a7d9f706-e99c-4702-b0c7-79cf9f23b9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bd67f534-47f6-4d3e-bf60-077d4d9ffe42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_RestructuringCharges_bd67f534-47f6-4d3e-bf60-077d4d9ffe42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_a4dd4bd5-c39a-4184-993c-723d202ed115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_PaymentsForRestructuring_a4dd4bd5-c39a-4184-993c-723d202ed115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_0d7fd796-cd70-416d-9e66-b915cb6620e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_0d7fd796-cd70-416d-9e66-b915cb6620e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_229e0026-2aea-43e7-a82e-bcf46171a7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_24469be7-d761-4050-a2b3-67feaa2f5030" xlink:to="loc_us-gaap_RestructuringReserve_229e0026-2aea-43e7-a82e-bcf46171a7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_9be81af9-f01e-442f-a1ce-41dbf7a5544a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_9be81af9-f01e-442f-a1ce-41dbf7a5544a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6a9f542-74b3-4596-8de7-3f7b6faf189b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:to="loc_srt_ProductOrServiceAxis_f6a9f542-74b3-4596-8de7-3f7b6faf189b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25d28e47-8124-48ce-b706-19101870d226" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f6a9f542-74b3-4596-8de7-3f7b6faf189b" xlink:to="loc_srt_ProductsAndServicesDomain_25d28e47-8124-48ce-b706-19101870d226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_25d28e47-8124-48ce-b706-19101870d226" xlink:to="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_e2fb568e-536c-4c84-9735-e3c2915767a2" xlink:href="biib-20240630.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_MSProductRevenuesMember_e2fb568e-536c-4c84-9735-e3c2915767a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_8fbf30cd-2c12-4d03-a47f-f9a391dc4d5c" xlink:href="biib-20240630.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_e2fb568e-536c-4c84-9735-e3c2915767a2" xlink:to="loc_biib_FumarateMember_8fbf30cd-2c12-4d03-a47f-f9a391dc4d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_f98d317d-9c8c-40ca-a62a-2eb37829c042" xlink:href="biib-20240630.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_8fbf30cd-2c12-4d03-a47f-f9a391dc4d5c" xlink:to="loc_biib_TECFIDERAMember_f98d317d-9c8c-40ca-a62a-2eb37829c042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_9defe4e5-bcba-4aa6-9cc3-e59c714826a9" xlink:href="biib-20240630.xsd#biib_VUMERITYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_8fbf30cd-2c12-4d03-a47f-f9a391dc4d5c" xlink:to="loc_biib_VUMERITYMember_9defe4e5-bcba-4aa6-9cc3-e59c714826a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_7b951388-12bc-4ad7-b460-69e274f78f40" xlink:href="biib-20240630.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_e2fb568e-536c-4c84-9735-e3c2915767a2" xlink:to="loc_biib_InterferonMember_7b951388-12bc-4ad7-b460-69e274f78f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_3af04440-6cda-4f27-9fae-62aaa88237b9" xlink:href="biib-20240630.xsd#biib_AVONEXMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_7b951388-12bc-4ad7-b460-69e274f78f40" xlink:to="loc_biib_AVONEXMember_3af04440-6cda-4f27-9fae-62aaa88237b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_300055c6-96f8-4026-b15d-a9f551094a32" xlink:href="biib-20240630.xsd#biib_PLEGRIDYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_7b951388-12bc-4ad7-b460-69e274f78f40" xlink:to="loc_biib_PLEGRIDYMember_300055c6-96f8-4026-b15d-a9f551094a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_43a4ffc4-b1fa-4ad4-a8f8-17583db65bfd" xlink:href="biib-20240630.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_TysabriProductMember_43a4ffc4-b1fa-4ad4-a8f8-17583db65bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_052be3e2-b18f-4a87-a18b-f8c8e075bd56" xlink:href="biib-20240630.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_FAMPYRAMember_052be3e2-b18f-4a87-a18b-f8c8e075bd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:href="biib-20240630.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember_9530ac5a-54de-4660-93bd-78eff6dc6d87" xlink:href="biib-20240630.xsd#biib_QALSODYMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:to="loc_biib_QALSODYMember_9530ac5a-54de-4660-93bd-78eff6dc6d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_c2acebae-77e1-4df0-a4cd-4ade5734ec36" xlink:href="biib-20240630.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:to="loc_biib_SPINRAZAMember_c2acebae-77e1-4df0-a4cd-4ade5734ec36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_a5670481-33b7-4e9a-9fc2-119b51fdf379" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_3da74694-e2d3-4412-a77b-6c50c5fe3d1c" xlink:to="loc_biib_SKYCLARYSMember_a5670481-33b7-4e9a-9fc2-119b51fdf379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:href="biib-20240630.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_99454f73-93ce-4da3-ad56-d7325f79d97c" xlink:href="biib-20240630.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_BENEPALIMember_99454f73-93ce-4da3-ad56-d7325f79d97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_8c10a8bd-0ff7-476a-b557-4005d85a410c" xlink:href="biib-20240630.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_IMRALDIMember_8c10a8bd-0ff7-476a-b557-4005d85a410c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_35830a36-29b2-4e44-a9ac-501da76e5fab" xlink:href="biib-20240630.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_FLIXABIMember_35830a36-29b2-4e44-a9ac-501da76e5fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_089c40d6-efcb-4609-bdc5-c81b63ef861a" xlink:href="biib-20240630.xsd#biib_BYOOVIZMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_BYOOVIZMember_089c40d6-efcb-4609-bdc5-c81b63ef861a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember_88ad67c8-2979-4a3c-bec3-5727486fee06" xlink:href="biib-20240630.xsd#biib_TOFIDENCEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_090373b6-2de4-4a3c-9483-04337e504d25" xlink:to="loc_biib_TOFIDENCEMember_88ad67c8-2979-4a3c-bec3-5727486fee06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember_cf353e6f-72e7-48ac-9ca3-c37c5c755dd8" xlink:href="biib-20240630.xsd#biib_OtherProductsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_106a64be-0eb2-4963-8048-0d3719e5e5ad" xlink:to="loc_biib_OtherProductsMember_cf353e6f-72e7-48ac-9ca3-c37c5c755dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember_bc924543-4782-46b1-908d-6becaf748713" xlink:href="biib-20240630.xsd#biib_ZURZUVAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherProductsMember_cf353e6f-72e7-48ac-9ca3-c37c5c755dd8" xlink:to="loc_biib_ZURZUVAEMember_bc924543-4782-46b1-908d-6becaf748713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember_73992970-792e-4dac-b690-46bce7276e4f" xlink:href="biib-20240630.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherProductsMember_cf353e6f-72e7-48ac-9ca3-c37c5c755dd8" xlink:to="loc_biib_FUMADERMAndADUHELMMember_73992970-792e-4dac-b690-46bce7276e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6ade0631-d0c0-4d6d-b827-5087fe249ef0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:to="loc_srt_StatementGeographicalAxis_6ade0631-d0c0-4d6d-b827-5087fe249ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5f796566-ef70-4bcc-9dd6-db05f3415025" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6ade0631-d0c0-4d6d-b827-5087fe249ef0" xlink:to="loc_srt_SegmentGeographicalDomain_5f796566-ef70-4bcc-9dd6-db05f3415025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1ac2b51f-bea3-488d-9c2d-e574d79442e2" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5f796566-ef70-4bcc-9dd6-db05f3415025" xlink:to="loc_country_US_1ac2b51f-bea3-488d-9c2d-e574d79442e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2dcc17df-0fe7-49da-86f3-f419f7a0b5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5f796566-ef70-4bcc-9dd6-db05f3415025" xlink:to="loc_us-gaap_NonUsMember_2dcc17df-0fe7-49da-86f3-f419f7a0b5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_586d53f7-dd5d-42f0-9049-de96989bd252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eea3e1cc-0449-41ad-b9d0-e100f173fd10" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_586d53f7-dd5d-42f0-9049-de96989bd252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a87b278e-b7be-4e3d-ac32-d134b270154e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_586d53f7-dd5d-42f0-9049-de96989bd252" xlink:to="loc_us-gaap_Revenues_a87b278e-b7be-4e3d-ac32-d134b270154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_720fa531-3fa5-4583-a606-019b2c2622d7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_366b7ebe-199a-4639-ac7a-703cf703740d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_720fa531-3fa5-4583-a606-019b2c2622d7" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_366b7ebe-199a-4639-ac7a-703cf703740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_528fc509-ea53-4dc5-b996-5b3738765cba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_366b7ebe-199a-4639-ac7a-703cf703740d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_528fc509-ea53-4dc5-b996-5b3738765cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_528fc509-ea53-4dc5-b996-5b3738765cba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_4ecd2774-7af2-45df-90a8-0efd9af7b0df" xlink:href="biib-20240630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:to="loc_biib_ReserveforCashDiscountsMember_4ecd2774-7af2-45df-90a8-0efd9af7b0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_7678a9e1-1b4b-43ef-a12e-b3b1a209e48c" xlink:href="biib-20240630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:to="loc_biib_ContractualAdjustmentsMember_7678a9e1-1b4b-43ef-a12e-b3b1a209e48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_d4e5b9d7-1e37-4b78-b48a-00aed9c8620f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7557bb2f-a884-4219-8074-83cde07a6235" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_d4e5b9d7-1e37-4b78-b48a-00aed9c8620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_366b7ebe-199a-4639-ac7a-703cf703740d" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d6a5c2a-5745-458c-b397-0f92a374b36d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d6a5c2a-5745-458c-b397-0f92a374b36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9a7c20e4-29d6-4180-9815-e4fbe388ea91" xlink:href="biib-20240630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9a7c20e4-29d6-4180-9815-e4fbe388ea91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_d1b8627f-e4c2-4eff-a1d1-41d1a7046139" xlink:href="biib-20240630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_d1b8627f-e4c2-4eff-a1d1-41d1a7046139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_39f888c7-ec10-4fbb-ba73-2285dd6e6f5c" xlink:href="biib-20240630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_39f888c7-ec10-4fbb-ba73-2285dd6e6f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_4a2efa21-2292-4d30-b9f9-4712bc2f20a6" xlink:href="biib-20240630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_4a2efa21-2292-4d30-b9f9-4712bc2f20a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d928353d-905a-494c-9216-1bcbab811146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d04109fd-65db-4516-88b4-3aaaea9671ac" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d928353d-905a-494c-9216-1bcbab811146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_ea516eda-e7e9-400d-800d-e1bda24bf0e3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b783ceda-b239-410c-b0c1-6594543747c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_ea516eda-e7e9-400d-800d-e1bda24bf0e3" xlink:to="loc_us-gaap_StatementTable_b783ceda-b239-410c-b0c1-6594543747c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e7b04ffb-a326-42bd-86a1-66f8b9736309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b783ceda-b239-410c-b0c1-6594543747c6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e7b04ffb-a326-42bd-86a1-66f8b9736309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_de5596ab-8599-4987-8fb9-561bf3f95994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e7b04ffb-a326-42bd-86a1-66f8b9736309" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_de5596ab-8599-4987-8fb9-561bf3f95994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e6d03bfe-ee05-45e4-8547-7da5cc85cd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_de5596ab-8599-4987-8fb9-561bf3f95994" xlink:to="loc_us-gaap_AccountsReceivableMember_e6d03bfe-ee05-45e4-8547-7da5cc85cd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9af6b48a-9c7e-4b22-957a-cc466a128b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_de5596ab-8599-4987-8fb9-561bf3f95994" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9af6b48a-9c7e-4b22-957a-cc466a128b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d6ad605c-3f2b-4039-8ebb-a0dfeef67987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b783ceda-b239-410c-b0c1-6594543747c6" xlink:to="loc_us-gaap_StatementLineItems_d6ad605c-3f2b-4039-8ebb-a0dfeef67987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e2a880c9-ad8d-44af-928b-cc9df4ff66ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6ad605c-3f2b-4039-8ebb-a0dfeef67987" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e2a880c9-ad8d-44af-928b-cc9df4ff66ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_66bc312c-cec1-4393-b488-53f3db7b8512" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_66bc312c-cec1-4393-b488-53f3db7b8512" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b50460b1-7ff5-41ad-879b-43e0ee4b20e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:to="loc_srt_ProductOrServiceAxis_b50460b1-7ff5-41ad-879b-43e0ee4b20e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d999477-4808-4f3d-82da-198bb5399e10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b50460b1-7ff5-41ad-879b-43e0ee4b20e0" xlink:to="loc_srt_ProductsAndServicesDomain_9d999477-4808-4f3d-82da-198bb5399e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_e79510bf-8490-4fe4-904b-7829ab02fb6e" xlink:href="biib-20240630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9d999477-4808-4f3d-82da-198bb5399e10" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_e79510bf-8490-4fe4-904b-7829ab02fb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember_a892677c-f48a-4bed-bf00-dfac52a27939" xlink:href="biib-20240630.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9d999477-4808-4f3d-82da-198bb5399e10" xlink:to="loc_biib_RoyaltyAttributedToOCREVUSMember_a892677c-f48a-4bed-bf00-dfac52a27939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1457d871-7a1e-42bc-8824-19d22c18b681" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:to="loc_srt_MajorCustomersAxis_1457d871-7a1e-42bc-8824-19d22c18b681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_457a9abe-bff2-4568-be60-a400304d0915" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1457d871-7a1e-42bc-8824-19d22c18b681" xlink:to="loc_srt_NameOfMajorCustomerDomain_457a9abe-bff2-4568-be60-a400304d0915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_5c5e8896-ec10-43b9-9641-4856ba0b9a0b" xlink:href="biib-20240630.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_457a9abe-bff2-4568-be60-a400304d0915" xlink:to="loc_biib_RocheGroupGenentechMember_5c5e8896-ec10-43b9-9641-4856ba0b9a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dd1d6817-7cca-47e4-ab8c-a5563986959e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_9edb0ba0-bcd8-4321-a464-2e4444073c39" xlink:href="biib-20240630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:to="loc_biib_ShareOfCoPromotionProfits_9edb0ba0-bcd8-4321-a464-2e4444073c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_101887b9-998f-471c-8303-6ceb345ea274" xlink:href="biib-20240630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_101887b9-998f-471c-8303-6ceb345ea274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b09fb101-018e-428d-8a7e-bb0f41551f10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9510e9d7-ae87-4bf8-942f-6b8cd6425eda" xlink:to="loc_us-gaap_Revenues_b09fb101-018e-428d-8a7e-bb0f41551f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_1e320ca5-425a-49a2-bba4-dd2d77f218d6" xlink:href="biib-20240630.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6e730cdb-4f78-436a-a510-364fc590235a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_1e320ca5-425a-49a2-bba4-dd2d77f218d6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6e730cdb-4f78-436a-a510-364fc590235a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e368f97a-8307-4562-b782-3cbb32072f47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6e730cdb-4f78-436a-a510-364fc590235a" xlink:to="loc_srt_ProductOrServiceAxis_e368f97a-8307-4562-b782-3cbb32072f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e368f97a-8307-4562-b782-3cbb32072f47" xlink:to="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember_0804fa51-b29b-42e1-8ba2-8a932774fb91" xlink:href="biib-20240630.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:to="loc_biib_ContractManufacturingAndOtherRevenueMember_0804fa51-b29b-42e1-8ba2-8a932774fb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_d0bfa191-6de0-4523-9578-8fa92d192640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:to="loc_us-gaap_RoyaltyMember_d0bfa191-6de0-4523-9578-8fa92d192640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_bed54a7d-a295-4158-9524-29da9951d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5884056-f575-40c9-ae10-5f9a6b4e72ee" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_bed54a7d-a295-4158-9524-29da9951d5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b3a5f05b-c500-42e2-b2df-e98235c66221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6e730cdb-4f78-436a-a510-364fc590235a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b3a5f05b-c500-42e2-b2df-e98235c66221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_099b3320-1b07-4403-b9a0-25d9eae21c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b3a5f05b-c500-42e2-b2df-e98235c66221" xlink:to="loc_us-gaap_Revenues_099b3320-1b07-4403-b9a0-25d9eae21c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_66530852-ca6f-441a-98d2-b69d5607c1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_66530852-ca6f-441a-98d2-b69d5607c1a8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b6b6682e-22aa-4e86-9ba6-bce8ed19effd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:to="loc_srt_ProductOrServiceAxis_b6b6682e-22aa-4e86-9ba6-bce8ed19effd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c50ae59f-b818-4e56-a397-88487ffda567" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b6b6682e-22aa-4e86-9ba6-bce8ed19effd" xlink:to="loc_srt_ProductsAndServicesDomain_c50ae59f-b818-4e56-a397-88487ffda567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_232d2e50-a622-4046-b23b-e3c4ec1ec1db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c50ae59f-b818-4e56-a397-88487ffda567" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_232d2e50-a622-4046-b23b-e3c4ec1ec1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_ba3dae93-1b5b-44eb-984b-61f4c0f4813b" xlink:href="biib-20240630.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c50ae59f-b818-4e56-a397-88487ffda567" xlink:to="loc_biib_LEQEMBICollaborationMember_ba3dae93-1b5b-44eb-984b-61f4c0f4813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c5fb4e00-6e91-4ac0-860c-c1c6f9245786" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:to="loc_srt_MajorCustomersAxis_c5fb4e00-6e91-4ac0-860c-c1c6f9245786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6d72aae1-0c21-4611-9d9d-15bae73bf9ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c5fb4e00-6e91-4ac0-860c-c1c6f9245786" xlink:to="loc_srt_NameOfMajorCustomerDomain_6d72aae1-0c21-4611-9d9d-15bae73bf9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_0a04ed35-da42-4de5-9ec3-de1b766cf489" xlink:href="biib-20240630.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6d72aae1-0c21-4611-9d9d-15bae73bf9ae" xlink:to="loc_biib_DistributorOneMember_0a04ed35-da42-4de5-9ec3-de1b766cf489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_7d89b212-14fd-4432-94ce-93d0fff93d9a" xlink:href="biib-20240630.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6d72aae1-0c21-4611-9d9d-15bae73bf9ae" xlink:to="loc_biib_DistributorTwoMember_7d89b212-14fd-4432-94ce-93d0fff93d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f968e69-2bd4-4528-9636-1e39049f8f25" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7c7c4822-d909-4c3b-8c3c-95e0338b7975" xlink:href="biib-20240630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7c7c4822-d909-4c3b-8c3c-95e0338b7975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_93c96789-b2a4-4cd2-94d4-980b2742efe3" xlink:href="biib-20240630.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_biib_NumberOfWholesalers_93c96789-b2a4-4cd2-94d4-980b2742efe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c726fe14-b74b-495a-829e-ea6d9b2a95bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_us-gaap_Revenues_c726fe14-b74b-495a-829e-ea6d9b2a95bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_444476f4-c015-4d1a-927f-4af35b06c55c" xlink:href="biib-20240630.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_047aca7e-8d8e-4f36-bb3c-8580d34f465d" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_444476f4-c015-4d1a-927f-4af35b06c55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_03e0c8c1-e99a-4bb1-a470-65ae78eaa364" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_821948b3-375a-4009-bf6a-b74538de3f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e0c8c1-e99a-4bb1-a470-65ae78eaa364" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_821948b3-375a-4009-bf6a-b74538de3f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_edb08113-1509-45d9-9a13-112ba3b6a347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e0c8c1-e99a-4bb1-a470-65ae78eaa364" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_edb08113-1509-45d9-9a13-112ba3b6a347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3f1e222f-bd1d-4200-ad3a-53196a8f3250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e0c8c1-e99a-4bb1-a470-65ae78eaa364" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3f1e222f-bd1d-4200-ad3a-53196a8f3250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_4d6412a0-7ba0-4d08-8b2f-2bf96d58926b" xlink:href="biib-20240630.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e0c8c1-e99a-4bb1-a470-65ae78eaa364" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_4d6412a0-7ba0-4d08-8b2f-2bf96d58926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d3c8ffac-c8b0-4eed-ba22-699e54287773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e0c8c1-e99a-4bb1-a470-65ae78eaa364" xlink:to="loc_us-gaap_InventoryNet_d3c8ffac-c8b0-4eed-ba22-699e54287773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_28cfac31-360f-4dd6-b72e-6c54517ba853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e0c8c1-e99a-4bb1-a470-65ae78eaa364" xlink:to="loc_us-gaap_InventoryNoncurrent_28cfac31-360f-4dd6-b72e-6c54517ba853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_43afae15-7180-4ed5-85ac-d744c2d30fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_43afae15-7180-4ed5-85ac-d744c2d30fd2" xlink:to="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_052e284f-0823-48d2-ac10-03238ca4bbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_052e284f-0823-48d2-ac10-03238ca4bbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34f4046e-099a-4d03-8d24-838e162bb6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_052e284f-0823-48d2-ac10-03238ca4bbfa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34f4046e-099a-4d03-8d24-838e162bb6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_72710344-e118-4318-9b69-beaf601a30ab" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34f4046e-099a-4d03-8d24-838e162bb6c0" xlink:to="loc_biib_EisaiMember_72710344-e118-4318-9b69-beaf601a30ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e881f6f2-fbf5-4d66-80b7-3f418e15708a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e881f6f2-fbf5-4d66-80b7-3f418e15708a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55c0b196-c4db-4fa4-85af-918803941e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e881f6f2-fbf5-4d66-80b7-3f418e15708a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55c0b196-c4db-4fa4-85af-918803941e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_2f0348f1-90d2-458f-84e2-03f5ef595642" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55c0b196-c4db-4fa4-85af-918803941e0f" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_2f0348f1-90d2-458f-84e2-03f5ef595642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_2829897b-5bd5-4aa4-bfd7-4a5b842ccb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_d37c30c8-6cc9-4ef6-af8d-d5f0b9edea43" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_2829897b-5bd5-4aa4-bfd7-4a5b842ccb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_75b6f8d7-1959-4d5f-a4c9-20e6e3b20ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_2829897b-5bd5-4aa4-bfd7-4a5b842ccb2f" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_75b6f8d7-1959-4d5f-a4c9-20e6e3b20ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_2040a1ee-4e8c-4ed7-bb31-a5061af188ec" xlink:to="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_afc1b068-6a39-4475-9787-81df5ab29029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_afc1b068-6a39-4475-9787-81df5ab29029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2a922474-ed73-424d-9342-f433c94ff47d" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2a922474-ed73-424d-9342-f433c94ff47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5904dbb6-4f90-4735-a78e-039af07842c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_us-gaap_ProfitLoss_5904dbb6-4f90-4735-a78e-039af07842c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_380e41de-16df-48c0-bb76-f1fe2e22d056" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fbdfefba-87a7-43c8-850d-1bbcdb43a801" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_380e41de-16df-48c0-bb76-f1fe2e22d056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_34c84ff7-6c59-428f-a9ad-0876cf22159e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_34c84ff7-6c59-428f-a9ad-0876cf22159e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac7a1601-0349-4102-bd1c-d2b553b71015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0e68161e-35ab-48a2-bcd6-2a7b803c5f0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac7a1601-0349-4102-bd1c-d2b553b71015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_d4d448d7-5a2f-4507-84f4-4d37ee5a308d" xlink:href="biib-20240630.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac7a1601-0349-4102-bd1c-d2b553b71015" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_d4d448d7-5a2f-4507-84f4-4d37ee5a308d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_447ac14b-9df9-4fca-8a2a-ab2753765ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac7a1601-0349-4102-bd1c-d2b553b71015" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_447ac14b-9df9-4fca-8a2a-ab2753765ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89a9a179-e969-4586-9c57-916f4e696e8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:to="loc_srt_RangeAxis_89a9a179-e969-4586-9c57-916f4e696e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0cb9247e-4c80-4715-ab4b-58b4fbef7442" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_89a9a179-e969-4586-9c57-916f4e696e8c" xlink:to="loc_srt_RangeMember_0cb9247e-4c80-4715-ab4b-58b4fbef7442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05ad731c-6c2c-40af-ae8c-263c6d806843" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0cb9247e-4c80-4715-ab4b-58b4fbef7442" xlink:to="loc_srt_MinimumMember_05ad731c-6c2c-40af-ae8c-263c6d806843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3ad51d2b-6020-4207-96b9-2e0042f4942d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0cb9247e-4c80-4715-ab4b-58b4fbef7442" xlink:to="loc_srt_MaximumMember_3ad51d2b-6020-4207-96b9-2e0042f4942d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8d106640-cf50-43e9-9586-0bb0773aa76b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_67bb7846-93e9-4250-8659-c2db62a9386b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8d106640-cf50-43e9-9586-0bb0773aa76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0f0a621d-826f-458c-b8fd-6123839bb022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8d106640-cf50-43e9-9586-0bb0773aa76b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0f0a621d-826f-458c-b8fd-6123839bb022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8d106640-cf50-43e9-9586-0bb0773aa76b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2cf9bbfc-f022-48fb-aae3-1d1f390296a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2cf9bbfc-f022-48fb-aae3-1d1f390296a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_76980326-1486-4f95-a68e-c4b87146203d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_76980326-1486-4f95-a68e-c4b87146203d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_584fcf14-267a-4456-88a4-d9c2ea34c67d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a364402-2705-45b8-8f31-a5d8ec4a0924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_584fcf14-267a-4456-88a4-d9c2ea34c67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f248205f-bd38-46c6-9350-3710d00a7af6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_34c84ff7-6c59-428f-a9ad-0876cf22159e" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f248205f-bd38-46c6-9350-3710d00a7af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_715e6466-07ed-44f1-bf50-7cee02d2917b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f248205f-bd38-46c6-9350-3710d00a7af6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_715e6466-07ed-44f1-bf50-7cee02d2917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_715e6466-07ed-44f1-bf50-7cee02d2917b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e3b8645b-3b7e-42b6-9257-e918ebfcfa53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e3b8645b-3b7e-42b6-9257-e918ebfcfa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_2278831b-1510-4d01-8d49-03b21b53fb5a" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:to="loc_biib_PriorityReviewVoucherMember_2278831b-1510-4d01-8d49-03b21b53fb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_c890b0aa-f698-49e2-8af5-41c0a103afd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fcb0713f-37be-4970-9022-17ebb164fdf8" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_c890b0aa-f698-49e2-8af5-41c0a103afd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8bece34-9729-45cf-bf62-82b961750a27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f248205f-bd38-46c6-9350-3710d00a7af6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8bece34-9729-45cf-bf62-82b961750a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14b5e32e-42d1-4a15-87fb-ff0f2ac87d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8bece34-9729-45cf-bf62-82b961750a27" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14b5e32e-42d1-4a15-87fb-ff0f2ac87d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_97f8851e-c729-4c52-954d-c3f4253708d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_34c84ff7-6c59-428f-a9ad-0876cf22159e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_97f8851e-c729-4c52-954d-c3f4253708d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8636c235-8382-468c-9a2e-24230b7297fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_97f8851e-c729-4c52-954d-c3f4253708d2" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8636c235-8382-468c-9a2e-24230b7297fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1a21a849-019a-4e38-b22b-4d6b50911638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_97f8851e-c729-4c52-954d-c3f4253708d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1a21a849-019a-4e38-b22b-4d6b50911638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f400d0df-3619-424a-bbbb-4917cbf3f889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_97f8851e-c729-4c52-954d-c3f4253708d2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f400d0df-3619-424a-bbbb-4917cbf3f889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76aa6d72-c6c3-40b4-a48c-6c50087fae1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76aa6d72-c6c3-40b4-a48c-6c50087fae1a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_92134afd-4980-41ec-aa30-2610d08b1a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_92134afd-4980-41ec-aa30-2610d08b1a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4793c0c0-cb48-4c3a-9c8a-3321584ba175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_92134afd-4980-41ec-aa30-2610d08b1a9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4793c0c0-cb48-4c3a-9c8a-3321584ba175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_a65719a9-84fb-40cb-8fe2-1098ce6b2830" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4793c0c0-cb48-4c3a-9c8a-3321584ba175" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_a65719a9-84fb-40cb-8fe2-1098ce6b2830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0685590c-b851-4165-bf6a-a1ecede6d839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0685590c-b851-4165-bf6a-a1ecede6d839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0685590c-b851-4165-bf6a-a1ecede6d839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_55a51abc-ec5a-4687-b360-f8e1dabbb44b" xlink:href="biib-20240630.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_55a51abc-ec5a-4687-b360-f8e1dabbb44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_33e981c8-9677-4f77-a725-29c588ea96aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_33e981c8-9677-4f77-a725-29c588ea96aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bbacd757-a38e-47e6-9aee-742ca17c126d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bbacd757-a38e-47e6-9aee-742ca17c126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_2aae53f0-2f9e-42c0-a44b-b550d0db021d" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_biib_SKYCLARYSMember_2aae53f0-2f9e-42c0-a44b-b550d0db021d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_caab8ad5-e657-47a0-8d9a-03b13711629c" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_biib_PriorityReviewVoucherMember_caab8ad5-e657-47a0-8d9a-03b13711629c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CompletedTechnologyMember_22a6e6b1-6f9f-4f7e-a41f-db89fc5fecaf" xlink:href="biib-20240630.xsd#biib_CompletedTechnologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_554b4f01-a618-46f9-b140-c00bf2acbd63" xlink:to="loc_biib_CompletedTechnologyMember_22a6e6b1-6f9f-4f7e-a41f-db89fc5fecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f64a55e-b61e-47c7-b4d0-d006695abcc9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_srt_RangeAxis_3f64a55e-b61e-47c7-b4d0-d006695abcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bba12694-5155-4ebe-ad9e-65f77ba65ae4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3f64a55e-b61e-47c7-b4d0-d006695abcc9" xlink:to="loc_srt_RangeMember_bba12694-5155-4ebe-ad9e-65f77ba65ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fb5887d6-a53b-4699-bcd5-50a50835475c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bba12694-5155-4ebe-ad9e-65f77ba65ae4" xlink:to="loc_srt_MinimumMember_fb5887d6-a53b-4699-bcd5-50a50835475c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a6a38b42-bbcc-4318-be1b-ac63368f9fc1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bba12694-5155-4ebe-ad9e-65f77ba65ae4" xlink:to="loc_srt_MaximumMember_a6a38b42-bbcc-4318-be1b-ac63368f9fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca1bc9d6-375e-49d0-a4c4-95a466ffd397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca1bc9d6-375e-49d0-a4c4-95a466ffd397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca1bc9d6-375e-49d0-a4c4-95a466ffd397" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b2d553b1-464c-4176-907d-5a566294b3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b2d553b1-464c-4176-907d-5a566294b3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_36f06b9c-8e40-42c1-a471-a5fa47d37995" xlink:href="biib-20240630.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:to="loc_biib_PriorityReviewVoucherMember_36f06b9c-8e40-42c1-a471-a5fa47d37995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_9dcc44d8-0dba-48b3-89b3-5a0f28090b57" xlink:href="biib-20240630.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_702a422c-ee8b-4eaa-ba92-015f1dab5dbb" xlink:to="loc_biib_SKYCLARYSMember_9dcc44d8-0dba-48b3-89b3-5a0f28090b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_115323ab-4b72-4115-9eb4-5dcf8f6c1dfd" xlink:to="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9c1532e3-5b69-4969-83b1-44e39bbe026c" xlink:href="biib-20240630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9c1532e3-5b69-4969-83b1-44e39bbe026c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f3e70127-30a1-426d-87fd-5b3b7addc284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f3e70127-30a1-426d-87fd-5b3b7addc284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b1fefd17-468c-415a-b8bc-17ce4dbdc53e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b1fefd17-468c-415a-b8bc-17ce4dbdc53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_8ef35768-2a3c-400e-86fe-c76aa695f903" xlink:href="biib-20240630.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_8ef35768-2a3c-400e-86fe-c76aa695f903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_908df63d-126f-4f9d-925a-518c5eb2ffda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_908df63d-126f-4f9d-925a-518c5eb2ffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_84c1a91f-57b3-4193-a7d7-da8803d4f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0fe6ea3f-7785-4e9d-9559-0f8ac06b0236" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_84c1a91f-57b3-4193-a7d7-da8803d4f9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a8c9a01-9708-4bd7-b93a-91374a56fc07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b0fb635b-7310-4502-a849-b88a12783f61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a8c9a01-9708-4bd7-b93a-91374a56fc07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b0fb635b-7310-4502-a849-b88a12783f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_aa9f788f-37d0-4e4c-8cc7-90e39613f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a8c9a01-9708-4bd7-b93a-91374a56fc07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_aa9f788f-37d0-4e4c-8cc7-90e39613f9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3e72970d-7229-4cff-9046-93f0b5d06aae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a8c9a01-9708-4bd7-b93a-91374a56fc07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3e72970d-7229-4cff-9046-93f0b5d06aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d229896a-c894-46ac-b40c-0969081bda9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a8c9a01-9708-4bd7-b93a-91374a56fc07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d229896a-c894-46ac-b40c-0969081bda9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0152619e-73f4-4a27-a133-f2291a64d65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a8c9a01-9708-4bd7-b93a-91374a56fc07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0152619e-73f4-4a27-a133-f2291a64d65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1af28a29-8581-4ec4-bbfb-9fa7c771f80f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a8c9a01-9708-4bd7-b93a-91374a56fc07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1af28a29-8581-4ec4-bbfb-9fa7c771f80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_360814fa-015e-45bd-9e9d-01787fe2e5af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_bfcbbbae-a9f0-4bf2-bd69-4b1f70b0cc87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_360814fa-015e-45bd-9e9d-01787fe2e5af" xlink:to="loc_us-gaap_GoodwillRollForward_bfcbbbae-a9f0-4bf2-bd69-4b1f70b0cc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_55e0c42e-c49d-4e2f-976d-12d88974d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bfcbbbae-a9f0-4bf2-bd69-4b1f70b0cc87" xlink:to="loc_us-gaap_Goodwill_55e0c42e-c49d-4e2f-976d-12d88974d0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_39363904-3d5a-4459-a59d-5e8ed37a19d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bfcbbbae-a9f0-4bf2-bd69-4b1f70b0cc87" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_39363904-3d5a-4459-a59d-5e8ed37a19d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_162ecf47-f8e3-436c-b478-1d7daf752776" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bfcbbbae-a9f0-4bf2-bd69-4b1f70b0cc87" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_162ecf47-f8e3-436c-b478-1d7daf752776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a028315-1564-426c-ae14-c3d0a234f723" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bfcbbbae-a9f0-4bf2-bd69-4b1f70b0cc87" xlink:to="loc_us-gaap_Goodwill_3a028315-1564-426c-ae14-c3d0a234f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_542be1f4-3df1-49e8-8e92-40f6f8fe9acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_360814fa-015e-45bd-9e9d-01787fe2e5af" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_542be1f4-3df1-49e8-8e92-40f6f8fe9acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b37eabec-552c-4bb5-9fa0-21506cb897b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b37eabec-552c-4bb5-9fa0-21506cb897b8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1974e03-4f6b-4eb1-9425-07a1f351f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1974e03-4f6b-4eb1-9425-07a1f351f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1974e03-4f6b-4eb1-9425-07a1f351f65c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c460cb6c-f578-449f-8eb8-ac4569807514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c460cb6c-f578-449f-8eb8-ac4569807514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bdc77bca-6593-4526-8d97-6354341593ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bdc77bca-6593-4526-8d97-6354341593ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0ba3f6a4-e5cb-49de-9563-c8d9b206c298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f842f574-cdae-4d57-938b-cbd9be3e5d2f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0ba3f6a4-e5cb-49de-9563-c8d9b206c298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebc4758c-7283-442b-8adb-c228aed38ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0b2b78d-bc96-4322-b69c-d7ec8ee9c56d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebc4758c-7283-442b-8adb-c228aed38ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a06449c6-0bc9-444f-8e74-789e40326dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebc4758c-7283-442b-8adb-c228aed38ead" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a06449c6-0bc9-444f-8e74-789e40326dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7052f701-b92f-4e06-b9d2-325cde728f15" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7052f701-b92f-4e06-b9d2-325cde728f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f48072eb-fe70-47a6-a299-f1ddef6ecfe9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7052f701-b92f-4e06-b9d2-325cde728f15" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f48072eb-fe70-47a6-a299-f1ddef6ecfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_f018566d-34e7-4a23-8fbf-42238d7f1e77" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f48072eb-fe70-47a6-a299-f1ddef6ecfe9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_f018566d-34e7-4a23-8fbf-42238d7f1e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d38e9ab-5088-464e-9d17-e79cf2daff45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15a8463b-1570-456b-8a14-128b636902fd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d38e9ab-5088-464e-9d17-e79cf2daff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b3f7228-3c94-43d2-b944-ce89ac27320f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d38e9ab-5088-464e-9d17-e79cf2daff45" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b3f7228-3c94-43d2-b944-ce89ac27320f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b3f7228-3c94-43d2-b944-ce89ac27320f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_49493ace-df66-435a-a03c-dc674c1d01dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_49493ace-df66-435a-a03c-dc674c1d01dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4028c241-8b4a-4b65-9808-1acbfef5f705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4028c241-8b4a-4b65-9808-1acbfef5f705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_f79b1177-8e6f-493f-b4cb-ce9a5da14583" xlink:href="biib-20240630.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_f79b1177-8e6f-493f-b4cb-ce9a5da14583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_7e09f83d-1652-4760-acab-d0681f0c9732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_7e09f83d-1652-4760-acab-d0681f0c9732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_75341c0a-12ce-4b41-99a4-f8b714acc2b4" xlink:href="biib-20240630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_75341c0a-12ce-4b41-99a4-f8b714acc2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_eeda8739-ad69-46ac-87eb-5b6913621428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_DerivativeAssets_eeda8739-ad69-46ac-87eb-5b6913621428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_98f47ec0-13b7-4d8c-8922-fd84526ab6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bb80989-f79d-4639-8820-961c05a5b618" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_98f47ec0-13b7-4d8c-8922-fd84526ab6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b3f7228-3c94-43d2-b944-ce89ac27320f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_275207bc-a600-43e4-8543-bdf0a0d0b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_275207bc-a600-43e4-8543-bdf0a0d0b2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_3ddeed52-65a2-45d2-8489-df2025ecf9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_3ddeed52-65a2-45d2-8489-df2025ecf9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3a417b02-2881-4b3f-a64a-f6192f38b596" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_573ceb7a-150d-487b-92dc-7f8a77e21dd5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3a417b02-2881-4b3f-a64a-f6192f38b596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_035c05bd-b359-44b2-b757-5f5a51022e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_035c05bd-b359-44b2-b757-5f5a51022e82" xlink:to="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_16664e0a-9a0a-4569-91f7-e5f130b6d98b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:to="loc_us-gaap_CreditFacilityAxis_16664e0a-9a0a-4569-91f7-e5f130b6d98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_47304b4e-adf6-4fc0-86b4-5cfe6ec8343f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_16664e0a-9a0a-4569-91f7-e5f130b6d98b" xlink:to="loc_us-gaap_CreditFacilityDomain_47304b4e-adf6-4fc0-86b4-5cfe6ec8343f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e89bde2a-7c55-4461-b63e-583babb96662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_47304b4e-adf6-4fc0-86b4-5cfe6ec8343f" xlink:to="loc_us-gaap_SecuredDebtMember_e89bde2a-7c55-4461-b63e-583babb96662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8aaba9e1-66d8-4e51-9419-a72d23751234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:to="loc_us-gaap_DebtInstrumentAxis_8aaba9e1-66d8-4e51-9419-a72d23751234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94ba2027-56e7-4aa6-9799-9d70024f7270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aaba9e1-66d8-4e51-9419-a72d23751234" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94ba2027-56e7-4aa6-9799-9d70024f7270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_a88d8fc9-f267-4e9f-87d4-6e4f095b9018" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_94ba2027-56e7-4aa6-9799-9d70024f7270" xlink:to="loc_biib_TheCreditFacilityMember_a88d8fc9-f267-4e9f-87d4-6e4f095b9018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ea3d5933-4b24-4033-ac16-e0d15171db90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ea3d5933-4b24-4033-ac16-e0d15171db90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_093e2739-1247-43af-98ab-930010e40fda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea3d5933-4b24-4033-ac16-e0d15171db90" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_093e2739-1247-43af-98ab-930010e40fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a7540d79-d440-48e9-bd1b-1b00bbb90a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_093e2739-1247-43af-98ab-930010e40fda" xlink:to="loc_us-gaap_LineOfCreditMember_a7540d79-d440-48e9-bd1b-1b00bbb90a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_94d17cb9-0b4a-4856-94b7-14d85a902868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a17e3e0d-a19e-4434-8070-0adc3ac2dd7b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_94d17cb9-0b4a-4856-94b7-14d85a902868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8cad79e8-b35b-4569-8006-bccd626470ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94d17cb9-0b4a-4856-94b7-14d85a902868" xlink:to="loc_us-gaap_AssetImpairmentCharges_8cad79e8-b35b-4569-8006-bccd626470ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ab6e2bb8-4dde-42b0-8230-17ffcfae214e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94d17cb9-0b4a-4856-94b7-14d85a902868" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ab6e2bb8-4dde-42b0-8230-17ffcfae214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20240630.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71830ddf-4ae6-4b27-969d-baa498c21b55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71830ddf-4ae6-4b27-969d-baa498c21b55" xlink:to="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aa534a93-fe36-4981-b5ae-9539f8edca69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_DebtInstrumentAxis_aa534a93-fe36-4981-b5ae-9539f8edca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa534a93-fe36-4981-b5ae-9539f8edca69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_90486ac2-ae06-4c43-a404-689169dbf78d" xlink:href="biib-20240630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_90486ac2-ae06-4c43-a404-689169dbf78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_6c7cba07-1baa-4e98-9a73-eb4dd709c78a" xlink:href="biib-20240630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_6c7cba07-1baa-4e98-9a73-eb4dd709c78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_2b75d08d-c74c-4fe9-b178-b5a188f99625" xlink:href="biib-20240630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_2b75d08d-c74c-4fe9-b178-b5a188f99625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member_067df86d-71c6-4bb4-a159-c2e3c6a592ea" xlink:href="biib-20240630.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_SeniorNotes3.250DueFebruary152051Member_067df86d-71c6-4bb4-a159-c2e3c6a592ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_7b56f1f9-84e8-45e9-8c67-2668760fb33f" xlink:href="biib-20240630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_7b56f1f9-84e8-45e9-8c67-2668760fb33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_80c35542-920b-4ff1-aeb8-0a23e64f11ac" xlink:href="biib-20240630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_80c35542-920b-4ff1-aeb8-0a23e64f11ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentPortionOfNotesPayableAndTermLoanMember_06d9050a-81a6-4565-806e-f8423aa4c584" xlink:href="biib-20240630.xsd#biib_CurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_CurrentPortionOfNotesPayableAndTermLoanMember_06d9050a-81a6-4565-806e-f8423aa4c584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_341bc596-fff5-4580-901c-e853ba7bc53c" xlink:href="biib-20240630.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_341bc596-fff5-4580-901c-e853ba7bc53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_ba0b31a4-b6be-46de-8fe4-ddbbc7799796" xlink:href="biib-20240630.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_ba0b31a4-b6be-46de-8fe4-ddbbc7799796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_5249bf19-9ce5-40c8-8893-cd41b4e3f39b" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_TheCreditFacilityMember_5249bf19-9ce5-40c8-8893-cd41b4e3f39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_298f3d32-f3da-48fd-a38d-a65338cfcc40" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_298f3d32-f3da-48fd-a38d-a65338cfcc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_9bda28c0-37c4-4ac4-bca1-bb96c23ce5d4" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d1d5235c-7678-437d-acb3-27e3c38fef0e" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_9bda28c0-37c4-4ac4-bca1-bb96c23ce5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_21ae4853-6b09-46b9-a127-9b3c59801c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_21ae4853-6b09-46b9-a127-9b3c59801c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584f33b5-41e5-4219-b4bd-711ca26ae658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21ae4853-6b09-46b9-a127-9b3c59801c8b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584f33b5-41e5-4219-b4bd-711ca26ae658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_423fff63-d692-4095-9fc6-f0ac0d0271a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584f33b5-41e5-4219-b4bd-711ca26ae658" xlink:to="loc_us-gaap_SeniorNotesMember_423fff63-d692-4095-9fc6-f0ac0d0271a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_dd849585-bc5f-42df-a37a-d4aaf060b975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584f33b5-41e5-4219-b4bd-711ca26ae658" xlink:to="loc_us-gaap_LineOfCreditMember_dd849585-bc5f-42df-a37a-d4aaf060b975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0731c56f-c859-40df-83bd-0602c017669b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c538c0e-f5b1-4c12-bc59-0e39d28d13d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0731c56f-c859-40df-83bd-0602c017669b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_5e9ec909-049e-4929-8590-40c292fcdb8c" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0731c56f-c859-40df-83bd-0602c017669b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_5e9ec909-049e-4929-8590-40c292fcdb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0cf3dcc8-d80a-4c75-9f5c-681be4de3362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_CreditFacilityAxis_0cf3dcc8-d80a-4c75-9f5c-681be4de3362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_06569e6d-0546-4a1a-8a0e-b9dfd901a8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_0cf3dcc8-d80a-4c75-9f5c-681be4de3362" xlink:to="loc_us-gaap_CreditFacilityDomain_06569e6d-0546-4a1a-8a0e-b9dfd901a8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_6826b876-5cd3-41f7-b27e-6793f50d1ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_06569e6d-0546-4a1a-8a0e-b9dfd901a8a2" xlink:to="loc_us-gaap_SecuredDebtMember_6826b876-5cd3-41f7-b27e-6793f50d1ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d0cc9e1-ca19-4e0c-948f-5f143cc52dec" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_f4638461-83fa-41c6-bcce-a6c5e7a8263f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_f4638461-83fa-41c6-bcce-a6c5e7a8263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_fd1d76b3-ed40-4986-aebe-ddc73681b1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_NotesPayableCurrent_fd1d76b3-ed40-4986-aebe-ddc73681b1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_11156e68-f951-48c1-af81-fdde896a64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_NotesPayable_11156e68-f951-48c1-af81-fdde896a64b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8d0b75f8-afaf-4d57-aff6-ae4a4d10ac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8d0b75f8-afaf-4d57-aff6-ae4a4d10ac3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_886e3e66-fe3a-432a-933e-4d23f916e478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbf92f0b-96db-479c-aa56-f76d3f6f2bc5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_886e3e66-fe3a-432a-933e-4d23f916e478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2873a42-74db-494f-90aa-83d395bfe6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fb5b54c7-c99c-401f-81d0-c6b5076fe3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2873a42-74db-494f-90aa-83d395bfe6dd" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fb5b54c7-c99c-401f-81d0-c6b5076fe3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0d486899-b694-46e9-a399-df29a67259a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fb5b54c7-c99c-401f-81d0-c6b5076fe3cb" xlink:to="loc_us-gaap_InvestmentTypeAxis_0d486899-b694-46e9-a399-df29a67259a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_930b5ee5-97dc-4a88-962d-02201d07982b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0d486899-b694-46e9-a399-df29a67259a4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_930b5ee5-97dc-4a88-962d-02201d07982b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05197a08-c69d-4196-9ddd-56fa45cc2caa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_930b5ee5-97dc-4a88-962d-02201d07982b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_05197a08-c69d-4196-9ddd-56fa45cc2caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_9bd701ea-376c-4366-af9b-3154eeae4828" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fb5b54c7-c99c-401f-81d0-c6b5076fe3cb" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_9bd701ea-376c-4366-af9b-3154eeae4828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_0f812659-7483-4466-8c22-95d4e06b894a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9bd701ea-376c-4366-af9b-3154eeae4828" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_0f812659-7483-4466-8c22-95d4e06b894a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_6a4325b1-9289-4ce8-aabf-21846da45862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_0f812659-7483-4466-8c22-95d4e06b894a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_6a4325b1-9289-4ce8-aabf-21846da45862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7c3b6b96-9b4e-4935-a95f-1cba2b32c8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_051c46d9-288b-48ff-a9fc-e65189db1d65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7c3b6b96-9b4e-4935-a95f-1cba2b32c8d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_051c46d9-288b-48ff-a9fc-e65189db1d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_83370384-d345-4a02-9b28-3705949caa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_051c46d9-288b-48ff-a9fc-e65189db1d65" xlink:to="loc_us-gaap_FinancialInstrumentAxis_83370384-d345-4a02-9b28-3705949caa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cf3afd0-dad5-4417-b6b0-486cf4ebe648" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_83370384-d345-4a02-9b28-3705949caa5d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cf3afd0-dad5-4417-b6b0-486cf4ebe648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_18110c2e-2192-42e7-88d1-34237c7a21fb" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cf3afd0-dad5-4417-b6b0-486cf4ebe648" xlink:to="loc_biib_EquitySecuritiesCurrentMember_18110c2e-2192-42e7-88d1-34237c7a21fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_e55204d6-62ae-4a23-83d6-4d86f5817adb" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cf3afd0-dad5-4417-b6b0-486cf4ebe648" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_e55204d6-62ae-4a23-83d6-4d86f5817adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76efcc2a-1af8-481d-bd73-e366613310f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_051c46d9-288b-48ff-a9fc-e65189db1d65" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76efcc2a-1af8-481d-bd73-e366613310f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76efcc2a-1af8-481d-bd73-e366613310f3" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_6ceaffac-2f0e-44e1-9ac0-72b9d0491fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_6ceaffac-2f0e-44e1-9ac0-72b9d0491fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_2ba00e49-8399-4f6e-8f10-e2d4c0539dd3" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_2ba00e49-8399-4f6e-8f10-e2d4c0539dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e316b857-b7a6-40fe-aaa1-eeae6de0883a" xlink:href="biib-20240630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e316b857-b7a6-40fe-aaa1-eeae6de0883a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_14b0c799-242c-414b-a90a-74d4cb565889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d5a13781-0ab6-4cca-b4e6-cceae02f6080" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_14b0c799-242c-414b-a90a-74d4cb565889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f3d48c8-c6f6-4bdf-8d10-3c0e42524296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_582aa35a-3c0f-4891-a5e4-bf0cbb851fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f3d48c8-c6f6-4bdf-8d10-3c0e42524296" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_582aa35a-3c0f-4891-a5e4-bf0cbb851fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_06aa1e03-42ae-4b84-8a6b-0178add33842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f3d48c8-c6f6-4bdf-8d10-3c0e42524296" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_06aa1e03-42ae-4b84-8a6b-0178add33842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_e91ddfff-5ba3-4834-bf14-5d5bd47f267c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f3d48c8-c6f6-4bdf-8d10-3c0e42524296" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_e91ddfff-5ba3-4834-bf14-5d5bd47f267c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20240630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_de76105b-9d44-4d18-bf7a-f6737c154ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_de76105b-9d44-4d18-bf7a-f6737c154ac9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_66e064b2-7468-4418-88bc-22361771a23b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_66e064b2-7468-4418-88bc-22361771a23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c0fee6a-a883-4061-8ff5-9733c6378e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_66e064b2-7468-4418-88bc-22361771a23b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c0fee6a-a883-4061-8ff5-9733c6378e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_de0ca5ca-2582-49f9-bf2e-47a4309d2fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c0fee6a-a883-4061-8ff5-9733c6378e2b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_de0ca5ca-2582-49f9-bf2e-47a4309d2fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16d671ba-4868-4ec3-b257-64342a979d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fcf7f792-12e6-4dcd-a7a6-9b71a9e76e6a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16d671ba-4868-4ec3-b257-64342a979d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_8dcdd957-5dd6-4548-b410-0814205d11bb" xlink:href="biib-20240630.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16d671ba-4868-4ec3-b257-64342a979d72" xlink:to="loc_biib_StrategicInvestmentsMember_8dcdd957-5dd6-4548-b410-0814205d11bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_14b5b2fb-f01a-431d-9474-2a059b6ce870" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43744969-7e74-4829-8b19-dd6cff7ea4bb" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_14b5b2fb-f01a-431d-9474-2a059b6ce870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_b8c06480-ca99-4283-9e1a-e2a4d6d41175" xlink:href="biib-20240630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_14b5b2fb-f01a-431d-9474-2a059b6ce870" xlink:to="loc_biib_StrategicInvestmentPortfolio_b8c06480-ca99-4283-9e1a-e2a4d6d41175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c6ef649b-f864-4e94-b29e-88436cffecde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c6ef649b-f864-4e94-b29e-88436cffecde" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_44a703a7-7747-4035-bee5-458dd5cbc406" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_44a703a7-7747-4035-bee5-458dd5cbc406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_aa92232f-6bf4-4163-88aa-23fcbb79ae1d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_44a703a7-7747-4035-bee5-458dd5cbc406" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_aa92232f-6bf4-4163-88aa-23fcbb79ae1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_8adbe842-da4d-4653-bb19-61bd6d35a54f" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_aa92232f-6bf4-4163-88aa-23fcbb79ae1d" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_8adbe842-da4d-4653-bb19-61bd6d35a54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_srt_CurrencyAxis_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_f07dbf5d-4c57-4470-8c49-88f2a7e2bb8e" xlink:to="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_e2e63a09-191a-4ec0-a453-80d39d723748" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:to="loc_currency_EUR_e2e63a09-191a-4ec0-a453-80d39d723748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_49ab5714-4914-497b-8c08-0427d48f79b9" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CHF"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:to="loc_currency_CHF_49ab5714-4914-497b-8c08-0427d48f79b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_00bec304-69aa-4a47-bed9-43b7a52c6284" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:to="loc_currency_JPY_00bec304-69aa-4a47-bed9-43b7a52c6284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_e06b41b2-708a-4514-b274-95dc258ba1c6" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_48893631-f8e8-42b1-b097-f682bffa462b" xlink:to="loc_currency_CAD_e06b41b2-708a-4514-b274-95dc258ba1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_12f280d8-4185-461a-936e-b83b6c3f59ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_12f280d8-4185-461a-936e-b83b6c3f59ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_22b41e97-cb0a-4313-8614-e811bad7a2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12f280d8-4185-461a-936e-b83b6c3f59ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_22b41e97-cb0a-4313-8614-e811bad7a2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_16188b8a-adc0-4d5e-9f34-897fe6d4a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_22b41e97-cb0a-4313-8614-e811bad7a2ab" xlink:to="loc_us-gaap_SalesMember_16188b8a-adc0-4d5e-9f34-897fe6d4a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_c024f92f-3b9f-4f9f-a667-da56148556c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_22b41e97-cb0a-4313-8614-e811bad7a2ab" xlink:to="loc_us-gaap_OperatingExpenseMember_c024f92f-3b9f-4f9f-a667-da56148556c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ffe90b21-2874-4226-b7b0-bc21618e0198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ffe90b21-2874-4226-b7b0-bc21618e0198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_66bf05a6-824c-45f3-b41b-33ecbb98bae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ffe90b21-2874-4226-b7b0-bc21618e0198" xlink:to="loc_us-gaap_HedgingRelationshipDomain_66bf05a6-824c-45f3-b41b-33ecbb98bae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_6c2f95bf-3c9a-4d10-bfd4-661446224cf4" xlink:href="biib-20240630.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_66bf05a6-824c-45f3-b41b-33ecbb98bae7" xlink:to="loc_biib_CashflowsrevenueMember_6c2f95bf-3c9a-4d10-bfd4-661446224cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_6643457a-7dbd-4655-a972-9ea200307111" xlink:href="biib-20240630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_66bf05a6-824c-45f3-b41b-33ecbb98bae7" xlink:to="loc_biib_CashflowsoperatingexpensesMember_6643457a-7dbd-4655-a972-9ea200307111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d9320598-b855-402b-bf03-d4dd975d0ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_49c52cc6-f4a4-4e29-8598-cf1d5b3cf5b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d9320598-b855-402b-bf03-d4dd975d0ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_698cf0d7-44b9-48cb-8550-767f701cdb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d9320598-b855-402b-bf03-d4dd975d0ecb" xlink:to="loc_us-gaap_ForeignExchangeContractMember_698cf0d7-44b9-48cb-8550-767f701cdb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8e81e94a-e70b-4c02-be34-e63a05aad166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8e81e94a-e70b-4c02-be34-e63a05aad166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8e81e94a-e70b-4c02-be34-e63a05aad166" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_ce6cfded-b96f-4678-a502-c1f547c49c32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_ce6cfded-b96f-4678-a502-c1f547c49c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_49e1cfdc-b23e-40f3-8a07-775570c8787d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_49e1cfdc-b23e-40f3-8a07-775570c8787d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_a6935378-e890-464f-ac07-267108e32171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f598ce42-c610-4095-aa82-5b1710a2aa6a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_a6935378-e890-464f-ac07-267108e32171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_22f2e354-0cd2-4e8f-b613-945029c702cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_HedgingDesignationAxis_22f2e354-0cd2-4e8f-b613-945029c702cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_40acfd7d-e8ed-4bbc-8c9c-4fae0e6be636" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_22f2e354-0cd2-4e8f-b613-945029c702cf" xlink:to="loc_us-gaap_HedgingDesignationDomain_40acfd7d-e8ed-4bbc-8c9c-4fae0e6be636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d2db6812-3f58-4d9f-952d-382dca52c82d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_40acfd7d-e8ed-4bbc-8c9c-4fae0e6be636" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d2db6812-3f58-4d9f-952d-382dca52c82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2686c8f6-a646-4ed5-b1c9-4fb6832f7658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_40acfd7d-e8ed-4bbc-8c9c-4fae0e6be636" xlink:to="loc_us-gaap_NondesignatedMember_2686c8f6-a646-4ed5-b1c9-4fb6832f7658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f322ca5-7014-4020-bcad-4160442045c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_srt_RangeAxis_0f322ca5-7014-4020-bcad-4160442045c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6edbd062-7e34-4f80-b5b2-fcc4dac88b3b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0f322ca5-7014-4020-bcad-4160442045c8" xlink:to="loc_srt_RangeMember_6edbd062-7e34-4f80-b5b2-fcc4dac88b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_378de9e6-057b-4c51-a77f-f7448df7a6dc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6edbd062-7e34-4f80-b5b2-fcc4dac88b3b" xlink:to="loc_srt_MinimumMember_378de9e6-057b-4c51-a77f-f7448df7a6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7099c10-6925-438a-af8a-95b88e67bca9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6edbd062-7e34-4f80-b5b2-fcc4dac88b3b" xlink:to="loc_srt_MaximumMember_a7099c10-6925-438a-af8a-95b88e67bca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_302b4d11-983f-451b-b8d2-58ce5c23ef08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_TypeOfArrangementAxis_302b4d11-983f-451b-b8d2-58ce5c23ef08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2df77776-2e47-4480-ab63-d889537d9772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_302b4d11-983f-451b-b8d2-58ce5c23ef08" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2df77776-2e47-4480-ab63-d889537d9772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1292c77d-aa7d-4bfb-bd80-aed19a3da864" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_2c140ddf-f15e-490d-89c7-7faaacf1c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_2c140ddf-f15e-490d-89c7-7faaacf1c6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_e305a5f6-5410-4121-88b9-7a716155d20c" xlink:href="biib-20240630.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_biib_UnrealizedGainOnDerivatives_e305a5f6-5410-4121-88b9-7a716155d20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_d990322c-3846-4f29-bf38-11e897b475f9" xlink:href="biib-20240630.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_biib_UnrealizedLossOnDerivatives_d990322c-3846-4f29-bf38-11e897b475f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_f9cff309-9c7f-4891-91bc-69b5533aff70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_f9cff309-9c7f-4891-91bc-69b5533aff70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_1de9d5ee-75ab-4e0d-91dc-cba8ab2ca058" xlink:href="biib-20240630.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_1de9d5ee-75ab-4e0d-91dc-cba8ab2ca058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_eba3cf84-e439-4219-a6c6-684b8f99dd89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_eba3cf84-e439-4219-a6c6-684b8f99dd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_e7876ca8-e3a2-46e8-8b4c-cc401cc67c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_e7876ca8-e3a2-46e8-8b4c-cc401cc67c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_6427852f-7e2a-429e-9d9f-20b97e1c8689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_DerivativeNotionalAmount_6427852f-7e2a-429e-9d9f-20b97e1c8689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_60358d95-00d6-4027-9572-298df0088b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_60358d95-00d6-4027-9572-298df0088b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bf6a1df4-8790-4dfd-8b4a-6000a39c128b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bf6a1df4-8790-4dfd-8b4a-6000a39c128b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_66e0cf86-e326-4db1-94a1-c4b457530ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_66e0cf86-e326-4db1-94a1-c4b457530ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_ad1d6f04-5ab6-4c3e-964a-09294dc83a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_ad1d6f04-5ab6-4c3e-964a-09294dc83a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1f502bbf-529d-477d-a7e3-5635715d0302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1c47de14-5dcb-4b3e-9672-4099f586d124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1f502bbf-529d-477d-a7e3-5635715d0302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0bac3626-b104-4d7b-a973-429c66d43fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0bac3626-b104-4d7b-a973-429c66d43fbe" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_4e67a5d1-5d6b-4141-a9f2-643246a573a8" xlink:href="biib-20240630.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:to="loc_biib_FacilityLocationAxis_4e67a5d1-5d6b-4141-a9f2-643246a573a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_5c68f425-d9c8-4095-ab52-dae34847c768" xlink:href="biib-20240630.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_4e67a5d1-5d6b-4141-a9f2-643246a573a8" xlink:to="loc_biib_FacilityLocationDomain_5c68f425-d9c8-4095-ab52-dae34847c768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_bc43b17e-ec67-4044-84a5-a37c35378e95" xlink:href="biib-20240630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_5c68f425-d9c8-4095-ab52-dae34847c768" xlink:to="loc_biib_SolothurnSwitzerlandMember_bc43b17e-ec67-4044-84a5-a37c35378e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_acbdc68c-175a-4fb5-812d-6ae386d3c73f" xlink:href="biib-20240630.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:to="loc_biib_FacilityTypeAxis_acbdc68c-175a-4fb5-812d-6ae386d3c73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:href="biib-20240630.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_acbdc68c-175a-4fb5-812d-6ae386d3c73f" xlink:to="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_dccdd32f-6e4a-4892-a71b-0c74c65b150f" xlink:href="biib-20240630.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:to="loc_biib_BiologicsManufacturingMember_dccdd32f-6e4a-4892-a71b-0c74c65b150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_df18b395-5e85-4c4e-8676-0a0d6115e164" xlink:href="biib-20240630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_df18b395-5e85-4c4e-8676-0a0d6115e164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_9137663c-d361-437c-8589-28e19a2adacc" xlink:href="biib-20240630.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_2d18ecbf-cffe-4535-9874-c761738800d3" xlink:to="loc_biib_AdministrativeSpaceMember_9137663c-d361-437c-8589-28e19a2adacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f1001ca-66f9-4e80-a25a-ce3b75d91df6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d19ac12-80e3-4f0a-a62c-cb6e2b605613" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d19ac12-80e3-4f0a-a62c-cb6e2b605613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ec7eab0f-145b-4f27-937c-1d712ef8cae9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_Depreciation_ec7eab0f-145b-4f27-937c-1d712ef8cae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_8d7a98da-1ff5-4d76-b9c0-f1990ef40078" xlink:href="biib-20240630.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_biib_NumberOfSquareFeet_8d7a98da-1ff5-4d76-b9c0-f1990ef40078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_9da3aedb-a52d-4cc1-8fb6-81d79bddc958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_ConstructionInProgressGross_9da3aedb-a52d-4cc1-8fb6-81d79bddc958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_07a05ab6-1d43-4cc4-b040-885893962c06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_07a05ab6-1d43-4cc4-b040-885893962c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_cee5d6c8-4f9e-4b72-96c1-f46165a9b3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd1f83c4-b022-4810-8fc9-f66b4c12c2d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_cee5d6c8-4f9e-4b72-96c1-f46165a9b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#LeasesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2b655efa-d314-4650-8698-993bc421ad09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1ea8de92-b222-4963-9818-0711879aa748" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b655efa-d314-4650-8698-993bc421ad09" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1ea8de92-b222-4963-9818-0711879aa748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_908a6432-b516-4b76-8672-64e5e9444195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1ea8de92-b222-4963-9818-0711879aa748" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_908a6432-b516-4b76-8672-64e5e9444195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23cd5a17-7379-4031-860a-ee1d3daf84b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_908a6432-b516-4b76-8672-64e5e9444195" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23cd5a17-7379-4031-860a-ee1d3daf84b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_65440dc1-4ede-4da4-92e1-20077389df06" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23cd5a17-7379-4031-860a-ee1d3daf84b4" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_65440dc1-4ede-4da4-92e1-20077389df06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1ea8de92-b222-4963-9818-0711879aa748" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_293ad221-3c1b-417e-bf57-9b57ca808ca8" xlink:href="biib-20240630.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_biib_OperatingLeaseArea_293ad221-3c1b-417e-bf57-9b57ca808ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0c7f7976-40e5-4b4b-a4f5-3da6716d812f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0c7f7976-40e5-4b4b-a4f5-3da6716d812f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_2e38304d-6f45-465e-8d98-a224b395cabb" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_2e38304d-6f45-465e-8d98-a224b395cabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_985475cb-628d-4f57-b77d-6546a2eda662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_985475cb-628d-4f57-b77d-6546a2eda662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_b371efbf-955c-4dfd-aa66-33a36eda77fe" xlink:href="biib-20240630.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e838e0c4-2bcc-4f89-a2c3-5de0b1682f2a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_b371efbf-955c-4dfd-aa66-33a36eda77fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_df909f16-5d1a-4333-88f1-b1a5b3f7eea6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_df909f16-5d1a-4333-88f1-b1a5b3f7eea6" xlink:to="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_73b3e507-977b-4351-8ee5-fce3c56648ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_DebtInstrumentAxis_73b3e507-977b-4351-8ee5-fce3c56648ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_73b3e507-977b-4351-8ee5-fce3c56648ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_2691e95c-7a24-4ae9-af58-435bab5a8c9a" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_2691e95c-7a24-4ae9-af58-435bab5a8c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_41b314e0-3a70-42b3-81ae-f9d8b0008c2e" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_41b314e0-3a70-42b3-81ae-f9d8b0008c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember_1ebb1948-0450-415a-b10e-bdd14e6f5c4e" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_TheCreditFacilityTerminatedMember_1ebb1948-0450-415a-b10e-bdd14e6f5c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_20b38601-6144-4006-bb26-34ff07e88913" xlink:href="biib-20240630.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_TheCreditFacilityMember_20b38601-6144-4006-bb26-34ff07e88913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember_1137be18-055f-45cd-b05c-a54d7cc62b60" xlink:href="biib-20240630.xsd#biib_A2023TermLoanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ff084eb-15c4-403e-a1f3-13f65846c3a2" xlink:to="loc_biib_A2023TermLoanMember_1137be18-055f-45cd-b05c-a54d7cc62b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e374d48c-b9a7-47f4-a09b-8671c48e75d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e374d48c-b9a7-47f4-a09b-8671c48e75d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_39c52fbf-8537-44ca-8342-8383edf11147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e374d48c-b9a7-47f4-a09b-8671c48e75d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_39c52fbf-8537-44ca-8342-8383edf11147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b842d679-8a53-4cc1-82c8-47f9118900db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_39c52fbf-8537-44ca-8342-8383edf11147" xlink:to="loc_us-gaap_LineOfCreditMember_b842d679-8a53-4cc1-82c8-47f9118900db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_621a10f4-90fc-4018-9426-6c3f69449c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_CreditFacilityAxis_621a10f4-90fc-4018-9426-6c3f69449c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_621a10f4-90fc-4018-9426-6c3f69449c50" xlink:to="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_bbc36097-f39e-464d-8905-2e55979e341f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:to="loc_us-gaap_SecuredDebtMember_bbc36097-f39e-464d-8905-2e55979e341f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember_7ea45a70-6196-4f14-a592-6068c365045a" xlink:href="biib-20240630.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:to="loc_biib_FloatingRate364DayTrancheMember_7ea45a70-6196-4f14-a592-6068c365045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_81662cc1-afbd-4144-9833-47f2b5189b5e" xlink:href="biib-20240630.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8fd13090-0ed0-4b6d-ac72-acc9e3c3ca61" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_81662cc1-afbd-4144-9833-47f2b5189b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f374b718-7fa7-4297-b190-ea98d1882136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f374b718-7fa7-4297-b190-ea98d1882136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967940ec-2330-43c7-8d66-b389ca0a40f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f374b718-7fa7-4297-b190-ea98d1882136" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967940ec-2330-43c7-8d66-b389ca0a40f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_0cf82075-eb39-45c3-8a73-54ebb0371c93" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967940ec-2330-43c7-8d66-b389ca0a40f3" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_0cf82075-eb39-45c3-8a73-54ebb0371c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4a2c1def-2041-49aa-abcc-a0b742cced16" xlink:to="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4ba14944-6ca1-4b68-8db6-4f845228b4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4ba14944-6ca1-4b68-8db6-4f845228b4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_de5d530c-b09e-42cf-abeb-cffaf142821c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_de5d530c-b09e-42cf-abeb-cffaf142821c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_6f74b9bc-7d0a-47c9-9f74-b2c07072ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97409cad-0043-47f3-98ea-1a9122821d1e" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_6f74b9bc-7d0a-47c9-9f74-b2c07072ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2a3b27f9-b894-4e45-bb59-b8b7829dd84b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_95ebbd94-687f-4825-abdd-50968351c88a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2a3b27f9-b894-4e45-bb59-b8b7829dd84b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_95ebbd94-687f-4825-abdd-50968351c88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_bd75bb69-e30c-497a-9f09-180e2249a697" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_95ebbd94-687f-4825-abdd-50968351c88a" xlink:to="loc_srt_ShareRepurchaseProgramAxis_bd75bb69-e30c-497a-9f09-180e2249a697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_b8815dd7-440f-43da-97ca-b1319f49e90a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_bd75bb69-e30c-497a-9f09-180e2249a697" xlink:to="loc_srt_ShareRepurchaseProgramDomain_b8815dd7-440f-43da-97ca-b1319f49e90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_57e00fb5-1253-417b-b48e-f2f0ab874e03" xlink:href="biib-20240630.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_b8815dd7-440f-43da-97ca-b1319f49e90a" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_57e00fb5-1253-417b-b48e-f2f0ab874e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b78e7698-07d9-489e-9492-7ead5af3c7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_95ebbd94-687f-4825-abdd-50968351c88a" xlink:to="loc_us-gaap_ClassOfStockLineItems_b78e7698-07d9-489e-9492-7ead5af3c7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_71ea88be-c70c-425d-821d-0a378a77e8f0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b78e7698-07d9-489e-9492-7ead5af3c7c7" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_71ea88be-c70c-425d-821d-0a378a77e8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_3d57d284-2d10-40c0-a9e4-20c6bca40bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b78e7698-07d9-489e-9492-7ead5af3c7c7" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_3d57d284-2d10-40c0-a9e4-20c6bca40bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c4c24f53-a0f3-429e-98c8-e09ac4db9126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_33f585f1-91d8-4f55-9082-59d026ef1d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c4c24f53-a0f3-429e-98c8-e09ac4db9126" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_33f585f1-91d8-4f55-9082-59d026ef1d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37c329a8-2a3a-40c1-b93a-5e70ea6d8769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_33f585f1-91d8-4f55-9082-59d026ef1d1e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37c329a8-2a3a-40c1-b93a-5e70ea6d8769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37c329a8-2a3a-40c1-b93a-5e70ea6d8769" xlink:to="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a5770077-9209-4499-9847-e3c0efd2d5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a5770077-9209-4499-9847-e3c0efd2d5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_94f5acc3-293e-4fc8-b96c-b18f03f19c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_94f5acc3-293e-4fc8-b96c-b18f03f19c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_fbe02460-8117-4eb3-8b36-67f08e44b201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_fbe02460-8117-4eb3-8b36-67f08e44b201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ea8c2e81-4c76-432c-b518-f2bc86a312d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ef1f10a-e728-4a70-aac7-ab018630d5d4" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ea8c2e81-4c76-432c-b518-f2bc86a312d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_33f585f1-91d8-4f55-9082-59d026ef1d1e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e6bc31a9-6cd4-46c4-850d-4406e8dd3a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e6bc31a9-6cd4-46c4-850d-4406e8dd3a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_230b7c23-b68c-40cd-89cf-f71a9c89791c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_230b7c23-b68c-40cd-89cf-f71a9c89791c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a81a3303-8f2c-4d90-bb31-71038f3c1afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a81a3303-8f2c-4d90-bb31-71038f3c1afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1e8d8932-abdb-4fa4-b978-6c75e3eff719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1e8d8932-abdb-4fa4-b978-6c75e3eff719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a9fdce9-ac7e-4c47-8dfd-5c4478e24db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a9fdce9-ac7e-4c47-8dfd-5c4478e24db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8984995b-3772-4081-8736-a36019175f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8984995b-3772-4081-8736-a36019175f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2481af88-ca88-4aec-a10e-2bb874aae6af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bec01ad3-e204-4806-93b8-7b45bd6db73d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2481af88-ca88-4aec-a10e-2bb874aae6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_00b29a40-c4bf-4450-a83c-214b310163c3" xlink:href="biib-20240630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_00b29a40-c4bf-4450-a83c-214b310163c3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e79f582c-3b76-4b56-a33f-941bf3d2de2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e79f582c-3b76-4b56-a33f-941bf3d2de2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0026cf25-ad5b-4771-86c0-c20a677831ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e79f582c-3b76-4b56-a33f-941bf3d2de2c" xlink:to="loc_us-gaap_EquityComponentDomain_0026cf25-ad5b-4771-86c0-c20a677831ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e665190f-6c71-4994-945b-1f5f4755a3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0026cf25-ad5b-4771-86c0-c20a677831ee" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e665190f-6c71-4994-945b-1f5f4755a3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_577643f4-52bc-4818-969d-91891a8649f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0026cf25-ad5b-4771-86c0-c20a677831ee" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_577643f4-52bc-4818-969d-91891a8649f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6b5d32a6-db85-4a81-b867-b7714adae9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6b5d32a6-db85-4a81-b867-b7714adae9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cdf9dbaf-c37c-472b-a880-80ee8d8d47ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6b5d32a6-db85-4a81-b867-b7714adae9c2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cdf9dbaf-c37c-472b-a880-80ee8d8d47ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_edff8cf6-7f76-4bee-893d-282508428828" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cdf9dbaf-c37c-472b-a880-80ee8d8d47ad" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_edff8cf6-7f76-4bee-893d-282508428828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d55393cd-c12c-4401-a72d-15cbed59a1bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d55393cd-c12c-4401-a72d-15cbed59a1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b6575378-3520-46ec-894f-da53a9d0f1b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d55393cd-c12c-4401-a72d-15cbed59a1bd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b6575378-3520-46ec-894f-da53a9d0f1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_16740855-2215-430f-b3f5-0d4eae340480" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b6575378-3520-46ec-894f-da53a9d0f1b9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_16740855-2215-430f-b3f5-0d4eae340480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6c865f61-e755-46ac-850e-fa7075a14f82" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_235986fa-e630-4951-8b90-6db014f3ec28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_235986fa-e630-4951-8b90-6db014f3ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fcd188c3-4df1-4f31-bcc7-99bc5af28268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fcd188c3-4df1-4f31-bcc7-99bc5af28268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2e667ae9-8458-45d2-a806-8ae666888e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_Revenues_2e667ae9-8458-45d2-a806-8ae666888e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_91ba29ad-b020-49cb-b8f8-0190ed8156ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_OperatingExpenses_91ba29ad-b020-49cb-b8f8-0190ed8156ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb0c5db9-4fd4-4ce1-b0c3-ca1f8d9c46e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_NetIncomeLoss_eb0c5db9-4fd4-4ce1-b0c3-ca1f8d9c46e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fcbe0b1a-10df-4106-8560-4c4e7b5941ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b7a18abb-157c-43ad-b303-536cf3eeb344" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fcbe0b1a-10df-4106-8560-4c4e7b5941ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_322e73d1-3071-4dc3-809a-a7977c2b3661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_457237d8-f076-4e80-9661-475a78b3f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_322e73d1-3071-4dc3-809a-a7977c2b3661" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_457237d8-f076-4e80-9661-475a78b3f09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf561f01-4713-43b7-a24c-4ef343347ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_457237d8-f076-4e80-9661-475a78b3f09d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf561f01-4713-43b7-a24c-4ef343347ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf561f01-4713-43b7-a24c-4ef343347ed4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_2df161d2-c28e-4752-8f7d-dcbba642aebc" xlink:href="biib-20240630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_2df161d2-c28e-4752-8f7d-dcbba642aebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_5b3ae2c3-18bf-4220-9b22-e66770adc63d" xlink:href="biib-20240630.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:to="loc_biib_MarketStockUnitsMember_5b3ae2c3-18bf-4220-9b22-e66770adc63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_15848b74-9c7c-4873-b7aa-d09b51d8c7c6" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7baa6aa-c341-4419-bed5-7841d3b1e64f" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_15848b74-9c7c-4873-b7aa-d09b51d8c7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57ba6632-06bc-4ca1-9765-8fb128330b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_457237d8-f076-4e80-9661-475a78b3f09d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57ba6632-06bc-4ca1-9765-8fb128330b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d532eed1-8d1d-461a-93e0-e3e028799cf4" xlink:href="biib-20240630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57ba6632-06bc-4ca1-9765-8fb128330b6b" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d532eed1-8d1d-461a-93e0-e3e028799cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_271050b9-cbaf-4ce6-925a-cbb603d4dcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d532eed1-8d1d-461a-93e0-e3e028799cf4" xlink:to="loc_us-gaap_NetIncomeLossAbstract_271050b9-cbaf-4ce6-925a-cbb603d4dcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f25ba3c4-cd00-4b2a-82c8-3d8e637441dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_271050b9-cbaf-4ce6-925a-cbb603d4dcd9" xlink:to="loc_us-gaap_NetIncomeLoss_f25ba3c4-cd00-4b2a-82c8-3d8e637441dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d532eed1-8d1d-461a-93e0-e3e028799cf4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_743317ac-ab02-4ba3-8e93-5f2b53e66310" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_743317ac-ab02-4ba3-8e93-5f2b53e66310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_ae26bfa0-d102-459d-883e-5745ed4c7e77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_ae26bfa0-d102-459d-883e-5745ed4c7e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_901ff6bc-3435-438a-a3c7-3f4dd1bf781b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_ae26bfa0-d102-459d-883e-5745ed4c7e77" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_901ff6bc-3435-438a-a3c7-3f4dd1bf781b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ddacecbb-f341-4e6c-82e9-021a86ca592d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_ae26bfa0-d102-459d-883e-5745ed4c7e77" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ddacecbb-f341-4e6c-82e9-021a86ca592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5933716-230d-47dc-94b8-e8d8e32d205a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c28d667-7dd8-4e7a-8d19-d1b6ee17bb07" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5933716-230d-47dc-94b8-e8d8e32d205a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5aabf297-8782-4f78-8aff-f8cb4ae6ddf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5aabf297-8782-4f78-8aff-f8cb4ae6ddf9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_67075d1a-62f2-430c-8d21-8c06edb693df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_67075d1a-62f2-430c-8d21-8c06edb693df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_67075d1a-62f2-430c-8d21-8c06edb693df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c202c0a6-784e-4239-b41e-2761ba348207" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c202c0a6-784e-4239-b41e-2761ba348207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_39d750f3-dde2-4308-8635-0bd9269000fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_39d750f3-dde2-4308-8635-0bd9269000fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_b1087ce0-5108-4701-927e-2e8f3987c438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_99ec69b6-25a6-4b0d-ba61-9ce5ca04a3d7" xlink:to="loc_us-gaap_ParentMember_b1087ce0-5108-4701-927e-2e8f3987c438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dbd676b2-6989-43b1-8c9e-16844c0e1709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dbd676b2-6989-43b1-8c9e-16844c0e1709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04384318-d017-43b9-9cd1-00dc269bec2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dbd676b2-6989-43b1-8c9e-16844c0e1709" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04384318-d017-43b9-9cd1-00dc269bec2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_3b82fbd6-f92c-4e3a-8534-9babadafac94" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04384318-d017-43b9-9cd1-00dc269bec2d" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_3b82fbd6-f92c-4e3a-8534-9babadafac94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a8c78b2-dd26-48ba-9734-12db60577ce4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24120813-557c-4b76-9aa5-15392d0b963b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24120813-557c-4b76-9aa5-15392d0b963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_047e25c9-70fb-480c-b0a7-2bd373be5200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_047e25c9-70fb-480c-b0a7-2bd373be5200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_25c970c3-6073-4d57-ac5b-b9c5ae15f755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_25c970c3-6073-4d57-ac5b-b9c5ae15f755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2a03fbd5-012e-4aa4-8913-f71ebb554b5a" xlink:href="biib-20240630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2a03fbd5-012e-4aa4-8913-f71ebb554b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d12512bb-64a9-41b5-ab78-ccf1f94f8036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_21d98f88-4183-4df7-b5cb-d2eb4d3eb117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d12512bb-64a9-41b5-ab78-ccf1f94f8036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b8d7cab8-1a4d-4da6-a961-802482cc491e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_OperatingExpenses_b8d7cab8-1a4d-4da6-a961-802482cc491e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_515c0182-8397-463f-9a4c-3a6b9c82bbee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_515c0182-8397-463f-9a4c-3a6b9c82bbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_99a74d73-4f32-4722-b1ca-92d177091d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_472fdeb9-52e9-4f08-b7c4-1a41baea075f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_99a74d73-4f32-4722-b1ca-92d177091d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18c7e0d4-fa0e-4958-9045-6f8d4bb0c326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18c7e0d4-fa0e-4958-9045-6f8d4bb0c326" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83e3f55b-f641-424a-af92-acf2292ffb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:to="loc_us-gaap_AwardTypeAxis_83e3f55b-f641-424a-af92-acf2292ffb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_83e3f55b-f641-424a-af92-acf2292ffb5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_350c0c4a-fa50-4b93-80b5-16b1e35fb3f1" xlink:href="biib-20240630.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_MarketStockUnitsMember_350c0c4a-fa50-4b93-80b5-16b1e35fb3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_1627daac-c450-4303-a8e9-3dfb47df9c6c" xlink:href="biib-20240630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_1627daac-c450-4303-a8e9-3dfb47df9c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_1b47f5b4-31f9-4263-94d3-75d1c1e8c4b7" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_1b47f5b4-31f9-4263-94d3-75d1c1e8c4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_805d74f3-c84f-4843-b5cb-cf43e0fc1c43" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_805d74f3-c84f-4843-b5cb-cf43e0fc1c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_670ca511-3ee8-4b32-b90d-b08ffc8dbf9c" xlink:href="biib-20240630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_670ca511-3ee8-4b32-b90d-b08ffc8dbf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b25c7b55-d8a8-4b2e-a3bd-03dd23a7fc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_413c9a17-4ed2-4194-a034-89f360375740" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b25c7b55-d8a8-4b2e-a3bd-03dd23a7fc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6573ece0-ffe0-47ea-81ba-0ba78939982c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6573ece0-ffe0-47ea-81ba-0ba78939982c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e1b98c8-44fb-4fc4-a2be-1a24a5f22d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6573ece0-ffe0-47ea-81ba-0ba78939982c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e1b98c8-44fb-4fc4-a2be-1a24a5f22d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_9c13ea6d-cd86-4464-8cb5-efe0359cc7f6" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e1b98c8-44fb-4fc4-a2be-1a24a5f22d4b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_9c13ea6d-cd86-4464-8cb5-efe0359cc7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_240ca4fb-079a-4867-b574-f88654a5de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c34a8ab6-f7d2-42c0-a25b-bcfd81643af3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_240ca4fb-079a-4867-b574-f88654a5de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:href="biib-20240630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_240ca4fb-079a-4867-b574-f88654a5de4a" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ed46ff72-a5e8-4d96-a3fe-e17ff9c53c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ed46ff72-a5e8-4d96-a3fe-e17ff9c53c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55b43710-7724-4619-8a0f-26074c738e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55b43710-7724-4619-8a0f-26074c738e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cdc5cc1f-cf43-4813-a17d-31be145c0f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cdc5cc1f-cf43-4813-a17d-31be145c0f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_715d1512-8deb-4d8b-99ba-7e17adf3cc23" xlink:href="biib-20240630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_496b47e1-0165-40d9-9c82-167aa9fd85fa" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_715d1512-8deb-4d8b-99ba-7e17adf3cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#SharebasedPaymentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07a7d086-9f1d-4949-8947-0be91003cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f6573c11-c69d-4047-9885-d796c748f128" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07a7d086-9f1d-4949-8947-0be91003cafa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f6573c11-c69d-4047-9885-d796c748f128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_670cbdb5-1686-47e9-b131-7c6501f0392b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f6573c11-c69d-4047-9885-d796c748f128" xlink:to="loc_us-gaap_PlanNameAxis_670cbdb5-1686-47e9-b131-7c6501f0392b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b888b8bb-e93e-4302-af11-3c84b7138059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_670cbdb5-1686-47e9-b131-7c6501f0392b" xlink:to="loc_us-gaap_PlanNameDomain_b888b8bb-e93e-4302-af11-3c84b7138059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OmnibusEquityPlan2024Member_4b26ddd9-229d-4275-8b52-2c7ae5f75d2f" xlink:href="biib-20240630.xsd#biib_OmnibusEquityPlan2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b888b8bb-e93e-4302-af11-3c84b7138059" xlink:to="loc_biib_OmnibusEquityPlan2024Member_4b26ddd9-229d-4275-8b52-2c7ae5f75d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f6573c11-c69d-4047-9885-d796c748f128" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28173464-23fd-4a35-97c8-0a76e5c6edc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28173464-23fd-4a35-97c8-0a76e5c6edc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_7a801d2d-42e4-468f-b8a9-8db1a9526754" xlink:href="biib-20240630.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_7a801d2d-42e4-468f-b8a9-8db1a9526754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e078422-66d5-41f8-a79a-d09f5fe5f35b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_791e126f-db47-4d5f-91ba-1831e9416271" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e078422-66d5-41f8-a79a-d09f5fe5f35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_67d0ab73-69e7-4d05-8f99-8050f24bb879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_67d0ab73-69e7-4d05-8f99-8050f24bb879" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b003fdf0-7dad-411e-87e0-2655e1eed613" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:to="loc_srt_StatementScenarioAxis_b003fdf0-7dad-411e-87e0-2655e1eed613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_caa5079d-0671-4110-b27c-d94f7855c277" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b003fdf0-7dad-411e-87e0-2655e1eed613" xlink:to="loc_srt_ScenarioUnspecifiedDomain_caa5079d-0671-4110-b27c-d94f7855c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5f4d63a7-3683-4571-b367-a4848b53d7ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_caa5079d-0671-4110-b27c-d94f7855c277" xlink:to="loc_srt_ScenarioForecastMember_5f4d63a7-3683-4571-b367-a4848b53d7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_104661ff-27ae-4aba-adb3-7feba8695694" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_104661ff-27ae-4aba-adb3-7feba8695694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b3c4d4cd-1fa2-4147-85f2-85b14ffc2260" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_104661ff-27ae-4aba-adb3-7feba8695694" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b3c4d4cd-1fa2-4147-85f2-85b14ffc2260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_373692a5-e5e3-4ad0-b051-fcaca2445286" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b3c4d4cd-1fa2-4147-85f2-85b14ffc2260" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_373692a5-e5e3-4ad0-b051-fcaca2445286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_65df1d95-a5ff-4c37-9db4-f7adcd3cda1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f9193885-71f1-4397-971e-25d93d28d1bc" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_65df1d95-a5ff-4c37-9db4-f7adcd3cda1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_a483159b-ad59-4a19-bcf0-5b113dc67141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_65df1d95-a5ff-4c37-9db4-f7adcd3cda1f" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_a483159b-ad59-4a19-bcf0-5b113dc67141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a4ad8a5f-a464-4d81-a83c-1b5a1b0a44ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a4ad8a5f-a464-4d81-a83c-1b5a1b0a44ad" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ca6b988c-b622-4a8d-ab91-46ac04d1dff7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ca6b988c-b622-4a8d-ab91-46ac04d1dff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e24ae1af-d9ff-490f-adb2-dd98ae6a0015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e24ae1af-d9ff-490f-adb2-dd98ae6a0015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_418b2c21-336d-4bd2-b71c-4869b29a2139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_418b2c21-336d-4bd2-b71c-4869b29a2139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_915282f6-66c1-463a-ad14-573ab95d0203" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_915282f6-66c1-463a-ad14-573ab95d0203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_da35145a-56f0-4a62-ba2a-4f6701c1780d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_da35145a-56f0-4a62-ba2a-4f6701c1780d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_79651cfb-443f-4e39-a85a-f6fafb3230a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_79651cfb-443f-4e39-a85a-f6fafb3230a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9248ea7c-57eb-433a-b06d-3bb9cb4c927a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9248ea7c-57eb-433a-b06d-3bb9cb4c927a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b6b22836-0386-4f9b-8df5-da88f4875ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a554e05e-de12-4ed1-b4a9-eeabf2bcca6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b6b22836-0386-4f9b-8df5-da88f4875ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ebed923f-d1c7-4721-aa48-8c9629cb276a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ebed923f-d1c7-4721-aa48-8c9629cb276a" xlink:to="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a8c09f48-5d3f-47a5-9ce3-794ce4fef573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a8c09f48-5d3f-47a5-9ce3-794ce4fef573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2d98f2a0-bafe-4b60-b061-05645144dd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a8c09f48-5d3f-47a5-9ce3-794ce4fef573" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2d98f2a0-bafe-4b60-b061-05645144dd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_c4d9ee6c-1025-4542-817c-55c1cf25f63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2d98f2a0-bafe-4b60-b061-05645144dd3f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_c4d9ee6c-1025-4542-817c-55c1cf25f63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_55bb62e5-a364-4684-a67d-744e7efb5f98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:to="loc_dei_LegalEntityAxis_55bb62e5-a364-4684-a67d-744e7efb5f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c9394315-a6a9-423a-a904-a5b99a6ef0ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_55bb62e5-a364-4684-a67d-744e7efb5f98" xlink:to="loc_dei_EntityDomain_c9394315-a6a9-423a-a904-a5b99a6ef0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_665b10cf-30ca-4555-8dbc-3ae067e489d9" xlink:href="biib-20240630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c9394315-a6a9-423a-a904-a5b99a6ef0ba" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_665b10cf-30ca-4555-8dbc-3ae067e489d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8904aa17-111d-4c16-a723-561edfc3335d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8904aa17-111d-4c16-a723-561edfc3335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3f024896-90de-4416-91e5-1ab9988e68d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8904aa17-111d-4c16-a723-561edfc3335d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3f024896-90de-4416-91e5-1ab9988e68d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_79741fa7-a909-47b9-bb50-e04a8d7e592d" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3f024896-90de-4416-91e5-1ab9988e68d4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_79741fa7-a909-47b9-bb50-e04a8d7e592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3756abb0-1536-4817-be8a-23eb2dcf746b" xlink:to="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_528530bf-4b84-4b49-90a6-f38d5dd5a829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_528530bf-4b84-4b49-90a6-f38d5dd5a829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9efbf3d2-daa7-43ab-8cf1-5db021eec108" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_InterestExpense_9efbf3d2-daa7-43ab-8cf1-5db021eec108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_338af6b4-daf8-4723-bfaa-31ed88554df0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_338af6b4-daf8-4723-bfaa-31ed88554df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_23154b04-fb55-424a-ab03-c51b6a1ad3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_23154b04-fb55-424a-ab03-c51b6a1ad3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d2fd122d-6404-43c0-b105-44887d51be12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d2fd122d-6404-43c0-b105-44887d51be12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1966c744-d54e-4b47-a8af-db582d69bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ae7a5df-1c37-4835-8260-7dd479444ea1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1966c744-d54e-4b47-a8af-db582d69bed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_782d09a1-c33d-4eb6-aa00-b6b63a0db8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_782d09a1-c33d-4eb6-aa00-b6b63a0db8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_6db93fa0-5291-415a-91cb-a9d5fce3352b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_6db93fa0-5291-415a-91cb-a9d5fce3352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_da3acff9-3820-4276-a88d-11192dea5f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_54eb1444-d9c2-4407-864c-031ee669364e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_da3acff9-3820-4276-a88d-11192dea5f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_819408e4-f181-45c8-ae4c-948ebae18c11" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_993fe9f4-75e6-4698-98f5-5ae14fd4c490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_993fe9f4-75e6-4698-98f5-5ae14fd4c490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_aa79d243-1378-461c-96e2-ba8d344655d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_aa79d243-1378-461c-96e2-ba8d344655d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_056eb2ef-934c-40b7-a9af-4ac6d2a54d32" xlink:href="biib-20240630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_biib_Collaborationexpensesaccrual_056eb2ef-934c-40b7-a9af-4ac6d2a54d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_f9c3c14a-426d-4394-990a-d5695cf148ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_f9c3c14a-426d-4394-990a-d5695cf148ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_e3d7b154-d00e-46a6-84fb-35bf6ebe45fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_e3d7b154-d00e-46a6-84fb-35bf6ebe45fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2767cab3-621e-4098-b883-d8c1ab7adbed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2767cab3-621e-4098-b883-d8c1ab7adbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f6154b10-9c74-44ab-9547-30758d4a0236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2c730740-7835-4255-baf3-43e965952dad" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f6154b10-9c74-44ab-9547-30758d4a0236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20240630.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1a5d309-1cdd-4f72-ab33-53c8b11526d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1a5d309-1cdd-4f72-ab33-53c8b11526d1" xlink:to="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_331be4d3-a38e-4c00-9629-b5a590aa8994" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:to="loc_dei_LegalEntityAxis_331be4d3-a38e-4c00-9629-b5a590aa8994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_331be4d3-a38e-4c00-9629-b5a590aa8994" xlink:to="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_a6f2d130-eba9-49a2-ade2-5ef6be0462c2" xlink:href="biib-20240630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_a6f2d130-eba9-49a2-ade2-5ef6be0462c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoMember_66787e5d-fbb3-4d54-ade2-74c40b6603d8" xlink:href="biib-20240630.xsd#biib_SangamoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:to="loc_biib_SangamoMember_66787e5d-fbb3-4d54-ade2-74c40b6603d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_96a1bdad-d978-42f5-a70b-0194357669ad" xlink:href="biib-20240630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_727b1bda-4223-499f-a4cf-16371cd38de7" xlink:to="loc_biib_SageTherapeuticsIncMember_96a1bdad-d978-42f5-a70b-0194357669ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47330f29-3e93-43cb-90e5-1ad8f50d815b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ded7bb0a-ed53-48b9-a70d-b3bebd4e30d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47330f29-3e93-43cb-90e5-1ad8f50d815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_6326a7a5-89a2-4d04-a7b1-f39d3dc6528b" xlink:href="biib-20240630.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47330f29-3e93-43cb-90e5-1ad8f50d815b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_6326a7a5-89a2-4d04-a7b1-f39d3dc6528b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4dcec18f-1a0e-4584-8e8d-846befffc274" xlink:to="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0e73c09-cdfb-4a21-90ed-136034ffa52f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0e73c09-cdfb-4a21-90ed-136034ffa52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_bf0b71df-4f66-4bd0-9865-0199f21bd516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_bf0b71df-4f66-4bd0-9865-0199f21bd516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5135f447-232c-4d94-bdb6-c973c8d0ebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5135f447-232c-4d94-bdb6-c973c8d0ebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_235b6a6a-11f2-433c-bcdc-b094926c160e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_235b6a6a-11f2-433c-bcdc-b094926c160e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_07ad7f0a-d406-4dad-b141-e7b43f01c009" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a553254-d620-4571-a355-15de9c80dd2b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_07ad7f0a-d406-4dad-b141-e7b43f01c009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3be238f-cf2f-474a-8478-13e7877cfa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3be238f-cf2f-474a-8478-13e7877cfa0f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38ab3009-810a-4b42-8aba-744d7488a0b1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:to="loc_srt_ProductOrServiceAxis_38ab3009-810a-4b42-8aba-744d7488a0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91a2a042-a8f1-4e7c-98ef-1019d4d3f1fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_38ab3009-810a-4b42-8aba-744d7488a0b1" xlink:to="loc_srt_ProductsAndServicesDomain_91a2a042-a8f1-4e7c-98ef-1019d4d3f1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_81f3e2cf-b62b-4eb7-b45f-2cc824d9fe8e" xlink:href="biib-20240630.xsd#biib_OCREVUSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_91a2a042-a8f1-4e7c-98ef-1019d4d3f1fd" xlink:to="loc_biib_OCREVUSMember_81f3e2cf-b62b-4eb7-b45f-2cc824d9fe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember_0c2e01f8-2369-42e8-8a8b-3a41f168641a" xlink:href="biib-20240630.xsd#biib_MosunetuzumabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_91a2a042-a8f1-4e7c-98ef-1019d4d3f1fd" xlink:to="loc_biib_MosunetuzumabMember_0c2e01f8-2369-42e8-8a8b-3a41f168641a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5135de98-3c58-4957-b171-60c771e67d29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:to="loc_srt_RangeAxis_5135de98-3c58-4957-b171-60c771e67d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d004e96f-53fc-4426-92bb-a44f6a00afbd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5135de98-3c58-4957-b171-60c771e67d29" xlink:to="loc_srt_RangeMember_d004e96f-53fc-4426-92bb-a44f6a00afbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e444a5af-2e85-4182-8c01-4c7a2a5c4277" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d004e96f-53fc-4426-92bb-a44f6a00afbd" xlink:to="loc_srt_MinimumMember_e444a5af-2e85-4182-8c01-4c7a2a5c4277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_23b21987-a547-4aed-84a2-fb6254bd88e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d004e96f-53fc-4426-92bb-a44f6a00afbd" xlink:to="loc_srt_MaximumMember_23b21987-a547-4aed-84a2-fb6254bd88e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_87c54be2-2a39-4d8d-b127-b251c64cd8a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:to="loc_srt_StatementGeographicalAxis_87c54be2-2a39-4d8d-b127-b251c64cd8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_81746452-9c01-42f6-8fbb-d1b2c019ec5e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_87c54be2-2a39-4d8d-b127-b251c64cd8a8" xlink:to="loc_srt_SegmentGeographicalDomain_81746452-9c01-42f6-8fbb-d1b2c019ec5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_248bcfb6-36be-467f-a69d-10025d747b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_81746452-9c01-42f6-8fbb-d1b2c019ec5e" xlink:to="loc_us-gaap_ForeignCountryMember_248bcfb6-36be-467f-a69d-10025d747b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4cda15a-e085-43d8-aa2c-a2e4d9921330" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_92b319aa-3565-44ea-be36-36cb08c289e6" xlink:href="biib-20240630.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_92b319aa-3565-44ea-be36-36cb08c289e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_0a7941ea-cb0f-45b7-bb28-29f53dee49bb" xlink:href="biib-20240630.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_0a7941ea-cb0f-45b7-bb28-29f53dee49bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_5126839f-6846-4b03-b9f7-8b29a4615e84" xlink:href="biib-20240630.xsd#biib_Reductioninroyaltyrate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_Reductioninroyaltyrate_5126839f-6846-4b03-b9f7-8b29a4615e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_eaa81581-5b11-4798-8ad1-133be6ad7aef" xlink:href="biib-20240630.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_PeriodOfCollaborationAgreement_eaa81581-5b11-4798-8ad1-133be6ad7aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts_c6dfe22b-7a1c-411c-be54-1a1f963767cc" xlink:href="biib-20240630.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_172e99fe-48d4-4f43-9886-16bdbd632298" xlink:to="loc_biib_PercentageOfFutureDevelopmentCosts_c6dfe22b-7a1c-411c-be54-1a1f963767cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6af9c58-a1bd-462b-be15-4cab35985eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bfb33cf-fbb7-4a9c-8067-c5b07c7d6d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6af9c58-a1bd-462b-be15-4cab35985eb3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bfb33cf-fbb7-4a9c-8067-c5b07c7d6d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b0471a0e-6701-43cb-8479-525a6ac64e4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bfb33cf-fbb7-4a9c-8067-c5b07c7d6d83" xlink:to="loc_srt_ProductOrServiceAxis_b0471a0e-6701-43cb-8479-525a6ac64e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1de777ff-bb42-40ad-88ba-02dbf53a3c85" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b0471a0e-6701-43cb-8479-525a6ac64e4a" xlink:to="loc_srt_ProductsAndServicesDomain_1de777ff-bb42-40ad-88ba-02dbf53a3c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_62be4653-e46e-47df-b34b-849536147463" xlink:href="biib-20240630.xsd#biib_RituxanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1de777ff-bb42-40ad-88ba-02dbf53a3c85" xlink:to="loc_biib_RituxanMember_62be4653-e46e-47df-b34b-849536147463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_c538b7f2-dca1-41fe-abe9-38725566967b" xlink:href="biib-20240630.xsd#biib_GAZYVAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1de777ff-bb42-40ad-88ba-02dbf53a3c85" xlink:to="loc_biib_GAZYVAMember_c538b7f2-dca1-41fe-abe9-38725566967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bfb33cf-fbb7-4a9c-8067-c5b07c7d6d83" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_fa91eaf8-a064-41e5-a66f-824330ddc6e0" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_fa91eaf8-a064-41e5-a66f-824330ddc6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_5f94a738-db19-4f24-b5e9-cdfdbcdea938" xlink:href="biib-20240630.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_5f94a738-db19-4f24-b5e9-cdfdbcdea938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_5da8701a-48fd-4157-9b81-fb5027066d60" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_5da8701a-48fd-4157-9b81-fb5027066d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_d0dcc2d3-cf30-431f-aec8-075eb3d305e4" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_d0dcc2d3-cf30-431f-aec8-075eb3d305e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_17d30a7e-fd00-4467-b669-0dd6431ae594" xlink:href="biib-20240630.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_17d30a7e-fd00-4467-b669-0dd6431ae594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_e27cc73c-015c-4fd0-8044-527209ef9d65" xlink:href="biib-20240630.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_e27cc73c-015c-4fd0-8044-527209ef9d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_d7be0cc7-c0b7-43b3-865b-9aa401b3071e" xlink:href="biib-20240630.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_d7be0cc7-c0b7-43b3-865b-9aa401b3071e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_009c3f03-54ae-4f3a-8e8f-0aab2c5ec360" xlink:href="biib-20240630.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5dc8549-df1c-4617-9b52-849e40b9905c" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_009c3f03-54ae-4f3a-8e8f-0aab2c5ec360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17520a2a-a6c7-472e-9ffa-5b4896b8f6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17520a2a-a6c7-472e-9ffa-5b4896b8f6eb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca45aa4b-9037-478e-a9ef-8f6532bf85f2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:to="loc_srt_ProductOrServiceAxis_ca45aa4b-9037-478e-a9ef-8f6532bf85f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab4b13f4-4b26-4f42-8b4d-0716c92d32f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ca45aa4b-9037-478e-a9ef-8f6532bf85f2" xlink:to="loc_srt_ProductsAndServicesDomain_ab4b13f4-4b26-4f42-8b4d-0716c92d32f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_2ea2ce3a-1271-44ec-aee2-9d25b71fe306" xlink:href="biib-20240630.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab4b13f4-4b26-4f42-8b4d-0716c92d32f1" xlink:to="loc_biib_LEQEMBICollaborationMember_2ea2ce3a-1271-44ec-aee2-9d25b71fe306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_afc39522-db09-4a17-b5a7-71cd1e7fb48e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_afc39522-db09-4a17-b5a7-71cd1e7fb48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5568bde7-c17e-4e49-8f17-a4753011e714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afc39522-db09-4a17-b5a7-71cd1e7fb48e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5568bde7-c17e-4e49-8f17-a4753011e714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_b8887eaf-2817-41f5-98e2-0c26951a2507" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5568bde7-c17e-4e49-8f17-a4753011e714" xlink:to="loc_biib_EisaiMember_b8887eaf-2817-41f5-98e2-0c26951a2507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24f718a7-6269-4187-839e-a79d136d4b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_029bf16f-969b-441c-ac68-3a80c62881f1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24f718a7-6269-4187-839e-a79d136d4b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement_15017746-73b1-4392-8f55-316c3daf640c" xlink:href="biib-20240630.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24f718a7-6269-4187-839e-a79d136d4b3d" xlink:to="loc_biib_AccruedPaymentToTerminationAgreement_15017746-73b1-4392-8f55-316c3daf640c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsMadeToTerminationAgreement_aa2f214b-9fba-4a14-9c79-f705ad5eaa13" xlink:href="biib-20240630.xsd#biib_PaymentsMadeToTerminationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24f718a7-6269-4187-839e-a79d136d4b3d" xlink:to="loc_biib_PaymentsMadeToTerminationAgreement_aa2f214b-9fba-4a14-9c79-f705ad5eaa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e35aad90-54ca-4c44-a422-ee7bcc461882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e35aad90-54ca-4c44-a422-ee7bcc461882" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_32ce83c7-6e72-4d27-8a27-ddbe76248a36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fa0aa2fe-a607-4a79-a74f-f29fe4dff80a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_32ce83c7-6e72-4d27-8a27-ddbe76248a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b57d4b3a-2ae7-4d29-9492-4b2f6c74cc13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_32ce83c7-6e72-4d27-8a27-ddbe76248a36" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b57d4b3a-2ae7-4d29-9492-4b2f6c74cc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8237a7e-24da-4fb2-933b-598082578ef7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:to="loc_srt_ProductOrServiceAxis_b8237a7e-24da-4fb2-933b-598082578ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d786a0b8-a8ec-49e4-b11e-c419b6dd452c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b8237a7e-24da-4fb2-933b-598082578ef7" xlink:to="loc_srt_ProductsAndServicesDomain_d786a0b8-a8ec-49e4-b11e-c419b6dd452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_2f2afe3b-dabc-403a-9a4a-aa6ba8cbd0a7" xlink:href="biib-20240630.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d786a0b8-a8ec-49e4-b11e-c419b6dd452c" xlink:to="loc_biib_E2609andBAN2401Member_2f2afe3b-dabc-403a-9a4a-aa6ba8cbd0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c99e06a4-0209-4ba4-bc2f-ce8e055775f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c99e06a4-0209-4ba4-bc2f-ce8e055775f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cfc5934-7251-43b8-b1db-4daf952bcdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c99e06a4-0209-4ba4-bc2f-ce8e055775f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cfc5934-7251-43b8-b1db-4daf952bcdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_9c55526f-1085-4b95-a298-2a032d116e53" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cfc5934-7251-43b8-b1db-4daf952bcdfa" xlink:to="loc_biib_EisaiMember_9c55526f-1085-4b95-a298-2a032d116e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0d95232-c95d-4efd-9ba3-73355236659d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_2be90489-a67a-4405-a587-89920b2e671e" xlink:href="biib-20240630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:to="loc_biib_ExpenseIncurredByCollaboration_2be90489-a67a-4405-a587-89920b2e671e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_c548371c-cc09-4ff4-b233-52cff8f33dfb" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_c548371c-cc09-4ff4-b233-52cff8f33dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_0913376c-8198-4ca3-9965-ac5ca000264b" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3fe3f45-749b-4228-bc4d-4a4376c5492d" xlink:to="loc_biib_Expenseincurredbythecollaboration_0913376c-8198-4ca3-9965-ac5ca000264b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6326bf55-8b5a-41f6-a025-9be35c5b7681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6326bf55-8b5a-41f6-a025-9be35c5b7681" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad352321-374b-4328-8d76-64231f40c160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5bbed40-6224-44ce-aabf-b3ed8b3ee4be" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad352321-374b-4328-8d76-64231f40c160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_23e2b9f1-b5d7-47e3-a930-cfcd62202306" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad352321-374b-4328-8d76-64231f40c160" xlink:to="loc_biib_EisaiMember_23e2b9f1-b5d7-47e3-a930-cfcd62202306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_30178907-ee54-4902-80e0-98345c0be4b3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:to="loc_srt_RangeAxis_30178907-ee54-4902-80e0-98345c0be4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0447c47f-68a1-4a98-81b6-f8ea69ec9546" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_30178907-ee54-4902-80e0-98345c0be4b3" xlink:to="loc_srt_RangeMember_0447c47f-68a1-4a98-81b6-f8ea69ec9546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af7ddb69-d5ce-4c2b-9672-62a602314553" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0447c47f-68a1-4a98-81b6-f8ea69ec9546" xlink:to="loc_srt_MaximumMember_af7ddb69-d5ce-4c2b-9672-62a602314553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_999eca34-8b16-49ba-a128-e8647c6d8577" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:to="loc_srt_StatementScenarioAxis_999eca34-8b16-49ba-a128-e8647c6d8577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_667157b2-aa0f-495e-93c3-7a6f40778b28" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_999eca34-8b16-49ba-a128-e8647c6d8577" xlink:to="loc_srt_ScenarioUnspecifiedDomain_667157b2-aa0f-495e-93c3-7a6f40778b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_dd573579-edbf-4cf1-bfce-4c34eaf199fe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_667157b2-aa0f-495e-93c3-7a6f40778b28" xlink:to="loc_srt_ScenarioForecastMember_dd573579-edbf-4cf1-bfce-4c34eaf199fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cba2d18e-f933-4e5f-92e3-8f9f03bf1326" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d99b6e43-6b85-420a-8f41-0fae69344297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d99b6e43-6b85-420a-8f41-0fae69344297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ff57b691-2ef6-4ba6-98d9-c3193731a934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_us-gaap_InventoryWriteDown_ff57b691-2ef6-4ba6-98d9-c3193731a934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator_22a4fe6b-d1f1-4998-a568-b183f83b4e31" xlink:href="biib-20240630.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_biib_AccountsReceivableFromCollaborator_22a4fe6b-d1f1-4998-a568-b183f83b4e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator_8c54ce12-1296-40c1-ba6d-7065d74ac2c3" xlink:href="biib-20240630.xsd#biib_AccountsPayableToCollaborator"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c374ac7c-e8ae-49a5-80e5-5442bca60f96" xlink:to="loc_biib_AccountsPayableToCollaborator_8c54ce12-1296-40c1-ba6d-7065d74ac2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_358f0fdf-df5c-4d41-8490-3f0af66e0fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_358f0fdf-df5c-4d41-8490-3f0af66e0fe7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19200724-c6f3-4a43-a7c4-f852b524a496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19200724-c6f3-4a43-a7c4-f852b524a496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_89411526-ae45-4b02-944b-e34ab183311c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19200724-c6f3-4a43-a7c4-f852b524a496" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_89411526-ae45-4b02-944b-e34ab183311c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eae9aa73-a132-420a-9837-62b6360b11da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_89411526-ae45-4b02-944b-e34ab183311c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eae9aa73-a132-420a-9837-62b6360b11da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3a91711-4d25-416c-ba8d-01182f51da8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_89411526-ae45-4b02-944b-e34ab183311c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3a91711-4d25-416c-ba8d-01182f51da8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d58ef02a-7173-4d22-b7ee-f85061e6d9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d58ef02a-7173-4d22-b7ee-f85061e6d9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7145057-a907-4908-8c19-ccb3e375bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d58ef02a-7173-4d22-b7ee-f85061e6d9ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7145057-a907-4908-8c19-ccb3e375bed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_51e2043a-fb9d-4797-bc72-6aee7718c012" xlink:href="biib-20240630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7145057-a907-4908-8c19-ccb3e375bed3" xlink:to="loc_biib_EisaiMember_51e2043a-fb9d-4797-bc72-6aee7718c012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_506b80c6-0c81-4617-a35d-1978971e8fdd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:to="loc_srt_ProductOrServiceAxis_506b80c6-0c81-4617-a35d-1978971e8fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59036f12-56dd-4b16-9c92-16cd4aec8c7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_506b80c6-0c81-4617-a35d-1978971e8fdd" xlink:to="loc_srt_ProductsAndServicesDomain_59036f12-56dd-4b16-9c92-16cd4aec8c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_6247390d-c05b-4493-a6de-2b62ad6d7322" xlink:href="biib-20240630.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_59036f12-56dd-4b16-9c92-16cd4aec8c7c" xlink:to="loc_biib_LEQEMBICollaborationMember_6247390d-c05b-4493-a6de-2b62ad6d7322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc4e3f4c-7d06-42c9-8697-3e10fa08962a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_95fb7304-4cf9-4a52-8a09-b91721921544" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_biib_Expenseincurredbythecollaboration_95fb7304-4cf9-4a52-8a09-b91721921544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9aa157b2-7792-4efc-9a84-ba3d81f25c23" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9aa157b2-7792-4efc-9a84-ba3d81f25c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_b5de06ee-597c-4ef7-81b0-074774c9ef21" xlink:href="biib-20240630.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_b5de06ee-597c-4ef7-81b0-074774c9ef21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c98fc958-f926-4da8-a47b-1c41faa52968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3f36197-bf32-4820-9951-3b37f2febce9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c98fc958-f926-4da8-a47b-1c41faa52968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_319c48ad-79be-4571-b0c9-b1ffedd126e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_319c48ad-79be-4571-b0c9-b1ffedd126e5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ba7e5c0b-e623-4947-ae85-b18a05ebbad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ba7e5c0b-e623-4947-ae85-b18a05ebbad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0887ce46-4ee4-4d6d-8e2b-1c76060f9edb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba7e5c0b-e623-4947-ae85-b18a05ebbad6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0887ce46-4ee4-4d6d-8e2b-1c76060f9edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_67700d65-a091-4f80-ab96-e32cd6ddee63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0887ce46-4ee4-4d6d-8e2b-1c76060f9edb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_67700d65-a091-4f80-ab96-e32cd6ddee63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_08e826c5-b645-4079-9604-c99213d48238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_08e826c5-b645-4079-9604-c99213d48238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40ba7f13-6b6d-426a-8308-b2b1bf21c405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_08e826c5-b645-4079-9604-c99213d48238" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40ba7f13-6b6d-426a-8308-b2b1bf21c405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_a2ee7e1c-bfbd-4149-80c2-5cc7617f725d" xlink:href="biib-20240630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40ba7f13-6b6d-426a-8308-b2b1bf21c405" xlink:to="loc_biib_UCBPharmaS.A.Member_a2ee7e1c-bfbd-4149-80c2-5cc7617f725d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de728f49-ea9c-4bbc-a2d2-6421f440c4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37691836-2a0b-4418-8eea-200292365ca7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de728f49-ea9c-4bbc-a2d2-6421f440c4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_675c85b3-1ca4-4a18-8f19-c5a1281771a8" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de728f49-ea9c-4bbc-a2d2-6421f440c4e2" xlink:to="loc_biib_Expenseincurredbythecollaboration_675c85b3-1ca4-4a18-8f19-c5a1281771a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9ded1850-390b-4368-a473-a0afe1daccb0" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de728f49-ea9c-4bbc-a2d2-6421f440c4e2" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9ded1850-390b-4368-a473-a0afe1daccb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_adaff9d6-2c0f-4e3a-8f0f-daa953110e00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_adaff9d6-2c0f-4e3a-8f0f-daa953110e00" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c5eadb6-07ef-47c8-a465-8293ebbe72f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fa7bb3b6-e1e9-4e77-b686-ebfceb91e1de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c5eadb6-07ef-47c8-a465-8293ebbe72f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fed9a078-0736-471f-a8ac-f2295ca540f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c5eadb6-07ef-47c8-a465-8293ebbe72f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fed9a078-0736-471f-a8ac-f2295ca540f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_78a94e5f-e7b0-4f42-be20-22e8ff4397e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c5eadb6-07ef-47c8-a465-8293ebbe72f2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_78a94e5f-e7b0-4f42-be20-22e8ff4397e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d5f133b8-986b-45ec-8c13-964e9a4e1690" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d5f133b8-986b-45ec-8c13-964e9a4e1690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df691c2e-cb88-4efa-b28b-a771d6345034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5f133b8-986b-45ec-8c13-964e9a4e1690" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df691c2e-cb88-4efa-b28b-a771d6345034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_8b80afe4-e62c-4442-b655-65c82ffa5c5b" xlink:href="biib-20240630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df691c2e-cb88-4efa-b28b-a771d6345034" xlink:to="loc_biib_SageTherapeuticsIncMember_8b80afe4-e62c-4442-b655-65c82ffa5c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:to="loc_srt_StatementScenarioAxis_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dfee4ca0-fbff-4f74-91db-71acad3a61cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_aa315946-fb99-4a5a-a2b2-fbc9e42dc20f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_dfee4ca0-fbff-4f74-91db-71acad3a61cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_67c2821f-7013-4351-9f02-c0d89e55b01a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_dfee4ca0-fbff-4f74-91db-71acad3a61cf" xlink:to="loc_srt_ScenarioForecastMember_67c2821f-7013-4351-9f02-c0d89e55b01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6d6bfb-fb3d-40c9-97d3-3e4020e527de" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_392f5c1d-070d-483d-9d3e-a27c1970d141" xlink:href="biib-20240630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_392f5c1d-070d-483d-9d3e-a27c1970d141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_4ec69178-babe-4026-a148-41b5bf77c116" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_Expenseincurredbythecollaboration_4ec69178-babe-4026-a148-41b5bf77c116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_0ed29e9d-9493-4e11-bab1-440ec9c31f64" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_0ed29e9d-9493-4e11-bab1-440ec9c31f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_4ed6565f-d64a-4fec-a41e-de8bd99d69be" xlink:href="biib-20240630.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_4ed6565f-d64a-4fec-a41e-de8bd99d69be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_b5b01c65-77a8-40e2-b2e9-58e31af36a9f" xlink:href="biib-20240630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a19bef88-a8d6-4a0c-bafa-7b8d2996debe" xlink:to="loc_biib_Collaborationprofitlosssharing_b5b01c65-77a8-40e2-b2e9-58e31af36a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d8d0e9a-0805-44bd-b309-04741f0e6dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d8d0e9a-0805-44bd-b309-04741f0e6dd5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5dc419df-7a6d-4715-a523-8bccdb1fdb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5dc419df-7a6d-4715-a523-8bccdb1fdb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c5527093-e5fc-4808-a368-379264f029fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5dc419df-7a6d-4715-a523-8bccdb1fdb1a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c5527093-e5fc-4808-a368-379264f029fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4c5b26de-86d3-450e-891d-e9963536dc97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c5527093-e5fc-4808-a368-379264f029fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4c5b26de-86d3-450e-891d-e9963536dc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b36be539-e346-45e5-9176-58756ab25b00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b36be539-e346-45e5-9176-58756ab25b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb53db1d-5dc1-44ad-a7a9-d418da4f7914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b36be539-e346-45e5-9176-58756ab25b00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb53db1d-5dc1-44ad-a7a9-d418da4f7914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_e62a73df-4d08-43b9-8c4a-6c4b3b009c5d" xlink:href="biib-20240630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb53db1d-5dc1-44ad-a7a9-d418da4f7914" xlink:to="loc_biib_DenaliTherapeuticsIncMember_e62a73df-4d08-43b9-8c4a-6c4b3b009c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d820b1e-71ad-4d40-a910-00e6d942477c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10959ff2-e0b4-4456-a523-25afff4ca12f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d820b1e-71ad-4d40-a910-00e6d942477c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_edfa13b8-4e51-4110-bb91-6df23faf6464" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d820b1e-71ad-4d40-a910-00e6d942477c" xlink:to="loc_biib_Expenseincurredbythecollaboration_edfa13b8-4e51-4110-bb91-6df23faf6464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_668c5d48-ac6b-4c6f-b6c2-ea018cdefaeb" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d820b1e-71ad-4d40-a910-00e6d942477c" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_668c5d48-ac6b-4c6f-b6c2-ea018cdefaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73c752ac-ac8f-4d33-b7f7-dd4e298fab70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_855852b5-fb00-4a17-aff1-712e65940af9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73c752ac-ac8f-4d33-b7f7-dd4e298fab70" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_855852b5-fb00-4a17-aff1-712e65940af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_947f3753-d42f-4bf3-9a9d-8befd69f4b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_855852b5-fb00-4a17-aff1-712e65940af9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_947f3753-d42f-4bf3-9a9d-8befd69f4b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc249c0d-68ef-4848-937c-a96358471ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_947f3753-d42f-4bf3-9a9d-8befd69f4b42" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc249c0d-68ef-4848-937c-a96358471ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e59b1f7-736f-4a38-9a3a-a634ef87d619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc249c0d-68ef-4848-937c-a96358471ae4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e59b1f7-736f-4a38-9a3a-a634ef87d619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8589f60-e83b-4871-bfb5-7b6aaeb6ac94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_855852b5-fb00-4a17-aff1-712e65940af9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8589f60-e83b-4871-bfb5-7b6aaeb6ac94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_f246ce05-dad3-4e26-98a3-d29da1ff99a6" xlink:href="biib-20240630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8589f60-e83b-4871-bfb5-7b6aaeb6ac94" xlink:to="loc_biib_Expenseincurredbythecollaboration_f246ce05-dad3-4e26-98a3-d29da1ff99a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_6497db64-983d-484f-a38a-0fb464de9d6e" xlink:href="biib-20240630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8589f60-e83b-4871-bfb5-7b6aaeb6ac94" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_6497db64-983d-484f-a38a-0fb464de9d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf4acc1b-6d8d-49b0-997a-d13dbec31ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d21a7246-da80-4ac7-b82d-c3f3bd77dad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf4acc1b-6d8d-49b0-997a-d13dbec31ec5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d21a7246-da80-4ac7-b82d-c3f3bd77dad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5b7db595-5b8f-49ed-bb70-4c8999b30c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d21a7246-da80-4ac7-b82d-c3f3bd77dad9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5b7db595-5b8f-49ed-bb70-4c8999b30c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d13e8b2b-a4bd-4f42-94bd-c94ef5427f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b7db595-5b8f-49ed-bb70-4c8999b30c8b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d13e8b2b-a4bd-4f42-94bd-c94ef5427f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_1f0772e1-2870-4ec5-b5af-b77ad35a8621" xlink:href="biib-20240630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d13e8b2b-a4bd-4f42-94bd-c94ef5427f5c" xlink:to="loc_biib_OtherresearchanddiscoveryMember_1f0772e1-2870-4ec5-b5af-b77ad35a8621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c92dcbe6-7365-47dd-af89-7e57f84c6bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d21a7246-da80-4ac7-b82d-c3f3bd77dad9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c92dcbe6-7365-47dd-af89-7e57f84c6bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f5721227-31a9-4f78-91d4-e03696cfb5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c92dcbe6-7365-47dd-af89-7e57f84c6bd9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f5721227-31a9-4f78-91d4-e03696cfb5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_597f0ed5-0654-4812-9fd1-f9ef38d5cb93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_597f0ed5-0654-4812-9fd1-f9ef38d5cb93" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e4b54172-a9d6-4fdb-bc06-80012bdae85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e4b54172-a9d6-4fdb-bc06-80012bdae85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_890cbdbd-9918-455f-b9bf-719e9d3ab7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e4b54172-a9d6-4fdb-bc06-80012bdae85c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_890cbdbd-9918-455f-b9bf-719e9d3ab7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_205f0bab-a597-40c4-b731-67219b37544e" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_890cbdbd-9918-455f-b9bf-719e9d3ab7dd" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_205f0bab-a597-40c4-b731-67219b37544e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_675a93b9-2e69-44a7-b6d2-b309e8446d35" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_675a93b9-2e69-44a7-b6d2-b309e8446d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e05753f9-c12a-45cd-8b5f-6ba6926488cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_675a93b9-2e69-44a7-b6d2-b309e8446d35" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e05753f9-c12a-45cd-8b5f-6ba6926488cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_007c45f2-6263-44e8-a0ca-282580c2faf2" xlink:href="biib-20240630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e05753f9-c12a-45cd-8b5f-6ba6926488cd" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_007c45f2-6263-44e8-a0ca-282580c2faf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc667fd-85f6-424d-b971-d4ab600d2388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc667fd-85f6-424d-b971-d4ab600d2388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9b75fa00-e97f-4514-9be7-ce30b5b2a5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc667fd-85f6-424d-b971-d4ab600d2388" xlink:to="loc_us-gaap_RelatedPartyDomain_9b75fa00-e97f-4514-9be7-ce30b5b2a5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_7d366009-6536-49b1-b799-3b067f46bf01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9b75fa00-e97f-4514-9be7-ce30b5b2a5b2" xlink:to="loc_us-gaap_RelatedPartyMember_7d366009-6536-49b1-b799-3b067f46bf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45cf1008-0584-4263-86e2-41159c932f92" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_a6f4f55a-a0de-436b-9931-58d097084da4" xlink:href="biib-20240630.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_a6f4f55a-a0de-436b-9931-58d097084da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_6650dfd7-fc14-4d56-a913-f2eb167e85ba" xlink:href="biib-20240630.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_6650dfd7-fc14-4d56-a913-f2eb167e85ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_58651e5b-2c5a-4870-8af1-ef4565477cc5" xlink:href="biib-20240630.xsd#biib_AccruedMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_AccruedMilestonePayments_58651e5b-2c5a-4870-8af1-ef4565477cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_48d71d5c-f56f-48ca-89cc-b5d37de0615e" xlink:href="biib-20240630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_48d71d5c-f56f-48ca-89cc-b5d37de0615e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension_e35ef01c-f21a-492d-82f1-91024653861f" xlink:href="biib-20240630.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_CollaborativeArrangementTermExtension_e35ef01c-f21a-492d-82f1-91024653861f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_76503be7-8c73-47c7-8496-1c61fbc1a958" xlink:href="biib-20240630.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_ContractOptionExerciseFee_76503be7-8c73-47c7-8496-1c61fbc1a958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementContractOptionExerciseFeePaid_61b9fdb4-b132-407d-a1c0-6563d280f8f0" xlink:href="biib-20240630.xsd#biib_CollaborativeArrangementContractOptionExerciseFeePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_CollaborativeArrangementContractOptionExerciseFeePaid_61b9fdb4-b132-407d-a1c0-6563d280f8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_95a34780-e95b-40e7-86b3-eeb222fbd201" xlink:href="biib-20240630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_biib_Collaborationprofitlosssharing_95a34780-e95b-40e7-86b3-eeb222fbd201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_f8e5a758-f659-45be-a662-cdba67cd4c39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_us-gaap_AccountsReceivableNet_f8e5a758-f659-45be-a662-cdba67cd4c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_5e401a0d-7acd-43b4-ab4e-b7ffeac54b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5b0e01-7c31-4449-a4b9-7136c9832deb" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_5e401a0d-7acd-43b4-ab4e-b7ffeac54b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_07ebb746-9394-435d-b414-00af0e2cc6e0" xlink:href="biib-20240630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_102664ef-86e5-4105-b726-c7addfffee44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_07ebb746-9394-435d-b414-00af0e2cc6e0" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_102664ef-86e5-4105-b726-c7addfffee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4ceb5db3-02b2-458a-b576-ca06d627d8a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_102664ef-86e5-4105-b726-c7addfffee44" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4ceb5db3-02b2-458a-b576-ca06d627d8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0fdaa736-8342-4083-b973-3bea91d6c7d0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4ceb5db3-02b2-458a-b576-ca06d627d8a1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0fdaa736-8342-4083-b973-3bea91d6c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_ab3f67bc-16fc-4c81-8792-9d135f9dc74a" xlink:href="biib-20240630.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0fdaa736-8342-4083-b973-3bea91d6c7d0" xlink:to="loc_biib_NeurimmuneMember_ab3f67bc-16fc-4c81-8792-9d135f9dc74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_102664ef-86e5-4105-b726-c7addfffee44" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_f2e5809a-4516-4d6b-a1ad-a80209d42e67" xlink:href="biib-20240630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_f2e5809a-4516-4d6b-a1ad-a80209d42e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_eb31db10-469e-4a2c-ac80-1e2028e71edb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_eb31db10-469e-4a2c-ac80-1e2028e71edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_152a5314-8e2d-4bb9-95a5-8361fe4b5ec9" xlink:href="biib-20240630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f217c208-1224-4bab-b107-b55b453ced09" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_152a5314-8e2d-4bb9-95a5-8361fe4b5ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20240630.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_a3ed2599-e8ae-4e5a-b412-86ab9776bb72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_210ce860-c68b-4f86-b98d-c420a27828de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_a3ed2599-e8ae-4e5a-b412-86ab9776bb72" xlink:to="loc_us-gaap_LossContingenciesTable_210ce860-c68b-4f86-b98d-c420a27828de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e6e33b0c-9584-4f61-8f01-c236d5c84152" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_210ce860-c68b-4f86-b98d-c420a27828de" xlink:to="loc_srt_LitigationCaseAxis_e6e33b0c-9584-4f61-8f01-c236d5c84152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_09149326-84f3-4ca2-b123-f55fc3eeeaf6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_e6e33b0c-9584-4f61-8f01-c236d5c84152" xlink:to="loc_srt_LitigationCaseTypeDomain_09149326-84f3-4ca2-b123-f55fc3eeeaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_3676005c-3c82-4988-9a94-77a24ed4577d" xlink:href="biib-20240630.xsd#biib_GenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_09149326-84f3-4ca2-b123-f55fc3eeeaf6" xlink:to="loc_biib_GenentechMember_3676005c-3c82-4988-9a94-77a24ed4577d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember_5ed2294d-2ee8-40cc-a694-e0e3aa486121" xlink:href="biib-20240630.xsd#biib_LenderDisputeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_09149326-84f3-4ca2-b123-f55fc3eeeaf6" xlink:to="loc_biib_LenderDisputeMember_5ed2294d-2ee8-40cc-a694-e0e3aa486121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_847e936c-1f68-44c6-94e3-ff2fe03fb715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_210ce860-c68b-4f86-b98d-c420a27828de" xlink:to="loc_us-gaap_LossContingenciesLineItems_847e936c-1f68-44c6-94e3-ff2fe03fb715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_ad3c8925-093f-43d7-a5ec-12ce317b12eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_847e936c-1f68-44c6-94e3-ff2fe03fb715" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_ad3c8925-093f-43d7-a5ec-12ce317b12eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_e5904096-0a59-4a41-ae1e-382dcf747124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_847e936c-1f68-44c6-94e3-ff2fe03fb715" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_e5904096-0a59-4a41-ae1e-382dcf747124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20240630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20240630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20240630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20240630.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_MarketStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20240630_g1.jpg
<TEXT>
begin 644 biib-20240630_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
MGP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3
M 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!
ML0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q
M GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#
M9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^
M!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%
MU07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/
M!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)
M$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS
M"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-
M)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z
M#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2
M)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P
M%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8
M&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC
M&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?
M$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=
M(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G
M&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI
M*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP
M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43
M-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z
M=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B
M0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%
MWD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB
M3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2
M?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:
M66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@
M5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>3
M9^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO
M>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6
M=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_
MY8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AI
MB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1
MJ)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5
MFT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:D
MQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZA
MKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y
M2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4
MQ%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/
M-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IV
MVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WF
MEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,
M\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_
M;?___]L 0P " 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+
M"0@("@@'!PH-"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'
M" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
M-(WX]OH,"MBBBOJ:-&G2A[.E%)=EH2%%%%:@%%%% !1110!\H_\ !:S_ )1[
M>*O^OW3_ /TKBK\0:_;[_@M9_P H]O%7_7[I_P#Z5Q5^(-?OWA?_ ,BF?_7R
M7_I,3\+\2?\ D:Q_P+\Y!1117Z,?GY^\G_!)[_E'K\-/^O*X_P#2N>OHBOYO
M_#WQ^\>>$=&@TW2?&WB[2]/M05AM;36+B&&$$DD*BN .23P.I-7O^&H?B9_T
M43QU_P"#ZZ_^.5^/YAX9U\3BJF(5=+GE*5N5Z7=^_F?K& \1J.'PU/#NBWR1
M4;W6MDEV/Z,J*_G-_P"&H?B9_P!%$\=?^#ZZ_P#CE'_#4/Q,_P"BB>.O_!]=
M?_'*X_\ B%.(_P"@A?\ @+_S.K_B)]#_ )\/_P "7^1_1E6+XX^(>@?#+0I-
M4\2:UI.@Z;#]ZZU"[CMH5]MSD#/M7\\K?M0?$MEY^(GCH@\$'7KKG_R)7)Z[
MXCU#Q1??:M3O[W4;D@+YMU.TTF!T&YB36U'PIGS?OL0K>4=?Q?\ F9UO$^'+
M^ZP[OYRT_!'Z6?\ !0S_ (+7:?J/AS4/!OP;N+B:2]1K>]\3-&T*PH>&6T5@
M&+$9'FL!CJF20Z_F.S;CD\D\DGO117Z;DF0X3*J'L,*M]V]V_-_ILC\XSC/,
M5F=;VV*>VR6R7DOZ;"BK?A_P[J'BS6K;3=*L;S4]1O'$=O:VD+333N>BHB@L
MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
M<!2563 X!D(   %?I/!?'%7,JWU+&17/9M26E[;IKO;733R1^><8<&4LNH_7
M,))\E[-/6U]FGVZ:Z^9\C4445^F'YR?I%_P;Q?$J:W\9_$7P=)*6M[NRMM9@
MC)XC>)S#(1_O"6+/^X.G?]2J_'__ (-];21OVP/%$X7]U'X.N(V;T9KVR('X
M[6_*OV K^<_$2E&&=U''JHM^MK?H?T!P#4E/)H*71R2]+W_4*\R_:;_9$\!_
MM<^#_P"Q_&NBQWOD@_9+^$B*^T\GJT4N,KT&5.5; RIQ7IM%?&X?$5:%15J,
MG&2V:=FCZZOAZ=:FZ5:*E%[IJZ9^//[3?_!"CXC?#.ZN+[X?W=MX]T499+<L
MMIJ<(]"C'RY,#NCAC@_(.E?&OC[X7^)/A5K#:?XG\/ZUX?OE)'D:C926LAQW
M <#(]QQ7]*%4]<\/6'B?3GL]2L;/4+23[T%S"LT;?56!%?I&5^)^.HQ4,9!5
M%W7NOYZ-/[D?GN9>&^#K2<\)-T_+XE\M4U][/YGZ*_H,\2?L!?!+Q9,TEY\+
M? _F.VYGM])BMF<\G),87).><]:YZ+_@EE^S_#?M<K\,M#\QB209;AH^>OR&
M3;^G%?30\5, U[U&=_+E?ZH^=EX98Z_NU86^:_1GX*5O?#_X4^*/BQJOV'PO
MX=USQ%>9QY.FV,ETX^H13@>YXK]\O"W[!?P5\'.K6/PM\#+(O*O/H\-RZGU#
M2*Q'X&O4M)T:ST"Q2UL;6VLK6/A(;>)8XU^BJ,"N+%>*U)+_ &;#MO\ O22_
M!)_FCLPWAA4;_P!HKI+^ZK_BVOR/R%_9D_X(3_$;XEW=O??$&\M? >BMAWM@
MR7>IS+Z!$)CCR.[N64GE#R*_33]F']CWP#^R%X2.E>"]%CM))U47FH3GSK[4
M".AEEQDCJ0J@("3A1DUZA17YYG?%F8YI[N(G:'\L=(_/J_FV?>9-POE^6>]0
MC>?\SU?^2^204445\V?1!1110!^(_P#P4_\ @#X\\6_MX?$34M*\$^+M4T^Z
MO(&ANK31[B:&8"UA!*NJ$'D$<'J#7@O_  R]\3/^B=^.O_!#=?\ QNOZ,J*_
M3L#XF5\-AZ>'5!/DBHWYGK9)=O(_-\9X<T,1B)UW6:YI-VLM+N_<_G-_X9>^
M)G_1._'7_@ANO_C=?:7_  0J^#7C#X>?M<>(KWQ!X5\2:'9R^$+F!)]0TR>U
MB:0WEDP0,Z@%B%8XZX4^AK]8**QS;Q&KX[!U,)*BDIJU[O3\#;*_#^C@L7#%
M1K-N#O:RU_$****_-S]""BBB@ K\6?\ @K1\!O'7C3_@H'\0-2T?P7XLU;3;
MC^SO)N[/2+B>"7;IMJK;75"IPRD'!X(([5^TU%?0\-<03R?%2Q,(*3<7&S=M
MVG?\#P>(LAAFV&CAIS<4I*5TK[)JWXG\YO\ PR]\3/\ HG?CK_P0W7_QNC_A
ME[XF?]$[\=?^"&Z_^-U_1E17V_\ Q%;$?] Z_P# G_D?%_\ $,*'_/\ ?_@*
M_P S\>_^"+_P0\:> _VWK'4-<\(>*-%L%TB]0W-]I4]O"&*+@;W4#)],\U^P
ME%%?"\19]/-L7]:G!1=DK)WVO_F?;</Y)'*L+]6A)R5V[M6WM_D>;_MAZ5=:
MY^R/\4K*QM[B\O+SPAJT$$$$9DEGD:RF5451DLQ)   R2:^.K7X4:]>_\$P_
MV>-!N/#>L27UEXWTR74-/DT^0S6\ OKHNTL97<J!6!)8  $9ZU^AM%9Y?G4\
M)25*,;VFIWOVBXV_&YICLGCBJKJRE:\'#;HY)W_ _'3QA^P=XV\)_#+]H"RN
MM'\0:MI_P^%MH/@FV6TEF:Y@N=;@NGFMU"DN1"N7(SCSF'.TD%?L717V&"\2
ML50C)2I*5W?=K[*3Z=6G)^;9\EC/#K#5W%QJN-E;9/[3:^Y-17DD%%%%?FI^
MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20240630_g10.jpg
<TEXT>
begin 644 biib-20240630_g10.jpg
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MH8]9CO/$.J)/)<M<2*@81RA 2NP<<=*_3#Q'#+<>'K^""-G=[.5411DL2A
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M^.%_^SI^S3\(=/\ %WB+0-'M]2\6ZAKOB(Z9IVCI<%OLT#.D$\DL\JH[A @
M4!BW4#Y^\;_ GXX^(/V$-+\3^)?AOJD_Q#\?_&'2/&GC#1;'3Y9)[#S=1A98
M6CP71+:SB@C8-]SRFSCFO2=2N?&7[)'[:OQ(^,6K_!_QCXK\'_%G2]%GBU/P
M3X>FU6?2M0TZV>U:WGMX TJI)&4=9 I4-E3CD@ OZ[_P48TWPM^RUXX^/7B?
MX275AXB^&OB.WT3QMX(N-64O974EW;0%H[B.)A-$8[E9HW6/]X%VX4Y(U;']
MKKXS^&/B=X-T/XZ?LVQ^%/"_Q$U?^RO"^KQ>*4N[ZTOFADG@@O[40JL+RI$_
M^JDE",-K$_>'A7Q0^ 7QN\=_LK?'SXO7OPFUJSU_XM^/= U#1/! M/.U&WTN
MQOM/BB>>*+=LF:**6:2,$^6H&3D-CZ _;<\%>,/&/B#X'7'A/PQ?ZDFC?'/2
MM1U=[&T>46=FEE?J]Q+M!V1JSH"YP 7 SR* .!_99^+W[8/BK]N'XO\ @OXA
M^"=&70=,OM"34;-/'<]S'X>232VDC^Q1-:*LWGMM>4?N=K,?OXR?/_V/?VF_
MVA/AM^Q5<^,_ G[/<?BOP[X)U?Q)=>*-5U?Q8;&ZNHTU6]GE2PB,$OVCRH&4
MEG>-2P,:[F4X]>\!WOB3X*?M]_%6X\5_"_Q==:5\49/#,OAGQ#HGAJXOM/1K
M:R-G.EU/"K+:%7 ;,I4;#G-97[,_PQ^(?AS_ ()@>)?AQKW@75;+Q!<Z;XT6
M'1;G3Y$NI6N+[46@ B(W$R+)&5X^8.N,Y% ':_$W]LVZMI_A?X5^ OP_M_$W
MB'XNZ/-JWA>+7M9_LNS@L(K:&X>:>41RN6V3QXBC1F/S<@+D]I\"/B?\7O'4
MNN>'/C7\#I?!VLZ#<Q1BXM-4^WZ7JT4B%EFM+DQQ,V""'1XU9"0.<U\Z^-OA
MYHLO[*OP,^'W[1_[$^O>//#.F_#S38-9NO#]K<2:]X7U2.QMD"BU@V72HVUU
M=H7W*T:ADX!KH?V ?!/Q \)?%?QN_A#2_B7I7P?ETRQ7PQI'Q5DN/ML>IAI/
MM#6D5T3<0VOEF,$2XW.<C.#@ M_\%?[RQL?V++R?5[U[>Q/B_05U"5)FCQ;G
M4H!*"R$,!LW9QSBL;]GWX:_\$F/''Q5TN+]GY]*U+Q5I4Z:IIL5GX@U5WB>W
M=7$NV678P5@IPP(/<&NO_P""I'A3QGXO_90FL? ?@C6/$5_:^+M"O3I6@Z>]
MU=20P:C#+(4C0$MA%)_"M'PS^WA:^)O$FG^&U_9!^/-@=0OHK87VI_#26&VM
MO,<+YDLAD.R-<Y9NR@GM0!B:5^VC\?OBGXO\?>"/V??V5[36KGX=^+[O1M6O
M=;\:BPM;M851HQ _V5R;B3<^8R-D0"%I3Y@4:%Y^WYH6M?L_?#WXK?"[X;7V
MN>)/BE?C3?"/@R>]2V<WJ>9]J$\Y5A%#;^3,7E"MPHPOS<7?V'?!/B_P9J_Q
MOF\6^%[_ $Q=9^.^L:EI+7UH\0O;.2TL%2XBW ;XV9' <9!*GG@U\]_"KX+?
M'#X4_LY_LZ?'5?A#XAO]4^$OBSQ+)XG\%P:<PU1M-U.XOH))X;=\-+)&DD<J
MQCYG5\B@#O8/B'\:]>_X*1_"SPQ\:_AK;>&-0LO 7B69FT3Q VH:9J,;FSVO
M'(T4+AT*.'22,%<J0S!\CI;#]M_XV>// FK_ +0_P7_9GL]>^%VCRW;0:I=^
M+_LNKZY:6KND]Y8V?V9XS&#'(466:-Y0O 7<*P6U;XA?M(?MU> ?B+:_ CQK
MX?\  VG>!/$FE-K?B70IK"=[F<6F[?!(-]NA 41M*%:1DEVKM0,WD'P<^"?@
MOX _!@_L^_%G_@GUXY\8?$/P^;FPTW4M#TJ[ET7Q*K2R&VN3?I*+>UC9&3S!
M*49,-\I/RT ?47Q _;-^VM\/_"_[-'@B#QOXD^)>B-KF@V]]JIT^RLM(6.-W
MOKN81RO&N98T5%C9F<E>"*X3]G?QY\2O&/\ P4F\=6?Q1\!OX9U73?A'I%O=
MZ7!J_P!MLI7_ +0NG%Q;3;4,D;JZC+1HX964K\N36\2?#CQG^RY\<OA9^T=X
M>^ ]_=>&[#X73>"O%OA3X?VDNJ2^'C)/#>126T*J);J 3(T3,J[@H5MO.*U_
MV>+OXG_$;]OOQE\=/$'P5\2^%O#&J?"[2[#P[<^(M-:WEN1#?W1;S4/^HE+,
M["%CY@B,3,JE]H /J&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&_%;]HGX"_
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MF#R3IC6:&W\O^YY>-NWVQBCPWX5\+^#-+70_!_ANPTJR1BR6>FV:01*3U(1
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MKK/AKPYXCTHZ#XA\/V5_8G;FRO;1)8CMY7Y&!'&!CCBL/_A1GP2_Z([X5_\
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M]M_Q#\7=1/Q?TNZU...31Y-)T]7MKM(Y3_9UHA@EEW,(HVF(=%F.UMH8??\
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M"]):WMWU7QG'X8M-(UKQ3>ZA<W3RQPJN8+<3NWV:VWC<L,851A<@[1@ X?\
M;-\$^#_ 7Q$_9WTCP5X8L-*MKCX^Q7EQ!I]JL2RW$ME>O+,P4#<[L2S,<DDY
M)KO_ -LWX(>/OBEI'@[Q]\'M7TFW\9?#WQ?#KGA^UUZ1DLM2/E202V<KJ"T?
MF1RL%< E6"]B2,#X@?\ !.[1?B;X@TSQ)XO_ &KOC'<3Z'K?]K:$H\16 33K
MO:ZJ\0^PY&U9&49)X/>NM\0?L?>"?'7P;'P<^*'Q$\9^*5M]935M+\3ZOK2)
MK&F7L>##/;7-O%%Y3QG.TA3]]@=P)% 'S;^V_K_[6/Q8TOX6Z?\ $GX6Z/\
M#F)?C+X<&C:3:^*4U>_U?4A=9#!XHXT@MH8!/*S9+LRID(JG=:NOA[\<_P!H
MS]LCXD?&']B+XFI\*H] OSX2\>^(-3MTU./Q3JUG!'MQITB;(_LZ2)&+DR!F
M!^5"-V??_AG^Q9X*\#?$JP^+WC7XI^.OB'XBT:VE@\/7_CW6HKI='65=LK6T
M4$,,22.H"M*5:0CC=@FD\;_L6^#]?^(>J_%+X<_%KQY\.M8U]D?Q$_@76H88
M-4E10BSS6]S!/"90H"^8J*Q Y)H \T_X)VS^*_AW\4?B9^SY\=]'^U_%2TFL
M==\4^.H=4:[A\56TZ-%;3KN1#:B)8O*%N%"(!\F037TWXK\$^#_'5I;:?XT\
M,6&K6]I?17EM;ZC:K-''<1G,<H5@1N4\J>H(!'(!K@/AM^R'\-/AEX7\6Z/I
MNO>)=2UGQS:M!XI\9ZWK+7.L7H\EH8SYY4+'Y2.PC1$5$SD+R<NT[]ERR\/_
M  $T3X ^$?C=\0-'M="<&#Q'8ZU"=6N%W2,4FGE@=74F3GY ?D7GCD \^_89
M_P"2]_M)_P#97$_]-EK7TE7SU\/O^">6B?#'Q9J7C+PK^U5\88[O7-9CU37E
MD\0V)34[A51=TP%D"P*(J'!' [=:^A: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KS+]HO]I2P^!DFC>$]$\"ZQXL\7^*!=_\
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M> HY)( !)Q7G/[)W[7OA[]K1O&=SX9\#:OHMIX4\1+ID+ZW&89[Y&MXYTN#
MRAH RR A'^;!!(4DJ/2_%?@GP?XZM+;3_&GABPU:WM+Z*\MK?4;59HX[B,YC
ME"L"-RGE3U! (Y -> _L,_\ )>_VD_\ LKB?^FRUH ^DJ*** "BBB@ HHHH
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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MS%%%%42%%%% !7[+_L2_\FD_#W_L5K7_ - K\:*_9?\ 8E_Y-)^'O_8K6O\
MZ!7/B?A1U87XV>HT445QG<%%%% !1110 4444 %%%% !1110 5\4_P#!3O\
M:W_:$_9Y^*/AWP[\'OB!_8]G?Z ;F[A_LJTN-\OGNN[,\3D< # (%?:U?G%_
MP6D_Y+7X2_[%9O\ TIDK6BDZFIC7;C3NCR[_ (><_MP_]%N_\MK3/_D:C_AY
MS^W#_P!%N_\ +:TS_P"1J\%HKMY(=D<'M*G=GO7_  \Y_;A_Z+=_Y;6F?_(U
M'_#SG]N'_HMW_EM:9_\ (U>"T4<D.R#VE3NSWK_AYS^W#_T6[_RVM,_^1J/^
M'G/[</\ T6[_ ,MK3/\ Y&KP6BCDAV0>TJ=V>]?\/.?VX?\ HMW_ );6F?\
MR-1_P\Y_;A_Z+=_Y;6F?_(U>"T4<D.R#VE3NSWK_ (><_MP_]%N_\MK3/_D:
MC_AYS^W#_P!%N_\ +:TS_P"1J\%HHY(=D'M*G=GO7_#SG]N'_HMW_EM:9_\
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MFWRP^W'MC%<H22<DTHPY6.<^96"BBBK,PHHHH *_9?\ 8E_Y-)^'O_8K6O\
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M0 4444 %%%% !1110 4444 %%%% 'YQ?\%I/^2U^$O\ L5F_]*9*^-*^R_\
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MD(O103T%,I\_D>>_V8N8]Y\OS -VW/&<=\4RM#,**** "OV7_8E_Y-)^'O\
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M_#C]H3Q5\/\ PI/\/[_PQH'B?P[->?:QH7BC3C<007)4*9HF1TEA<J "4<9
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M:_\ H%>HUY=^Q+_R:3\/?^Q6M?\ T"O4:\V7Q,]:'P(****DH**** "BBB@
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M (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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M +%9O_2F2OT=K\XO^"TG_):_"7_8K-_Z4R5M0_B&&)_A,^-****[CS@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _9?]B7_DTGX>_P#8K6O_ *!7J->7
M?L2_\FD_#W_L5K7_ - KU&O-E\3/6A\""BBBI*"BBB@ HHHH **** "BBB@
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M#@@@]"#VIE;E[X1\;ZE>3:CJ-K+<7%Q*TD\\]VCO(['+,S%LDDDDD\DFHO\
MA!/%?_0*_P#(\?\ \573_K3PS_T'4?\ P;#_ .2.2Z,BBM?_ (03Q7_T"O\
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M>2_L&_\ )FOPU_[%&T_] KUJOSW$?[Q/U?YGZIA/]TI_X5^04445B= 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M?'_!87_DL7A7_L66_P#2B2OD*OKW_@L+_P EB\*_]BRW_I1)7R%7\^\6_P#)
M18CU7Y(_,\Z_Y&E7U_1!1117SIY8445]*?LY?"CX4^%/"6A>/_B!X/U#Q)=^
M+?"WB6[MHQ=)#8V4-G:W*M&28G+W#>6Q#97RMR, Q%=N P-3'U_9Q:25KM]$
MVH]-=VE\^QT8;#RQ-3E3MW?S2_-H^:Z*[3Q+X6^&OBKXA:5HGP8UZXM[#68X
M0Z>*9TB_LNX=B'CEN %1XTP&\W:ORGD9!SVOQD^#?P;\&?LZZ)XU^'GB*?7=
M3?Q=<Z5JVO8>.VN3';I(5MXVY\I2^ [ ,Y!. " ''+ZTX5)Q::@KMWWVVZO=
M>G6ST''"U)1G)-6CY[^GW_YGBU%=Y\,]3^ OACPE>>)/B/X9O?$^NM?+!IOA
ML7DEG:1P;<M<331_.YW?*(T*]R2<X'1?&7P#\,=2^!OAS]H#X=>$KGPL=5UN
MZTJ\\.SZB]U#(T2*XN;:27]X8_FV,&+8;@'CDA@93P[JQG%M+F<=;I72OMR]
M5IS7\A1P[E2<U):*]M;VO;M;Y7N>0T5I^#=3\-:-XFM-3\8>%VUK389";O2T
MOVM3<+@@+YJ@E.<'(';'>O=_A]=?LH>+/"7B+XA:_P#LKW&E:'X>M )+S_A/
MKN5KJ]ER+>TB7RUW.Y!9CGY$1F.< $P>"CC';VL8O71\VR5V[J+5DN[Z!0PZ
MKZ<Z3\[_ 'Z)H^=:*5B"Q*K@$\#TI*X3G"BBB@ K]>?V-?\ DU?P%_V+-M_Z
M#7Y#5^O/[&O_ ":OX"_[%FV_]!K]$\./^1E6_P '_MR/J.%O][J?X?U1Z711
M17[ ?<!1110 4444 %%%% !1110 4444 %?F%_P74_Y+MX,_[%)O_2J2OT]K
M\PO^"ZG_ "7;P9_V*3?^E4E>KDW^_P ?1_D>)Q!_R+)>J_,^'****^S/SX**
M** /L;]CWQS\(?BYX$\.?";7?B!?>%=?\&>#/&%LMO<:>\^F:E!>V-X[WK/&
MVZ&6%)&W;E;>D2A3G KRWXDZY^T/^RW\9O!OQ U[QUI'BNXTK0$?P'XEBF&H
M6%SI^)HXS$S!6/EL\@"N T;@>BFNA_99_:+^ -M!:>'OCA\,H[.^T/P9KNFV
M'BS0=02QDO;:>QNE^RW,1A=)9F,KQQS\,&=-X< YY:^^/_P0^(WQ5\%V?Q.^
M%^K:?\+?!>FO96'A70]1$][)&6DF9I)Y#'O>6X?=(5V83(3!&3YD:<XXB?NM
MQUOL][[==>S[^A[$JM.>%A::4KJS5UMR_$MM$MUV5KZG1?L(P^)/ 7Q)G_;.
M^).L75CX/\,K>-J^J7LIW^(+R:&15TZ'=_Q\RRNX9QR%4%G(XJGXJE'AG_@G
M-H+>'$%NOC/XG7\^OF XWK:01K;V['NB^8\@4\;CGKBMCXT?&_\ 8P^..KVU
MSXG\0?%VSTS3(?(T'PYI.B:3!I^DP?\ /*"$3X4=,L<NQ&68FN!^%'QL^&=O
M\+=8_9W^-FCZY=>$+W6UUG1=3T+R3J&CWZH8C(L<K+',DD6$>,LOW0P((JE&
M<Y>T<7>ZTMT5_O:;O^1+E3IQ]BI*S4K._5VOZ)I6_%G2:'*WC/\ X)MZ_;^(
M93*W@KXE64GAZ64Y:%+RWD6XMT)Z(S1K*5'&X9KQ+P7XAM?"7BS3O$][X;L-
M8BL+M)WTO58V>VNMISY<JJ060XP0",C(S7HGQ?\ C3\.Y?A-I?[//P'TC6;?
MPO::P^LZMJ?B(1+?:OJ#1^4CO'"S)#'%'E40,WWF8G)K*\:WW[,.K?$+0&\%
M:/XNTGPLFCV\?B42^1/?->C?YTEN&DV%#^[VAF7HW XK>DG%2NG:3;]/^'W.
M:LXRE'EDKQ27J_\ );?(]8^/?Q2\:?&+]@SPMXV\=ZFMQ>2_%74HH8H85B@M
M8$L+<1P0Q( L42#A44 #ZDD_,M?26I_%O]A[4_@!I7P DOOBLMGI7B>YUJ/4
M!HNF>:\DT,<1C*_:L!0(P<]>:^=-5&F+JERNB/.UD)W^R-=*JRF+<=A<*2 V
MW&0"1G.#1A5RQ<>6VKZ=+AC7SSC+F3T2>M]4M2"BBBNHX@HHHH _<;]@W_DS
M7X:_]BC:?^@5ZU7DO[!O_)FOPU_[%&T_] KUJOSW$?[Q/U?YGZIA/]TI_P"%
M?D%%%%8G0%%%% !1110 4444 %%%% !1110 4444 %%9'CKQ]X)^&/A:[\;_
M !$\6:?HFD6*;KO4=3NEAAC!. "S$#). !U)( !)KQB]_;]TB^D:X^&G[*?Q
ML\8Z=UBUK1? ?V:UN%_O1'4)K9Y%QT*J0>QH ]^HKQ[X;_MO_!OQSXIM/A]X
MKTKQ1X \2ZA)LTW0/B+X<FTF:^;^[;R29@N&_P!F*1VX/%>PT %%%% !1110
M 4444 %%%% 'Y\?\%A?^2Q>%?^Q9;_THDKY"KZ]_X+"_\EB\*_\ 8LM_Z425
M\A5_/O%O_)18CU7Y(_,\Z_Y&E7U_1!1117SIY85]7?L9:#^T5X3T6'7/AIXB
M;Q#X1UCPUK,UYI&GI]KAL=42RN!#;W%NZDQR,ZPXP LH<+E@<'Y1K<\ ?$3Q
M5\,]8GUWPC?_ &>XN-.N;*5CD@Q3PO"_&>NUR0>QP>U>EE.,IX#&QJSYK+K%
MV:U7WIK1KKW.O!5X8:NIRO\ )V?_  ?0]-_:V\)V:>*/"D5KX#L-%\::IX?6
M;Q?X8\.VX$5M=F601XA0D12O"$=XA]TD' R<Z.O> ?'3_L.>'M*3P7JQND^)
M%_*]L--E\Q4-G  Q7;D D$9Z<5XAI&O:YH&KQ>(-!UF[LK^"3?!>VERT<T;?
MWE=2&!Y/(/>NG_X:)_:!_P"BZ>,O_"GN_P#XY71''X.=6M4J1:YURV5O+5[7
M;M=V25W?0T6)H2G.4DUS*VEO+7IKIJ;'PZ^'OQM\'>&X/V@/AE8P7IT_4I].
MO8(--2^GTR3R\9N;:6)U5'5F"L01E3]T@5Z#\?KSQ9\1_P!EG1_BI\>-#;2_
M%]KXE_LOP\[6QLSJ6F>27D;[(-J(J2;1YD:*IS@@DYKPSP_\0_'_ (2UN;Q-
MX5\<ZQIFI7)8W&H:?J<L,\I8Y8M(C!FR3DY/)J'Q3XS\8>.=2_MKQMXKU+6+
MS;M^UZK?27$NWTW2$G'XU%/'T*.#G1BI>\K.+?NWT]^W?3[^MM"8XFG"A*"O
MJMKZ7_F]?ZO;0G\;?#WQK\.+^UTSQQX<N-,N+VPCO;6*Y !EMY,[)!@]#M/Y
M5Z9\?X1\/_@)\+?A/8G9_:6BR^+-7V]+B>\D:.!F]T@AVC_>/K7E.O\ BCQ-
MXKN8;SQ3XBO]2FM[9;>WEU"[>9HH5SMC4N2549.%' R:CU?Q!KVO_9CKVMW=
M[]BM$M+/[7<M)Y$"9V1)N)VHN3A1@#/ KFCB*-&%:--/WTDKVNE=-_?:WH9*
MK3IQFH)^\K+TNF_R*E%%%<)SA1110 5^O/[&O_)J_@+_ +%FV_\ 0:_(:OUY
M_8U_Y-7\!?\ 8LVW_H-?HGAQ_P C*M_@_P#;D?4<+?[W4_P_JCTNBBBOV ^X
M"BBB@ HHHH **** "BBB@ HHHH *_,+_ (+J?\EV\&?]BDW_ *525^GM?F%_
MP74_Y+MX,_[%)O\ TJDKU<F_W^/H_P CQ.(/^19+U7YGPY1117V9^?!1110
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M2]K6C=W:VC445HELD?ROQUQ/GF!XMQ="A6M",E9<L7]E=XMGMG_#8G_5.O\
MRK__ &FC_AL3_JG7_E7_ /M->)T5[G_$O_A'_P!"W_RMB/\ Y:?)?ZY<2?\
M/_\ \EA_\B>V?\-B?]4Z_P#*O_\ ::/^&Q/^J=?^5?\ ^TUXG11_Q+_X1_\
M0M_\K8C_ .6A_KEQ)_S_ /\ R6'_ ,B>V?\ #8G_ %3K_P J_P#]IH_X;$_Z
MIU_Y5_\ [37B=%'_ !+_ .$?_0M_\K8C_P"6A_KEQ)_S_P#_ "6'_P B>V?\
M-B?]4Z_\J_\ ]IH_X;$_ZIU_Y5__ +37B=%'_$O_ (1_]"W_ ,K8C_Y:'^N7
M$G_/_P#\EA_\B>V?\-B?]4Z_\J__ -IH_P"&Q/\ JG7_ )5__M->)T4?\2_^
M$?\ T+?_ "MB/_EH?ZY<2?\ /_\ \EA_\B>V?\-B?]4Z_P#*O_\ ::/^&Q/^
MJ=?^5?\ ^TUXG11_Q+_X1_\ 0M_\K8C_ .6A_KEQ)_S_ /\ R6'_ ,B>V?\
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M_(\3B%VRN7JOS/SFHKURBOGO^(U_]0'_ )5_^YGYYS'D=%>N44?\1K_Z@/\
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M HHHH **** "BBB@ HHHH *_HM_X)J_\F#?"3_L1[+_T"OYTJ_HM_P"":O\
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M8/\ PO\ ]*9_''B+_P EKC/\2_\ 28A1117V)\4%%%% !1110 4444 %%%%
M!1110 4444 %?T,?\$X+3Q<_["'PH:SU:U2(^"K+RT>W)(&SN:_GGK^BW_@F
MK_R8-\)/^Q'LO_0*_'?&;_D2X;_KY_[:S]I\$_\ D=XG_KW_ .W(]7^Q>-_^
M@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HK^=3^DS'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
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M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**\L]4Q_L7C?\ Z#=E_P"
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M%W[=S8SG&XXZFNCH **** "BBB@ HHHH **** /QZ_X./_\ DY'P!_V([_\
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M$_\ 7O\ ]N1[?1117\ZG])A1110 4444 %%%% !1110 4444 %?CU_P<?_\
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M$_\ 7O\ ]N1[?1117\ZG])A1110 4444 %%%% !1110 4444 %?CU_P<?_\
M)R/@#_L1W_\ 2R:OV%K\>O\ @X__ .3D? '_ &([_P#I9-7Z+X5_\EC2_P ,
M_P#TEGYMXL_\D56_Q0_]*1^=%%%%?U.?R8%%%% !1110 4444 %%%% !1110
M 4444 %%%% ']%O_  35_P"3!OA)_P!B/9?^@5[?7B'_  35_P"3!OA)_P!B
M/9?^@5[?7\3YW_R.L3_U\G_Z4S^Y\B_Y$F%_Z]P_])04445Y9ZH4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^/7_!
MQ_\ \G(^ /\ L1W_ /2R:OSHK]%_^#C_ /Y.1\ ?]B.__I9-7YT5_7?A_P#\
MD=@_\+_]*9_''B+_ ,EKC/\ $O\ TF(4445]B?%!17N_[(GP-^&7B[P!XZ_:
M%^+NBZYKVC?#^XTB'_A%_#UVEM+>S7T\L:2SSM'+Y%M'Y+;R$)9I$4%>370_
M\%(]&_94M/C=XZC^#^C:SX7\5Z/\2-2TW6/#$ICGTNZMDED O;1XXH_LHWKM
M-JP< .NU\*0?'_MFB\U^HQA)M7O))63M%V>M]IQ=[65UKO;VO[$K+*?K\JD4
MG:T6W>2O-76EMX25KW=GIM?YGHKZR^$?['7[._\ PS]\2?$'CGXDV_BGX@:/
M\+&\4:;I/AF[9K#P\IEMU1;J=2!-=D3C,"Y2(*P<EB OSU\%/A9;?%_QW%X2
MU+XB:!X4L4MI;K4=?\279BMK2WC&YVPH+22$<)$@+.Q"CK6F'S?!XE5I1O:D
M[-M/71.\5NUKIIKTNK-Y8C)L;AG1C*SE55TDT[:M6D]D]-==.MG=+DJ*^A?V
MZO@;\ /A!X8^$VO?L]S:O=:;XL\$RZA>ZKK>4GU&9+V:#[1Y(9E@5A&"L:GY
M5P&);).5\#OB=^RE;^&]$^'OC']A6_\ '7BRXN3;'5;3XE7MD^I32SMY*);0
MP,JL \<8 )+%<]6J:>;*O@(XJA1G--M6]V,ERMIM\\HI*Z[WU6F]JJ90\/F$
ML)7K0@TD[^_*+YDFDN2$FW9]K:/7:_A]%>]?\%!?#W[.7@'XMVOPL^ ?PR'A
MV]\.V M_'"P^)Y]5@.KG!FMH99@"RVY!B+@+O</QA5)\_P#V?+?X 'QO/JO[
M2-_K7_"/Z=I4]U!I.@*%N-8O% \FR\XJPMD<D[IBK;54@#)!&U#,(XC+EC%3
MDDU=1LG+RT3:UW6MK/5K4QQ&72P^9/!NI%M.SE=J*[ZM)Z;/2]UHGH<+17U3
MX;\#_LK_ +5OP(^*'BCX??L\3_"[7/AKX937K35['Q9>:E8:C'YZ1&RN5O"Q
M2>3?^[:-EW,I^7"X/RM3P./CC74CR2A*#2E&5KJZ4EK%RB[IK9^MA8[+IX&-
M.?/&<*B;C*/-9V;B])1C)6:>Z]+A1117>>>%?T6_\$U?^3!OA)_V(]E_Z!7\
MZ5?T6_\ !-7_ ),&^$G_ &(]E_Z!7X[XS?\ (EPW_7S_ -M9^T^"?_([Q/\
MU[_]N1[?1117\ZG])A1110 4444 %%%% !1110 4444 %?CU_P ''_\ R<CX
M _[$=_\ TLFK]A:_'K_@X_\ ^3D? '_8CO\ ^EDU?HOA7_R6-+_#/_TEGYMX
ML_\ )%5O\4/_ $I'YT4445_4Y_)@4444 %%%% !1110 4444 %%%% !1110
M4444 ?T6_P#!-7_DP;X2?]B/9?\ H%>WUXA_P35_Y,&^$G_8CV7_ *!7M]?Q
M/G?_ ".L3_U\G_Z4S^Y\B_Y$F%_Z]P_])04445Y9ZH4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^/7_!Q_P#\G(^
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MO2^%J2BVDOEKX?\ P\\<_%;QC8?#[X;>%+_6];U.;RK#3--MVEFF;!)PH[
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M_P#2R:OSHK^N_#__ )([!_X7_P"E,_CCQ%_Y+7&?XE_Z3$****^Q/B@HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH _'K_ (./_P#DY'P!_P!B._\
MZ635^=%?HO\ \''_ /R<CX _[$=__2R:OSHK^N_#_P#Y([!_X7_Z4S^./$7_
M )+7&?XE_P"DQ"BBBOL3XH**** "BBB@ HHHH **** "BBB@ HHHH *_HM_X
M)J_\F#?"3_L1[+_T"OYTJ_HM_P"":O\ R8-\)/\ L1[+_P! K\=\9O\ D2X;
M_KY_[:S]I\$_^1WB?^O?_MR/;Z***_G4_I,**** "BBB@ HHHH **** "BBB
M@ K\>O\ @X__ .3D? '_ &([_P#I9-7["U^/7_!Q_P#\G(^ /^Q'?_TLFK]%
M\*_^2QI?X9_^DL_-O%G_ )(JM_BA_P"E(_.BBBBOZG/Y,"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#^BW_@FK_R8-\)/^Q'LO\ T"O;Z\0_X)J_\F#?
M"3_L1[+_ - KV^OXGSO_ )'6)_Z^3_\ 2F?W/D7_ "),+_U[A_Z2@HHHKRSU
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#\>O^#C_ /Y.1\ ?]B.__I9-7YT5^B__  <?_P#)R/@#_L1W_P#2R:OS
MHK^N_#__ )([!_X7_P"E,_CCQ%_Y+7&?XE_Z3$****^Q/B@HHHH **** "BB
MB@ HHHH **** "BBB@ K^BW_ ()J_P#)@WPD_P"Q'LO_ $"OYTJ_HM_X)J_\
MF#?"3_L1[+_T"OQWQF_Y$N&_Z^?^VL_:?!/_ )'>)_Z]_P#MR/;Z***_G4_I
M,**** "BBB@ HHHH **** "BBB@ K\>O^#C_ /Y.1\ ?]B.__I9-7["U^/7_
M  <?_P#)R/@#_L1W_P#2R:OT7PK_ .2QI?X9_P#I+/S;Q9_Y(JM_BA_Z4C\Z
M****_J<_DP**** "BBB@ HHHH **** "BBB@ HHHH **** /Z+?^":O_ "8-
M\)/^Q'LO_0*]OKQ#_@FK_P F#?"3_L1[+_T"O;Z_B?._^1UB?^OD_P#TIG]S
MY%_R),+_ ->X?^DH****\L]4**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH _'K_ (./_P#DY'P!_P!B._\ Z635^=%?
MHO\ \''_ /R<CX _[$=__2R:OSHK^N_#_P#Y([!_X7_Z4S^./$7_ )+7&?XE
M_P"DQ"BBBOL3XH**** "BBB@ HHHH **** "BBB@ HHHH *_HM_X)J_\F#?"
M3_L1[+_T"OYTJ_HM_P"":O\ R8-\)/\ L1[+_P! K\=\9O\ D2X;_KY_[:S]
MI\$_^1WB?^O?_MR/;Z***_G4_I,**** "BBB@ HHHH **** "BBB@ K\>O\
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M )([!_X7_P"E,_CCQ%_Y+7&?XE_Z3$****^Q/B@HHHH **** "BBB@ HHHH
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M(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O OC7_P5!_88_9V^)NI_!SXQ_''^Q_$
MFC^3_:.G?\(SJ=QY/FPQSQ_O(+9XVS'*C?*QQNP<$$#WVOP*_P""UG_*37XE
M_P#<&_\ 3+8U]OP#PU@>*<XJ83%RE&,:;E[K2=U**ZJ2M:3Z'PGB%Q1C^$\E
MIXO!QC*4JB@U--JSC-])1=[Q77OH?J=_P^L_X)E?]'+?^6;K7_R'75?!3_@J
M#^PQ^T3\3=,^#GP<^./]L>)-8\[^SM._X1G4[?SO*ADGD_>3VR1KB.)V^9AG
M;@9) /\ /!7U/_P13_Y2:_#3_N,_^F6^K]*SKPIX=R[)\3BZ=6JY4Z<Y*\H6
MO&+:O:"=KK75'YADGBYQ)F6=8;"5:5%1J5(0;49WM*23M>HU>STNGZ'[ZT44
M5_/Q_1045^<]S+^P3?\ [:WQ^B_;5U^SCO+;Q7IH\/1:AK%_#LMSIL)DV+;.
MHQOQU&<UTGP8O7D_8G_:DUKX2>*=7O?A = UK_A4<NK:C-//#"FC2_;/*:=C
M,EO]H_U2R8; +8^8D@'WI17Y[?LJ^!O^"1GQ*^&GP[\*:]?Z5J'CK6O#VE0:
MC9MXCU99I]4DMXQ*A"S! QE+<# STXK7_:GT?XG^#?V]=8^.WP3N-0N+[X2_
M"O0=5E\*P7#&+6M(:\U**_M-A)!E\A1)&QR=\*\$D8 /O*BOFSQE\2O#OQ0_
M:[_9J\?_  _\0?;=!\1>%?%M]93PR$)<1/9Z>Z%E]1NZ'E3D<'-?,_P@/_!.
M35?B=\;W_;*\16"^*(?CSXEBL$U'6]1A=-/$R>4%6WD";0YFQQGKVQ0!^E=%
M?#/[87PJ_9H\-VW[-OPYT2.VL/AAK7C^XN;F.;7KF*VGM9]/EF#O/)*) K,5
M89<=0..E2V&C_ 3X(?MN?"3PG^PIXZ%PWB2;4H_B)X3T/Q=/JFGMI*6I9+VX
M1YI5MY(YM@C?*ERQ7GD$ ^X:*^ OV\?$_P 0-9^/>O\ [4G@76-0_LC]F&\\
M/^?IMG,?+U26[F6?5XR!P=EC+:!O3YN_%>Q?M[>(H]0UW]F_6/#FKL]GJ7QY
MT1XY[:4A+B![.[9>GWE(P<'VH ^FZ*P/BL[Q_"[Q))&Q5ET"\*L#@@^0]>5?
M\$S+JZOOV!OA5=WMS)-+)X2@,DLKEF8Y;DD\F@#W2BBB@ HHHH **** "O*O
MB1^VS^S%\(O&E[\//B'\3/[/UC3_ "_MEG_8M[+Y?F1K*GSQ0LARCJ>"<9P>
M<BO5:_*S_@I%_P GH^,_^X=_Z;K6OF>*\ZQ619="O0C%MS4?>3:LU)]&M=#R
M,YQ];+L*JE-)MRMKZ-]&NQ]Q?\/(OV+O^BS?^6[J/_R/6Y\-_P!MG]F+XN^-
M++X>?#SXF?VAK&H>9]CL_P"Q;V+S/+C:5_GEA5!A$8\D9Q@<X%?DA7N/_!-W
M_D]'P9_W$?\ TW75?%Y;QYF^,S&C0G3II3G&+LI7LVD[>]N>#A>(\=7Q5.G*
M,;2DEL^KMW/U3HHHK]:/M0HK\Y[F7]@F_P#VUOC]%^VKK]G'>6WBO31X>BU#
M6+^'9;G383)L6V=1C?CJ,YKM_P!ECX):#^T_\ OC3\+/!'C76V^#FN>(4C^#
M.JWVI3S7>F/' C33V[3-YZ6Z7@5HD<@L@;/#DD ^X:*^%O"?[2WQ8_:T^'VB
M?L"ZV][I'Q074KG1?C?J%IN1M,T>P,8N;R*0 ?-?H\,43 8S<2D<(#78^,_
MNB?M9?MKZG^RGXM>ZC^%?PB\$Z9/?^#["]EMH-7U.]W&V6Y,3*TEO#;Q#;$3
MC?R<CB@#ZXHKY(TKP1I'["?[;GPY^&'P8FN[#X<_%ZQU:RO/!\M]+/9Z1JUC
M;K<Q7=JLK,8?-3=$Z*0AP"1P,8_[-WP*^''_  423Q=^U#^U)I5QXKL+[QCJ
M6E^ /#UWJ4\=CHFDV<S6Z-'#$ZK]HD='=Y3ELA=I7% 'V?17P9??#OXA^)?
M7[1O_!._3/&FM:G-X L=-\1?"75KR_DEU"WBFB-Y;V)G)WL(KBW\E68EC'*0
M20 !Z/\ %S]J34_C1_P3>\.^.OAM?+!XG^,ECIOA?1/(./L^J:BXM;K:1T,
M%V^>WD9XZ@ ^K**^5/#'A;3O!W_!4;1OA/I,MQ_8FE_LJBRM[22=B#'%K<4*
MD\\ML&-W6O._VQOV-/V5?#]QH'[-/[/7P=B7XG?$*1XM*NV\0:E*GA[34(^U
MZO.AN<;8ERL:MQ)*R@!L,M 'W?17.?"'X8>'?@M\+]!^$_A.6YDT[P_I<5E;
M37LYEFE"+@R2,?O.QRQ/3). !Q71T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5^!7_!:S_E)K\2_^X-_Z9;&OWUKX<_;"\!_\$6]:_:,\1:E^UGI7F_$&3[)
M_P ) _G^(USBSA$'%FP@_P"/<0_<_'YLU]WX>\087AO.JF)KTYS4J;C:"3=W
M*#O9M::=]['P'B/P[BN)LCIX6A4A!QJ*5ZC<591FK)I/77MM<_$:OJ?_ ((I
M_P#*37X:?]QG_P!,M]7V-_PJ_P#X-S_^@'_Y,^+O_BJ],_8]\!_\$6]%_:,\
M.ZE^R9I7E?$&/[7_ ,(^_G^(VQFSF$_%XQ@_X]S-]_\ #YL5^G9WXF91C\EQ
M.&AAJZ=2G.*;A%).46DV^=Z:ZZ/0_*LB\,<WR_/,+BIXK#M4ZD)-*<FVHR3:
M2Y%=NVFJU/N.BBBOYV/Z4/C+P%\6_%W[,7[6OQXU'Q3^R]\6_$&G^+O%>G7F
MAZKX/\"S7UK/%%IT43D2;E!P^1QGH?2J'A[X8?&/QWX%_:Q^,EG\#->\':1\
M3O \UMX/\"ZC:HNIW][%I-U!+>/:0LXAFN)'C4("7D*Y;)P3]N44 ?)/[/?[
M:=_\,/@%X'^&GB3]BW]H!M1\.^#],TR_:V^%\SQF>"UCB?8QD!*[D.#@9'85
MZ!\/?#WBN_\ V]?%/Q2N?!FK66AZM\(- @M;V_L'C0W"WM_));%B-HF19$+I
MDE=PSUKW:B@#XF^'W[-7Q?\ @7_P4:\'>$O#GA"]NOA!I<'B76_"NIV]L[6^
M@R:G##]HTMV VQ(MQ TL2G'RW)49*G"_LV?'#Q;^RQXK^,OA'QQ^R;\9M6.O
M?'/Q%KVDZEX8^'TUW:7-E<21+%(DNY0V[RF8$ @@J03FOMBB@#Y#_:&L;O\
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M.D^)?@;3_'*>$==T$:A$SC2/$VFFSOK;#LN)8224)VY ST(/>MVBB@ HHHH
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M\78?&OA34=)?5?CYXHU+3%U&S>$W5G-/&8KB/<!OC< E7'!QP:^@Z "BBB@
MHHHH **** "BBB@ K\D?^"G/_)\7C?\ [AO_ *;+6OUNK\D?^"G/_)\7C?\
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MMXTBXMG$0_=+&/E';GG-?3M?$G[7?_)P_B'_ +=/_22&OAN/^+<TX-R:GC<
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20240630_g11.jpg
<TEXT>
begin 644 biib-20240630_g11.jpg
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M]=6(Q]U/[3@CMP.ZSOS6+\7-"\3>(?V;/VS;/PS87-WY'QG@N]4L[,$R3Z?
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M:T/]BOX;_'[]I+QM'#J?BO0K$M]DTUY+C4]0FCW>3;6MLC/+(QR0D:' !.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH SM1\(^$]7\0:=XLU;PQIUUJNCK,ND:G<64;W%B)
ME"S"&1@6BWJJAMI&X  YQ5ZXM[>[MWM;J!)8I4*21R*&5U(P00>"".U/KRK]
MDO\ :;M/VEO@5IGQFUG0;;PXVIZU?Z=#I\FIB8&2WO9K90KLJ;F?R=P4+D9Q
MSC- '5_#WX%?!'X27MWJ7PI^#GA7PQ<WX_T^X\/>'K:R>YYS^\:%%+\\\YYK
M;T7PKX7\-W-_>^'?#=A83:K>&[U26RLTB:\N"JJ9I2H!D<JJKN;)PH&>!5F?
M4M.MKR#3KF_ACN+D.;:!Y0'EV@%MJDY; ()QTS69J?Q&^'NBFV&L>.]&M#>W
M36UF+G5(H_/G4[6B3<PW.#P5&2#VH V2 P*L 01R#7&>'_V<OV>O":3Q^%?@
M1X,TQ;K4X-1NET_PO:0B:\@9FAN6V1C=+&S,R2'YE+$@C)KJ]4U72]#TZ;5]
M:U*WL[2WC+W%U=3+''$HZLS,0%'N:@\->*O"_C/2EUSP?XDL-5LG8JEYIMXD
M\3$=0'0D$CZT &I>%?"^L:UIWB35_#=A=:CH[ROI%_<V:/-8M*ACD,+L"T1=
M"58J1N4X.16!XR_9_P#@/\1O$UMXT^(/P3\(Z[K-F%%IJVL^&[6ZN8 IRH26
M6-G7!Y&#Q5CXQ_$NW^#OPRUGXEW/A36M=&DVGFIH_AW3GNKV\<L%2.*-!DDL
MP!)PJC+,0JDCPGQQ^V)^U+\ M#L/B[^TQ^S!X?T;P#=ZE:6NK7/A[QPU_J7A
MU;F9(8Y;J)K6.*91)(BMY,C$;LC=CD ^G  H"J  !P!6+X\^&WP[^*>AGPQ\
M3O .B^(]-+ASI^O:5#>0%AT;RY59<\GG%>;_ !S_ &E/&?A;XLZ/^SA\!/AU
M9>*O'FKZ/)K%U'J^KM8Z=HNF))Y0N[J9(I9#OE_=I'&A9BK$E0O+OV?_ -IC
MQ/X]^)7B']GOXW?#JW\)?$'PU8P:C+I]AJIO;'5=-E8HE]9S-'&[1^8IC=71
M61L YSP >@_#WX4?"WX1Z5)H7PI^&N@>&+&63S);/P]HT%E$[_WBD*J"??%+
MH_PL^&/AY]+DT#X<:#8MH9N3HK6>CP1'3S<L6N/(VJ/*\UB2^W&\DELUO5Y=
M^TU^TE+\!H/#GACPCX N?%WC7QKJK:=X0\+6UXEM]KD2,RS32SN"(8(HP7=]
MK$9&%.<@ [^+P;X0@\5R^/(?"NFIKD]BME/K2V,8NY+96WK"TV-YC#?,$)P#
MSC-2:WX8\-^)6LG\1^'K'4#IU\E[IYO;1)3:W*!@D\>X'9(H9@'7##<<'FO#
M?"?[5?QM\$_&GPS\$OVL?@GH_AV3QPT\/A+Q-X3\2/J.GSW<49E:SG$L$,D$
MAC!*MAE<\#H:D\0?M0?'#X@_%3Q3\-/V3/@YH'B.W\"7267BGQ%XL\32Z=:/
MJ)C$K:?:B&WG:65$9-[ML1&8*<]: /;CX8\-'Q*/&9\/6)UA;$V2ZL;1/M(M
MBXD,'FXW>67 ;9G;N .,TS1?!_A+PW<ZC>^'?"VG6$VKW9NM6ELK&.)KV<J%
M,LQ4 R.5 &YLG  SQ7BVB_M_?#@_LQ>)?VB/&WA35=$O?!>J2Z+XL\&';/?V
M>M)*D(L(RN%F:226+RY!A6656.WY@.;\7?ME?M1_ CP[:?&/]I_]EC1M!^']
MQ=VT6L7GA_QL=0U+PU'/(L237D)MHXY4#N@?R78KG/S8H ]R\#_ 3X%_#'7;
MOQ3\-?@OX3\/:G?@B^U'0_#EK:3W )W$2211JSY//)/-;NF>%?#&B:MJ.OZ-
MX<L+2_U>6.35KVULTCFO71!&C3.H#2%4 4%B2%  X%4OB3\1O!WPD\ :O\3O
M'VL1V.C:)827>H73\[8U&<*!RS$X55'+,0!DD5YC^Q5^U9XH_:K\/>+M3\8_
M"&7P5J'A3Q=)HD^CW&IBZF&VV@G!E(C01R 3A60;@K*?F- 'J5O\// %IH%_
MX4M/ VCQ:7JLL\NJ:;'ID2V]X\Y)F:6,+MD:0DERP)8DYS6;X1^!7P1^'\6F
MP^ O@YX5T1-'N)Y](32/#UM;"QEG0)/)"(T'E-(@"N5P6  .174LRHI=V  &
M22> *Q?#/Q+^'/C2_GTOP=X_T35KJU&;JVTS589Y(1G'S*C$KSQS0!<'A7PN
M/%!\;CPW8?VT; 6)U?[&GVHVH?S!!YN-_E[R6V9V[CG&:YI/V;_V=X_'/_"S
MX_@+X+7Q+Y_G_P#"1+X6M!?>;G._[1Y?F;L\YW9K=UWX@^ O"]I)?^)?&^CZ
M=!#="VFFOM2BA1)B,B,EV #D$':><&M&XU'3[2P?5;J^ABM8XC+)<R2A8UC
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M%M+U&YW"W@NXI;:'*NP*^;&2JD<]10!]%VUM;V=O':6D"111($BBC4*J*!@
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M9^'6I:I;>)-;X>TA,EM"R&WM0?.8%OFG" KB(UE?\$U?CGHGBKXR_'#PW:^
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M&?A%XO\ B=:3:OKNN2B?5]5G2"7Q!KMY(\\QC0GEG;?MC&2$0#D@D^!?M=^
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MQQ1&WG= 2@PZ.58*Y(KWF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ_;WEQ,=&:Q13<%?,DEBV;<J(D9L*,UN^/\ ]I#XS?&KXR_![P3^V)^SM=_
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MDQ&TB^4R[@VS^&@#Z3HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#/Z__P!.Y?\ DO\ \D?I+_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M7YM?\
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MGJ%,K,0/855U+Q9XIUK1[#P]K'B74+O3]+#C3+&YO'DALPY!<1(Q*Q[B 3M
MS@9JDF2Y+3R/K[Q#^U#^V'\._B[)\$?"GP,N9?#.ER2Z-I7A.?2+FYENM/W[
M%(O23.Q= ")%?RQP0NT 5\[?M9^!/ 7PS_:*\5>!OAE=F71=/OU2U#7/G&%S
M$C2P;\G=Y<K21Y))^3DDY-8MC\>/CCI?AX>$M,^,OBNWTI8O*73(/$5REN$Z
M;?+#[<>V,5RA))R32C#E8YSYE8****LS"BBB@ K]E_V)?^32?A[_ -BM:_\
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M1KS9?$SUH? @HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQYP4444 %%%% !1110 4444 %%%% !1110 4444 ?LO^Q+_R:3\/?^Q6M?\
MT"O4:\N_8E_Y-)^'O_8K6O\ Z!7J->;+XF>M#X$%%%%24%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G%_P %I/\
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M-;'[:FF_ *W^*'BM/ASIFI:%K^G>-;ZRU'0I"DMC/"LCXN;=D1/(^9<& A@
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MGJUJD1\,VWEH]N20-O<UZ=]B\;_]!NR_\!C_ (UYLOB9ZT/@1L45C_8O&_\
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M]BM:_P#H%>HUYLOB9ZT/@04445)04444 %%%% !1110 4444 %%%% !1110
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M?'O6=.N-'UCXW^+[NTNX'ANK6Y\2W4D<T; JR.K2$,I!((/!!Q7!?\))HO\
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MFOPU_P"Q1M/_ $"OPYK]QOV#?^3-?AK_ -BC:?\ H%>#G_\ N\/7]#Z;A?\
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M0 4444 %%%% !1110!^87_!=3_DNW@S_ +%)O_2J2OAROT9_X+"_\EB\*_\
M8LM_Z425\A5\WC?%7^PL5+ ?4^?V>G-[2U^NW([;]V?FN=2_X5*OK^B/(Z*]
M<HKE_P"(U_\ 4!_Y5_\ N9Y?,>1T5ZY5S1- UOQ)>/I^@:5/>3QVTMP\5O&6
M98HHVDD<@?PJBLQ/8 FFO&ER=EE^O_7W_P"YC3;=DCQ>BO7**7_$:_\ J _\
MJ_\ W,7,>1T5ZY11_P 1K_Z@/_*O_P!S#F/(Z*]<HH_XC7_U ?\ E7_[F',>
M1T5ZY11_Q&O_ *@/_*O_ -S#F/(Z*]<HH_XC7_U ?^5?_N8<QY'7[C?L&_\
M)FOPU_[%&T_] K\E:_7G]C7_ )-7\!?]BS;?^@UZ>5\?_P"MU66'^K>RY%S7
MY^:_2UN6/<^GX7=\7/\ P_JCTNBBBO;/MPHHHH **** "BBB@ HHHH ****
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M/?VA/C-HW[//B?\ 9A\#V?A?Q1>?V9:/H>C>7J^E[P1'<KJ!)FF=#AG,I97
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MW\NJN>;?$O4;'7/BY8Q_%WX:2^"I(5@A\5VFC:7]FFE8$F2X2V<*D4CH1\H
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M_P#XW1_PT5\9/^AQ_P#*?;__ !NN)HH_XAUX??\ 0GPO_A/2_P#D _MO.O\
MH)J?^!R_S.V_X:*^,G_0X_\ E/M__C='_#17QD_Z''_RGV__ ,;KB:*/^(=>
M'W_0GPO_ (3TO_D _MO.O^@FI_X'+_,[;_AHKXR?]#C_ .4^W_\ C='_  T5
M\9/^AQ_\I]O_ /&ZXFBC_B'7A]_T)\+_ .$]+_Y /[;SK_H)J?\ @<O\SMO^
M&BOC)_T./_E/M_\ XW7] '_!.W5]1U_]AOX6:UJUQYMS<^#+.2>78%W,4Y.%
M  _ 5_.37]%O_!-7_DP;X2?]B/9?^@5^8^*'"W#.0Y70JY9@:-"4IV;ITH0;
M7*W9N,4VKZV9^P^#>88_&9SB8UZLII4]I2;^TN[/;Z***_$S^B HHHH ****
M "BBB@ HHHH **** "OS/_X+@>'=9UGXX^#IM-L_,5/"C*Q\Q1@_:9/4BOTP
MK\^/^"PO_)8O"O\ V++?^E$E>3G>>XOAS+Y8[#1BYQ:5I)M:NSV:?XGB<0NV
M5R]5^9^?O_"">*_^@5_Y'C_^*H_X03Q7_P! K_R/'_\ %5Z+17Q/_$8^)_\
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MB/PUXTT;2Q8'5-.DG>VD6YME)2&:.5!]P[65QW&3]!4 %%%% !1110 4444
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M%!/"C@#@5SE%9NE2=55&ES)-7ZV=KK\$:*M55)TE)\K:=NEU>S]5=_>>D_\
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M_"__ $IG\<>(O_):XS_$O_28A1117V)\4%%%% !1110 4444 %%%% !1110
M4444 %?T,?\ !."T\7/^PA\*&L]6M4B/@JR\M'MR2!L[FOYYZ_HM_P"":O\
MR8-\)/\ L1[+_P! K\=\9O\ D2X;_KY_[:S]I\$_^1WB?^O?_MR/5_L7C?\
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M5?T6_P#!-7_DP;X2?]B/9?\ H%?COC-_R)<-_P!?/_;6?M/@G_R.\3_U[_\
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M5^=%?UWX?_\ )'8/_"__ $IG\<>(O_):XS_$O_28A1117V)\4%%%% !1110
M4444 %%%% !1110 4444 %?T6_\ !-7_ ),&^$G_ &(]E_Z!7\Z5?T6_\$U?
M^3!OA)_V(]E_Z!7X[XS?\B7#?]?/_;6?M/@G_P CO$_]>_\ VY'M]%%%?SJ?
MTF%%%% !1110 4444 %%%% !1110 5^/7_!Q_P#\G(^ /^Q'?_TLFK]A:_'K
M_@X__P"3D? '_8CO_P"EDU?HOA7_ ,EC2_PS_P#26?FWBS_R15;_ !0_]*1^
M=%%%%?U.?R8%%%% !1110 4444 %%%% !1110 4444 %%%% ']%O_!-7_DP;
MX2?]B/9?^@5[?7B'_!-7_DP;X2?]B/9?^@5[?7\3YW_R.L3_ -?)_P#I3/[G
MR+_D287_ *]P_P#24%%%%>6>J%%%% !1110 4444 %%%% !1110 4444 <A\
M:K'XW77A.*\^ .O:#::]97RW!LO$UG))9ZG $=6M7>(B2W+%E83*'*M& 492
MPKQ34/\ @H+\3/AS*=&^.?\ P3\^,=AJ*<//X(T:'Q'IS^Z7-O(AP>H#(I]0
M#Q7TU10!\U:5^UG^UC\>)!I/[/'[%OB'PG;RG;)XM^- 72H+,?WUT^%WN;D]
M<*#&#QEES7T-X5L-=TOPQIVF>*=?75=3MK"&+4=42T6W%Y.J 23")21&'8%M
M@)"YQDXJ_10 4444 %%%% !1110 4444 ?CU_P ''_\ R<CX _[$=_\ TLFK
M\Z*_1?\ X./_ /DY'P!_V([_ /I9-7YT5_7?A_\ \D=@_P#"_P#TIG\<>(O_
M "6N,_Q+_P!)B%%%%?8GQ04444 %%%% !1110 4444 %%%% !1110 5_1;_P
M35_Y,&^$G_8CV7_H%?SI5_1;_P $U?\ DP;X2?\ 8CV7_H%?COC-_P B7#?]
M?/\ VUG[3X)_\CO$_P#7O_VY'M]%%%?SJ?TF%%%% !1110 4444 %%%% !11
M10 5^/7_  <?_P#)R/@#_L1W_P#2R:OV%K\>O^#C_P#Y.1\ ?]B._P#Z635^
MB^%?_)8TO\,__26?FWBS_P D56_Q0_\ 2D?G11117]3G\F!1110 4444 %%%
M% !1110 4444 %%%% !1110!_1;_ ,$U?^3!OA)_V(]E_P"@5[?7B'_!-7_D
MP;X2?]B/9?\ H%>WU_$^=_\ (ZQ/_7R?_I3/[GR+_D287_KW#_TE!1117EGJ
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'X]?\''_ /R<CX _[$=__2R:OSHK]%_^#C__ ).1\ ?]B.__ *635^=%
M?UWX?_\ )'8/_"__ $IG\<>(O_):XS_$O_28A1117V)\4%%%% !1110 4444
M %%%% !1110 4444 %?T6_\ !-7_ ),&^$G_ &(]E_Z!7\Z5?T6_\$U?^3!O
MA)_V(]E_Z!7X[XS?\B7#?]?/_;6?M/@G_P CO$_]>_\ VY'M]%%%?SJ?TF%%
M%% !1110 4444 %%%% !1110 5^/7_!Q_P#\G(^ /^Q'?_TLFK]A:_'K_@X_
M_P"3D? '_8CO_P"EDU?HOA7_ ,EC2_PS_P#26?FWBS_R15;_ !0_]*1^=%%%
M%?U.?R8%%%% !1110 4444 %%%% !1110 4444 %%%% ']%O_!-7_DP;X2?]
MB/9?^@5[?7B'_!-7_DP;X2?]B/9?^@5[?7\3YW_R.L3_ -?)_P#I3/[GR+_D
M287_ *]P_P#24%%%%>6>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?CU_P ''_\ R<CX _[$=_\ TLFK\Z*_1?\
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MO\,__26?FWBS_P D56_Q0_\ 2D?G11117]3G\F!1110 4444 %%%% !1110
M4444 %%%% !1110!_1;_ ,$U?^3!OA)_V(]E_P"@5[?7B'_!-7_DP;X2?]B/
M9?\ H%>WU_$^=_\ (ZQ/_7R?_I3/[GR+_D287_KW#_TE!1117EGJA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X]?
M\''_ /R<CX _[$=__2R:OSHK]%_^#C__ ).1\ ?]B.__ *635^=%?UWX?_\
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MU_$^=_\ (ZQ/_7R?_I3/[GR+_D287_KW#_TE!1117EGJA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%9VI>&=/U6Z-W<3W*L5 Q%<%1Q["@#1
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:M#3=.@TJU%I;O(RAB<RN6//N:
M+%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X]?\
M!Q__ ,G(^ /^Q'?_ -+)J_.BOT7_ .#C_P#Y.1\ ?]B._P#Z635^=%?UWX?_
M /)'8/\ PO\ ]*9_''B+_P EKC/\2_\ 28A1117V)\4%%%% !1110 4444 %
M%%% !1110 4444 %?T6_\$U?^3!OA)_V(]E_Z!7\Z5?T6_\ !-7_ ),&^$G_
M &(]E_Z!7X[XS?\ (EPW_7S_ -M9^T^"?_([Q/\ U[_]N1[?1117\ZG])A11
M10 4444 %%%% !1110 4444 %?CU_P ''_\ R<CX _[$=_\ TLFK]A:_'K_@
MX_\ ^3D? '_8CO\ ^EDU?HOA7_R6-+_#/_TEGYMXL_\ )%5O\4/_ $I'YT44
M45_4Y_)@4444 %%%% !1110 4444 %%%% !1110 4444 ?T6_P#!-7_DP;X2
M?]B/9?\ H%>WUXA_P35_Y,&^$G_8CV7_ *!7M]?Q/G?_ ".L3_U\G_Z4S^Y\
MB_Y$F%_Z]P_])04445Y9ZH4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!^/7_!Q_P#\G(^ /^Q'?_TLFK\Z*_1?_@X_
M_P"3D? '_8CO_P"EDU?G17]=^'__ "1V#_PO_P!*9_''B+_R6N,_Q+_TF(44
M45]B?%!1110 4444 %%%% !1110 4444 %%%% !7]%O_  35_P"3!OA)_P!B
M/9?^@5_.E7]%O_!-7_DP;X2?]B/9?^@5^.^,W_(EPW_7S_VUG[3X)_\ ([Q/
M_7O_ -N1[?1117\ZG])A1110 4444 %%%% !1110 4444 %?CU_P<?\ _)R/
M@#_L1W_]+)J_86OQZ_X./_\ DY'P!_V([_\ I9-7Z+X5_P#)8TO\,_\ TEGY
MMXL_\D56_P 4/_2D?G11117]3G\F!1110 4444 %%%% !1110 4444 %%%%
M!1110!_1;_P35_Y,&^$G_8CV7_H%>WUXA_P35_Y,&^$G_8CV7_H%>WU_$^=_
M\CK$_P#7R?\ Z4S^Y\B_Y$F%_P"O</\ TE!1117EGJA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X]?\ !Q__ ,G(
M^ /^Q'?_ -+)J_.BOT7_ .#C_P#Y.1\ ?]B._P#Z635^=%?UWX?_ /)'8/\
MPO\ ]*9_''B+_P EKC/\2_\ 28A1117V)\4%%%% !1110 4444 %%%% !111
M0 4444 %?T6_\$U?^3!OA)_V(]E_Z!7\Z5?T6_\ !-7_ ),&^$G_ &(]E_Z!
M7X[XS?\ (EPW_7S_ -M9^T^"?_([Q/\ U[_]N1[?1117\ZG])A1110 4444
M%%%% !1110 4444 %?CU_P ''_\ R<CX _[$=_\ TLFK]A:_'K_@X_\ ^3D?
M '_8CO\ ^EDU?HOA7_R6-+_#/_TEGYMXL_\ )%5O\4/_ $I'YT4445_4Y_)@
M4444 %%%% !1110 4444 %%%% !1110 4444 ?T6_P#!-7_DP;X2?]B/9?\
MH%>WUXA_P35_Y,&^$G_8CV7_ *!7M]?Q/G?_ ".L3_U\G_Z4S^Y\B_Y$F%_Z
M]P_])04445Y9ZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!^/7_!Q_P#\G(^ /^Q'?_TLFK\Z*_1?_@X__P"3D? '
M_8CO_P"EDU?G17]=^'__ "1V#_PO_P!*9_''B+_R6N,_Q+_TF(4445]B?%!1
M110 4444 %%%% !1110 4444 %%%% !7]%O_  35_P"3!OA)_P!B/9?^@5_.
ME7]%O_!-7_DP;X2?]B/9?^@5^.^,W_(EPW_7S_VUG[3X)_\ ([Q/_7O_ -N1
M[?1117\ZG])A1110 4444 %%%% !1110 4444 %?CU_P<?\ _)R/@#_L1W_]
M+)J_86OQZ_X./_\ DY'P!_V([_\ I9-7Z+X5_P#)8TO\,_\ TEGYMXL_\D56
M_P 4/_2D?G11117]3G\F!1110 4444 %%%% !1110 4444 %%%% !1110!_1
M;_P35_Y,&^$G_8CV7_H%>WUXA_P35_Y,&^$G_8CV7_H%>WU_$^=_\CK$_P#7
MR?\ Z4S^Y\B_Y$F%_P"O</\ TE!1117EGJA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'X]?\ !Q__ ,G(^ /^Q'?_
M -+)J_.BOT7_ .#C_P#Y.1\ ?]B._P#Z635^=%?UWX?_ /)'8/\ PO\ ]*9_
M''B+_P EKC/\2_\ 28A1117V)\4%%%% !1110 4444 %%%% !1110 4444 %
M?T6_\$U?^3!OA)_V(]E_Z!7\Z5?T6_\ !-7_ ),&^$G_ &(]E_Z!7X[XS?\
M(EPW_7S_ -M9^T^"?_([Q/\ U[_]N1[?1117\ZG])A1110 4444 %%%% !11
M10 4444 %?CU_P ''_\ R<CX _[$=_\ TLFK]A:_'K_@X_\ ^3D? '_8CO\
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M -M9^T^"?_([Q/\ U[_]N1[?1117\ZG])A1110 4444 %%%% !1110 4444
M%?CU_P ''_\ R<CX _[$=_\ TLFK]A:_'K_@X_\ ^3D? '_8CO\ ^EDU?HOA
M7_R6-+_#/_TEGYMXL_\ )%5O\4/_ $I'YT4445_4Y_)@4444 %%%% !1110
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M 4444 %%%% !1110 4444 %?CU_P<?\ _)R/@#_L1W_]+)J_86OQZ_X./_\
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MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
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M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
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M@#TOX)?MX_L@?M&>)/\ A#?@U\?-"UG5RC/'I8D>"XF51EC''.J-)@ D[0<
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M*Q^&D*.5CU_5#?P6]YK+8X>%%:6VM^H.Z:3C(K](K3_CTB_ZYK_*@"2BBB@
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MXE53';DY!Q(R\$'H:\?;Q#I'[7/_  4B\%^/?@5:)<^'/@K8ZQ:^,_'=JO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFWQU_P %=_\
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M;:SXJATN(>(-3LK58(9[O;F0QHH "!B0.!D ' SBNCH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K^;;]NC_D]KXQ?]E4\0_^G*XK^DFOQD_:C_8>_8C\6_M-
M?$7Q5XL_X*2_V%JNI^.]7N]3T3_A3NI77]GW$E[*\EOYR3!9?+8E/,4 -MR
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M"_$K0)?"?Q&\%Z3K^E3,&FTW6].BN[>0CH6CE5E./<4 ?,_C_P 5>&OVG/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^$?[7O_ "=E\4/^RB:W_P"E\U?NY7X1_M>_\G9?%#_LHFM_^E\U?09!_&GZ
M'RW%'\"GZO\ (\[KT3]D+_D[+X7_ /91-$_]+X:\[KT3]D+_ ).R^%__ &43
M1/\ TOAKZ2M_!EZ,^2P_^\0]5^9^[E%%%?G9^K'R;X8\0?M@?M _M-_&/P-X
M'_:JB\%Z'X \16%AI>GIX#L=09TGL8YV+22E6R&+=<]?:MN_\>?M'_!;]J3X
M&? /QQ\<(O%]KXX;Q;/XAOV\+6M@TT=G8VLMK&JQ;MFQWD)92"V_!R *\_\
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M^';C4#\0_@E9^!KZRM8MP?75T]+C1)F7^)FE\V$D]$]: /3OA)^V'\;?B?\
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M9XU09P/@=I &3G_F)7% 'TS1110 4444 %%%% !1110 4444 %%%% !1110
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M-3\8PSZ!!;OXDM=.CM[F2")$#?9Y3 TRIY9R6"]<UZ%\:OVHIKKX1?"7XP?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ-:^'?#>D6NGZ?8VZ6]C86-NL4-O$BA4C1% 5%4  *   ,"@"U1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20240630_g12.jpg
<TEXT>
begin 644 biib-20240630_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"":'PC_P""F?P[_8IBF\*Z!\.H/!>J?#OP]H[,MMX5NM?TV*/4KFQCY%N
MS-<A4PB.F5  Q0!^QEMK.D7E_/I5IJMM+=6NW[3;1SJTD.[D;E!RN>V>M1>)
MK_6=*\-ZAJGAW0#JNH6UC++8:6+I(#>3*A*0^8_RQ[V 7<W"YR>!7Y,^(/\
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M_P *_$_@JR$MOX<\:?%[P/J>H>+M)LW8^7'+);WR6VI2PJ0$FE1"^T>8IZ4
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M#O\ 8SL?^"A'AK]J[PM^RQ\%=,\#Z%\-+O19/ 5G\+].BCDUQ]1@N;?5UC2
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M/[(W[,7PZ_8P_9G\%?LL?"8W;>'_  /H,.F:?/?R!Y[C;DO/*0 #))(SR-M
M7<YP , >C4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT%=QCC8+N7.,C+/V8/VY?V5?VREUF+]G3XMV^N7OAR6./Q!HEWIMWINIZ89
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MJ6W,,'Q$UBWU-KJ?5K88!N+:U119)<D%9,N(V9$^4 ^_J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%
M_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+
MO^29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGP?X4^&?PV2]N]-%GJRI'J,]_?7T<,MV\D*>2L2P11HK,?F8DG[.HH _//\
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M")AA#D%8P!C./H.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 ?4W_#RW_JBO_EQ_P#W-1_P\M_ZHK_Y<?\ ]S5\LT4 ?4W_  \M_P"J*_\
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M  KK^RMFGR7/VK^U_/SM9!MV^2G7=USVZ5\05[E_P3Y_Y+Q-_P!@"X_]&14
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MWXAOJ_AO0OLUP=.EC,GVJ5_E+(2,,Q'851KK_@I_R.+?]>3_ ,UH ]9HHHH
M**** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
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MO^"G_(XM_P!>3_S6@#UFBBB@ HHHH **** "BBB@ HHHH **** "O*/VY_\
MDT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I
M6[6%\+O^29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\W
M^//_ !^:;_URE_FM>D5YO\>?^/S3?^N4O\UH \_HHHH **** "BBB@ HHHH
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MB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\
MT-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH ****
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M?[1&BW<;7^A^*?"7A'3;.WBM88V,L4']F22I=LS G.XG(V@4 >^T5^?GP/\
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M\>?^/S3?^N4O\UH \_HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Z_X*?\CBW_7D_P#-:Y"NO^"G_(XM_P!>
M3_S6@#UFBBB@ HHHH **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\
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MBBB@ KS?X\_\?FF_]<I?YK7I%>;_ !Y_X_--_P"N4O\ -: //Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
MO^"G_(XM_P!>3_S6N0KK_@I_R.+?]>3_ ,UH ]9HHHH **** "BBB@ HHHH
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M1I>JQ!?*MY+R.3=8SR([E)&,:L$90Q.0/F?_ ()*Z5X]N==\#^#?V1_'6O\
MQ"T%O@8FK?$_PU<^(!>:7X:UP1VYM+>WGD)2SN)G:X1[,/E50L4&T;?V\U[0
M])\3:+=>'M=L8KFSO8&AN;>9 RR(PP00>#7.? ?X(_#W]F[X.^'/@7\*]*:S
M\/\ A;2+?3=+BD</(8H8UC5I'P-[D*-SGECR: /Q@^!?[ 7[*O[>/P8U;]J/
M]K'XJ:;!\2?$33'QT;?QAI_A]_"5S!,Z_8I;%W38\/EJ"UZDKOL#DD%:][_8
MD^,WB?PM^PK>_'G]ISQWI4/@?PQXSO\ P[X:^)-XD%C:Z_I-O="ULK]40A=L
MIS&K(NUM@()R2?T)^(/[&?['_P 6?%__  L+XJ?LI?#7Q-K^Y3_;GB#P+I][
M>97&#YTT+/Q@8YXP*ZCQK\)/A3\2?!/_  K3XB_#+P]K_AS$0_X1_6M%@NK'
M$1!C'D2HT?R%05^7Y<#&,4 ?GM^U!\*/V7C^US\-/#G[67@&SA\3W&@7]Q\/
MM6\6WD$>@W3>;%YUJ))91;R7@Q'*D;@L  R_-MKA_"7PKT'6O^"K^A:/^QUH
MNB7$EG\.=3?XV-X.O;1].6-I81I2W3V[^0+WS1.55CYWE9.-E?J%\2/A-\*_
MC'X3D\!?%[X9^'_%6A2LK2Z+XDT:"^M'*_=)AF1D)&3CCC-1_"WX-?"#X'>&
M_P#A#?@I\*O#?@_2/-,O]E>%M"M]/MMYZMY4"(N3@<XS0!XA_P *!^+?_0I_
M^3]O_P#'*/\ A0/Q;_Z%/_R?M_\ XY7TG10!\V?\*!^+?_0I_P#D_;__ !RC
M_A0/Q;_Z%/\ \G[?_P".5])T4 ?-G_"@?BW_ -"G_P"3]O\ _'*/^% _%O\
MZ%/_ ,G[?_XY7TG10!\V?\*!^+?_ $*?_D_;_P#QRC_A0/Q;_P"A3_\ )^W_
M /CE?2=% 'S9_P *!^+?_0I_^3]O_P#'*/\ A0/Q;_Z%/_R?M_\ XY7TG10!
M\V?\*!^+?_0I_P#D_;__ !ROLO\ 8[\.:SX4^ VF:)K]G]GNH[FY+Q>8KX!F
M8CE21T/K7#U[%\(?^1%MO^NLO_H9H Z:BBB@ HHHH *\W^//_'YIO_7*7^:U
MZ17F_P >?^/S3?\ KE+_ #6@#S^BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@I_R.+?\ 7D_\UKD*Z_X*
M?\CBW_7D_P#-: /6:*** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>
M_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH Z3X:^#=*G^'.@3O<W8+Z)
M:L0MTP&3"M;?_"#Z1_S\WO\ X%M47PN_Y)GX=_[ 5I_Z)2MV@#'_ .$'TC_G
MYO?_  +:O&=<B6#6[R!"2$NI%!8Y. QKWZO!/$?_ ",-_P#]?LO_ *&: *5%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7J'PR\+Z?J?@^"\N)[E6:20$1W#*.&(Z"O+Z]B^$/_(BVW_767_T
M,T 7O^$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
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MEOJWBEK6Y>15%J[9BD*G.5[BN9KK_@I_R.+?]>3_ ,UH ]!_X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#+L_"6FV-TEW#<71:-LJ'N6(_$5J444 %%%%
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M1Q;_ *\G_FM<A77_  4_Y'%O^O)_YK0!ZS1110 4444 %%%% !1110 4444
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MHHH **** "BBB@ HHHH *Z_X*?\ (XM_UY/_ #6N0KK_ (*?\CBW_7D_\UH
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M_'G_ (_--_ZY2_S6O2*\W^//_'YIO_7*7^:T >?T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=?\%/\ D<6_
MZ\G_ )K7(5U_P4_Y'%O^O)_YK0!ZS1110 4444 %%%% !1110 4444 %%%%
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M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
MDF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %>">(_^1AO_ /K]E_\
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M %%%% !1110 4444 %>Q?"'_ )$6V_ZZR_\ H9KQVO8OA#_R(MM_UUE_]#-
M'34444 %%%% !7F_QY_X_--_ZY2_S6O2*\W^//\ Q^:;_P!<I?YK0!Y_1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5U_P4_Y'%O^O)_YK7(5U_P4_P"1Q;_KR?\ FM 'K-%%% !1110 4444
M %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[
M+_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %>">(_\
MD8;_ /Z_9?\ T,U[W7@GB/\ Y&&__P"OV7_T,T 4J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8OA#_ ,B+
M;?\ 767_ -#->.U[%\(?^1%MO^NLO_H9H Z:BBB@ HHHH *\W^//_'YIO_7*
M7^:UZ17F_P >?^/S3?\ KE+_ #6@#S^BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@I_R.+?\ 7D_\UKD*
MZ_X*?\CBW_7D_P#-: /6:*** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y
M-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/
M_1*5NUA?"[_DF?AW_L!6G_HE*W: "O!/$?\ R,-__P!?LO\ Z&:][KP3Q'_R
M,-__ -?LO_H9H I4444 %%%% !1110 4444 5->U[0O"NB7?B;Q/K5IINFZ?
M;/<7^H7]RL,%M"BEGDDD<A415!)8D  9-> ?LS?\%4/V)?VL?C!XF^"'PB^.
M7AZ\UW0=8^Q:7;?VU;D^(HA:0W#W6G@/FXB4RO&2HR&@D.-N&.Y_P48_9I\:
M_M>?L<^+O@)\.==TRPUS53876FG7$=K"ZEL[ZWO!:700%C;S_9_)DP"=DA.&
M^Z?A?]G;]I+P/H7[3OQ$\'_\%$/V&M0\*M>?M&:%/H?BS2YH-8\/>$/$R>']
M%M[&!KZ QR6ID$<#QR>6(\72QR$;7P ?I?\ &3XS_"O]GOX::M\8OC7XZT_P
MWX9T.V\_5-8U.79%"F0 .,EF9B%5%!9F(5020*GOOBIX TSX5S?&V^\21Q^%
MK?P^VN3:N8G*+IZP?:#/M"[\>4-V-N[VSQ7R)_P66_9#^'7Q%_9:^,G[2WQ*
MUS7-?NO"_P &]73P=X5U#4"=%T2\6TN-^IQ6@ 5[UEDV">3<8U5?+"'+'Z=_
M93_Y-=^&W_8@Z/\ ^D4- 'A$O_!=3_@E)!$T\_[75@B(I9W?PSJP"@=23]DX
MKW+QY^UC^SG\+O@)9_M/?$;XM:7HG@34--M;ZP\0:F7A2YBN8UDMQ'&RB5Y)
M%8%8@AD.<;<@BO"_VO\ 4IOVL_VR?!7_  3EM9V/@^PT+_A/_C5'&Q U#38K
MD0Z9HKD<&.YNU:6:,X+06I7[LASY?_P43^(GC"7_ (*K?L^?!WPM\'D\<7FC
M>"-=\2> _"E[>BTTN7Q$98;6*]O9BD@ABLK1;N=7$;NK$+&ID=* /J3]G#]O
M_P#9#_:T\3ZCX'^!'QBAU37M)M1=7_A_4=(O=+U!+<L%$XM;Z&&9XMQ \Q5*
M99>?F&?8Z^+_  S\5?BGX7_;X^&/@K_@H1^S3\.8?&/B+2=9MO@[\5OASJMW
M<V\4R6XFOM)N$NXHY87:!&D1R6C?:0H5BV/K?XA_$'P9\)_ >L_$[XB^(K;2
M-!\/Z9-J&L:G>/MBM;:)"\DC'T"@G Y/0<T <G\>?VM?V<_V8M4\*Z'\=_BM
MI_AV]\;ZTFD^%+.Z26274KQF11&B1(Q #21@N0$4R("PW#/HM?E%^U]X0\9_
M&CX*>%/^"B7QO\/W.FZ]\0OCMX#L_AYX;OTVR^%O!ZZU%):P,O\ !=7;8O+G
MG.6AB./( K]7: "BBB@ HHHH **** "BBB@ KV+X0_\ (BVW_767_P!#->.U
M[%\(?^1%MO\ KK+_ .AF@#IJ*** "BBB@ KS?X\_\?FF_P#7*7^:UZ17F_QY
M_P"/S3?^N4O\UH \_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *Z_P""G_(XM_UY/_-:Y"NO^"G_ ".+?]>3
M_P UH ]9HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\>_\ 8!?_
M -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"2
M9^'?^P%:?^B4K=H *\$\1_\ (PW_ /U^R_\ H9KWNO!/$?\ R,-__P!?LO\
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M0NSE44=!N9C]2:Z"B@ HHHH **** "BBB@ HHHH *]B^$/\ R(MM_P!=9?\
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MU9T<,Y0=GI^9PO\ PUK_ -4__P#*K_\ :J/^&M?^J?\ _E5_^U5XW17\Z?\
M$4>.O^@O_P ITO\ Y \/^T<9_-^"_P CV3_AK7_JG_\ Y5?_ +51_P -:_\
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MYS2DN2FKI^:@FODS;#8[%5*\8REHWV7^1]N4445_3I]"%%%% !1110 4444
M%%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
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MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]T_X)[?\
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M444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\
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MS<Y_Y%=;_"SVN'/^1[A_\2/LRBBBOR4_?@HHHH **** "BBB@ HHHH ****
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\
MV K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "O!/$?_(PW_\ U^R_^AFO>Z\$
M\1_\C#?_ /7[+_Z&: *5%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7L7PA_Y$6V_ZZR_^AFO':]B^$/_ "(M
MM_UUE_\ 0S0!TU%%% !1110 5\M?\%%O^0SX5_Z];O\ ]"BKZEKY:_X*+?\
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MCYO\$/F<_1117\['AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_)#8.S=LP7((4$D@XKT.N;^,O@H?$GX0>*_AT?%3Z$-?\-7VFG6X[6"=M/\
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M*W: "OS/^+'_ "5+Q+_V,%Y_Z/>OTPK\S_BQ_P E2\2_]C!>?^CWK\,\;_\
M<,'_ (I_DCQ\W^"'S.?HHHK^=CPPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K[R_87_Y-OTC_K[N_P#T>]?!M?>7
M["__ ";?I'_7W=_^CWK]:\&?^2KJ?]>9?^E0/2RK_>7Z?Y'KU%%%?U$?1!11
M10 5\M?\%%O^0SX5_P"O6[_]"BKZEKY:_P""BW_(9\*_]>MW_P"A15[O#?\
MR.*?_;W_ *2SY;C/_DG:OK'_ -*1\V4445^GGX@%%%% !1110 4444 %%%%
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MW/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[
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MXT4LTD$F'56 'O7CO]@3]B_XG^+[_P ??$']FOPGJ^M:I/YVHZE?:8KRW$F
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M)B/)\O=O ^??CC% '85Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
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MZB69)5CN(5=1(C!T< @_,K ,#U! (Y%3T4 FT[H**** "BBB@ HHHH ****
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M(6XU&]DEN'3=\PB#B,'E4% 'L=>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
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M[PW_ ,CBG_V]_P"DL^6XS_Y)VKZQ_P#2D?-E%%%?IY^(!1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH *[#X(_\CFW_ %Y/_-:X^NP^"/\
MR.;?]>3_ ,UKTLG_ .1I1_Q(#URBBBOU8 HHHH **** "BBB@ HHHH ****
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\
MV K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "OSE^*7_)3?$?_8>O/_1SU^C5
M?G+\4O\ DIOB/_L/7G_HYZ^QX/\ X]7T7YL_.O$/_=J'K+\D8-%%%?=GY8%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?</[%'_)O.D_]?5U_Z/>OAZON']BC_DWG2?\ KZNO_1[U\SQ9_P BR/\
MB7Y,^VX!_P"1U+_ _P XGJ]%%%?G)^Q!1110 5YK\??^/S3/^N4O\UKTJO-?
MC[_Q^:9_URE_FM>'Q'_R**GR_P#2D!Y[1117YF 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5V'P1_P"1S;_KR?\
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M^LO$?_095_\ !D_\P_L7)O\ H&I_^ 1_R.4_X4C\+_\ H6/_ "=G_P#BZ/\
MA2/PO_Z%C_R=G_\ BZZNBC_67B/_ *#*O_@R?^8?V+DW_0-3_P# (_Y'*?\
M"D?A?_T+'_D[/_\ %T?\*1^%_P#T+'_D[/\ _%UU=%'^LO$?_095_P#!D_\
M,/[%R;_H&I_^ 1_R.4_X4C\+_P#H6/\ R=G_ /BZ/^%(_"__ *%C_P G9_\
MXNNKHH_UEXC_ .@RK_X,G_F']BY-_P! U/\ \ C_ )'*?\*1^%__ $+'_D[/
M_P#%T?\ "D?A?_T+'_D[/_\ %UU=%'^LO$?_ $&5?_!D_P#,/[%R;_H&I_\
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MR\1_]!E7_P &3_S#^Q<F_P"@:G_X!'_(Y3_A2/PO_P"A8_\ )V?_ .+KZ$^
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M_P!#->_UX!XD_P"1BO\ _K]E_P#0S7R'%W\"EZO\@*5%%%?# %%%% !1110
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M>V/@;PU%\)=-\4>%? I>*XU+3DN-0GMU?4+A 1]J=(BS0QLT<09$RSJ[%?\
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M 5V'P1_Y'-O^O)_YK7'UV'P1_P"1S;_KR?\ FM>ED_\ R-*/^) >N4445^K
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M_767_P!#->-5[+\'O^1#M?\ KK+_ .AFOI>%?^1E+_"_S0'3T445^A@%%%%
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M2 4444 %%%% !1110 5V'P1_Y'-O^O)_YK7'UV'P1_Y'-O\ KR?^:UZ63_\
M(TH_XD!ZY1117ZL 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P
M"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_
MR3/P[_V K3_T2E;M !7@'B3_ )&*_P#^OV7_ -#->_UX!XD_Y&*__P"OV7_T
M,U\AQ=_ I>K_ " I4445\, 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5[+\'O^1#M?\ KK+_ .AFO&J]E^#W_(AV
MO_767_T,U]+PK_R,I?X7^: Z>BBBOT, HHHH *\U^/O_ !^:9_URE_FM>E5Y
MK\??^/S3/^N4O\UKP^(_^114^7_I2 \]HHHK\S **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[#X(_P#(YM_UY/\
MS6N/KL/@C_R.;?\ 7D_\UKTLG_Y&E'_$@/7****_5@"BBB@ HHHH **** "B
MBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH
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MK117Y+_\/-/VWO\ HMG_ );>F_\ R-1_P\T_;>_Z+9_Y;>F__(U'_$ >,?\
MG_A__ JG_P J#_B)>1?\^ZOW1_\ DS]:**_)?_AYI^V]_P!%L_\ +;TW_P"1
MJ/\ AYI^V]_T6S_RV]-_^1J/^( \8_\ /_#_ /@53_Y4'_$2\B_Y]U?NC_\
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MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (>:?L0_]%L_\MO4O_D:OR7HH_X@#P=_S_Q'_@5/_P"5!_Q$O/?^?=+[I?\
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M>C1ZF2\?9QF.:T<+5ITU&<DG92O\KR?Y'[+T445^='ZZ%%%% !1110 4444
M%%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
M'=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %?SF_M0_\G,?$
M3_L>M7_]+9:_HRK^<W]J'_DYCXB?]CUJ_P#Z6RU^L^%/^^8K_#'\V?EOB?\
M[IAO\4OR1PM%%%?M9^.A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7[??\$4_^4>WA3_L*:K_ .ETU?B#7[??\$4_
M^4>WA3_L*:K_ .ETU?G/BA_R3L/^OD?_ $F9^@^&W_(_G_U[E_Z5$^KJ***_
M 3]S"BBB@ K\MO\ @XG_ .1S^%G_ &"]6_\ 1EK7ZDU^6W_!Q/\ \CG\+/\
ML%ZM_P"C+6OM/#[_ )*RAZ3_ /2)'Q_'G_)+U_6'_I<3\W****_I _GL****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_I$CX_CS_DEZ_K#_P!+B?FY1117]('\]A1110 4444 %%%% !1110 4444
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MELM?K/A3_OF*_P ,?S9^6^)_^Z8;_%+\D<+1117[6?CH4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^WW_!%/_E'M
MX4_["FJ_^ETU?B#7[??\$4_^4>WA3_L*:K_Z735^<^*'_).P_P"OD?\ TF9^
M@^&W_(_G_P!>Y?\ I43ZNHHHK\!/W,**** "ORV_X.)_^1S^%G_8+U;_ -&6
MM?J37Y;?\'$__(Y_"S_L%ZM_Z,M:^T\/O^2LH>D__2)'Q_'G_)+U_6'_ *7$
M_-RBBBOZ0/Y["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %?M]_P $4_\ E'MX4_["FJ_^ETU?B#7[??\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?:O\
MP06_Y/@N_P#L1;__ -'VM?%5?:O_  06_P"3X+O_ +$6_P#_ $?:U\[Q;_R3
M6+_P,]_A;_DHL+_C1^R]%%%?RZ?TJ%%%% !1110 4444 %%%% !1110 5Y1^
MW/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[
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M7X,T>X+:MJL[O&I>3&!:6B^8"TQ.Y]K)&-WS+Y+XRT[PGX#^.FJZ3=>'7O\
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M%% !1110 4444 %%%% !1110 5]J_P#!!;_D^"[_ .Q%O_\ T?:U\55]J_\
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M,0/;.*K:]XW\:>*M-TW1O$_B_5-2L]&MS;Z1:7^H231V,)Q^[A5V(B7@?*H
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M/^P7JW_HRUK[3P^_Y*RAZ3_](D?'\>?\DO7]8?\ I<3\W****_I _GL****
M"BBB@ HHHH *T/#?A7Q)XPU"32O"NAW.H7,5G<7<D%I"798((FFFD('\*1H[
ML>P4GM6?7Z$_\$]O#VNM\%O#^L_LL:-X5U#6V\*^+U^)'F6=C<ZXFI_8[M=*
MB$=T&D^R-_HP"P@H[EQ+D%A7DYUF?]E8/VR2;V5W:*=F]7K:]K+O)I=3U,GR
MW^U,7[)MI;Z*[>J6BTOO=]DF^A^>U%>M_&;6-+\3?'_3(OV@/@S/\-I;9+:W
M\>6'AS1!9W$[J29;R*RD"1P321E?D4+$6&[ W&O5_P!I3Q/\,?&?_!.WP=J_
MPG^%=KX5T:S^+6I6&G6YE\^\N(4T^!O.NYR!YT[L[,Q "J-J* J"G/,Y4Y4(
MNF_WC2O=.*NF]_M7MI;IJ[:)J&71G&M)5%^[5[6=W9I;=+7UOUT5]6ODVBO3
M_P!F#X-^'_B1XCU+QS\3YYK3P!X)LAJGC.]A;:\L6[;#8PMT^T7,N(4';+/T
M0U[+^WQ?7?QZN/V?]5TWP[IFCW?B_P #11V]AIEJL5O:^9JEQ%#$JJ!\D:;$
M!/)"C/-.MFD*6/AAE&Z=^:5](OE<DO-V5WM9-/J@HY9.K@9XARLU:T;:R7,H
MM^2N[+NTUT/DNBOT7^(&F_M3_"+XI-\$OV6O&_P^^'G@[0+O^Q_#/A7Q3JVF
M6EYXTE@;R;BZGBN%,EU]HN$D4-*4C("K&>,GX?\ VDAJ(^/'BI=8^$=OX#O!
MK$HO/"%H&$.F3?QQQANB;LLH'R@,-ORXK'*\X693LHQ2:YE:=W;^]&RL_1R2
M::;3M?7,LI>70NY-M/E=XV5_[KN[KU46TTTFKVXBBO3_ -E_X.>'OB+XBU/Q
M[\4)9K7P!X(LEU3QE=PMM>:/=MAL(6Z?:+F7$*>@+OT0UZI_P4I\9#XD:%\%
M/B(WAS3M)?6OAC]I.GZ5:K#!;)_:%TL<2*H'RHBH@)YPHR2:WJ9E&&8PPD8W
MO=-WTB^5R2\VTKO:R:?4QIY=*67SQ4I6M9I6W7,HM^23=EO=IKH?+E%%%>F>
M:%%%% !1110 4444 %?:O_!!;_D^"[_[$6__ /1]K7Q57VK_ ,$%O^3X+O\
M[$6__P#1]K7SO%O_ "36+_P,]_A;_DHL+_C1^R]%%%?RZ?TJ%%%% !1110 4
M444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\
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MUNWLK>\]$DETLM#KCFT)5*M2K3YG-<NC:LM++J[^ZM6VWUN]3W7P9^U+X/\
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M_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\
MT2E;M87PN_Y)GX=_[ 5I_P"B4K=H *_G-_:A_P"3F/B)_P!CUJ__ *6RU_1E
M7\YO[4/_ "<Q\1/^QZU?_P!+9:_6?"G_ 'S%?X8_FS\M\3_]TPW^*7Y(X6BB
MBOVL_'0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#_ $?:U\55]J_\$%O^3X+O_L1;_P#]'VM?.\6_\DUB_P# SW^%O^2BPO\
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MG_Y'/X6?]@O5O_1EK7ZDU^6W_!Q/_P CG\+/^P7JW_HRUK[3P^_Y*RAZ3_\
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M_P#*/;PI_P!A35?_ $NFK\0:_;[_ ((I_P#*/;PI_P!A35?_ $NFK\Y\4/\
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M_P#8BW__ */M:^=XM_Y)K%_X&>_PM_R46%_QH_9>BBBOY=/Z5"BBB@ HHHH
M**** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7
M_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "OYS?VH?
M^3F/B)_V/6K_ /I;+7]&5?SF_M0_\G,?$3_L>M7_ /2V6OUGPI_WS%?X8_FS
M\M\3_P#=,-_BE^2.%HHHK]K/QT**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *_;[_@BG_RCV\*?]A35?\ TNFK\0:_
M;[_@BG_RCV\*?]A35?\ TNFK\Y\4/^2=A_U\C_Z3,_0?#;_D?S_Z]R_]*B?5
MU%%%?@)^YA1110 5^6W_  <3_P#(Y_"S_L%ZM_Z,M:_4FORV_P"#B?\ Y'/X
M6?\ 8+U;_P!&6M?:>'W_ "5E#TG_ .D2/C^//^27K^L/_2XGYN4445_2!_/8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5]J_\$%O^3X+O_L1;_\ ]'VM?%5?:O\ P06_Y/@N_P#L1;__ -'VM?.\
M6_\ )-8O_ SW^%O^2BPO^-'[+T445_+I_2H4444 %%%% !1110 4444 %%%%
M !7E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^
M'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 5_.;^U#_R<Q\1/^QZU?_TM
MEK^C*OYS?VH?^3F/B)_V/6K_ /I;+7ZSX4_[YBO\,?S9^6^)_P#NF&_Q2_)'
M"T445^UGXZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %?M]_P13_Y1[>%/^PIJO\ Z735^(-?M]_P13_Y1[>%/^PI
MJO\ Z735^<^*'_).P_Z^1_\ 29GZ#X;?\C^?_7N7_I43ZNHHHK\!/W,****
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M[_@BG_RCV\*?]A35?_2Z:OQ!K]OO^"*?_*/;PI_V%-5_]+IJ_.?%#_DG8?\
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MC_A4WPK_ .B:>'__  30?_$4?\12X@_Y]4O_  &?_P F'_$-,B_Y^5?OC_\
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ME_XQ_P#0+T3_ ,+#2_\ Y)H_X9?^,?\ T"]$_P#"PTO_ .2:_H,_X5-\*_\
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MV]+C8LEU)(AWP%T.58'ACC/.#7U[_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\
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M/_AE_P",?_0+T3_PL-+_ /DFC_AE_P",?_0+T3_PL-+_ /DFOZ#/^%3?"O\
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M /AE_P",?_0+T3_PL-+_ /DFC_AE_P",?_0+T3_PL-+_ /DFOZ#/^%3?"O\
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M/_"PTO\ ^2:_H,_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\
MB*/^(I<0?\^J7_@,_P#Y,/\ B&F1?\_*OWQ_^0/Y\_\ AE_XQ_\ 0+T3_P +
M#2__ ))H_P"&7_C'_P! O1/_  L-+_\ DFOZ#/\ A4WPK_Z)IX?_ /!-!_\
M$4?\*F^%?_1-/#__ ()H/_B*/^(I<0?\^J7_ (#/_P"3#_B&F1?\_*OWQ_\
MD#^?/_AE_P",?_0+T3_PL-+_ /DFOJ#_ ()(Z0?V8OVJ+CXD?''7-$T/17\)
MWEFM[_PD%G<YG>6!E39;RN_(1N<8XZ]*_6S_ (5-\*_^B:>'_P#P30?_ !%'
M_"IOA7_T33P__P"":#_XBN+,?$3.LSP-3"U:=-1FK.RE?7M>;7X'9@. <GR[
M&T\52J5'*#NKN-OG:*_,X7_AN[]D/_HO&B?]]2?_ !%'_#=W[(?_ $7C1/\
MOJ3_ .(KNO\ A4WPK_Z)IX?_ /!-!_\ $4?\*F^%?_1-/#__ ()H/_B*^"/N
M#E?"?[87[,WCGQ'9^$?"7QBTF^U+4)A%9V<)??*YZ*,KC->E5BZ?\-OAWI-[
M'J.E^ =%MKB%MT,]OI4*.A]0P7(/TK:H **** "BBB@ HHHH **** "BBB@
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M17P.\6^!9O"NF_L[S:/_ &UXMU/40UMJ,%]I;:D\X7RU\A88@-V6?(8-P.*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6*11+QMR>E_9U_8#U/\ 9_\ B,/B!JG[=O[0/Q%A^P36K^&OB5XUL]0TN02
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M.]L"]\=0L5BE=E!=9H6EW+MD>N/_ &A[;P!X@_X-K?$/[3?@OXO-K'B_XO\
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MT"&.W2:54CC2&%&98X88XXD#-A 6)/L] !1110 4444 %%%% !1110 4444
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M+I[1+K?M\O:9XW3;NW97.W&#0!UU%%% !1110 4444 %%%(S*JEF(  R2>U
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M?ASPQ::]\0M7\7>,I-$T'PO;7;.+."6>&TNIY[J<12ND20@"-0[-CBN7OO\
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M^VI\1OA-+X=UWX1:SXBT#QI\.8-<^V30Z]I=T]O'IL=UY$?F/=,UH8V\D?\
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M1110 4444 %>"^,?^1NU7_L)3_\ HQJ]ZKP7QC_R-VJ_]A*?_P!&-7R/%O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\C\2?##QSJ'B+4+^TT/?%/>RR1/
M]IB&Y2Y(."V1P:]<HKSLQRRAF<(QJMJVNEOU3 \6_P"%2_$'_H7_ /R;B_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20240630_g13.jpg
<TEXT>
begin 644 biib-20240630_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV\_L[5K56\VSN_$VFOY4T9R#F.3:RG(Y(YH ^^:*_&O]ANQ\)7/_  4UM/\
M@E7XY^+\FN? 3X&>-M=\0_L]V=Y8S>3XBUNS%K,^A27DIV7O_"//>7+1Q(6.
M_P MG/\ H@0?LI0!\?\ _!([_@KKX+_X*L>$O&FHZ?\ !O4? &N^"M3LTN_#
MVIZLEZUSIUY"9+34(Y%CC&R5H[A-NT[3 <G)P'_&O_@K?X,^$O\ P5#^'G_!
M,K2O@YJ.O7_C.UB;6?&=OJR16GA^YFMKZZ@M)(C&S32O!8M)@,NU)8SSG%?
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M_P!0T>#2O$7B7X3^)+>S;7K.W+&WCOK>\MKJVN&BWN(Y3%YJJY4/M  ^C:*
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MTTC3KV]B$-UJUS)>S2S7-TT.88TPL<*,Y&YV+#Q/4/\ @G#_ ,%9/^&V-?\
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M9Q!)<VU\D6IF+>=DLRHQP ^X 4 :W_!!'3/@EX9_X)9?#?P'\"?'NK>(-/\
M#[ZI9ZY+K^B?V7?66M-J5S/J-G-9;G^R&&YFEC6(,P"!"&<$,?L6O$?^"?/[
M$WAS]@;]G*W^"&E>/-0\6:M>ZY?Z_P",/%^JVZ0SZ[K5].T]W>-$A*0AG.%C
M4G:B*"S$%C[=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
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M\8?#W3=5UZ]@M(X$FNIH5>1Q'& B DGY5  KS'_@JU^V1\:/V=O%GP,_9_\
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M-7_C%^SK^S[^T1I]EI/[0'P*\&^.K739FFTZV\8^&+34X[61@ SQK<QN$8@
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MM/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHKY/_X*3_\ (<\)?]>EY_Z%%0!]845^6=% 'ZF45^6=% 'ZF45^6=%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_'YIO\ URE_FM 'G]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V
MK3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>;_ !Y_X_--_P"N4O\
M-:](KS?X\_\ 'YIO_7*7^:T >?T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %=?\ !3_D<6_Z\G_FM<A77_!3
M_D<6_P"O)_YK0!ZS1110 4444 %%%% !1110 4444 %%%% !7E'[<_\ R:/X
M]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"
M^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !6+X7^(W@/
MQMK6O^'/"/B[3]2O_"VJ+IOB.TL[E9)--O&MX;E8)E',;F"X@E"GG;*AZ$5X
M;_P5FUO]ICP[_P $_/B'K/[(UMXBD\:PVMD8O^$.A$FLIIIO[<:D^GJ0=UXM
M@;IH<#=Y@4IEPHK\[_\ @DQI'[ 7Q._;4^)NI_LB_MX^-/!/C.Q^-6GW_A[P
MWXD\>:K)J/C?P]'X=TG[?9:CI6MS;[QFNUOPTYC^T0-'E'6..,  _9RBOS=;
MX&_!7_@I'_P5I_:$^!?[?B3>*-'^$FE>&8OA+\)=4UJXMM,;3KW3Q<7FN_98
MI$6^F:Z=K<S,&$ C6,X8J1YQ\)OVY_!__!.#XE?MN_LR? KQO?>+?A[\"?A?
M;^.?AGHVL:U-J<7A_46MI8KS1([J9WDDM%O1; 1[V\AC<1YW*P !^M-%?AY9
M>"_^"6EQ^SI%\3/VI8OV@/%/Q1GT]+CXB?MI^&O#WB&ZLO"/B>109WMM4MF$
M,-M97)\D16T;6T8A6.3YMU?0O_!3#]H3P'J_Q%_9[_87^-G[3OB#4/A9JGPX
MG\;?%?Q'X1DG75OB9:VYL[#3--M5TH&:;^T;VZ$LD-H,RJH5-JY( /T^HK\U
MO^"=/A;_ ()\>#?V\;;0OV/='^+7[.?B0^#[V?Q+^S]\0/#&H:18^.+)F00Z
MO;V]^[QF6VDW9EMF$I#LLB@;\_?'[0]G\6]1^ 'CG3_@#?V]KX\G\':G'X)N
MKO;Y4.KM:2"S=]_R[1.8R<\8!SQ0!V-%?SZ^#_CA_P $;[C]CQ/AKX]\)_$$
M?MZ'3&T&\%]J>L1^-C\0O+,8NX]8>9;>*W-]B56,XA$6U6C)_=G]V/V==.^+
MFD?L^^!=)^/^J6]]X\M?!NEP^-KVT*^5<:NMI$MY(FT ;6G$A& !@C% '944
M44 %%%% !1110 4444 %%%% !1110 4444 %>;_'G_C\TW_KE+_-:](KS?X\
M_P#'YIO_ %RE_FM 'G]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !77_!3_D<6_Z\G_FM<A77_!3_ )'%O^O)
M_P":T >LT444 %%%% !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_
M .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS
M\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%% 'F'[7]U^UCIGP1N]>_8
MLTWPOJ?CK3-1L[RWT#Q<[Q6NMV<<Z-=6"W"L!:330ATCG971'(W* =Z_E%X;
M^&7[17_!1O\ :6^+7@W2/^"?.K?#_P 46O[6'A7Q9KGQ5\8ZOH_VCX;1:=H?
MAV2>TM);6XEGN[R>.U(181Y!BO8W=U.Y4_:RJNGZ'HFDW5Y?:5H]K;3ZC<"?
M4)K>W5'NI0BQB20@9=MB(NXY.U%'0"@#X._X*4:)\ ?&?[2%KI?[</\ P22\
M:?%/PCI^@02?#[XM?"KPU>^(-3BN"TAO--O(=,$=]8H"4:/F6"4.Q+(V5'"_
MLW_\$Q+K]ISX7_M(^+/%O[.X^!'A?XP_"^#X:?!CX<W6FPVU]X6\.6L5W(E_
M>VT#%(;BYU"\>[:W)+H(P'9F=B?TUHH _-3X>_M7?'GX/_\ !/[3O^"=^H_\
M$I?C'>_%?0?ANG@.#1-)\%";P7JEPEE]A6]&NEA9)82@"9_-9955V5D9ADYF
MJ_\ !/#XN_L&C]C3]J_1OA/J7QDU?]G'X:7'@;XDZ#X2B6YU5K.[LEC&HZ3#
M,4-P;6?SD\D$2203_* 5(K]/J* /@*'6/BC_ ,%(O^"BWP&^._@K]E7XE?#C
MX?\ P"?Q#JVL>,?BOX1F\/7^M7FHZ:UA%I=A97.+EHOG,TTSHL9$*J"3@GNO
MVE/&G[5O[=G[,O[4G[*_P,^#GC7X2^,=!L[GP[X \;>)0]C:>*VD20_:=/N
MJE876,Q><I.PSJV1BOL.B@#\N-;\5_LGZS^PB/V%KG_@A-\:&U%/#3:9:_#<
M_ W_ (E\.KF#ROM*Z_\ \>"GSOG_ +1^T^:1^]Y?Y:^V_P#@F]\&/C9^SM^P
M=\*/@?\ M'>+CKGCCPQX*LK#Q)J!O#<_Z0B?ZKSCS*(E*Q>9_%Y>[O7ME% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5YO\>?^/S3?^N4O\UKTBO-_
MCS_Q^:;_ -<I?YK0!Y_1110 4444 %%%% !1110 445D^-/'G@OX<Z3%KWCS
MQ18Z193ZC::?#=:A<+$CW5U.EO;P@MU>2:2.-5ZLS@#DT :U%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5U_P %/^1Q;_KR?^:UR%=?\%/^1Q;_
M *\G_FM 'K-%%% !1110 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O
M_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\
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M=>(+GPEYOBK7-7:#_A)XO$*V^)(]S?Z3%=1W *1PK@* J(NS /[&?"S]F/\
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M93U!4$<BK-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=?\
M!3_D<6_Z\G_FM<A77_!3_D<6_P"O)_YK0!ZS1110 4444 %%%% !1110 444
M4 %%%% !7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN
M_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 5X)XC_Y&&_\ ^OV7
M_P!#->]UX)XC_P"1AO\ _K]E_P#0S0!2HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]B^$/_ "(MM_UUE_\
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M+O\ DF?AW_L!6G_HE*W: "O!/$?_ ",-_P#]?LO_ *&:][KP3Q'_ ,C#?_\
M7[+_ .AF@"E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5[%\(?\ D1;;_KK+_P"AFO':]B^$/_(BVW_767_T
M,T =-1110 4444 %>;_'G_C\TW_KE+_-:](KS?X\_P#'YIO_ %RE_FM 'G]%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !77_!3_D<6_Z\G_FM<A77_!3_ )'%O^O)_P":T >LT444 %%%% !1
M110 4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW
M_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVN1^&?BSPW#\./#\,NL0JR:):*RD]
M"(4XK<_X3'PQ_P!!J#_OJ@#2KP3Q'_R,-_\ ]?LO_H9KVG_A,?#'_0:@_P"^
MJ\4UZ6.;7+V:)PRO=R,K#N"QP: *E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7L7PA_Y$6V_P"NLO\ Z&:\
M=KU3X6^(]#T[P;;VE]J<44BR2$HQY&6- ':45F_\)CX8_P"@U!_WU1_PF/AC
M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5>;_ !Y_X_--
M_P"N4O\ -:[;_A,?#'_0:@_[ZK@/C1J^FZM=:>VG7B3!(Y Y0],E: .(HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Z_X*?\CBW_ %Y/_-:Y"NH^$>HV.F>*VN=0N5BC^R.NYSQG*\4 >P45
MF_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E15"V\4>'[R=;6UU6)Y'.$13R3
M5^@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\
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MG""!$S')G8H&>5KTNO-_CS_Q^:;_ -<I?YK0!Y_1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*]B^$/\ R(MM_P!=9?\ T,UX[7L7PA_Y$6V_ZZR_^AF@#IJ*** "BBB@ KS?
MX\_\?FF_]<I?YK7I%>;_ !Y_X_--_P"N4O\ -: //Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^"G_(XM
M_P!>3_S6N0KK_@I_R.+?]>3_ ,UH ]9HHHH **** "BBB@ HHHH **** "BB
MB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NOA=_R
M3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H *\$\1_P#(PW__ %^R_P#H
M9KWNO!/$?_(PW_\ U^R_^AF@"E1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5[%\(?^1%MO\ KK+_ .AFO':]
MB^$/_(BVW_767_T,T =-1110 4444 %>;_'G_C\TW_KE+_-:](KS?X\_\?FF
M_P#7*7^:T >?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %=?\%/^1Q;_ *\G_FM<A77_  4_Y'%O^O)_YK0!
MZS1110 4444 %%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\ ^AK7J]>4
M?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@
M*T_]$I6[0 5X)XC_ .1AO_\ K]E_]#->]UX)XC_Y&&__ .OV7_T,T 4J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O8OA#_R(MM_UUE_]#->.U[%\(?^1%MO^NLO_H9H Z:BBB@ HHHH *\W
M^//_ !^:;_URE_FM>D5YO\>?^/S3?^N4O\UH \_HHHH **** "BBB@ HHHH
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M7^:T >?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %=?\%/\ D<6_Z\G_ )K7(5U_P4_Y'%O^O)_YK0!ZS111
M0 4444 %%%% !1110 4444 %%%% !7E'[<__ ":/X]_[ +_^AK7J]>4?MS_\
MFC^/?^P"_P#Z&M '=?"[_DF?AW_L!6G_ *)2MVL+X7?\DS\._P#8"M/_ $2E
M;M !7@GB/_D8;_\ Z_9?_0S7O=>">(_^1AO_ /K]E_\ 0S0!2HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]
MB^$/_(BVW_767_T,UX[7L7PA_P"1%MO^NLO_ *&: .FHHHH **** "O-_CS_
M ,?FF_\ 7*7^:UZ17F_QY_X_--_ZY2_S6@#S^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@I_R.+?]>3_
M ,UKD*Z_X*?\CBW_ %Y/_-: /6:*** "BBB@ HHHH **** "BBB@ HHHH *\
MH_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"
MM/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H *\$\1_\C#?_ /7[+_Z&:][KP3Q'
M_P C#?\ _7[+_P"AF@"E1110 4444 %%%% !1110 45Q'[1W[07PZ_99^"^M
M_';XJW%XNBZ'%%YL.FVAN+JZFFF2""V@B',DTLTL42+D M(,D#)'RY^SA_P5
M+^,'BSX^>+_AS^TC^Q[XT\&^'Q\3K+PIX:UR&*QOET2YN=*L+J"RU<6=U,\,
MDC7.\7"*T"">.)V5D<@ ^VJ*^>?C?^V=\8M$^.-_^SC^RG^R+JGQ.\2Z!I-M
MJ'BO4=2\21>'M$TE+D,;>$WLT4K3W#JC-Y<,3A5P68<@'[-O_!0?PU\8/#WQ
M0L_B_P#"O6?AOXS^"KK_ ,+-\'7\R:D]A#):M=P7-M-:@B\AF@1VC**'8J1L
MY7< ?0U%?%OB;_@J)^TYX+^$DG[6/BS_ ()G>*+'X-6]DNJ7NO3>/+#_ (2*
MUT@X;^T)-%V?*HC(D:+[3YBKDLHP<>H?M"?M^:#\-C\//!_P#^&&H_%7QQ\5
M]/?4O ?A;1;^*QBGTV.&.:74;N[N!LL[54EC^=E9F:151&.< 'T%17SM\ ?V
MXO'?BOX\)^RQ^U9^S5>?";Q_J6B3ZSX5ME\3P:UI7B*R@=$N#:7T4<69H2Z&
M2"2)'".KC<N2/HF@ HKY?_;?_P""G7@O]CCXL>"?@S8?#'4/&6M>)M9TRWU\
M:=J"6\/AJRO[Y+&UNKEV1MS2SLXCA #.MO,V5"9/U!0 4444 %%%% !1110
M4444 %>Q?"'_ )$6V_ZZR_\ H9KQVO8OA#_R(MM_UUE_]#- '34444 %%%%
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M_P"J?_\ E5_^U4?\11X%_P"@O_RG5_\ D _M'!_S?@_\CV2BO&_^&M?^J?\
M_E5_^U4?\-:_]4__ /*K_P#:J/\ B*/ O_07_P"4ZO\ \@']HX/^;\'_ )'L
ME%>-_P##6O\ U3__ ,JO_P!JH_X:U_ZI_P#^57_[51_Q%'@7_H+_ /*=7_Y
M/[1P?\WX/_(]DHKQO_AK7_JG_P#Y5?\ [51_PUK_ -4__P#*K_\ :J/^(H\"
M_P#07_Y3J_\ R ?VC@_YOP?^1[)17C?_  UK_P!4_P#_ "J__:J/^&M?^J?_
M /E5_P#M5'_$4>!?^@O_ ,IU?_D _M'!_P WX/\ R/9**\;_ .&M?^J?_P#E
M5_\ M5'_  UK_P!4_P#_ "J__:J/^(H\"_\ 07_Y3J__ " ?VC@_YOP?^1[)
M77_!3_D<6_Z\G_FM?-G_  UK_P!4_P#_ "J__:J]1_9%^.__  LCXJR>'O\
MA%?L6W29IO.^W>9T:,8QL7UZY[5UX'Q#X/S+&0PN&Q/-4F[17)45V_-P27S9
M4,=A:DE&,M7Y/_(^FZ***^T.L**** "BBB@ HHHH **** "BBB@ KRC]N?\
MY-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T
M2E;M87PN_P"29^'?^P%:?^B4K=H *\$\1_\ (PW_ /U^R_\ H9KWNO!/$?\
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MN<OE^9\PT445_(Q\R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>Z?\$]O^2\S?\ 8OW'_HR*O"Z]T_X)[?\ )>9O^Q?N/_1D5?5\#?\
M)7X'_KY$Z,)_O4/4^W****_M$^L"BBB@ HHHH **** "BBB@ HHHH *\H_;G
M_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\
MT2E;M87PN_Y)GX=_[ 5I_P"B4K=H *\$\1_\C#?_ /7[+_Z&:][KP3Q'_P C
M#?\ _7[+_P"AF@"E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5[%\(?^1%MO^NLO_H9KQVO8OA#_ ,B+;?\
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MU'7KRW\;:8+%=/UC1-9EAC\V?RR7C25H_+=)4W(W#<D,!YU^S1\%OA[\ _\
M@IIXN^'GPUTA[:QB^"&E3W,]S<//<WUS)JMTTMS<3.2\TTC<M(Q)/ X  %QR
MC"+ZW&HYQG2CS1BTK[QUD[VM:6G+\7Q72LF>RC[U[W7_  #ZS\4^*?#?@CPW
M?>,/&&N6NF:5IEJ]SJ&H7LPCAMX4&YG=FX4 #.:J?#WXB>"_BKX%TSXF?#_7
MH]2T+6;);O3-1C1D2>%AD. X# $>H!KS3]K3]FWP3\:M$N/&'Q)U75=1TSPU
MX>O9[+P@UX5TJXO1&SQW=S !_I$D6T>6')122VTG!%#_ ()D_P#*/[X1_P#8
MD6?_ *#7)+ X/^Q/K<9MU%.,6K6BDU-[[M^[OHM;:[D\D?8\R>M_\S(;_@K/
M_P $]5!+?M'68 ZG^PM1_P#D>O;?A?\ $_P+\9_ .F?%#X9^($U70=8@,VF:
MA'#)&L\88KN"R*K 94]0,]>E>,_MJ^)]:^(GC/P/^Q%X-U:XLI_B5/<W/C+4
M+*4I-9>&;-5:\567F-[EGCM5?L)9#U&1[UH6AZ-X8T2S\->'=+@L=/T^UCMK
M&RM8@D4$**%2-%'"JJ@  = *US+#Y72P%&K0A.$ZEW:4XS7(FXWTIPLW)-+?
M2-^J'4C34$TFF_.^GW(X#XY?M>?LZ_LV:OIN@_&KXD1Z+>ZO;2W&G6W]G75P
M\T4;*KOB")\ %U'..M2? []K'X ?M(WNHZ?\%O'IUJ;2HHY+]?[*N[?RE<L%
M.9XD!R5;@9Z5YC\>/!G[6!_;<T/XB_L^> ?#]Q:?\*MO-&E\3^+;UQI^F32Z
ME!<.&@@83W$A6WC"HIC4[B3(-I!V_@G^T/\ &^Q_:%NOV4_VI?#7AJ+Q'/X:
M;Q!X7\2>##<)IVKV23+#/$T-RSR6]Q$[H2N]U97R",<],LJP3RI5:/OU>3G=
MJD=%=W_=\E]%NN?F^U;E13I1]G=:NU]_TM^I[Q1117S)SA1110 4444 %%%%
M !7NG_!/;_DO,W_8OW'_ *,BKPNO=/\ @GM_R7F;_L7[C_T9%7U? W_)7X'_
M *^1.C"?[U#U/MRBBBO[1/K HHHH **** "BBB@ HHHH **** "O*/VY_P#D
MT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*
M5NUA?"[_ ))GX=_[ 5I_Z)2MV@ KP3Q'_P C#?\ _7[+_P"AFO>Z\$\1_P#(
MPW__ %^R_P#H9H I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>Q?"'_ )$6V_ZZR_\ H9KQVO8OA#_R(MM_
MUUE_]#- '34444 %%%% !7R;_P %*_\ D.>$O^O2\_\ 0HJ^LJ^3?^"E?_(<
M\)?]>EY_Z%%7YYXJ?\D/B?6G_P"G(G#F7^YR^7YGS#1117\C'S(4444 %%%%
M !1110 5\B?MH?LH_M/W=Q?>*?V<OC#+?Z;XC^('AO5]3\$>)M*DU&+3[NVU
M*R8WMI,)XWAMT$"2RV_S*5CDV&,L,?7=%>CE>:8C*<4J]%)[74DFG9I[-=TM
M59KHS2G4E2ES(\6^$'[._P 3O@/X)\;>*]'\;Z5XR^*/C?5AJVL:WKUJ^G:=
M/<I%'!# L4'FO!;Q0QA% ,CDY))S@>8:5\#?^"C>E?M0ZQ^U!'IOP3>_U?P9
M:>'9-+;Q#J_DQQ07,LXE#?8MQ8F4@CI@"OKBBNJEGV+ISJSG"$W45FW'[.EH
MI)I**Y59)*UK+0:K23;:3N>0?'/3?VR_$GAN/PO\)]$^&+PZGX;:VU^7Q%K.
MHQ-#>2(R2?9Q#;.'B (*E]K'N!7-_L/_  F_:_\ V?OAYX4^!?Q:MOAM<>%_
M"_A];"+4_#NK:A+?S/&,1L8YK:., \[OFX[ U]!T5BLVJ+ 2PBI0Y6[WL[W2
M:3O?=)M(7M'R<ME8\@TW]GOQ:O[=FI_M4ZQJVG2Z.WPPM_"VBV222&Z@D%\]
MU.[*4"!6/E@$,6.S!  %='^T/I/[1.L>";2U_9E\4>'-)U]=9MWO+GQ/!));
MM8#=YR*$1SYA^7:<8X/(KO**PEF%>=>G5FE+D2BDTFK1V377S[L7.W)-]#QW
MXV_#O]J^V^*=E\7OV:?B=H<T1TC^SM9\ >.I+E-)N<2&1+R":V5Y+:Y&2C'R
MW5UP" 5R<SX)?LZ_&6X^/UW^U;^U#XI\.W7BE/#9\/\ AOP]X/CG.F:+8O,L
MTS>;<!9+B>5U3+E(PJIM"X/'NM%;1S;$PPKHQC%7CRN2BN9Q[7_!OXFO=;MH
M/VLE&W_#A1117EF84444 %%%% !1110 5[I_P3V_Y+S-_P!B_<?^C(J\+KW3
M_@GM_P EYF_[%^X_]&15]7P-_P E?@?^OD3HPG^]0]3[<HHHK^T3ZP**** "
MBBB@ HHHH **** "BBB@ KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V
M 7_]#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ KP3Q
M'_R,-_\ ]?LO_H9KWNO!/$?_ ",-_P#]?LO_ *&: *5%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7L7PA_Y$
M6V_ZZR_^AFO':]B^$/\ R(MM_P!=9?\ T,T =-1110 4444 %?)O_!2O_D.>
M$O\ KTO/_0HJ^LJ^3?\ @I7_ ,ASPE_UZ7G_ *%%7YYXJ?\ )#XGUI_^G(G#
MF7^YR^7YGS#1117\C'S(4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5[I_P3V_Y+S-_P!B_<?^C(J\+KW3_@GM_P E
MYF_[%^X_]&15]7P-_P E?@?^OD3HPG^]0]3[<HHHK^T3ZP**** "BBB@ HHH
MH **** "BBB@ KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#
MNOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ KP3Q'_R,-_\
M]?LO_H9KWNO!/$?_ ",-_P#]?LO_ *&: *5%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7L7PA_Y$6V_ZZR_^
MAFO':]B^$/\ R(MM_P!=9?\ T,T =-1110 4444 %?)O_!2O_D.>$O\ KTO/
M_0HJ^LJ^3?\ @I7_ ,ASPE_UZ7G_ *%%7YYXJ?\ )#XGUI_^G(G#F7^YR^7Y
MGS#1117\C'S(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME_D4Z*N?V3_T\?\ CG_UZ/[)_P"GC_QS_P"O1_Q SQ3_ .A?_P"5:'_RT/\
M6#*/^?O_ )++_(IT5<_LG_IX_P#'/_KT?V3_ -/'_CG_ ->C_B!GBG_T+_\
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M* "O8OA#_P B+;?]=9?_ $,UX[7L7PA_Y$6V_P"NLO\ Z&: .FHHHH ****
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M?@S^V'^R!<>"M?>UDET[QAX*US^W_"FK>6!O5;KRH;FQE(.Y8KN",, 0DDC
MBOD7Q]_PUS^TY^TY\"O^":#?\%"O&NEFP^!5[\3OC+\4OA:;+2=4UZ::[BM=
M-AAD2%XK6W\Z69Q&J$2PQ#.2-P^IO^"3/QW^)/[2'[ 7@;XH_%WQ7'XA\0_:
M-9T>_P#$L5LL*ZX-,UB]TV/4=B?*IN8[1)SM 7,IV@#% 'T;7E'[<_\ R:/X
M]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"
M^%W_ "3/P[_V K3_ -$I6[0 5X)XC_Y&&_\ ^OV7_P!#->]UX)XC_P"1AO\
M_K]E_P#0S0!2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8/B9XB@0DA-=NU!8Y.!,]?AGC?\ [A@_\4_R1X^;_!#YF%1117\['AA1110
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M9Y$*S6>3Y)8J9 ,_,LBM_%0!W=>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
M%?F?\6/^2I>)?^Q@O/\ T>]?IA7YG_%C_DJ7B7_L8+S_ -'O7X9XW_[A@_\
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MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\
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MD-0GG\%:/\,H-<\*^"9-2EMK/Q%?R7<L=S<S+&R_:C D:*L+$A0[/MY)K/\
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MZ:ZTK7="DL-,-\UU:,75((]]Z?M#;3$T6P$; %^K/B_X9^%<?[8/B#4/@_\
MMC7/P@^)M[X=L)?&%A?Z7;36'B&R4.EM<B&_58YY8E5HS- Y\L81AR0?H+X?
M?!3X>?##Q1XJ\8>#M$6VOO&.L+J>MR@#YYUMH;<;, ;5V0(=O3<6;JQJ3XD_
M!+X,?&6"VM?C!\(_#'BN*S8M:1^)= MKY8">I03HP4G Z5]CCN*,-B\9&:4[
M*'*Y2<)REI#2:E'EG%.-TI:\SY[K2*ZYXB,IIZ[>3[;Z:[?J?'7[*3^%? /Q
MU^.O[:'AO6?%7Q'\.>'_  M9Z/>^+K2*.[O/&&I6[2W.H36J)Y<+I I@MT6(
M+$%A"IG:29OVPO#'_!.CXQ_!77?VS-*^.=G:>(_[*&M^&]<M_'$MRHU*"W'V
M6,:5<326S2;TC1H1 'W$_=<EJ^VO#_A[0/">BVWAOPMH=GIFG6<0BL[#3[9(
M88$'141 %4>P&*Y&#]E[]FBV\:_\+)MOV=_ L?B+[1Y_]OIX1LA>^;G/F>>(
MO,W9YW9S6,.):+S+ZX_:0E'EBN227-"*BN22LE9\MW9.*NUR-)6E8A>TYM5Z
M=NS_ *^1S?PD_:/MM(^!OPGU?]J'6[+PSXT^(&F:=;)I=W&T+W6K30QEH$CQ
M\CEFSY9QM)VGI7/_ !;^(?[(?[1OC?7_ -E#X^:E?:+J?A&]M=16PU7Q)<:"
MVI));OY=W:36US$]U !)(C#.U7'S+D*:]H\2^ O OC.]TS4O&'@O2=5N=%O5
MO-&N-2TZ*=["Y7&V:%G4F*08&'7!&.M9WQ)^"7P9^,MO;VGQ?^$?ACQ7%:$F
MUB\2:!;WRPD]2@G1@N?:O(H8S+X8KVZC.$GS.\))<CYKQY-G91]VS:>MT]+&
M49P4KZKTZ>A\R_\ !.67P]X#^/\ \6_V=_V??$J>(?A!X9;3[O1=4C:.X6QU
MBY5VO+);Q!F\P CLSL[QG"LQ)Y^P:S/"'@OP=\/M @\*> O">F:)I=J"+;3=
M(L([:WB!Y.V.,!5_ 5IUAG&/AF>/EB(Q:NHK75R:BDY2LDN:37,_-]7JU5FJ
MD^8****\PS"BBB@ HHHH **** "OO+]A?_DV_2/^ON[_ /1[U\&U]Y?L+_\
M)M^D?]?=W_Z/>OUKP9_Y*NI_UYE_Z5 ]+*O]Y?I_D>O4445_41]$%%%% !7R
MU_P46_Y#/A7_ *];O_T**OJ6OEK_ (*+?\AGPK_UZW?_ *%%7N\-_P#(XI_]
MO?\ I+/EN,_^2=J^L?\ TI'S91117Z>?B 4444 %%%% !1110 5!J&EZ9J\"
MVNJZ=!=1+,DJQW$*NHD1@Z. 0?F5@&!Z@@$<BIZ* 3:=T%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5[9^P3_R7";_ + -Q_Z,BKQ.O;/V"?\
MDN$W_8!N/_1D5>;G/_(KK?X6>UPY_P CW#_XD?9E%%%?DI^_!1110 4444 %
M%%% !1110 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:
MT =U\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5NT %?F?\ %C_D
MJ7B7_L8+S_T>]?IA7YG_ !8_Y*EXE_[&"\_]'O7X9XW_ .X8/_%/\D>/F_P0
M^9S]%%%?SL>&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?>7["__ ";?I'_7W=_^CWKX-K[R_87_ .3;](_Z^[O_
M -'O7ZUX,_\ )5U/^O,O_2H'I95_O+]/\CUZBBBOZB/H@HHHH *^6O\ @HM_
MR&?"O_7K=_\ H45?4M?+7_!1;_D,^%?^O6[_ /0HJ]WAO_D<4_\ M[_TEGRW
M&?\ R3M7UC_Z4CYLHHHK]//Q **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *]L_8)_Y+A-_P!@&X_]&15XG7MG[!/_
M "7";_L W'_HR*O-SG_D5UO\+/:X<_Y'N'_Q(^S****_)3]^"BBB@ HHHH *
M*** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0U
MH [KX7?\DS\._P#8"M/_ $2E;M87PN_Y)GX=_P"P%:?^B4K=H *_,_XL?\E2
M\2_]C!>?^CWK],*_,_XL?\E2\2_]C!>?^CWK\,\;_P#<,'_BG^2/'S?X(?,Y
M^BBBOYV/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OO+]A?_DV_2/\ K[N__1[U\&U]Y?L+_P#)M^D?]?=W_P"C
MWK]:\&?^2KJ?]>9?^E0/2RK_ 'E^G^1Z]1117]1'T04444 %?+7_  46_P"0
MSX5_Z];O_P!"BKZEKY:_X*+?\AGPK_UZW?\ Z%%7N\-_\CBG_P!O?^DL^6XS
M_P"2=J^L?_2D?-E%%%?IY^(!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7MG[!/\ R7";_L W'_HR*O$Z]L_8)_Y+
MA-_V ;C_ -&15YN<_P#(KK?X6>UPY_R/</\ XD?9E%%%?DI^_!1110 4444
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M/&C[!:?\\O\ QXU-11_J#P)_T*L-_P""*7_R(?VCF'_/Z?\ X$_\R'[!:?\
M/+_QXT?8+3_GE_X\:FHH_P!0>!/^A5AO_!%+_P"1#^T<P_Y_3_\  G_F0_8+
M3_GE_P"/&C[!:?\ /+_QXU-11_J#P)_T*L-_X(I?_(A_:.8?\_I_^!/_ #(?
ML%I_SR_\>-'V"T_YY?\ CQJ:BC_4'@3_ *%6&_\ !%+_ .1#^T<P_P"?T_\
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M?^"*7_R(?VCF'_/Z?_@3_P R'[!:?\\O_'C7W+^Q)$D/[.^DI&N!]JN^,_\
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
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M'%/_ +>_])9\MQG_ ,D[5]8_^E(^;****_3S\0"BBB@ HHHH **** "BBB@
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M1117YF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\:/'_AS3_P!DF_\ "6N0?'K0M>U3QWXBU#3_ #O!J6>EZ.\L%N\$LDMQ<2I
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MY)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 5^<OQ2_Y*;XC_ .P]>?\
MHYZ_1JOSE^*7_)3?$?\ V'KS_P!'/7V/!_\ 'J^B_-GYUXA_[M0]9?DC!HHH
MK[L_+ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K[A_8H_P"3>=)_Z^KK_P!'O7P]7W#^Q1_R;SI/_7U=?^CWKYGB
MS_D61_Q+\F?;< _\CJ7^!_G$]7HHHK\Y/V(**** "O-?C[_Q^:9_URE_FM>E
M5YK\??\ C\TS_KE+_-:\/B/_ )%%3Y?^E(#SVBBBOS, HHHH **** "BBB@
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M7_)3?$?_ &'KS_T<]?HU7YR_%+_DIOB/_L/7G_HYZ^QX/_CU?1?FS\Z\0_\
M=J'K+\D8-%%%?=GY8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?</[%'_)O.D_\ 7U=?^CWKX>K[A_8H_P"3>=)_
MZ^KK_P!'O7S/%G_(LC_B7Y,^VX!_Y'4O\#_.)ZO1117YR?L04444 %>:_'W_
M (_-,_ZY2_S6O2J\U^/O_'YIG_7*7^:UX?$?_(HJ?+_TI >>T445^9@%%%%
M!1110 4444 %?D/_ ,%>/%WA9/VE?%OAO]NSQ)X\TCPPGCSX>-\&C%J.J67A
M>70_[1L&UZ=IK%DA^WI_IA9[AA+'&L308(5J_7BOSP_X*J?%7]L?P#HNH>!_
MB=^S2OCWX;ZE\9/ NH^!_$_@JXM$FMX8M?TMVT;4+.[G5GGEFB=(IT)BD-P@
M?R@#M]/*9<N+7RZV>ZV;Z^757 ^C?V;?#NN>"?V2]<G_ &2OVD;;XSV][)?7
MGPJU7QCXF.HVEK&Z@0:=/J4+2375O#*KCS'+3*A,9)*+CP3]B[P3\;_AQ_P6
M$^(WAWX^?'>^\=^)-1^ &BZMK%V(/LNFV=Q+JUTGV;3[4$BWM8TC55!+.YWR
M.Q:1J[K]A+X7?$#]D3X<_&G]HCXC?L]:AX,T[QUX[/B70O@KX&M4U>[T6V%K
M;6IVPV.8GN[EXFN)(H"RKD#<2"!Y-X4_:H\0:1_P5&\8?M7WG[%'[18\(:U\
M&=)\-6,R_!353.;^WU&YN)%,7EY">7*F&[G([5O"$Y.M&%I)K?2[>FE_+RT>
MX%G_ (*U^*/AQ\/_ -L?X9>+/^"@T&N7G[+%UX0O-/N+?3I[IM-M?&#7(:*X
MU:WM&$MQ;FT!2(%759"QVC+&K_\ P2Q\0? SX@?M?>.?&O\ P3@%]:?LVVG@
MF+3=5M&NKB/3+OQ@+P.)]-LKIC+;(MEO25PD4<K&+"MLWG5^,&B:[\//^"A<
M/[;_ ,;OV5/'?Q0\!:S\-M,M/AT^@^#WUF_^'FH*\DMXDNDC,\,EP'B)N88W
MD0QF)MHK(^&/P-U[]HK_ (*!WO[3?[,?P!\<_ 'PG/\ "W6= \;^+-:\+#P]
M?>*=5NR@L9X=,F D>2S.^;[5<1*68*GS 5JG#ZGR-V]W>_NWO>W+OS=+]^G4
M#SC_ (+6_$7Q?^UO^S9\<-1^'7BF_P!.^&'P#LE@N]2TN[>'_A)_&37$$3VX
M=""]KIT,S!QD![N90<_9CG]0?#Y)T&Q).2;.+)/^X*_,S]MS_@EC^U!\&O\
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MZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\
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MDBNH%D598W#QN P(#*ZJRGJ"H(Y%6:*-@"BBB@ HHHH **** "BBB@ HHHH
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M?C[_ ,?FF?\ 7*7^:UX?$?\ R**GR_\ 2D!Y[1117YF 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5V'P1_Y'-O\
MKR?^:UQ]=A\$?^1S;_KR?^:UZ63_ /(TH_XD!ZY1117ZL 4444 %%%% !111
M0 4444 %%%% !7E'[<__ ":/X]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z&M '
M=?"[_DF?AW_L!6G_ *)2MVL+X7?\DS\._P#8"M/_ $2E;M !7@'B3_D8K_\
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M_7*7^:UZ57FOQ]_X_-,_ZY2_S6O#XC_Y%%3Y?^E(#SVBBBOS, HHHH ****
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MS7O]> >)/^1BO_\ K]E_]#-?(<7?P*7J_P @*5%%%?# %%%% !1110 4444
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MO8$)(2[D4%CDX#&OH&O /$G_ ",5_P#]?LO_ *&:^0XN_@4O5_D!2HHHKX8
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M]6S?^7G_ /<='_$'_$7_ * ?_*M'_P"6!_KUPK_T$?\ DD__ )$^\**^#_\
MA]G_ -6S?^7G_P#<='_#[/\ ZMF_\O/_ .XZ/^(/^(O_ $ _^5:/_P L#_7K
MA7_H(_\ ))__ ")]X45\'_\ #[/_ *MF_P#+S_\ N.C_ (?9_P#5LW_EY_\
MW'1_Q!_Q%_Z ?_*M'_Y8'^O7"O\ T$?^23_^1/O"BO@__A]G_P!6S?\ EY__
M ''1_P /L_\ JV;_ ,O/_P"XZ/\ B#_B+_T _P#E6C_\L#_7KA7_ *"/_))_
M_(GWA17P?_P^S_ZMF_\ +S_^XZ/^'V?_ %;-_P"7G_\ <='_ !!_Q%_Z ?\
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M;_R36+_P,]_A;_DHL+_C1^R]%%%?RZ?TJ%%%% !1110 4444 %%%% !1110
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M*A1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
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MXB?]CUJ__I;+7]&5?SF_M0_\G,?$3_L>M7_]+9:_6?"G_?,5_AC^;/RWQ/\
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MZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "CV\*?]A35?_2Z:OQ!K]OO^"*?_ "CV\*?]A35?_2Z:OSGQ0_Y)V'_7R/\
MZ3,_0?#;_D?S_P"O<O\ TJ)]74445^ G[F%%%% !7Y;?\'$__(Y_"S_L%ZM_
MZ,M:_4FORV_X.)_^1S^%G_8+U;_T9:U]IX??\E90])_^D2/C^//^27K^L/\
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M% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\
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MZU?_ -+9:_6?"G_?,5_AC^;/RWQ/_P!TPW^*7Y(X6BBBOVL_'0HHHH ****
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MK_\ I;+7ZSX4_P"^8K_#'\V?EOB?_NF&_P 4OR1PM%%%?M9^.A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[??\
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MGPI_WS%?X8_FS\M\3_\ =,-_BE^2.%HHHK]K/QT**** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
M%?SF_M0_\G,?$3_L>M7_ /2V6OZ,J_G-_:A_Y.8^(G_8]:O_ .ELM?K/A3_O
MF*_PQ_-GY;XG_P"Z8;_%+\D<+1117[6?CH4444 %%%% !1110 4444 %%%%
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MB?\ Y'/X6?\ 8+U;_P!&6M?J37Y;?\'$_P#R.?PL_P"P7JW_ *,M:^T\/O\
MDK*'I/\ ](D?'\>?\DO7]8?^EQ/S<HHHK^D#^>PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[5_X(+?\GP7?_8BW
M_P#Z/M:^*J^U?^""W_)\%W_V(M__ .C[6OG>+?\ DFL7_@9[_"W_ "46%_QH
M_9>BBBOY=/Z5"BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UK
MU>O*/VY_^31_'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_ $2E;M87PN_Y)GX=
M_P"P%:?^B4K=H *_G-_:A_Y.8^(G_8]:O_Z6RU_1E7\YO[4/_)S'Q$_['K5_
M_2V6OUGPI_WS%?X8_FS\M\3_ /=,-_BE^2.%HHHK]K/QT**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_;[_@BG_RC
MV\*?]A35?_2Z:OQ!K]OO^"*?_*/;PI_V%-5_]+IJ_.?%#_DG8?\ 7R/_ *3,
M_0?#;_D?S_Z]R_\ 2HGU=1117X"?N84444 %?EM_P<3_ /(Y_"S_ +!>K?\
MHRUK]2:_+;_@XG_Y'/X6?]@O5O\ T9:U]IX??\E90])_^D2/C^//^27K^L/_
M $N)^;E%%%?T@?SV%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?:O_!!;_D^"[_[$6_\ _1]K7Q57VK_P06_Y/@N_
M^Q%O_P#T?:U\[Q;_ ,DUB_\  SW^%O\ DHL+_C1^R]%%%?RZ?TJ%%%% !111
M0 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
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M/^P7JW_HRUK[3P^_Y*RAZ3_](D?'\>?\DO7]8?\ I<3\W****_I _GL****
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M;UBUU:77N>#Q+E>(SG)JF$H-*4N6U[VTDGT3?3L?C!17ZK_\.,;#_GV\"?\
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M_P"?;P)_W_UO_P"2Z/\ AQC8?\^W@3_O_K?_ ,ET?\12X?\ ^?57_P !A_\
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M  XQL/\ GV\"?]_];_\ DNC_ (<8V'_/MX$_[_ZW_P#)='_$4N'_ /GU5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&47PU\-W5SXFNKIWGGBEN8M.-_/-/+([-*)C,Q;[W2OO?]@KX3?&'X,?LO\
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MQYX:F=4-G.FER3+Y\0(D2>!0TZ[D=0P#*? -5B\=_P#!0?\ X*@? /\ :4^
M7[&OQ+^%VD?".?6;GXC?%/XF^!9?"]WKEC<V1@@T."VN=EU?H\I\QFD010A2
MRMN;! /TAHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBOF[QU_P4'_ .$+\;:QX._X
M5']I_LG5;BR^T_V_L\WRI63?M\@[<[<XR<9ZF@#Z1HKY9_X>6_\ 5%?_ "X_
M_N:M7P+_ ,%!_P#A-/&VC^#O^%1_9O[6U6WLOM/]O[_*\V54W[?(&[&[.,C.
M.HH ^D:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K\W?CG_ ,EM\8_]C5J'_I3)7Z15^;OQ
MS_Y+;XQ_[&K4/_2F2@#E:ZKX&?\ );?!W_8U:?\ ^E,=<K75? S_ )+;X._[
M&K3_ /TICH _2*BBB@ HHHH ^(?^#@;P5#\3OV!=/^%=YK=_IUIXK^,O@;1+
M^\TNY:&>.WN]?L[>4HZD$'9(U8O_  3W_;UN_@__ ,$B_%?C?]J+43<^,_V5
M[?7/!7Q+A>4^;>ZAH(,5N59OFD>[M_L3*YSO>XX+=3ZA_P %>_AI\0_BK^S;
MX.\/?#/P/JNOW]I\=_ .I75GH]A)<2Q6=MXBLIKBX94!(CBB1Y'<\*JDD@"O
MFG]J_P#8!_:-\2?\%?M.\,_#CPA=3?L]_'Z^\.>,_CI>):N]I;:KX3:26&T<
MK\D8OV72E8'#2^1*?FV,0 >/?\$O/"7C?]G;3/\ @HUX=_:Q75O&>JZ?\-O#
M'B;XC:#<:_/9O=:AJ?@^]UC5[&&X3<]H&N+NXA62,;HP%8#*@5[]/XQT77_V
MAO\ @EEJ_P ./#]YX9\-ZYX1\17.G^&9-<FOS96;> #);VLMS)A[LQ*57SI!
MN<IO(!)HU3]GWXZ2?'[_ (*CZY'\'_$K67Q)^'7AZU^'UT-%F\OQ)/%X'GM9
M(K%MN+IUN&6%ECW$2$*>>*N>"_@'\;[/X@_\$P+^Z^$?B..#X<> M6MOB!*^
MC3!?#DS^ A:)'?';_HS-<_N0)-I,GR]>* /3D_X*(_M7_'KX@?$2V_8#_8T\
M/?$#P9\*O$]WX;U_Q/XO^)AT&3Q%K-H!]ML='A2PN5E\EF$9N+AX(7DW*I(4
MO4?CK_@L-X)U#]ECX)_'?]F[X2W/BSQ%^T#XKC\,> O"?B+6H]%BLM547 NX
M=2NV286_V:2TGB<1I*[R(%C5MVX?(7PI_9-^"_[#WC'XK_!;]KG_ ()>_&#X
MJZA??$S6_$?PV\>_#'PIJ6M67B32=0N#<V]M<36DZQZ?>0N[PR"Y$4>%#AV4
MYKW7XL_ #0?!W_!-WX6_!_XU?\$9=,\2^ +[6Y]0^*'P@^'6LOJ^I^!7G-Q-
M%>Z:BB.6^N!+*!<&VF25//F\KSU)) />/AO^TO\ \%#M7?QK\,/B?^P3H6C^
M/-"T"WU3P?JNF_$>6Z\'^)A),8WMCJ9T])[*YCP6:%[5R5PP.UA7S7_P2;_X
M*&?M"_#O_@DIJO[9?_!0ZSM9? _@ZT\2:E#X\'CJXUG7=<DA\0:E"UG);3VT
M0B*.L=I;_OW$BK%D1 [53_@EU\&?&?PZ_;RO=0_8]^'G[1'@C]FK_A7%Q%XE
M\,?'_P#M2WMO^$B-W";/^QK36':^C*P"<32$")AM&6.RO-_AS^RY\</CG_P1
M=^)__!%;5?@=\0/"OQ7\._\ "2ZCIFM^(O!EW;>&-:EA\8/K-@MIK+)]CG%R
M);=0BR;P/.9E"QL: /ID_P#!3[]K7X,7/P_^)?[</[!NG?#GX6?$KQ#I^B67
MB/2/B4-6U/PI>7[!+$:U9FR@2%)9&1'DAFE6!F"OG.:T_&/_  4J_:6\7?MF
M_%W]A3]DG]BJP\7^*?A0NAW.H>)O$OQ!.DZ+]DU'34O$:=ULII(YV=VAB@C6
M7S!#+*[PA K^-_M<_%CX[?\ !7+X$^#OV'/#'["_QE^'FK^(O&OA[4/BYK_Q
M#\$S:3H_A/3]-OX+Z\^RWTQ\O4YGDMEB@6U,@=7WN8P#7O/[&_PL^(_A+_@J
M3^V5\3/$_@'5].\/^+KOX?GPOKE[ITD5KJZVOA]H;C[/*P"S"*4['VD[6.#@
MT 9>F?\ !8SP);_L,WG[5'C7X&:]I_C?3_B3/\,Y_@_8ZA#=W]QXXCU Z>-&
MM[H;8I@\P#B?"CRLN5RNRMKP5^WA^TW\-OC_ /#_ .!?[>_[+'AGP#%\6KFY
MLO 7B;P1\19-?LX]6BMWNO[(U#SK"S:"X>"*4QR1^;%(T90$'&?B[XH?\$\/
MVB/C%^QW\59_^&>-8UO5? __  47\0_%K2OAYJJR:=+XXT"+495>*TDD* BX
MM+J9X90P5VC4*22*]<_9Q^&7[+OQ>_:D^&][^SM_P1T^(7A>T\-ZD^M^)OB#
M\:O#^J>'%\*S10M]F73X+V1VU&\:9@A,0,*)O8RG.* /T6\5^((_"?A;4O%4
MNDZA?KIFGS7;6&DVC7%U<B-"_EPQ+S)(V-JH.68@#K7Q'\3O^"F_[>?P!^!<
M7[;7[0G_  3KT/PO\'(/L=UXCT^3XIR2>-/#^EW$\48OKK3&TU+;S(UE5Y+1
M;LR1_,I;<A%?6'[4MG\;=1_9F^(>G_LTWD%M\19_ ^JQ^ [BZ9!''K)M)19L
MQ?Y !/Y9RWRCOD9K\4OVF/V0?!OQG_X)<:Y\-_A'_P $IOCUXG_:;G\%6TGC
MKQY\6O">LR7=MJ<7E/J-S;W]\[KJ4T\B2QP0Z?YBGSD8K'&C8 /TS_:1_P""
MC_Q@^'?[=UO_ ,$\OV=OV2U^('C35OA-;>-]*U:]\9C2],M8'U*ZLIC?/]EE
M,$$7V>,B2/S9)9+F.)80-TJT/ O_  5P\/\ A?\ 9V^.OQ1_;)^#\WPZ\6?L
MXZBMC\2?">D:TFL17#SVL%SI\FGW(2'SUO$N85B61(V5WVN !N,GA7X7?$@_
M\%Q+GXX2_#S6H_",O['VF:)'XEFTN5+/^TE\2W=P]EYQ7:)Q$R2&+.X*02,5
M\Y?M4_L"?M*_M0W/_!1GX>^ _ E_I^H^/O$?P[UKX87^LVCV]CXCN=&TC2[H
MPP32!8Y%:XLC;,V[:CM\Q7:< %?_ (*1_M._M]>)OA%\$$_::_8NL?AKI/B[
M]I#X?2:1J'A;XE'6+K2F.L02?V?J\)M+;R)'B$@WP-/%O4QL5+(6_5:OR^_;
MI_:6_:&_X*!?#;X.?#WX1?\ !.[XY:#=Z%\=O WB+XES^-_ -UIT.AP6NKVY
MFAMF=<ZB5=C(T\ :W2""61Y%)16_4&@#YI_9V_X*(?\ "_/^">WBC]O#_A4'
M]D_\(W!XOD_X17_A(//^T?V'>7UMC[3]G39Y_P!BW?ZH^7YN/GVY;SWX@_\
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MTZ!&N'6.YB*2A$+1YR1VH _2+39+^;3K>;5;6."Z:!#<PPRF1(Y"!N56(&X
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MZWJFA^&;M<;[>_U*TM)+6VD0D!U:3]T?]9LP<>D?M ?MO_LO_LR_#30?BO\
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M.V^85,$2+Y>=H(SC))KX$U9O@-\:?^"/G@GP!\1O^"P=JOPP\4^$O#GA[3O
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MWP/U7P5K'P]N)XEU<>,F@GMFL#8D^<+V34F\Q5V;\N)>GS5J:1XA\-?LR_\
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MT;^SUX&^(%MILK2Z=;^-O"5GJL=J[ !FC6ZC<(3@9*X)P*[FB@"AX7\*^&/
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M&OLJ*H'L*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\9?%']J_X_>'/B;XB\/:-X]\FSL-=O+>TA_LJ
MU;9$DSJJY:(DX  R237V;7YW?&S_ )+-XN_[&>__ /2B2OJ>%L/A\1B*BJP4
MDDMTGU\SX7CK&8O!X2BZ%24&Y._*VNGD=/\ \-D?M(?]%&_\I%G_ /&:W?A=
M^U?\?O$?Q-\.^'M9\>^=9W^NVEO=P_V5:KOB>9%9<K$",@D9!!KQ2NG^"?\
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M*_MP_L=^"_"GA/XN>,8?"F@>(O 7Q4FUVXT36KB"::TM-0MY]-M RR^0Z>=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7O\ B8+X>UB15M+NYFL7D>+R)3)M+;</MK*^(?[*_P $/&'QK_9I\:_L _\
M!*WXJ>%+7PA^T1X6U3XC?$7X@>!=8L-6ALA)(C0E=3+7EU$K-YUQ=L/L\0A3
M]ZQD^7]E** /Q/L[KQM\0OVF?VH_%7AKP7^V!-X'\;_&#4M+U*?]DO3M"E\*
M>(+.TM8+&61WU0B\CU-FBDAN[BQ**[QE5?*%AW7QV^%O[.7[3?A[]FG]K?\
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M GQ1^SA\9M-N;SPMXPTMM/UNUL[Q[>62!B"0LB?,ARHY% 'Y[?M=>._VA_\
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MB_P/J>F:C<R7.@WT4"R6]_F\6VC?Y9+JY6-&EN(5C:3YROTG^PA\&OBUX)^
MG[8^B>,/AGKNEWGBW]HOXCZKX8M;_2Y8I-6L;N&(6MS;JR@S12D$(ZY#XX)K
M[BHH _+[XN?LW_M :I_P;!^!OV<=,^"GBF?Q_9>!_A_;W?@J'0IVU2&:VUS2
M9;F-K8+YBM%'%*[@KE5C8G !KKO^"G7PJ_9S^*G[4"?\-N?\$L_B7XUT/3_#
MUJOPW^./P,LM6U/68)293=6%ZFBF*]LQ%(P>'<)[=Q*[91BR5^B=% 'QQ_P1
M7\#_ +3O@+X!>-=*^.S_ !)B\)2_$F_E^"^G?&2^^T>*K+PN88!#'?L6:1/W
MPN#'',3*D94-@;0/L>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OG?QM_P5<_8$^'7C/5_A]XR^/7V/5]"U.XT
M[5;3_A%M5D\BY@D:.6/>EJRMM=6&5)!QD$CFOHBOYX/VU_\ D\OXM_\ 93M>
M_P#3C/7VO!7#>!XDQ56EB922A%-<K2W=M;IGQW&/$.-X>PU*IAHQ;DVGS)O9
M7TLT?L)_P^-_X)P_]'&?^6AK'_R)6GX)_P""KG[ GQ%\9Z1\/O!OQZ^V:OKN
MIV^G:5:?\(MJL?GW,\BQQ1[WM55=SLHRQ &<D@<U^#=>F_L4?\GE_"3_ +*=
MH/\ Z<8*^^Q7AED-#"U*D:E6\8M_%'HK_P A\/A?$?/*^)A3E3IVDTMI=7;^
M<_H?HHHK\,/VD**** "BOE+_ (+,?'K]I?\ 9X_8O7Q5^R'XTL/#_C[6_B'X
M8\-Z'JVJ:9#>00-J6JV]D2\4RLI&)NN,CJ.:VO\ @GQ^W;I7[2?_  3A\-?M
MB?&.[AT34=)\,78^*<<T8B&D:KI7FP:L'C'^J59K::0+VC9>H() /I.BOS<_
MX(R_\%)_VI/VC_&7[2_B/]O/QIHVA^&O 5IX5\5^&[6YT^VT^/POH&MZ3<:T
MD5U,H4N8;.2U61Y6)4Q.21DU]!^ O^"Q'["GQ#\:^&/!^F^,?&.F6WCG4X=-
M\#>*O$_PMU_2="\17DW^I@L]2O+*.VF>7_EGB0"4X"%BRY /J"BOGW]H+_@J
M/^Q'^S)X\U?X3?%7XLW4?B_1I](AN?">D>%]1O\ 4)WU-+J2S%O%;V[FYW1V
M5T[&+<(EBS*4W)NX_P#8K_;7\0>*M/\ VJ?'?[47Q)TK3_"_P:_:"U_P_IVK
MWL,-G!I6@66F:9<J)G4#?M:XF8R/ESN R< 4 ?65%>)?$K_@HC^R7\)/@;X2
M_:#\=?$#4K30_'Y@3P+IP\(:HVM:_+,F^*&UTD6WV^61DPVSR,A2&;"G-9?A
MC_@IM^R=XU^#_C3XO>%M=\5W'_"O+BUMO&WA%_ASK2>)=%GN71($GT5K07X#
MEPP<0E"BR.&*QNR@'T#17QQ_P2Q_X*S>!_VY/V&8/VH/C2B>"]4\/^&AJWQ&
MO+WPSJ6D:!I\;276)+6]U!?*NXECMF:1X9I1&<;BNY17>? K_@JM^Q9^T/\
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M2B>;)&X *1,&X//T9\;;#X6_'?Q#^SWH?Q)_X+'6_C\:I\7M \0?"G0?A_\
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M&>U:S54CQD#RRH&3S\F_ 'Q%X0\%_P#!(7]B[XO7\ \.>"_"?[?$NIZU=ZE
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MD_D^=&#R%EZM]]OI>H-+TO3-#TRWT71=.@L[.T@2&TM+6%8XH8U 5415 "J
M   , #%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20240630_g2.jpg
<TEXT>
begin 644 biib-20240630_g2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;OPKI_C[PYXFO?CE\,=&UBYN-'30[:S!L-9FM99'2SG^WE88YD"F4LZ'.7R
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M9X7CAN8RT,AN8UD\D [?T[JKK&AZ)XAM4L=?T>UOH([B*=(;RW65%EB=9(Y
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M HHHH \P_:5_;+_9L_9 M-(OOVBOB1_PCL6O231Z2W]CWEWY[0A#(,6L,A7
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MK4CQZ;I__",:I!YS)&TC#S)K9$7"(Q^9ATQUP*^@:_GY_P""/?\ RDB^%_\
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M6>%?_ B3_P"(H_X>D?\ !/G_ *.L\*_^!$G_ ,10![Y17@?_  ](_P""?/\
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M<'_S\C]Z_P P_L_'_P#/J7_@+_R*E%6_[*M/^AR\*_\ A8Z=_P#'Z/[*M/\
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M_P#$4?\ #TC_ ()\_P#1UGA7_P ")/\ XB@#WRBO _\ AZ1_P3Y_Z.L\*_\
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M;_XBC_A1GP2_Z([X5_\ ">MO_B*ZFB@#EO\ A1GP2_Z([X5_\)ZV_P#B*/\
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MGUJ[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1[Y+:>XL;& W.HWTDKJP@M[:W7<TA4YDDAB W2K7G/[+7PX^-O[07[7&K_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'57P3@E6&>QHHH Z/X?^"])^&W@+1/AUH$L\ECH&D6VG63W3AI6A@B6)"Y
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20240630_g3.jpg
<TEXT>
begin 644 biib-20240630_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KX5_X*,_\%;O'G[/?BS4?@Q^R#^SGKWQ&\5^$/&_
M@S2OB!JH:RMM'T8ZUJ=G%!I9FNKF$R7]S;W*B/RU>.#[3%+,RH&%?=5?D_\
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M]H_Q)^(/BCQ-I'[29\:_&3QIJWP/\66-SX@U>ZTN^%]?I'<Z7&]R3+(D<5M
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MXN^*]E+\1_&VKN/WNI:IKLAU%II/5A%-#$/185':@#ZVHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OC7_@HG_P1E_9[_;AUV+XK^&Q?^"/B)<^)?#ESXB\7>&?
M$FHZ6^LZ?IVI6UPT5S'9S(EQ<+!"Z6]Q(IDMY!$R.OEKC[*HH \[_9A_91^
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MJ<>K-_8]G=^>L*6QC&+J&0+@R/\ =QG/.<"OSX_X?6?\%-?^CEO_ "S=%_\
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M'7RQ11_JMPQ_T T?_!4/_D0_ULXI_P"@^M_X-G_\D?4__#ZS_@IK_P!'+?\
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MD'_(KA\_S84445YA[(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"I__ ")RM%=5_P *;\7_ /06\*_^%UI/_P DT?\ "F_%_P#T%O"O_A=:3_\
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M?"__ +"-[_Z;KJOZ!J_G^_X)N1Z1\ _VVO ?Q=^+7CCPKI/AW1;VZDU+4/\
MA+]/G\E7LIXU/EPSN[9=U'RJ>N>F37["_P##TC_@GS_T=9X5_P# B3_XBOP#
MQ7S# 9CGU&IA*L:D522;C)25^>;M=-ZZK0_HCPBR[,,MX>K4\91E3DZK:4XN
M+:Y(*]FD[73U\CWRBO _^'I'_!/G_HZSPK_X$2?_ !%'_#TC_@GS_P!'6>%?
M_ B3_P"(K\O/U4]\HKP/_AZ1_P $^?\ HZSPK_X$2?\ Q%'_  ](_P""?/\
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MY:3IMGM;J%9(Y%]&5@01[&K%% '+?\*,^"7_ $1WPK_X3UM_\11_PHSX)?\
M1'?"O_A/6W_Q%=310!RW_"C/@E_T1WPK_P"$];?_ !%'_"C/@E_T1WPK_P"$
M];?_ !%=310!RW_"C/@E_P!$=\*_^$];?_$4?\*,^"7_ $1WPK_X3UM_\174
MT4 <M_PHSX)?]$=\*_\ A/6W_P 11_PHSX)?]$=\*_\ A/6W_P 174T4 <M_
MPHSX)?\ 1'?"O_A/6W_Q%'_"C/@E_P!$=\*_^$];?_$5U-% '+?\*,^"7_1'
M?"O_ (3UM_\ $4?\*,^"7_1'?"O_ (3UM_\ $5U-% '+?\*,^"7_ $1WPK_X
M3UM_\11_PHSX)?\ 1'?"O_A/6W_Q%=310!RW_"C/@E_T1WPK_P"$];?_ !%'
M_"C/@E_T1WPK_P"$];?_ !%=310!RW_"C/@E_P!$=\*_^$];?_$4?\*,^"7_
M $1WPK_X3UM_\174T4 <M_PHSX)?]$=\*_\ A/6W_P 11_PHSX)?]$=\*_\
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MO_A/6W_Q%'_"C/@E_P!$=\*_^$];?_$5U-% '+?\*,^"7_1'?"O_ (3UM_\
M$4?\*,^"7_1'?"O_ (3UM_\ $5U-% '+?\*,^"7_ $1WPK_X3UM_\11_PHSX
M)?\ 1'?"O_A/6W_Q%=310!RW_"C/@E_T1WPK_P"$];?_ !%'_"C/@E_T1WPK
M_P"$];?_ !%=310!RW_"C/@E_P!$=\*_^$];?_$4?\*,^"7_ $1WPK_X3UM_
M\174T4 <M_PHSX)?]$=\*_\ A/6W_P 11_PHSX)?]$=\*_\ A/6W_P 174T4
M <M_PHSX)?\ 1'?"O_A/6W_Q%'_"C/@E_P!$=\*_^$];?_$5U-% '+?\*,^"
M7_1'?"O_ (3UM_\ $4?\*,^"7_1'?"O_ (3UM_\ $5U-% '+?\*,^"7_ $1W
MPK_X3UM_\11_PHSX)?\ 1'?"O_A/6W_Q%=310!RW_"C/@E_T1WPK_P"$];?_
M !%'_"C/@E_T1WPK_P"$];?_ !%=310!RW_"C/@E_P!$=\*_^$];?_$4?\*,
M^"7_ $1WPK_X3UM_\174T4 <M_PHSX)?]$=\*_\ A/6W_P 16YH'AOP[X4T\
M:1X7T"RTVT#EA:V%JD,88]3M0 9/K5VB@ HHHH **** "BBB@ HHHH ****
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7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20240630_g4.jpg
<TEXT>
begin 644 biib-20240630_g4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?T ^&K\:YKSWBVXTVS^SOYUR96XC$<>Y]YX7;D]*_%C]G/\ ;F_X*'_LO_\
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M_P!EWPK]JU34)/,N]6O9=9U*:[U"YD/,EQ<7#RSR.>KR-T&!7KGP4_X(9_\
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M7_/S\)?Y'Z(45^=__#^W_JU+_P OK_[AH_X?V_\ 5J7_ )?7_P!PT?V1F/\
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M HHHH **** "BBB@ HHHH _'7_@KE_R?;XK_ .O'3/\ TAAKYIKZ6_X*Y?\
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M -.2/Y%\4_\ DN<5Z4__ $W ****^^/ST**** "BBB@ HHHH **** "BBB@
MHHHH ^EO^"/?_*2+X7_]A&]_]-UU7] U?S\_\$>_^4D7PO\ ^PC>_P#INNJ_
MH&K^;_&3_DHZ'_7I?^ES/Z:\%?\ DFJ__7Y_^D0"BBBOR,_8@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH _'7_@KE_R?;XK_ .O'3/\ TAAKYIKZ6_X*
MY?\ )]OBO_KQTS_TAAKYIK[[ _[G3_PK\C\PS+_D85?\3_,****ZCB"BBB@
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M **** "BBB@ HHHH ^EO^"/?_*2+X7_]A&]_]-UU7] U?S\_\$>_^4D7PO\
M^PC>_P#INNJ_H&K^;_&3_DHZ'_7I?^ES/Z:\%?\ DFJ__7Y_^D0"BBBOR,_8
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH _'7_@KE_R?;XK_ .O'3/\
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M*"OZN\,?^2*PWK/_ -.2/Y%\4_\ DN<5Z4__ $W ****^^/ST**** "BBB@
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MY5_^YA_Q W_J8?\ E+_[J?@317[[?\.A_P!F;_H?_BG_ .''O?\ &C_AT/\
MLS?]#_\ %/\ \./>_P"-'_$:_P#J _\ *O\ ]S#_ (@;_P!3#_RE_P#=3\":
M*_?;_AT/^S-_T/\ \4__  X][_C1_P .A_V9O^A_^*?_ (<>]_QH_P"(U_\
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M=#_LS?\ 0_\ Q3_\./>_XT?\.A_V9O\ H?\ XI_^''O?\: /J:BOEG_AT/\
MLS?]#_\ %/\ \./>_P"-'_#H?]F;_H?_ (I_^''O?\: /J:BOEG_ (=#_LS?
M]#_\4_\ PX][_C1_PZ'_ &9O^A_^*?\ X<>]_P : /J:BOEG_AT/^S-_T/\
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M$$$<$&I:SO!_A31/ GA'2O _AJV,.G:-IT%CI\+.6,<$,:QQKD\G"J!DUHT
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20240630_g5.jpg
<TEXT>
begin 644 biib-20240630_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\*_\%&?^"MWCS]GOQ9J/P8_9!_9SU[XC
M>*_"'C?P9I7Q U4-96VCZ,=:U.SB@TLS75S"9+^YM[E1'Y:O'!]IBEF94#"O
MNJOR?_X*S_LTZ+XC\1>,OVH/V$_VV4T3Q-J?QY^&F@?%_P  FSM=8T:7Q+;:
MYH\&F7=S$=L]E<VZR6;R+%(!/' (V )9J /T#_9L_;(\!?M!_!_7/BQK_A#Q
M#\-Y/"&JWFF>.=!^(]I'I]QX?N[5%>?SI1(UO) (W61;F*5X71@0V0P7R_\
M9%_X*U_!']MO]L+QA^S%\"?".KWNA>%_!-MXBT[XCW*F'3_$<4M[):,UA&Z!
MI[99(I%6Z!V2-')L#*%D:#]AKX\?$3]M3PA\9_V1/V]_A9X&U/Q7\,/%@\(^
M/D\+PRW'AOQ/:7-C!>0RQPW6YTWPSA)K:0OM92"<-M7BOA'I>F:'_P '"7Q(
MT71=.@L[.S_9+\,06EI:PK'%!$FN7ZJB*H 50   !@  "@#[IKY7^-?[7?\
MP4H\!_%'7/"OPC_X)&WOCCPQI]V8])\7CXZ:!IBZG"%!\[[-<?O(1DD;7YXS
MWKZHKX\_X+1?%+QE9_ #P;^R%\+/$=UI/BC]H_XE:9\.;?5[!\7&EZ5=%Y=6
MO8_0QV$-P@8<JTR,.E &G^Q__P %1;;XZ_L6>-?VZ_VC_@>_P@\%>#;W5!]N
MNO%=OK4&J6&G@K/?VLUK&JS0F9)88C'O$QCS&6#H3PK_ /!6;]KCPWX!TO\
M:;^)W_!)CQSHGP5U26VE?Q+:^-K+4/$VG:;<NJPZA=>'H(C*D>)$=XHYY9HU
M))C^4BL7_@X%\#V/P2_X(>>+O WP8\ VR^%_!3>$8&\,6Q\N#^Q++6].#6V>
M=L0CC57/.(PY.1FLO]L_X(?MR_L@_LB^*_\ @HCHO_!3OQOK'Q)\ >'W\5:]
MX5U2#3QX"UB"!1+<:3;Z8MNLEO"\8:*"83M<;BK-(S-D 'T=^V!^WY/^S]\0
M_!G[.WP(^!&K?%SXM>/[*YU+P_X'TC5H-.AM=*MR@GU/4+VX!2RM5:1(U8J[
M22,$1&.<,_9+_;>^+_Q@^-/B#]F/]J+]CK7OA#X_T30(=>M(DUV/7M"UG3))
MO(\ZTU2"*)#*DHVO;RQQ2@$,%9=Q7XRGT;]H7]J__@N+JNF^$?BKK'PETOQW
M^R1X6U^3Q)H\-N_B"VT1=0N#/I6GR7,4D5L[WMTC37'ENT8MP%56E5T]T_9Y
M\1?M"?L=?\%/;']@+QA^TQXJ^+WP^^('PIU#QCX9O?'\MO=:_P"%KVPO;>WG
MAENX(HC<V<ZW *-*I=)(]H)&XL ?4W[5'[37PF_8W_9\\4_M,_'#5YK+PQX1
MT[[7J+VL'FSS,SK%#;PID;YI97CBC7(#/(H) .1\J^+/^"MO[3O[/OA32_C_
M /ML?\$P_$?PR^#6H7UI!J/CB+XBV&KZCX:BNI4BM[G5M*BB1[6+?)&)/+EG
M:(MAEW?*?MGQ7X8\)^,-"FT'QQX>T[5-,D*O<66JVD<\#;&#JS)("IVLH8$C
M@@'M7P'^UKX^U+_@M<NH?L"_LF0R7/P-'B"VA^.OQS48TZ\M[.ZCGDT#09/^
M7^ZEDA5)KI,P6Z;AND=PH /T,1TD021N&5AE64Y!'K2TRVMH+.WCM+6)8XHD
M"1QJ,!5 P /PI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5\K?$[_ (+0_P#!.CX1?M<Z9^QUXY_:=\'V6O7=A?R:KJLWB:T6
MPT2]MYK6)=.O93)B"ZE^T.R(V,"WD#%3M#?4UQ$9X'@69XRZ%1)&?F7(ZCWK
M\.M#\,?'+_@F)\>/A=^RQ^U[^P._Q;^'_A#X'?$;2[O6_A,;?5;CQEH-YJ^A
M3W>KWVDW/E2I/$%@6Y3?*TKW&^-F"-0!^XGVNT^R?;_M4?D>7YGG;QLV8SNS
MTQCG-<3^SW^TU\!?VKO!5W\1_P!G/XGZ;XNT"RUR[TB?6-(9GMS>6S[)HT<J
M!*%8C#IN1@059@<UY#>?LU?LJ?\ !0']CCX5>&/AG\0O$,'P+;2M.O\ 3/#?
MA'6Y["U\3:(MGY=MI=\W_'P;,*R>9;[D9C$$D. RGRO_ (-_-"T3PO\ LQ?%
MOPSX:T>UT_3M._:B^(%KI]A90+%#;01ZJR1Q1HH"HBJ H4    "@#[@\0Z_H
M_A30+[Q3XAOEM=/TVSENKZY<$B*&-"[N0 3@*">.>*^.Y/\ @X:_X(X0QM++
M^VKIRJH)9F\)ZR  .I)^Q5]H5\8?\%$?$6I_M3_M2_#/_@D[X9U.:WT3QCI-
MUXW^.LMI,T<K>#+&=(4TS<I!5-2OGCMI"I!^SQ7"_P = 'U=\)?BM\/_ (Z?
M#'0/C+\*?$2ZOX9\4:5!J>@ZI'!)$MW:3('BE"RJK@,I!&Y0<'I7(?#']M#]
MEWXS_'SQI^R_\+/C'IFN>._AXD;>-- L4E9M+WD *\I01,P8[6579D8%6 *D
M#SS_ (*!_M*>+/@!X \*_LT_LK:?IY^,7Q8O3X:^%&E?9E-MH\<<0-WK,\2C
M LM.MLS,H&&<0Q ?O1CYP_X)\_LW> OV2/\ @LU\1?@%\.GN;BRT/]EWPK]J
MU34)/,N]6O9=9U*:[U"YD/,EQ<7#RSR.>KR-T&!0![A\4/\ @N5_P2K^#'Q(
MUWX1_$O]K:PTSQ%X9U:XTS7--;PUJTIM;N"0QRQ%XK1D8JZL"58CC@U[-^RE
M^V+^S;^V_P##6X^,'[+/Q/@\6^&[76)M*GU2WL+FW5;R)(WDBVW$4;$J)4R0
M,9.,Y! \O_X*K_M+_$GX$?L_:-\-/V?-2CM?BK\9_&EA\/\ X;7DB;UTR^OR
MWG:HZ]2EG:1W%SG!&^*-2,-7L7[-/[//PY_92^!?AO\ 9^^%-A+#HOAK3Q;Q
M37,GF7%Y,27GN[B0\RW$TK232R'EY)'8]: &?M(?M1?L^_LA?#.;XP_M*?%;
M2O"'AV&YCMEO]4E;-Q<29V6\$2!I+B9L,5BB5G(5B%(!QR7[*_\ P42_8T_;
M4UK5_"O[.'QLM]:UO08$GU?PYJ.D7NDZI:P,0JSM9:A!!<>420/-$>S) W9(
MKY[_ ."I\6J?!S]MG]F3]NGXD?#/7O%GPB^%]QXFM?&8\/:%-JLOA>_U"TMX
M['77LH%>6:*+RIHVE1&:#S0R@E@#XI^TS^W#\._VE/\ @J+^QG\;_P!COPCK
M>IZ-9?$#5/"?B#XEWGAJ[TJVU6VU+2YW?2K?[9%%+?QPK:R7,K*K16\@@PV^
M1@H!^K-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?&O\ P43_ .",O[/?[<.NQ?%?PV+_ ,$?
M$2Y\2^'+GQ%XN\,^)-1TM]9T_3M2MKAHKF.SF1+BX6"%TM[B13);R")D=?+7
M'V510!XQ\._V$?@=\#/V;=7_ &9/V:I_$'PVTW6KF>\O?$OA;66DUQ[^9U::
M_>^OA<//=/L4-+-YA*@+T50/#;'_ ((E^&M-^,]_^T18_P#!1[]J&+QMJGA^
M#0]0\2+XWT?[3/IT,KS16S'^R<;%DD=AQU8U]LT4 ?-'Q9_8D\1_$/\ ;8_9
MU^/4?Q"\4-IGP5\/Z^NJ7MUKR8UZ>ZLX+*"*[MT1?/E;=-<M.-JHT 4(?.S'
MZ'\:OV0?A?\ 'GX]_"7]HCQMJ>M)K7P:U;4]2\*V=C=1)9W$]]9-92FZ1HV:
M0)&Q*;&3:W)+#BO5** ,CQ_X!\%_%3P-K'PS^(_AFSUKP_X@TR?3M:TC4(1)
M!>VLR&.6&13PRLC$$>AKY(L/^"('[/4UAI/P[^(?[2GQV\;_  MT&\MY](^"
MOC+XBB\\,Q);NKVUM+&+=;N[MH61"D%S<RQC8H*L !7V=10!XE^UM^P5\(/V
MN]3\,^-];\5^+_!'CCP4\_\ PB'Q&^'&N_V9K>E13J%N+=)622*6"4*N^&:.
M2,[0=N>:J?LG_P#!/;X1?LI>._$/QG3Q]XY^(OQ&\4V,.GZW\2/B?X@74M7D
MT^)B\5A$T<4,%K;*Y+^5!%&K.0S;BJD>\44 ?*E__P $C_@OJ7[&OQ%_8AN?
MV@?C$?#7Q-\6W.N^(-<_X36,ZQ";B2!Y;&WN#;E8[)A (S 4;*2RJ20]<KX%
M_P""+.F?"_P=IGP[^&__  4T_:MT'0=&LTM-)T;2/B'I=O:V<"#"Q111Z4%1
M0.@  K[5HH BLK8V5E#9FYEF,42H9IVR\F!C<Q &2>I/K4M%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U[1;/Q'H5[X>U"6
MX2WO[22VG>SNY()51U*L4EC*O&V"<.I#*<$$$ U^8>N_\$T_^"JO@;]KGX>?
M#WX4_MW0:CX%T+X0^+/#>A?%;Q=\-_[1UWPUIMW>:*5T^XE%['%?WS);*8+M
MXU 6UF,D<C%2/U'HH ^<K#]GS]HK]C7]EGX;?LQ_\$X?#?P[U'3O!&D1:3<-
M\6]>U"V+VT40"S*]A;2[YI)-[R95%RWR@=!XO_P3=_90_P""K/[&-QJO@'Q]
M9?L]ZEX/\7_%K6O&/B>^T?Q1KK:E:)JEV;F>&UCDT](I#&3A/,=<]R*^]:*
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A'_@M_\
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M%_\ D.C_ (?6?\%-?^CEO_+-T7_Y#KY8HH_U6X8_Z :/_@J'_P B'^MG%/\
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M/G^;"BBBO,/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFO!7_DFJ_P#U^?\ Z1 ****_(S]B"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#\=?^"N7_)]OBO_ *\=,_\ 2&&OFFOI;_@KE_R?;XK_ .O'3/\ TAAK
MYIK[[ _[G3_PK\C\PS+_ )&%7_$_S"BBBNHX@HHHH **** "BBB@ HHHH **
M** "BBB@#] _^"#/_(Q_$S_KQTK_ -#NJ_1VOSB_X(,_\C'\3/\ KQTK_P!#
MNJ_1VOBLX_Y&$_E^2/T/(/\ D5P^?YL****\P]D**** "BBB@ HHHH ****
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MZZK^@:OYO\9/^2CH?]>E_P"ES/Z:\%?^2:K_ /7Y_P#I$ HHHK\C/V(****
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M-"^+OP]U;X:^)KS4+>PUBU-O=3:5>M;7"*2#F.5/F0\=10!OT5\L_P##H?\
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M=#_LS?\ 0_\ Q3_\./>_XT?\.A_V9O\ H?\ XI_^''O?\: /J:BOEG_AT/\
MLS?]#_\ %/\ \./>_P"-'_#H?]F;_H?_ (I_^''O?\: /J:BOEG_ (=#_LS?
M]#_\4_\ PX][_C1_PZ'_ &9O^A_^*?\ X<>]_P : /J:BOEG_AT/^S-_T/\
M\4__  X][_C1_P .A_V9O^A_^*?_ (<>]_QH ^IJ*^6?^'0_[,W_ $/_ ,4_
M_#CWO^-'_#H?]F;_ *'_ .*?_AQ[W_&@#X;_ ."N7_)]OBO_ *\=,_\ 2&&O
MFFOUZ_X=#_LS?]#_ /%/_P ./>_XT?\ #H?]F;_H?_BG_P"''O?\:]^AGGL:
M,:?L[V26_;Y'R^)X;^L8B=7VMN9MVY>_S/R%HK]>O^'0_P"S-_T/_P 4_P#P
MX][_ (T?\.A_V9O^A_\ BG_X<>]_QK7_ %A_Z=?^3?\  ,?]5?\ I]_Y+_\
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MI^WM^R+^VU!K!_9F^--EXBN_#TJ1^(-%FL;K3]3TPN"4-Q8WL4-S &P=K/&
MVTX)P<;O[3W[5G[//[&/PENOCI^T_P#%33O!_A6SNH;:;5M1$C@S2MMCC2.)
M6DD<\G:BDA59CA58@ ]"HJCX8\2Z'XS\-:=XP\,Z@MWINK6,-YI]TBD":"5
M\;@, 0"K X(!YJ]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 45XY^U;_P % ?V/OV(SH]K^TS\;++P]J'B%G&@Z
M%;Z?=:EJFHA/OM!8V,4US*B]W6,J"0"036U^R]^V!^S1^VCX E^)O[,'Q?TO
MQ=I%K>O9W\ECYD4]A<K]Z"YMYE2:VE P?+E1&P0<8(- 'I-%?+WQ/_X+1?\
M!,7X._$O5?A/X_\ VK]*M]5T'41I_B&YLM%U&]TW1[O<%,%YJ-M;26=I(&.U
MEFF0J<A@"#7TOH6NZ)XHT2S\2^&=8M=1TW4;6.YT_4+&X6:"Y@D4.DL<B$JZ
M,I#!@2"""#0!:HKA_&/[2/P2^'_QN\&_LX>,/'UO8^-OB#:ZC<>#M DMYFDU
M.*QB66[975"B^6C*QWLN<\9-><_M-_\ !43]A']C[Q]%\*?CY\?(-.\426 O
MI/#FC:#J.LW]K:'I<7$&FV\\EM">TDJHI )S@4 >_45PGPM_:>_9W^-?P/B_
M:5^%?QI\-ZUX EL)KT^+K358_L,,$(8S/+*Q A\O:WF"3:8RK!@I!KQGX:_\
M%H/^"9/Q;^).C_"GP/\ M4Z?+JGB._%EX:N=1T#4[#3=9N22JPV>H75M'9W;
MLPPJPS.7) 7)(R ?4-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^?\ ^V98V?QP
M_P""[O[+WP!^)5HE[X0\'?#OQ-\0--T:[7?:WNOQO'9V\[QGY9)+9&:6(D91
MG+#DT?\ !?#3K/X<^&_V>?VOO!EJEM\0/A[^TAX8M?#^IVZ[;FZL-2G:TO\
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M_L>_![]A[]GK1?@?\'?AOH'AJ**V@N?$4/ARV,=O?:M]E@AN+OD LTAA7YB
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M_A31/ GA'2O _AJV,.G:-IT%CI\+.6,<$,:QQKD\G"J!DUHT %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20240630_g6.jpg
<TEXT>
begin 644 biib-20240630_g6.jpg
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M&R^_9Y_9^^ FJ_$CQ/H.G07WBU;36;;3K/18IP6@CEN+@[6GD4;UB R5^;(
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M?!?[5GA_]CR:RUS4/%.OX4W>FV<3V.FRF&2=(;F5I59)&BC+A%1SM9"<!@:
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M/7/AK\)?@G\1OB=?>%K@V_BBZ\ >'X[FTTRX RUL\TTT2O.!UCCW$'(.""
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M(M*\9_VE-K-I#(DC6MA"L*-;B5T4%Y6)5"1ACPWHG[2WQ"^.GPN^(GP:\#?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %17D
M\EM:O/#;-,RKE8DZM["I:* ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MB
MB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V
M** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6M#3;R>^M1/<6$ELQ8CRI2
M,_7BK%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFJ:MJLUPAAEOKDPR,V,RA0.$7< .6)(!YM^R?^R1\-/V[/@A;?M:_M@:3?\
MB7Q7X^GNM0TL-KEU#%X9L/.DCM;6P6*1%A"QJK[P-[,Y+$]^4NOVL_CW\!_V
M%_C_ /#Z3QG=ZSXU^"?BA/#NC^+-0_>W4FEWEQ#'9WTY(.^>.&60EB#S$I;=
M\Q/H_P#P3O\ VCOA;\$_V8K;]G/]H?XBZ%X-\:?"E[K1_$VE>(=5BLV\J*9V
M@NH?-*F:"2%HV61<@DGVSD_LQ6GA76?A1^T3^V;\5_AMJ>L>"OBCKMS>V/A^
M/26ENM5\.6=N;>*<6[%6_?(97"G!VA6!Y!H U/&O_!,W]F#P/\#=3^*&@^,_
M$=AXZTGP]+JD?QB/C.].HO=10F7[9*YF,;QL1EDV["A(&#AJ]>_8$_: UG]J
M+]C[P+\</$HC_M36-*>/5FB0*LEW;S26TT@4<*&DA9PHX ; KY5UFP_X)S?#
M/X%Q>/\ PK^U[XN\?>%X;5)O!GP5N/B0;^SO+SK:6 TU1]ID E\L>1,S(F/G
M7 ->X_LWZIX$_P"";7_!/'P1'^U#XG/A^'2;)3KMPUC/=&WO[ZYEN6A*6T;L
M2LD[(2%(^7KCF@#OOVJ/V?[[X_0:%I?BCXTW_AKP!I4]Q>>.=$TN9[.378%C
MS'%+?)*C6]NA#-(H'SJ?O)M!KYAU;P-\ /@C^U_\(M*_X)O>)8O[6U?Q*8OB
M5X8\)>))=1TQ_#^P^?=WJ>;)'!(AQY;,59W;C<0*^D_C_P#M8_!SX2^,O#?P
MS^.WAXVW@SX@:5<P?\)CK<47]AB4J/\ 0+LR<1^;$SG]Z A&1S\VWYD_:BB_
M92\%_%;X5/\ \$Z;KPG8_%;4/']A"^F?"J>W6"[T;+&\_M&"R/D_9P@!+2 ,
M,$J<!R #] :*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OSL^)'P#_:N_8W^-/P7\!? 7
M6O"_CSPO9>./$%Y\-_#.O"2PO;-I],OYKBSENU)CDB$<DYCD90WF;0<+P/T.
MO;.UU&SET^^@66">)HYHG&0Z,,$'V(.*^'?&_P"P)^U'\*_BM\*?"O[-?[26
MH)X*T'Q)JLV@_P!O^$X=3?P1%-IETA_?-*C74+>888HY!F-I$.Y@N" >^_ _
MXG_#[]O?]GG7=&^(/PON=)"ZM>^&O'_@K4;O+V-_;NOVFU::$KYBG<K;UV[E
M?D Y%>:V/ACPYX+_ ."P'AOPGX0T&STO2]/_ &:)H+#3K"W6&&WB76P%1$4
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M^G:>]O[_ ,'64TUQ*QRSN[Q%G8DDDDDDT ?._P#P3>^*7PLUGXU_M!^'M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJG_X''_,/[1R_P#Y_1_\"7^9[C17AW_#R+]B[_HLW_ENZC_\CT?\/(OV+O\
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M>+35^UUU.BE6HUX\U.2DO)W_ ""BBBN@T"BBB@ HHHH **** "BBB@ HHHH
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M '=1_P#3?<U^J-?L_AW_ ,B2I_U\?_I,#[SA?_D7R_Q/\D%%%%?>GT@4444
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M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V*\,_X*2_\ )F'C#_>T
M[_TX6U>M_P#"#Z1_S\WO_@6U>)?\%%?"VG:;^QYXNO8)[EG1M/P)+AF'-_;C
MH?K7E9[_ ,B3%?\ 7N?_ *2SBS'_ )%];_#+\F?F!1117\X'Y8?7G[%7B;P?
MXZTSX8?#_2/B?;>'=8\)>+[J]U;P]>F2*/Q$LS*T<L;J"KS1JOEA'YQTP.OC
M?[1'A']H[X<^&- \!_&&[%]X?@EN)_"VH0W,-Y;N'VB18;E<MM^53Y18 ==O
M.:[[]BJQ_9Y\4_$;X=W$.M7/AGQOHFM8N[6:VFN;7Q$"[-&R."?LTJJ=I! 0
MX!&"37'_ !>\=_"SPQ\#-)_9T^'WC2Y\7)!XKEU[5M<^PR6D$3F'R1:VRRC?
MMQN9F*@%L$ YX^PQ$H5<ABZDTFDTG&>]E22C*#UOIK9))QYM;W?N5&IY<G.2
M71-2WLH:.._KM9J_77M?VC/"?[,VK_$R'5_'W[0,T;7&@:3;V5GX5T<:BMG'
M%8P1%[B7S%4$NKGRTW,%P3@MBJ/P5_9<@\*?MD^!?"'B'4[3Q%X<U2$Z]HNJ
MV<1\G5+2*"6XC_=MRK%X@K1G..G(()Y_7?V=_@SXZO8O%?P5_:(\)Z5H-S!&
MTVE^.-8-IJ.G2;1YD;*(R)P#DAH\YSC'&3N>(?VH?!WPR^,OPRG^%5U/K6A_
M"_3A8OJ3PF%M6,I?[6\:-RB,KLJ!N1U/%-O"?7/K.+IPBE4C).,N;F7,G+2[
MO'EN[V5G9:7L-NC[?VU:,4N9--.]]=>KNK:[*VWD3:SX#TOQ5\:I/$GQ'_;!
MLM!^)UWJHG2S32KB>VTN\+9CM9+Y6"1&,XC(562/;MSQ7CWQYM/B58?&/Q%:
M_&(*?$RZD_\ ;#QPQQK)*<'S%$:JN&!# @#(8'O7I.M_L[_!_P 3>-KGQ[9_
MM6>#H?!U]?->2/>7LHUB&%V+M$;/RR[S#)7(.UB,Y&<5P_[47Q;TWXY?'?Q!
M\3-%LI;>QOIXH[".?_6&"&%(8V?K\S+&&(R<%L9.*X,SC%823FE&3G=6FY<Z
MM*\W[S5UI:2LGS.RTTYL6DJ+<E9N6EI7YE9WD]7KMJK7N]#JH[=?V>OV;+77
MX%\OQ?\ $Z&9+>?I)IN@HVQ]O]UKE^-W_/)"!C<:\6KV+]N'Q?X4\3?&BWT?
MP#K]GJ>@^'/#&FZ1I%W83"2%HHK=6(4KP<.[@X[@UR/PY^&W@GQEX$\6^*O$
MOQ9L=!U#P_9Q3:/HMU;J\FM.PDW1QL9%*E=BYPK_ .L' [\F/INIC?JM%IQI
MII:I)\JO)W;MJTWYZ)=$8XF#GB/8T]HZ+5=-W\W=_<ET.C_9[\(:%X8T74?V
MEOB/IL=QHGAB=8M$TVX'RZSK+#=!;X_BCC_UTO\ LJ!SNKJ/VO?$VN>,_@C\
M&_%OB;49+O4-2T?5[F]N93\TDCWVYC^9Z=!7->'OVN_$.B_#C1/A;J?P=\ :
MWIF@++_9YUO09)Y TK;I')$P!9CC) &<"NW_ &D/VD/"7C']GSP%X9T/P-X"
M:]N=%O$U.'3]-/FZ _VD%4MQYA^S[U&X@[LY)KTJ-3 ?V36HTZMO<3::=W/G
M@WZVMRKLKRZLZH2P_P!2G",_LJ^F[YH_\,O+7N?-U%%%?+'CGN?_  3:_P"3
MS_!_^[J/_ION:_5&ORH_X)U6,.I?MA^$K*=G5'74,F-RIXL+@]1]*_3_ /X0
M?2/^?F]_\"VK]G\._P#D25/^OC_])@?><+_\B^7^)_DC8HK'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VK[T^D-BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_
M  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?
M_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -B
MBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^
M$'TC_GYO?_ MJ /C/_@LS_K?AS_NZO\ ^V5?#]?:G_!8+1+31I?AX+669O,7
M5MWG2EL8^Q],].M?%=?@G&O_ "4U?_MW_P!(B?F^?_\ (VJ?+_TE!7N'PU_;
MM^,W@3X;ZOX(OO$DNHSMIMO;>&+R_L;:Y;33'<1R'+31LTB>6K*JL6"MM( P
M*\/HKP,)C<7@9N=";BVFG9VT>G_#=GJ>;1Q%;#R<J<FF]-#I#\8/B>WQ*7XP
MOXWU!O$Z78N5UEYLS"0#:.3QMV_+MQMV_+C'%>@2?MM?$:&YEU_0/AYX#T?Q
M%.K>;XLTOPI%'J)9AAY Y)1';)RRH#R:\;HJJ68XZA?V=1J[N]>O?U\]QPQ6
M(IWY9/77Y]_7SW+<.M:A'K:>(9YS<72W8N7EN6+F63=N)<DY;)Z\Y.:U_BO\
M3O$OQE^(6I_$SQ>MN-2U:59+H6D92,%45!M4DD#"CN:YVBN?VM3V;IW]UM-K
MS5[/\7]YESSY'&^CU^?],]8^&/[7_CSX7?#!OA!8> _!NK:))>-=7%OX@\/B
M[\^4D$-(&8*Y7  )&0 *I>/?VE[SQ[X3N_"4OP/^&FD+>! =1T'P9#:W<.UU
M?]W*IRF=NT^JDCO7FE%=;S/'NBJ3J/E2M;3;L;_6\2Z?)S:6M\CM/$?QV\;>
M*/@OX>^!&IQ6(T3PU>3W.G/% PG+RO([;VW$,,RMC ':MKP9^U7XW\,>$;+P
M-XD\%^$O%^G:5N&C1>,-"6\?3U)R4B?<K!,\["2O'3'%>8T5$,PQL*G/&;O9
M1_[=5K+S2LK>A*Q->,N92=[)?);(Z7XJ?%SQU\9O$P\5>/=56XGCMTMK2""!
M88+2W3[D,,: +&@R< #N2<DDUS5%%<U6K4K5'.HVY/=O=F4YSJ2<I.[85]R?
M\$9O]5\1O][2/_;VOANOMC_@C[H=IK,7Q#^U2S+Y;:3M\F8KG/VSKCKTKZ;@
MK_DIJ'_;W_I$CUL@_P"1M3^?_I+/NRBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VK][/T@V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VK0TW3H-*M1:6[R
M,H8G,KECS[F@"Q1110 4444 %%%% !1110 5X]^UG^T3XL^#S>%/AI\*?A=#
MXQ\;_$#4Y[#P[HM]?BULUC@@,]S<W$I5L1QQC)4#<Q8 5[#7@O[=/P9_:+^*
M6G^#/$G[+/\ PB=GXP\)^(7U"PUSQ->W$)LE:%HI$C$4<@E25':.2-UP4.00
MRJP .5O=;_X*P:@($O/V?O@+*EI.LUHL_B74'\B1<A77,/RL 2 1@C)KZ6\,
M2^(IO#>GS>+[6U@U9[&)M4AL9&>".X*#S%C9L%D#[@">2,9KYET?Q?\ \%?K
MM7LCX<_9MO+JW^6Z^RZ[K(VM[KL8KT/!-?37AA_$<GAO3W\8PV<>KM8Q'58]
M.9FMUN=@\T1%_F*;]VTMSC&>: +U%%% !1110 4444 %%%% !7AG_!27_DS#
MQA_O:=_Z<+:O<Z\,_P""DO\ R9AXP_WM._\ 3A;5Y6>_\B3%?]>Y_P#I+.+,
M?^1?6_PR_)GY74445_.!^6$ME?7NF7<=_IMY+;SQ-NBF@D*.A]01R#41))R3
M111=VL 4444 %%%% !1110 4444 %%%% 'N?_!-K_D\_P?\ [NH_^F^YK]4:
M_*[_ ()M?\GG^#_]W4?_ $WW-?JC7[/X=_\ (DJ?]?'_ .DP/O.%_P#D7R_Q
M/\D%%%%?>GT@4444 %%%% !1110 4444 %%%% !1110!\-_\%F?];\.?]W5_
M_;*OA^ON#_@LS_K?AS_NZO\ ^V5?#]?@G&O_ "4U?_MW_P!(B?F^?_\ (VJ?
M+_TE!1117RQXX4444 %%%% !1110 4444 %%%% !7W)_P1F_U7Q&_P![2/\
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MAW_R)*G_ %\?_I,#[SA?_D7R_P 3_)!1117WI](%%%% !1110 4444 %%%%
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M\<**** "BBB@ HHHH **** "BBB@ K[D_P"",W^J^(W^]I'_ +>U\-U]R?\
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MR3C\S7T?X8N-?O/#>GW?BO38+/5);&)]2L[:?S8X+@H#)&CX&]5;(#8&0,T
M7J*** "BBB@ HHHH **** "O#/\ @I+_ ,F8>,/][3O_ $X6U>YUX9_P4E_Y
M,P\8?[VG?^G"VKRL]_Y$F*_Z]S_])9Q9C_R+ZW^&7Y,_*ZBBBOYP/RP****
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M^X_^-T?\-%?!O_H<?_*?<?\ QNC_ (AUX@_]"?%?^$]7_P"0#^V\E_Z":?\
MX''_ #/JG_@FU_R>?X/_ -W4?_3?<U^J-?D-_P $M_C/\-?%O[<_@GP_X?\
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M/X^T74+=;+PF-<O-:T[Q#:2,1(T<\R%[::+&XB1@C+PNYF^3VWP;\<X?A/\
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M2ZY]<_I7Q_B9_P D3BO^X?\ Z<@?:>%O_)=83_N)_P"FIGZKT5C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2U_)Q_7AL45C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2
MZO\ ]"A>_P#?2UH:;>3WUJ)[BPDMF+$>5*1GZ\4 6**** "BBB@ HHHH ***
M* "O!?$GC_\ ;C^!ES)#??!K3?C%H"R$V^K^&-4ATG6H8LYQ/97'[BX< XWP
M2INQGRES7O5% 'S:G[='QSU^7^RO _\ P3>^+TVHMPJ>(3IVEVN[CK</<LH'
MO@_2O1O@=;_M3ZUJ]SXX_:&O?#6B6UQ:>5IG@7PP&NULR75O.N;^55:>8 ;-
ML21Q %C\YP5],HH **** "BBB@ HHHH **** "OE7_@ME_RC.^(W_731O_3Q
M95]55\J_\%LO^49WQ&_ZZ:-_Z>+*O>X5_P"2GP/_ %^I?^EQ/G^+/^26Q_\
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MJ][A7_DI\#_U^I?^EQ/G^+/^26Q__7FK_P"D2/P-HHHK^SC^(PHHHH ****
M"BBB@ HHHH **** "BBB@#ZJ_P"")W_*3'X<?[FL_P#IGO:_?*OP-_X(G?\
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M!^@>%O\ R76$_P"XG_IJ9^I=%%%?R<?UX%%%% !1110 4444 %%%% !1110
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MR#XH?\EUB_\ N'_Z:@%%%%?='P(4444 %%%% !1110 4444 %%%% !7ZH_\
M!M'_ ,>_QH_W_#O\M3K\KJ_5'_@VC_X]_C1_O^'?Y:G7PGB9_P D3BO^X?\
MZ<@?H'A;_P EUA/^XG_IJ9^I=%%%?R<?UX%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%9WB[Q=X;\!^&[SQAXPU>*PTRPB\V\O)\[(D
MR!DXR>I% &C17DO_  W=^R'_ -%XT3_OJ3_XBC_AN[]D/_HO&B?]]2?_ !%
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MUIX8_P"@ZC_X-A_\D'^J?%/_ $ 5O_!4_P#Y$\SHKTS_ (9 ^//_ $ =$_\
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MJBO)?^&[OV0_^B\:)_WU)_\ $4?\-W?LA_\ 1>-$_P"^I/\ XB@#UJBO)?\
MAN[]D/\ Z+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_\ B* /6J*\E_X;N_9#_P"B
M\:)_WU)_\11_PW=^R'_T7C1/^^I/_B* /6J*\E_X;N_9#_Z+QHG_ 'U)_P#$
M4?\ #=W[(?\ T7C1/^^I/_B* /6J*\E_X;N_9#_Z+QHG_?4G_P 11_PW=^R'
M_P!%XT3_ +ZD_P#B* /@C_@Y<_X^?@O_ -<_$/\ /3:_+2OU$_X+BZKX?_;!
MG^&+_LZ>+-$\1#P\FLC6#_;=M:?9_/-CY7_'U)'OW>3)]W.-O.,C/P/_ ,,@
M?'G_ * .B?\ A::3_P#)5?TYX?9_D6"X0PU'$8JG":Y[QE4BFKU)M73::T=_
M0_EGQ&X>S_'<9XJOAL)5G!\EI1ISDG:G!.S2:=FFO4\SHKTS_AD#X\_] '1/
M_"TTG_Y*H_X9 ^//_0!T3_PM-)_^2J^S_P!:>&/^@ZC_ .#8?_)'Q'^J?%/_
M $ 5O_!4_P#Y$\SHKTS_ (9 ^//_ $ =$_\ "TTG_P"2J/\ AD#X\_\ 0!T3
M_P +32?_ )*H_P!:>&/^@ZC_ .#8?_)!_JGQ3_T 5O\ P5/_ .1/,Z*],_X9
M ^//_0!T3_PM-)_^2J/^&0/CS_T =$_\+32?_DJC_6GAC_H.H_\ @V'_ ,D'
M^J?%/_0!6_\ !4__ )$\SHKTS_AD#X\_] '1/_"TTG_Y*H_X9 ^//_0!T3_P
MM-)_^2J/]:>&/^@ZC_X-A_\ )!_JGQ3_ - %;_P5/_Y$\SHKTS_AD#X\_P#0
M!T3_ ,+32?\ Y*H_X9 ^//\ T =$_P#"TTG_ .2J/]:>&/\ H.H_^#8?_)!_
MJGQ3_P! %;_P5/\ ^1/,Z*],_P"&0/CS_P! '1/_  M-)_\ DJC_ (9 ^//_
M $ =$_\ "TTG_P"2J/\ 6GAC_H.H_P#@V'_R0?ZI\4_] %;_ ,%3_P#D3S.O
MU1_X-H_^/?XT?[_AW^6IU^?7_#('QY_Z .B?^%II/_R57W[_ ,$.M:\.?L?0
M_$Y/VC/%VB>'3XA;1CH__$ZMKO[1Y'V[S?\ CU>39M\Z/[V,[N,X./BO$//\
MBQO"&)HX?%4YS?):,9Q;=JD&[)-MV2OZ'W'AQP]G^!XRPU?$X2K""Y[RE3G%
M*].:5VTDKMV]3]4Z*\E_X;N_9#_Z+QHG_?4G_P 11_PW=^R'_P!%XT3_ +ZD
M_P#B*_F4_J4]:HKR7_AN[]D/_HO&B?\ ?4G_ ,11_P -W?LA_P#1>-$_[ZD_
M^(H ]:HKR7_AN[]D/_HO&B?]]2?_ !%'_#=W[(?_ $7C1/\ OJ3_ .(H ]:H
MKR7_ (;N_9#_ .B\:)_WU)_\17>_#OXF> _BSX<7Q=\.?$UMJVFM,\2WEJ3L
M+K]Y>0#D9% &[1110 4444 %%%% !1110 4444 %%%% !4.H:=I^K64FFZK8
MPW-O,NV6WN(@Z./0J<@CZU-10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\
MHFGA_P#\$T'_ ,17044 <_\ \*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFG
MA_\ \$T'_P 17044 <__ ,*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\
MP30?_$5T%% '/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30?_$5
MT%% '/\ _"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!10!S
M_P#PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%=!10!S_\
MPJ;X5_\ 1-/#_P#X)H/_ (BC_A4WPK_Z)IX?_P#!-!_\17044 <__P *F^%?
M_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\17044 <_P#\*F^%?_1-/#__
M ()H/_B*/^%3?"O_ *)IX?\ _!-!_P#$5T%% '/_ /"IOA7_ -$T\/\ _@F@
M_P#B*/\ A4WPK_Z)IX?_ /!-!_\ $5T%% '/_P#"IOA7_P!$T\/_ /@F@_\
MB*/^%3?"O_HFGA__ ,$T'_Q%=!10!S__  J;X5_]$T\/_P#@F@_^(H_X5-\*
M_P#HFGA__P $T'_Q%=!10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA
M_P#\$T'_ ,17044 <_\ \*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFGA_\
M\$T'_P 17044 <__ ,*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\ P30?
M_$5T%% '/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30?_$5T%%
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M%% '/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30?_$5T%% '/\
M_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!10!S_P#PJ;X5
M_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%=!10!S_\ PJ;X5_\
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M\UUI&H17,<<RQ(6C9HV(# ,I*GD9'K0!TU%%% !1110 4444 %%%% !1110
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MKE;F5P9EDC#JZA<$GC& -_P7X1T?XU?MW_M)_![XER7^H^&YO#O@W.E+JUQ
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M3X5?''XK?LP?%'QYX7GGU3XAZU;1^)W@UN\A6>(Z0TH1%CF58<-_%&%8]R:
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MRW&O_),U_P#MW_TN)X^?_P#(IJ?+_P!*1\.T445^"'YN?<7_  1E_P":D?\
M<'_]OJ^XJ^'?^",O_-2/^X/_ .WU?<5?O?!7_),T/^WO_2Y'Z1D'_(II_/\
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MB[OH&^&WB;PHVHSZ)H^F"!0T92QGC-O<>8"S,RL[$$C P6M_'SPA^SY\9O\
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MB5X.#^ KC58T\)^%(;H6=O;W5A+;F2.6=?,GG>1XRY<1JJ0J%!))/U#10 $
MC!%?+'AS]E_]M7]EJ^U/PI^QG\3?A]J7@&_U.XO],\)_$RRO@_AYYY&DEAM;
MBS):2$R,S!)!D;L9SEF^IZ* /"/V6OV4_'_PY^)/B_\ :/\ VB/B%IWB;XB>
M-[>VL[YM#L&MM-TJP@&([.U1V+LN?F9W.YB%XSN9O-_A[^P1\?M+_9>\0_L#
M>._''@^;X8RZ-J%GX8\3:6EV-=B:6[-S;FY@<"!E1F8-LD!8*HXR6KZ_HH ^
M1_B-^RY^WU\=_P!G/4OV9/B=\4/AIH>C/X:?3TU7PE:WQN]7DCAVVR3"90EG
M"TBQM,(A*S*&1-H8UU_QI_9+^*WBSX4?!]OAGXK\/VOCKX0WNGWMB=:CG?2]
M0>*R-K<0.T8$J(X)*N%)&T?+SD?1-% 'S;\3OV8_VF/&7BGP5^U/X+\8>"O#
MOQF\-:1<Z1K-H(;NZ\/:UILLQD%G(Q"7"!3MD5P,ARPP1@CJO@E\+/VK[GXK
MS_&3]ISXO:/B+26T_1_ 7@)KI-&@W.&>[G>X(>ZN#C:I*JJ+G ).1[110!\V
M:;\*_P#@I#\*3J/@KX:?&7X=^-/#D][<3:/J_P 3(-1.L:?%*[.()6MB4O%C
MW;5+&,D #@ */0OV./V:K/\ 9+^ &D?!:#Q,VLSVD]S=ZCJ?V40)<75Q.\TI
MCB4D11AG*J@)PJC.3DUZC10 4444 %%%% !7P[_P6:_YIO\ ]QC_ -L:^XJ*
M\K.LL_MC+*F$Y^7FMK:]K23VNNUMSCQ^$^O825#FM>VMK[-/R['X=T5^XE%?
M!?\ $-?^HK_R3_[<^;_U3_Z??^2__;'P[_P1E_YJ1_W!_P#V^K[BHHK[W)<L
M_L?+*>$Y^;EOK:U[R;VN^]MSZ3 83ZCA(T.:]KZVMNV_/N>-?\% ?V;?%7[7
M/[)GBG]G[P5KNGZ9J6NO8FWO=4+^1'Y%]!<-N\M6;E8F P#R170_M7_L_:)^
MU)^SMXJ^!.N2QPC7M+:.RNY%R+2\0B2WGXY^29(V(') ([UZ)17JG8?.7Q0_
M9'^-?Q1^%?PM\53?%+2M+^-/PK"SZ9XK2VDN=/OIV@$%W%.C!)##<HJE]N&4
M],CKJ_#KX6?ML>,/BUHGQ%_:5^+WA?2-'\-QS&U\&_#!KY;;6+B1-GFW\UT5
M9T3ED@5=NX@ECCYO>** /GW7?AC^WU\.OB/XCUCX%?%[P3XI\,>(]4?4+?1?
MB>M^+C0)'4!H+6>TW;[;(W+$RKMS@'JS9/@;_@G]?VO[+?Q6^#/Q$^(=I=>)
M?C%J>IZOXDU?1]+,%C8WUW&JJMM SEC%&40_,V]_F)(R,?3%% 'F/[+F@?M-
M>$?!*^$/VD)? \[Z396EGHM[X-ENR;F.*,H\EPEPBB-SMC(5"1RW/2LW]L']
MF+5?VBO#GAW6O /C2/PUXX\"^(8M<\&:]/:>?#%<H"KP3QY!>"5#M< YX4\X
M*M[!10!\VZ3^S/\ M._&_P",7@WXG?ME^+O ZZ7\/+\ZIX=\)_#^"\:"\U78
M4CO;J:[PP\H%C'$B\,V2QP0>V\$?L]>)O#'[9GCG]I.[UNPDTKQ3X3TK2K.P
MC+_:(9;5I2[OE=NT[QC!)X.0*]<HH *^=?@#^PK'\&/VQ?BK^TA<:]:W>D>-
MU!T#15#EK![DQRZF9 PV?OIX86&W.0/FZ<_15% 'SI^P9^PC;_LA^#?'?A/Q
M/KMMKZ^*_$<OV1\NPBT..(0V5E)O YCC,@(&5'F8!/4\IX'_ &4OV\O@'\.K
MS]F7]G_XV> 5\ "2YB\,^(_$>G7LFO\ A^SG=W,*1QD073Q;V\MW9.<9& %'
MUM10!\V^)?V [/1/@W\#/@C\'-;M;32OA%\2])\27<VJEO,U"&V%TUP1Y:D>
M=++<-)@X7);D<5VW[4O[/7B;X[^(OA7K/AW6["S3P%\3K'Q+J*7I?-Q;P0SH
MT<>U3^\)E!&[ X/->N44 ?.GCK]F;]HGX<_M)>(_VD?V0?%?@Y)/'NGVD'C?
MPOXZBNEM);FT0QV]];RVH+I((SL:,KM;DDY(VVOV1OV4?BW\#OCC\4OC;\7O
MBAI_B?4OB5#HDMS/8VCVX@N+2*Y22-8FR$@59HHXAO=BD67.XU] T4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20240630_g7.jpg
<TEXT>
begin 644 biib-20240630_g7.jpg
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M(%CBA0=%5% "@>@&*^;+O_@J%X!MO#3?%*+]FCXPS_#Y5\T_$&+P:@T\VO\
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M+*-+982"#$(@-@0@D;<8P:BF\">![GPA_P *]N/!NE2:!]D%K_8;Z=$;/R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[/?P:\/_ !'^'MQK%U?^"OMGC%=(NO#:7,C2R6<ZR0N)X$E=F1HSOPS9'(P
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M&N;^$7PZ_:4^,W_!/RQ_:V\<?ME_$33/&-IX%GU;P]:^']76#3HA:PR-$;N
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M3I/Q]^$GA[X7^!/!OB^T\2:A8VWBU=9U/6;JUW&"%&BACC@ARS;R27P1CTH
M^M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ J";3--N+^#59]/@>ZMD=+:Y>(&2)7V[PK$94-M7
M('7:,]!4]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%>3R6U
MJ\\-LTS*N5B3JWL*EHH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@
M#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275
M_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7
M_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?
M^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O
M?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6
MMBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_
MX275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^
MA0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_
M^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X2
M75_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X
M275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A
M0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK
M8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^E
MH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EK0TV\GOK43W%A);,6(\J4C
M/UXJQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>1_MX^//
MBQ\,?V0/'OCWX'V\S^)],T0RZ>]M;":2W7S$6:=$.0S10F64 @C,8R#TH ]%
MTSQYX/UCQCJOP^TOQ!;S:UHEK:W&K:<A/F6L5SYGD.PQT?R9<?[AK7K\VOV<
M/@U\%_CC^T?\1;S]F']MSQ;'KT/A#PQ?>%O'1\;37]W>WK?V@UT+VUED"W:
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M4^&?'<#->>%[/QI?^)+)K\*I#26\>H3>5<84D[,%L<[>,@ ^W**** "BBB@
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M^#/B9X@_X1^#5F\+0:3J>C:FZ%H/DMCY4\#D$,2H9>N>/GZ'XA>)?VS?CO\
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M@?1]*\?>(HM8URVTN"+6=5@M! EY=+&HEF6->(U9PS!1T!Q7SC\'[K_AH/\
MX*6?$CXC:J#-I/P9T.S\*^%$?F--0O4-QJ-PO]V4*L<!/=.*^I* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *XC]HCXH>,_@S\)=2^)?@;X3W
MWC:[TIHI;CP_I5SY=U-:^8HGDA&QO-DCC+.(A@OMV@@D5V]% 'Y-_''X@_\
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M6VE7GACP4!$JZ=X2N19L$23S-A.U@RL_S/N!+DDDDG->?:-_P3 \(>'-(MM
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MU4:%X4^+OA?4[XOM%GI^OVTTN[TV(Y.>1QBNHH **** "BBB@ HHHH ****
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M-?\ 5M__ )>'_P!QT?\ #YK_ *MO_P#+P_\ N.OAVBC_ %UXF_Y__P#DL/\
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MB%\%?B=\>;)IOA=X=\8WMQXLDEL9+JUL[UK"1--N;B)%8F-)RP#%2%=TSUH
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M45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5]Z?2&Q16/\ \(/I'_/S>_\
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M;]7]PS]CTD_M2^  3T\46F/^_@K ^-,,UQ\;O%EO;Q,\DGBJ_5$1<EB;EP
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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M 4444 %%%% !1110 5X9_P %)?\ DS#QA_O:=_Z<+:O<Z\,_X*2_\F8>,/\
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M8F5=)22T[(]S_P"";7_)Y_@__=U'_P!-]S7ZHU^5W_!-K_D\_P '_P"[J/\
MZ;[FOU1K]:\._P#D25/^OC_])@?:<+_\B^7^)_D@HHHK[T^D"BBB@ HHHH *
M*** "BBB@ HHHH **** /AO_ (+,_P"M^'/^[J__ +95\/U]P?\ !9G_ %OP
MY_W=7_\ ;*OA^OP3C7_DIJ__ &[_ .D1/S?/_P#D;5/E_P"DH****^6/'"BB
MB@ HHHH **** "BBB@ HHHH *^Y/^",W^J^(W^]I'_M[7PW7W)_P1F_U7Q&_
MWM(_]O:^IX*_Y*:A_P!O?^D2/8R#_D;4_G_Z2S[@HHHK][/T@**** "BBB@
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M_P"WM?#=?<G_  1F_P!5\1O][2/_ &]KZG@K_DIJ'_;W_I$CV,@_Y&U/Y_\
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M_I+.+,?^1?6_PR_)GY74445_.!^6!1110 4444 %%%% !1110 4444 %%%%
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MG"VKRL]_Y$F*_P"O<_\ TEG%F/\ R+ZW^&7Y,_*ZBBBOYP/RP**** "BBB@
MHHHH **** "BBB@ HHHH ]S_ .";7_)Y_@__ '=1_P#3?<U^J-?E=_P3:_Y/
M/\'_ .[J/_ION:_5&OV?P[_Y$E3_ *^/_P!)@?><+_\ (OE_B?Y(****^]/I
M HHHH **** "BBB@ HHHH **** "BBB@#X;_ ."S/^M^'/\ NZO_ .V5?#]?
M5/\ P7Z^,?\ PJ>?X4+_ ,(Y_:'V]-<_Y?/*\O8=/_V&SG?[=*_.K_AL3_JG
M7_E7_P#M-?'YKX/^(W%./GFF5X'VE"I;EE[6C&_*E%Z2J1DK2BUJEM=:'XUQ
M7Q-DF7Y_6P^(J\LX\MURR>\(M:J+6S/;**\3_P"&Q/\ JG7_ )5__M-'_#8G
M_5.O_*O_ /::\_\ XE_\7/\ H6_^5L/_ /+3YW_7+AO_ )__ /DL_P#Y$]LH
MKQ/_ (;$_P"J=?\ E7_^TT?\-B?]4Z_\J_\ ]IH_XE_\7/\ H6_^5L/_ /+0
M_P!<N&_^?_\ Y+/_ .1/;**\3_X;$_ZIU_Y5_P#[31_PV)_U3K_RK_\ VFC_
M (E_\7/^A;_Y6P__ ,M#_7+AO_G_ /\ DL__ )$]LHKQ/_AL3_JG7_E7_P#M
M-'_#8G_5.O\ RK__ &FC_B7_ ,7/^A;_ .5L/_\ +0_URX;_ .?_ /Y+/_Y$
M]LHKQ/\ X;$_ZIU_Y5__ +31_P -B?\ 5.O_ "K_ /VFC_B7_P 7/^A;_P"5
ML/\ _+0_URX;_P"?_P#Y+/\ ^1/;**\3_P"&Q/\ JG7_ )5__M-'_#8G_5.O
M_*O_ /::/^)?_%S_ *%O_E;#_P#RT/\ 7+AO_G__ .2S_P#D3VRON3_@C-_J
MOB-_O:1_[>U^5_\ PV)_U3K_ ,J__P!IK]&_^" OQA_X6S!\5S_PCO\ 9_V!
M]#_Y>_-\S>-0_P!A<8V>_6O0RKP?\1>%L?#-,TP7LZ%._-+VM&5N9.*TC4E)
MWE)+1/>[T/HN$^)<DS#/Z.'P]7FG+FLN62VC)O5I+9'Z*T445]@?LH4444 %
M%%% !1110 4444 %%%% !1110 4444 %?*G_  4SB^%EIK7PA\4?M':IITOP
MOTOQE<R>,M!U&\4+>.]G(EG<-;E@UW%!.0TD:!R%D+%656KZKKX_^)W[5VN_
M$LKH7Q-_X)%_$7Q9::?=.UF-;\-:?>Q*W*^9&)BP7([C!P: +EMIW_!#Z[MT
MN8I/V9PKJ"HENM"1@/=68$'V(KZD\)KX73PMIB>"#8_V*-/A&D?V84-M]EV#
MRO**?*8]FW;MXVXQQ7Q#_P +%^&G_2"'Q!_X;G1O_B:^V? DT%QX'T:XMO"C
MZ#')I5NT>AR0K&VG*8E(MBB?*IC'R;1P-N!Q0!JT45%>3R6UJ\\-LTS*N5B3
MJWL* ):*Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O
M?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6
M@#8KYP_X*U^,O^%?_P#!/_QWXM_LW[7]E?2O]'\[R]V[5+1/O8.,;L].U>[_
M /"2ZO\ ]"A>_P#?2U\M?\%HM<U&\_X)L_$2WG\.7-NC/H^99&7"_P#$WLSV
M_*O1R?+\'F^;8? XN/-2JSA":NU>,I*,E=--73:NFFNC/$XFK5<-PYC*M-VE
M&E4:?9J#:W/R,_X;$_ZIU_Y5_P#[31_PV)_U3K_RK_\ VFO$Z*_=_P#B7_PC
M_P"A;_Y6Q'_RT_D7_7+B3_G_ /\ DL/_ )$]L_X;$_ZIU_Y5_P#[31_PV)_U
M3K_RK_\ VFO$Z*/^)?\ PC_Z%O\ Y6Q'_P M#_7+B3_G_P#^2P_^1/;/^&Q/
M^J=?^5?_ .TT?\-B?]4Z_P#*O_\ ::\3HH_XE_\ "/\ Z%O_ )6Q'_RT/]<N
M)/\ G_\ ^2P_^1/;/^&Q/^J=?^5?_P"TT?\ #8G_ %3K_P J_P#]IKQ.BC_B
M7_PC_P"A;_Y6Q'_RT/\ 7+B3_G__ .2P_P#D3VS_ (;$_P"J=?\ E7_^TT?\
M-B?]4Z_\J_\ ]IKQ.BC_ (E_\(_^A;_Y6Q'_ ,M#_7+B3_G_ /\ DL/_ )$]
ML_X;$_ZIU_Y5_P#[31_PV)_U3K_RK_\ VFO$Z*/^)?\ PC_Z%O\ Y6Q'_P M
M#_7+B3_G_P#^2P_^1/;/^&Q/^J=?^5?_ .TT?\-B?]4Z_P#*O_\ ::\3HH_X
ME_\ "/\ Z%O_ )6Q'_RT/]<N)/\ G_\ ^2P_^1/OO_@DI^TE_P )_P#\% /
M?A+_ (0S[)]J35?](_M'S-NW2[M_N^6,YVXZ]Z_:&OP'_P""+US-9_\ !2;X
M=W,%F]PZIK&(HR,M_P 2B]'?\Z_>#_A)=7_Z%"]_[Z6ORGCC@_AW@K-X8'):
M'LJ4H*;7-.=Y.4HMWG*3VBE:]M-MS^AO";,\=FO#E6KBI\TE5DKV2TY(/HEW
M9L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM?&GZ>;%%8_\ PDNK_P#0
MH7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O
M_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*
M%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>
M_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ?F-_P '+G_'S\%_
M^N?B'^>FU^6E?I]_P<BZE=ZC<_!O[5I$UIL3Q!M\X@[LG3>F/3'ZU^<7PH^%
MGCGXV_$?1OA/\-=$;4==UZ]6UTVS5PN]SSDLQ 55 +,Q.%523P*_J_PYJ4Z/
M N&J3=HI5&V]DE4G=L_D7Q,IU*W'V*ITTW)NFDEJVW3A9)=V<]17V=K_ /P2
M]\':S\&/!-I\)?VE?A_K?Q%UK6]<LS90:S<K9^()K46FVRT^>6!8FGC,K EF
M1)3,FQCM-?*G@7X0_$_XF_$*'X4?#_P)J>K>(Y[IK=-'LK5FF$BMM8,/X IS
MN9L*H!)( )KZC YWEN84ISI3LH7OS)QLDVN;6WNMQ=GMH^J:7RF/R+,\NJPI
MU87<[<O*U*[:3Y=+^\E)76^JZ--\Y17L?[9/['?B']C7Q%X2\+>)_'6E:]=^
M)_!UOKKRZ*=]O;>;+-&84E#$3@&(GS%PK9X&.3XY79A,7AL?AXUZ$N:$MGWU
MMU.'&8/$Y?B98?$1Y9QW7;2_0**]E_8Z_8A^+W[97CNW\/\ @V&/2=!2]BM]
M8\8:JA2QL6D8*D>XD"6=V952!3O=F'1<L/-OB;X+E^&WQ(\0_#J?4%NWT#7+
MO3GNDCV"8P3/$7"Y.T';G&3C-33Q^#JXR>%A-.I%)R2Z)[7Z+TWZ[%U,OQM'
M!PQ<X-4YMJ+?5K>W5KSVZ7NF8=%?2WB7]A3X._!"/3O#G[6O[8%EX'\8:CIL
M%_+X2TKP5=ZU+ID,RAXQ>2Q/&D4A4[C&GF,!@\@@GB_B-^Q-\6/!_P >?#'P
M)\'7-AXNG\=V=G?^!-8T.1OLNM65T6$4Z^8%:( HXD$@'EF-\\#<>2CGF5XA
M^[4TLVFXRC%I;N,I)1DDM;Q;TUV.ROD.:X=>_3UNDTI1E).6RE&+<HMO2TDM
M=-SQVBOJJU_X)\_L]:CXZ'P%TW_@H9X1F^);77V"/1/^$5OAH\FHYV_9%U7[
MA8O\@;RMI;Y1SQ7S?\1?A]XN^$_CS6/AGX^T=]/UK0M1EL=3LY""8IHV*L,C
MAAD9# D$$$$@UK@LVP.83<*,G=).SC*+:>TDI)7CYJZ\S+'91C\NIJ=:*Y6V
MKQE&:4EO%N+ERR_NNS\C%HKU;]F#]E37?VCV\2^)+SQQI7A+P?X)TV._\8^+
MM:61X-.AD<I$BQ1*9)II&#!(U'S%2,@X!Z^^_8Q^$GCSP/XE\3_LJ_M66OC[
M4O"&B2ZSKGAK4O!]UHMXVG0X\^YMO,>1)Q&#N9-ROM!(!. 9K9QE^'Q#HSD[
MJR=HR<8MVLI22<8WNG[S6C3V:*H9+F6)PZK0@K23:3E%2DHWNXQ;4I6LU[J>
MJ:W3/GJOU1_X-H_^/?XT?[_AW^6IU^5U?J+_ ,&W.IW>G6_QD^RZ/-=[W\/[
MO)(&W U+KGUS^E?+^)G_ "1.*_[A_P#IR!]7X6_\EUA/^XG_ *:F?JO16/\
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M;U;X(6/[27[17QZT_P"'/@[6M3GL/#,G]ASZKJ&LS0'$[06L+(!%&V5:1Y%
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M Z&L3X>?#_Q?\5O'6D?#7P#HLNHZUKFH166F64.-TLTC!5&3PHR<EC@  DD
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M+_DIZ7_7F/\ Z74/W;P6_P"26K?]?I?^D4PHHHK\G/UX**** "BBB@ HHHH
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MLWX\_%G]D[4?'%U\=/V<3\3K#QQ/XR_MZ$^*%TTV%N[7#7!V"'+EED*[0<C
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M6IUOXF?\D3BO^X?_ *<@8>%O_)=83_N)_P"FIGZET445_)Q_7@4444 %%%%
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MFU^6E?J7_P '+G_'S\%_^N?B'^>FU^6E?UEX:_\ )$X3_M__ -.3/Y!\4/\
MDNL7_P!P_P#TU ****^Z/@0HHHH **** "BBB@ HHHH **** "OU1_X-H_\
MCW^-'^_X=_EJ=?E=7ZH_\&T?_'O\:/\ ?\._RU.OA/$S_DB<5_W#_P#3D#]
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MY*>E_P!>8_\ I=0_I[P6_P"26K?]?I?^D4PHHHK\G/UX**** "BBB@ HHHH
M**** "BBB@ HHHH _*[_ (.7/^/GX+_]<_$/\]-K\M*_4O\ X.7/^/GX+_\
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M%_\ KGXA_GIM?EI7ZE_\'+G_ !\_!?\ ZY^(?YZ;7Y:5_67AK_R1.$_[?_\
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MG>+O%WAOP'X;O/&'C#5XK#3+"+S;R\GSLB3(&3C)ZD4 :-%>2_\ #=W[(?\
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M_P"2J/\ 6GAC_H.H_P#@V'_R0?ZI\4_] %;_ ,%3_P#D3S.BO3/^&0/CS_T
M=$_\+32?_DJC_AD#X\_] '1/_"TTG_Y*H_UIX8_Z#J/_ (-A_P#)!_JGQ3_T
M 5O_  5/_P"1/,Z*],_X9 ^//_0!T3_PM-)_^2J/^&0/CS_T =$_\+32?_DJ
MC_6GAC_H.H_^#8?_ "0?ZI\4_P#0!6_\%3_^1/,Z*],_X9 ^//\ T =$_P#"
MTTG_ .2J/^&0/CS_ - '1/\ PM-)_P#DJC_6GAC_ *#J/_@V'_R0?ZI\4_\
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MZD_^(H ]:HKR7_AN[]D/_HO&B?\ ?4G_ ,11_P -W?LA_P#1>-$_[ZD_^(H
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M\_\ 0!T3_P +32?_ )*H_P"&0/CS_P! '1/_  M-)_\ DJC_ %IX8_Z#J/\
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M44 %%%% !1110 4444 %0ZAIVGZM92:;JMC#<V\R[9;>XB#HX]"IR"/K4U%
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M%% '/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30?_$5T%% '/\
M_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!10!S_P#PJ;X5
M_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%=!10!S_\ PJ;X5_\
M1-/#_P#X)H/_ (BC_A4WPK_Z)IX?_P#!-!_\17044 <__P *F^%?_1-/#_\
MX)H/_B*/^%3?"O\ Z)IX?_\ !-!_\17044 <_P#\*F^%?_1-/#__ ()H/_B*
M/^%3?"O_ *)IX?\ _!-!_P#$5T%% '/_ /"IOA7_ -$T\/\ _@F@_P#B*/\
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M?B&'5="URS6YTV_@SMD0\8(."K @JRD JRD$ @BI/AP WPZT%6 (.B6N0?\
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M?1=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_C5^W?^TG\'OB7)?ZCX;F\.^#<Z4NK7$"1_N)Y28VAD1HB71"2A&[&#D<4
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MK_M6_LYW'@?QUX?CM+SQ1X>M];?R]1@X-O=PWEHT;N@*("-Q !4;G!8#S_\
MX)B_"+X8_#__ ()D6GQPT?Q=)X'UW7O!FIKKGCF>_GN(].CCN[H+=+;S2F!#
M&%##:JY*\YR<@'W37%_$_P"//@;X2>,O!?@7Q6MZ;[QYKCZ5H?V6W#H)UA:4
MF0EAL7:IY&>>U?GC\7U_9VTC]F+5_BY\ _@_^T/?>+-'T)M2T;X[7$6IP)=W
M42B3[?+)=W:[[>0@EL0LH1CM7@5Z7^UW\%/A5\<?BM^S!\4?'GA>>?5/B'K5
MM'XG>#6[R%9XCI#2A$6.95APW\485CW)H ^]Z*^%OVN_%FGVW[57@+]A6/PG
M\0[[X9>&_AM_PD&M^&/AZMW<WNKJ+@V5K;W,J2B<VL?E[F/F?.[J&)."-K]E
MR7Q-\._VP=/\+? ;X&?%GPU\)_$GANZ'B'2?'.DWB6&CZK#^\@N;9[B20Q><
M@>)T#!2VPXSC !]GT5^9WB/_ (53X)\9^.I?^"F?PM^,L7BB?Q7J$VB?%+19
M=4ET>QTLOFS-C)93;+<1IAMAB)!^_DY0?>?[+>NZ!XD_9[\)ZOX7^,\OQ#L'
MTA$MO&=PH$NJ*A*>9* !B0%2KAAOW*V[YLT =]1110 4444 %?#O_!9K_FF_
M_<8_]L:^XJ^'?^"S7_--_P#N,?\ MC7RW&O_ "3-?_MW_P!+B>/G_P#R*:GR
M_P#2D?#M%%%?@A^;GW%_P1E_YJ1_W!__ &^K[BKX=_X(R_\ -2/^X/\ ^WU?
M<5?O?!7_ "3-#_M[_P!+D?I&0?\ (II_/_TIGE_[9?[3%C^Q_P#LY>(/VAM2
M\(RZ[#H+6@?2X+P0--Y]W#;##E6"X,H;H<[<=\UY?XF_;A_:R^&6@W7CSXO_
M /!-7Q5I?AG2X6N-9U/1?'VCZK/:VZC+RBVAD#R!5!8X(P 22!57_@MC_P H
MT?B+_P!=='_].]G7$?M8?M;_ +>OA7X;VO@GQ]^RUX1\ 67C_5X?"<?C:[\?
M?VK;:/+?*T0GEA@ME8 +NPY.P,%W @X/U)[!]C_#GX@^$OBQX"T?XF> M72_
MT77M.BOM,NT4CS89%#*2#RIP<%3@@@@X(K:KX,_:BMM2_9?\(_L\?\$[_!FI
M^-KSP[K$%ZOC"[\"VDAUG5;+3[=)9;> 1,'C6>65C)L8,D:D;B,YL_#>&[^%
M/[3OP]OOV1?V;/C/X6\+:OJ,NE_$K1/%&CW_ /9+VLD>(+\&YFE$4\,H4EUQ
MN0L#U.0#[JKE_C7\7?"7P$^%&O?&3QV+HZ/X=T]KS4!8PB28QKC.Q20">>F1
M7P[\?K;PIX;_ &H_B'K?_!0GX'_%;Q3X8N[Z!OAMXF\*-J,^B:/I@@4-&4L9
MXS;W'F LS,K.Q!(P,%K?Q\\(?L^?&;_@DEXG\9^#_C=K/Q2T[PAIVI3>%/$>
ML:C<Q7M@Q=<6ETH:-IGB1E7%PI)7:<8*T ?>?A[7++Q-H%CXDTT.+?4+.*Y@
M$JX;9(@=<CG!P15RO,OV1_@I\-O@C\$M'TCX::'/8V^JV%KJ-^D^J7-T9+E[
M:)6<&XD<H"%7Y5(48X R:\R_X*$>-/&NJ^-?@_\ LI^$?&.I>';;XJ^+Y[;Q
M)K6C7)@NUTNS@$\]M#*.8GFW*N]>0 1R"10!]-5X9\6?VM?B+HG[0;?LV_ '
M]GS_ (3O7-.\.Q:UXEN+OQ7%I-MIEO-(T<*!WBE,TKE&.P!0%P=W7'D'QI^$
MWA;_ ()Z?&?X.?$K]F^]UK2=$\;?$FQ\$^,_"=QX@N[ZSU)+Y)!%=[+F60I/
M"T1;>I!;.#D%MV1\(?V/?@&G_!4;XC:0OA_6O(\/>%/#^M:4O_"::KNCO7GF
M=G=OM6Z9-R+^ZD+1@9 4 D$ ^Z:*Y_XL^!(_BA\+O$?PWDU&:S&O:'=:>+VW
MD9)+=IHF02HRX*LI8,".00*_/3XE?M!?'WXO?L(?"3X9?#/Q#=V7Q(T)=6U#
MQ<RSNUP#X3AD$L4NT@EKBX%GU.&,O.>10!^E=%?)E_\ M&6OQG_:#\/?%KP;
M=7,_A7X<? RY\=W]G:7+!+B^U6'%G;3 <%EMH+I@".#(#C/3E/V8?V-/#?[8
M'[+>E?M+?''XA>*[OXG^.K*;5[/QAIWBJ]M6\//([FVBL8(I5BBCA4)\A4[C
MNSQ@  ^WJ\V_:#_:*LO@'K?P]T6\\*RZF?'_ (]M/#$,D=V(OL3SQRN)V!4[
MP/*QM&,[NO%?%OBK]H?X\?M%?L$?LT>-;/QY-HWC?7_CEI_AO4/$%L,!IE75
M+(W;(N%E^XDY0C87&,8&*]$_:0_9T^'?[,I_9X\"?#F76)X;W]I32]1U._U[
M6I[^[OKQ[*=))Y))F.&81)E4"ID$A02<@'VO7FWPV_:+LOB+^T9\2_V>H?"L
MMK-\-X-$DGU1KL.M]_:-M+.H5-H,>P1[3DG=G/%>#:/\/] _;J_;5^+>B?'2
M_P!4U#P=\*9M,T7POX1M=9N;.U-W/;&>YOIQ;R(TLN[Y(R3A5[9P:7]@KX>-
M\*?V]?VF? ,7BK5-8M=/MO!:Z==:U>M<W4=LUA=O' \SY>41*PC5W+.51=S$
MY) /L&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /RQ_P"#EW_FBO\ W,G_ +BZ_+&OZG**_6>&?%#_ %=R2EE_U3GY
M.;WO:<M^:4I;<CM:]MS\@XH\*?\ 67/:V9?7/9^TY?=]GS6Y8QCOSJ][7V6]
MC^6.OU._X-HO^:U?]RW_ .Y2OU.HHXF\4/\ 6+)*N7_5.3GY?>]IS6Y91EMR
M*][6W#A?PI_U:SVCF7USVGL^;W?9\M^:,H[\[M:]]GM8*XC]I'X$^%?VFO@9
MXE^!'C2XF@T[Q)IIMI+FW ,EO(&5XIE!X)21$< \';@]:[>BOR8_7SY(;X ?
M\%3/$'PW;]GCQ9^T/\*X?#,^G?V5>>.=.T"_;Q#-8E/+8^2[BV2=DR"X/!.1
M\PW5WOQA_8S_ .$A^'7P1^%OPGU.TT[2?A'\1?#^M!-3=V>XL--AFB,:E%.Z
M9A(IRV 3N)(KWJB@#R/]J#]GKQ-\=/%GPJ\0>'M;L+.+P%\2+7Q'J27I?=<0
M10S1F./:I^<F0$;L# /-'PO_ &>O$W@7]KKXJ?M#:CK=A-IGCS2]!M=.LH2_
MGV[6,$L<ADRH7#&0%=I/ .<5ZY10!\Q_ +]D#XU?"OPIXF_97\:WW@K7O@QK
MDNMB"5'NX==2VU!Y9#;NFPP':TSCS P)&" ",5E>$_V;_P#@H]\.?A9#^S%X
M'_:#^'J^$+"Q&E:+X]N])O?^$DT_30NR-5@1A;//''A$DWK]T$C/(^L:* /
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M0/FZ<_15% 'SI^P9^PC;_LA^#?'?A/Q/KMMKZ^*_$<OV1\NPBT..(0V5E)O
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20240630_g8.jpg
<TEXT>
begin 644 biib-20240630_g8.jpg
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MH8]9CO/$.J)/)<M<2*@81RA 2NP<<=*_3#Q'#+<>'K^""-G=[.5411DL2A
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M^.%_^SI^S3\(=/\ %WB+0-'M]2\6ZAKOB(Z9IVCI<%OLT#.D$\DL\JH[A @
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M["%CY@B,3,JE]H /J&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHKYA_8R_:_N[_P#9.\%?$G]HSQC<W^L>+_B->^%M/OH]
M.0&:ZDU2[M[2-EA1510D04OC^')))S0!]/45RWBGXQ>!_!WQ/\*?"#7+V9-;
M\:1ZA)H,*6S,DJV422S[G'"861<9ZYXKRK5_^"DO[.=C;ZI>:+8>,M?@\/7U
MW;^*;GPYX,O+V/0A;3R02RW;QH1$FZ*1@,EBB%PNW!H ]^HKSOXC_M3_  6^
M&7P\T+XEZIXEEU*R\6- GA&TT"RDOKO79)X_,B2T@B!>4LGS9 P!RQ IWP9_
M:8^'?QKUO5?!NDV&N:'XCT.**;5?"_BK1I;"_@@ER(IQ'(,21,58"2,LN002
M#Q0!Z%17,_&.3XLQ?#+63\"K319O%K6FW0U\13R1V2S%@-\IC5F(52S!0!N*
MA25!+#Y?_:3;]I[]BWP-HOQS@_;'UWQWKL_B73-/U#P)K^AZ;'9^)#<W,<+V
M^GPV\"36TJJ[2+MDDXC.[=SD ^QJ*^=_B_X_^*_QJ_:O7]D7X1_$R]\%:3X?
M\)Q^(/'GBC1K6WEU%S<3-%::?;&XCDC@)"/,\A1CM"JN.<K\"?B1\6_A9^U1
MJW[&OQH^(<_C&WNO"2^)_ ?BW4;2""^EM5N/L]S8W7D(D<LL;E'6144LC'=R
M. #Z'HHKRO\ :?D_:8U=/#'P[_9N>'1G\0ZN\7B;QW/;P7(\.6$<32%X[:5O
MWT\K 1(2KHI)+@94T >J45\L7>M?'O\ 9'_:6^&/PZU[]H35_B3X5^)VI7NE
M7&G^*["S74M+NH;9KA;N":UBB\R'Y=KHZD(""#D\2^$=6^-_[:_Q*^(.K>$O
MVA-?^'G@CP+XLN/"WAZ#PE96376JZA:*OVN\N9;N";=")7\M(D"A@A).>: /
MJ*BOESX;?M*?M3Z[\"?B;\/=*\):;XK^-'PQ\2?\(]N01VEIJJR^4UKJTD9=
M1&AMY3,\*'):%U3&Y0.>_:/@_:P_8@^#4G[5-W^V!K/CRXT*\L6\6^$/$&@:
M?#IVKQ3W,5N\5DMO"DMG(#+F/YY,E0&#9H ^Q**X+]HWXY67P$^&4GBV+1WU
M76]0NXM,\)^'H7"RZOJMP=EO:KZ M\SM_!&CN>%->7?\$Z?B+\?/&FG?%'PO
M^T3\1XO$^M^#_B;<:*E_;Z=#;0I&EG:2-'$D:+^[$DLFTOE]I&2: /HZBN>^
M*OQ5\ ?!+P!J/Q0^*'B.+2M#TJ)7O;V2-WV[G5$540%G=G955%!9F8  DUP'
M@K]M;X9^*OB#HWPT\0>!O'7A#4?$OFCPT_C3PA<:=!JDD:&1HHI'! EV*7\M
M]C$#@9XH ]@HKQ/Q9^WQ\#_#?BO7_A_HVC^,/$_B'PQJ;V>MZ%X1\)76H75J
M$BBE:=UB7"PXF0!R1O;<J!BK ;^J?M@?L_:9\ +#]IK_ (3D7/A/5A$NCW%E
M9RRW%_<22&*.UAMU7S7N#*&C\H+N#*P(&UL 'IM%?+LW[:&I_$#]LSX/_"'P
M;#XG\,6VKV7B.;QAX3\6>&&L+N:.*SBDLIL3(28]XFPT3X+*ZMRNT?0_Q*US
MQ;X9^'NN>(? 7A!O$&N66E7$VCZ&ERD)O[I8R8H?,D8*@9P 6)X!)]J -NBO
MD+XD>!/VX_A/^SIK'[5/B;]LZ\3QIX?\.3:_JW@ZX\.V \-A883/)IJQB+SQ
MPIB$_G;R<-QFM[QY^TE\5?CCK/P>^!_P5UJ3P3J_Q-\%CQ?XJUL6D5S=Z!HZ
MP0L88$F4QF>6:=81(ZL$"LVTG& #Z?HKYL\)^,OC#^S'^U?X4_9U^)WQ>U/Q
M[X1^)>F:@_A'6_$=M:IJ>EZG8QK--:S26T44<T4D+%T8H'#(5Y%)HOPC_;;^
M/$VM?$3Q_P#M&^(/A*_]L7</@[P7X:TO3+J.RM(I6CAN+Z26.;[6\H42E%=4
M"L ",D  ^E**^9?@/\</VK?VEOV.O[8^']WX5LOB%;>*KKPYJ7B:[A<Z?Y5K
M>M;SZI;0 $3-Y:[TA9E0R9R=HV'!^*%_^T'^Q[\5/A6]K^U9K_Q'7Q[X\L_#
MVO\ @SQ7IFG^;+!.',NH61M((I(%MPN]E.Z/:PW,,#(!]<4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&_%;]HGX"_
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MF#R3IC6:&W\O^YY>-NWVQBCPWX5\+^#-+70_!_ANPTJR1BR6>FV:01*3U(1
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MKK/AKPYXCTHZ#XA\/V5_8G;FRO;1)8CMY7Y&!'&!CCBL/_A1GP2_Z([X5_\
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M]M_Q#\7=1/Q?TNZU...31Y-)T]7MKM(Y3_9UHA@EEW,(HVF(=%F.UMH8??\
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MK;4M*U2TCNM.U"SE$D5S"ZADD1APRLI!!'4&@"_1110 4444 %%%% !1110
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MD P%51@* . !7R1_P_D_X)1?]'5?^6-KO_R#1_P_D_X)1?\ 1U7_ )8VN_\
MR#1_8^;?] \__ )?Y!_K#D'_ $%TO_!D/\SZ]HKY"_X?R?\ !*+_ *.J_P#+
M&UW_ .0:/^'\G_!*+_HZK_RQM=_^0:/['S;_ *!Y_P#@$O\ (/\ 6'(/^@NE
M_P"#(?YGU[17R%_P_D_X)1?]'5?^6-KO_P @T?\ #^3_ ()1?]'5?^6-KO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_GV_X.+?\ E)9JO_8HZ3_Z*:OZ":_GV_X.+?\
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M^K*O_,C_ /WNK\L:*]O_ (AGP1_T"?\ E2K_ /)G@_\ $4>.O^@O_P ITO\
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M_P"(EW_JRK_S(_\ ][J_+&BC_B&?!'_0)_Y4J_\ R8?\11XZ_P"@O_RG2_\
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M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
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M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
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M/ED!/^M%?9O]G:?_ ,^,/_?H5\;?\$%/^4>VE_\ 8T:I_P"C5K[/K^..,?\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_#+_@O7_RD)U3_L5]+_\
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M+U_\I"=4_P"Q7TO_ -%-7QA7V?\ \%Z_^4A.J?\ 8KZ7_P"BFKXPK^R.#O\
MDE<%_P!>H?DC^*N-?^2NQW_7V?YA7IW[.G[-=_\ '1-:\6:WXZT?PGX0\+&T
M_P"$D\3:V9FC@:YD9(((HH(Y)9IY"DFU%7&(V)( KS&O=_V2OBSXT^#_ ('\
M23>)?@+#XY^%?B;6-,T[Q9:ZCY\$$5_$TDUF\5W"0UO<*#*0>0RL0RG(KT\V
MJ8JE@9/#/W[I+9.SDK\O-[O-:_+?3FM?0\O**6$JX^,<2O<LV]VKJ+MS<OO<
MO-;FMKRWMJ6?VXOV-_#G[.GC3Q'JWPG^*>C>)O"FF^-KSP^]K%=N-4T:ZB9R
MMM=PRQQESL1@)X@T3E&PPR =+4/V'/@S\,+K3? O[3?[8NF^!O'6I65O<S>%
MX?!]UJ46C"=%DACU"ZCD06\A5E9D1)2@8%N#FO1/^"D_P1^!GC7Q!\7_ -H_
MX.3>(]*U[P?\79=%\>Z1KTT4UI>SW4UR4N["5%5ER\#EH7W%0X(; ^;Q_P""
M'[.,_P 2=./[3G[6'CJ]\._#2WNPM[X@U"5I=2\22Q@#[!ID;G=<S$*$,G^J
MA )=OEVGYK YAB,1DM*M4Q4H.*M+W(^TE-QBXQ2:E&3:=_=C>5XZJTK_ $^/
MR[#X?/*M&GA8S4G>/OR]E&"E)2DVG&44FK>]*T6I73O&S-'_ & OC!+^TYXE
M_9E\6ZSHVB7'@S2KG6?%?B2YN'DT^RTB"%)VU!2BEY8VBDB9 J[F\Q00O.+%
MS^R3\&_'7@_Q/K?[,_[47_"9ZMX0T*?6]7T#5_!<^CR3Z=;X-Q<6LC32I+Y:
ML'*/Y;E Q .,5[)^S[^T+XH^-G[87Q._;TU>^L_#'@7PMX7"^*_#K:4-3%]H
M+K#I]OHH@9XUF:94B5I&9%5@7..%.[\*?'?[(W[2O@KXB? []B;X/7?P9\?^
M(_#VHS)>:E>/K$6NZ3#$9[C2UN)7W:<)4C).Q"I"E6<C KFQ&<9W0FG5NN2-
M+VCBHNG"3LZGM+ISLDTU[-NT6G*VYU8;)LBQ$&J5G[257V:FYJI."TI^RLU"
M[::?M4KR34;_  GSM^QE^P1\6_VQ_%MG9:1<0>&O#-Q?"SE\8:W&5M3<E25M
MK<$J;JX.TGRHR2H!9BJC->):E9G3M1GT]I-Y@F>,L!C.TD9_2OI/_@EIXV\8
M:Q^W5\&?!>J^)[^XT?1_$<[:5I<MTQM[1I89GD:./.U6=N68#)P,G@5\Y^)O
M^1CU#_K^E_\ 0S7TV%Q&.>=5Z%:2<%"$HI+:\JBU>[;45?9+9+=OY;%X? +(
M\/7HQ:FYSC)M[\L:;T6R2<G;=O=O9+K?V?/@9??'SQO/X:'C71?#6FZ9I4^J
M:]XAU^Y*6^GV4(!DDVJ"\S\JJQ1JSNS   9(]'UK]C;X6>+OA7XJ^)?[+O[3
ML/CR?P-IZZCXIT#4?",^C7<=AO$;7=OYDLJW$:,R[@2C*#DKD@'Q#0_"_B+6
M;*^U_3/"VH:AIVC1QSZS<6=J[1VD+2!%:615(B5G8(&; +, ,DXK[*^ ?BGX
M!?'#X(?%SX.?LE_"74OA7XNN? 5WJNK:EJWB!M>&MZ19%)KC31<-'!]AWX5M
MRQL'VA68# /%G>*QV#FJ]*I+D3BFDH.$5S+F=2]ZFL7IR6MHWIJ=N183 8V#
MH5J<>=J33;FIR?*^54[6IZ26O/>^J6NA\1T445],?+A7[F_\$%/^4>VE_P#8
MT:I_Z-6OPRK]S?\ @@I_RCVTO_L:-4_]&K7Y=XN_\DK'_K['\I'ZOX-_\E;+
M_KU+\XGV?1117\R']2A1110 4444 %%%% !1110 4444 %%%% !1110!ROQL
M.MK\+M6/ASXMV/@2]\J/R/%FI6,-S!IY\U,L\<[I&P893YF'+@]0!7S?Y_QY
M_P"DS'@#_P ('0__ ),KZ%_:*B2;X,:[%)\"X/B6I@CSX'N5MF35?WR?(1<@
MQ?+_ *SYQC]WQSBOGKXI?"#X:>"?'5[X9\#?\$5_"?B[2[=83;>(-/TGPO;0
MW1>)'<+'/MD78[-&=P&2A(R"#0!Z3^S#)\27\:7P\9_M\>&?BO;?V6WEZ'HG
MAK3K*2U?S(_])9[6>1F4#*;2 ,R YR!7N-?/?[(WA_3=)\>ZC/9?\$TM,^"S
M-I#*?$5E%H:M>CS8S]D/]G,9,''F?-\O[KUQ7T)0 4444 %%%% !1110 444
M4 %?AE_P7K_Y2$ZI_P!BOI?_ **:OW-K\,O^"]?_ "D)U3_L5]+_ /135^I>
M$7_)52_Z]2_.)^4>,?\ R2,?^OL/RD?&%%%%?TT?RT%%%% !1110 4444 %%
M%% !1110 4444 ?N;_P04_Y1[:7_ -C1JG_HU:^SZ^,/^""G_*/;2_\ L:-4
M_P#1JU]GU_''&/\ R56-_P"OL_S9_:O!7_))8'_KU#\D%%%%?-'TX4444 %%
M%% !1110 4444 %%%% !1110!^&7_!>O_E(3JG_8KZ7_ .BFKXPK[/\ ^"]?
M_*0G5/\ L5]+_P#135\85_9'!W_)*X+_ *]0_)'\5<:_\E=CO^OL_P PKT']
MG_\ :<^+G[-FL7EY\-_$$26&KI'%K^B:CI\%[8ZG$C;E6:WN$>-RI)VL5W*2
M=I&37GU%>]7P]#%472K14HO=-77W,^>P^)Q&$K*K1DXR6S3LU\T>Y?MD?MS?
M$O\ :P\=:H]S)%IG@MO%-UK&B^$[73;:VBCDE=L37/V=%^U7&P[6FD+,<M@C
M<<];\0O^"H_C/XKSZ?/\1OV3?@EJ_P#9-@ECI45YX2O#'96R?=AA07H6)!_=
M4 5\P45YJR#)U1I4E125._+:ZM>U]FM7;5[L]1\19S*M5JNLVZC3E>SO:]M&
MGHKZ+9=#UG0?VPO'W@OXNZG\5_ASX%\'>'8-;TL:9K?@W3-!W:%J%F54/!-:
M3O('5R@<Y;(;YE*FMC4_V[/%UGX8U?P[\(_@9\-OAS-K^GR6&L:UX*T"X2_N
M+208EMUGN[F=H(W'#"'R\CCI7AU%;2RC+9R4I4T[)+KK;;FU]ZW3FO8PAG.9
MTXN,:K2;;Z:7WY=/=OUY;7/;_P!G3]N'6_V9!H>I^!?V>?AE?:_X?GEFL/%F
MM:+>2ZB7=W;<SQW:(2JN47"#"J <GDX'C[]IQ/&OBGP_XOTG]GWX<^&+OP_J
MZZB!X;T:YB34)%='"7*S7,GF1Y3[HV\,W//'E]%-93EZQ,L1R>^]W=Z[Z;VM
MJ[+97T$\WS%X6.'<_<CLK1T>FNU[Z*[W=M3V*Q_;?^,6C?'WQ%^T!X=TKPUI
MUSXMMVM?$?A>WT-6T34+1D1'M9+.0NK1-L4X)R&R00:T/%/[>'CB]\ :W\.?
MA;\&?AU\-[/Q/9FS\2W?@/0)H+O4K1CN:U>>YN)W2%CC='&4# 8.1Q7AM%2\
MFRN4HR=)>ZDE_P!N_#=;/EZ7O;H4LZS6,9155^\Y-]_>^*SW7-UM:_4****]
M,\L*_<W_ ((*?\H]M+_[&C5/_1JU^&5?N;_P04_Y1[:7_P!C1JG_ *-6OR[Q
M=_Y)6/\ U]C^4C]7\&_^2ME_UZE^<3[/HHHK^9#^I0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *^4?'/@OQ]\=/VG/'?@_XI_M@^.?AAIFA262^!O#G
M@K6;72FU.P>TB>;4&FFAD:ZS<M-"57 B,(!^\"?JZO@CXU>(?^"?6D?MK_$?
M3?V^M2LO$&J-)IS^$/[9LKV^L]'L#I\!:Q$,2,EO+YI><N5Q(MPA#%U=5 /I
M+]G+]GO3/A'XNO=?L?VOOB7\0VN--:W.D^-?&%MJ-M;@R(WGI'%!&5D&W;N)
M(P[#'->RU\T?L6:W_P $R]3^(NIP_L4:-X9MO$:Z(S:F^B:!<VDAL?.BW!FE
MB0%?,\K@'.<''%?2] !1110 4444 %%%% !1110 5^&7_!>O_E(3JG_8KZ7_
M .BFK]S:_#+_ (+U_P#*0G5/^Q7TO_T4U?J7A%_R54O^O4OSB?E'C'_R2,?^
MOL/RD?&%%%%?TT?RT%%%% !1110 4444 %%%% !1110 4444 ?N;_P $%/\
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M11^(-253U^SVMH%MU<=FEF=0<$QN/E/NFGVTUEI\%G<7\MU)#"J274X4/,0
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M/7RTE /S&HG5K.$90:UTV;U^]=/(NG1PZJ2C4C+W==TK+[G>[T6O5'$?"?\
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MM&,#KBMS_@FYX1M?&/[8GA6UGT^"\EL([[4;"SN" DUW;6<TUN"3P,3)&W_
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M8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!^(G_!>O\
MY2$ZI_V*^E_^BFKXPK[)_P""[M_9ZE_P4"U.ZL;A98SX8TP!UZ9\HU\;5_9'
M!W_)*X+_ *]0_)'\5<:_\E=CO^OL_P PHHHKZ0^8"BBB@ HHHH **** "BBB
M@ HHHH *_<W_ ((*?\H]M+_[&C5/_1JU^&5?N!_P0B\1:)IO_!/W3+6^U***
M0>)]3)1CSCS17Y=XN_\ )*Q_Z^Q_*1^K^#?_ "5LO^O4OSB?;E%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5?S(?U*:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
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MY9 3_K!7U/\ V=I__/C#_P!^A7R[_P $;_\ DR?3_P#L8=0_]&"OJBO@L?\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH *_,W_@J/_P G87O_ &!++_T
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MHI)?)6..M5E7K2J2WDV_OU"BBBM3,*_3/_@ES_R:=9?]AN]_]#%?F97Z9_\
M!+G_ )-.LO\ L-WO_H8KY+C3_D3K_&OR9]1PC_R-7_A?YH^B:***_*#],"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\S?^"H__ "=A>_\ 8$LO_0#7Z95^9O\ P5'_ .3L+W_L"67_ * :
M^NX+_P"1P_\  _S1\OQ=_P BI?XE^3/G6BBBOU8_,PHHHH **** "BBB@ HH
MHH **** "BBB@#],_P#@ES_R:=9?]AN]_P#0Q7T37SM_P2Y_Y-.LO^PW>_\
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M*E_B7Y,^=:***_5C\S"BBB@ HHHH **** "BBB@ HHHH **** /TS_X)<_\
M)IUE_P!AN]_]#%?1-?.W_!+G_DTZR_[#=[_Z&*^B:_$,\_Y'%?\ QO\ ,_8L
MG_Y%5'_"OR"BBBO*/2"BBB@ HHHH **** "BBB@ HHHH **** /S-_X*C_\
M)V%[_P!@2R_] -?.M?17_!4?_D["]_[ EE_Z :^=:_<,C_Y$]#_ OR/QW./^
M1K6_Q/\ ,****]0\T**** "BBB@ HHHH **** "BBB@ K],_^"7/_)IUE_V&
M[W_T,5^9E?IG_P $N?\ DTZR_P"PW>_^ABODN-/^1.O\:_)GU'"/_(U?^%_F
MCZ)HHHK\H/TP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OS-_X*C_\ )V%[_P!@2R_] -?IE7YF_P#!4?\
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M17_!4?\ Y.PO?^P)9?\ H!KYUK]PR/\ Y$]#_ OR/QW./^1K6_Q/\PKT_P"
M?PS\&:]X5\3?%CQ]IVIZIIWA6:PC_L329UA>YDNI'57EE9'\N%/+.XA2264
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MN?\ DTZR_P"PW>_^ABOHFOG;_@ES_P FG67_ &&[W_T,5]$U^(9Y_P CBO\
MXW^9^Q9/_P BJC_A7Y!1117E'I!1110 4444 %%%% !1110 4444 %%%% 'Y
MF_\ !4?_ ).PO?\ L"67_H!KYUKZ*_X*C_\ )V%[_P!@2R_] -?.M?N&1_\
M(GH?X%^1^.YQ_P C6M_B?YA4UA?7>F7L6HV$[1302!XI$8@JP.0<BH:*]1I-
M'F[&OX]\<>(?B3XQU+QUXKNQ-J&J7DES=.HPN]V+$*/X5R>!VK7@_: ^/%K
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M_P +_-'T31117Y0?I@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$<31:5XAEMH0J# (1> ?4]Z]5HH \%_X=U? _P#Z&[QW_P"%?/1_P[J^!_\
MT-WCO_PKYZ]ZHH \%_X=U? __H;O'?\ X5\]'_#NKX'_ /0W>.__  KYZ]ZH
MH \%_P"'=7P/_P"AN\=_^%?/1_P[J^!__0W>._\ PKYZ]ZHH \%_X=U? _\
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M=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ]ZHH \%_X=U? __H;O'?\
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M *&[QW_X5\]'_#NKX'_]#=X[_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\
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M1110 4444 %%%% !1110 4444 1W=W:V%K+?7US'#!#&TDTTKA4C0#)9B>
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MZ .N\-_\%&OV*?%OC*U\"Z#\?--EO+^]-GI]U)9745A>7&=OE0WLD2VTKDC
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M;0K:"U:*VN#*55+I[D%Y'FBRA(')X) /K&BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO!KJJX:E.I1FX5$TUNGHU\CLIU*=6"G!II[-:H****@L**** "BBB@ HHHH
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M4L"4.]%.Y<'BM']K/XL>-_A3)\,%\%:E';#Q-\7-'T+5_,MDD\VQN%G,L8W
M[2=B_,,$8X->=_\ !2'5;'P%XI^!/QH\4W M/#?A;XO6K>(M5D!\K3H;BUG@
M6>9NB1"1E4N> 6&3S3?VKOB[\+/C-\2O@?\ "GX2?$/1?$VNGXNZ=K\]CH&I
MQ7C6VF65O<R3W4IB9A'&-R*"V-S. N>< 'U%7R/\'/'?[5_[:%YXU\<_#_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPDLO&MK^U;K>EZ[X=\+V U/1?B+I]I%92:C:+$\EQ'<V:.?*FAV??0".16&
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MVPG;D XXK!\??LY_L]_%;6H_$GQ1^!'@SQ+J,*!(K_7_  O:7DR*.@#S1LP
M],UPW[>?[0WC#]G+X.:7KG@*;2K/5?$OC+3/#=MKNO(6L-$^V2E&O[A05S'&
MJDX) W%<Y&0<K1O!G[=OPL\7^&O$$'QYLOB]X<U+4X;;Q3I6I>&]/T>?3[20
M<W]G-;E%<1G#&&0.SJ2%;.#0![5J_P /_ ?B#P>WP]U[P3I%]H#P)"^AWFFQ
M2V;1(040PLI0JI52!C VC'2M*PL+'2K&'3-,LHK:VMHEBM[>",(D2*,*BJ.%
M4   #@ 5+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?*W_!7O_DVO0_^QYMO_2.]KZIKYW_X*7Z1
M\(=:^!.DVOQI^,G_  @^E+XM@>WU;_A'KC4_-N/LMT%@\J AERI=MYX'EXZL
M*\G/,'B<PRBMAL/'FG)62[OYGGYK!U,OJ175=6E^+T/S#HKUK_A OV!/^DA7
M_F)M5_\ BJ/^$"_8$_Z2%?\ F)M5_P#BJ_(_^(?<9?\ 0'+[X_\ R1^=_4*_
M>/\ X'#_ .2/L'_@D)_R;7KG_8\W/_I'95]4U\[_ /!-#2/A#HOP)U:U^"WQ
MD_X3C2F\6SO<:M_PCUQIGE7'V6U#0>5.2S84(V\<'S,=5-?1%?KN1X/$Y?E-
M'#8B/+.*LUV?R/T3*H.GE].+Z+HT_P 5H?-/_!4?PSK\WP7\&_&#0]%NM2A^
M%?Q7T'QIJ]A90F266PLY76X*H.6V),9#Z+&3VIO[:?[7?P&UC]CCQ39?#7XE
M:)XKU?Q_X8N=#\&:'H.HQW=WJMY?PM;Q)'"A+G!EW-D#:%(.#Q7TP0",$9!Z
MBOG3XC_L+7>B_'.T_:._9$U;P3\/_$C:/+IFMP7G@"&[M+^-Y?,%R!#) \=R
M"64R;CYB%5;A17JGH'F6H?#;XY_\+ ^!'[+7PCN_"\^J? OX;6>N^)6\4_:)
M=/?4'M?[+LUQ;D-YBA;^5.< !3Z9L?LU_P#"V?@1^V+\7/@G\;CX>CG^)_A@
M>.]%'A=9UT_[7$#9WZ()R7\U\0RN"3TR.#@?8&E^%M TK5;OQ):Z%81:MJ<4
M":MJ=O9)'->^4I$?F.!N<(&8*&)VAB!U-,U/P7X.UO7K+Q5K/A/3+O5--AFB
MT[4KJPCDN+6.8!94CD8%D5P &"D!@ #F@#Y8_P""7?[1/[/WA']@7X:>&_%G
MQT\':7J-IHLB75AJ/B>T@FA;[3,<.CR!E."#@CO6C^T /V _VG?CA>? _P#:
MM\%:=IGB'0=.M;SP?XDUK5AIKZS8SKYGG:=>PRHTJ1R;E:,MPP+;2"37L/\
MPQM^R#_T:I\-O_"&T_\ ^,UT?CCX,?![XG:%:^%_B5\)_#7B'3+$ 66G:YH5
MO=P6^  -D<J,J8  X X H ^+?A5X-UO7_B9\</V(?@#^T)K7Q"^&NH_!>Y2#
M4=<UW^U%\->(+SS;:/3X[P9RC0LTICR=NW!Y#$^L_L4_M@? C0?V,/#-I\4/
MB-HWA/5_AUX:M]!\::'KM_';7>EW>GPK;R(\#D/\WE;D !W;@!D\5]#>!OAY
MX ^&&@IX6^&O@;1_#VF1N733=#TR*T@5CU(CB55!.!SCM6/XI_9Y^ 'CGQ;#
MX_\ &WP-\'ZQKUN5,&MZKX9M;B[C*_=VS21EQC Q@\8H ^!O'GAS6](_X)9>
M//C+XNTJ?1U^)_QWB\<6UCJ*>5):65[KMGY!D!^[NBB63Z2 FOI;]L_]M7]G
M_2?V>/$_A#X>_%'P_P"+_%WBO1KG1/"7A7PSJT.H7FHW]U$T$2B*!F;8&D#,
MQP  1G) /O\ XQ\$>"_B)X?F\)_$#PAI>NZ5<,AGTS6-/CNK>0JP92T<BLIP
MP!&1P0#6)X(_9]^ GPRU;^WOAO\ !#PAX>OMA3[;H?AJUM)=IX(WQ1J<'TS0
M!XO\6/V>M+\)?\$G=5^ OQ'L8=0E\*_!EH[D[LJM_8Z?YJ2QD=-EQ"KJ?]D5
MVO\ P3Z\*Z'X3_8E^%L.AV?E_P!I>!]-U;4)&<N]S>WENEU<SNQR6=YI9'))
M_BKUK5M)TO7M+N=#US3;>]LKVW>"\L[N%9(IXG4J\;HP(964D%2"""0:31M&
MTCP[I%KX?\/Z5;6%A86R6]C8V<"Q0V\**%2-$4!415  4    "@#F?BWX;^-
MGB.QLXO@M\5=#\+7$4K&^FUOP@^KK<(0-JJJ7EMY9!R2<MG.,"NC\.VVN67A
M^QL_$^K07^I16<2:C?6MF;>*YG" 22)$7<Q*S98(7?:"!N;&3<HH ^1_V./B
MQ\,O@G\=/VAOA/\ %SQ_HWAG6[CXOW?B.SL]>U**T-UIMY:6QAN(C*RB1/W;
M E<[3C.,BNB_8R\=>$M9\0_'_P#:4LM;A;P3JOQ :XTWQ#D_9KNUL-)M(+BZ
MB<<20B2&4"1<JWEM@G%>U?$;X"_ SXPW-M>_%OX,>$_%,UFNVTE\1^'+6^:
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M^;9G;GG&:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=>ETU]Z9\[Q;CJF6<-XG%0BI.$;I2O9ZK>S3^YH^0O\ A7W_  3*_P"DH?\
MYA/6O_BJ/^%??\$RO^DH?_F$]:_^*KX:HK^A_P#B&>4_]!-;[Z7_ ,J/YL_X
MB9FG_0+1^ZK_ /+3]]_^"1^C_ O1/V<-;M/V?OCS_P +$T9O&]R]SK7_  BU
MUI'D77V.S#6_DW)+MA!&^\?*?,QU4U]2U\"_\&Z'_)DOBG_LJE]_Z;=,K[ZK
M^>.*<#3RSB'$X6G)R4)63=KO1;V27W)'])\)XZIF?#F&Q4XJ+G&[4;V6^UVW
M][8R>""Z@>VN84DCD0K)'(H*LI&""#U!':N+\(?LS_LX?#[Q/_PFW@+]G[P1
MHFLY8_VOI'A2SMKK+?>/FQQA^<G//.:Y?]NS]H7Q+^R_^S/K?Q;\'Z=83:I!
M=65C93:N6%E9R75U%;BYN"N#Y4?F;R 1G &1G(Y&W\&_M\_#IM#^(GAG]H_2
M_C!87%_:KKWA6\\+Z=I*2V4KJLMSI]U R[6C4F0),T@=5(#;MH/@'T1[Y_PB
M/A/_ (2S_A/?^$8T[^W3IWV#^VOL4?VO[)YGF?9_.QO\K?\ /LSMW<XSS2:U
MX,\'^)-5TW7?$7A33;^]T:=I]'O+VQCEEL967:SPNP)B8KP2I!(XKYL\:>+O
MVI_BK^W/XN_9^^%?[1L7@?0O#7@G2M6B4>#;/4GGFN))D<%IBK*/D!ZGZ5E+
M^T[^T?\ "_1OV@?@M\4/&&CZ[XL^&'PSF\4^$O&NF:(MJ+N&2RN9(Q=6I9XT
MFCFA'"G:ZG.!CD ^J;CPCX3NO$]OXVNO#&G2:S:6KVMKJ\EE&;J&!R&>))2-
MZHQ )4'!(&14NO\ A_0?%>C7/ASQ1HEGJ6GWD1CN["_MDFAG0]5='!5A[$8K
MX\^/O[5'[76A_"+]G?Q-\#I['4O$?C7PR^N>)](GTZ(_VXMKH\6HSVL>%)A>
M4+,J>7@[G4#M7J'QE_:O?5/V=/AS\>_@%XCC.G^-/'7ABS6XEMDD)LKW4(8+
MB%E8$)(%9XV_B1E/((H ]:^''P7^#OP=MKBR^$7PG\->%8;M@UW%X<T*WL5F
M8="XA10Q&3U]:R/$7[+/[,?B_7+KQ/XL_9S\!ZIJ5[*9;W4-1\(64\]PYZN\
MCQ%G8^I)->*^*?%G[57Q;_;B\<_ 7X7?M(Q>!]"\*>$M'U*",>#+/4GGENC,
M'RTQ5E \L'J>O:M_]G;XO_'GPW^U-XD_8\^/_C?2/&=U8>#+7Q3H7B_2M%&G
M2-:RW+VSVUU;H[QI*'4,A0C<G)'.  >S>!OA+\*OA>LB?#3X9>'O#HEA6&4:
M%HL%H'C5Y'5#Y2+E0\LK = 9'/5CG0U/P?X2UK7]-\5ZQX6TZ[U31A,-(U*Y
ML8Y+BQ\Y DODR,"T6]0%;:1N P<BOE.3]M'XQVW_  4"M/",]U9_\*;O_%5S
MX MYC:()!XDAT^*\,GFXWD-([VH7.W=&QQD9'MOQJ^%_[1WC#Q-'KGPF_:O'
M@;28K!8Y]*;P/9ZD'F#.S3F:=PRY4JNWH-F>YH ] \*^$O"G@3P_;>$_!'AG
M3]&TJS4K::9I5E';V\ +%B$CC 506))P.I)[TGA;P=X1\#:5_87@GPMINCV/
MG23?8M*L8[>+S'8L[[(P!N9B6)QDDDFOG3_@GS\0/VE/C!KGC/XA_$#XVIXQ
M^',&H'2_ 6JOX5M=-DUEX6VW-^@@_P"7?S%:*,ECOVLV%P >=^$?[:/QC\3?
MMYS>#/%5U9_\*I\8ZEKWA_X<F.T02'5-%6W%U*TP&725Q>A 3@^6,=.0#ZM\
M,>$?"?@K36T?P;X8T[2+1[B2=[73+*.WC:61BTDA5  69B69NI))-87Q%_9_
M^ _Q@O8-1^+7P3\(^*;BU39;3^(_#=K?/$N<X5IHV*C)/ ]:ZZB@"IH/A_0?
M"NCV_AWPOHEIINGV<8CM+&PMEAA@0=%1$ 51[ 5;KYZ_;E^)WQN\)>-?A%\,
M_@E\2HO"EQX]\:S:5J6K2:'!J!CA6SEF!6*;C.Y!T(Z]:YWQ?X\_:T_9'^*G
MPX'Q8^/ND_$KPK\0?&]MX4N;&3P;#I6H:=<W,<C0W4+V\A66-6C/F*Z\*>.N
M5 /J>N+\3?LW?L[^-?%R_$#QE\!/!>KZ\C*R:WJ?A:TN+Q2OW2)GC+@CMSQ7
M/_%']L[X!?"3QK<_#KQ#KFL:AK6G6B7>M6'ACPKJ&KOI-LXRLUW]B@E%LI W
M#?@E?F (YK8\4?M._ ;P?\'[+X]ZU\2K$^$]4$']E:K9![G[>\QQ%%!'"K23
M2,<@1HI?(/'!P =1XP\$>"_B%X>F\(^/O"&EZYI-P4-QIFL:?'<V\I5@R[HY
M%*MA@",C@@'M1XH\#^"O''AR3P=XU\'Z7K&D3($FTK5-/CN+9U'0&*12I [
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?PG9:O<:D-"MM0U379+EI!BV2[S$D$(0!VV.V]L< \<__P $N_VB?V?O"/[
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M/AOPGJ.JKH\3KO1[M[2"1;?*?-AR&V_-C!!KQ+XB6G@SXE>*/A-IWC+_ (*
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(O\
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M:2WH<=&\]HS)D=CG(K6^(?PK^&'Q<T5/#?Q7^'&@^)].CG$T=AXAT>"]A60
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20240630_g9.jpg
<TEXT>
begin 644 biib-20240630_g9.jpg
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MO*U2\:9IY[VZ^P6:LL6\\M-<R;44D#,@!('-=))^RU\6[7_@HK=>%K+0)O\
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M%CXE6YTK7&U'3-1T=7,<MU#,\,,B&*0;9(WC##<C L&X\"_:M_:N_:%^+'[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\"ZCX\T^#6?%[1N&1]27S\V=IN4$6O\ K7QF0K\JUZ!\<?$W@[X-?MF_"O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKS+]HO]I2P^!DFC>$]$\"ZQXL\7^*!=_\(WX9T00K).MM&KSSRRSR
M1Q0P1AX]SLW5U !)KC/V'_VR/$7[1/@OP[I7Q8^%VL>&?%>I>";/Q EU+:1G
M2]9M950-<VDT4D@0;W4F"4K*@=<@X) !] 45\W:7^W#\9OB?87WQ#_9N_8YU
M/QMX!LKR>"V\3R>+[73[C6! [)-+86<B,9X]R,$9WB\PC &>*Z/QA^VUX63]
MF?PW^T?\'?!USXNC\7ZWIND:!H<EXEA/)>W=XMH()7D#+"\<Q9'!R 4;G'-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(O!^BR!KH6P8!KF<@,+6W&X#S9  Q(50S'%>V:;>#4=.@U!8]@GA60*3G&X
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M2M?'EII6DZ;I/A]=!;1=7O0\,&I&!9)_MVS+#:9%*;BRJ3DCWJ]_8A^#NL?
M/P[\ /$6J^)=1MO"5PMUX<\47&N,NMZ?=J[NEU'>1A665=[#(&"N 016?X7_
M &$/!%EX^T3XB_%+XS?$7XD7GAB\%YX;M/'>OPSVFFW:C:MRD%M;P(\R@G;)
M('*DY&#S0![C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5^&7_!>O_E(3JG_ &*^E_\
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MW_K[/\V?VKP5_P DE@?^O4/R04445\T?3A1110 4444 %%%% !1110 4444
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M&J?^C5K[/KXP_P"""G_*/;2_^QHU3_T:M?9]?QQQC_R56-_Z^S_-G]J\%?\
M))8'_KU#\D%%%%?-'TX4444 %%%% !1110 4444 %%%% !1110!^&7_!>O\
MY2$ZI_V*^E_^BFKXPK[/_P""]?\ RD)U3_L5]+_]%-7QA7]D<'?\DK@O^O4/
MR1_%7&O_ "5V._Z^S_,****^D/F HHHH **** "BBB@ HHHH **** "OW-_X
M(*?\H]M+_P"QHU3_ -&K7X95^YO_  04_P"4>VE_]C1JG_HU:_+O%W_DE8_]
M?8_E(_5_!O\ Y*V7_7J7YQ/L^BBBOYD/ZE"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBJ5]XBT339_LM_J4<4@ .QCSB@"[16;_ ,)C
MX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_
MWU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I5^&7_  7K_P"4A.J?
M]BOI?_HIJ_;O_A,?#'_0:@_[ZK\/O^"[M_9ZE_P4"U.ZL;A98SX8TP!UZ9\H
MU^I>$7_)52_Z]2_.)^4>,?\ R2,?^OL/RD?&U%%%?TT?RT%%%% !1110 444
M4 %%%% !1110 4444 ?N;_P04_Y1[:7_ -C1JG_HU:^SZ^(_^"$7B+1--_X)
M^Z9:WVI112#Q/J9*,><>:*^RO^$Q\,?]!J#_ +ZK^..,?^2JQO\ U]G^;/[5
MX*_Y)+ _]>H?DC2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J^:/IS2HK-_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J
M#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^
M^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_
M (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#\1/^"]?_*0G5/^Q7TO_P!%-7QA7V3_
M ,%W;^SU+_@H%J=U8W"RQGPQI@#KTSY1KXVK^R.#O^25P7_7J'Y(_BKC7_DK
ML=_U]G^84445](?,!1110 4444 %%%% !1110 4444 %?N;_ ,$%/^4>VE_]
MC1JG_HU:_#*OW _X(1>(M$TW_@G[IEK?:E%%(/$^IDHQYQYHK\N\7?\ DE8_
M]?8_E(_5_!O_ )*V7_7J7YQ/MRBLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZK
M^9#^I32HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^
M^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJKEC?V>I0"ZL;A98R2 Z],T
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MV?7\<<8_\E5C?^OL_P V?VKP5_R26!_Z]0_)$/\ 9VG_ //C#_WZ%']G:?\
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M_DE<%_UZA^2/XJXU_P"2NQW_ %]G^84445](?,!1110 4444 %%%% !1110
M4444 %?N3_P08L[2;_@GQI;S6L;M_P )1J?+("?]:*_#:OW-_P"""G_*/;2_
M^QHU3_T:M?EWB[_R2L?^OL?RD?J_@W_R5LO^O4OSB?9/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%345_,A_4I#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U%
M$/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A4D<44*[(
M8U1?15P*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M::U+"QXTK8FI.,J/MI^\FK<TN9P^*VBE:[:<--6UOZ%\5O$O[<'B7X">//\
MA=/B+X:?&GP[:Z0W]K:7X?U_3;Z\\!W!<>7?Q+8JKP+&V481%H""P?Y0U?"U
M?7'P2\%^"OV%[?QM\7_B%^T;\//$MQJ7@/5?#WAOPKX"\4QZO-K,]] 8%:X$
M0Q;VT8;S6\[:Y** A;BOD>O4X=A3I.M"C&/L[IJ48N$6VM4HWMI97DM[V?O1
M;/*XDG4JJA.M*7M+23C*:G))/W6Y6O[UW:,M5:ZM&204445]*?+G[F_\$%/^
M4>VE_P#8T:I_Z-6OL^OC#_@@I_RCVTO_ +&C5/\ T:M?9]?QQQC_ ,E5C?\
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MW;DU&*6RU;2U:7=I'AX'!5<PQ*HTVD[-MO9**<I-VN]$F]$V^B;/"**^F/\
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M._OM-U>2VV_8IM3M;6WE4,%CC"AGCWK&A(( -?:-?)]_XX^.7[-?[6OQ,OO
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M7QA7]D<'?\DK@O\ KU#\D?Q5QK_R5V._Z^S_ #"OH?\ 80\%?M237.L?%/\
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M3^S#)\27\:7P\9_M\>&?BO;?V6WEZ'HGAK3K*2U?S(_])9[6>1F4#*;2 ,R
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M8F&/]:..:^R/^$EU?_H4+W_OI:^2/^""G_*/;2_^QHU3_P!&K7V?7\<<8_\
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M"A>_]]+6Q10!^%7_  79O)[[_@H!J<]Q826S'PQI@\J4C/\ JCSQ7QQ7V?\
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MKQ-_S_\ _)8?_(A_J9PU_P ^/_)I_P#R1P/_  H__J:/_)+_ .SH_P"%'_\
M4T?^27_V==]11_KKQ-_S_P#_ "6'_P B'^IG#7_/C_R:?_R1P/\ PH__ *FC
M_P DO_LZ/^%'_P#4T?\ DE_]G7?44?ZZ\3?\_P#_ ,EA_P#(A_J9PU_SX_\
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M/\PHHHKZ0^8"BBB@ HHHH **** "BBB@ HHHH *_<W_@@I_RCVTO_L:-4_\
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M5_9'!W_)*X+_ *]0_)'\5<:_\E=CO^OL_P PHHHKZ0^8"BBB@ HHHH ****
M"BBB@ HHHH *_<W_ ((*?\H]M+_[&C5/_1JU^&5?N;_P04_Y1[:7_P!C1JG_
M *-6OR[Q=_Y)6/\ U]C^4C]7\&_^2ME_UZE^<3[/HHHK^9#^I0HHHH ****
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M"SN+^6ZDAA5)+J<*'F( !=@@5<GJ=H R> !Q0!-1110 4444 %%%% !1110
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M]HESI%MJ/C*.S@@T:VN$V3O$ML[F>8QED5V\M5W%MIZ5X16^'4TY-WMIOO\
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M ((*?\H]M+_[&C5/_1JU^&5?N;_P04_Y1[:7_P!C1JG_ *-6OR[Q=_Y)6/\
MU]C^4C]7\&_^2ME_UZE^<3[/HHHK^9#^I0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_+G_ (*N>$]$UC]K
MN]O;[3_,D.A6(+>:PX"'L"*_4:OS-_X*C_\ )V%[_P!@2R_] ->CE>10XAQ/
MU6=>K15G+FI2Y):=+V>COJK=$?-<5S=/+$U_,OR9\L?\*_\ #'_0(_\ )A__
M (JC_A7_ (8_Z!'_ ),/_P#%5NT5]%_Q"S"_]#7&_P#@]?\ R!^<?6:AA?\
M"O\ PQ_T"/\ R8?_ .*I8_ /AA)%<Z,&P0=K3O@^WWJW*ELKN73[V&_@6-G@
ME61!+$KJ2#D95@0PXY!!![TO^(68;_H:XW_P>O\ Y %B:ESZRU+3?AU^TCX.
M\3?$[X7_ !C/A?7]8\;>'KV.U\3336J:1?V]I>QPVL%U$678VZ0QD!0H3# $
MBO-_AGX%U'4-%^-/P'\47]MI'Q'\57MJT[:GJ2VW]J/!=2R7=H)RP16D9U<
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MCL-D&&I1C&T816J?1>I_.7$?!^68S/L37G.:<IR;LXVU?^$^5_\ AF_XT?\
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ME\'?VI/''PY^&OA=IO#VGZ[(=#9M1AREI(!+$A+N&)5'5,GD[<]Z\R_X9O\
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M+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\
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MY1Z04444 %%%% !1110 4444 %%%% !1110!^9O_  5'_P"3L+W_ + EE_Z
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MG6OW#(_^1/0_P+\C\=SC_D:UO\3_ #"BBBO4/-"BBB@ HHHH **** "BBB@
MHHHH *_3/_@ES_R:=9?]AN]_]#%?F97Z9_\ !+G_ )-.LO\ L-WO_H8KY+C3
M_D3K_&OR9]1PC_R-7_A?YH^B:***_*#],"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O*OBU^Q_\ #'XR^,9/&_BGQ!XIM[N6".)HM*\0
MRVT(5!@$(O /J>]>JT4 >"_\.ZO@?_T-WCO_ ,*^>C_AW5\#_P#H;O'?_A7S
MU[U10!X+_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/7O5% '@O\
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MOGH_X=U? _\ Z&[QW_X5\]>]44 >"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\
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M;F%+BWF62.10T<B,"K*1D$$=13J "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445ROQ=^-?PR^!'AN#Q?\ %;Q-_96G7-\MG#<?8II]TS([A-L*.P^6-SDC
M''7D5=.G4K34*:;;V2U;^1%2I3I0<YM)+J]$=517B'_#QW]C+_HLG_EO:C_\
MCT?\/'?V,O\ HLG_ );VH_\ R/7=_9&;?] \_P#P"7^1Q_VIEG_/^'_@4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%N0WF*%OY4YP %/IFQ^S7_PMGX$?MB_%SX)_&X^'HY_B?X8'CO11X76==/\
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M10OEMM*ELMNV@ [/59Y;72[FZA;#QV[LAQG!"DBO(?\ @GO\8O'OQ_\ V-O
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M\)^"M-;1_!OAC3M(M'N))WM=,LH[>-I9&+22%4 !9F)9FZDDDUA?$7]G_P"
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M"*\Z\$_ML_ 'Q[#KT.D:GK]MJOAK23JFK^&M5\'ZC::LEF#@3QV4T"S7"$X
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MP>,M2_;>N?@]INLP0>$O#'PQ&M>)@T$?-_=7K1VJM*PS&%AMKER 0#N4G..
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M XR/K7,?"/PI^T%X<N[V3XU?&;P[XJAEC06$6B>!Y-(:W8$[F=GOKGS 1@
M+C!Y.>.NT30]%\,Z-:^'?#>CVNGZ?8VZ6]C86-NL4-O$@"I&B* J*H  4
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M5L?_ $VZG7W[7P%_P<;?\F1>%O\ LJMC_P"FW4ZY<;_NL_0^8XS_ .27Q?\
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M37A?B*%KW_@E_P#M"^.-#A9/"?BGXWW6K>!&"%8IM*DUO3E6:%3C;$\T<[J
M ,'(ZT ?:G[)>N:KXF^$47B#5/CAKOQ -U?RF+7?$7@P:#<*JA4:'[(+:W*H
M'5V5F3)#_>8 &N6_9X^/OC34/C3\=/A'\9O$$$C?#SQ);ZAI%W]E2$1:#>V8
MN+=3L \SRS',I<Y8XP22*]VKX'_X*87'BKX3?M+6\G@6"87'[07PSE^'$)MT
M)":F=1MTBN&(Z,+:^G /I'QR* /2O^">O[<?C7XY_!CXA^.?V@K=;#4O"&H-
MK MQ;)$8O#UW8IJ&GN0N <P%QN/)" DYS76?"']K>S\ ?LD_#CXJ_M9^,=OB
MCQSIL=W9Z;I>BR3WE_)< W$5O;V=I&TDAC@DB5BJ<8RY!.3\[_\ !0/PO?\
M[/\ \9K7X:?"[3YK;3?V@/AE9?#:TBM4R([^WO[:UCD<C@ :?>SH,]?+^M>O
M?$>3PI\&?^"F'PRUOX@7=II/A"?X/:CX>\$W6H2K':VFLI>02/$KOA8Y'LU"
M+D@N%*C)XH ]F^'?[6'P'^*/@+Q#\1O"GC*3[#X129O%5K?Z5<VM]I'E1&5U
MN+26-9T(16(&SYL';NKQS]J'_@H;X'/[-'Q#\8?LJ^/WOO$7A30M/U"/51H$
MSV< N;BV C,D\0B>7RIQNBR73=AE5E('%>/]5TCXA_M/_M(?$3X4:E;WWAC3
MOV=6T3Q3J6G2![:YUY5O)43S%RLDD5JP5L$E-P4X/%0?&[PYHGA;_@@U8:9H
M&G16L,GPM\.74J1+C?//)9332'U9Y9'=CW+$T ?4GQK_ &G_ (/? '4-*T'Q
M_K-_)J^N>8=(T#0=#NM3U"[2, R2);6D<DGEH",N0%'3.>*X/]D_]J*Z_:*_
M: ^,>CZ%XN@U7PAX9N- 3PMY5CY+V_VC3S)=1R!E602"=65DE :-E9"%((KF
MK;Q-X?\ AU_P53\2WWQ8U>TTU?$GPCTZ'P+J.J3K%%)%;WDS7UK%(Y"^9O>.
M5HP=VW#8P,U!^PWXP\"^/_VR_P!IGQA\-KZVO-'O-=\-BWO[( P7<D>FO#-+
M&PXD4S1R#>N0Q!8$YS0!]4T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7QU_P %N/!O[/OCC]E3P_I/[2/[2'_"K]#C^(5I-::__P (?=ZW
M]HNQ8WZK:^1:D.FY&E?S#\H\K;U85]BU^<__  <Y?\F%^$?^RO6'_IKU6NW+
ML%1S+'4\-6ORS=G;<^?XJG"GP[B93@I)1V=[/5;\K3^YH^"O^&>O^"4O_27_
M /\ -?\ 7?\ XY1_PSU_P2E_Z2__ /FO^N__ !ROB"BON?\ B&_#O>?_ ($O
M_D3^=/K^7_\ 0#2_\"K_ /RX_HG_ ."(_@W]GWP/^RIX@TG]F[]I#_A:&AR?
M$*[FN]?_ .$/N]$^SW9L;!6M?(NB7?:BQ/Y@^4^;MZJ:^Q:_.?\ X-C?^3"_
M%W_97K__ -->E5^C%?#9C@:.6XZIAJ-^6#LK[G]%\*SA4X=PTH044X[*]EZ<
MS;^]L" 1@C(/45\Z?$?]A:[T7XYVG[1W[(FK>"?A_P")&T>73-;@O/ $-W:7
M\;R^8+D"&2!X[D$LIDW'S$*JW"BNL_;L_:%\2_LO_LSZW\6_!^G6$VJ075E8
MV4VKEA96<EU=16XN;@K@^5'YF\@$9P!D9R.1M_!O[?/PZ;0_B)X9_:/TOXP6
M%Q?VJZ]X5O/"^G:2DME*ZK+<Z?=0,NUHU)D"3-('52 V[:#Q'T![[I?A;0-*
MU6[\26NA6$6K:G% FK:G;V21S7OE*1'YC@;G"!F"AB=H8@=33-3\%^#M;UZR
M\5:SX3TR[U3389HM.U*ZL(Y+BUCF 65(Y&!9%< !@I 8  YKQ[4?CWXPT;_@
MH9=? [6/$EI:^";/X%GQ3<QW$,2"&\75FMWG:8C<J"$<@G:,9]ZS_@!\6/C;
M^UP_C#XR>!O& \,?#F\L;C2/A<QTF&:XU"XC9T?791*I(B\T;8H#@,B%G4$B
M@#O/^&-OV0?^C5/AM_X0VG__ !FNC\<?!CX/?$[0K7PO\2OA/X:\0Z98@"RT
M[7-"M[N"WP !LCE1E3  ' ' %?/?PI_;^U;1/V6?%.N_'?1DD^*OPXU;_A&/
M$?A:Q0+)J^MN_EV'V9 .4O"T;*RKM&9"!M2I?B5\;?VIO!</PF_9)T/Q5HMU
M\8OB#9W-YXF\676DJ]CX?LX$\VZGCMHRBS%2X@@#'#F/+G)Y /HSP-\// 'P
MPT%/"WPU\#:/X>TR-RZ:;H>F16D"L>I$<2JH)P.<=JQ_%/[//P \<^+8?'_C
M;X&^#]8UZW*F#6]5\,VMQ=QE?N[9I(RXQ@8P>,5Y3X7D_;0^ WQN\*^%/B-X
M^G^+G@CQ?)/9ZAKL'@Z"POO"]XD9DBEE%F!$]I)M:,LZAD8K\QSAMG]DCXT_
M$'XL?$/XT>'_ !OJL5S:^#?B?/HV@)':I&8+-;6"0(Q4 N=TC'<V3SUH ]9\
M8^"/!?Q$\/S>$_B!X0TO7=*N&0SZ9K&GQW5O(58,I:.164X8 C(X(!K$\$?L
M^_ 3X9:M_;WPW^"'A#P]?;"GVW0_#5K:2[3P1OBC4X/IFN<_;,^+_BCX*_L^
M:QXE^'GE-XLU*:UT7P=#+&'$FK7TZ6MM\A!#[7E$A4@@K&V:Q/V"_CIX\^-W
MP$GE^+MU!)XY\(^)=3\->-#;6ZQ)_:%G.R[@B@!0T30O@ #YSCB@#V75M)TO
M7M+N=#US3;>]LKVW>"\L[N%9(IXG4J\;HP(964D%2"""0:31M&TCP[I%KX?\
M/Z5;6%A86R6]C8V<"Q0V\**%2-$4!415  4    "OC?]C^7_ (*!_M3_ ++7
MAG]H:W_;?L-)U#Q#:7$T>CW'POL)[>-XKF6$(TBNCE6\H$D $;N,XY=+^W#^
MT'J?[(_@/]M^PTRT_LGP[XBNK'XR>&=*LEGAO+"*Z>RGU"RD8&4"%XQ.JAL%
M68.2(R2 ?9]%>(>*?C]XB^)?[0?@KX*?L\>);62P&FP^*_'OB*"&.XBAT612
M+.TC+ J);Q^0>&6&)W7JIK@/!/Q#_:;_ &NOB_\ $_1OAU^TY8_#+3?AWXSN
M/#EEX=T_PG9ZEJ%V8%0F_NC>;BL,K,WEK&J953\^020#Z=\/^$?"?A-[^3PM
MX8T[3&U74)+_ %-M/LHX3>7;A0]Q+L \R5@J@NV6.T9/ INE>"O!NA7^IZIH
MGA+3+.ZUN83:S<VMA'')?R!=@>9E4&5@ORY;)QQ7*?LZ:C^T%=>!;C3/VE=!
MTJW\1:7JUQ9Q:KHDJ_9=;M$(\F_2(.S6QD4_-"QRK*2, @#OJ .2\"? +X$_
M"W6KKQ)\,?@KX2\.:C>J5O;_ $'PY:V<UP"<D.\4:LXSSR3S2?$']G[X#?%G
M5+?6_BI\$O"/B:]M%"VMYX@\-VM[+"H.0$>:-BHSSP:Z/Q!=SZ?H-]?VS 20
M6DLD9(SA@I(_45\?_LJ1?\%!OVE?V7_#'[0=E^W!ING:CXATQ[N/1KSX86,M
MJCK+(@C>1'1]IV#+* 1G@'% 'UMK/@/P/XC\(R?#_P 0^#=*O]!EMEMY=$O=
M.BELWA7&V,PLI0H,#"XP,"E\%^!O!7PV\,VW@KX=^#]+T#1K+?\ 8])T73X[
M6V@WNSOLBB547<[,QP!DL2>2:\6_9^_;H\%^+_V+O#W[5OQZU#3_  NEZ\UE
MJ*VOF313WT-W+:%;1%#R3^:\+-'&@=R&Q\Q4FN[^#W[4/P@^.&NWWA#P?J>J
M6>O:9:I=7WAWQ+X>O-)U".V=MJ7 M[R*-WB)X\Q05R0"03B@#:^(OP/^"OQ?
MEM)OBS\(/"_BA[ DV+^(O#]M>FV)ZF,S(VS\,5J:UX(\%^)/#!\$>(O".EW^
MBM''&VD7NGQRVI2-E:-?*92F%*J5&."H(Z"O)=8_X*)?LG:%KMUI>H>/-1%A
M8:F=.U#Q3%X6U"31+6[#^689-16 VRD.=I8R;5/!8<US7QV_X*%^&?@M^U?X
M4^ MSX?U>YTJ_P!,U&?Q'?6?@K5;R9)(X+:6U%FUO$R7*$3MYK1B01D ,4/4
M ^DZS->\%^#O%5]IVI^)_">F:E<Z/=BZTBXO[".9[&?&/-A9P3$^.-RX/O6G
M7C'CS_@H#^RO\./%FI^$O$GCV^=M!O!:>(]5TWPU?WFFZ-.< 17=Y! \$#@D
M!@S@I_%MH ]4U[P7X.\57VG:GXG\)Z9J5SH]V+K2;B_L(YGLI\8\V%G!,3XX
MW+@^]1>.?A[X!^)_A^3PG\2_ ^C^(M*E=7ETS7=,BN[=V'0F.564D=CBOG#]
MOS]MNW^$5QX'^%?PU^)-_H&J^,M?LS?>*M,\$W6LK8Z,\4\C3V@6WEM[F=S"
MBK&/,8*Y<QXPU?0/PL.IZA\)]&N;GX@:AKUQ>Z1'/%XBU+1DL;FY65=\<LEL
M(HUA?:RYC,:$$890<B@"UX=^&7PV\(>#6^'7A/X?:'I?AYH9(6T+3M)A@LS&
MX(=# BA-K D$8P0>:DU#X?> =6\&+\.-5\$:/<^'4M8K9=!N-,B>R$$>WRXA
M 5V;%VKM7&!M& ,"OF;X;?MF_$V'_@F]XN^.'Q#NH+GXC^"GUK0-46&S1$DU
MZWNWM;5/*4!1O=[7*X_CQBFZ3^VC\4KW_@E[=?M!W!@3XEV=G)X>N(#;1_N_
M$@OO[,7,0&S)G9)-F-N&Z8XH ^D_B)\)_A9\7M*BT+XL?#3P_P"*+&";S8+/
MQ%HT%[%')C&]4F1@&QW S5OPWX$\#^#IY[GPCX-TK2I+J&"*YDTW3HH&FC@3
MRX48HHW+&GRH#PJ\# K@/B9^U?\ "#]GZ]TKX>?$WQ;J.J^*Y](6ZETKPWX:
MN]3O9(4PDEX]O90R&&(N&^9@JY!"YP16E!^U9^SY=_!FS_:#LOB7:7'@^_O+
M:TM]9M[>:1?/GN4M8XGC5#)&_GR+&RNH*$G?M ) !Z%17S/\0?VXM(\;:M\+
M;_\ 9O\ %TEWHFO_ !G@\+:_?SZ)(D-_;&QNIG^S//&/,C+1QXGBRIVD!B,U
MZ)\3_P!L_P#9]^$?CZ7X9>*_$VI3ZS96D=WK%MH7AN^U(:1;R9*37CVD,BVJ
M,!D&0K\OS?=YH ]4HKQ7]@SXY>*OVA?@KJ/Q"\6>(;756'CG7;'3KZRBC6*2
MQM[^6*WV^6 K#RE7Y_XNN3FO:J "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OSG_ .#G+_DPOPC_ -E>L/\ TUZK7Z,5\Y_\%.?V ?\ AXY\!=(^"'_"
MV?\ A#?[*\7V^N?VG_8/]H^;Y5K=6_D^7Y\.W/VG=NW'&S&TYR/2R?$4<+F=
M*M5=HQ=V_P#AM3Q.),'B,?D=?#T(\TY1LE=*[]79'\S]%?KM_P 0K/\ U?=_
MYB__ .^='_$*S_U?=_YB_P#^^=?J/^M60?\ /[_R6?\ \B?A7^H/%G_0-_Y/
M3_\ DCU[_@V-_P"3"_%W_97K_P#]->E5^C%?.?\ P3&_8!_X=Q_ 75_@A_PM
MG_A,O[5\7W&N?VG_ &#_ &=Y7FVMK;^3Y?GS;L?9MV[<,[\;1C)^C*_+\YQ%
M'%YI5K4G>,G=/;\]3]UX;P>(P&1T,/7CRSC&S5T[/U5T>9?M<?%'X=?";X,W
M.O\ QC^'=QXC\&WE];Z=XLBCL4N8+"PG;9)>7,3<O;QY4OM#, <XP"1\:_M-
M?##]D[]EOX5+\>O^">?[1MQX:\8OJ-FWA3P=X/\ '3:GI_BBXEN(T^RG3VEE
M\Y7#,<)A5QG'%?HI/!!=0/;7,*21R(5DCD4%64C!!!Z@CM7%^$/V9_V</A]X
MG_X3;P%^S]X(T36<L?[7TCPI9VUUEOO'S8XP_.3GGG->8>V?*GQ\^!NH?M)?
M\%5-&^'GBOQ!+I>@3_L^6MUXYTBR?YM8LX]<E8Z<9!RD3S^49".7CC9,@.2.
MX_9?C7]CO]JSQ'^Q-?*+;P9XQ%SXM^#^?EBM\MNU+2(^P\ISYZ(.D;L2<FOI
MG_A$?"?_  EG_">_\(QIW]NG3OL']M?8H_M?V3S/,^S^=C?Y6_Y]F=N[G&>:
M36O!G@_Q)JNFZ[XB\*:;?WNC3M/H]Y>V,<LMC*R[6>%V!,3%>"5()'% 'RG\
M4_A!\/=2_P""POP[\57?AZ-KJX^'%_JUT-Y$=Q?64HM[6YDCSM>6**YE5'()
M7Y<8VC&A^UGJNF_L_P#[>GPC_:K\>W L_!EYH&I>#=>UV?BWT>XG99[22=SQ
M'')(&CWG"KC+$"OIVX\(^$[KQ/;^-KKPQITFLVEJ]K:ZO)91FZA@<AGB24C>
MJ,0"5!P2!D5+K_A_0?%>C7/ASQ1HEGJ6GWD1CN["_MDFAG0]5='!5A[$8H \
MJ\0?MD?#^?XZ^#?@!\(WL/&VL>)'GN=;DT36HY(O#VEQ1%C>W#1JX^:0QQI&
M2A<OPW&#Y'^QK\9O@_\ #7XV?M&:5\1?BOX:T"ZG^-%S+!;:WKMO:R21_8K8
M;U65U)7((R.,@U],?#CX+_!WX.VUQ9?"+X3^&O"L-VP:[B\.:%;V*S,.A<0H
MH8C)Z^M9'B+]EG]F/Q?KEUXG\6?LY^ ]4U*]E,M[J&H^$+*>>X<]7>1XBSL?
M4DF@#PS]I#Q5XP_:8_:2^&/@#]ESQ5X,UJ'P;9W7CS4KW5KN2ZTJ:57?3;%-
M]FQ+.)'O9  P :VYZ8K(_9E_X7#\!O\ @H)X[^&GQT/AN-_C#X8A\5Z0?"JW
M"6']H6.+2[BC6X)?SGB,<S\D?*"".E?4O@;X2_"KX7K(GPT^&7A[PZ)85AE&
MA:+!:!XU>1U0^4BY4/+*P'0&1SU8YT-3\'^$M:U_3?%>L>%M.N]4T83#2-2N
M;&.2XL?.0)+Y,C M%O4!6VD;@,'(H _-W]F?]BSQ1\5O^"1^F^./A7\;_B?9
M^*KOPOJ-QIGAVR^(%_'I%Q)%>W!-H+))%C"S)&T9 Q\TI;K7VU^R-J/P3^+?
M['7@ZY^&'@C3;#P7K?A185\-PQ!K>W1U:.YM'!SO*R>=&Y;)9@Q))))])\*^
M$O"G@3P_;>$_!'AG3]&TJS4K::9I5E';V\ +%B$CC 506))P.I)[TGA;P=X1
M\#:5_87@GPMINCV/G23?8M*L8[>+S'8L[[(P!N9B6)QDDDF@#Y;_ .".'PY\
M)^!OV9];OO#^GLMS>>/]7M;F[GF:662"RN&M+6(NY)V1PQ(BKG YP.36;XO\
M'_\ !./]L/XC>)=4^,NA0?#_ .*/A35IM.U::Y\2_P!AZW$L1VPWBO%,JW,,
MD6QHY2)%VE1G@5];>&/"/A/P5IK:/X-\,:=I%H]Q).]KIEE';QM+(Q:20J@
M+,Q+,W4DDFL+XB_L_P#P'^,%[!J/Q:^"?A'Q3<6J;+:?Q'X;M;YXESG"M-&Q
M49)X'K0!X5_P3)\;>-->LOB9X';XN:K\0_ OA+QK_9OP_P#'>M7(N;C4;?R%
M:>$W( %TL,AV"89#9.#M"JOM'Q'\)?M$:WXQLM2^%OQK\.>']#B@C6_TG5?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030855504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,661,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531040303104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,464.9<span></span>
</td>
<td class="nump">$ 2,456.0<span></span>
</td>
<td class="nump">$ 4,755.4<span></span>
</td>
<td class="nump">$ 4,919.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">546.0<span></span>
</td>
<td class="nump">592.7<span></span>
</td>
<td class="nump">1,088.2<span></span>
</td>
<td class="nump">1,255.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">513.9<span></span>
</td>
<td class="nump">584.2<span></span>
</td>
<td class="nump">966.8<span></span>
</td>
<td class="nump">1,154.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">553.8<span></span>
</td>
<td class="nump">548.0<span></span>
</td>
<td class="nump">1,135.3<span></span>
</td>
<td class="nump">1,153.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">86.9<span></span>
</td>
<td class="nump">52.9<span></span>
</td>
<td class="nump">165.2<span></span>
</td>
<td class="nump">103.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">62.4<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
<td class="nump">128.0<span></span>
</td>
<td class="nump">114.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of priority review voucher, net</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="nump">85.2<span></span>
</td>
<td class="num">(121.2)<span></span>
</td>
<td class="nump">178.9<span></span>
</td>
<td class="num">(51.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">1,766.2<span></span>
</td>
<td class="nump">1,747.9<span></span>
</td>
<td class="nump">3,591.9<span></span>
</td>
<td class="nump">3,772.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax (benefit) expense</a></td>
<td class="nump">698.7<span></span>
</td>
<td class="nump">708.1<span></span>
</td>
<td class="nump">1,163.5<span></span>
</td>
<td class="nump">1,146.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">115.1<span></span>
</td>
<td class="nump">114.8<span></span>
</td>
<td class="nump">186.5<span></span>
</td>
<td class="nump">165.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">583.6<span></span>
</td>
<td class="nump">593.3<span></span>
</td>
<td class="nump">977.0<span></span>
</td>
<td class="nump">980.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 583.6<span></span>
</td>
<td class="nump">$ 591.6<span></span>
</td>
<td class="nump">$ 977.0<span></span>
</td>
<td class="nump">$ 979.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="nump">$ 4.09<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="nump">$ 6.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 6.70<span></span>
</td>
<td class="nump">$ 6.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">145,600<span></span>
</td>
<td class="nump">144,700<span></span>
</td>
<td class="nump">145,400<span></span>
</td>
<td class="nump">144,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">145,900<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
<td class="nump">145,900<span></span>
</td>
<td class="nump">145,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,899.6<span></span>
</td>
<td class="nump">$ 1,845.8<span></span>
</td>
<td class="nump">$ 3,611.5<span></span>
</td>
<td class="nump">$ 3,609.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">444.5<span></span>
</td>
<td class="nump">433.4<span></span>
</td>
<td class="nump">838.5<span></span>
</td>
<td class="nump">832.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 120.8<span></span>
</td>
<td class="nump">$ 176.8<span></span>
</td>
<td class="nump">$ 305.4<span></span>
</td>
<td class="nump">$ 477.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531033978864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 583.6<span></span>
</td>
<td class="nump">$ 591.6<span></span>
</td>
<td class="nump">$ 977.0<span></span>
</td>
<td class="nump">$ 979.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">34.8<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(27.0)<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">598.1<span></span>
</td>
<td class="nump">590.8<span></span>
</td>
<td class="nump">984.7<span></span>
</td>
<td class="nump">971.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 598.1<span></span>
</td>
<td class="nump">$ 592.5<span></span>
</td>
<td class="nump">$ 984.7<span></span>
</td>
<td class="nump">$ 973.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531033855104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,908.9<span></span>
</td>
<td class="nump">$ 1,049.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,506.1<span></span>
</td>
<td class="nump">2,527.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">615.3<span></span>
</td>
<td class="nump">1,182.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,108.5<span></span>
</td>
<td class="nump">6,859.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,249.3<span></span>
</td>
<td class="nump">3,309.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">389.4<span></span>
</td>
<td class="nump">420.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">8,232.9<span></span>
</td>
<td class="nump">8,363.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,227.4<span></span>
</td>
<td class="nump">6,219.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">915.1<span></span>
</td>
<td class="nump">928.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">681.5<span></span>
</td>
<td class="nump">745.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,804.1<span></span>
</td>
<td class="nump">26,844.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of term loan</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">281.6<span></span>
</td>
<td class="nump">257.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">354.5<span></span>
</td>
<td class="nump">403.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">2,472.1<span></span>
</td>
<td class="nump">2,623.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,108.2<span></span>
</td>
<td class="nump">3,434.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and term loan</a></td>
<td class="nump">6,292.0<span></span>
</td>
<td class="nump">6,788.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">590.6<span></span>
</td>
<td class="nump">641.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">367.5<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">556.7<span></span>
</td>
<td class="nump">781.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,915.0<span></span>
</td>
<td class="nump">12,045.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments, contingencies and guarantees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Inc. shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.000 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $&#8212; per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">407.5<span></span>
</td>
<td class="nump">302.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(146.0)<span></span>
</td>
<td class="num">(153.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">18,604.6<span></span>
</td>
<td class="nump">17,627.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">15,889.1<span></span>
</td>
<td class="nump">14,799.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">26,804.1<span></span>
</td>
<td class="nump">26,844.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $2.5 and $2.4, respectively</a></td>
<td class="nump">1,627.1<span></span>
</td>
<td class="nump">1,664.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $2.5 and $2.4, respectively</a></td>
<td class="nump">$ 451.1<span></span>
</td>
<td class="nump">$ 435.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029117520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts Receivable, Allowance for Credit Loss, Current</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531034224672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 977.0<span></span>
</td>
<td class="nump">$ 980.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">306.4<span></span>
</td>
<td class="nump">229.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">44.4<span></span>
</td>
<td class="nump">36.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationOfInventoryStepUp', window );">Amortization of acquired inventory step-up</a></td>
<td class="nump">134.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">143.4<span></span>
</td>
<td class="nump">147.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(47.1)<span></span>
</td>
<td class="num">(170.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">61.6<span></span>
</td>
<td class="num">(26.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of priority review voucher, net</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">60.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(188.2)<span></span>
</td>
<td class="num">(65.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="num">(115.6)<span></span>
</td>
<td class="num">(127.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(82.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(103.0)<span></span>
</td>
<td class="num">(55.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by (used in) operating activities</a></td>
<td class="nump">1,179.0<span></span>
</td>
<td class="nump">942.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(79.4)<span></span>
</td>
<td class="num">(137.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,682.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(4,120.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity interest in Samsung Bioepis</a></td>
<td class="nump">406.8<span></span>
</td>
<td class="nump">788.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of priority review voucher</a></td>
<td class="nump">103.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(84.1)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">57.5<span></span>
</td>
<td class="nump">103.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow provided by (used in) investing activities</a></td>
<td class="nump">400.5<span></span>
</td>
<td class="num">(1,706.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(40.8)<span></span>
</td>
<td class="num">(54.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings</a></td>
<td class="nump">650.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Net (distribution) contribution to noncontrolling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow provided by (used in) financing activities</a></td>
<td class="num">(684.8)<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">894.7<span></span>
</td>
<td class="num">(817.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(35.7)<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,049.9<span></span>
</td>
<td class="nump">3,419.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">1,908.9<span></span>
</td>
<td class="nump">2,617.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">$ (15.1)<span></span>
</td>
<td class="num">$ (6.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationOfInventoryStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Inventory Step-Up</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationOfInventoryStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531032246384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">167.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 13,388.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 73.3<span></span>
</td>
<td class="num">$ (164.9)<span></span>
</td>
<td class="nump">$ 16,466.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 13,397.9<span></span>
</td>
<td class="num">$ (9.5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">980.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979.5<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(84.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">153.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">14,460.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
<td class="num">(172.8)<span></span>
</td>
<td class="nump">17,446.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">14,466.9<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">13,787.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
<td class="num">(172.0)<span></span>
</td>
<td class="nump">16,854.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,796.6<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">593.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591.6<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">74.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">14,460.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
<td class="num">(172.8)<span></span>
</td>
<td class="nump">17,446.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 14,466.9<span></span>
</td>
<td class="num">$ (6.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">14,799.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">302.5<span></span>
</td>
<td class="num">(153.7)<span></span>
</td>
<td class="nump">17,627.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">977.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">977.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(64.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">149.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">15,889.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">407.5<span></span>
</td>
<td class="num">(146.0)<span></span>
</td>
<td class="nump">18,604.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">15,213.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">329.5<span></span>
</td>
<td class="num">(160.5)<span></span>
</td>
<td class="nump">18,021.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">583.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 15,889.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 407.5<span></span>
</td>
<td class="num">$ (146.0)<span></span>
</td>
<td class="nump">$ 18,604.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029124656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD and we have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.</span><span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023 the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531123515008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS (omaveloxolone), the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid Reata shareholders $172.50 in cash for each issued and outstanding Reata share, which totaled approximately $6.6&#160;billion. In addition, we agreed to pay approximately $983.9&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $590.5&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $983.9&#160;million paid to Reata's equity award holders, we recognized approximately $393.4&#160;million as compensation attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the year ended December 31, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a $1.0 billion term loan under our term loan credit agreement. For additional information on our term loan credit agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,602.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of $172.50 per outstanding Reata common stock based on 38.3&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Preliminary Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made year-to-date to the amounts initially recorded as of the acquisition date on September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.847%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date<br/>(as adjusted)<br/>June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,259.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,200.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(300.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(916.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,719.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $4.9&#160;million, deferred tax liability by $4.1&#160;million and goodwill by $9.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total inventory acquired was</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $1.3&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be within approximately 3 years from the acquisition date. For the three and six months ended June 30, 2024, amortization from the fair value step-up adjustment was approximately $90.1&#160;million and $134.2&#160;million, respectively, which includes approximately $46.0&#160;million of inventory used for clinical purposes rather than for commercial sale during the second quarter of 2024, and therefore reflected within research and development expense within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets are comprised of $4.2&#160;billion related to SKYCLARYS commercialization rights in the U.S., $2.3&#160;billion of IPR&amp;D related to the omaveloxolone program outside the U.S., which had not yet received regulatory approval in the E.U. as of the acquisition date, $100.0&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $40.0&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing a discount rate of 14.3% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $4.2&#160;billion intangible asset will be amortized over its expected economic life. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon SKYCLARYS </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receiving E.U. regulatory approval in February 2024, we began selling the product in certain countries in Europe, and began amortizing the $2.3&#160;billion I</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PR&amp;D asset related to the program outside the U.S. over its expected economic life using an economic consumption model. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $121.2&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $473.5&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expenses:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expense, primarily comprised of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $28.4&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the year ended December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Assumptions in the Allocations of Purchase Price</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of Reata, along with the estimated fair values of the assets acquired and liabilities assumed in the Reata acquisition, have been included in our condensed consolidated financial statements since the closing of the Reata acquisition on September 26, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of income taxes. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Human Immunology Biosciences</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, aMR, PMN and IgAN. Felzartamab has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for development in the treatment of PMN and has received ODD in the treatment of antibody-mediated rejection in kidney transplant recipients. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we made an upfront payment to HI-Bio of approximately $1.15&#160;billion which was funded through available cash on hand. Additionally, we may pay up to $650.0&#160;million in potential milestone payments to the former shareholders of HI-Bio. We expect this transaction to be accounted for as an acquisition of a business and recognized within our condensed consolidated financial statements during the third quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to lead program felzartamab, the HI-Bio pipeline acquired includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial, and the potential for continued development in a range of complement-mediated diseases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029128944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Dispositions</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $2.3&#160;billion. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing, with approximately $1.3&#160;billion in cash to be deferred over two payments. The first deferred payment of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$812.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2023 and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second deferred payment of $437.5&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2024, we recognized</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> gains</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$1.4&#160;million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$7.5&#160;million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to reflect the changes in fair value associated with the passage of time related to the second deferred payment </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">due to us, which was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2023, we recognized gains of approximately $2.6&#160;million and $13.7&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the first deferred payment due to us. Additionally, for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2023, we recognized gains of approximately $3.6&#160;million and $9.8&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the second deferred payment due to us. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $103.0&#160;million upon the closing of the PRV purchase, of which approximately $14.4&#160;million is payable to Ionis. Our net portion of approximately $88.6&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028351424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring, Business Transformation and Other Cost Saving Initiatives</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Fit for Growth Restructuring Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,000 employees and we expect to incur restructuring charges ranging from approximately $260.0&#160;million to $280.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimate we will incur total integration charges ranging from approximately $35.0&#160;million to $40.0&#160;million, related to severance and employment costs, which are expected to be paid by the end of 2024. These amounts were substantially incurred during 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions from our 2023 Fit for Growth program and Reata Integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531123527376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,149.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,209.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">429.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,845.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">783.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">361.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">893.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">955.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,140.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,225.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,182.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,334.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">880.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">958.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,592.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,018.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,611.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,502.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,106.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,609.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 25.4% and 12.3% of gross product revenue for the three months ended June 30, 2024, and 25.5% and 12.0% of gross product revenue for the six months ended June 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 27.0% and 9.3% of gross product revenue for the three months ended June 30, 2023, and 27.2% and 8.4% of gross product revenue for the six months ended June 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,765.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(797.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,058.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(477.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(643.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">910.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:67.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">964.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Manufacturing, Royalty and Other Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, our share of contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated statements of income.</span></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we are not the principal, as well as royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041124288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,821.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,926.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,617.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,506.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,527.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,617.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recorded approximately $1.3&#160;billion of acquired inventory, which includes measurement period adjustments, related to SKYCLARYS as a result of our acquisition of Reata in September 2023. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income when the inventory is sold, which is expected to be within approximately 3 years from the acquisition date. For the three and six months ended June 30, 2024, amortization from the fair value step-up adjustment was approximately $90.1&#160;million and $134.2&#160;million, respectively, which includes approximately $46.0&#160;million of inventory used for clinical purposes rather than for commercial sale during the second quarter of 2024, and therefore reflected within research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029134976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired and in-licensed rights and patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-22 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,515.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,595.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,919.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,180.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,440.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,739.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13-31 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,548.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,439.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,548.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,429.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,063.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,035.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,028.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,728.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,869.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,859.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,267.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,035.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,232.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,232.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,869.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,363.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, amortization and impairment of acquired intangible assets totale</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$86.9 million and $165.2 million, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $52.9 million and $103.1 million, respectively, in the prior year comparative periods. The increases were primarily due to amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS. For the three and six months ended June 30, 2024 and 2023, we had no impairment charges.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between 2 to 31 years, with a remaining weighted average useful life of 12 years for acquired and in-licensed rights and patents and 10 years for developed technology and other. In connection with our acquisition of Reata in September 2023 we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately $4.2&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset, with an estimated fair value of approximately $2.3&#160;billion, from IPR&amp;D to completed technology.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. The carrying value associated with our IPR&amp;D assets as of December 31, 2023, related to the IPR&amp;D programs we acquired in connection with our acquisition of Reata in September 2023, with an estimated fair value of approximately $2.3&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset from IPR&amp;D to completed technology.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease priority review voucher that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $100.0&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">680.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,219.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,227.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029100688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,816.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,513.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,506.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value as of June 30, 2024 and December 31, 2023. In addition, there have been no changes to our valuation techniques as of June 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of June 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan 364-day tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan three-year tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,718.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,747.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,721.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,018.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">969.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,448.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,292.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,137.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,788.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,448.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,292.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,287.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,938.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of June 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of June 30, 2024, compared to December 31, 2023, are primarily related to increases in U.S. treasury yields partially offset by a decrease in credit spreads used to value our Senior Notes since December 31, 2023. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041115216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our money market funds approximates fair value due to their short-term maturities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable equity securities, classified as available-for-sale:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">948.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(542.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(563.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.747%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of December 31, 2023, we have sold all of our marketable debt securities. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three and six months ended June 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, our strategic investment portfolio was comprised of investments totaling $352.3 million which are included in investments and other assets in our condensed consolidated balance sheets. As of December 31, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, our strategic investment portfolio was comprised of investments totaling $460.7 million which are included in other current assets and investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of June 30, 2024, was primarily due to the decrease in the fair value of our investment in Sage common stock as well as the sale of a portion of our Denali and Sangamo common stock during 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028388448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of June 30, 2024 and December 31, 2023, had durations of 1 to 15 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,420.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,658.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of approximately $3.4&#160;million to be settled over the next 15 months, of which approximately $1.9&#160;million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2024 and December 31, 2023, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,199.3 million and $1,301.5 million as of June 30, 2024 and December 31, 2023, respectively. Net losses of $5.7 million and $30.0 million related to these contracts were recorded as a component of other (income) expense, net for the three and six months ended June 30, 2024, respectively, compared to net losses of $7.2 million and $5.4 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028318848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,537.4 million and $2,402.5 million as of June 30, 2024 and December 31, 2023, respectively. For the three and six months ended June 30, 2024, depreciation expense totaled $71.9 million and $141.2 million, respectively, compared to $64.5 million and $126.6 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we built a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility includes 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of December 31, 2023, we had approximately $728.8 million capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of this facility (the first manufacturing suite) received a GMP multi-product license from the SWISSMEDIC and was placed into service. The second manufacturing suite, which was also licensed to operate by the SWISSMEDIC, became operational in the first quarter of 2024, resulting in approximately $717.3&#160;million of fixed assets being placed into service. Solothurn has been approved for the manufacture of LEQEMBI by the FDA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028315696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6100 Legacy Drive Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $121.2&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531135165872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text">Credit Agreement<div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement (2023 Term Loan). On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid $350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion of the three-year tranche being subsequently repaid during the second quarter of 2024. As of June 30, 2024, the 2023 Term Loan was paid in full. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531141322272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and six months ended June 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of June 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(147.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.372%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029036576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">583.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041116000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:42.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Omnibus Equity Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 our shareholders approved the 2024 Omnibus Equity Plan for share-based awards to our prospective and current employees, non-employee directors, officers or consultants. Awards granted from the 2024 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2024 Omnibus Equity Plan consist of 3.7 million shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) on the date that our shareholders approved the 2024 Omnibus Equity Plan, plus shares that were subject to awards under the 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) that remain unissued upon the cancellation, surrender, exchange, termination or forfeiture of such awards. The 2024 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a 1.5-to-1 ratio.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not made any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan since our shareholders approved the 2024 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan in the future, except that unused shares under the 2017 Omnibus Equity Plan have been carried over for use under the 2024 Omnibus Equity Plan. Awards outstanding under the 2017 Omnibus Equity Plan and the Directors Plan as of the date our shareholders approved the 2024 Omnibus Equity Plan will remain outstanding and subject to the terms and conditions of the 2017 Omnibus Equity Plan and the Directors Plan, as applicable, and the relevant award agreements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 our shareholders approved the 2024 ESPP. The 2024 ESPP, which became effective on July 1, 2024, replaced the 2015 ESPP, which expired on June 30, 2024. The maximum number of shares of our common stock that may be purchased under the 2024 ESPP is 2.5 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531123532176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, compared to the same periods in 2023, the changes in our effective tax rates include the impact of changes in jurisdictional profit mix, including non-cash tax effects of changes in the value of our equity investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our effective tax rate for the six months ended June 30, 2024, also reflects the resolution of an uncertain tax matter during the first quarter of 2023 related to tax credits.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $25.0&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041146736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(156.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(105.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(105.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $51.4&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $27.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $117.7&#160;million, partially offset by a decrease in the fair value of Sangamo common stock of approximately $10.9&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the six months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $68.3&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $17.6&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the six months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $78.0&#160;million, partially offset by a decrease in the fair value of Sangamo and Ionis common stock of approximately $47.4&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">964.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata related accrued expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,472.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $556.7 million and $781.1 million as of June 30, 2024 and December 31, 2023, respectively, and included accrued income taxes totaling $191.7 million and $403.2 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029074416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 19:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative and Other Relationships</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">U.S.:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">Canada:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0&#160;million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUNSUMIO (mosunetuzumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for 30.0% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COLUMVI (glofitamab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 Roche announced that COLUMVI, in combination with chemotherapy GemOx (glofitamab-gxbm), demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma</span><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN and LUNSUMIO Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0&#160;million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $350.0&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was 35.0%.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0&#160;million of operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was 35.0%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023 we accrued a $31.0&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. As of December 31, 2023, we paid approximately $16.0 million of the $31.0&#160;million payable. The remaining portion was subsequently paid in January 2024. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the six months ended June 30, 2023.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEQEMBI (lecanemab) Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in Japan (September 2023), China (January 2024), South Korea (May 2024), Hong Kong (July 2024) and Israel (July 2024).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of LEQEMBI in the U.S., we began recognizing our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated statements of income, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s discussed above were approximately $10.3&#160;million and $1.4&#160;million as of June 30, 2024 and December 31, 2023, respectively. Amounts payable to Eisai related to the agreements discussed above were $171.8&#160;million and $118.4&#160;million as of June 30, 2024 and December 31, 2023, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD and potential treatment of MDD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. In July 2024 we and Sage announced that the Phase 2 KINETIC 2 dose-range study of BIIB124 did not meet its endpoints. Based on these results, we discontinued our further development of BIIB124 for the potential treatment in essential tremor.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. ZURZUVAE for PPD became commercially available in the U.S. during the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. The CRL stated that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies would be needed. We and Sage are continuing to seek feedback from the FDA and evaluating next steps.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. During the fourth quarter of 2023 we accrued a milestone payment due to Sage of $75.0&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, we recognized net profit-sharing expense of approximately $6.5 million and $11.5 million, respectively, to reflect Sage's 50.0% share of net collaboration results in the U.S. for ZURZUVAE for PPD, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease (LRRK2 Collaboration) and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transport Vehicle technology. In July 2024 we terminated our license with Denali for the ATV-enabled anti-amyloid beta program. This termination also results in the termination of the exclusive option agreement, as discussed above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2024, we recorded approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.6&#160;million and $2.8 million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2024 we accrued a $15.0 million milestone upon the FDA approval of OPUVIZ in the U.S., which was recognized in intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $165.0 million in additional development, regulatory and sales-based milestones. The timing of the commercial launch of OPUVIZ in the U.S. is subject to ongoing litigation involving our collaborator, Samsung Bioepis, in which the court has entered a preliminary injunction against us and Samsung Bioepis restraining the offer for sale or sale of OPUVIZ in the U.S.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million by August 2024, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024 we exercised our option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years. In connection with this exercise, we paid Samsung Bioepis an option exercise fee of $60.0&#160;million in July 2024.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June 30, 2024, we recognized net profit-sharing expense of approximately $55.9&#160;million and $116.5&#160;million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $56.9 million and $114.0 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufacturing, royalty and other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements di</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$19.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $9.9&#160;million as of June 30, 2024 and December 31, 2023, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$93.6&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$73.7&#160;million as of June 30, 2024 and December 31, 2023, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2023 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028356640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2007 we consolidated the results of Neurimmune as we determined we were the primary beneficiary because we had the power through the collaboration to direct the activities that most significantly impacted the entity's economic performance and we were required to fund 100.0% of the research and development costs incurred in support of the collaboration. The collaboration and license agreement with Neurimmune was for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023 we notified Neurimmune of our decision to terminate the Neurimmune Agreement. Subsequent to the termination, we reconsidered our relationship with Neurimmune and determined that we were no longer the primary beneficiary of the variable interest entity. As a result, we recorded a net gain on the deconsolidation of Neurimmune of approximately $3.0&#160;million, which was recorded in other (income) expense, net within our consolidated statements of income for the year ended December 31, 2023, included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024 and December 31, 2023, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $22.8 million and $16.4 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028369184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. If an estimate of the possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are defendants in three securities actions, one filed by Nadia Shash and Amjad Khan in November 2020 in the District Court and related to ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022 in the District Court and related to ADUHELM and one filed by Thomas Allen Gray in the U.S. District Court for the District of Colorado related to statements about our compliance controls, 2023 earnings guidance and other matters. All allege violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and members of the Board of Directors are named as defendants in three derivative actions, one filed by The Booth Family Trust in February 2022 in the District Court, one filed by Elaine Wang in July 2022 in the District Court and one filed by Jonathan Blaufarb in July 2024 in the U.S. District Court for the District of Colorado. The Booth and Wang actions relate to ADUHELM and other matters, and the Blaufarb action relates to statements about our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#167;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. The Booth and Wang actions are stayed.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Technical Boards of Appeal of the European Patent Office upheld the validity of Fresenius Kabi Deutschland GmbH's (Fresenius Kabi's) European Patent 3 145 488 (the EP '488 Patent), which expires in May 2035. In June 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of the EP &#8216;488 Patent. In March 2024 the D&#252;sseldorf Regional Court dismissed Fresenius Kabi's claim of infringement of the German counterpart of the EP '488 Patent and Fresenius Kabi has appealed to the Higher Regional Court of D&#252;sseldorf.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Former Convergence Shareholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $200.0 million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed suit against us in the High Court of Justice of England and Wales on one of the previously asserted claims, seeking payment of $49.9&#160;million, interest and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the District Court dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had alleged violations of the federal RICO Act and state laws. In December 2023 Humana appealed to the United States Court of Appeals for the First Circuit and the appeal is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California, alleging that it is owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs. We estimate that the royalties claimed total approximately $88.3&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lender Dispute</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2024, BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP filed suit against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement with Reata and seeking payment of approximately $23.2&#160;million, plus interest, costs and attorneys' fees.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received subpoenas from the SEC seeking information relating to ADUHELM and its launch. We have also received subpoenas from the DOJ and SEC seeking information relating to our business operations in several foreign countries. The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TYSABRI Biosimilar Patent Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 Mylan Ireland filed an action in the General Court of the European Union to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041182320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 583.6<span></span>
</td>
<td class="nump">$ 591.6<span></span>
</td>
<td class="nump">$ 977.0<span></span>
</td>
<td class="nump">$ 979.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029179776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041070768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD and we have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023 the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531040923488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,602.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of $172.50 per outstanding Reata common stock based on 38.3&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div>September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.847%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date<br/>(as adjusted)<br/>June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,259.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,200.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(300.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(916.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,719.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $4.9&#160;million, deferred tax liability by $4.1&#160;million and goodwill by $9.0&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531123495600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions from our 2023 Fit for Growth program and Reata Integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531123500320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,149.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,209.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">429.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,845.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">783.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">361.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">893.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">955.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,140.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,225.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,182.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,334.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">880.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">958.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,592.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,018.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,611.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,502.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,106.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,609.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,765.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(797.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,058.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(477.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(643.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">910.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:67.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">964.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028374768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,821.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,926.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,617.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,506.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,527.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,617.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531143225776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired and in-licensed rights and patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-22 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,515.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,595.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,919.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,180.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,440.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,739.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13-31 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,548.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,439.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,548.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,429.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,063.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,035.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,028.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,728.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,869.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,859.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,267.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,035.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,232.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,232.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,869.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,363.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">680.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,219.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,227.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028322608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,816.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,513.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,506.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan 364-day tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan three-year tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,718.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,747.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,721.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,018.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">969.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,448.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,292.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,137.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,788.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,448.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,292.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,287.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,938.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of June 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041142480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable equity securities, classified as available-for-sale:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">948.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(542.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(563.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.747%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041116288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,420.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,658.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock', window );">Derivative Instruments, Unrealized Gain (Loss)</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041175568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(147.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.372%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531123494080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">583.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531123546896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:42.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531123521056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029132352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(156.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(105.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(105.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $51.4&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $27.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $117.7&#160;million, partially offset by a decrease in the fair value of Sangamo common stock of approximately $10.9&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the six months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $68.3&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $17.6&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the six months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $78.0&#160;million, partially offset by a decrease in the fair value of Sangamo and Ionis common stock of approximately $47.4&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">964.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata related accrued expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,472.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041140256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text">Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock', window );">Summary of activity related to the UCB collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock', window );">Summary of Activity Related to Sage Therapeutics</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Sage Therapeutics</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to the UCB Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531032589824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030622992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553.8<span></span>
</td>
<td class="nump">$ 548.0<span></span>
</td>
<td class="nump">$ 1,135.3<span></span>
</td>
<td class="nump">$ 1,153.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,227.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,227.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,219.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(583.6)<span></span>
</td>
<td class="num">(593.3)<span></span>
</td>
<td class="num">(977.0)<span></span>
</td>
<td class="num">(980.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546.0<span></span>
</td>
<td class="nump">$ 592.7<span></span>
</td>
<td class="nump">1,088.2<span></span>
</td>
<td class="nump">$ 1,255.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards', window );">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 983.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,193.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,602.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate', window );">Fair Value Indefinite Lived Intangible Assets Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices', window );">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Fair Value Adjustment to Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Clinical Inventory | Fair Value Adjustment to Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Secured Debt | The Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 1,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Indefinite Lived Intangible Assets Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Businesses, Gross, Outstanding Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ClinicalInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ClinicalInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531245656592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Purchase Price Consideration (Details) - Reata Pharmaceuticals, Inc<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 6,602.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices', window );">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</a></td>
<td class="nump">590.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 7,193.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="nump">$ 172.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired', window );">Number of common stock shares acquired | shares</a></td>
<td class="nump">38.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number of Common Stock Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030787008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Preliminaty Purchase Price Allocation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,227.4<span></span>
</td>
<td class="nump">$ 6,219.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther', window );">Accrued expense and other(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Contingent payable to Blackstone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(916.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,719.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total assets acquired and liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,193.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther', window );">Adjustment, accrued expense and other</a></td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability', window );">Deferred tax liability</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill', window );">Adjustment, goodwill</a></td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531038834400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of priority review voucher, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 88.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">$ 103.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Equity Method Investment, Amount Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 437.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531038842624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 34.4<span></span>
</td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="nump">$ 44.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">46.3<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">$ 34.3<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">$ 41.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531034590944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Restructuring and Related Cost, Expected Cost Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Restructuring and Related Cost, Expected Cost Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction', window );">Expected operating expense reduction</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Expected number of positions eliminated | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities, Expected Operating Expense Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041091808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 34.4<span></span>
</td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="nump">$ 44.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531031730320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="nump">$ 44.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Costs | 2023 and 2022 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">$ 75.4<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payment</a></td>
<td class="num">(11.9)<span></span>
</td>
<td class="num">(42.2)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAdjustment', window );">Foreign currency and other adjustments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending</a></td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 45.5<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023And2022CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023And2022CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531042652960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,464.9<span></span>
</td>
<td class="nump">$ 2,456.0<span></span>
</td>
<td class="nump">$ 4,755.4<span></span>
</td>
<td class="nump">$ 4,919.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,899.6<span></span>
</td>
<td class="nump">1,845.8<span></span>
</td>
<td class="nump">3,611.5<span></span>
</td>
<td class="nump">3,609.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">846.7<span></span>
</td>
<td class="nump">801.0<span></span>
</td>
<td class="nump">1,592.8<span></span>
</td>
<td class="nump">1,502.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,052.9<span></span>
</td>
<td class="nump">1,044.8<span></span>
</td>
<td class="nump">2,018.7<span></span>
</td>
<td class="nump">2,106.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,149.8<span></span>
</td>
<td class="nump">1,209.3<span></span>
</td>
<td class="nump">2,225.7<span></span>
</td>
<td class="nump">2,334.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">582.4<span></span>
</td>
<td class="nump">636.7<span></span>
</td>
<td class="nump">1,085.6<span></span>
</td>
<td class="nump">1,182.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">567.4<span></span>
</td>
<td class="nump">572.6<span></span>
</td>
<td class="nump">1,140.1<span></span>
</td>
<td class="nump">1,151.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">418.0<span></span>
</td>
<td class="nump">400.4<span></span>
</td>
<td class="nump">799.8<span></span>
</td>
<td class="nump">783.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">188.3<span></span>
</td>
<td class="nump">196.8<span></span>
</td>
<td class="nump">337.9<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">229.7<span></span>
</td>
<td class="nump">203.6<span></span>
</td>
<td class="nump">461.9<span></span>
</td>
<td class="nump">418.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">252.2<span></span>
</td>
<td class="nump">254.2<span></span>
</td>
<td class="nump">506.5<span></span>
</td>
<td class="nump">528.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">44.1<span></span>
</td>
<td class="nump">66.5<span></span>
</td>
<td class="nump">87.8<span></span>
</td>
<td class="nump">141.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">208.1<span></span>
</td>
<td class="nump">187.7<span></span>
</td>
<td class="nump">418.7<span></span>
</td>
<td class="nump">387.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">165.8<span></span>
</td>
<td class="nump">146.2<span></span>
</td>
<td class="nump">293.3<span></span>
</td>
<td class="nump">254.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">144.2<span></span>
</td>
<td class="nump">130.3<span></span>
</td>
<td class="nump">250.1<span></span>
</td>
<td class="nump">223.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">250.9<span></span>
</td>
<td class="nump">302.4<span></span>
</td>
<td class="nump">494.5<span></span>
</td>
<td class="nump">548.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">145.4<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="nump">285.2<span></span>
</td>
<td class="nump">312.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">105.5<span></span>
</td>
<td class="nump">122.4<span></span>
</td>
<td class="nump">209.3<span></span>
</td>
<td class="nump">235.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">182.8<span></span>
</td>
<td class="nump">220.3<span></span>
</td>
<td class="nump">361.3<span></span>
</td>
<td class="nump">392.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">117.2<span></span>
</td>
<td class="nump">145.9<span></span>
</td>
<td class="nump">228.4<span></span>
</td>
<td class="nump">248.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">65.6<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
<td class="nump">132.9<span></span>
</td>
<td class="nump">144.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">68.1<span></span>
</td>
<td class="nump">82.1<span></span>
</td>
<td class="nump">133.2<span></span>
</td>
<td class="nump">155.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">34.1<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">39.9<span></span>
</td>
<td class="nump">48.0<span></span>
</td>
<td class="nump">76.4<span></span>
</td>
<td class="nump">91.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">462.2<span></span>
</td>
<td class="nump">483.1<span></span>
</td>
<td class="nump">893.5<span></span>
</td>
<td class="nump">955.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">248.7<span></span>
</td>
<td class="nump">259.9<span></span>
</td>
<td class="nump">462.5<span></span>
</td>
<td class="nump">505.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">213.5<span></span>
</td>
<td class="nump">223.2<span></span>
</td>
<td class="nump">431.0<span></span>
</td>
<td class="nump">450.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">37.9<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">37.9<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">534.1<span></span>
</td>
<td class="nump">438.0<span></span>
</td>
<td class="nump">958.0<span></span>
</td>
<td class="nump">881.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">237.5<span></span>
</td>
<td class="nump">156.7<span></span>
</td>
<td class="nump">463.4<span></span>
</td>
<td class="nump">303.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">296.6<span></span>
</td>
<td class="nump">281.3<span></span>
</td>
<td class="nump">494.6<span></span>
</td>
<td class="nump">577.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">429.1<span></span>
</td>
<td class="nump">437.1<span></span>
</td>
<td class="nump">770.4<span></span>
</td>
<td class="nump">880.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">157.3<span></span>
</td>
<td class="nump">155.8<span></span>
</td>
<td class="nump">305.8<span></span>
</td>
<td class="nump">302.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">271.8<span></span>
</td>
<td class="nump">281.3<span></span>
</td>
<td class="nump">464.6<span></span>
</td>
<td class="nump">577.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">Completed technology for SKYCLARYS (U.S.) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">75.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">Completed technology for SKYCLARYS (U.S.) | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">198.1<span></span>
</td>
<td class="nump">195.1<span></span>
</td>
<td class="nump">395.0<span></span>
</td>
<td class="nump">387.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">187.0<span></span>
</td>
<td class="nump">188.1<span></span>
</td>
<td class="nump">380.2<span></span>
</td>
<td class="nump">372.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">117.3<span></span>
</td>
<td class="nump">109.2<span></span>
</td>
<td class="nump">236.0<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">117.3<span></span>
</td>
<td class="nump">109.2<span></span>
</td>
<td class="nump">236.0<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">58.8<span></span>
</td>
<td class="nump">108.0<span></span>
</td>
<td class="nump">113.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">58.8<span></span>
</td>
<td class="nump">108.0<span></span>
</td>
<td class="nump">113.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">30.9<span></span>
</td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">30.9<span></span>
</td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_QALSODYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_QALSODYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BYOOVIZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TOFIDENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZURZUVAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531034836784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,062.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,765.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(9.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,058.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(643.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,116.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">173.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">399.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(260.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(155.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">162.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">857.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,355.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(27.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(797.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(477.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">910.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(11.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 43.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column E<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column D<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column C<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column C<br> -Subparagraph (2)<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column B<br> -Publisher SEC<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531141342384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,116.0<span></span>
</td>
<td class="nump">$ 1,062.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">151.5<span></span>
</td>
<td class="nump">135.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 964.5<span></span>
</td>
<td class="nump">$ 926.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531027599984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,464.9<span></span>
</td>
<td class="nump">$ 2,456.0<span></span>
</td>
<td class="nump">$ 4,755.4<span></span>
</td>
<td class="nump">$ 4,919.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">103.4<span></span>
</td>
<td class="nump">103.6<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
<td class="nump">216.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">444.5<span></span>
</td>
<td class="nump">433.4<span></span>
</td>
<td class="nump">838.5<span></span>
</td>
<td class="nump">832.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember', window );">Royalty Attributed To OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 336.3<span></span>
</td>
<td class="nump">$ 325.5<span></span>
</td>
<td class="nump">$ 639.0<span></span>
</td>
<td class="nump">$ 609.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531027607248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,464.9<span></span>
</td>
<td class="nump">$ 2,456.0<span></span>
</td>
<td class="nump">$ 4,755.4<span></span>
</td>
<td class="nump">$ 4,919.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember', window );">Contract manufacturing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">183.1<span></span>
</td>
<td class="nump">252.2<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="nump">53.2<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 120.8<span></span>
</td>
<td class="nump">$ 176.8<span></span>
</td>
<td class="nump">$ 305.4<span></span>
</td>
<td class="nump">$ 477.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531038991536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,464.9<span></span>
</td>
<td class="nump">$ 2,456.0<span></span>
</td>
<td class="nump">$ 4,755.4<span></span>
</td>
<td class="nump">$ 4,919.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">25.40%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">25.50%<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 120.8<span></span>
</td>
<td class="nump">$ 176.8<span></span>
</td>
<td class="nump">$ 305.4<span></span>
</td>
<td class="nump">$ 477.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNonControlingInterestRecognized', window );">Share of non-controling interest recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNonControlingInterestRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Non-Controling Interest Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNonControlingInterestRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030367760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 401.2<span></span>
</td>
<td class="nump">$ 426.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">1,821.2<span></span>
</td>
<td class="nump">1,926.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">395.0<span></span>
</td>
<td class="nump">255.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InventoryNetCurrentAndNoncurrent', window );">Inventory</a></td>
<td class="nump">2,617.4<span></span>
</td>
<td class="nump">2,609.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">2,506.1<span></span>
</td>
<td class="nump">2,527.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 111.3<span></span>
</td>
<td class="nump">$ 81.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Net Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531034834512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 583.6<span></span>
</td>
<td class="nump">$ 593.3<span></span>
</td>
<td class="nump">$ 977.0<span></span>
</td>
<td class="nump">$ 980.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">546.0<span></span>
</td>
<td class="nump">$ 592.7<span></span>
</td>
<td class="nump">1,088.2<span></span>
</td>
<td class="nump">$ 1,255.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Fair Value Adjustment to Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="num">$ (90.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (134.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531033981648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 14,063.9<span></span>
</td>
<td class="nump">$ 11,728.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,035.0)<span></span>
</td>
<td class="num">(5,869.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">8,028.9<span></span>
</td>
<td class="nump">5,859.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="nump">14,267.9<span></span>
</td>
<td class="nump">14,232.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">6,035.0<span></span>
</td>
<td class="nump">5,869.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">8,232.9<span></span>
</td>
<td class="nump">8,363.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">2,340.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember', window );">Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">10,515.3<span></span>
</td>
<td class="nump">8,180.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,595.9)<span></span>
</td>
<td class="num">(2,440.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">7,919.4<span></span>
</td>
<td class="nump">5,739.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 2,595.9<span></span>
</td>
<td class="nump">2,440.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 3,548.6<span></span>
</td>
<td class="nump">3,548.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,439.1)<span></span>
</td>
<td class="num">(3,429.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">109.5<span></span>
</td>
<td class="nump">119.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 3,439.1<span></span>
</td>
<td class="nump">$ 3,429.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531042570032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 86,900,000<span></span>
</td>
<td class="nump">$ 52,900,000<span></span>
</td>
<td class="nump">$ 165,200,000<span></span>
</td>
<td class="nump">$ 103,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife', window );">Weighted-Average remaining useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife', window );">Weighted-Average remaining useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_CompletedTechnologyMember', window );">Completed Technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_CompletedTechnologyMember', window );">Completed Technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">4,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_CompletedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_CompletedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028327936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2024 (remaining six months)</a></td>
<td class="nump">$ 185.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">565.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">660.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">680.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">710.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">$ 720.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041170336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Changes in Goodwill (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 6,219,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from Reata acquisition</a></td>
<td class="nump">9,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">6,227,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531034013968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 1,449.7<span></span>
</td>
<td class="nump">$ 610.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">302.7<span></span>
</td>
<td class="nump">416.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">38.5<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,816.1<span></span>
</td>
<td class="nump">1,506.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">302.7<span></span>
</td>
<td class="nump">416.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">302.7<span></span>
</td>
<td class="nump">416.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,449.7<span></span>
</td>
<td class="nump">610.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">38.5<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,513.4<span></span>
</td>
<td class="nump">660.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Current, Fair Value Disclosure,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041135584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531039078096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 5,448,900<span></span>
</td>
<td class="nump">$ 6,287,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">6,292,000<span></span>
</td>
<td class="nump">6,938,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,721,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,718,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">1,747,600<span></span>
</td>
<td class="nump">1,746,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,018,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">1,100,800<span></span>
</td>
<td class="nump">1,100,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,279,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,275,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">1,494,300<span></span>
</td>
<td class="nump">1,493,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">466,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">474,600<span></span>
</td>
<td class="nump">472,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">969,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">1,474,700<span></span>
</td>
<td class="nump">1,474,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_CurrentPortionOfNotesPayableAndTermLoanMember', window );">Current Portion Of Notes Payable And Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TermLoan2023ThreeYearTrancheMember', window );">2023 Term Loan Three-Year Tranche | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember', window );">Non-Current Portion Of Notes Payable And Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">5,448,900<span></span>
</td>
<td class="nump">6,137,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">$ 6,292,000<span></span>
</td>
<td class="nump">$ 6,788,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Line of Credit | Reata Pharmaceuticals, Inc | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember', window );">Credit Facility Floating Rate 364-Day Tranche | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_CurrentPortionOfNotesPayableAndTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_CurrentPortionOfNotesPayableAndTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TermLoan2023ThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TermLoan2023ThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029110208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,449.7<span></span>
</td>
<td class="nump">$ 610.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,449.7<span></span>
</td>
<td class="nump">$ 610.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531031183232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">$ 800.2<span></span>
</td>
<td class="nump">$ 979.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(497.5)<span></span>
</td>
<td class="num">(563.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">302.7<span></span>
</td>
<td class="nump">416.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">800.2<span></span>
</td>
<td class="nump">948.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(497.5)<span></span>
</td>
<td class="num">(542.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">$ 302.7<span></span>
</td>
<td class="nump">$ 406.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041147600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 1,275.5<span></span>
</td>
<td class="nump">$ 1,682.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041070768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 352.3<span></span>
</td>
<td class="nump">$ 460.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030434112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedGainOnDerivatives', window );">Unrealized Gain on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedLossOnDerivatives', window );">Unrealized Loss on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.5)<span></span>
</td>
<td class="num">(34.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized Gain (Loss) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="num">(34.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months', window );">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</a></td>
<td class="num">$ (5.7)<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="num">$ (30.0)<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 1,199.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,199.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,301.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,658.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,658.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">$ (2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,420.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,420.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">69.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 142.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Loss on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531027480528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 2,537.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,537.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,402.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">71.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.5<span></span>
</td>
<td class="nump">141.2<span></span>
</td>
<td class="nump">$ 126.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 3,249.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,249.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,309.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 728.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, Plant and Equipment, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 717.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531031704336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details Textual) - Reata Pharmaceuticals, Inc<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 121.2<span></span>
</td>
<td class="nump">$ 121.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531034519664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details) - Line of Credit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember', window );">Credit Facility Floating Rate 364-Day Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche | Floating Rate 364-Day Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember', window );">The Credit Facility, Terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Secured Debt | Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember', window );">2023 Term Loan | Floating Rate 364-Day Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths', window );">Repayments of Short-Term Debt, Maturing in More than Three Months</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember', window );">2023 Term Loan | 2023 Term Loan Three-Year Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=biib_FloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=biib_FloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=biib_TermLoan2023ThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=biib_TermLoan2023ThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531028981840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Repurchases (Details) - 2020 Share Repurchase Program - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531042498720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (160.5)<span></span>
</td>
<td class="num">$ (172.0)<span></span>
</td>
<td class="num">$ (153.7)<span></span>
</td>
<td class="num">$ (164.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(146.0)<span></span>
</td>
<td class="num">(172.8)<span></span>
</td>
<td class="num">(146.0)<span></span>
</td>
<td class="num">(172.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(146.0)<span></span>
</td>
<td class="num">(172.8)<span></span>
</td>
<td class="num">(146.0)<span></span>
</td>
<td class="num">(172.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="num">(25.0)<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">22.3<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">34.8<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(20.3)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(10.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(18.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(147.5)<span></span>
</td>
<td class="num">(141.1)<span></span>
</td>
<td class="num">(126.1)<span></span>
</td>
<td class="num">(163.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(153.1)<span></span>
</td>
<td class="num">(144.5)<span></span>
</td>
<td class="num">(153.1)<span></span>
</td>
<td class="num">(144.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(27.0)<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(27.0)<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (153.1)<span></span>
</td>
<td class="num">$ (144.5)<span></span>
</td>
<td class="num">$ (153.1)<span></span>
</td>
<td class="num">$ (144.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531040295776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">$ (85.2)<span></span>
</td>
<td class="nump">$ 121.2<span></span>
</td>
<td class="num">$ (178.9)<span></span>
</td>
<td class="nump">$ 51.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">115.1<span></span>
</td>
<td class="nump">114.8<span></span>
</td>
<td class="nump">186.5<span></span>
</td>
<td class="nump">165.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,464.9<span></span>
</td>
<td class="nump">2,456.0<span></span>
</td>
<td class="nump">4,755.4<span></span>
</td>
<td class="nump">4,919.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 583.6<span></span>
</td>
<td class="nump">591.6<span></span>
</td>
<td class="nump">$ 977.0<span></span>
</td>
<td class="nump">979.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">$ (4.9)<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="num">$ (7.0)<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030812624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 583.6<span></span>
</td>
<td class="nump">$ 591.6<span></span>
</td>
<td class="nump">$ 977.0<span></span>
</td>
<td class="nump">$ 979.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">145,600<span></span>
</td>
<td class="nump">144,700<span></span>
</td>
<td class="nump">145,400<span></span>
</td>
<td class="nump">144,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">145,900<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
<td class="nump">145,900<span></span>
</td>
<td class="nump">145,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030642496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (72.9)<span></span>
</td>
<td class="num">$ (74.1)<span></span>
</td>
<td class="num">$ (149.0)<span></span>
</td>
<td class="num">$ (153.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
<td class="nump">76.3<span></span>
</td>
<td class="nump">144.3<span></span>
</td>
<td class="nump">157.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="num">(5.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
<td class="nump">73.7<span></span>
</td>
<td class="nump">138.7<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
<td class="num">(13.3)<span></span>
</td>
<td class="num">(26.3)<span></span>
</td>
<td class="num">(28.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553.8<span></span>
</td>
<td class="nump">548.0<span></span>
</td>
<td class="nump">1,135.3<span></span>
</td>
<td class="nump">1,153.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 393.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, General and Administrative Expense</a></td>
<td class="nump">196.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="nump">$ 197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">54.7<span></span>
</td>
<td class="nump">59.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.6<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
<td class="nump">98.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.2<span></span>
</td>
<td class="nump">$ 60.4<span></span>
</td>
<td class="nump">$ 112.4<span></span>
</td>
<td class="nump">$ 123.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531038991120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (72.9)<span></span>
</td>
<td class="num">$ (74.1)<span></span>
</td>
<td class="num">$ (149.0)<span></span>
</td>
<td class="num">$ (153.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">72.9<span></span>
</td>
<td class="nump">76.3<span></span>
</td>
<td class="nump">144.3<span></span>
</td>
<td class="nump">157.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="num">(5.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">70.6<span></span>
</td>
<td class="nump">73.7<span></span>
</td>
<td class="nump">138.7<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">58.3<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="nump">115.6<span></span>
</td>
<td class="nump">121.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">22.2<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041186816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments - Narrative (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plans (in shares)</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_OmnibusEquityPlan2024Member', window );">Omnibus Equity Plan 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based compensation arrangement, authorized (in shares)</a></td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatioOfNumberOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio Of Number Of Shares Reserved Under Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatioOfNumberOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_OmnibusEquityPlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_OmnibusEquityPlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029168032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030579920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(5.20%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">GILTI</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.20%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030525920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (20.1)<span></span>
</td>
<td class="num">$ (75.9)<span></span>
</td>
<td class="num">$ (37.5)<span></span>
</td>
<td class="num">$ (156.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">61.3<span></span>
</td>
<td class="nump">49.1<span></span>
</td>
<td class="nump">130.5<span></span>
</td>
<td class="nump">111.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">(Gains) losses on investments, net</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="num">(105.4)<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
<td class="num">(27.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (gains) losses, net</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">85.2<span></span>
</td>
<td class="num">(121.2)<span></span>
</td>
<td class="nump">178.9<span></span>
</td>
<td class="num">(51.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains) losses recognized on equity securities</a></td>
<td class="nump">30.4<span></span>
</td>
<td class="num">(106.5)<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="num">(28.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains) losses realized on equity securities</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="num">(105.8)<span></span>
</td>
<td class="nump">55.5<span></span>
</td>
<td class="num">(29.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,116.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,062.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">228.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">319.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">193.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Reata related accrued expense</a></td>
<td class="nump">77.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">689.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">2,472.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,472.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,623.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">$ 117.7<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">$ 78.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 964.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 964.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 926.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030145376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.8<span></span>
</td>
<td class="num">$ (105.8)<span></span>
</td>
<td class="nump">$ 55.5<span></span>
</td>
<td class="num">$ (29.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains (losses) realized during the period on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 781.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 6,602.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">117.7<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030188624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - OCREVUS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage', window );">Royalty operating profit threshold for highest royalty rate percentage</a></td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Collaboration agreement term</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MosunetuzumabMember', window );">Mosunetuzumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfFutureDevelopmentCosts', window );">Percentage of future development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfFutureDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Future Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfFutureDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period Of Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty operating profit threshold for highest royalty rate percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MosunetuzumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MosunetuzumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030310640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Profit Sharing (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of co promotion operating profits first fifty million</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">Until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">Until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales trigger gross sales threshold</a></td>
<td class="nump">$ 350.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029087792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Eisai (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsMadeToTerminationAgreement', window );">Payments Made To Termination Agreement</a></td>
<td class="nump">$ 16.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccruedPaymentToTerminationAgreement', window );">Payable Due To Termination Agreement</a></td>
<td class="nump">$ 31.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedPaymentToTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Payment To Termination Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedPaymentToTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsMadeToTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Made To Termination Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsMadeToTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531142175536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details) - E2609 and BAN2401 - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</a></td>
<td class="nump">$ 90.6<span></span>
</td>
<td class="nump">$ 86.2<span></span>
</td>
<td class="nump">$ 177.9<span></span>
</td>
<td class="nump">$ 194.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">45.4<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">89.0<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">68.9<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">155.8<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 137.7<span></span>
</td>
<td class="nump">$ 17.1<span></span>
</td>
<td class="nump">$ 311.6<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531158240176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">$ 44.4<span></span>
</td>
<td class="nump">$ 36.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccountsReceivableFromCollaborator', window );">Amounts receivable</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccountsPayableToCollaborator', window );">Amounts payable</a></td>
<td class="nump">$ 171.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccountsPayableToCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, To Collaborator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccountsPayableToCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccountsReceivableFromCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, From Collaborator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccountsReceivableFromCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531041049808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 553.8<span></span>
</td>
<td class="nump">$ 548.0<span></span>
</td>
<td class="nump">$ 1,135.3<span></span>
</td>
<td class="nump">$ 1,153.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNonControlingInterestRecognized', window );">Share of non-controling interest recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNonControlingInterestRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Non-Controling Interest Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNonControlingInterestRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029109680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details) - Research and development - UCB Pharma S.A. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="nump">$ 14.3<span></span>
</td>
<td class="nump">$ 33.1<span></span>
</td>
<td class="nump">$ 32.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="nump">$ 16.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531031850192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNetProfitFromSageTherapeuticsPercent', window );">Share of net profit from sage therapeutics, Percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">$ 62.4<span></span>
</td>
<td class="nump">$ 56.9<span></span>
</td>
<td class="nump">$ 128.0<span></span>
</td>
<td class="nump">$ 114.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">52.1<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="nump">98.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="nump">$ 27.3<span></span>
</td>
<td class="nump">$ 49.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNetProfitFromSageTherapeuticsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Net Profit From Sage Therapeutics, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNetProfitFromSageTherapeuticsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531032019472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details) - Research and development - Denali Therapeutics - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="nump">$ 22.1<span></span>
</td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="nump">$ 38.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">$ 13.2<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="nump">$ 23.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531027128176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Other Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 513.9<span></span>
</td>
<td class="nump">$ 584.2<span></span>
</td>
<td class="nump">$ 966.8<span></span>
</td>
<td class="nump">$ 1,154.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531038727120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Samsung Bioepis (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.4<span></span>
</td>
<td class="nump">$ 56.9<span></span>
</td>
<td class="nump">$ 128.0<span></span>
</td>
<td class="nump">$ 114.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
<td class="nump">$ 56.9<span></span>
</td>
<td class="nump">$ 116.5<span></span>
</td>
<td class="nump">$ 114.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContingentCommercializedRightsNumberOfProducts', window );">Contingent Commercialized Rights, Number Of Products | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share percentage</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccruedMilestonePayments', window );">Accrued milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementTermExtension', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementContractOptionExerciseFeePaid', window );">Option exercise fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementContractOptionExerciseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contract Option Exercise Fee Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementContractOptionExerciseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementTermExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementTermExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentCommercializedRightsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Commercialized Rights, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentCommercializedRightsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531030780224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 22.8<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Deconsolidation, gain (loss), amount</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140531029954032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.9<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_GenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_LenderDisputeMember', window );">Lender Dispute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="nump">$ 23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_LenderDisputeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_LenderDisputeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>128
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MF*@!ZO<]Y_+UHA[@_-+5ZK]02P,$%     @ 9X$!6042>MU\!   31(  !@
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MS"!*%S:.@JXL!EC8;!F.=?%>=/$NI@OC\)@IP>%XPC8 5@1V.G5V9:U<Z%M
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MY*AZ5E83<@6L4.<HY\HD.="T4.)&6J\:S*@3C0.SY' O.;2// AF*LWG*.-
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M[0?<Z?$!YDH8_X5M:SLFX[PQ5E4[,$50<=G^V>,N#WN >/@"(-D!DM\%#':
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M!;?P61G3@ZS1KCR.Y:1U-/:.7!_9I$F?#GJS+_68S:BS>:9@V"D8GE0PIQ:
M%%0!=&_RAQ[43,.&B0;AG JV4$(P;:!&:F,EU?;%L=A;%W&T%UC4CZ+X(/R3
MD?SE28TZG:.3.C-55527_R"RY8_C Y'1Z$#ER3C^5&6XUZ;<$W'+])I+ P)7
M1!_UWY(WW;;==F)5[3O74EGJ@WY8TDN%VAG0_DHI^S1QS;![^])?4$L#!!0
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M[$#( LQ%H>QO]'BPC0<HWRDM-H?!@&##R^HO?3H$HC4 _/@'X,, ?#P@[1E
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M[HMO5X<IOG&6:KEDE:(?U_?[(Z^/.:N*O%95]E0+K$IKW75 XUK[YPG@G">
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MM2N7M5 '#D43!=$Z<)[A/I%]-QE4"P7Z-6Q0V@)*BZ T J51*(UYBF?75%<
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M_'BT1;\F37]83] )@O59J9]NQI]N;@?#S6*OKDY9S#)"56)\!?*FI@W^TD7
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M2]G?+65PE@+KDFK-P$#$QR=3/^PDMFQ\P3JQ95X<BD0WS>Q<M^W %+WK5%$
M\:J^BMC%M(WNP+:&]!<+$+H!Q/M=Z7R@A(MLVU-D9+(UY3A>=&.F2/VI#-;
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M=XEZM:N&'&4M.;,$)^BZ*^[26O:_U1&^4[;A_JD,>6Q\_8.F6MZU<ZOIZF6
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M4S6+R60QWH;K8-7;[:EZW0)Q1=,P?I-2=HC),;ST!0#LTJ=,CD:%7\G4TW/
M]W54LYB.9N>OP$0^^6JR!6C"E8/&S^>H6JZWW>0U)=781%#9NJ(2?,-AWJNG
MJ2Y^+LY&L\D$TU]7)T")C#+R06ZZ58*+V6C.8P%)QA(,DA74@[@W;4;"3OG7
M3\,R.%:[XHQ_3.6CISQA7]/9=#PC[5A"V\B).X>C%/-L.@&9?PY^NVBH+&/E
M/9M"6:^>4QJG63GJPT_PO/>%S+X"SE%T/V/1:73(0P#IY+P;O\"KZ<7X_/F.
MC'U8Q'K3\<OG89/[XV"$8AS*F]%</G,B$T*\I6:YZ,<P\&+T8@KQQ;\9DS_
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M#37!#!N<*QITJTNV2%7TT!?FH6O'&7Y_4? Q=@C7J,F\*O2C*'UWW9?5/[5
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M8?)-Y%3%)K3X NM(!^'4+*,I_16 7 =@PW2_W([$S2^_LHJN5Y>_CE$\I>6
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M*FC[DFC;1-:S,41*6N;JK/?CH']Z)Z2/D5: MRYQ;Y$H-A''/+-FH9^6*I]
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M98T8V8L SBN'8(</,;!]I:[^!E!+ P04    " !G@0%9-"]&P6X(  !,%P
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6S=6&MSVS86_2L8U9.Q9VB*
MI)Y.;,_XD72]?:S'3MKI[.P'B(0D;$E" 4#)ZJ_ON0!)4;'L:=KNE_V0&(2
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MI0?<9?$PB,:#\(P=CX-H, JC$Y@9)5/,Q'$PP6#*CD?!='P63D]@ZW1T%D:
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MPX:09U7(Q>.0PS0C*=$0"B,4U5D8TB3SI^ Z8 YF6T!0YP$J0J$-22Y@*6Q
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MCOKLT@ &$>PY!*0,2P?LYY^.!O'@';M=2$N!!K2R>'\0[=<[5USQ5*+)A+[
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M2EE<5?QCCKLA:6> ]YE2=K]P ;K;YNP?4$L#!!0    ( &>! 5F>)*9PY@,
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M/V0$Z/M""-UTS 3MC=;D+U!+ P04    " !G@0%9C&#6*F(#  ":!P  &0
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MU2P"T[\$_<'I-DS?G78TR\.VIL<3C6>@^U)38@X'KV!XCM?_ E!+ P04
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MYH0,Y'@ WB^M#=T-+[#]JGGU;U!+ P04    " !G@0%9AJ:W=M8%  "$#0
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M,0,B2WEB#1K#-;TE:UD18'SO= ZV)EFP/]]H_R"^PY>YCO36VR^F2.7QX/5
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M7^T/5&CO_.U#\K7<L^<^X=8NTQ*?211X ]XOO$^;!S:P_? Z^1]02P,$%
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M$SXJA(G3E7_(C[5SNO3#&7!L9^D [D\T]J?-A 2LONR<_ U02P,$%     @
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MFN$KOM!N9!F.$VUMA;1I1S)MI!<4PN"8V,Q05;63ANR"%BA39.Q$H8KU4D
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MB5]?7S)'7U-;MLH)P*\M*>].3QY; N#2EE#3J18%2+ZWT;X[:#VN-/#DPD]
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M!=6;U2YH.498.2(MGKZ<.C39Y^MY+IC:7@?NPP]8NBS&AAIL[*%CE3'#[F/
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M!5[^>Y]-PI8[]V]),?3<E3)1KS80)$[9&[7Q^K=?MO<&+QXXT$YSH)V'I/_
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M@>F3#1<%5GHKMJXL!>#,@@KJ^IXW= M,F!-'UK82<<0K10F#E4"R*@HL'F=
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M5_W3J)F&0*W&WNE8Y<Z7$SC+4?2F)H;78!15.E4"RDIU/NK( IN5WL55A!-
M&36QOBB5SG./@\1R,R"I9/U&Y[T.M-@-1VM?9]$ZCCU97A-,V(P.D>MRYA(W
MY2SJ)7_.#!#.__4O[PX/WKXOZJ/P\1)=98#@[^A!)]!^"O2&;TQFX P5:7B
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M4=H+F]J$ !A?!68A$K\#.VU4 Q A[W'_HG_5.R/K9<J4.H-4DY<M&61_I*T
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M'ND&7)\XV"1\H0V:EWL__3]02P,$%     @ 9X$!624U04CU!   O@H  !D
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MC@P5MJFW$\57II&><X5MN1F6^!T$0@O@_PO.U6:B-W!?5I._ %!+ P04
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M_AI+0^ME/NZ%>NK,U"SG%Q-L&L/UGD]6;UZ%:?#V2 SS/H;Y,>O#VV,.]AC
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MJ(J#'[M)M^MBRUA5NQ5MK2PN?([<X8;--1W [QNE[ -##OJ=??4/4$L#!!0
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M*'A/XLCW_"<:W>CNN B\Z6-@]#O_.D#'_0#M=QYC+O%36/&@=03X,/5M##K
MKXFW*-B*HZV!]5HOS4/G7;.6O/4V>;:4"1LH@7,[>VOZ@%%)\N;93:'P U;7
M4/)T6B"(L(WG 5#2].TZ/K@ MF4:SXZ^)E9#B ,9/U6>-S8)>M#N&JI ":J'
M# B'=G]6!0?R!FJWE1TR^Y9U-6Z81Z!H(S3/.?; :?T33(HGT%\&/21U";F+
MIQK-R1?(.Q(-L8*HI;:+P RP"Q1KNZDYQ(Z-(J%ER7.*4!=<4)%Q@*,-#%@2
M\/94"$E7(22OK1"L)]:G[ ,ZM-OTG,W1,*AR&KORKOI@_SJW:U<_74"O/;F]
MRK#=,2P(+NR1'O:KA:%]X>X$]J"FF(8E%!^0)KM.VM?1HV7<LS7"S=Y9RP"U
M5+AOAT[^%FH#<B&!#*(T_I#3!P)I*> 2M)%H/8I/,*O7SRV="%% B&C,*DMS
MZ#$L/TB)2VQSFE/B_K_T2.HYB*90C'UX8%1U*+=5)CXJ<_^QYR?^6W+#!(>L
M^&*!89K?L-HX-P:)=6,"-#:&PVN,SW@,I +/,/#L>)Q"/_3"G:HNP6%V*R*P
M8QB.$Z!"J%*FL1?9_M0^XVD$U)AX<&=\!9P8E_4!S@2> 5B"3W\RM?"P#S6-
M%^R'D_ADFK:+CV,KZ0-/^6T_ @V[#?K$YJK!I')8DH#$:>J%!*52H+J);8>
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MH$OS(Y!/@,J!]_,V,XA?E>-MOKZE\_Y7.K/MH/]:6TNEOFWHZC[)2UZW,+J
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MFE^$4(,UDY/:7\J&+/^5;$>K.V&UU#L'+5K8U,(BO'L46X7N_2(A=N#5DN(
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M<4^R*FF[+1(OC559N1@TR+@LWO2V],-C%OCE M_I70AR6KZDEHX.M5H1C=3
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MO$4<IL7_Y+G<=SP@BUV:Q9NRL*C!)HCV?_VOY1=1*Z#K;Q30RP)ZHX Q?:.
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MA[X20\)L),R9MD1AF4U]3=O=VUP?-I1#IRWE:./9K-8.[ 76AFFZ90VMAL!
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MS-^R-#<0GS\D"7]YDSLX'H9>_0]02P,$%     @ 9X$!630J6)Q#!@  \3P
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MZ+N#T;^'KSDJF#+Z;B\8YSRR%]WX*\Q\UW2["5"Q>;U?IDJSH)OT>'A5)^=
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MU_03O3][RVYQW'/MX/D'Q1DLCF"X(!6.0%2C.5P55CM"<0:+(Q@N2)2C'17
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M!B\^4#8 ]U=2FJ>)[:W=59K] 5!+ P04    " !G@0%9P5_" D($  #R%0
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M9E?LN&AQP5B\<++);]#N"><DS1_7@!= I8'X?4D(W[_( -4U[^A_4$L#!!0
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M,U@FLCV4VHD6=;.OSX6&4Z(9KN$<)]($P/.E$/IE8HZ*_I]!\0=02P,$%
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M;0/%N9 LJ\&J!QFAU2^^KX5H 11/-\"M >XI8/ 3@%<#O.=F&-2 P7,S^#7
M?RY@6 .&I?:56*72 99X/N5LCW@1K=B*B]*N$JT$)K286;>2JZ=$X>3\DNZ
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MP-?E@:E ,<NIK,Y2FM;F4/:B/(H\:5\XYTNGHSUPSL/JR/61OCH!OL)\3:A
M*:Q4*ML<J0T,KPY5JQO)MN4AX!V3DF7EY09P KP(4,]7C,G#39&@.=J>_P=0
M2P,$%     @ 9X$!6?" GY@Q!@  'RD  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C,N>&ULM9K1;MLV%(9?A?"*(0$:6R(E6^X< VG2=AF:(6C6[:+8A2+3
M-E%)=$G:3H8]_"A9%46+HN>4ODFLY)S?/P\/I8^2)EO*OO(EQ@(\96G.+WM+
M(59O!@.>+'$6\SY=X5S^9TY9%@MYR!8#OF(XGI5)63J GC<<9#')>]-)^;=[
M-IW0M4A)CN\9X.LLB]GS6YS2[67/[WW_PR>R6(KB#X/I9!4O\ ,6GU?W3!X-
M:I49R7#."<T!P_/+WI7_YCH(BH0RXD^"M[SQ&11#>:3T:W%P.[OL>84CG.)$
M%!*Q_+7!USA-"R7IXULEVJN_LTAL?OZN_KX<O!S,8\SQ-4W_(C.QO.Q%/3##
M\WB=BD]T^RNN!A06>@E->?D3;*M8KP>2-1<TJY*E@XSDN]_Q4U6(1H(?="3
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M__FY<>1V+;A+-8[2FOG242K0@<Y IU@'\5/G.G"*/*[4]%O9"GG0CR#/P76
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M,"L"Y/_GE(KO!\4[<O4[D=/_ %!+ P04    " !G@0%9IXY$=ET'  ![2
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M2,J/<QY,>%9LH+Z?"B&?%XH$Z_<-C?X'4$L#!!0    ( &>! 5F8*Q#(@ (
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MA-*BVU';"E:5S7A;*4O#LEGF]#JA=@ITOE;*[@3GH'OOXK]02P,$%     @
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M3]G3G[P.*"CU%EE25'_)4VWKC,AB4XAL50^6'JSB=/<_^EXGHC& ^D<&N/4
MM^\ KQ[@]1W@UP/\*C.[4*H\L$A$\\L\>R)Y:2W5R@=5,JO1,OPX+8_[K<CE
MN[$<)^9OHS@G7Z)DP\D''A6;G,N#*@KRDG$1Q4GQBOQ&/M\R\O+%*_*"Q"GY
M$">)/&#%Y43(Z4N1R:*>ZLUN*O?(5']MTC'QG#/B.JYO&'X-#V=\(8?3:KAG
M&,[@X1^B?#_<U8=/9,[VB7/WB7,K/>^(WNNBX**X,*5A-] W#RP+^:)81PM^
M-9*56O!\RT?S7W^AH?.[*2F88@Q)3$N8MT^8!ZG+XY?'VZBL<K+(4I'+BC>>
M1#N5L%(IKUK;.1U/+R?;9E+ F88F!4E,2XJ_3XH/)N4V6A6;])&\B3.^CHWY
M  6&GDV88@Q)3$M<L$]< );?^SBZBY-8Q-Q<@P%FUC#%&)*8EK5PG[40/-W^
M^+:)Q?,9R9Y2GA?+>"VOZ(++>80IASLMZC5*T1G[L]E!,8)3#LU.YYQ:W.?[
MN,_!N-6GW)G^,?>)+S9Y'J>/IOA!S:'G$*880Q+3<CG=YW)J^\$WQ4P8IAA#
M$M,2-MLG; :>?-=1L21<5MXV2LJ3SI2Y6?M#S_=GX_.#4FN;A=0YM&*@.Y;!
M4D<!I0.&*T'KJV3'NX1708MG4I1%5EVJC="XDYLV@O(<MQ6ZP<RGX2$9,-@Y
MV^ ;-$U1(*>6:4;C>F/_,.:V%:7CV6'(H$NV(2L.IB USF^22+9OU46!R#ZT
M;+IXGO-[F8"5[$Z+J.SOC#EPVP=^.@X.<V"P.C^T8K"/MCE0:$MAMOTG$U%B
MC-%K'\&I/&WI890&N\ )V\?Z%+!*%:U2_Z>HBZ+"*JH:PU+34Z=XE8)@U__*
M$!C.F'%X>+ZTK3QZ:,5@EVQ#5K!)8=H\7A5AKQC;5J88D?!3CU&!)?U9LB3_
MD1Y='CS-X,I!I4TL-3W%BC>I-7!25.)$56-8:GK6%'12F#H_BB7/27D.RM.Q
M_GP^(SE?<'D9DG!F3"<2.=;IW*D%36+SG,/R/06LN@I671A6_]YD0J+*31XO
M>%$N;[ZNUJ')#F(+\O(]W_*$T%>RBNV:2-B!P:N!F&H,2TU/OH)EEUHOH2(Q
M;9TU3#6&I:9GK;'N#/-VGW:REFB6WD'A77>;,-@1VT 55+LP5 ]M)-TV0YL:
M28.9J9&$G;,-7I&V"R\,]\7%6@8\TITF#';&-EC%QB[,QM8M9*T+1M]IPF#O
M;*-7F.S"F-S[4(?=P:*NQ6*IZ7E1:.W":'VT?:C'=19ZV\Q8Z*>@6U?1K0O3
M;5=+[:(B+JH:PU+34Z<0UX41MW?AM$&T53B=)@QVQO;FJ2)5#R;5H]50CX.B
MZS9A\.RVT2D4].!U4UP.[]=RPRX-K2Q4-8:EIA\.Q9B>]>8&#W5W ZH:PU+3
ML];8X  #JTW+#4L.3J?77>BGX%I/<:W7L>$A?DSCAW@1R0SM\O7QKIREPOQW
MZ7JCBMVU;[IA)P9G%74=&DM-/P"*M3UXXP14VJB;)E#5&)::GC7%Z![,Z'V:
M;L^PJFVZB6NP,]W%A3VRC5C1MP?3]]#NNY8#,:33A,%.V0:M8-P#B;7_'K5I
MG]NW!BO#[5O8)=N0%41[,$1;]]ZU;L?M6Y-5^_8M[*/M'CS%UC[,UGT/N]_>
M@]#>FPC/-7B/W2FXW%=<[L-<?K3K\ U;$P+:K@&#71@ZA_>_&>R&;9B*=WV8
M=[N:<!\5>E'5&)::GCH%O3[.ME[?M!.B=<_78&6XYPN[9!MR8\\NS+#'B\+O
M%6/;RA3C*3#15YCHPTNR^)S>KRF'W1I<::@,BJ6F'Q+%H'YH2^X^YKKO-:H:
MPU+3LZ8XUH<YUJ8IAR4'I[,;>[$FU'.DL->'L;=9[)_3[%BA>_8-.>S X(RB
MKF)CJ>G)5P#NSZS+&G4_!JH:PU+3O_VAD#V D;U/0QYTKXQWFS#8$=M %8$'
M,($/[<-K.3#H3A,&.V4;M.+Q -[CT!<J@^Y]#MTF#';&-EA%T %,T-8=>-"Y
MVGO=;<)@[VRC5S =X&QT"+HW.L S#?Z>UBD /&A\OPT&\*--1M"]Y\%@TMYY
M!\]O&Y^BV0"FV<XO\*$B+:H:PU+34Z>0-H"1MG?)="_)=ILPV!G;8!6;!C";
M'J^#W;AS*+II=W2G@+] P5\ K[[BDG>_%AMV:7!EH5(EEIK^[5A%E:%CR^(A
MZCY>5#6&I:9G32%J"".J38L-2PY.)VU="]H?>%A3[K(T:?SF1OD+*9+3'^.T
M( E_D/+.^%Q>=?+=CX[LGHAL7?T,QUTF1+:J'BYY=,_STD"^_Y!EXL>3\I<]
M]C_],O\?4$L#!!0    ( &>! 5GJ *5X4 (  ,0%   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8X+GAM;*U4;6_3,!#^*U9 :)-@SI)N0R.-M+5,%%&IVMCX
M@/C@)M?&FE^"?6G'O\=VTM!)68407V+?^9[G[K%SEVVU>;05 )(G*90=1Q5B
M?4FI+2J0S)[H&I0[66DC&3K3K*FM#; R@*2@21R?4\FXBO(L^!8FSW2#@BM8
M&&(;*9GY=0U";\?1:;1SW/)UA=Y!\ZQF:[@#O*\7QEFT9RFY!&6Y5L3 :AQ=
MG5Y.1CX^!#QPV-J]/?%*EEH_>F-6CJ/8%P0""O0,S"T;F( 0GLB5\;/CC/J4
M'KB_W['?!.U.RY)9F&CQC9=8C:/W$2EAQ1J!MWK["3H]9YZOT,*&+]FVL6=)
M1(K&HI8=V%4@N6I7]M3=PQ[ \0P#D@Z0_"T@[0!I$-I6%F1-&;(\,WI+C(]V
M;'X3[B:@G1JN_"O>H7&GW.$POV'<D <F&B!S8+8QX)X(+3F: C(N+/D*3]@P
M<4S>D?N[*3EZ?9Q1=(D]G!9=DNLV2?)"DI3,M<+*DH^JA'( /SF,/S^ ITYP
MKSK9J;Y.#A)^;M0)2>.W)(F3T5 ]_PQ_5D[:/T(:^-(7^*:P1#)3%DWC;Y]\
M_^("R Q!VA]#M]VRC8;9?-]?VIH5,(Y<8ULP&XCR-Z].S^,/0U+_$]DSX:->
M^.@0>WYEK1M47-;N+PS*BXJ9-=@AT2W316#RLVF3QQG=["LY%-&61_<:18++
MY.>')85N%+8]TWO[$745.I/^"6_GV]P5RI4E E8.&I]<N'XU[<QH#=1U:+NE
M1M?$85NY,0O&![CSE=:X,WR"?G#GOP%02P,$%     @ 9X$!66JY[(O,"
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MILK7S1,@'_*JRE?-RX44<UG4#=3WCWE>O;VI'RJY>^KHY/]02P,$%     @
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M<Z%-GW3#PKQD*&V V5\(H;<3FZ!]&],_4$L#!!0    ( &>! 5F_M.3Q; (
M #L&   9    >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;*U546_3,!#^*R<S
MH4V")DVR@D8;:6LU4<3$M#%X0#QXZ;6QYMB9[;1#XL=S=K+0B7;B82^-?;[O
M\WV?[>MXH\V=+1$=/%12V0DKG:M/HL@6)5;<#G2-BE:6VE3<T=2L(EL;Y(L
MJF24Q/$HJKA0+!^'V*7)Q[IQ4BB\-&";JN+FUQE*O9FP(7L,7(E5Z7P@RL<U
M7^$UNIOZTM LZED6HD)EA59@<#EAI\.3:>;S0\(W@1N[-0:OY%;K.S^9+R8L
M]@6AQ,)Y!DZ?-4Y12D]$9=QWG*S?T@.WQX_LYT$[:;GE%J=:?A<+5T[8>P8+
M7/)&NBN]^8B=GF//5VAIPR]LNMR80=%8IZL.3!540K5?_M#YL 489GL 20=(
M_A>0=H T"&TK"[)FW/%\;/0&C,\F-C\(W@0TJ1'*G^*U,[0J".?R<Z&X*@27
M,%?6F88.R%G8'3V<H>-"6OB*#ZZAQ>0(WL+-]0P.#X[@ (2""R$EG8X=1XZ*
M\UM$15?(65M(LJ>03XT:0!J_@21.LAWPZ?/P&18$'P9X^A0>D26]+TGO2Q+X
MLCU\7UR)!I1616,,J0=N+9('OX&RN,.5*,B;-5H7O-FE]]D-_.L\L34O<,+H
M^5DT:V3YZU?#4?QAE_H7(GOB1=I[D0;V=(\79XVEB+5P6MPWPHKP_GY\IAC,
M'5;VYR[UZ4NJ?R&R)^JS7GWV[$WX>]ZB/V^HM7%+35=]E_26;Q3X?!==Y^EQ
M,J!;N=[6]&]6-HH'[_JLMMAHZVG[MGK!S4HH"Q*7A*/\8P:F;57MQ.DZO/9;
M[:AWA&%)W1V-3Z#UI=;N<>(;2/]_D?\!4$L#!!0    ( &>! 5GIG@F(L@L
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MF_*-F>.OQU?DWA0OAC5^O\57*PS\[N(KKWP!KH8OW\?[X&?;?/L_HAN12M@
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M@?A]3BE_NBD*V)X@G/X/4$L#!!0    ( &>! 5E R+B3: 0  &X6   9
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M5]MW@DGR<%>&<4T?:9SMBR&WF803QBA')/QVB')I]>T&CU>IV)T- PJY1/=
M:3XH+8"B]0/:KNZQ>GE_*J#2R(&N]T%I'BC-!Z4%4+1^B-LJ!';>>D8%6JL
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MOI\R@XRVSD;9 J-LV!1;-ZI-ZXQ&F[@WE9F*LONV9MXK,QH0ZM>B0 ,:?'?
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M33*4S+9TCHIV%MI(YFAJEJ'-#;*T=)(BC-KM?B@95T$\*M=F)A[IP@FN<&;
M%E(RLYFBT.MQT FV"[=\F3F_$,:CG"WQ#MVG?&9H%C8H*9>H+-<*#"[&P:1S
M/AUZ^]+@,\>UW1F#5S+7^MY/KM-QT/:$4&#B/ *CWPHO4 @/1#0>:LR@">D=
M=\=;]#>E=M(R9Q8OM/C"4Y>-@V$ *2Y8(=RM7K_%6D_/XR5:V/(+Z\IV\"J
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MC0+W'?)=/]2,9WTY/-#)^7_>D^_VW@M&T,URH/@" ]\#I)2D>9%CE9U;$"<
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M],"!R-(4\A\WB+#]PK"-MX9'O-G*O,%<SG=P@U9(?MT]<'5GUB@)3A$5F%'
MT7IA7-M7D3W) XH>_V"T%P?7(!_*,V/?\IN[9&%8^1,A@F*90T#U]8)N$2$Y
MDGJ.[Q6H47/F@8?7;^AA,7@UF&<HT"TC_^)$;A?&S  )6L.,R$>V_X*J ;DY
M7LR(*#[!ONIK&2#.A&1I%:R>(,6T_(:OU40<!*B!]@<X58#3#G _"!A7 >-C
M&295P.18!K<*<(]E\*H []B :14P+<0J9[>0QH<2+N><[0'/>RNT_*+0MXA6
MBF":6W$EN?H5JSBY_%MN$0>WC I&< (E2D"(*:0QA@2LI&I0OI/@S$<28B+
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M%10OIKF% I8(#8#W:\[5J:,GJ$OB^5]02P,$%     @ 9X$!62_IEW4D P
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M9Q+TB].E5-3:3ZC(R7=3@")7P*G=&%VP2I,/9)[>?#[_=D'VXG'7YFL%@(?
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M803T\S7GZFYC%'1?->E/4$L#!!0    ( &>! 5FK!$:_' ,  ( )   9
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M GP =V7D ;8!'W4P$/E4RN $2 ;N5!2"OY0BRO%>DEB MP&6B*3BG5+^<A>
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MA<$WH#:R.$;"N- 81#OW';0)%M@$"VV"19; 6OQ"][CM=5\O)5>V+<6#5;3
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MI,S+LR/EC61Y<=;AGDG)LN)RAU&"N190SS=,[?&K&VV@/L&S_@]02P,$%
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M0O\,#5;5R*\V1I9NIDVEP0GIECG>DD!9 7P_D]*L-U9!<^]*_@!02P,$%
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MXLJ:66F-^X8U'KBG1*0<S$F"D@Y\=!H?G,!;,C)U>-Q]>&;N2<*O&V("S_X
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MF<K!'S$E(.]7E(K]1BFH_TJ$OP!02P,$%     @ 9X$!633\\!S,!0  W2L
M !D   !X;"]W;W)K<VAE971S+W-H965T.3DN>&ULQ9IK;]LV%(;_"N$50PNT
MEB5;<IPY!NKHL@W($C3H]IF6:)NH)&HDG<O0'S]24F1)55@;.T/S(=:%Y^'E
MO.*ACKA\9/R+V!,BT5.6YN)JM)>RN+0L$>])AL68%217=[:,9UBJ4[ZS1,$)
M3DJC++6<R<2S,DSST6I97KOCJR4[R)3FY(XC<<@RS)_7)&6/5R-[]'+A$]WM
MI;Y@K98%WI%[(C\7=UR=60TEH1G)!64YXF1[-?IH7T;.1!N4)?ZDY%&TCI'N
MRH:Q+_KDM^1J--$M(BF)I49@]?- KDF::I)JQ]\U=-34J0W;QR_TL.R\ZLP&
M"W+-TK]H(O=7HXL12L@6'U+YB3W^2NH.N9H7LU24_]%C778R0O%!2);5QJH%
M&<VK7_Q4#T3+P'%>,7!J ^=4@VEM,#W58%8;S$XU<&L#]U0#KS;P3C68UP;S
MTEG5Z):N\;'$JR5GCXCKTHJF#TK_EM;*(S374KR77-VERDZNE M3O&$<:T4@
MG"?H5NX)1Y](BK56Q)X6 GU ]S@3AWR'UI21@@KTUB<2TU2\0V\0S=$-35-=
M>FE)U2B-MN*Z >NJ <XK#;#1#<OE7J @3T@R8']MMI]^SSXPVWL&>TL-9C.B
MSLN(KATCT"?Q&$WM]\B9V M4<)8<8CG4+S/F]T.N,!.-<6;H\[V/WKYY-X#Q
M3\=,#9@ IC4A3&NBDX?X-4S'==/F89B6W.EI#P/G.-\1->]*43X9.<L_Q*\5
M05(="EQ.L(./057U;+AJ'7$N18%C<C52(440_D!&JY]_LKW)+T/:@83YD+
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MHOS6LZ?DH5ILL"U*U''*BO)4KT[B)JH<U32L(M#\)2C-!Z4%-:WS0N)],Y^
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MP%8!JQV([XX#->7VB2)854P;MH-Q)$DP!&K17:-QC&0GAH][?;!=$D5)XD8
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MN?@(W59MV6=@^Z2LVEBU5MXZ6^K $/DEY*Y#GF7^8RT9(K>$S&[9E0#O!B7
M*"1R3,@^3O54"XS"(;.$S&:!1<% @"&<VV"?W !%P1 322=DE@Y.R>CT1HBD
M$S)+9Y"2'8LOTCXT[-&Y:B2=.PB1=$)FZ?R"N6AMOO9=72RL_[QX3S&1=<+?
M.,GAV52I*]^#FOL'8(J)K!/^QIF/AQ-=^D17W36M+&D\BI!THD/.A0QZ4(3$
M$['/A2!,.D48(?5$!RUO(HJ))!2QES<(,Z:82$(1LX0>J[!C\?AT>2\VUA0>
MGI84$9QB9Y;0(YMO5F6W_HD_3#_&TLT,TY(B0A**F"6TQSP>YZ282$(1LX3&
M3OK*FDJ<U8T^IA**D(0B9@D1S'UFM!\RZ$(]Q402BI@E1#!_S3K*05(<(PG%
MS!)Z&M4X[DLS4_>%A<_J^CT4$TDH9I80Q?R/UD02BMGK'S 2,\C=8R2A^)"S
M]\.E24A",?N(&\*DF4>,)!0?<OAMD'G$<*77H8;?=IV(8B()Q=S#;PASV(60
MA&)F"6',01="$HJ9)?3"8.9(W$R0A1)F"V%,FFXFR$()LX4@YN#:3)"%$F8+
MC6,^;J68R$()LX5>&L)^..L4$UDH8;807&HDCB@FLE#";*'=8B,XVI$@_23L
MBPB>EA^-!R"XPIA[B7$_YG^I-@\#;R\@(N,D[&-O8"IE&'R0<1+VLB<OI7/]
M>'"W4YBVZ<J)!WR"F2+CI >8\1DYXRG237J(*9]CL=],,9%NTM^R..T%S,&%
MF2+=I,RZ&5M#1ZI)BHETD[(7/70*#43S%-DF9:]Y1B@'=,@U*;-K\$P?3<Y3
M))V463H8D]:W*;RQA5D\>$)RT)I(/"FS># F;<T,B2=C%@_&I*,%&7)/QGY'
M)<*D\Q09<D_&?D\EPDPH)G)/QGY7)<),*29R3W;0I0<9Q43RR0ZX;/I[?WO;
M(R:R4,9^;R7"G%%,9*&,V4(8DZ9O&;)0=D +?9]1"V7PGDOVU=1@K?P@&9Y-
M\8V8S!YZ6BT_FK_-IO#^R^GN3P?ZM[NW;PJUTK4JOO@C.[\]EV6^L*)[Z(\5
MA%%WZ].J+<OW?MO7^K.1Q?Z/"_9_NO#V7U!+ P04    " !G@0%98\012MT"
M  !<.P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=N];N) &$;A
M6T&^@-CS/[,*J;9)N\H-(&(@"F"$O=KD[A>1 M[1%MM$/A4:(SZ.7#Q"9N;Q
M5[]?36_#<=R]G<;%QV%_')?-;II./]IV7._ZPVI\&$[]\?+.9C@?5M-E>=ZV
MI]7Z?;7M6]MUL3W?SVB>'N]G+EX^3_W_3!PVF[=U_W-8_S[TQ^D?@]L_P_E]
MW/7]U"Q>5N=M/RV;]F-_NSRVUQ?S<)G<+)Y?E\WY^=4T[=Q!5H+L_$%.@MS\
M05Z"_/Q!08+"_$%1@N+\04F"TOQ!68+R_$%%@LK\0:93&3M 4H4U0&NC7!N
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MJMX1H'>L-IL ](ZJ=P3H'57O"- [JMX1H'=2O1- [Z1Z)X#>2?5. +V3ZIT
M>B?5.P'T3JIW NB=5.\$T#M5FP4!>B?5.P'T3JIW NB=5>\,T#NKWAF@=U:]
M,T#OK'IG@-Y9]<X O;/JG0%Z9]4[ _3.JG<&Z)VKS=X O;/JG0%Z%]6[ /0N
MJG<!Z%U4[P+0NZC>!:!W4;T+0.^B>A> WD7U+@"]B^I= 'H7U;L ]"[581V
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ 9X$!641U2$B]!0  N1X  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &>! 5G'UB*HIP<  ( E   8
M              " @0 .  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !G@0%9!1)ZW7P$  !-$@  &               @('=%0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 9X$!61#7N"$0!P
M1"   !@              ("!CQH  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( &>! 5G]/:]UK (   <'   8              " @=4A
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !G@0%9L4N_
MP#$(  !O)@  &               @(&W)   >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ 9X$!61FF );F#0  1:8  !@
M ("!'BT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &>!
M 5D],*(M+A   )0J   8              " @3H[  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !G@0%9'Q0-&=H1  "P,0  &
M        @(&>2P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ 9X$!620?%4[<!   : T  !D              ("!KET  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !G@0%96:OM!WX'   ,%
M&0              @('!8@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( &>! 5D=/W**+@P  &HD   9              " @79J  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 9X$!6>#>:,3!
M!   L0H  !D              ("!VW8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !G@0%9-"]&P6X(  !,%P  &0
M@('3>P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( &>!
M 5E_#;.*5PD  '@:   9              " @7B$  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ 9X$!6<]\'SAM!@  _Q$  !D
M         ("!!HX  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !G@0%9&JOQ&\ (   +&@  &0              @(&JE   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &>! 5GIE?3J?P0  'D*
M   9              " @:&=  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ 9X$!69XDIG#F P  AP@  !D              ("!5Z(
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !G@0%9+3"B
M.9,#  "-"   &0              @(%TI@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( &>! 5GTHD>\Z@4  -T2   9
M  " @3ZJ  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M9X$!68Q@UBIB P  F@<  !D              ("!7[   'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !G@0%98WM)BW,'  #A%   &0
M            @('XLP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( &>! 5F&IK=VU@4  (0-   9              " @:*[  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 9X$!66M=_,(:!@
MY1$  !D              ("!K\$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !G@0%9&_PD"CT9  !260  &0              @($
MR   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &>! 5E_
M"R^&U 4  +D/   9              " @73A  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ 9X$!67_&)2$S#@  N2,  !D
M     ("!?^<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &>! 5E4]44,B00  &4-   9              "
M@<<0 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 9X$!
M60Y^B'V-"@  T1\  !D              ("!AQ4! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !G@0%9Y8&=4<L"   A!@  &0
M        @(%+( $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( &>! 5GK@A(9U 0  +\+   9              " @4TC 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 9X$!6;(4<S^+!@  +A(
M !D              ("!6"@! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !G@0%909O"WQL$  ","P  &0              @($:+P$
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( &>! 5DC_M-_
M/P4  ,0/   9              " @6PS 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ 9X$!66F@-1Y$!0  IA$  !D
M ("!XC@! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !G
M@0%9F;DN=3,#  !(!P  &0              @(%=/@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &>! 5E7/\8#'P0  ',+   9
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M970T-BYX;6Q02P$"% ,4    " !G@0%97&6J*X4-   EF0  &0
M    @(&/5P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M &>! 5GTO7R8W@(  /<&   9              " @4ME 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ 9X$!6=$O_C$4!P  SS0  !D
M             ("!8&@! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !G@0%9*F9Q=1T'   $1P  &0              @(&K;P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( &>! 5G!^'@+! <
M !@]   9              " @?]V 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ 9X$!630J6)Q#!@  \3P  !D              ("!
M.GX! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !G@0%9
MGUV-*<$"   E"   &0              @(&TA $ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( &>! 5ED2=7%S 0  - ;   9
M      " @:R' 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ 9X$!6>&1I<>8%P   "@! !D              ("!KXP! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !G@0%9-^Y%NZ,$  !D%@
M&0              @(%^I $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( &>! 5FN5]\XBP(  %8'   9              " @5BI 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ 9X$!6<%?P@)"
M!   \A4  !D              ("!&JP! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " !G@0%9'M8BE\<#   S%   &0
M@(&3L $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( &>!
M 5E\XR8WD 0  #P:   9              " @9&T 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ 9X$!64N3$6C* @  )0@  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( &>! 5G!H%:[O0(  /L&   9
M  " @:31 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
M9X$!6=STN!#O!P  !D8  !D              ("!F-0! 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " !G@0%9Z@"E>% "  #$!0  &0
M            @(&^W $ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( &>! 5EJN>R+S @  (%4   9              " @47? 0!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ 9X$!606][DV0 @
M,P@  !D              ("!2.@! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " !G@0%9G_S:\9$#  !S$   &0              @($/
MZP$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( &>! 5F2
M)@AAK0(  "<'   9              " @=?N 0!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ 9X$!6;^TY/%L @  .P8  !D
M     ("!N_$! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &>! 5DJ_0I%7@(  #\&   9              "
M@70- @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ 9X$!
M63ZR]U*P!P  =#@  !D              ("!"1 " 'AL+W=O<FMS:&5E=',O
M<VAE970W.2YX;6Q02P$"% ,4    " !G@0%9/*>)7 0&  !-*   &0
M        @('P%P( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0
M   ( &>! 5E R+B3: 0  &X6   9              " @2L> @!X;"]W;W)K
M<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ 9X$!6>G<L2?\!0  3"D
M !D              ("!RB(" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q0
M2P$"% ,4    " !G@0%98LCE5YP%  #Z)0  &0              @(']* (
M>&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( &>! 5EI  [7
MV@(  ,('   9              " @= N @!X;"]W;W)K<VAE971S+W-H965T
M.#0N>&UL4$L! A0#%     @ 9X$!6?MFV-TA @  1@0  !D
M ("!X3$" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    " !G
M@0%9CZGL#;X#   ]#P  &0              @($Y- ( >&PO=V]R:W-H965T
M<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( &>! 5GFGFAP'0<  "TL   9
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M970Y,2YX;6Q02P$"% ,4    " !G@0%9BM4+&.8#   >#P  &0
M    @(&S3P( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    (
M &>! 5DOZ9=U) ,  *,+   9              " @=!3 @!X;"]W;W)K<VAE
M971S+W-H965T.3,N>&UL4$L! A0#%     @ 9X$!62Q39M]! P  X0P  !D
M             ("!*U<" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"
M% ,4    " !G@0%9JP1&OQP#  " "0  &0              @(&C6@( >&PO
M=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( &>! 5GM-?//A 4
M ,TC   9              " @?9= @!X;"]W;W)K<VAE971S+W-H965T.38N
M>&UL4$L! A0#%     @ 9X$!61Z6C% @ P  @PD  !D              ("!
ML6," 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4    " !G@0%9
M(.+6D0X#  !6#   &0              @($(9P( >&PO=V]R:W-H965T<R]S
M:&5E=#DX+GAM;%!+ 0(4 Q0    ( &>! 5DT_/ <S 4  -TK   9
M      " @4UJ @!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#%
M  @ 9X$!61_%+$D7 P  F D  !H              ("!4' " 'AL+W=O<FMS
M:&5E=',O<VAE970Q,# N>&UL4$L! A0#%     @ 9X$!61]68#-E P  \!
M !H              ("!GW," 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL
M4$L! A0#%     @ 9X$!68UI\4-* P  *A4   T              ( !/'<"
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !G@0%9EXJ[',     3 @  "P
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52P4&     &T ;0#T'0  8H@"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>744</ContextCount>
  <ElementCount>390</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>157</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Dispositions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Dispositions</Role>
      <ShortName>Dispositions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Acquisitions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails</Role>
      <ShortName>Acquisitions - Purchase Price Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Acquisitions Preliminaty Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails</Role>
      <ShortName>Acquisitions Preliminaty Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Dispositions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DispositionsDetailsTextual</Role>
      <ShortName>Dispositions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Dispositions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Revenues - Revenues by product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails</Role>
      <ShortName>Revenues - Revenues by product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Revenues- Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetailsTextual</Role>
      <ShortName>Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Leases</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails</Role>
      <ShortName>Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails</Role>
      <ShortName>Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Share-based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails</Role>
      <ShortName>Share-based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails</Role>
      <ShortName>Collaborative and Other Relationships - OCREVUS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails</Role>
      <ShortName>Collaborative and Other Relationships - Profit Sharing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails</Role>
      <ShortName>Collaborative and Other Relationships - Eisai (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails</Role>
      <ShortName>Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails</Role>
      <ShortName>Collaborative and Other Relationships - Samsung Bioepis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>101</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="biib-20240630.htm">biib-20240630.htm</File>
    <File>biib-20240630.xsd</File>
    <File>biib-20240630_cal.xml</File>
    <File>biib-20240630_def.xml</File>
    <File>biib-20240630_lab.xml</File>
    <File>biib-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20240630_g1.jpg</File>
    <File>biib-20240630_g10.jpg</File>
    <File>biib-20240630_g11.jpg</File>
    <File>biib-20240630_g12.jpg</File>
    <File>biib-20240630_g13.jpg</File>
    <File>biib-20240630_g2.jpg</File>
    <File>biib-20240630_g3.jpg</File>
    <File>biib-20240630_g4.jpg</File>
    <File>biib-20240630_g5.jpg</File>
    <File>biib-20240630_g6.jpg</File>
    <File>biib-20240630_g7.jpg</File>
    <File>biib-20240630_g8.jpg</File>
    <File>biib-20240630_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1484">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>135
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "biib-20240630.htm": {
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "biib-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "biib-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "biib-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 303,
   "keyCustom": 87,
   "axisStandard": 39,
   "axisCustom": 3,
   "memberStandard": 57,
   "memberCustom": 91,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 744,
   "entityCount": 1,
   "segmentCount": 157,
   "elementCount": 838,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1484,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.biogenidec.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "longName": "9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "longName": "9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952154 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "longName": "9952156 - Statement - Condensed Consolidated Statement of Equity Statement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "longName": "9952158 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.biogenidec.com/role/Dispositions",
     "longName": "9952159 - Disclosure - Dispositions",
     "shortName": "Dispositions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives",
     "longName": "9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.biogenidec.com/role/Revenues",
     "longName": "9952161 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.biogenidec.com/role/Inventory",
     "longName": "9952162 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "longName": "9952163 - Disclosure - Intangible Assets and Goodwill",
     "shortName": "Intangible Assets and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "longName": "9952164 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "longName": "9952165 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "longName": "9952166 - Disclosure - Derivative Instruments",
     "shortName": "Derivative Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "longName": "9952167 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.biogenidec.com/role/Leases",
     "longName": "9952168 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "longName": "9952169 - Disclosure - Indebtedness",
     "shortName": "Indebtedness",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.biogenidec.com/role/Equity",
     "longName": "9952170 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "longName": "9952171 - Disclosure - Earnings per Share",
     "shortName": "Earnings per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "longName": "9952172 - Disclosure - Share-based Payments",
     "shortName": "Share-based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "longName": "9952173 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "longName": "9952174 - Disclosure - Other Consolidated Financial Statement Detail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "longName": "9952175 - Disclosure - Collaborative and Other Relationships",
     "shortName": "Collaborative and Other Relationships",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "longName": "9952176 - Disclosure - Investments in Variable Interest Entities",
     "shortName": "Investments in Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.biogenidec.com/role/Litigation",
     "longName": "9952177 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.biogenidec.com/role/AcquisitionsTables",
     "longName": "9954472 - Disclosure - Acquisitions (Tables)",
     "shortName": "Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables",
     "longName": "9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "longName": "9954474 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "longName": "9954475 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "longName": "9954476 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "longName": "9954477 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "longName": "9954478 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "longName": "9954479 - Disclosure - Derivative Instruments (Tables)",
     "shortName": "Derivative Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "longName": "9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "longName": "9954481 - Disclosure - Earnings per Share (Tables)",
     "shortName": "Earnings per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "longName": "9954482 - Disclosure - Share-Based Payments (Tables)",
     "shortName": "Share-Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "longName": "9954483 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "longName": "9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "longName": "9954485 - Disclosure - Collaborative and Other Relationships (Tables)",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
     "longName": "9954487 - Disclosure - Acquisitions - Narrative (Details)",
     "shortName": "Acquisitions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
     "longName": "9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)",
     "shortName": "Acquisitions - Purchase Price Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-94",
      "name": "biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
     "longName": "9954489 - Disclosure - Acquisitions Preliminaty Purchase Price Allocation (Details)",
     "shortName": "Acquisitions Preliminaty Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.biogenidec.com/role/DispositionsDetailsTextual",
     "longName": "9954490 - Disclosure - Dispositions (Details Textual)",
     "shortName": "Dispositions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
     "longName": "9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "us-gaap:OtherRestructuringCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
     "longName": "9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
     "longName": "9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
     "longName": "9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-163",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
     "longName": "9954495 - Disclosure - Revenues - Revenues by product (Details)",
     "shortName": "Revenues - Revenues by product (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-299",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
     "longName": "9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
     "longName": "9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)",
     "shortName": "Revenues- Reserves for Discounts and Allowances (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-450",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "longName": "9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-458",
      "name": "biib:ShareOfCoPromotionProfits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "longName": "9954499 - Disclosure - Revenues - Other Revenues (Details)",
     "shortName": "Revenues - Other Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-462",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "longName": "9954500 - Disclosure - Revenues - Narrative (Details)",
     "shortName": "Revenues - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "biib:NumberOfWholesalers",
      "unitRef": "wholesaler",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "biib:NumberOfWholesalers",
      "unitRef": "wholesaler",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
     "longName": "9954501 - Disclosure - Inventory - Components of Inventory (Details)",
     "shortName": "Inventory - Components of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.biogenidec.com/role/InventoryNarrativeDetails",
     "longName": "9954502 - Disclosure - Inventory - Narrative (Details)",
     "shortName": "Inventory - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
     "longName": "9954503 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "shortName": "Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "longName": "9954504 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
       "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
       "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails",
     "longName": "9954505 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)",
     "shortName": "Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
     "longName": "9954506 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)",
     "shortName": "Intangible Assets and Goodwill - Changes in Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "longName": "9954507 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "longName": "9954508 - Disclosure - Fair Value Measurements (Details Textual)",
     "shortName": "Fair Value Measurements (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "longName": "9954509 - Disclosure - Fair Value Measurements (Details 1)",
     "shortName": "Fair Value Measurements (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "longName": "9954510 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "longName": "9954511 - Disclosure - Financial Instruments (Details 1)",
     "shortName": "Financial Instruments (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "longName": "9954512 - Disclosure - Financial Instruments (Details 3)",
     "shortName": "Financial Instruments (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "longName": "9954513 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-530",
      "name": "biib:StrategicInvestmentPortfolio",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-530",
      "name": "biib:StrategicInvestmentPortfolio",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "longName": "9954514 - Disclosure - Derivative Instruments (Details)",
     "shortName": "Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:UnrealizedGainOnDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:UnrealizedGainOnDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "longName": "9954515 - Disclosure - Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.biogenidec.com/role/LeasesDetailsTextual",
     "longName": "9954516 - Disclosure - Leases (Details Textual)",
     "shortName": "Leases (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-94",
      "name": "biib:OperatingLeaseArea",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "longName": "9954517 - Disclosure - Indebtedness (Details)",
     "shortName": "Indebtedness (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-523",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-583",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "longName": "9954518 - Disclosure - Share Repurchases (Details)",
     "shortName": "Share Repurchases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-585",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-585",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9954519 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9954520 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-630",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "longName": "9954521 - Disclosure - Earnings per Share (Details)",
     "shortName": "Earnings per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
     "longName": "9954522 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)",
     "shortName": "Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
     "longName": "9954523 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)",
     "shortName": "Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-674",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails",
     "longName": "9954524 - Disclosure - Share-based Payments - Narrative (Details)",
     "shortName": "Share-based Payments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-680",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-680",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "longName": "9954525 - Disclosure - Income Taxes (Details Textual)",
     "shortName": "Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "longName": "9954526 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "longName": "9954527 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "longName": "9954528 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
     "longName": "9954529 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)",
     "shortName": "Collaborative and Other Relationships - OCREVUS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-691",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-691",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
     "longName": "9954530 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)",
     "shortName": "Collaborative and Other Relationships - Profit Sharing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-694",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-694",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
     "longName": "9954531 - Disclosure - Collaborative and Other Relationships - Eisai (Details)",
     "shortName": "Collaborative and Other Relationships - Eisai (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-698",
      "name": "biib:PaymentsMadeToTerminationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-698",
      "name": "biib:PaymentsMadeToTerminationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
     "longName": "9954532 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-699",
      "name": "biib:ExpenseIncurredByCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-699",
      "name": "biib:ExpenseIncurredByCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
     "longName": "9954533 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)",
     "shortName": "Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-707",
      "name": "biib:AccountsReceivableFromCollaborator",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
     "longName": "9954534 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R95": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
     "longName": "9954535 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-708",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-708",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
     "longName": "9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "biib:ShareOfNetProfitFromSageTherapeuticsPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-713",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
     "longName": "9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-723",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-723",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
     "longName": "9954539 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)",
     "shortName": "Collaborative and Other Relationships - Other Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-727",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
     "longName": "9954540 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "shortName": "Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-734",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "longName": "9954541 - Disclosure - Investments in Variable Interest Entities (Details)",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "longName": "9954542 - Disclosure - Litigation (Details)",
     "shortName": "Litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-742",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-742",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.250% Senior Notes due May 1, 2030",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2020ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "A2020ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Share Repurchase Program",
        "label": "2020 Share Repurchase Program [Member]",
        "documentation": "2020 Share Repurchase Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023And2022CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "A2023And2022CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 and 2022 Cost Saving Initiatives",
        "label": "2023 and 2022 Cost Saving Initiatives [Member]",
        "documentation": "2023 and 2022 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "A2023CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Cost Saving Initiatives",
        "label": "2023 Cost Saving Initiatives [Member]",
        "documentation": "2023 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "A2023TermLoanMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Term Loan",
        "label": "2023 Term Loan [Member]",
        "documentation": "2023 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.150% Senior Notes due May 1, 2050",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AVONEXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AVONEXMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AVONEX",
        "label": "AVONEX [Member]",
        "documentation": "AVONEX"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r972"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r1279"
     ]
    },
    "biib_AccountsPayableToCollaborator": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AccountsPayableToCollaborator",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable",
        "label": "Accounts Payable, To Collaborator",
        "documentation": "Accounts Payable, To Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AccountsReceivableFromCollaborator": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AccountsReceivableFromCollaborator",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts receivable",
        "label": "Accounts Receivable, From Collaborator",
        "documentation": "Accounts Receivable, From Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r895",
      "r993",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net of allowance for doubtful accounts of $2.5 and $2.4, respectively",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r157"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Expenses and Other",
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "biib_AccruedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AccruedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued milestone payments",
        "label": "Accrued Milestone Payments",
        "documentation": "Accrued Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AccruedPaymentToTerminationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AccruedPaymentToTerminationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable Due To Termination Agreement",
        "label": "Accrued Payment To Termination Agreement",
        "documentation": "Accrued Payment To Termination Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Royalties and licensing fees",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r914"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded status of postretirement benefit plans",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r13",
      "r25",
      "r114",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r228",
      "r755"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on cash flow hedges",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r258",
      "r259",
      "r596",
      "r921",
      "r1109"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on securities available for sale",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r258",
      "r259",
      "r1109"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r115",
      "r237",
      "r751",
      "r787",
      "r788"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r25",
      "r602",
      "r605",
      "r658",
      "r783",
      "r784",
      "r1109",
      "r1110",
      "r1111",
      "r1126",
      "r1127",
      "r1128",
      "r1130"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r25",
      "r112",
      "r113",
      "r258",
      "r259",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r1109"
     ]
    },
    "biib_AcquiredAndInLicensedRightsAndPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AcquiredAndInLicensedRightsAndPatentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired and in-licensed rights and patents",
        "label": "Acquired And In Licensed Rights And Patents [Member]",
        "documentation": "Acquired And In Licensed Rights And Patents"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Consolidated Financial Statement Detail",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r972",
      "r1319"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r1126",
      "r1127",
      "r1128",
      "r1130",
      "r1244",
      "r1320"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustments Relating To Prior Years",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AdministrativeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AdministrativeSpaceMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative Space",
        "label": "Administrative Space [Member]",
        "documentation": "Administrative Space"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1019",
      "r1029",
      "r1061"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1022",
      "r1032",
      "r1064"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1023",
      "r1033",
      "r1057",
      "r1065",
      "r1069",
      "r1077"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r551"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r337",
      "r376"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and impairment of acquired intangible assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "documentation": "Amortization and Impairment of Acquired Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AmortizationOfInventoryStepUp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AmortizationOfInventoryStepUp",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired inventory step-up",
        "label": "Amortization Of Inventory Step-Up",
        "documentation": "Amortization Of Inventory Step-Up"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of change In reserves",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "documentation": "Analysis of amount of and change in product revenue reserves."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r167",
      "r232",
      "r276",
      "r318",
      "r321",
      "r330",
      "r331",
      "r373",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r592",
      "r597",
      "r634",
      "r745",
      "r835",
      "r927",
      "r928",
      "r972",
      "r1000",
      "r1198",
      "r1199",
      "r1270"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r241",
      "r276",
      "r373",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r592",
      "r597",
      "r634",
      "r972",
      "r1198",
      "r1199",
      "r1270"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614",
      "r960"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "biib_BENEPALIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BENEPALIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BENEPALI",
        "label": "BENEPALI [Member]",
        "documentation": "BENEPALI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BYOOVIZMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BYOOVIZMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BYOOVIZ",
        "label": "BYOOVIZ [Member]",
        "documentation": "BYOOVIZ"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r1286",
      "r1287"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74",
      "r420",
      "r1286",
      "r1287"
     ]
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted earnings per share",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "documentation": "Basic and diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "biib_BiologicsManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BiologicsManufacturingMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "documentation": "Biologics Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BiosimilarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BiosimilarsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biosimilars",
        "label": "Biosimilars [Member]",
        "documentation": "Biosimilars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r584",
      "r951",
      "r952"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r584",
      "r951",
      "r952"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessAcquisitionNumberOfCommonStockSharesAcquired",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock shares acquired",
        "label": "Business Acquisition, Number of Common Stock Shares Acquired",
        "documentation": "Business Acquisition, Number of Common Stock Shares Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r12"
     ]
    },
    "biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services",
        "label": "Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services",
        "documentation": "Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration obligations",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r147",
      "r587",
      "r615",
      "r616",
      "r617"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r585"
     ]
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment, accrued expense and other",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred tax liability",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Adjustment, goodwill",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets and liabilities, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Contingent payable to Blackstone",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued expense and other(1)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred tax liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identifiable net assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "negatedTerseLabel": "Operating lease liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired and liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed",
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Abstract]",
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "BusinessOverviewPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business Overview",
        "label": "Business Overview [Policy Text Block]",
        "documentation": "Describes an overview of the company and its operations."
       }
      }
     },
     "auth_ref": []
    },
    "currency_CAD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CAD",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Canadian dollar",
        "label": "Canada, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CHF": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CHF",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swiss franc",
        "label": "Switzerland, Francs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Instruments",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r126",
      "r272"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r126"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1282"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents",
        "label": "Cash Equivalents, at Carrying Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CashflowsoperatingexpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CashflowsoperatingexpensesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows, operating expenses",
        "label": "Cash flows, operating expenses [Member]",
        "documentation": "Cash flows, operating expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CashflowsrevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CashflowsrevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows, revenue",
        "label": "Cash flows, revenue [Member]",
        "documentation": "Cash flows, revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r320",
      "r481",
      "r482",
      "r483",
      "r485",
      "r488",
      "r493",
      "r495",
      "r791",
      "r792",
      "r793",
      "r794",
      "r940",
      "r1087",
      "r1119"
     ]
    },
    "biib_ClinicalInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ClinicalInventoryMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Inventory",
        "label": "Clinical Inventory [Member]",
        "documentation": "Clinical Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment",
        "label": "Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment",
        "documentation": "Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment."
       }
      }
     },
     "auth_ref": []
    },
    "biib_CoPromotionProfitSharingFormulaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CoPromotionProfitSharingFormulaTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Co-promotion profit sharing formula",
        "label": "Co Promotion Profit Sharing Formula [Table Text Block]",
        "documentation": "Co-promotion profit sharing formula."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "biib_Collaborationexpensesaccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "Collaborationexpensesaccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration expense",
        "label": "Collaboration expenses accrual",
        "documentation": "Collaboration expenses accrual"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Collaborationprofitlosssharing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "Collaborationprofitlosssharing",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration profit sharing/(loss reimbursement)",
        "label": "Collaboration profit (loss) sharing",
        "documentation": "Collaboration profit (loss) sharing"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CollaborativeArrangementContractOptionExerciseFeePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CollaborativeArrangementContractOptionExerciseFeePaid",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercise fee paid",
        "label": "Collaborative Arrangement, Contract Option Exercise Fee Paid",
        "documentation": "Collaborative Arrangement, Contract Option Exercise Fee Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaborative and Other Relationships",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r173",
      "r184"
     ]
    },
    "biib_CollaborativeArrangementTermExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CollaborativeArrangementTermExtension",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "label": "Collaborative Arrangement, Term Extension",
        "documentation": "Collaborative Arrangement, Term Extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangements and non-collaborative arrangement transactions",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments, contingencies and guarantees",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r160",
      "r748",
      "r821"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r991",
      "r992",
      "r994",
      "r995",
      "r996",
      "r997",
      "r1126",
      "r1127",
      "r1130",
      "r1244",
      "r1317",
      "r1320"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r102",
      "r822",
      "r841",
      "r1320",
      "r1321"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value $\u2014 per share",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r750",
      "r972"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "biib_CompletedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CompletedTechnologyMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completed Technology",
        "label": "Completed Technology [Member]",
        "documentation": "Completed Technology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss) attributable to Biogen Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r254",
      "r256",
      "r264",
      "r739",
      "r763",
      "r765"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r59",
      "r69",
      "r254",
      "r256",
      "r263",
      "r738",
      "r763",
      "r764"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r149",
      "r254",
      "r256",
      "r262",
      "r737",
      "r763"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r210",
      "r282",
      "r592",
      "r593",
      "r597",
      "r598",
      "r663",
      "r901",
      "r1103",
      "r1104",
      "r1105",
      "r1197",
      "r1200",
      "r1201"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r210",
      "r282",
      "r592",
      "r593",
      "r597",
      "r598",
      "r663",
      "r901",
      "r1103",
      "r1104",
      "r1105",
      "r1197",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r922"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "biib_ContingentCommercializedRightsNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ContingentCommercializedRightsNumberOfProducts",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Commercialized Rights, Number Of Products",
        "label": "Contingent Commercialized Rights, Number Of Products",
        "documentation": "Contingent Commercialized Rights, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractManufacturingAndOtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ContractManufacturingAndOtherRevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing revenue",
        "label": "Contract manufacturing and other revenue [Member]",
        "documentation": "Other corporate revenues [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractOptionExerciseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ContractOptionExerciseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercise fee",
        "label": "Contract Option Exercise Fee",
        "documentation": "Contract Option Exercise Fee"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractualAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ContractualAdjustmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual adjustments",
        "label": "Contractual Adjustments [Member]",
        "documentation": "Contractual adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r701"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost and expense",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r280",
      "r281",
      "r455",
      "r483",
      "r662",
      "r684",
      "r743",
      "r918",
      "r920"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r1195"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r1195",
      "r1196"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]",
        "documentation": "Information by currency."
       }
      }
     },
     "auth_ref": [
      "r1264"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "biib_CurrentPortionOfNotesPayableAndTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CurrentPortionOfNotesPayableAndTermLoanMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Portion Of Notes Payable And Term Loan",
        "label": "Current Portion Of Notes Payable And Term Loan [Member]",
        "documentation": "Current Portion Of Notes Payable And Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Provisions Relating To Sales In Current Year",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "documentation": "Current provisions to product revenue reserves relating to sales in current year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indebtedness",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r274",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r440",
      "r441",
      "r451",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r467",
      "r474",
      "r475",
      "r477",
      "r649"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r93",
      "r94",
      "r156",
      "r159",
      "r282",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r971",
      "r1120",
      "r1183",
      "r1184",
      "r1185",
      "r1265",
      "r1266"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, gross",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r159",
      "r478"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r971",
      "r1120",
      "r1265",
      "r1266"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r282",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r971",
      "r1120",
      "r1183",
      "r1184",
      "r1185",
      "r1265",
      "r1266"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r43",
      "r46",
      "r80",
      "r142",
      "r143",
      "r282",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r971",
      "r1120",
      "r1265",
      "r1266"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gains",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized losses",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt and equity securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152"
     ]
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable equity securities",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeconsolidationGainOrLossAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deconsolidation, gain (loss), amount",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r556"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r181",
      "r1122"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r556",
      "r746"
     ]
    },
    "biib_DenaliTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "DenaliTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denali Therapeutics",
        "label": "Denali Therapeutics Inc [Member]",
        "documentation": "Denali Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r36"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r318",
      "r326",
      "r331",
      "r927",
      "r928"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r613",
      "r614",
      "r624",
      "r633",
      "r801",
      "r802",
      "r803",
      "r805",
      "r806",
      "r808",
      "r809",
      "r810",
      "r812",
      "r813",
      "r828",
      "r829",
      "r877",
      "r879",
      "r881",
      "r882",
      "r883",
      "r884",
      "r920",
      "r960",
      "r964",
      "r992",
      "r1248",
      "r1249",
      "r1250",
      "r1318"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r813",
      "r827",
      "r828",
      "r829",
      "r831",
      "r832",
      "r833",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839",
      "r849",
      "r850",
      "r851",
      "r852",
      "r855",
      "r856",
      "r857",
      "r858",
      "r877",
      "r878",
      "r881",
      "r883",
      "r990",
      "r992",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1258",
      "r1259"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset, fair value",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r111",
      "r152",
      "r153",
      "r242",
      "r920"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, fair value",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r111",
      "r152",
      "r153",
      "r242",
      "r920"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r77",
      "r154",
      "r810",
      "r813",
      "r827",
      "r828",
      "r829",
      "r831",
      "r832",
      "r833",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839",
      "r849",
      "r850",
      "r851",
      "r852",
      "r855",
      "r856",
      "r857",
      "r858",
      "r877",
      "r878",
      "r881",
      "r883",
      "r920",
      "r990",
      "r992",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1258",
      "r1259"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Instruments",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r600",
      "r607"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r72",
      "r75"
     ]
    },
    "biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Unrealized Gain (Loss)",
        "label": "Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]",
        "documentation": "Derivative Instruments, Unrealized Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Notional Amount",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1242",
      "r1243"
     ]
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeRemainingMaturity1",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Range of durations of foreign currency forward contracts",
        "label": "Derivative, Remaining Maturity",
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Designated as hedging instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology and other",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1176",
      "r1177",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of dilutive securities:",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Abstract]",
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues by product",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Payments",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r519",
      "r548",
      "r549",
      "r550",
      "r954"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Dispositions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dispositions",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r131"
     ]
    },
    "biib_DistributorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "DistributorOneMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor One",
        "label": "Distributor One [Member]",
        "documentation": "Distributor one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DistributorTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "DistributorTwoMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor Two",
        "label": "Distributor Two [Member]",
        "documentation": "Distributor two."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DivestituresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "DivestituresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]",
        "documentation": "Divestitures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "biib_E2609andBAN2401Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "E2609andBAN2401Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "E2609 and BAN2401",
        "label": "E2609 and BAN2401 [Member]",
        "documentation": "E2609 and BAN2401 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "EUR",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Euro",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income per share:",
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc.",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r304",
      "r306",
      "r311",
      "r312",
      "r313",
      "r317",
      "r582",
      "r589",
      "r610",
      "r611",
      "r740",
      "r766",
      "r923"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r306",
      "r311",
      "r312",
      "r313",
      "r317",
      "r582",
      "r589",
      "r610",
      "r611",
      "r740",
      "r766",
      "r923"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r314",
      "r315",
      "r316"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r956"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r558",
      "r572",
      "r956"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes on foreign earnings",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r562",
      "r956",
      "r1123",
      "r1234"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GILTI",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1234",
      "r1236"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchased intangible assets",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization."
       }
      }
     },
     "auth_ref": [
      "r1123",
      "r1234",
      "r1236"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1123",
      "r1234",
      "r1235"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r956",
      "r1123",
      "r1234"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Credits and net operating loss utilization",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r1123",
      "r1234"
     ]
    },
    "biib_EisaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EisaiMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eisai",
        "label": "Eisai [Member]",
        "documentation": "Eisai [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capitalized share-based compensation costs",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax effect",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee stock purchase plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenues from major distributors",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "documentation": "Entity wide percentage of revenue from major distributors."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r223",
      "r257",
      "r258",
      "r259",
      "r288",
      "r289",
      "r290",
      "r292",
      "r297",
      "r299",
      "r301",
      "r319",
      "r374",
      "r375",
      "r413",
      "r496",
      "r570",
      "r571",
      "r579",
      "r580",
      "r581",
      "r583",
      "r588",
      "r589",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r650",
      "r653",
      "r658",
      "r761",
      "r783",
      "r784",
      "r785",
      "r799",
      "r862"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r578",
      "r1089",
      "r1090",
      "r1091",
      "r1238",
      "r1239",
      "r1240",
      "r1241"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, ownership interest",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Amount Sold",
        "label": "Equity Method Investment, Amount Sold",
        "documentation": "Amount of the entity's equity method investment which has been sold."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected profit share percentage",
        "label": "Equity Method Investments, Expected Profit Share",
        "documentation": "Equity Method Investments, Expected Profit Share"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EquitySecuritiesCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "documentation": "Equity Securities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r632",
      "r913"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (gains) losses recognized on equity securities",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r1156"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: Net (gains) losses realized on equity securities",
        "terseLabel": "Net gains (losses) realized during the period on equity securities",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r1156"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized (gains) losses recognized on equity securities",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r1156"
     ]
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EquitySecuritiesNonCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "documentation": "Equity Securities, Non-Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1019",
      "r1029",
      "r1061"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1016",
      "r1026",
      "r1058"
     ]
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "biib_ExpenseIncurredByCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ExpenseIncurredByCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total development expense incurred by the collaboration related to the advancement of LEQEMBI",
        "label": "Expense Incurred By Collaboration",
        "documentation": "Total expense incurred by collaboration."
       }
      }
     },
     "auth_ref": []
    },
    "biib_Expenseincurredbythecollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "Expenseincurredbythecollaboration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "documentation": "Expense incurred by the collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "Expensereflectedwithinstatementsofincome",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "documentation": "Expense reflected within statements of income"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FAMPYRAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FAMPYRAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAMPYRA",
        "label": "FAMPYRA [Member]",
        "documentation": "FAMPYRA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FLIXABIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FLIXABIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FLIXABI",
        "label": "FLIXABI [Member]",
        "documentation": "FLIXABI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FUMADERMAndADUHELMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FUMADERMAndADUHELMMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FUMADERM And ADUHELM",
        "label": "FUMADERM And ADUHELM [Member]",
        "documentation": "FUMADERM And ADUHELM"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FacilityLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Location [Axis]",
        "label": "Facility Location [Axis]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FacilityLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Location [Domain]",
        "label": "Facility Location [Domain]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FacilityTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Type [Axis]",
        "label": "Facility Type [Axis]",
        "documentation": "Facility Type"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FacilityTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Type [Domain]",
        "label": "Facility Type [Domain]",
        "documentation": "Facility Type"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentToInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentToInventoryMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Adjustment to Inventory",
        "label": "Fair Value Adjustment to Inventory [Member]",
        "documentation": "Fair value adjustment to acquisition-date inventory allocated (included) to (in) reported pro forma earnings (supplemental pro forma information)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assets and liabilities recorded at fair value",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614",
      "r624",
      "r960"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614",
      "r624",
      "r960"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r612",
      "r614",
      "r615",
      "r616",
      "r617",
      "r623",
      "r624",
      "r626",
      "r668",
      "r669",
      "r670",
      "r936",
      "r937",
      "r948",
      "r949",
      "r950",
      "r960",
      "r964"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614",
      "r615",
      "r617",
      "r960",
      "r1249",
      "r1260"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r621",
      "r622",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r734",
      "r960",
      "r965"
     ]
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Indefinite Lived Intangible Assets Discount Rate",
        "label": "Fair Value Indefinite Lived Intangible Assets Discount Rate",
        "documentation": "Fair Value Indefinite Lived Intangible Assets Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r508",
      "r513",
      "r614",
      "r624",
      "r668",
      "r948",
      "r949",
      "r950",
      "r960"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r508",
      "r513",
      "r614",
      "r615",
      "r624",
      "r669",
      "r936",
      "r937",
      "r948",
      "r949",
      "r950",
      "r960"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r614",
      "r615",
      "r616",
      "r617",
      "r624",
      "r670",
      "r936",
      "r937",
      "r948",
      "r949",
      "r950",
      "r960",
      "r964"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614",
      "r615",
      "r617",
      "r960",
      "r1249",
      "r1260"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r612",
      "r614",
      "r615",
      "r616",
      "r617",
      "r623",
      "r624",
      "r626",
      "r668",
      "r669",
      "r670",
      "r936",
      "r937",
      "r948",
      "r949",
      "r950",
      "r960",
      "r964"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value, Measurements Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1260"
     ]
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r73",
      "r78"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r476",
      "r493",
      "r607",
      "r631",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r762",
      "r931",
      "r960",
      "r962",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r973",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1245",
      "r1248",
      "r1249",
      "r1250",
      "r1257",
      "r1260"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average remaining useful life",
        "label": "Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life",
        "documentation": "Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "verboseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r387",
      "r407",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r909",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remaining six months)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1326"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r909",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r909",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r909",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r909",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r410",
      "r411",
      "r702",
      "r703",
      "r909"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r407",
      "r703",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r407",
      "r410",
      "r411",
      "r412",
      "r702",
      "r909",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r410",
      "r411",
      "r909"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r1177"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FloatingRate364DayTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FloatingRate364DayTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floating Rate 364-Day Tranche",
        "label": "Floating Rate 364-Day Tranche [Member]",
        "documentation": "Floating Rate 364-Day Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559"
     ]
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months",
        "documentation": "Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative contracts",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614"
     ]
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative contracts",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange (gains) losses, net",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r638",
      "r859"
     ]
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange contract",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r920",
      "r948",
      "r959",
      "r960"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1023",
      "r1033",
      "r1065"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1023",
      "r1033",
      "r1065"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1023",
      "r1033",
      "r1065"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1023",
      "r1033",
      "r1065"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1023",
      "r1033",
      "r1065"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "biib_FumarateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FumarateMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fumarate",
        "label": "Fumarate [Member]",
        "documentation": "Fumarate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FutureContingentMilestoneTypesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "documentation": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FutureContingentMilestoneTypesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Contingent Milestone Types [Domain]",
        "label": "Future Contingent Milestone Types [Domain]",
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage to be received",
        "label": "Future Royalties Percentage To Be Received On Sale Of Product",
        "documentation": "Future royalties percentage to be received on sale of product."
       }
      }
     },
     "auth_ref": []
    },
    "biib_GAZYVAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "GAZYVAMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GAZYVA",
        "label": "GAZYVA [Member]",
        "documentation": "GAZYVA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain on interest rate swap",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on sale",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of priority review voucher, net",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r76"
     ]
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on investments in equity securities",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1113",
      "r1114"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of priority review voucher, net",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "biib_GenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "GenentechMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Genentech [Member]",
        "documentation": "Genentech"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning of period",
        "periodEndLabel": "Goodwill, end of period",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r388",
      "r735",
      "r928",
      "r932",
      "r961",
      "r972",
      "r1160",
      "r1167"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill resulting from Reata acquisition",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r932"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1158",
      "r1170"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated impairment losses related to goodwill",
        "verboseLabel": "Accumulated impairment losses related to goodwill",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r397",
      "r932"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r932"
     ]
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillOtherIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Goodwill, Other Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of roll forward of the changes in goodwill",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r599"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "biib_HumanImmunologyBiosciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "HumanImmunologyBiosciencesMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Human Immunology Biosciences",
        "label": "Human Immunology Biosciences [Member]",
        "documentation": "Human Immunology Biosciences"
       }
      }
     },
     "auth_ref": []
    },
    "biib_IMRALDIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "IMRALDIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMRALDI",
        "label": "IMRALDI [Member]",
        "documentation": "IMRALDI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r1118",
      "r1179",
      "r1182"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "verboseLabel": "In-process research and development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income tax (benefit) expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r162",
      "r166",
      "r741",
      "r757",
      "r925",
      "r927",
      "r1132",
      "r1134",
      "r1135",
      "r1136",
      "r1137"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r17",
      "r22",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r133"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r420",
      "r425",
      "r618",
      "r620",
      "r625",
      "r780",
      "r782",
      "r846",
      "r909",
      "r963",
      "r1288"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r425",
      "r618",
      "r620",
      "r625",
      "r780",
      "r782",
      "r846",
      "r909",
      "r963",
      "r1288"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1237"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r554",
      "r558",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r573",
      "r575",
      "r576",
      "r577",
      "r796",
      "r956"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax (benefit) expense",
        "terseLabel": "Income Tax Expense (Benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r182",
      "r300",
      "r301",
      "r318",
      "r327",
      "r331",
      "r557",
      "r558",
      "r574",
      "r771",
      "r956"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax assets and liabilities",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expense and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on strategic investments",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r269"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities, net of effects of business acquired:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other changes in operating assets and liabilities, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock units",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r313",
      "r518"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r405",
      "r409",
      "r933"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r409",
      "r412",
      "r933"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost and net",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r409",
      "r933"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r405",
      "r409",
      "r933"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1023",
      "r1033",
      "r1057",
      "r1065",
      "r1069",
      "r1077"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1081"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1081"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1081"
     ]
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "documentation": "Intangible assets excluding goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "totalLabel": "Net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r1177",
      "r1179"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r321",
      "r325",
      "r328",
      "r331",
      "r648",
      "r927",
      "r928"
     ]
    },
    "biib_InterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "InterestInSubsidiary",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest in subsidiary (less than given percentage)",
        "label": "Interest In Subsidiary",
        "documentation": "Interest in subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNetAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income (Expense), Net",
        "label": "Interest Income (Expense), Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_InterferonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "InterferonMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interferon",
        "label": "Interferon [Member]",
        "documentation": "Interferon"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r915"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "terseLabel": "Inventory, current",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r912",
      "r972"
     ]
    },
    "biib_InventoryNetCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "InventoryNetCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory",
        "label": "Inventory, Net Current and Noncurrent",
        "documentation": "Inventory, Net Current and Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, noncurrent",
        "label": "Inventory, Noncurrent",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r917"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r916"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess and obsolescence charges related to inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r324",
      "r331",
      "r927",
      "r1112"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r804",
      "r805",
      "r808",
      "r811",
      "r868",
      "r870",
      "r872",
      "r875",
      "r876",
      "r885",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r992"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type Categorization [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r804",
      "r805",
      "r808",
      "r811",
      "r868",
      "r870",
      "r872",
      "r875",
      "r876",
      "r885",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r992"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, All Other Investments [Abstract]",
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable equity securities",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1246",
      "r1247",
      "r1257"
     ]
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Variable Interest Entities [Abstract]",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "documentation": "Investments In Variable Interest Entities."
       }
      }
     },
     "auth_ref": []
    },
    "biib_IonisPharmaceuticalsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "IonisPharmaceuticalsInc.Member",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ionis",
        "label": "Ionis Pharmaceuticals Inc. [Member]",
        "documentation": "Ionis Pharmaceuticals Inc."
       }
      }
     },
     "auth_ref": []
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "IonisSangamoDenaliAndSageMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "documentation": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "auth_ref": []
    },
    "currency_JPY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "JPY",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Japan, Yen",
        "label": "Japan, Yen"
       }
      }
     },
     "auth_ref": []
    },
    "biib_LEQEMBICollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "LEQEMBICollaborationMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEQEMBI Collaboration",
        "label": "LEQEMBI Collaboration [Member]",
        "documentation": "LEQEMBI Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Litigation",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "biib_LenderDisputeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "LenderDisputeMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Dispute",
        "label": "Lender Dispute [Member]",
        "documentation": "Lender Dispute"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Remaining Lease Term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r1267"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1268"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r93",
      "r94",
      "r95",
      "r97",
      "r98",
      "r99",
      "r100",
      "r276",
      "r373",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r593",
      "r597",
      "r598",
      "r634",
      "r820",
      "r924",
      "r1000",
      "r1198",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r161",
      "r753",
      "r972",
      "r1121",
      "r1157",
      "r1261"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r227",
      "r276",
      "r373",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r593",
      "r597",
      "r598",
      "r634",
      "r972",
      "r1198",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r1246"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r96"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable and term loan",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r159",
      "r464",
      "r479",
      "r936",
      "r937",
      "r971",
      "r1280"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r40",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r439",
      "r552",
      "r934",
      "r1191",
      "r1192"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r439",
      "r552",
      "r934",
      "r1191",
      "r1192"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Brazil tax assessment, including interest and penalties",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Estimate of Possible Loss",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r438",
      "r439",
      "r552",
      "r934"
     ]
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MSProductRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "MSProductRevenuesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MS Product Revenues",
        "label": "MS Product Revenues [Member]",
        "documentation": "MS Product Revenues [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r943",
      "r983",
      "r987",
      "r1204",
      "r1285",
      "r1289",
      "r1290",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "biib_MarketStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "MarketStockUnitsMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Market stock units",
        "label": "Market Stock Units [Member]",
        "documentation": "Market stock units."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r193",
      "r195",
      "r196",
      "r198",
      "r221",
      "r222",
      "r434",
      "r435",
      "r436",
      "r437",
      "r515",
      "r552",
      "r617",
      "r700",
      "r779",
      "r781",
      "r789",
      "r812",
      "r813",
      "r869",
      "r871",
      "r873",
      "r874",
      "r886",
      "r907",
      "r908",
      "r930",
      "r940",
      "r953",
      "r964",
      "r965",
      "r969",
      "r970",
      "r984",
      "r1202",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r193",
      "r195",
      "r196",
      "r198",
      "r221",
      "r222",
      "r434",
      "r435",
      "r436",
      "r437",
      "r515",
      "r552",
      "r617",
      "r700",
      "r779",
      "r781",
      "r789",
      "r812",
      "r813",
      "r869",
      "r871",
      "r873",
      "r874",
      "r886",
      "r907",
      "r908",
      "r930",
      "r940",
      "r953",
      "r964",
      "r965",
      "r969",
      "r984",
      "r1202",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "biib_MosunetuzumabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "MosunetuzumabMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mosunetuzumab",
        "label": "Mosunetuzumab [Member]",
        "documentation": "Mosunetuzumab"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r943",
      "r983",
      "r987",
      "r1204",
      "r1285",
      "r1289",
      "r1290",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flow from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flow from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to Biogen Inc.",
        "terseLabel": "Net income (loss) attributable to Biogen Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r128",
      "r163",
      "r225",
      "r252",
      "r255",
      "r259",
      "r276",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r310",
      "r373",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r582",
      "r589",
      "r611",
      "r634",
      "r760",
      "r843",
      "r860",
      "r861",
      "r998",
      "r1198"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r150",
      "r252",
      "r255",
      "r297",
      "r300",
      "r301",
      "r759",
      "r1111"
     ]
    },
    "biib_NeurimmuneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "NeurimmuneMember",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neurimmune",
        "label": "Neurimmune [Member]",
        "documentation": "Neurimmune."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "biib_NonCurrentPortionOfNotesPayableAndTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "NonCurrentPortionOfNotesPayableAndTermLoanMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Portion Of Notes Payable And Term Loan",
        "label": "Non-Current Portion Of Notes Payable And Term Loan [Member]",
        "documentation": "Non-Current Portion Of Notes Payable And Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1023",
      "r1033",
      "r1057",
      "r1065"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of World",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "biib_NoncontrollingInterestCapitalContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "NoncontrollingInterestCapitalContribution",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution from noncontrolling interest",
        "label": "Noncontrolling Interest, Capital Contribution",
        "documentation": "Noncontrolling Interest, Capital Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r496",
      "r1126",
      "r1127",
      "r1128",
      "r1130",
      "r1320"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not designated as hedging instrument",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_NonrecurringAdjustmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrecurringAdjustmentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrecurring Adjustment [Axis]",
        "label": "Nonrecurring Adjustment [Axis]",
        "documentation": "Information by nonrecurring adjustment directly attributable to business combination included in pro forma revenue and earnings."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_NonrecurringAdjustmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrecurringAdjustmentDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrecurring Adjustment [Domain]",
        "label": "Nonrecurring Adjustment [Domain]",
        "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r159",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of term loan",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable, fair value",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r93",
      "r94",
      "r1247",
      "r1257"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r929",
      "r1133"
     ]
    },
    "biib_NumberOfSquareFeet": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "NumberOfSquareFeet",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of square feet",
        "label": "Number of Square Feet",
        "documentation": "Number of Square Feet"
       }
      }
     },
     "auth_ref": []
    },
    "biib_NumberOfWholesalers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "NumberOfWholesalers",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of wholesalers",
        "label": "Number of Wholesalers",
        "documentation": "Number of Wholesalers"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OCREVUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OCREVUSMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OCREVUS",
        "label": "OCREVUS [Member]",
        "documentation": "OCREVUS"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OmnibusEquityPlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OmnibusEquityPlan2024Member",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omnibus Equity Plan 2024",
        "label": "Omnibus Equity Plan 2024 [Member]",
        "documentation": "Omnibus Equity Plan 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expense",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "negatedTerseLabel": "Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "biib_OperatingLeaseArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OperatingLeaseArea",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Area",
        "label": "Operating Lease Area",
        "documentation": "Operating Lease Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r972"
     ]
    },
    "biib_OtherAssetsCurrentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OtherAssetsCurrentFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets, receivable",
        "label": "Other Assets, Current, Fair Value Disclosure,",
        "documentation": "Other Assets, Current, Fair Value Disclosure,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments and other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "biib_OtherClinicalProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OtherClinicalProgramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other clinical programs",
        "label": "Other Clinical Programs [Member]",
        "documentation": "Other Clinical Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r249",
      "r761"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r25",
      "r258",
      "r640",
      "r643",
      "r646",
      "r761",
      "r1109"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r249",
      "r761"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r249",
      "r251"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r761"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r20",
      "r253",
      "r256",
      "r261",
      "r297",
      "r640",
      "r641",
      "r646",
      "r736",
      "r761",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss), net of tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r13",
      "r149",
      "r253",
      "r256",
      "r297"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r114",
      "r115",
      "r761"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r78"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component of accrued expenses and other",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expense and other",
        "terseLabel": "Total accrued expense and other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r972"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other (income) expense, net",
        "terseLabel": "Other (income) expense",
        "negatedTerseLabel": "Other (income) expense",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "biib_OtherProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OtherProductsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Products [Member]",
        "documentation": "Other Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Depreciation and Other Costs",
        "label": "Other Restructuring Costs",
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "biib_OtherresearchanddiscoveryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OtherresearchanddiscoveryMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and discovery",
        "label": "Other research and discovery [Member]",
        "documentation": "Other research and discovery [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OtherrevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "documentation": "Other revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OtherrevenuesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other revenues [Table Text Block]",
        "documentation": "Other revenues [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1021",
      "r1031",
      "r1063"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1024",
      "r1034",
      "r1066"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1024",
      "r1034",
      "r1066"
     ]
    },
    "biib_PLEGRIDYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PLEGRIDYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PLEGRIDY",
        "label": "PLEGRIDY [Member]",
        "documentation": "PLEGRIDY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "biib_PayablesToDivestitureOfInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PayablesToDivestitureOfInterestInJointVenture",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables to divestiture of interest in joint venture",
        "label": "Payables To Divestiture Of Interest In Joint Venture",
        "documentation": "Payables To Divestiture Of Interest In Joint Venture"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentDueAtFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PaymentDueAtFirstAnniversaryMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Due At First Anniversary",
        "label": "Payment Due At First Anniversary [Member]",
        "documentation": "Payment Due At First Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentDueAtSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PaymentDueAtSecondAnniversaryMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Due At Second Anniversary",
        "label": "Payment Due At Second Anniversary [Member]",
        "documentation": "Payment Due At Second Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1115"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r1117"
     ]
    },
    "biib_PaymentsMadeToTerminationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PaymentsMadeToTerminationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments Made To Termination Agreement",
        "label": "Payments Made To Termination Agreement",
        "documentation": "Payments Made To Termination Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r266",
      "r338"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transaction value",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r586"
     ]
    },
    "biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PaymentsToAcquireBusinessesGrossOutstandingEquityAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to Acquire Businesses, Gross, Outstanding Equity Awards",
        "label": "Payments to Acquire Businesses, Gross, Outstanding Equity Awards",
        "documentation": "Payments to Acquire Businesses, Gross, Outstanding Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of co promotion operating profits first fifty million",
        "label": "Percentage Of Co Promotion Operating Profits First Fifty Million",
        "documentation": "Percentage of co promotion operating profits first fifty million."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four",
        "documentation": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Second GAZYVA Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three",
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option three."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Until Second GAZYVA Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two",
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option two."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfFutureDevelopmentCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PercentageOfFutureDevelopmentCosts",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future development costs",
        "label": "Percentage Of Future Development Costs",
        "documentation": "Percentage Of Future Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units settled in cash",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "documentation": "Performance Stock Units Settled in Cash [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units settled in stock",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "documentation": "Performance Stock Units Settled in Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PeriodOfCollaborationAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PeriodOfCollaborationAgreement",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "label": "Period Of Collaboration Agreement",
        "documentation": "Period Of Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Plan assets for deferred compensation",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential future milestone payments commitment to third party",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "documentation": "Potential future milestone payments commitment to third party approximately."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r991",
      "r994",
      "r995",
      "r996",
      "r997",
      "r1317",
      "r1320"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r481"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value $0.000 per share",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r749",
      "r972"
     ]
    },
    "biib_PretaxProfitSharingFormulaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PretaxProfitSharingFormulaTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pretax profit sharing formula",
        "label": "Pretax Profit Sharing Formula [Table Text Block]",
        "documentation": "Pretax Profit Sharing Formula [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PriorityReviewVoucherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "PriorityReviewVoucherMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Priority review voucher",
        "label": "Priority Review Voucher [Member]",
        "documentation": "Priority Review Voucher"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDivestitureOfInterestInJointVenture",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from divestiture of interest in joint venture",
        "label": "Proceeds from Divestiture of Interest in Joint Venture",
        "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1116"
     ]
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (distribution) contribution to noncontrolling interest",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities and sales",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r1140"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sales and maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equity interest in Samsung Bioepis",
        "label": "Proceeds from Sale of Equity Method Investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of intangible assets",
        "label": "Proceeds from Sale of Intangible Assets",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of strategic investments",
        "label": "Proceeds from Sale of Other Investments",
        "documentation": "Amount of cash inflow from the sale of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of priority review voucher",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing, royalty and other revenue",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product, net",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r219",
      "r332",
      "r701",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r910",
      "r941",
      "r982",
      "r984",
      "r985",
      "r988",
      "r989",
      "r1106",
      "r1193",
      "r1194",
      "r1204",
      "r1285",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r219",
      "r332",
      "r701",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r910",
      "r941",
      "r982",
      "r984",
      "r985",
      "r988",
      "r989",
      "r1106",
      "r1193",
      "r1194",
      "r1204",
      "r1285",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "verboseLabel": "Net income",
        "terseLabel": "Net income",
        "negatedTerseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r252",
      "r255",
      "r270",
      "r276",
      "r291",
      "r297",
      "r300",
      "r301",
      "r373",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r582",
      "r589",
      "r591",
      "r594",
      "r595",
      "r611",
      "r634",
      "r741",
      "r758",
      "r798",
      "r843",
      "r860",
      "r861",
      "r957",
      "r958",
      "r999",
      "r1111",
      "r1198"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Additions",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r175",
      "r179",
      "r180"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, net",
        "terseLabel": "Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r656",
      "r742",
      "r756",
      "r972"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "biib_QALSODYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "QALSODYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QALSODY",
        "label": "QALSODY [Member]",
        "documentation": "QALSODY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r193",
      "r195",
      "r196",
      "r198",
      "r221",
      "r222",
      "r434",
      "r435",
      "r436",
      "r437",
      "r507",
      "r515",
      "r542",
      "r543",
      "r544",
      "r552",
      "r617",
      "r671",
      "r683",
      "r700",
      "r779",
      "r781",
      "r789",
      "r812",
      "r813",
      "r869",
      "r871",
      "r873",
      "r874",
      "r886",
      "r907",
      "r908",
      "r930",
      "r940",
      "r953",
      "r964",
      "r965",
      "r969",
      "r970",
      "r984",
      "r992",
      "r1186",
      "r1202",
      "r1249",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r193",
      "r195",
      "r196",
      "r198",
      "r221",
      "r222",
      "r434",
      "r435",
      "r436",
      "r437",
      "r507",
      "r515",
      "r542",
      "r543",
      "r544",
      "r552",
      "r617",
      "r671",
      "r683",
      "r700",
      "r779",
      "r781",
      "r789",
      "r812",
      "r813",
      "r869",
      "r871",
      "r873",
      "r874",
      "r886",
      "r907",
      "r908",
      "r930",
      "r940",
      "r953",
      "r964",
      "r965",
      "r969",
      "r970",
      "r984",
      "r992",
      "r1186",
      "r1202",
      "r1249",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ]
    },
    "biib_RareDiseaseProductRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "RareDiseaseProductRevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rare Disease Product Revenue",
        "label": "Rare Disease Product Revenue [Member]",
        "documentation": "Rare Disease Product Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RatioOfNumberOfSharesReservedUnderPlan": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "RatioOfNumberOfSharesReservedUnderPlan",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ratio of total number of shares reserved under the plan",
        "label": "Ratio Of Number Of Shares Reserved Under Plan",
        "documentation": "Ratio Of Number Of Shares Reserved Under Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from marketable debt securities",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gains) losses on investments, net",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "biib_ReataIntegrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ReataIntegrationMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata Integration",
        "label": "Reata Integration [Member]",
        "documentation": "Reata Integration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReataPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ReataPharmaceuticalsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata Pharmaceuticals, Inc",
        "label": "Reata Pharmaceuticals, Inc [Member]",
        "documentation": "Reata Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r25",
      "r258",
      "r640",
      "r645",
      "r646",
      "r761",
      "r1109"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1016",
      "r1026",
      "r1058"
     ]
    },
    "biib_Reductioninroyaltyrate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "Reductioninroyaltyrate",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in royalty rate",
        "label": "Reduction in royalty rate",
        "documentation": "Reduction in royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r514",
      "r659",
      "r660",
      "r747",
      "r754",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r840",
      "r842",
      "r867"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r659",
      "r660",
      "r661",
      "r662",
      "r747",
      "r754",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r840",
      "r842",
      "r867"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r514",
      "r659",
      "r660",
      "r747",
      "r754",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r840",
      "r842",
      "r867",
      "r1269"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of borrowings",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r794"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of Short-Term Debt, Maturing in More than Three Months",
        "label": "Repayments of Short-Term Debt, Maturing in More than Three Months",
        "documentation": "The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r280",
      "r281",
      "r455",
      "r483",
      "r662",
      "r684",
      "r743",
      "r919",
      "r920"
     ]
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs, percentage",
        "label": "Research and Development Costs, Percentage",
        "documentation": "Research and Development Costs, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense asset acquired",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r909",
      "r927",
      "r1278"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReserveforCashDiscountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ReserveforCashDiscountsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounts",
        "label": "Reserve for Cash Discounts [Member]",
        "documentation": "Reserve for Cash Discounts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1017",
      "r1027",
      "r1059"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1018",
      "r1028",
      "r1060"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1025",
      "r1035",
      "r1067"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r424",
      "r427",
      "r432"
     ]
    },
    "biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected operating expense reduction",
        "label": "Restructuring And Related Activities, Expected Operating Expense Reduction",
        "documentation": "Restructuring And Related Activities, Expected Operating Expense Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r426",
      "r429",
      "r431"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Cost, Expected Cost Remaining",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected number of positions eliminated",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expense",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r428",
      "r429",
      "r1187"
     ]
    },
    "us-gaap_RestructuringChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringChargesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r137"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r429",
      "r430"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r431"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restructuring reserve, beginning",
        "periodEndLabel": "Restructuring reserve, ending",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r430"
     ]
    },
    "us-gaap_RestructuringReserveTranslationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveTranslationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency and other adjustments",
        "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r144",
      "r752",
      "r786",
      "r788",
      "r795",
      "r823",
      "r972"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r288",
      "r289",
      "r290",
      "r292",
      "r297",
      "r299",
      "r301",
      "r374",
      "r375",
      "r413",
      "r570",
      "r571",
      "r579",
      "r580",
      "r581",
      "r583",
      "r588",
      "r589",
      "r601",
      "r603",
      "r604",
      "r606",
      "r609",
      "r650",
      "r653",
      "r783",
      "r785",
      "r799",
      "r1320"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r260",
      "r276",
      "r318",
      "r322",
      "r323",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r373",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r634",
      "r741",
      "r927",
      "r1198"
     ]
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "documentation": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "documentation": "Revenues from anti-cd20 therapeutic programs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RituxanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "RituxanMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RITUXAN",
        "label": "RITUXAN [Member]",
        "documentation": "RITUXAN."
       }
      }
     },
     "auth_ref": []
    },
    "biib_RocheGroupGenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "RocheGroupGenentechMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Roche Group Genentech Member",
        "documentation": "Roche group Genentech."
       }
      }
     },
     "auth_ref": []
    },
    "biib_RoyaltyAttributedToOCREVUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "RoyaltyAttributedToOCREVUSMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Attributed To OCREVUS",
        "label": "Royalty Attributed To OCREVUS [Member]",
        "documentation": "Royalty Attributed To OCREVUS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty and other revenue",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty operating profit threshold for highest royalty rate percentage",
        "label": "Royalty operating profit threshold for highest royalty rate percentage",
        "documentation": "Royalty operating profit threshold for highest royalty rate percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "biib_SKYCLARYSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SKYCLARYSMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completed technology for SKYCLARYS (U.S.)",
        "label": "SKYCLARYS [Member]",
        "documentation": "SKYCLARYS"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SPINRAZAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SPINRAZAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPINRAZA",
        "label": "SPINRAZA [Member]",
        "documentation": "SPINRAZA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SageTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SageTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sage Therapeutics",
        "label": "Sage Therapeutics Inc. [Member]",
        "documentation": "Sage Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Sales [Member]",
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesReturnsAndAllowancesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns",
        "label": "Sales Returns and Allowances [Member]",
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SalesTriggerGrossSalesThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SalesTriggerGrossSalesThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales trigger gross sales threshold",
        "label": "Sales Trigger Gross Sales Threshold",
        "documentation": "Sales trigger gross sales threshold."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SamsungBiosimilarAgreementMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Samsung Bioepis",
        "label": "Samsung Biosimilar Agreement [Member]",
        "documentation": "Samsung bio-similar agreement."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SangamoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SangamoMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sangamo",
        "label": "Sangamo [Member]",
        "documentation": "Sangamo"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r1102",
      "r1129"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r302",
      "r516",
      "r1088",
      "r1129"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r584"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of fair and carrying value of debt instruments",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]",
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r599"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of fair value and presentation of derivatives",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted earnings per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r956",
      "r1234"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r578",
      "r1089",
      "r1090",
      "r1091",
      "r1238",
      "r1239",
      "r1240",
      "r1241"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assets and liabilities recorded at fair value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r407",
      "r410",
      "r411",
      "r412",
      "r702",
      "r909",
      "r933"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r932"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of roll forward of the changes in goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r409",
      "r412",
      "r933"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r108",
      "r109",
      "r110"
     ]
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Disclosure of information about long-lived, depreciable assets that are subject to operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense), net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r656"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r431"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r134",
      "r135"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r136"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r140",
      "r142",
      "r143",
      "r144",
      "r234",
      "r235",
      "r236",
      "r320",
      "r481",
      "r482",
      "r483",
      "r485",
      "r488",
      "r493",
      "r495",
      "r791",
      "r792",
      "r793",
      "r794",
      "r940",
      "r1087",
      "r1119"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Variable Interest Entities [Table]",
        "label": "Variable Interest Entity [Table]",
        "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r592",
      "r593",
      "r597",
      "r598",
      "r679",
      "r680",
      "r681"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated future amortization for acquired intangible assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1178"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r194",
      "r197",
      "r199",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r333",
      "r334",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r803",
      "r807",
      "r809",
      "r870",
      "r872",
      "r876",
      "r887",
      "r894",
      "r897",
      "r898",
      "r899",
      "r900",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r911",
      "r942",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r986",
      "r992",
      "r1204",
      "r1285",
      "r1289",
      "r1290",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative",
        "terseLabel": "Selling, General and Administrative Expense",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotes3.250DueFebruary152051Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SeniorNotes3.250DueFebruary152051Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051",
        "label": "Senior Notes 3.250%, Due February 15, 2051 [Member]",
        "documentation": "Senior Notes 3.250%, Due February 15, 2051"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.200% Senior Notes due 2045",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.050% Senior Notes due 2025",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.625% Senior Notes due 2022",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SettlementLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata related accrued expense",
        "label": "Settlement Liabilities, Current",
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income",
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement, authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ]
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense included in total costs and expenses",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "documentation": "Share based compensation expense included in costs and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfCoPromotionProfits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ShareOfCoPromotionProfits",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA",
        "label": "Share Of Co Promotion Profits",
        "documentation": "Share of co promotion profits."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfNetProfitFromSageTherapeuticsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ShareOfNetProfitFromSageTherapeuticsPercent",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of net profit from sage therapeutics, Percent",
        "label": "Share Of Net Profit From Sage Therapeutics, Percent",
        "documentation": "Share Of Net Profit From Sage Therapeutics, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfNonControlingInterestRecognized": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ShareOfNonControlingInterestRecognized",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of non-controling interest recognized",
        "label": "Share Of Non-Controling Interest Recognized",
        "documentation": "Share Of Non-Controling Interest Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r273"
     ]
    },
    "biib_SolothurnSwitzerlandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SolothurnSwitzerlandMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Solothurn, Switzerland",
        "label": "Solothurn, Switzerland [Member]",
        "documentation": "Solothurn, Switzerland [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r102",
      "r105",
      "r106",
      "r223",
      "r257",
      "r258",
      "r259",
      "r288",
      "r289",
      "r290",
      "r292",
      "r297",
      "r299",
      "r301",
      "r319",
      "r374",
      "r375",
      "r413",
      "r496",
      "r570",
      "r571",
      "r579",
      "r580",
      "r581",
      "r583",
      "r588",
      "r589",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r650",
      "r653",
      "r658",
      "r761",
      "r783",
      "r784",
      "r785",
      "r799",
      "r862"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r194",
      "r197",
      "r199",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r333",
      "r334",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r803",
      "r807",
      "r809",
      "r870",
      "r872",
      "r876",
      "r887",
      "r894",
      "r897",
      "r898",
      "r899",
      "r900",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r911",
      "r942",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r986",
      "r992",
      "r1204",
      "r1285",
      "r1289",
      "r1290",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r319",
      "r653",
      "r701",
      "r790",
      "r800",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r822",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r831",
      "r832",
      "r833",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r842",
      "r844",
      "r845",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r862",
      "r993"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r302",
      "r516",
      "r1088",
      "r1092",
      "r1129"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r319",
      "r336",
      "r653",
      "r701",
      "r790",
      "r800",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r822",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r831",
      "r832",
      "r833",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r842",
      "r844",
      "r845",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r862",
      "r993"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1020",
      "r1030",
      "r1062"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plans (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r101",
      "r102",
      "r144"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock award plan, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r101",
      "r102",
      "r144",
      "r528"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r102",
      "r144"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock award plan",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r102",
      "r105",
      "r106",
      "r144"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r47",
      "r101",
      "r102",
      "r144"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Repurchase Program, Authorized Amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Biogen Inc. shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r67",
      "r223",
      "r224",
      "r258",
      "r288",
      "r289",
      "r290",
      "r292",
      "r297",
      "r299",
      "r374",
      "r375",
      "r413",
      "r496",
      "r570",
      "r571",
      "r579",
      "r580",
      "r581",
      "r583",
      "r588",
      "r589",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r640",
      "r642",
      "r646",
      "r651",
      "r658",
      "r784",
      "r785",
      "r797",
      "r824",
      "r841",
      "r863",
      "r864",
      "r892",
      "r999",
      "r1121",
      "r1157",
      "r1261",
      "r1320"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r275",
      "r480",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r496",
      "r608",
      "r865",
      "r866",
      "r893"
     ]
    },
    "us-gaap_StockholdersEquityOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityOther",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Stockholders' Equity, Other",
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "biib_StrategicInvestmentPortfolio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "StrategicInvestmentPortfolio",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Strategic investment portfolio",
        "label": "Strategic Investment Portfolio",
        "documentation": "Strategic investment portfolio."
       }
      }
     },
     "auth_ref": []
    },
    "biib_StrategicInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "StrategicInvestmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Investments",
        "label": "Strategic Investments [Member]",
        "documentation": "Strategic investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r664"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r664"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r664"
     ]
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Sage Therapeutics",
        "label": "Summary of Activity Related to Sage Therapeutics [Table Text Block]",
        "documentation": "Summary of Activity Related to Sage Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of activity related to the UCB collaboration",
        "label": "Summary of Activity Related to the UCB Collaboration [Table Text Block]",
        "documentation": "Summary of Activity Related to the UCB Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total reserves included in consolidated balance sheets",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "documentation": "Summary of share-based compensation expense associated with different programs."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TECFIDERAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TECFIDERAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TECFIDERA",
        "label": "TECFIDERA [Member]",
        "documentation": "TECFIDERA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TOFIDENCEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TOFIDENCEMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TOFIDENCE",
        "label": "TOFIDENCE [Member]",
        "documentation": "TOFIDENCE"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "biib_TermLoan2023ThreeYearTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TermLoan2023ThreeYearTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Term Loan Three-Year Tranche",
        "label": "Term Loan 2023 Three-Year Tranche [Member]",
        "documentation": "Term Loan 2023 Three-Year Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityFloatingRate364DayTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TheCreditFacilityFloatingRate364DayTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility Floating Rate 364-Day Tranche",
        "label": "The Credit Facility Floating Rate 364-Day Tranche [Member]",
        "documentation": "Credit Facility Floating Rate 364-Day Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityFloatingRateThreeYearTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TheCreditFacilityFloatingRateThreeYearTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility Floating Rate Three-Year Tranche",
        "label": "The Credit Facility Floating Rate Three-Year Tranche [Member]",
        "documentation": "The Credit Facility Floating Rate Three-Year Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TheCreditFacilityMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility",
        "label": "The Credit Facility [Member]",
        "documentation": "The Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityTerminatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TheCreditFacilityTerminatedMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility, Terminated",
        "label": "The Credit Facility, Terminated [Member]",
        "documentation": "The Credit Facility, Terminated"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one",
        "label": "Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One",
        "documentation": "Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in any 12 months under option one",
        "label": "Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One",
        "documentation": "Threshold of gross sales to be achieved in any twelve consecutive months under option one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Time-vested restricted stock units",
        "label": "Time Vested Restricted Stock Units [Member]",
        "documentation": "Time vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trademarks and trade names",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r476",
      "r493",
      "r607",
      "r631",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r762",
      "r960",
      "r962",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r973",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1245",
      "r1248",
      "r1249",
      "r1250",
      "r1257",
      "r1260"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, treasury stock, shares",
        "periodEndLabel": "Ending balance, treasury stock, shares",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r102",
      "r105"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r429",
      "r430"
     ]
    },
    "biib_TysabriProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "TysabriProductMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TYSABRI",
        "label": "TYSABRI product [Member]",
        "documentation": "TYSABRI product [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_UCBPharmaS.A.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "UCBPharmaS.A.Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UCB Pharma S.A.",
        "label": "UCB Pharma S.A. [Member]",
        "documentation": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain (Loss) on Derivatives",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r855",
      "r856",
      "r857",
      "r858",
      "r880"
     ]
    },
    "biib_UnrealizedGainOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "UnrealizedGainOnDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain on Derivatives",
        "label": "Unrealized Gain on Derivatives",
        "documentation": "Unrealized Gain on Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_UnrealizedLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "UnrealizedLossOnDerivatives",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Loss on Derivatives",
        "label": "Unrealized Loss on Derivatives",
        "documentation": "Unrealized Loss on Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r172",
      "r174",
      "r176",
      "r177"
     ]
    },
    "biib_VUMERITYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "VUMERITYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VUMERITY",
        "label": "VUMERITY [Member]",
        "documentation": "VUMERITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r287"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity [Line Items]",
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r597",
      "r598",
      "r679",
      "r680",
      "r681"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "documentation": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dilutive potential common shares",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r313"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares used in calculating:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc.",
        "terseLabel": "Weighted average number of common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r313"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "biib_ZURZUVAEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240630",
     "localname": "ZURZUVAEMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZURZUVAE",
        "label": "ZURZUVAE [Member]",
        "documentation": "ZURZUVAE"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>136
<FILENAME>0000875045-24-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-24-000025-xbrl.zip
M4$L#!!0    ( &>! 5D<&_?-W]L" '\(*P 1    8FEI8BTR,#(T,#8S,"YH
M=&WL?6MWXKBV[??S*WRSSSV[>HQ \7ZDNG,'(:2:W4E( ZF]J[^<(6P![C(V
M+=M)Z%]_EV2;1P()),:2;.U[;E? QI;6FEJ/*6GIY__W-+.T!TQ<T[%_^6<Q
M7_BGAFW=,4Q[\LL_6X-VM_O/_W?^7S__GUSN/Q?]:^W2T?T9MCVM33#RL*$]
MFMY4\Z98^[=#?I@/2+NSD#=VR"R7"W[6=N8+8DZFGE8JE"K1;=%5<M9$A4*S
M6*OE4%$?Y2IZM9!KE%$]9S1&5=1L%JJE,3J=G(T*1E.OCHJYJCX>PVV-4@ZA
M42.GUZNC:K/:0,WZZ-0XJ^J51JU6;Y9U/*I@'3=*8[T^PJ-2HUBJ8;W"WCOU
MH,_0;]L]P[KQR\G4\^9GGS\_C8B5=[&>GS@/G^'"9]K@D_#&)\NT?RQO?7Q\
MS#^6\PZ9?"XVF\W/[.KR5M?<=F.I4"A^_L_-]4"?XAG*F;;K(5O'T:_,IXT?
ML<8$/RN6/YLVO !3#:QN]W+0UHW?1&U?W?W9(\AVJ3J0!PJF#ZOF"HU<N;AL
M++S'W/7F GWS9C,-;&X7&%S8$!@T</MC7VM=J9 KE'+%4O00W2<$X+C8_LKH
MZJ:BX [C61O#WM0^!Q?#6W=KDP(D>IY+5OT8(W?$;H,O-UZJ.[[MD5W-#"YN
M_,#WR$ZA-S_#U>6-;FZ"T/QE$\(+&T]]@=%-7=++(^0N=3DRS='&[2/3F6#;
M-*#ANC-CCR[4RH6E2EVG4BK67T-+< ?[P9F%P(:<8#MW/S@Y_WF*D7'^\PQ[
M2*,_S^&_?//AEY.V8WM@3W+#Q1S:I0>??CGQ\)/WF:GA\_E__==__>R9GH7/
M:8-S4:M^_AQ\^?/GX-$CQUB<_VR8#YKK+2S\RXEANG,++<YLQ\;0 //IC-Z(
M2?"G:1C89G_"]5LP:L34@_<_>7T\_N5$S\$@L=&,/@F;9QT;7K=H0^L(LKJV
M@9]^PXL3S03[,<Z5JB?G!?A?HUXM5*H_?]YXZ@$O:3-$>U>FJR/K.T:D8QN7
M8&=/M&"4_'("P^K,@&]R,WC*-&>@51MJ)^?%TN=R\?VOCZS[ZOU7\(V[?$/]
MY)Q*/ZX7W,'MCK'YBL;)^>^E][^@!4\WV!LL-%D^M'ER/D:6BW<\]XH@G1H@
MS;?-X*GN%!'LGCQ[$Y@E&!KF#![URTGW]FH+/)P9Z&7@.?J/ 7M$S_>H_:3N
M=%.'MC_+&8Z7"Q]XHE&!P+,*4:-AV)T7*]736JUX6JLL11*U]9Q]L89B@L>8
M6D/L;AE\=.2?N<SQ0%\TYJ[./!ART%5S-K>H26#?30GMZL8XRS^Y!HQ"]K[5
M2\)WNHY/V"?F1\ZH %G[0P%&W\\P<GV"SX-/P<6?/V]>BS[39[QXG@]M>/ZP
MT-B<W0\N#WT6((_I9_E,,!M@]M9O91A!GD/>^=H7OZ=?7F+;F9GVML?N*YJ-
M1WS>;/UKO7;QA(Z+%U*DNCX++QXD1D#P"),=*I[#GP<]S?UK_+)MX ?/Z(6#
MGH0!S\X"X^T][817#WKDX]2QL OC\V5WV4-7UP]Z[)PXAJ_O4$EX<9\'AE:*
M/9/:P^A[S&Q2] D0 I_')B8:LP1X:^S8[OZVZ<J>_WC9@LVGSYDMCSZ!S2,>
M=5S,7^0*1?B_Z'>K:\MF&FNWUG+4M6]>B3Y'+_F\T>_M8B@)((8@>/;"GM5S
MY:40HBOOZ5GYV#T+]138A."C 2][FENF;GHWF(Y[S3#A*LL:3R :/KL+X-HC
M TP>3!VWGDPP_V&0&ET-?OKSYZU/7'9^^>)W *V2/- J2AW;U5'>7QWE^-11
M5>H0R0S7E#IVCHY]U1'CZ*C+HPX6!?7Q [9][(Z),P-_:>I&J>!-(;">8Q\^
M09 T(6CFIM*Q-)2NI/$Z3:4K:5Q2L:"4)8W#*AX]G3U: -&RC?!RCVHKE3ZJ
M>/0T.R7JX>.6BO)R!8F/'AZ>2%[N(/'1P\/W')U+D,3('SV)E\2:'CU[EF1<
M'#TS/9A;7^_:1[CUXM$3N<.Z5H8(*Z9I@Y)P:4_D4OK8HFO)[@"\BR%=$A1,
M<;L7B_4KFV[HUK')VL7X_<]Q\%42+IV110EQC@3ADI:/**$OXS 0+B^10@-Q
MC@'A4@^A#9$ R6))N)E->33&)TXN"3?Y*:Z5$V& "3<Y*HFZ.(TNP;+04HS.
M6;@L-+;(KRQL%CKP (GT-YV__& I]]RQX:/[G/^D:Z )-M@J[V,'W.6XU@P*
MFW?N*?:UE?72R%S8-'-/F;<,PZ1^!EEWR#2Z=AO-30]9TLA?V"1S7_GKNC_S
MF1MGDRST/H*G]&D/N&OKS@Q+HPMAT\T]=='''C)M;'00L4U[<H3%%D<2O+!9
MXYZ"'Q*V\V'!3'_@!:21O0CS9D?JFK"YDC#C68")V[)P2TAE\( B*$ZX]:0B
MA>L"**@B>QJ;6&PO@K)D3WZ3Y1SBHGHJLN>_"7(.L<E<^IR7#^<0F_QESW,%
MX!QBTX7LJ6_2G$-L@A=VWE-<SB$VV<N>F"<8Z\2XG*8B>Z:=5*P3I\QE3Y)Y
MQ#HQRK\J?0[,.=:)4Q>RI[B)QCIQ"E[V)#?I6"=.V<N>["8_"<%A65U5I<22
M*D[V_#G120@>"I(]S^8V"<%#62HQ/V2]:5P+%:HJ,4]>YBHQYRK_FDK,Q=&%
M2LPY"5XEYOQD+WMB?H?H,0S2B%OV#/O6L6F/B&-98&*ZT#>"77G$+T*9H"-U
M3?8,,V&&C4]=HIKTJ>61S*T(NI$]_TS*-HN@*^GS5NY,-1_%U65/>)-CJCDI
M2/8LF ]3S4E9LF?.R3+5<:W<J\N>-"?(5,<F<]DS9TY,=6SREWV*60"F.C9=
MJ%R?D^!E3]\Y,-6QR5[V]#P9ICHV<<N>8?-AJN,2?T/V/#G!R#[&<FX-V;/?
MI"+[.&4N>Q++([*/4_ZR9[.\(_LX=2%[EIMH9!^GX&5/;Y..[..4O>SI; *1
M?9SBECV)Y1#9QRE^V?/8Y!=J<"A9W9 ]_4UJH08'W31ESXUY+=3@H2O9$VHA
M%FKP4)SL67FB"S5X*$CZM)W70@T>RA(VK[_P70CF7+>E@[)<II"-\\R1A^ZF
MB,R0SDXP1Y8+1N_8+'HS5ZK%$6LWA<WJ!1'[\Z&Q+O@WAL;ZK1\:&L)E__1D
MY:4-&^C81M";0#OL4OC-E4.PCHX>MU5RA?K^>Z";<1DL84F"-L'@-ZZ0;EKF
M\Y.4!ECWX?(E'KVE%:X#=>^7TXYTP?X1GPII[;W#*=Z40UQOO';L":0C,_KF
MX6+^[$3Q:Q!%;QR\61H?("S?(H@/.$YUPZ:P! K7$7UEVJ:'KR%WA(@7A#LQ
M1Q9NN2[VW(O%#?K3(6T+N>Y:@P:_?6]?M_K?![)HOE@0EI^11_71C[KV'7%T
M:'(?NQ@1?=H"IXX?L.7,9\>><X@5$\+R0/)@@C7H#H1.0'Y]_&#BQV^.#T(C
M\L! 6%9),A@$7*0%OX.F@(F8$#23INITL2 L=R5(3/8\ SR@"M;ZAO*/9(#%
M0J8XJ[U?SH[#AC23F/:D9?SIN]XJ-UN.9V22;\CR\>J&H=.U'^!?AR1P)#.'
MDUN*A4QQ;:F""X<:>\6"<+1?-N#R9DLHQ0D!A>'K7H\,,'DP=;S6_RCF2+LU
M$Y;_E"Q038:^B)$O+!8R11@>1_4BT!>Q8D*QF;+2%W'"H*B835GIBUAAH,C,
M;2\/5L,M9\ZO'1VM&K":HF6+'K]B&Q-D@3MH&3. @>L1N/D!=Y[F\%@LU*+B
MC:7?'XHJB\+2GP-_Y.*_?/A1A\;U+Z=^G]V0S/3ZK_X,V=W9S+<=RYDL+DS'
MU4ULZT?'1[#HHK1GUK%^Z\?P(2POJO"Q286OJ_QCOD0XEC58XS3%AF_AWCA8
MPWF#O:ECT)P_X!M>?HOQ+9JM$P4#\.B^/:$Z,6>FA4AK0C ^>M1?BJ^D:K$H
M'*4IH6XV[&II?S:'W1H3FU,4EFRDAK0W;A$"43-^ML@K<UH2EG,314N;=JX2
MUW1L43C&BTGVRO=\@MO05D@8J#Q-"XR98V.JC@U2 2WH<R]]W/*N3.)Z+=N&
M7(*XZ.-T>%8@(!S!]7X(##!TSE 8.!0#)>'8+84!H2?)2L+Q8 HP0D_ZEX3C
MOU2@(7!YZV)).#Y,X47@7;;%DG!DFG)(8AL8X1@^!1BQ+8QP3"*EA-N.3XO(
MS$$&BV=4;]>Q3??EG&]>J(PD-@JQ)!R%*(QZ-N>OXB,-A.,.5W7*Z,9I'2PI
M&-$["ZU/'+:H66@[KC= #ZP$D^F9;/U! @L/.-18*):$H_>$UA*G]+@L' %'
MK5>?NOU5^8L;TS9G_NS8B[7J<4WBEH4CJ;8)%3W))53AB!P.B]"DMW$\...R
M<)2.0L[A,0R/7+TL'+ES$'*V[X ( 9-JO/"R-,)Q.PHO0ML7X:B=HVHI=K2N
MFMB>(C))K5D1CF)2,!'1FBA>3(;!K'@Q"<9213A>3.6,AX]O'HQJ13CR3R'G
M<)O#8Z*W(C?#F=WLD9>ED9O7S"Y>>-D78=E,E4:*9%:$)3$53$2R)MGB+F75
MDI34(:L:0P^IFQ VQCXZA#FM*8FS?G%%.'+OW6M*>$!$($4*R__)Q@\<'P(B
M\,55Q41*BQ<>X7M5;OZ1.RN0$:NBN$;)4,+%E@C+,":9/8A. / R(5+2B1D$
M!Q?+(26)F!'?+R5SEQ&/*R5?QUA5B,5H=:BC<O";!M2AU2T,&@N2AV>U83NS
MN>4L,!Y =$B0K;\5%'Z,'WI6L/E#_%!5.*)/(6"?HF@Q(D!8AE A0,!#\VK"
M$H0*+O'-",8'%V'Y00675V>@8JLQ7A.6^U,(>'4O?7P(D)+7RR0"1" ,:E(R
M?0HNG/;.U*3D_C()ER.M<:E)R3!F'0'E.!$@'(_YQB'#PT[[JGO9Z;?B6&NX
MG ;ZBNDY@_,I+;(7O$RGA?G(XNQ^D+HH03CB4A"5KQVT?9_2N>":<)1E3+J7
M5!]UX3A!0<9B N:74]1=%X[7$T3E29I?7KH7CM$3Q/SRTH=P_-K'S>)'5?[M
M_J;3[PZ_I]3A"D>1Q6@5E>I?5;UP=%>VU2$<]Y09V\O+VPK)-67+]O)2O6R<
M4\K5(1L-=.7/$('NRL\Z</*V#=F(IH0TG@'.MR$;X;2GZF55AVP<4'IL+R=O
MVQ"29>*O\0P0O@TAZ2;^MI>7.F2C@%K?>K>=_\AO>7GY6B$Y)M[ZSD+,*R35
M]%'%RZH,V<B?M%A=7EY6-G8I=5:7D^*;LI%,B5A=7LJ0C?:YN^Y\[7<OWZ+<
M);"[G/QL4S9F*2&-9R#>;<I&,>VI>EG5(1OMDQ[;R\O;RL8LI=#V\E*];"13
M0K:7ESIDHWYHK30RQB2>\OG9C'QE8Y@2TWD68E_9Z*:]E2^G0DH%V6B@-%E@
M/EZW5)"-;4JE!>:E?-F(I\0L,"^%"$D'\=U;,5RX:$3,\(Z4>EXA>2=!=EAD
M @"RT5"94(J0!%&&K#$O+RPD$Y5%:\P+ ++14IE0BI!T$5]K?-6ZN?N>TAI+
MI:*0=)0@9CC=FI>-E$JW-H1DB;)@>#EYVJ)L+%3Z#"\OS0O)0V56&[*10C>#
M\&(?/V#;_WA!9_[3<KQ\KI#4DT"J3__ZB%)12!HJ1@S(JA?9V*$4FF5>'EE(
M#DH@U6=@T41)2%I*(+/,2R]"DD9\:8K!7?>VW_HCI<1424ABZN/JD,D(\U*]
MD!15=D>BD+Q1)FPO+V\K&S>50MO+2_6R<5,I'XE"TD2<;>]OW]O7K?[W04K=
MK9 ,E" 3=&G7O6P45,KU41:2#LJ&^04W6N3@<<NR,4UI-+^\="\=YY1R?<A&
M!/W>NA[TTE"PAY>_%9)JXJ[P#'"^9=DHI_TT+ZLV9&.!4F-X>7E:(7DF[@I/
MF/#EHGDAZ2;NAI>7-H0D@/@2#GU$\*7I8N3BS;4NZ?2]%=DXIR0)B*QA04@R
M2NEGJ1\A":-LFFM.,[05(3FJC)MK7EB0C;[*FGZ$))GXFNN+SFWGKG7=3:F#
MEHW(VE,=23H!654O&Z65\I$H),^4"=O+R]L*R65ER_9R4GU52 XKLR.Q*AN-
MU+WIMZXOCST0T[N.HBHD+\5=X1F(>JM"TE$?UKRLVI"-$$J-X>7E:85DF+@K
M/ LAKVQ,4S*&EY<V9"-_KJZ[_VE=I,#P\O*T0M)+W!6>A8A7-III/\U+JHV:
M;,Q/:@PO)T];DXU;2I_AY:5YV4BF9 PO+VW(1OQ<?._UOG7_D-_P\O*TLG%+
MR2@\ Q%O33:2:3_-RZH-V8B?U!A>7IY6-FXI?8:7E^9E(YF2,;R\M"$D\<-W
M1=FP=]6][-RV.^GTM74AV25!-END7?>R$4UIUX>0]$\VS"\GCUL7DF/*F/GE
MI7O9Z*:TZT,Z$LAT7'-F6HBDX(@B7CY7.JXI,:5G@/>M2T<\[:U]634B'2&4
M)B/,R_,*R3L)H?0,<, -(2DH(8PP+XW(1@S]<=__X_Y;ZZW$1 (+S,GM-H2D
MGOAK/ ,Q<$-("NKCJI=5';*Q0NFQO;R\K6R\4PIM+R_5R\8^)61[>:E#-CKH
MZOZF==GIW[1LHW5Y_VOG^D9^*\S+[\I&/"6N^RS$PK(140>#0%+%-&7CB-)H
MF3EYY:9L;%2J+3,O$,A&4"5NF7DI1C;ZJ.=-,0FOIV#*CI=#EHVF2E+M&8B4
MF[*15H?H7U:=R,8FI<P4\_+ LK%6:37%O/0O&W.5I"GFI1.)B*1HB(17Y;?#
M?-QON2 11Y6LSM,?#Y<+$I%4J1OP?(Q\N2 1)Y7> <]+^;+Q7L-.FV[?ZK?D
M'^^5_8\2CM7&R\9Y):7RA/T[%]W+QG?MJWM9]2$;UY4B\\OG)/=R03:>*XWF
MEY?N9>.XDC*_O/0A)+_%MU3)M_N;3K\[_)Y.AUL4DMT2I%))RE4O$;>5!74(
M23MEPO9R\K9%(;FF;-E>7JJ7C7-*N3IDHX&N_!DBT%WY60=>WE8VHBDAC6>
M\RW*1CCMJ7I9U2$;!Y0>V\O+VPK),O'7> 8(WY*0=!-_V\M+';)10*UOO=O.
M?^2WO)Q\;4E(CHFWOC,0\Y:$I)H^JGA9E2$;^9,6J\O+R\K&+J7.ZO)2O&PD
M4R)6EY<R9*-][JX[7_O=R[<H=PGL+B\_*QNSE)#&LQ#ORD8Q[:EZ2=51EHWV
M28_MY>1MR[(Q2RFTO;Q4+QO)E)#MY:4.V:B?+C2?C#%Q;/FM+R]_*QO#E)C.
M,Q#[EF6CF_96OJP*D8T&2I,%YN5U96.;4FF!>2E?-N(I,0O,2R%"TD%\]U8,
M%RX:$7._RB&2>MZ*D+R3(#LL,@$ V6BH3"A%2((H0]:8DQ>N",E$9=$:\P*
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MSZL[U6!,L*.(0,]K9]B!L@D,.1@_7[1@)$TPO1O:"\/(L?&I1IP%LKP%^V6
MF#E:!(IECD^S3)V6G;,GIS20M] H](NG\**_?#,\;P_P!OJF8Y,F QJ:$!S
MXXOFH2<M"ML")"Z;HH-U_,(>"P,"C4R+SCRQ1NL8K"B,()?:,9Q#<VK-D 7
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M=:+,S=-O;.9,F:,VV+JH%],WJXY$!,8Z9QR\VWBV6(3FLRI;2=X1;P1/FHY
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MR"!(UKNO:B7LD-)M.X,.YI;%&\C2V@XT#4WPLO:Q@L@6:65QB]$M?@PW%JD
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M/613,6W27*O%,\7BR7FQ4E4',XL8V.R Q!LK:3\,B1*%1$5M/Y/(2AP9$>7
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MU ;W%X/N9;?5[W8&'[5NR?2@W;N][-P..I<:_#7H77<O6T/X,!C"/S>=V^%
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M!4?*Y@A#B?*W.16*G81K%68J2&S[A&!;7V@>/-FU6 2HH:5N,AL 'F9K7T2
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M/CW>?1M>#Y[@C\<G^.?[S>W3HW3W5;H://Y5^OKM[A_EV-.G4"!7)7@NO,8
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MPN+=SV%=>DZBF]HIAYMZE]$1!?%EX+%"DK-8!=5MB=-9O&0IX!Q-F%B*#[[
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M0TSFU,*2KV<0K&P&1"X27GC*3625_)!!G 3PN#'\]>E1@RNDQD](0S]S.1C
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MDM H=EY#Y(=OEOG\Q.P9$F^<M.A@)F4O)I62I,6^Q]-\K@.OU!4R ZM%OQ@
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M+ >,)X.I8V$B5,%9-_ZM@MTT4T?HL\/_<_6+JVNERS^-K/%[$%XVWOVB2C\
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MP"*8/-RT&DC'51)LW.A@4)@?;Z7%'RC- <9!2!E_.0:LA$F0X1>7J_5(H'A
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MM4:CH4?ZK2?7\Z-XEVAM#P/ ]S954TYQR<3!7P58;3,B#PDKH]:T'"ME HN
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M\^X>%D='M_S8N[BZ5F7I$7PH=T3&L%GI:Q@\A>Y+M'RME?T2<O(5$7Z%"]^
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MK7;,BK8C@HH[FWK7()'B3UTZ::9N :[L@J9?"OB<\*ADQT]A1Z6%]^6VZ:0
M:N-1*;!4)57$=+[9%#:&L[%Y\=&Q<R[>?]N_&(5!#YOC;VK'S$,8H#12UO;[
M9$"E P0L]H8+;;-S-$@0*01[1"9WSF.;<BA5?ZUU04U56$ZMJ<NYM=6I;^;.
M^SKW__W-5A7UHV 1ORSB3M!UN92"+BZR,J/(EHM&44[C5U<P"U\K F7BNO2(
M*&,[3@2+A"+8I A4WA3!N3C!7T,O"+WX'5S@5X^\2:_!N,=O=0&?LC87#^'@
M'EA1*4>P>_%"7BZ?X7O>[I/P<+EG$7^2KI=3TH5EFQU&ZA%@9!0$(^$@"1]6
ML(AG23?YDO1S<5(?0[=/7MSPCRBA,QVNBZ]1'O/:I)5/H1+.ZM$TTHZ^:85H
M)*O6-/726;#G[0@)7Y5[%O$GZ'8I!5T8L-E1M*._4R$H<HI!D7"#A*<J6,2Q
MH!LR5X)>:.NVAF64P6>EM<7>ZAQV'GS5(C^?L=IJ,LE= Q[V@S&28\J%S&.[
M*MP]O$ B5<NTWE5LF%H,MG\ZBJ'0FFS5M(JN.BR Q2=R^H2@"T&O=K&[H19?
M["[D7<C[N<C[(0_V.Q(7<*QKV$M U=1*G^K;A)DOF3V*'[919CD13>[B$[L*
MH ]E<^N)S0W2R=:100BA$$*NA;!L'2T,@[FCA9!%(8M<R^(A#\1B;%43;57-
MU!C[@IQ( FF@_^?8A2^<S8M8'BFQ]N^%H2 3%ND8WQ\%D8>[O0P)J#+0<Q_?
MO'[\/.7?PJ<F6Y7G'W&[L*MQO/DC"QOJ$>!U>! H*O(N+*JX,-58&;"Q\/=S
M.-=B3^2B&Q+WCPMW "N^=(=O[GN$1%_8V(OG3Q]N6@VDXRH)-FYT,"A,YJR4
M?28@ L0'(3V.+L&;(B&^"];E<K4>Z3E$R?^;9_1TVS0M1^N1KDYZQ%8'/:M+
MNJJMJ";IZ?^Q:LU'Q+H4#*0K5!IT9+S;7&8H"_ ,VV+?_QKPT@A0:WYJW_]Z
M<R>U[ZX:4NON6NI\^]1I7[=;#^V;3CEV<'?_>--)U.'CO71U?W=]<]>YN<:?
M.O>W[>O6(_SC<_NN=7?5;MU*G4=XX<O-W6-)MO=A[+MPC( A5Z=GDN>/2?^G
M-&T!.G7R!@KF^:QNXT*IS3_;BF<OJ\L:\<4-GT!WX*G@C#9.8[+D7A'JD#[V
MTHN!SKT,"G+1BJ4=FMHO(]<+7Q)IV\#(A0V9FS=T#/W^.0BE^)G _X>$T/5'
MW@_I!3[W'$D$M$Y?^L?8)Y(FUR555O6ZY*YNV)MM&#6-V_MS[(7PL;7;92G&
M6^=99N_BEC?>ZAZ5%GTI;6U'7<)_Y;+]C'3;K^MYW<M%7+;\_AR5]X/6A$6K
MMF&JJ0>GB&VFQ"0E(,%P"H%\RS["JNU:4S&-E-FSTV77L:W:B/30>!N^U_D%
MY>DQB2WH793H.,C):/,(G'9J32,M9KX'/C=,#"IRV::,Q3I:RA".#0 %=4KU
M] A;(M#)=U+"%^I^2"-@;="/&M(CO,?S>V"*1R22WDA(/P+G#8!#ZH\),G%)
M@P\F!\ #<6,WT=Z)H[)-D\-_@IZ'01SIS8N?I<X_OU_=MAZ^=QI2W@.%O@5^
MT.JP6NG9!25< *]F[N\"?U;Y,D]E&V*D:KM;3 <3@FO\!@YJ1/P93^4%GBHY
M7?<-XG&2M:LYU\[1TK6<2]]P:IYD[7JMZ0=K.H#AA44KK/<,YB6)&GN:GZ>Q
MIZ]F T\>UP>>\&M'7Z7,:5G0O#1.1- $EH)QF S)E;!HD'YD% ;]<0_UJD__
M\12Z+]%<_X(J#<9/SXGR753145T"HA(?53U^M#N.8&%1A$=#U_.I@H<S(75M
M*4H=SHK)T0!O#5X)5>1>*)$HAGW@Y\=T:JN$X(?O?@/2/4M RB<B=4G\1H@_
M5=X;)L3:AYI7:QJUIKH:O4-J[UC/H2;6FELFUM:3,],%4+RX\'7^DY1 "PCL
M M5=(.>,T ,:OMDQ=U=;,E$V;^'WR=>TDF]YF'Y_OJV!1Z"LTYINC5H3,]Q2
MY]"_F$"T+]'P[ 3D+@U'T9]W;,XZZN;0<9"W;*Z_=>YU0VK[N &?).<0930*
M_*)=!?Q,C"W0/QTRBLE+%T0-32"T@&;4F]E4X'(O="L>OE^X(] 1KW.],;4-
MOS4ZC2FX_ 6I'<#!(+VZPS'%$OWT#_HK4$SY+&-YV=RR5Z7GTT0!7<WUSP/I
M!4\^JI1V'UCN#3QWX3(PV2L8TK?PLC<$ I$(?@=T7V!OQ@D*S@(;L0]PBO>7
M1..Z4PL[46!@+L,I#BKT!8SF,0@EGJ&)02VY_?\;1S$-YC2DZW&(PHJD'GAA
M%$M_CMTP!MX!5:DI.V.9].9&THQ-$_;<-+XU$C5->D"U)9Z"X+O>$"DS4ZLD
M&@_C^:=#TAN"H@;Z]=PIC)+7Z67JFCX_,!#L<@#! C]+;6B[@# (@Q>I_?7A
M_[DOHX_7>&ZDS5TKIT$UW];#!"JPO2E_I 4&E2%<.=],2$;8&!\/$2J0<VBC
ME#SYR3XW]<Z?A22?W7A)ZX+<@E.=1#)3[2GZ)'13_2"&<R&&KW![SXLXP;M'
M:0"ZQ*- !MF.Z1+[0/Q9A#0Y"_"\H,J'BOE\<UUWZ/H],K')YCIH)NVP-9 $
MH P<-^,P)'[O72(_P/!'6RS$+QH,X6083TU # OTW#!\1P4V(].2#X_'U'P%
M,T<?5WQ->LDAI2GUB:^^L!#<V_R#,_-UD:K>/J>BT&14DRF9-%F5C[1*J^E9
MK].'I-?I;RN]3CG6R869O. 2H<(#ZQKT$OH"?2_"0&82]5QO!)NH[Q?W'?"'
M+A-51T$W!L-_[2/==XJMS]>MQ$F1!N,8) -^_83I:$'X+D7C[HL'>,0%AYA[
M0I_GPN>\L$^/A?>&]#O%+::I].<!V92E=5U<#]YV@AK=I+ARJJH=N3XG554+
MP6U+W=Z):A:91_]O3<J3PRJ58JB"9G0%+J!6 _J0T(<3=S2&<Q[!0F/.L";L
MPN1'R3?38RSRX)O=<,JBO0-DQ[J?Q;0GW 0MV4UX03'J;Y2SN@1:$6D!QLEQ
M;C5S:KN[ $P4M2ZU%H)9)[_HJD^LF0@/,K^?!"W@)YJ%EF 1Q,K'XPW6!R\D
MAV@ICYN;F7Q]3O3@4AX#X&BN *36<G'X-*=C8\Q&655,'320QT,2#+9D!B?K
M6%S&S8\1\H F,3W"XS\-@]X?"VI&JX&:Z+DCS(P)QV1CSLB)17A%G27D=E?(
MG=PJ7-!KA938[/26S@<RP'M?R20DY<'9\@-O"9.SKXL?@#</A\%;=)DECPAM
M06_P#O2A>9$KB9I IZ$[BLCE](>/<"*/AN[[I>?3C=(/?9S0>I+KB(E]*SF8
M] N37\]S_AIRDO<W:;TP^>;)KQOPJY_77[?LAJ7JJ;^2&TK.UPTM_4LV?6+3
MHA2[H>GFUD?MZ#'!;\_#M=ROI%H ;+[)*1ZM9=MGS')GJ0%-H4^2"'?">L-T
M"K6HQ;%TT[U$IUU-1W+D07.$EO1\=NI(?IC?=LP3 EBQD['TD65(:*5J>W<1
MX+SJ=K>5):V;'<D%$E#Q'JP6='*^TYNB%'<'BP/MM,)\WF: E_84VJA7C'T/
M']$ELGC)N8,'/[Z1X2OY0K5\JM!@_9Y9G- (T5@5#5.(!G^B@6?(XUN0*A%F
MK6F:_ S\J)Y$6$(B.)4(S!5.E0GL(&X+F3B<3-A")OB4B<_!.-W;L&M-2Q$B
M<3B1<(1(<"H2\-Y4D7! )%3.1&)WGX'%FEC1::"YX+"(3@,\K$=T&A"=!KC8
M7B&=!C:W%+ V70_#D:IU7?;=*9EV-ZT=*^!^_7XP?5C*=3G.42_+=7ER@TTS
M$ZE>P:Q##_,972F$7^%U^)L;]J<)@TG>:X3999@1\S0APC2-=OTB7-QVB]MN
M<=LM;KL/X2--57!]/6W^V+?=XL([A085\[)WY 0S]_BS%6PXKRK.QC*Z@['H
M\&&H,LWJF7)P4CZ!1A&M@UAKV"'"5H4(5#9YFB;/)P4T7VEI3:H8@=_A\!69
MJJ24W,>+Q3)" O9J[[PJ EA/"3]MD@5*^_:DZ1 8/?2_J<*@U9IRGH;-?,@!
M]^"?FYR;3?#"S<WT)KXB];(0\O"O48J\"F(W4G5JI*I60S_&T)1#IV9NOS-*
MC]9IHC[M2/5IJ4TBC]L+\A3U:<?86$K\:-H.4'3FW+P"=AW<OON\20DG_>](
M?V%2Q[PEWFT0K=0##[P?I'_Q%PGG28T+#>YL8T.#.VZ9ZO9.SM89W1>;^@V!
M\F2I <CTFJ,A40-\WO2A@(8A*Y=K(EMA+5O!VIRM@&M& =A]<4Y;AHH4!Y'B
M(%(<1(I#MA2'C6,1IB[(!;K1EZHU]:VQALV/+R_4),^A%!??BMPP'*.0ZVK;
M:JCR]D?MNIU<,TPF31N6?<4EAY#^GC6,M$EW3^PA9BBJF>YRJ>MCK^1,; DA
M'9 **4!7]$-UTLA&G<_8C>8WVHWFR[RW5I1"K12//E=2#WX3_:)K+^J!]0=?
M%:6E]5@I(U1L"Y^WDNW#F%(T6\<D-W>I6]"$!OU[[#0$=B4P^I,;>=&FGAW8
M<+<L24B4=9'4)</@39HT&UP*<+C=8!PG,8Y)MSR_+PWGQ$G:4[FS)E/A\'W:
MD"UICHL=^3S\.5[J7TC;YO:Q*1JAZ4U#[%M(&VM-&J<MO/G9(R$V.'R?YD+A
MR\GR:$<T[\\QG0,@C6-8U5^))] G<-R! 0GGP+CWO/"XTF9*Z7)#5_/E-QTA
M4TIM6+8M%E7B13F%)+KM2 3;?B>I9#EIMQZS^9/&CI)6M^$HQ;BQ*\V.$XF>
M)WFRR8JF^OI5 ?V3_3*@^@E\_%Z8'C>C\SB(. J)'G%86P;2[-[S&1'M7V-P
MGOI)F.(K6-DD^J4;_MR$;VC104[T7U_HV(_D-Q]NJ6VG9 &AH/0"I3NP"MHX
MV(\3<B<)0$C3^RX\\A4-T.0W;7\T7B:W*LC-3FY*R&]^,*,R?6&=R-I/>4Z0
MLJ6 9[]/GIROZ"!>%GC4[)5ENV]E@E@<WXNK;I[GE1L]2^3/L??J#I<";\7F
MN)U)KEJ%<\YT>\=H2$12R^_C?V[F>$J)NN;/2L,A4G5==QH6)WG?!2@K(3'5
MEY@=:9J,$I.2(;0H+$X-A,)6%?6C$!8A+.41EAV%=X<[7AQ9'"]"8KC87RZ)
M =P>_WAQ%-Z.EQV^V?0B%19*-LN6>->F=PGR"O*6]UV"O*<D;XGC8LFE$DW5
MP>A8_"Y%>(-.\Y!$6?11 DIM_Y5,RBY2C984XT2M-359K9(=+T"3+Z;" !I-
M@*;JH-D16]@%FASND<Z;>R3@='3'NT X&;S!J;H67U+TF11S3N?9'R/!0'R>
ML\\+GY$WGU%QRJ%"KN%3K[1.FQX9J*F%LW@<9_%S4HQ_-:G%OYJ0G^:)974$
MS%I3U0KK?",,-_Y M&N$1EX0Y;#D+-XL.8&OH_N912@I6RBI:H-HEW=Y2"7%
M7>Y0U=U-H/"%<#G/_O,5]HF^#N%[)_7\H(E M0U(&-)&>R\XB<P5K;8/[B1U
M/:][B8Q(RF;@!+F><.%J@0G9+!!85JVIV0V#DQ-"6"!'<Y/V@%%F&T21N4LP
M$P@[FJ-4K*)2A:*J-HPVN4K'450:;XJ*Q8JT&VH9K$@163]5+_DYY1-A2A4%
MO=944N90"$5;#8SL#)RO@R2''N4NQT$ Z.B1\4Q:QA1:IM(@V17YWDO+<'?_
MQF"M:7(YK+6LO:[VF)9T]O.0SFOBT<[\CXFGMW\YL"+3;A.V8C:40P_JY.$0
M$O(FY(W!XM\B;RDBY11;8B$$BB-8"8$JQ ,J[@!3:#\+0RDN2TC(&T>H$_)6
MB#.94=ZV>Y5*X9>5!YZ(6:J6T_2IV7N"+HS1.')CT-6QIJ?.+Q)+._32JIN7
M6.!-V]XQS6J<OU4^91G+<J*IKG[/Z$$J*MBT=L/D)'9[!+-5"$?YA8.MW&B'
M<.2P3KG+4!%R(^3F8&54^0\571PJ0CA.O[]CE(<5=ZAPEZXC^C7PUJ]!Y"ET
M5X89KP841%"Z"/)43+7O<J87 IQ9+1RS4 NG"*9Q:AD)<17B6K![OTM<<]A<
MA2<O"DD6DBPD.6O @>'@M<7!*\15B.M)0B %'KR%-\0YE213+_YGVM >_MOW
M7IN_T+^2U>.8V=E.YK],^M]/MY2L#;8S=$<1N9S^\'$:,/!\RE?ZH8\O;OCD
M^=-]8C!@96ETZ<FO/[YY_?@9D="0$S1,P@V3;Y[\N@&_^GG]=5UNZ&KZK^2&
MDO-U0\OWI$V+4M2&9=MB425>E&-N?53&L-B.9)3M96%*;47X)N*T73>48/PU
MJF6)ZF7I"W%1*]-NV1)H?E=ZP$$;(6Q(^N1&WG+RR4FH7HF)XRV@[D"Z)CWR
MTB6AI"EU2955C86Z'*4(;MWRA[8OP:.'<%I'62;49TT@JQ JLD; =^_YC(CV
MKW$0DWYB_WT-O1Z)J $%W]#J8>(<_5<R0"CYS8=;\DJ&DI(%A(+2"Y3NP"J\
M :S(CQ-RTZZ)E*;W77CD*]J:R6_:_FB\3&Y5D)N=W)20W_Q@1F7ZPCJ1M9_R
MG" ;B;6#7B7)0&\5WL$S"[WV,7;$5YU'5C<.@:6#["938/>[]"X\]G84&FR*
MO147*CO*-O*%RI3"9@2O1\=4N=8T%3EO6>]A@M("KE6 JWK\D=:*REK$)X L
M@+P)R-HA]:XJ]*Z :Z%PU4^A=UG+4T3",-?O$N05Y"WONP1Y>:LF*$F()0GX
MTXP)#+3$[U*$%YDT#:6X5M7%]P'ET!K9$;3(/>-=4?5:4U?,O,UCCV<QGRNG
M=_C[#)PV!*>YY/0.A[BPF>F*:G(?SCE7#.SP,@O$ &O!Q F:.I?$O$GF%1YL
M5N$9O^U 65=][W7E$1?X_DO%IH [(90>2(]X-*E &H3!B]1Q7Z(QIOMYP6WP
MY/5FYG+Q"S0::H8E?AP%D8?*XC(D0]H+ZR/>(%^H#7L]D;GK1@0?4&M^6$CP
MH?G3PMS/="P86Z8X4;63Y%4D+0TR#DI65!L,04UNR,((X(O;YO[<SF$(L!9P
M"!P<&@?;9I46C@--%CC@% ?;AHTR:W]-.8GVK_ <Y\-.X#L+I.\(:V[HW$3A
MGQ7VV"93:3A"Q_'%^1UASMR<SW'PG>J278!BSXAH$>I %^J 1\[OB(,>4AVP
M=N\[KF6T=Y#+/&F *XF5 FTO-L5+]PH/B;>)/ T.\S3*XLG@8/B)0*+F!%6<
MS(:'?<Z'PPO7I@C7ACKQ2._)M)T@O)X0^VJ!UEFM&;/6U*R&(:P9OGB_P;G9
M@_<Y[)E37?0*6#"Z-\6J!%NH!!YYO\'!.8Y*.-65CVB4O;51]O$Z^9VT3.@8
M+?DXE/@=L>WBIIOJR713V<P;UCIVETPA"^<J"SNB_;E&9^L*4SZS +L .Q>W
M&/G CH7-IMQ0!-@YP8( >YZ+FWQ@UYA25,2 :-X&1.\]T5A\D9BX7.C$Y6J=
M-94^4=ARPG*/NM3U6E-3\LZC$!UC!'"+36DK; RE?JI$%H'IZF*:+2,OOS(V
MA3(6P#U]0F%QRIC3<NO3IU&5^UWB1C-#K._TD\MXB 2><$ 9A_IXAU>7?YZ@
M;K.8#'R-#12B)$2I<#^SN%E_.O.L/R%E0LJXVWZAGF_^ \N0Q8$E1.D<16F'
M+U[<@66PSBW@:P;M=%63B;'XO6;:M"P<"WO4>;2.T] 5(^\X6DUKR(I5R!12
MT)^*;!3S*+5A6-NGK$Z<_>DO)Q*@T4+*K=>WJ4-)B[\L3K\1WC#2N%@UD:%K
MF%I$U[ 3*#B<G-R4'L@H)!$=P1H_$VF XUE?Z7C68$!?B0BHN?Z\5&[DOF.?
M1JD_WM3#37+A?Q(\=3R,9T\!%88_!^-0VJA4_3$.*%W7J\ZB7M56U>H-;;G\
MA<3/07_>1_+^S2=A].R-OI(0M8C[-#=6+M0%5:K6FKJ3DE'\]VDO9P]5$#P5
M?EC<*QEY0+(@9?O],1UANT"\/\=N" ]! JBRJM9I\>$;,/!9>B,2&9)>#)1=
MI?\(U]&0/L-[40#P7^X05I&<$T@Y^-\J<7<ONBZ-A@0P"!QR^](1 )@]5X="
M\BZ(B:35)3@:IV(%:SZUH "G@=013=3H$S^B1:,^U7HN,F_@^:[?\X!!40PO
MT%:FC96B[P1A=^,76$%ORPEX$(-'D3/M\QXP]+*EGSF@9J(P %JSIJT(LQ$8
M$EYO^"[%H=L'BJQ]M"'APR?W#B@Z0P_>@N2CR%UYW#4!M'MU0.\3D5P0HH[K
M/[DO :SN7>H2^/"+AX3OOB<R 'N<RL 4_'7ZF]=@"!3'WR7[DJB.AD^BH+_"
M4NKT0\!-U!,A_=603KC$QTW5"%W""*#IQ\AD?#PPD8)SHNI0YJE"Q*<A",83
M34C-$S@QW3@(&]+C,ZP-1)C44?9Q,R"'0UQ]Y,UF< (5AR1"E>PF(C[M)C!3
MS=$8E,<"R;)C;<)N'2VA]7-K8DPDUN_"IR9'O3S_B-L%](_CS1])L^-.AFO5
M7B'0PM_/X=S2>"(776#('Q?N %9\Z0[?W/<(;8Y%:051G3S<M!I(QU42;-SH
M8%"8GEH;Y(J&"*4Y'):(-F32&)15F%@;O[A<K4=Z#O%\_YMG]'3;-"U'ZY&N
M3GK$5@<]JTNZJJVH)NGI_[%JS4>JC #V>(&93+%TF\L,90&>85OL^U\#7AH!
M:LU/[?M?;^ZD]MU50VK=74N=;Y\Z[>MVZZ%]TRG'#N[N'V\ZB5OY>"]=W=]=
MW]QU;J[QI\[];?NZ]0C_^-R^:]U=M5NW4N<17OAR<_=8DNU]&/ONN(]G29U:
MGIX_)OW5=K[T;]"IDS<DYM?$AI1MZT*I<7J>;[<>MYZ[R7&;'+U/:/B\O 2X
MB:#WQ[%LR/DF68Q(Q:F#PI@>OIAEBYM)6O0\T ,/3F\XVP_8=3HCE^IH#DVL
MD.TV);"H-QRC?>4E[ .'0D,?X452Y(M_-C;*'#^0I!:0].P"/[J$^)O]P90@
MF[+4,;I]]SFU$*/],@(_"NEU]0S;)E&NX)J6+^ZG''Y%>JWI!VL>ZMH+8$V"
M+D6\>+.OBZ9&\:3MS0N([1C]>!2%GAN&'OX<+SJ>+OW,/\8^N&%R'0&FTW=?
MP^&,#KJD*?15K2&U_9ERH<;V$E_]0.J!_0J;G:(;GY_HGICTGGTP_TF4X^M*
M@&VJ;@$/42_T1HF6'4RWCE*-KXS"H$?ZP(1HYHH ?49@I\,K\,M7KS_U:[RP
M?S%R0W"7\-?H8<"Z7ND;D43XX"1,,/O]G,0O09\,2Z*HX;@9OP 7WY%<G;D?
M)+5ZO6#L4]_J*^C%'GJ@%Q*&SR4:/Y>^)'BF4*^?7(\7IL:E/;%NR;T]-KL:
M\TPWG&ZIDZQ)2>T;!>3"%8?T/V1(-<N<6260W^1L>L._0'W%\/QH0$*JH28*
M% 1\N+!+ST>6@QB.::QS2I.C*;5C,/KS#,!M/XK#<8)@D%SI:GZ %,1FU;"T
MKGM(/92^Q\0J3-UI"6![#9HPB5!*T7,0QA=@![R '1*#:D0@]D@8N_"%<U7D
MS?>7A,G0%GB?GB!X7@PF8>F)@MH0]^RZ0W@B?BV9=M6;=;Y,=#>><M.I+_7Y
MM0%H=^_BZEJ5J=W@CL@X!E+ \?<4NB^PIB!EZE!]_LR1^TYC BA4\&(XQHCC
M#^PDE+Q&/P[O'\$3?WAH&$4+-LY^4G<JC%Z3;KP9F$L1OW4;==DH[?2>P009
MDOO!U83O5'2CEM^_B6)*K_[LDCJZ'^!7+WPSC<<\PO,_#<$;7+!4P3P'VP>X
M"4X^\(17K_AQ>M4RM8+GR)\9S'VD]I*8)#<V+H@45?-)2$1=/ [J]+<1M65@
M.7T\!P;@@09OJQU@Z5]'O]6V#2WOK;:N-F0G_<IYTU7TYM<-32WD4EM1&YKI
MB$65>%&6GB4GH40M";8F$J5GY>1-B7#F"1AN[X^G$(["_L5D&WWZ9S539SV9
M)@]IX*!S>]W#W1!0TK363>7BZ%0H.0I&RC9RK/D)2R0IK7"D;_E#VY?@T4,,
MQ_ZT+^]3>TQLSE J#S#0'/NE&_[<7':R-I,IT_[/BX938S<7'<^35 )N!X?;
M#C7.2HR2]&2:C'631D%(4P,*E,1-QE$A$%U_>!?_;X_/%[>X(L7L%%_%TNJ)
M#_!OA3H-[C]B2.XV@!5HIG[1=VFBG-][9CV"LN*QL(*3@KV!G 4GF;:Y5T7)
M4?:7YV;9D.7M%25X>19]32*A^Y:4F*PE)5D84UQE5B[U*T1$B,B"B$PLCEQB
MP=K?Y,AB(9KYE+^ T)!W-(_8J>Y3\&O7FHIQ]&G( J0"I(L*-P68SDF *=I&
M\=8V2M%*(.@KL0J,T/N(\Z4T!)IS,00'K[@)@ANMB#WZ#%3!Z-O1&J9 O\B4
MBS8 C]W+@BU@)3!8( 89' ^3N<4#+[C+"J\CHHA#:VI'^QT&D]]4F2PK 8^2
MPV.+L6UJG$$B?\>1@F\EV)7D\:^'"EK9OA<VI_N>\J6[Y+P*O0O\B]XQKT.+
M@>21/L_'V\[C:C)^#@FY>"=NN.?M9!Y'XBS<A1W-X8IT6?5RW%D<S#$5>%K&
M4R[PL$Y7X>#"*P4C9^$D&,7[D&:M:<@<7QL)5F>0^A2^6B?A:T5M)[TA&_+?
MI0[QO2"4*.UI?6.'C.(D>U\Q:/:^(8RH8N!O%FA$99@X;^+M>=U2[(;%]6$H
M+*DC@2H_@AR*(-W*W0]=F%.GPH-U7"5CR10BJM(PA+7%%Q+L VH&2TDT@WGL
M:8 5-<;4AIIJC'UQWR5:0ZG)P@HK1BR<(RM(O-"LJY:1TJ6;IS-46&%' E5^
M!.']9UUW](;&-8+$V3O#@U)DZ4L6B.B)DG'R0D0@X=!(R)%PG)_M1J(9M(8M
MK+ ".&LT5#E+2$P7(;&"I*/(5-@L F.BP,B*G5=@A#%635#E1Y"%"()5<8X@
M<03/\;!OEFI>B-"XNVP[>>/N @F'1@)SVD$6MCM3S7!DME?4&-,:RO:0F"%"
M8@6)1?$I&+9<:SIF;G=4F%G51$UN96K3^P7=TCF_NQ:'ZQP/1TYOL&E@7=8=
MD>?%&Q)RW$'G9[LVU0Q'#G56ULQ*OWG\3+KA&&>:)"$O0Q'&5C'"D>-:/JNQ
MI=>:NFDV5*Z/2F%L'0DUJ1 Q "*@,T4>5UG.T'W3%%(P8.*P<#NOFA"L/C"K
MU1R7Q:E\M5"VU1+< 2I:PS)*8!.E5+2*ICDG%I)]N\OE=3/L6M.HZ[I=6-J6
MZ)QS=D#,CSJGUC3KJJ/F;G;!"^I$8Y0L&#IRVH,C(ZP4S<H=317H*3=Z\D-%
M0:A8=FXWX>#M=G(9FN6P,Q^#V!T>P*S,>"A,QN]I0+1^,,8OI_S:0[JJT7&\
M$/)4R^S9.VJ95PVI!S*_]V+JB8QS(<Y"G$\GSOEE5SN0$\.)[&X345XD\2CF
MRT9)/+G <6>T[QW.SRN#.I5!F]7C$Z+&%]:$J!U$U/++E8%RY6BL[O'1Y8HZ
MSS_3J>L+P]NGJ^)GIGW;1S;Z).'OFQ<_TS'V;N_/L1=YTQN8!^+&KO1&I'Y(
MWJ3_R@,+9SDIR5Z%Q37IQFT_BL/Q"_'CZ>S+U@N8(_.NQ,X"$K"4*,7"D;K)
M+&!I$ 8O= _+32KKL*Z74>A%I(\[<O/MPE"7BQFTU6W< F7O!U<AZ7OQ9[?G
M#;WX_8O[PWL9OWP*PC!X@TU=N2/X3?R>"O"-/;:F0XZEP3!P8WB,%+HQ61T'
M2.,7N3>E'WA3=LY-K3<2;4@ID[[K*?R5WMQ("LG(!0D& 1F,A\.&]#D *(,@
MXW>Z0W@]43L4U7XJ2$9#XD8$'N3VI:E*.:1PTL=FZOFK)C>D0"5%JTMMOP^"
M0_H^B:)CK'/KJNI2' #O"! .$-8G/@H9_$3U*?"U+PT\']CI 0^B&%Y 48\:
M,Y5-U>,$(G>@!T*OQZFZ? 1)&X"=*+VBH4B12=S>,_X7T81/35Y=RNM[(R&H
M3H+A17AB'V$>C)^>)=C7'R0&-'?A@Z^S,&0/90N.)DJY")[;(U%#PJ_N/;O^
M$SS0PYZ[:RO!%2Q]KYLF.J@&W1!7$:P/C*]+\"L)U"0L#4@(<C"DJX#W>GXO
M1-F@W_ZMT6F B,*_Q^&[].Z181]#J7 8ND/X6# 81"26NN^@DD#!T,_AQWI4
ME4C1".4KDL91\FBZA?7E1_"59'V-6\5Z8<&KSRN-<)]<GGDDSJ+"XX!"$WSM
M5'(H-L-QG]!#:7;@ (!?)$6^^&>*#L0SVO/'%,Y+6G"R !UO6$9!8IQ=4KQ[
MK^3CF]>/GZ=F^\*G)I:O//^(VX4EC^/-'UFP<I,1Z:?4N*JS0J*%OW'-:&MX
M1D^W3=-RM![IZJ O;'70L[JDJ]J*:I*>_A]L83KYT',X]W*?R$47M,$?%^X
MMGGI#M_<]PC-]\7#!TZ>R8I,JX'$7Z7;1NH,!H7Y9VNCXH$XB3L"^A6/"N3L
M&&0DQ'?!NERNUB.!80<VY]]V<PH8]4A/0CBYKM!<!2'ZY6>WN8P"%K0:ML6^
M_S6TIA&@UOS4OO_UYDYJWUV!X7IW+76^?>JTK]NMA_9-IQP[N+M_O.DD+O7C
MO71U?W=]<]>YN<:?.O>W[>O6(_SC<_NN=7?5;MU*G4=XX<O-W6-)MO=A[+MC
ML!Q(ORY--"WI_Y2F8M+M3P>5;Q(;N,"(U:4Z*S;QT/*-+R_P%9Q(0U&\'(:
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M6.;61=6E.,!@,- -9+I/_(B@%O.IGXC)0-+ \UV_!SB"]<$+]#*[L78-RY\
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M\-VI<8GDF-JAP%(> RN!/R\8_@'.MK\T013^I)]'GGMJ&*!NL])3;IKU]@'
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M44)(C-C*X3SO&J[M5Q4EDGNBXH0Q]'(M2T<W$8($4H;PI 3F9NT5@'MI@Y]
M*B3!BY%0(7M3UZ:1U..1KA$)KZ>0@NLBD=^VR:%FWUM"RL7?X.IA@0L(L4 +
MW*P_!NXU^X7G3></JL1B?$AW:;SL-3HJA[?XYJ.C7JF[_33^]BU@:_"O-](K
MK&4.LJ*!'I;8;.8YUR8^>_$NR3?T8?1>0>EKZ\?)S:WO0VP(3#/E7^,3:^E[
M_'5+]4U?NLM]V^(YF?N>C.>>^GBUTUV1Q7=+X!NE=04[,9@;Q @#,O6/K@7"
MQ6L-N"E:ERS@AWQF05X)S9@TJ"9NWR;Y#M^.E.#'<+&ZX9+%WN(Y[]@;6",
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MA^=J#L[0#'SQ7ZZEVU.=A$E=X$CYF>Y(2_TMF*\';KG55'M.#^:OL7>>@R_
MGC?FC^YE?'XT=L1Y>8(R#%K'H<2P;XOAM.=(NM*\<#J;F+,$76A*%ILMB&)\
M-C8-VD6%"H124:UJH$!P<C<^?:DZ#K.D*8T8YF//=<MVI'^[JN7P"<EX_A*-
M^/5X9 .\4(;YVGU- P_%P>TA%7_XVR=>D:('_!627?ZQ&?EFNQ-;G^JJI8-
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M@4OSG1AT/;U?GPK <YK"B(^LPD706WP)E,7ZQ+G7CAW3LQE$$*J#A<$6(]6
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M>O=)&40??\6"J1?5(.#/%X-K/Q3+E,GN1GMK+I*RW2; *\V&IH$I#\M$YVE
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M)"):]S0 OVY70;_1)UX9 AG"3J2E^HY )BL3U%VP> VQ%O972<#N004;>/2
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M#O:$'@(QS7^W"(YI_M%1Y"3!78NQDUX!18._,ZK!Q_9D$:A&*?T];9>#:BP
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M?H=/Z=*;VN)%ERPQA%*I$<3N$ND#) ]1>RI<G^)H-K,,)]AP#8W6(_=]H,(
M7_'R[@Q<]K/0!7(C.7+!FJ<OZ\Q?7\;\!.\ <[%8Q KR$(]!THJ\ZU/=F)?D
M!SH@R918>'!N8:J;.U<:"TY6W(-D1/@ILT9^.6+49\J:_SU(+X-_/S'+9UJ
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M^US.^@[XK^6PB^!JNK,_L?@Y3S1ZC>1BZ%J)VC@L1J39/#!97!#I.-("RX2
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M%2+I5^Q!-Z]U#X2B2V!K M)RB";[?!2]5DF(HM<J^XBB'\C(1>--)%ZBCX]
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MH;31'+A?+3J-.WR_J[50*FN?'6JW%@)%SSQ4YK0$'Y-;'/9?']G1MT4437T
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MU=6W?J>O=2\C.3.85-.YDV-Z[?[]U1T-Z=Z"DHE?+$ZF2<_5<1<K^Q.MPU#
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MP1@^_N1J+4__;E"ND3XB04WQOY%M,G?(KT',W"G6""]>V)28Y$<;BO9HA+O
M[A*(KI2!),$6X-D6\QTB<DZCGM2B3S2!ZG'B4UTPU48+WJ$7!*TML"L"+CE
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M^R6&0Z5KDX1AQ&"/DZ62#ZE)H +DB@S,>*F5A?-C435>O/[RHD4741@\%?4
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M"V;+KICU9#BVQ7VX*0\!=["C23&O?1*3/WJ,-[>@(9ZV3B0^7EPJ)1 _NZ2
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M? #W^CY,RO/[7J]]<Z<E<'X&>+Q-/D@RY&2-&>PRQ@:T)]^T1$:([@:!GIE
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MIQ[7/&&)8G@T+T8?@&3FLL/6'4IE'\$,2!#\1%ES+L4$$U8A]&!>0ZYS0(L
M*LZQ32:\<]P06;X&X0>(Y>N@2)H=S,'D2(X]V'3%4[M%AX7/G^EFDTN64HN
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M7;1)ZHDP2USLX2H%:X4G3X;O15<T5S/^UF%_!_"K7[YT/I6*A8B\K.J]8I+
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M%%6W:$)<;JQH7JNHNHU*F68!<&JW&ZB'6;S=3FT;2L5\\SC;H+Q;:I0:I9S
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MSE#[H[HFOQ5;8\55HFBZ19*8ZIJ\_Y0+15/5-3G+MUJIGBZE?>DVJ*[)R\Y
M/0.1^V.U3.8+G\-R5ZT\]T&>]-M6Q5RUN;5YM0\:'<DL4Z=#G8XU=(!<H;AU
M:IHZ'>ITG/3I*.=JQ>*VP;@,GXY-C)]7.RGIU-5W[RY]6(9(2_'PML@LQY?
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M)W8]7T_1!4:/KU'11.KOLCMJ#O/Z=]F:+AV1(%:F<A,?T\TD&93[;Z]$2K\
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M.\0*ELY7-G58<%&-#4NW\'A$KRR!:B:0(@R$.YO:CJ?@M.;AM)I[ ?AO%!7
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M\3>O.^+EX8;C>G,-Z_VIS;_6AT-F8A]53-H6]:942":>OS."P#Y8?B=^*9:
M7V+=I7672HAE#2@0I$ U<+(\[XMA DG^^8]2I?%AE-,NF(7%H#,<(+K/VI:+
MVW%Y_^_.9>?JFHI-D8H&LJ#\E%>'#4&@8"]CK'^=^).Y;:?B.L.C6M0'V"_=
M\AASHZ5D"7RPH$4VCH[6I^6U%E7X7; AFPR $<K%7,CR+A.3"6?@\I[, \0Z
M<&&=[MA #L$NU4R@$'#>6S*!61@$TX;C(H["S(GD4X&->>:=M2T;1L/D'=%6
M'!^WX"U#WP7!C#W!L2?T0WSW@I(K^(V58FB$]<1VEBM*%D9Z(N+386/L=NPF
M%:HF( 'P DAD0-,8\L+TN9+,OCYQ?>"*3X;-I@8O[<9?5 OYPH]A(:X4=[*F
M6[PX1_6Q^!LL;,>!5"L;/9-\J@9^&&5?3U1XPD!CBB7\]"6< ]T-?R(JTQE6
M/-):(M6X5KC,R'&?ZE0A%8A]WE?>]\X$!4:G46B[^7ZN*LUM&ZYNG%HU[$&6
ML'3"KUH-NVZU9^7=<G8_>H5@K]UO][ZV^X16<]'IGW?O;^[Z),9;5U?=WULW
MY^TL(!_THH7G4E1R>47[B!@;L+$HQ4!4(HR(\P3?,1>-)<-]% A(H&?"<>#
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M[/$8I@/N#].H;CNPH^$MW$2N*;;>FL*#6?3#^M(:A>+LC0Z^/BQU[-*<^''
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MF.!9,9D$8@+WL<"Q"\-\:ZAN_2&L6]B?GK_J9V2$/$3=EN&07Z_6AJEV,G8
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MLZ( #!^^U=#U8<']F .K9 +% 0K+B&.,*!T8$#*D@R3 AHUKN^Y<Q4$'\X5
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M00*YRF "/W(IQM9&C"\H++15L5,/MLJ1=Q@N\(C[Q",>F#SB=>LJ#J2G(M^
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M<,@4;=>L$"U$^)>,M,/-N+J:D>"\G>_@2/3C#!Q[]2L0<L6+8*1P%QKTB+%
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M#H8BK%OP&@/A.@+;E6';2FIV!A.$8QHX?NC _-D!]2T4$3<EP2YA4]N;JVZ
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M!3!R"SA#/;"K>(9.ZM8GV[,96H!T<(V3MR'R#2BYP/W6\6QWCOL<A.2#-L]
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MZ)N<)LH%"SAFQ"4I,Y)%*A)T;GU_Q'9X(D=22&6K+]X>V@8GOF%2:,I"KZ4
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MTIV^_&%,ZE7"?M464@A? V!:MR[DTU1"Q82<@.KVP4A&^@8/=-94,?SS7*>
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MX=%BT[+C@G"@]!LZ+]S@W*9074;'9^\<I"F (TRL+0;-S5J"E5LL7FI'7[.
MP\2B.[:V>EG_G7,3UO)"(JLU ?;,DA0F$#;AY"L!0%Z>&G[2E=%6UMEN%.[$
MP@0F,B-Q<O7*8-H'4\@<=]*YU.:4=A/<G<5(M,K]9/,!0_GI0"@ 270F"*=&
MZ5'(S7+2DP\DVJ3E2F$I3FTPM]*E]SI6,N,Z_AO"X(PDS3UR3 [PN-8&2SS2
MLU+M4]E3SVX T9ST[-9+9EH(Z,9\RAF?ISTR0N^K9-[[M@<:"LXBP;V=1Z_.
M#,;2CZBBP#?D[TO1@&LD ;G6"B5N'A( )B)[9BV9,P+S\V!PY4[J!@,"H(,
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MFJ*<$.V!D3^ 4ED2I"_11W>!7O(V<%R>HX4/\W;8E?E97%Q$3;]3*B20HFD
M3X*%CBGVYTNG,!]/=("JYG4<*+&LE.=7,V$7BF\'QF=>NN>%FCS#W9&,F3KK
M:7@A!S'AZD/25" &A3@'NS0J"@"ABUVWHA=E&+DIJZ-82# \[TVM(WN,$IO
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MH_5?HRS[@Z/NY5$<L2G^%8EN:'L!D1+L%R0,^I+/T>W^,/E%?$%E7_3[%1V
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M^,OA!LY*G'FR*#E9'4"!=#/(/>0/!;??!MZ67[D"TT=@L54VC"'S[!&#@Q9
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MOOG%T8S>/ KC)2X*?V39$7F'&L[E9QW57V]G_<$7Z:S'Y7+'G?6_8 /'XVP
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MP8^#X7^ 97\P+'M9]B?S158LC;%K%F!#[QUF9\7Z?S6L_RU? G;]'_['0V^
M.^*GWV@(-B.H#TJU7&9^\3B>DFGK^:'V]PYW -=23!=5$U_%91+OSNJY=?/
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MR2[Q<D70;,Z<3KOS,2F6_$J^G(-V^_SDTZ<6.'$GK8_N6;OU^13\V/(^3\[
M^7G[K#,%?YM]F;2]<_=L<M(Z<Z=37NQSIP7 Y'/+_?%L<G9^]AF<_SB13%_H
M%^K.X0(XO&L!_?)"OQ[-&5M^.3Y^?G[^\'SZ 9/9<:?=/CG^[>YV)(L>Q65]
M%/RQ4?IE0ORD_.FQ^'D"*$R*3Q":;!2?(#R# ?*@^\'%BV/1X?:GTW927G!#
M%?Q10!D(W)2_QTB+K9:0GA03\=^/Q>^BHG:K?=+JG.1(U92=5ONT=7J2;:3'
M4K)L"\^.HQ^/', 809.0P1N.]!6<@M#G)&'PGQ#X:(J@Q\7(AT)0-@ID?F:
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M7[Q[(CE73\Z??KQY_..-YS^H]=,BA/!D_=N+1_ONM@?I8\63__K]Q9MTC"?
MNEF_A%FJ+^B['_OU#U_,$RS74O\J78_N?*)^Q\X?8_5'3$BFQ \?^_SX'W][
M].A,'(OY%%]C>53__^?KYU=>&;OY.YQU&=,/:7[RI#[RY.E\EG'68Z9_]/-I
MEZNJWRSI:]5]/R_/"2,G^.<,5KFC7Q%?Z_<L/YWB3X_[[N1TBN<_.UY@^>EQ
M[+K(*@"X5;Q2][_O_8XGG_E),$VKZ5I\+^C[S9LJZ0.SAA^72']_)MMS:J;S
M=.6A:=7L?''^EU.(.%W_=++JV3N T\FKQ;QTRQ?SOI_X4+2..3#I*JXCH3@*
M3K**02KI57397Q5E9; G#M=(*-#'-1PV'_VDRO@)3I?]^4_64E]+_.;;SV2Z
M.Q]GLJJ?].MB?D(277:S%9F.EZ>X6&NG_QG)%N#9<V_A(_:_?%PN8+X@ P.+
M3\])ZOT?<_KM;$G:H=>\>SY;X@+[Y<3D8J0C23B3)",9D84('I@P64ANN+>I
M-!;,@.Q<E?0E_!XMTB/Z>UR0]7W\Z -62[DQQ&>\P2+= /95([!YXDF_.CE9
M?R8CX)Z<_WTA5IJ@;SD?I_+/P$I":(-F(O27CZ?51/R,,R1!3218H8O.S/&$
M3(?B61 8R4.%6+13W@H8!(DW2-D&1?(SBMBW Z/]I-X, G_@\C.L)]Y[@U%'
MQL$GIBU/1$*RS"@>8^;$6E:-%7^%@'VYN:0A)YPUPI-*'#&@E4,6="[,0=9"
M8;8EX('<S,,:O]TU?!VX.TIW&*P>+9>++JZ6$*?X=GZ'597*.TF+AUE5R4R
MS/, 3$I2'O!<LG=#XGD;(D=EXMJ!95AE-</4TWF_[(]F>6.+^PF!UQAI!./<
MU;0K:<K3<F0EDV-6 CC$V!@RUVG8E:>:<M"'3>E'\[. Y'2]8J>D@?X8%B3L
M24"94P'.BJE.1IK,O(^9D3H->,"<4'\MD=GB/6,R@'NI^!S6K67;#, OE\>X
MV$2@=3'5);?AE);@A!MK:!$9AL)KIGTBFF1&%JV)6)3*!4)C.'^9HE&9NR;0
M&$ 33<W;R_+;?)XKFV]P\;Y+V+^93_.$<P 3=6'*:" 7;BB$34K2EURCURP\
M3P,8NMNIV085ZENR%XT5T P0K[%'^IAC(N89OL?I_+16@3:L_O(Q35>U$GJ4
M_F?5+3 _GU',1_3VE8U)TIY;)P/S)7)*>H)C %HQ(U0)E+%R:6QCQ.Q![C:0
MTM\BI ZEPF:8^PVZ68T"7\Z>=?WIO.^JQ%X6"OQ@]JZCD/"H[W'93THHO!07
MF*)@@X1"J7#@&)C#8@W] CVVQM>6I&V#)?--.JTA=+,W<-;!UM')?+'L_G4F
MYEE^?G(*W:(B_67YC.UK5/HHLLZ1<A43 ],!- L*!0%=^6Q4CD)M%]WN\/)M
M,&*_)7MS$"VT=&S+Q2HM5S44?TH1^3MB6VNE0[:%$M@LF083:DF-,Q6Y#!H2
MHI+M/=8-.K:!AON6H-%,Z,W4_P;7Q83?<$;Q]Y3X.\HGW:PC\D@H[\_C\(GU
M6ELA%=-6UKJ5E Q*XN3_*/JV1@0M>&- ;$?9-A#QWR)$!E!,X_V/839TI%*<
MET16KP1/7Y1@@"JS^D/E>4PI?+.[>;M8Y_<X6Q&4C+(VHB?%^DC*1B@,).7#
M/MHLA;:<B]9E^?-WCZDF-1;DW33H.^AIN&(LF)P"J,2BUL0/=YZ!DX8E'G2)
MTIL06V]$?KD8^\#UJK'"9B_%78//WY]<E_0+^G[ UIZG\Y/3!1[3,^2/#M'G
M\\47'JCI9WNF&W4 W?+"/Y"R" +IQ&LO HK$<K)(T"N*Q0"6*1&S3MF$X'+S
M97XG.6VWU#5$FS+%-,AK-)Q%9(1]8)Y[G@TH5WAK$_:%+?6'WHEI@X$O[C7>
M2^)MMV%NX:]2=,[CJYI*D^"O;(:^@@6MR FEQ,4Z59A 50MS13+O%$7"&I73
M&:43K9? GB3?TS%^D\ ZI%9' T7++0K(AO%D-!'-.0-3$E.9?L.M" "M,Y>F
M4&PKL:/WT$WKRWZ=+][ %-]@6BVZ98?]4?[O5;^L_O0":YB\M-Y[EIVE1%D*
MPX(Q@5G)'687@F_>.->*]C'YB4,B^#Y+?C L'&3M/X7^^-?I_,/_Q?P.S^O^
M1X7"_]>8IM#W7>G2>:&W<I! YR0M,)%=9%IQP[P$S0JQ >AL%*YUL:PE_6-R
M4&-%]*"8. BJ7]4?K,E;/_6*,M$%+KO%.M'9M-:^FL+LMB7*=5!".,$PV'P6
M&H#SCD%T.G!)$4)JW>XZ$"OW[)\8MDHQ5K ?"BH'P3VY(%+F[.EJ03)+G]XN
MB&Y(YRNU?K<!P"V>R7$'64:&.BGB!24+69*0DU-.AB0C;WT"9QA.QM3B,5;0
M'P@G8R[B3<3!RWCTRA$4\JXS?H!27G&*!]# (D?"C,^1 2*O'>3!&9 N-C_=
M-V I[PL?O55+NTT. 6JQ(3B@1:US;?%3S*62$\5*,D/KCJ8]2;YG&CATIU,;
MH-W<KCB<6AMNCMU)-'UWUO1WJX.Y@PF?C2?S7IGP=8L&R+"#K\WK)MJ43.!>
M'PZ;N[ PI@3O : ZN-8?PJ?_#-,Z-^#-,>*R;[\-=\?'#^BKMV&HD5_>M-\A
MY)RES\Q%02J6D<*V(I!IBX:76*S&UD<^;NN W)7^LTAU.0D<$7T)S(04:-58
MSF*$0DCUR(',;?&M#V)=(6!,!=$=-'O=D.PNW&8>[-5B?HJ+Y:>:8R]KM\#_
MK+K33<8QL5IYR<&P)&N"G5-A07+*A(0%)9(QT'P/^$OTC,FW--!^,]&WJVV<
M'Y1Z@=#CZRK&E^7/_JR'>&)4X4 6D?E8SX(:;EC0/%!*'*1!(9TRS?>@OD30
MF,XG-8!#.^$W[,6\VD5.P+PXRU*/3WWHIM-)5DD"\,C,>A<5I651&,]*0BEU
MEH[[UJYM&[K&5(=J@([FJFAWDNC\[28(<E'%L22J_[).44@MB(2 426N?,ZM
MDY?[*-M\.\K>2:3-%/H,"R[69T@V#8L7B)MP622J(%E*Q(\VMHZ8T)Z)I(,0
MV0GZVEC%=U,SIL,]#93>2.QM-SHV-%#>N@E2DW*QEL49YD!\N9P9: 6L8/#)
M<NZE;GUZYU9"QG1\IX7SWUO8S?3^HH/83=<=%!.K9"R! @[/2QW_P3,+2466
MHT\"BRLBM)[5<NGU#3DYS[$4S\JD.B/'FE#/02'SJ!/S&JPV*?#@S7 ,C3"+
MW57;UP&\IZS;H7<^>_<6%R?/,"XG/D$L7BEFM/-U(EA@WM0SD.0W0]TQL[%U
M1'+Y_6/*5YOI>5?Y#A>>7&*M.DN57;8*(D,9336:0$$P!";I9Y!E<"FVMEE?
M(6E,B6HK'+34PD#UBW.*/EWRJ"X:XVRAT"G4D8X8(XO<:5:L,3H+CUPW;P;]
M&E%CRE1;P:.M)MK&M)>1^IF>"#X0, U+5G"F"W@6E2DLHK?18-$YMTYM[J9F
M3/EL,TBTD7TS+%PMOD<OD2)T"MZMJ\5W;UF(4;'@'93DBN*F=5_M%W8V=MB)
MAOZX_E>+R.]A6OM0UH, NK3$7']Q-,M7?W#IR8GWT0J%BF43"EGKP%G@.;)4
M7-!6RLAU:_#O1?"8(NC=<71C7_E@.FRWB%*:K]9T)B1*XK3NA)_+POF8+=K$
M$@1@.M0#I[[N85"DJ 770:36D=B7Z!E3.-X.-,TTT'#7X#V]>[[X5.- R '3
M>JY5R8+I[.J^A0HL%,S248KH8OO=@<_O'U/HW4[G.TMXB.+@.4.:(KJ4'9%@
M,R6#&5+=OB9B4C8V82U6#7+.ZMX- H?=]6FA[SVE/41IL Y.7,[37\?S*0FU
MKXYH^6E"KL9DA\0?"EE'V24&(3BFO#.1AP2F>:?IUVC:>XC1C4_<J<=+9VTA
MYFJ$ ^7#BH)F;Z"PH,@U<Y5SS*U]81O*QQ1J-<7?C:%(AU?T(#5[*<%I920S
M)5*.%NK4IGK4&@)% F2!K#,'J]F/IN;9'BZ[BKQE[_%)MSX<4KD[FSOS#F>I
M$E2LXB6@8*B1<H$BD?F4"@-=##?.9<%;9[-?(&=,0=B@F&BEDB'LPGG@8'7Q
MMNXD&B/KF28;62S$+B2?C1!9V=0Z3/O:#MC]^?ICOL3^%7RJEOB<L9*MLS$;
MYH4FQ=DH&"@1F!%>YN!T4LT+>+>0,5)WN8OV;TQTV5/HS8L.UVBA/-<9@_5R
M"B_KX7Y:N5 $B\$*;I/P);8./F^G9*0^L 4&&HB^&0S6H]2N$0* *09.:951
ME!NAX>2)3:[]4\IZ3_FP;;WC>PL9(W5X+0"PK] 'V\JY@*)W/IH86<IUTI2P
M@7G09)%BB5B$,%RT/J)P!RECJD4T1D$+X;<;,]PF<4-7P'MR8,0X)QM6,@L%
M'-%.\1E*G;UN/7ABB Q]!SNZ0.A7BT]K:OX3IBNL]Z)D:Z5CDF)4IE-4Y-:C
MKN-_K>4:L)36!S]N4C&J8Z\/ +(;IG<_/;4+OW)>WT@ TU?0Y>>SIW#:+6$Z
MJ:/DHU&9N6*0:55CP4Q1(86(&764SC<O/-Q!RI@"L!$ IX7"6@;OJY.J#LS;
MC.>82"F+\A:9A7I%DY%UZ#'6A"/) E*9I :(ZN]#XIBBO3&@;4 %-SSVN.E?
MNV1,*4"Q6M0;GS+4BS&,K9.$..-9&@$F42[3.G>XA8PQ18TC0-.^BFI:;IW/
M+E&1!/?*:,N27V<],I/U],A*=B8KZ5$VG\1WG88QM8F- "M[J:CAI3=+Z&:8
M?X'%C#CK+]G#9UBZU!&3/$?!BV*8*Y/)6>9MTLR $\"E*T&UON;OZU2-Z3C5
M",#46(T//HMK,U1R@/D=7WG-H69N?87!1O,\:G,5O>G58OZ>",P_?_JSKTWP
MM2.G7ZZO^%MV[\]V!451PJ0D6;1ZW0*?"'T.F?$0O)4JN=CZJ-SVU.T=0,&G
MM>#?SC=7CMT]AW=]5$2#L5:YNM]E'0D##/T+ Q.)IQ(-&JM:[\[<D\11E1L&
M@MF-Z&I +;8<49(0\_IZE4K3R[+.*\YDL29_@L"+5I"8=#:0)1:6!:$BLYF+
MY&W$X%H7?;].U9BJ$(?"4UM5#0:AHUG^'>H-><M/+\OOL/@+UX'$9[1/@BXE
MH>#,:4F^W5*VX67M!5 ^9F5E]-#:>-^;R#$5'AX(8&T5V0YO&[M*5O0RQ9<6
MPU610 FN"$F+HM#*T-P;1K&C9E(*"E53+.UO8+LGB?<L2WQ7WG$(+0[H'<\2
MIM]Q>3S/ERVO])"LLI:IA.2\17 D%,^9+X6(B\D*U[J2NC5Q8ZID/)BO;*&X
M 7%UY[RR29#&2&4\,PHR 5\Y,J\D!M3!Y(RR?AD<67>2-Z;"QH-AJXWRFCO(
MB\3CYN7FBB?);2&4V\BT-O6V0F]943EFJV21IGE(_S6B[CETYKMR@FTT-1R
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MO!UEWT+<.#R:]M99^XFD_R1*\-G\PVQ29#"6.\$H@J&<)WC)0 3)2G%8_Q.
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M^CZ_PL?G]62[[I>.Z=E!2[*W]LB6MB1[IN<%49<L"=T@H % V9I??[) @%>
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M,3"I!9,>@LZL=O?2=4Z:)@WGQIEB3<;69_T]D(Y4*5H2T8<M<.W&<87MRY4
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ME#67_L:%]^T;H?L?\Q5K16,.>DC-6PSH_3$L+M9./^%X=K[!2<5R2$Z #3:
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M4O.F5K= ' /;NTFVE\$/>2'$,'H3AOGE>%G.OP3'+'/:>@?<U-1696@CT[)
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MF1O91H.MZZ_ZB.$WO@Q3-G-CF #2DEAG*B>(4@A@S@BF;9%,]I@I><]E6,M
M>R#/+3">@"4C0"6L70RD@$2O!?W .RM;TW]/H+UQ:=VB5>QL\4&S7\.T3I[Y
MC,]K)LYH=OWU[%9'=^?G-2F:ZXZX487<CV<SVBEGLRL/OMPZN4)IT0I $VI>
MFC,0@^?@'??!&_2Z^632N_#LO&NFCYC/:@?8-4^9_?CERM_.ZX2,L,QH6GK
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MB<SR.MV6]F/E90$OLP26DT)TTL3T]6;;;45;]VR[;63>>&C2VSHE:J'LNDZ
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MO[Q;8EG9UTM,*$K4QB%H:1*H5%U\*S6@3*+V;#4V=!NKON$!^_=^=Y#YI+'
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MDB;Z1#;7]^4GI4Q5YTQF2E=2=9^^?WC,-PG3)* "0&6JGOZ:@P1)D5@"@$<
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M)B +GOY_Q^-ZS2.&/:<;R7_27'BM#;$/GW%**WU=$[&O)U6@]$T9S6>7/J?
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M;';2T*I>0(W%VT/^\=WETK(%#0L%N>=@4B;#1PM9$U\=N()>).Z%4<U]Q<<
M7K+B#Y=H#U& NR4^K'#!P.44G9RT0IL A:\)")I\82T6'3W0DZ.<:+F-M;T)
MSSDHOYF\>VCP=!^^8-X'26<6\%"/,L4DU! T")U\QBQX?#J_\IPC0H<X>WN)
M=.AL\#]Q.J7%?\T-HD'//JMI)&@STJ&B0$Q9C#6<YU*-[A5I@$R\"$X[EJ0J
MRNC6+<Z.&@62Q1N7C0<1DJI'%&U+AA;-LZP3!XHKW:;=G%L4:!<>[!0%VD7@
M)QL%"B88XT0&(1!!96? !R01Q>PR&3:YE!9-\U],%&@GI6[-V=Y!N,/E;'<
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M!]#0"1"K6EM,F0S,>R13B4DRRD2=1.HR-R($$UNG:I\$H;;TD#\^GW913//
M%!GPHV6 3%C.I%*0>;W*E/3%!T.N<\9B&$?)L-NM[:,/'=XEZ57ZDP:BZZ$F
MX]7-C$RNV>PB_NMF-!L]C$%PCA=3!)10&P8F8\"Q8$$6Q6EUVC+7VL18 ^5\
MC(P6LNXA5W\5K/KM-.=ER6 '@'W-DMD&[D@C95JHL@,]#M=#'X-EM@+5.K+
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ME*$.<5DD"">7HT)&+\]PX9I'R'XHVNRMDF$#?O^8UKP"$0NQMT0HK/;S=24
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M<A=E6 PF N$C@T/Y BX'!QAI _>.6<V;#SY;#^<(12C]*7(=90[40A]]759
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M3E;(_0R6#B9;JOLI:,<)G"20:Z\<[IS@LG7NU8D5[[:VUUM(NH>P[/8ZLRX
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M./WI;--MSEX"[\'Q^/Z*J0@=4$8%,3$&*@@$)Z(#F5PVTM*VF5I'+(]\[]=
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M\DBVKW^<XW53:!<!AYJ1]Y1P>QJ5U\*4'>"QNQV&&)CWI*#*2LD*^9 2?<T
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M"#PQ"A>-S,*QX@K;Z1QY]/&O%T%#V^H^NLR0VRV]#E)95[,6Y-XI5K\")DI
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M0AH*?]S3MC;OZ'.FAD\J@QDTH^!%H\&O4BK/LAXGQ,5&@ZSJ(V]84YJ,1D]
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M,5>41F32\]C7T3[E*B5^(@USM,23G-=BS$4P['#S0/2-O(F'[;PVDP3-I>T
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M/#1@-!_N#2X.1U?^AD6X5Z A:,B/[$.%AY;B7W8;-4UFN")1EZB:>(>.C9(
MS\??)LJ <*6)1Q0NXF-?*P; \:W6>#,D&L1!%PV(Q"I'Y8\W*9=!7DU]"*#M
MU(3[PW<;:!@(X?&%4*D]Q*0VG2VTB(3?\0%%G?/,VT1'+8X['$M7F)C,G:(7
MP*_2VO4I83&4J]4Q7\$NV; WD+#CPV/:VNC3ZA+?YJF<+2H(N;F&J3%W2'RI
MX^CH^.SCO9\WLB$6P?=T+C\Z\=]N\'Q:9 "N/"8)=J0'510H)SLY\B=._]B^
MS+EM#!#JY3&-35ZQC3$S!0?S0ZYH26Z@6*EB2N7%\IX+]?7:T;=?;)=2>[=5
M"2!.ZE-2=EF(,_Y^1EJQR-FQU-I:*RVC/.$^3>,SML4BOP#*6E(A>F-:=TG=
M1F9$G]>W'6KJSJ?4P35.;/84:Z(_ SA$\I^I@6<=5=WD$M=RJF&12323F$&%
M<\\+>KG>0;7<%I%WF_,+GFZFJ7O;AQ5OV%K@GW17.]0K'J:X/CDFIVR_#DJM
MMUFB.GU1G,W7OT [U'C+.B?4Y4_N:E$&*Q9WO7>=R!<9++[4.X0,F\C*0 U.
M9.+5]=VY3&V_8JX0]1#WH=^I073?@<+R/;!DO/H=!_;2[ ]JJ&8CZ5@_C2[*
M? \=M(;")!B?MT4TVRBIU4V88Z8G6EQC2'X1@6_3KA0FV;1#^F7W@Q6GA[I3
MEC?ZUB?S/ETMO7,&LLB_E17JO'E.D1H>US[>CLD1:%C)LC4*S!^+2P;_7;*K
MZ#)W=?1:I&*NJ_L3L\0R!R]"W62YK;I!PA!&$>G@]*3VII]Y8:@(A1<Z(Q#9
M]LF]27W1N4(1>*[R8L=UL=611L?@&NT&O\WF<=1?->56&+M1F3VWBNL--0WQ
MCA&OLNX8?'@A)_+^+/*GNQ:Z(%2/P@X=K0I1&</B<AJ]&(#+M,-,=[&/^**'
M/9@:-Q/-=ZH+5Q2/9A2Z.%,FN'AEO=8S-Y:I*%FCEO3;70:@QIQ9KN\2>3&T
M!\23,1*?_UN-%A-:>8NL,CS$F0$X>Q0W,&4?>]TZIK[?Z[6*PZ&Q1? N 1E
MRX7>A+47DVR_NLC_O$)^*N,6"5/=/\$ O'T[R "<0,9K*+X<;5F=&>@134XR
M"KVI'6:S6#2JLS6.4,]Y/F7(Q=F ,HX:&SZTZU,I5[TKK4=T]>Z8NGUD+_5\
MZ]XDURQ-:JHXBE@6@,O/72'/I5?:QBSZ4C0;2\>;3(JVK1:;UCI_.?@&J=BD
MJWA=W@X<^L')#A8O*1QQK<&?I X^B:C(J@WE%,H1\_&B2P^+X,\D>KF*"S^G
MEL._S\(77-L\;XN-[*W6_>.6P2JQ]"N&?),2H<B,[!K92%BUY\Y1 )CH?UI;
M2UT%>(OZEPC]I*9K_D7>WJ$&OD?IS7T#ZNY@S2VS?@MBQ0V,>>^6#1E:D'/4
M(Q!I\3F(,ZR4NB6H=!'NW:J%6B.#M4];(]5'/:OA&<VGVL$,P%0=1/F.WGX]
M*I<!T$HE]<0^42HR<GKL6U+C$EB>+YO>3LW8=@]/:XH;JZT?=+:>.GA84SOH
M^GL*?+"B+URKPE55LV&K=.7)F-\5.REOX\J-)XJ2PO&2+S)\X0;K=Z<YGN>.
MNJE<!>M\<797*"E9B0\\<A$N%Q"?!%46=4=KW0@0I !-4WI+7[WZ*M1RU"ET
M$5X,:8 MB!<K;A_A9=L0ET'M# #O!CE._=/UD"<2#$!:93TGZ+;>=^%40FUM
MN]UTSUVW*CW)2"LA/N%[R*GOLJIIRBS;)8U#V<D'=L!UFNP8H7@^;2 I1@)9
M=9=-(N_M?Y>A94YKTO"80L)K$%SW&8 ?(SOT43G6,.E(P,5-GGM,695Q@#X[
M[2%E ;U+BB-5+Z%B9-D](#OG9'Z1O^CU0:B^+"ZD>]_Z(;G#^=NO/Q8MMQ!+
MM=AJG< \:G#40HW>UP!E8^[PQ089V(,K$]GJ5N)A'FD7"NN:3,K.[300D-Q%
MRC6:-B%-D?\$=%]KW.IOLAPN':$Z^O#5!L)BG'I=R!QL&D_LUUB0.3;?9^U^
MN&R%:-\T! N5*>DCOW9LA]"\V8A[&(4EY'G96*I,:%&=L@G_?B^=]VHQM94J
M]:5IR\+$YC#%//[3VMS0^O'MN8V%[/R/=WKY)?N"BH5TW)WK?_3<15VM\23I
M:4FYL.6[^8=[)-//:'E2 Q1?.INO\2QL\:NT1%9^R?N2,&K8*'X5\VQAT(FB
M;!']F[[3HL< ^#  D:RX"E;]S (?\GV$7^G%\(*87 U%WP"CNYADJY?<39 [
MFGW=F-=GZMS<CBM@V% &@(".S#\_D-;3YUGD.=(8JM53 .-VFO1]6 \$GP('
MO7$=]X$IOFPV*6J?^G(98V:GU5/$TUSX6UCE:\V@1J,$>U( @+-V?+V%_SE/
M(>WW%GP1A(4HVN1N/\J;ZPQ2^HCA.(D<(_!@G 6>3TI,'\AONDA).;X[F1=N
M,UJ3\,.J8JW<&''KS9 :N9'@CK^'!W:P/W[A/NKLYBX(FN6[Q0 D? 0M*.X/
MICS!U$-[U2K#;,>EV4/J+T@O "W<F'4@E)Y*H%Z*\5&0Z/DR&DO%+*(N%8HW
MFNKP4)R?_9<KE/_]P;H:GO!UJK!4<S1T*]K&C*N4&U;NWW*E8;(^8W^/:V:A
MW%_@3&Z-[""D9+'X4&\U('#++V@HO"S0%*GH8(6I[X1Z3GQO!ME,(8)B:?X2
M4!>\O?#^C\U@3Q_D8K9A@(?K4).A_X^,!DV8Y8Q@!C;D7FBCXC;6^?$^7O&V
MM\WAL<R3M-*;^JOU1Z59NQ4.YNFBF%^/HA<G$I,#)A6MBGZXC[,$753)60NC
MCQ-*<F1'7DX?Z+O\-/D*%H6MZQU4\!KP=_G-UZSF9<#AY>[@526ESZ!J>1EX
MOS/5-7'$O3(&5RDPD:R'U#,P6"4D3S64B]1Z9SQ4Z?(A/[23<GG5G;L)//$R
M4,.<(":8L:\A^:[_SKX\R0.9>U<VTOM"N4\_&].O0P;IIXZ0V5JL=MGJBR_#
MQ8E(D5@X80A-RVAI1JX@A>10X"'GY]>+:@J16U?&Z5NRB4=9RGQC^;<]XLJ+
M7A'(-L_YQI3_[DD#Q=M%^UOX/C^-[/"8;M0JD3>\;UWW<"(UR]=X7,IX2&VS
MZ-+C/%J*Y0:J.FL5L^@;0\A1=0 1VSQ7\YIVNR4/N=Y5NI-2OS  +?/D4^#A
M%_X):G'I!WH'NL-Z(Q:F.E"JW/])I_\MQBDFWW4J&6%15UT%@L^7.X1J_N#K
M'DFZ<TB5@CP8(X2OUC  K@P )Y %.D*_&>GQ&UED2QK28@"R<G\S /../=@G
M'IG%SX(P6RE3Y7_S\%H@YN#]+N(&-<4M\<CO>S*U6>)SA;-;$/&YBN<RMNP3
MG[Q+5X(F[#O,3=QS71^/^Y\:?!,T3M\9=S4=.\AQS1KWK,[8RS7H$7*)\"CW
M3G+-0:7?K/$5S$I^C'FSC"DW$,\TT[&>S^C$(V-WFBY^-@I][5WC'B,'=894
MP0]:!]6[Z/)5N/#T;%_QH0ZBE^Q\"H5K:Z1)O1LJVH2?JR24(M/N_HRX 'T,
M_A64/$.DOI7G.>9)6\S7&9S=]J['* M?F[@M6Y$9VC46H:>U-OK;A\PV,NKF
ME2!I:*? 6N#ZV[GI$"DIY]^HR6^8>SO=>:3!2'*ZP'S4+2BD]I=S6K9479:Q
M39(Z\JT-NPL#<*DF_-R/9YD[Y^D_[S6"_@%&(TNE!I@X+AL^N$"[6&OX>\"?
M_!X0U7&>P^XOK9TVT#W[3Y!NNKR7& =&@Q  'F237VZ8[-OI14IMK+F6\Q-G
M0&&I'(IK3=ET.]# &TZ7L7./_OI16M<+26T3/C1,2YPH3[&39'IQN0/O[&*C
M<^?$S? /FE+#+2=_'S, %\L$@=)2(@@*]BWM006[2:0*TI:668-0@#0WBJS4
MO]4[E)Y?*&PIBGP5_+ ]#GP@3G0E"Q[^V$YA.O2R_BJH%K,C[T"Y0>48H_H6
M._MG-!=FWKU06UX3>Q6^VE?YGMVKS0U1$!+,_"'. &5Z]'PT"J?&A4,^9P#>
M3\#Z-)LL&0"FMJ&G=D&B%,F84Z]S;#\Y[G<^7YA)F9HMYXY=IZ+[549C%#@:
M@0)\U@6\EPDF5E.;3?!Q-"G*NPUU:$PU8I;]7[!P(/["6AAL/9N4R0"<^LP
ML%'S\UKZZ=?GF)5/:Y[.(GN@I4>##J'6F/*QU8&NM[E&O:^Z,$\6A]YD7E@'
MM</_DT&HZ; >5;L)3@]%4=D@J\ M@B\# .*EGP+N@\"@Q>OH,PS L#I>F<YZ
MCWX9UJF=<YX!R/-?]*1RAE&E]A-B0(M"R["#'09@P8P!D&/>937RF(3"\3$
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M)#FKNTBH&QF X373& 59>2?30TOX#J%!8&,?A(O%B%3FY)8WS+D@3MU=BK7
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M &02\\IS*.^B"37>@<YR_/-/_XB/2I5 -L$<N4@W3*B*K-M'6(0PK'V0WL$
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MY[6$#T&80T?*7:JQ9SRP>OY]R./M<E#474/#Z?CF*T[1#V-)6E@2^" =THC
M/: ].YHGB?MW6"_/-J@']WO]J+^J$^IU86WTK,JVR@XD+: X,K;-%#EN/$_B
M]F0 W$$/<?T7)N[4<B8H4S(@%*_#\)<D9+N "3Q$W?N+:X9]=KFS<LF5Q3[R
MY&V9-4#$B:77EF^O"=];YC(8*4,(DM;T2*Y8VT'O3H'L''C^QJ;PZOZNZ66Y
MDVWW7FIP5)[:U(%>-\D>#-;<*ZA'&08BJL965D((M;4M$ULPD4@&($*"I,@
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M@3.9LJPFOQ2*.L+&KI@YO@YZ-AL>_,,I,K!.<J0D58(!"-PB2J%:>J(_>1'
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M=Y[LS)Q:)>2O$@HB>+^G.L1;+WN'6_)+AX8'\;Z#GC7RZ_4M\X@0SOL-S&8
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MJ4 [&+YOB0&(,H]B #XS$?TMZD -M2C^BPF87 S 2<@R3-?R?]&^A*"EH&-
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M\H43GB0  M)2-.+N!<H]\>%8"Q\_F:F[M ,B-<CR?4Q'?#??, +DD8=^F);
M^EAI,6Z)J*N6S:NF<E:ZU%[KMCCZQ"W^R@W'_&AL] F.L($9%J:M1EG524#&
M"_W\A'ETOF\\<JULB^_$Y 6O[-K'%USU[TF2/77QK;7FU1S4F,UZW E;\'2/
M]84%E9/K*OY9;\.C&A;F@)54P1AUW^SD5"'AYYW8L,_F'SPUUW/&X4>'T+<I
MLJ$DGCVC3W)-:S,L%%T_3H=;HYCN_@XFOXB4.XB3VE2.'1F@S"P\&U4(_U#^
M9+]OEZ.+]%[$RM 9IL-</*C=_H)@W-@'R:]H*KRL$#!X2L=E/[(C(>+/L^;E
M*<[@/@(;=IZ;'L>&H8K9L&UM3O0*ZC90:P+QXQG$3D$-C0A1S6E\XN)VZ!D(
M3)[!P2IH-&W--2M/-DSD&#1C./!#W;>\'PF&U0']8TKQ)))ZR+G?3[]YG(9Q
M98KNBZA: [E]*;\0(6Q8";8^7)&D$#74HZ>2_37 Y$CDM5:_:SRW4T[RNEAZ
M+>G7/_K^6*SP[/2FU.=2:?F&QV<"(]:B4#YY#'F&(*;# Y'OO$2<('"9-QX;
ML[ (#3=^.DLVZ3XG7W:M:27&E_^P!]XD.02\VT"2?"S96F7BK5U,3$!D7J![
MW4\]=CDFY7"4E19$A U_I+;F6>5J1VLIGK1:>NC$L&DLC]3)E]XRCU$5AP^5
M)![B>QAUCBFU#2D%@2YM+@U0](A!M8;G?L5K<93UR' K;'OZQWPK.%88^TMH
M*U-=K@.70/^D(;?K#M[H*OJS!1"E9K-SZN )59Z,IY]V7XK%%?>GGG#T+Z?D
M3+W<[Z[G8D_LT)Q&Y1O1(8C9?>E3"JMRR<@LQKI++N8UPLO1X"W]-;"/E8F?
M)1R:?$YB3<![69/UF:CS)79MJS<@F9N='>,\K'?]O_N!GX.T^A_PM?H?B]PV
M_=FPU?,X%CH.C!:@$ X!4PYPBMROG=^?:YZ=74YG'L+7E5M"8BZP.5$Y<,SQ
M78^VS0NSJ1*-9VR8#BY31&%=@GE&18[UUV4"DQ-)P?/\PS&4U20??=20:3B*
M*@$AGORVCVBZ4-RC=<9!B+_T()/<>R^4#;L>+L>&[3)@0I?_3@)RY2\:T/^\
MS@0%,]6]K;I]!^<9RAX:J/_UM[)Q1]"\%"16NKHCUPM1M]U8?7'::O[^ XFI
M5G5W0R.-(JUJVY;TA?-ZZ6)VZ@IS:"1##WHT?.!1IE6/K)SJ?CPD  VF,D=?
M%VX_)\^+2K_\-/\QY$V41\D=)H[.AC'4Z%DT:_HG[PG$43M\VD*_E_OIY8 %
MD<3\!M8IQ=K:DWM/3[SAV%;&?T:,IZ/R$G%D'X;R@M[08 J]N?Y"2X:M_'=P
M8\JH;=@FT\S0L79<K0D\QN)[5[HH&( _H:CFY/:-[)D5ODWTJ$C/'RZ@GY(<
MSU8\^R[OZ-%SAA'%YN>]+:P9"A7$<N;9?SO;TN,P06BP=(#X_S).P NS[:AD
MWN5T9*%[1K[=J3KEJ_ZE?9\#=K]]KX4GKOQIH^%Z (>5P;5;U+2DO.$12XG!
MC:N7'8D/J\)V25N5MNPOFTKY>LT%U7G-EP79YA[6%W$*KAEY$'VU/ $4 V7R
ME&BVR-'*8N$SP-B[GTC4AA0JB1X<V2P45_E B*"#,MU R8#(LLW/'(DZ/%A3
M,\3+W*2H.= '/?!DH[P:$@R_'VP89 ,[:PHQ!#"F]M_/(AG#MS3Q#83MU9*=
M8TU25-5 4,,+V-[B8YV'Y]L J[(-@!^PK8/8,P<Y>"XBKNX?:O+&1_]A.ZB]
MT@ 2+4>Y;3IA_1,\Q<MF1[-PX\"V(3)9:JN-E:'02==FP^R<@^)CR<2A4^*]
MN9Z"PXF;^L4NPSF 1@QSE.D2/$[OF]P[9:RIZ[1A9OKH0S#Q= BE\GP(C1XX
M#>](F@U>Q33S5DYOB<1!$T)+H?8L8.EG::_+!YB'Y6O7+CN>G2\>\A^X;H3\
M,Q,F@+MUNAE-(KA(437!O<Z2Z@R?^>_MW[MM-UN_X"H].-[0_X)\/Q=?HWHO
MVKO28'XO^!+A1AD[_U3?(9LX?1#Z@;64];\S2?Q/"*F5D;=7$7;(W0L6&DZ5
M\C3'X3(URUYRF$=SPD"U;]9&'>$<,#[1#Z>4@2<CV+ _)2> X5<,+.]4O^>]
MT=0M>1(=/#_5XYR"G<%V'H.H.H5OEJ)IFVAFFG7^Y^GQMZCNS8 -C7[FE?0Q
MI;CRU:$KOSHK8N^/^+@NHCH. -HH;FGK;E#0ZUG_<^_B;=ULY-O(LD?7 3W4
M>Z\\P98 7V<$JY"%JMM20]^9MP7(S>JH*&BJ35?HXF1B?:?0 OR(JD!ZF\M$
MSF/CLH$E\J2T6U:L6-+XKFYN7IU305/KQKL <\FTDFN)Q>'NXM]H>?.+/ FQ
M99)G3"F>0C*KY";7I(NH! K--Z@USX'_EN&ZR[S8\$#!RK0;)A!G_4'^KM17
M"\UR7QQP;PZTR<!_ \93S3UK?%!AEUHHYMNK*$5CE=2B[--SD5HOM0L_%"\Y
M@9P&![FF'NX9VBHGI*TR;?I_4'.3)]OQ=E(*"]C9_1Y""WW3-UIT8H:HGLBN
MT,,YN[-$G_^<NR5UOE9?Y: #&3<(@#PQ5)'QZDCG;UY-3422>-SS9.7T\C+%
MH0_VRK6?I;@O#LCZ8SWPP;;9KM(XKH\&---6>YW43:MP^^J[ [(=+E[[DGJX
ME82F"S:0FFN:B\509LO%A3Y?FF_<6WF&NJ][MM+CM]F(AEK8P%Z .I0Z":<K
MFTR,QD0K!3)Y)G7O33JWQK\=-FU"JA[1%C_M-FNWX'N%&9M<;>GE&G7>LL[J
M\R_B+!UWEWG]UP/'7U7>)DRE<5]MQD.@UD)-'.PW5V_RRW& TAOND6GQ'K>2
M)V(DP,-[>,9EX3N_UD):M45RR/;('HN 6GV:LM8YS7PFT9@YN%JZ5"\0ED7.
M,W@9Y[GM8:5UOK\X'_6@>?_%ELL]%[0FU:7_K36":W<%GQ^J8#8<84L\TISL
M)55?'A<D]P=*J&RPF\8UG_?$WGH7#@R]Y,04 ;6JP'CD*[ZE3!<;$E%8QX;D
M#-?@J"WR-)WK6-S[D*<5,9NU"SO!TTL?N=&H+)T6[8Y2N/?>@F#5UL'$YRU:
MJ\J'=4B*:9N?M*99)1*CMOY$@]S\D)C1$VAZ=$^ET$HSFVFOS<;[DH5\FX4^
M:D>O^XJ^Y-">,Q+RRT8.?M!#_;J2]A1UH5%'*,CS0_54N=@4=NYNB6S*FWI-
MGAL0B@PO0%"A!"6")$NW82^^"4S<#$Q.;H,GY_-T9<;X@VV760S!G%F [W&F
M*[>!MBNL)L(F'/5)@<4QP=3_F5$TD #%QR@$UV294F(_,ET.C-SQZJ7.R'U2
MPY<[Z1)\S3+.=TLJB^AV)&VR\UFSKY&/=?-%8$:!';_]#IBR88$VZ%=L6#**
M!##6<4PC;\*P\NZE10C)_L)N)?FU7NRPU,.!''*KJK(AFTBZAV<S?EL,A,(K
M 9*Y1BC.\?ZB;[!AMPD-;-CF/(+^'5&<SX9ML6%\3%[$#&()#3#I__O?A_^!
MXN,6%<'<@YKRLA1<QE&65K"H=1TFD@W#0)E)2 IX,I&Z" 8#P6S82C= -00<
MG[)A:R"<?@)H1^11H7^3 /I^PD]*N=0H8F*0>(HP%P==$ NZ D%-YM6KDP,L
MB$H%V# BE(J0,L"A-C9LEHF@*+-A'X$GD.C/0A=&$08BMR'ZWWVB_UXZXT#+
MGG7GI95#5L.OJPPNULKR$5;DU\]6=^\L&HV'XG8Q+1G7P#:5&>RD+N]:_7;J
M;(BL7')Q&4SKD8.%5OVX0*WM"$9P8QI0=+D[WZG8<"]:]XJ2^_>!WV# Q,?>
M *.;"@*ZZE+7A.E*_UCAEHP8SX)0ZCTN&/A[K?7;>Y-?&RSX3GU# 1\;9@7E
MP]]2MM:N[E20 ]1.*&H]0MD!M7L*D634< 1ILDV.]6DB:_CSVTUY47XH?)V=
MQ)K3BZOGV+"W&,34ZDZKI,>6 V"<J0F?D':S>(,"$T_]O31AFIXPT0-:8^KT
MU 69U<"=ORD0(P34/@&F18C\A&4HATNKN,/JPM>MT*6=F=]\2$JL>L3Z@!TJ
MU<L"BI+FN TR&S9_'W&5*@^JNT&9P,ZJV#-T"T2 *YH3LW]0E%NH+80E JPI
M(6[_-4 VPD!<67L F&)!?\SXBPC,\:"*C)@,D@TS?( NLE6PZ<R+F-)GPYKE
M6G8JCI)PZ/^=]@7_WY<\;1%![FO04!MT.VA^3.#;)M=\^5&MPBO,L#SXQBJP
M;8#(N(38$GJT XTL,6@H*[V%?Z/L^^W\+[TX,M>_\,VB:!64YP@^P!X??$PL
MV^% VB>2XTT>:ZO@O671;?#-IJ&U<C+!#CAUBZI#"Z7.!LM,K>6XKQPD$BV*
M73]^*_7$GJK5XOAC(H :,!54"$C[CG[P'2SN!8V:2BMOCRC.>*Q7O['J@$Q\
MD1HVQLDJ P6)U[NE.DA2ELKDQ>)YL)WXQNR>;\% JE?'*ZZEZ"?BZ0PCYJ7B
M=_ZQDXWQAEK:-?N=SW+@,K/7E,]/2-99*+<@RF)B.^J%[KB,WI&C:JZ;_9>/
M53 )_Z%61V3;8,>6/428D)-VF]&5('O9<&%6"_[CBNN>Q<WH?WG:F*<D'#/4
M#AAHA'SC)^MX/6+K:"\;Q@&-EPS-1*<<N78B@.))QE(UD4\E\[Q2[GO5_D*7
ME'HBF>ZQA*_?=WS";Q1] 8#B9PDF)U/:Q[$2E69NW_407<9-LX%;]D]C&9.]
M)JU>EB'WV^WU /MCK]((&IT95"G>V;B>[.IVPA[<0N2J#&0DE? @W%WH29RJ
MO%,-);M^ ?3=+87J:.?G?Y*^5'V8N/ASJE2/Z.>;M7F/\!D8K">YT.4@$:O%
M2(^TP0.+LG3F\Y@NHM^M4?1#3O!P0"-VDW_LQHG?/Z,:)0,U-49RT]_?.'D#
M7X\VK%>>S""IW#FRU0@A<(D(#;<_;Y^I9*%*D\F6-D3+Q?EW(#Z30>C\W8:5
MZ0-Y_VO5Z_%8LL_$J-JE'%;"A*EJY_T5]Y=_$)23@2 GZD?,WWID0?]"$ 2<
M44%"]UNJ![0K=(_Q?R8SI!WVOP:&C3Z "ML2 5Z>!HKNKVX>8)'E^G"[2(IG
M;DD9;K=J^PX 4^B5G56U770]AYM=:=0C93;IP^$]Q'NQU/TVTDN',=],ULN>
MVIQ*?'J@4JKXN)OIY(/HHNLUPHO=!!@PGD@X8$%J)E=1.K5,VR/32GB_7II\
M*YCK] #^.(^?/K#.C0JFYP3IXP/K\?G?0-I.]P(SAE" LD>&"7ZTT;>%P"H3
MME*DYD939NM48JMR41;S\6K13ILF<0;%(GX*PJ)0$M@B ;-^+T5%@/M.0O>J
M1M4DQY&.YPAIQ^_$0]Z<U,;<C]A\2ZWS6\_*3S,;WA_5W!3 5M9[;YN O#!6
MVG(AO5*>@M,MM_U:_<ZAO#N=67SCC(YIR_J!$[F&FZ;81[AVE8W*JQ/V]^N;
M+S<TK<75 _D5V]78Y*(2U5]J)/L"O'0)+WDOTWB!\4HV*XOX$/\%\1!%EQ@(
M1CCA3UC>LG%A!4\XGDBGY>:)6CT,*AD-$/VY)O:0N^FZ7AM_S($U%F8!J#W#
MY'PTCOS#4]-A_6-K:.B!?5Q4<[_WM\0FT\VGZA&(1T=/9LV7#JMEQ3P%!_BH
M+:OIPQK#C-@DW\[/XR,1L398FA&X-_=9Q4(,X20:*T4-9![DFY#-2:D_A27Q
M'9L;^-UT\-?F04O-*\VR<T^LD SI%/S)BZ0DR#3>>J&-;*1QE'"F!@5,A1L>
MB\4I1,[7B,LK8>2Q: ]\WRLIZF>YDS9N'KE3A,IHICF!A*D*&J^,+U[7Q^CB
M6X8IB*,;>/KIE689>;7;8]R]/X9=';__+(./L::TFQ?)>G8XRDU41-QT91_%
M/6+D84>60(5:@HA3$GUQC&!KBT>"9ZU<''QP=!XV3!X2LB#W#V,@&P9RLF$P
M9@+%A'F\8S)K_H-7*(GKW3HDS<&%BP[A-P*M_&YP/?<\B4Q#=J$X@?%WJ+V8
M4\B3 \&Y$)2<&&VZ<=$22;NJ&H&K".3;."#",3^ <-2SLI*/D,^^,QUC(\CJ
M3:'G  +=M10K9""Z*QF"B,H1 E?Z^".F&MT!BL7OP&.!&I1?H:ESQXP((T4_
MBDU%N&#6_AS2+FVGD*]&DD.VM'\91']('%[HS A[(M@F:.T7<B[S'',:>J)!
M;GO*Z$\I/88\JX,+<;&IQ6Z7&H_S^MBTJ'HV%V&,!\@(II#<Q"*]AR90V2N"
M]?$R,2_H.\XQL[>1C)P WW-OVQ1AI$W6-0/H_@9B84)_/L1-=FSCWM#];_3\
M$E.BI0C1+7:V9ZHI=-?M:_1=&;(Y%'BMDEZ Z7(AC["ATMBNG$D1->8 RNHX
MI+1]U%Z '_&(SW^S*[]DT$VYL*GY66%')A?('"@S655[HM[5V/=M,^Q;]4P7
M2R^NW^A%X4).ZE%"U<ZN9=C2?^[ZC-@#L=*_<LRZYK^6#A"R\N%;1Z#@N#B"
M6/\ R,T"JQ?QX!4H5MR56L;2E29!I%P#D28V"LR[^Z/E4&Y +0&^ZKW3 S)/
M=A&"XVRISDGXUB$2HGX[I>(=&S;E NDX/X,;TJ(U;I;HWSV,Z):0PX=#P02+
MUF##2FW >++4I@:!AS">1UB-7 DB;NYGPWHL4S$Q$\[,<'M@ %+5U.O,E8;.
M+<$>*/J$LF':G];$((&O@@?B'@'_PBUTZ&9W*[!AT1O0GR_Q^+)A7V0P?29K
M*\&X5274.':F<[028LY("/5.$':N"?/*EZ*G?ACVW_SL6L4RCQ2 >F02?IO5
ML[.I*<F\@1]>^8?V+P0OB"[/?F+#!EJ ^8L('JH$J)$'<3]S9S<&$X;!_,/Z
M1[+4! '**<@3%&!"<TEO7([/*[1YB#<ZQZZX0*POL2%,]'7"IX\<_LO9?),[
M*,HGO^./ZK?J$9N00]'CP4>_\C^[%1Q;#1<NG+VJ(/1]!J.Y'JL;__!KW.^P
M+'6%O:.N<M-6-N5Z5D+_^F7$Q RP"YC+\+(!00($[58HFB)D%VH0R[]N8V)U
M&$]VL6&(KVS8&TUFIUMRI1QXRH8B!(8$!@ KD"%0%4))>+H48HDQ<=S#N_KL
MG[$+<&D/11.3N[.?]W^SYDW\>?*:NN%+U=9[7?60@ Q#(>3LT\2G5),8+V <
MRE3DYQ:VN,!]TPQWB"P*E&JJ;M6]TOB2WEQ]L=#!PO0K,&97C(^)G:>V,BMB
MU=Z5_?RIT>P/]L I+S@KYN...=<!^T=E>K_KN2>Z&]WFBBR_:OULQ,=O&2;R
M022$.0H%^0895Q(AK(COH!?6L++?/4<?I;BP.KW9(O6$8PX&@UWX^S6,A)L3
M"#[J)?P)8YM3INJCZLM#0ZPXMPT?4[K:N<EL55N= W$Z\?K&+^>BQT:)#K8E
M95C(S,G-DV=0-X!::54.B0;GX=F)JN^Y<^LL]2(S"Z>;/*9C+Y!]*7H;CU!J
M _.!S.-DQE6M 5".GNK+(:USE )^:%=^>:?MY>1\T.$+G6/O7=[B$DGM=<JJ
M:57&&RXN5OE=&,\M^(VZ/\*/U^Y<CFV]@^Q6(;02Y==7_^L+=%N=.WL!27"P
M^A9D9IKK>Z!OGEW2I$,S^ZV XA1R#K\PN866^B>V.S"P(L$\Y /J+5)ZP,I<
MQ'KN*V9;(V+K2/>_NV7DME( )!F9(!?DLK>WSU;_!5T5$_V7LS!S#V4%FSTN
MYS(^/&GWJE7%W-+Q?L=2@?1U8. )"C-PE>HP$1%'39F(K9JXYB1W]0[UP(=B
M)4FUU:S,XQ]H3Y4?^ASDLV?ZG&T?0V%3PRS4%^?6'9:?LQRNMADC. SV@MT]
M??:$P]B9_I!%M:OHXWULF TQ=.PTY5F5,%:?PIH<^CE\)WOABK8A?#QR7SD;
MEE]7I@)^3S56./W=P%-7'.=&0WQ<,(BY4NYJ;#>8V\&)F01JSP+V%L#059I6
MUY)L;BSRD->IRUWNYP8)7EW)I+$G(X%!NZ+[)J.[";P._83';-C02@,\+["I
M B%H.YR;/>*;8-1CKANY8-S@]_,>;__N/2:U0_6EHO"XR5-P[^)=$+%H5=MN
M;Z 4Z'^V[PETQII$&$FB#W5;)<);0"'$5TDI:.J>K0P%U@)%0/T?5?7Q42NI
M10_8@Z$\'L_TGZ^:+WNW*EEY[]]C^/X&_C9^IK574B]CWB@T+#;\VC'$U[G^
M=/-].>*I0M\=#.M"I/A(2@V)7!/P=W*J-TB.YLVWNMS6B==&1Y*5?WN<6GK%
M*2PZ#M/.>/?TRCEURZHH68.PL],2UN6?T\EVC)O0].>O+&V0G(\16PXZBG=5
M-_+@Z(P*(';OZP5/+1/EN:_8ZPY;I'[W4/S!12%S_Z5.%V]?^1&D%&O>VD.Z
MW;=%%%38X&(>W@3W2;DSGGMMGY2[Q5#'[E!>>S/2#QFKJ^%D.-I:%?S@G4%K
MYC6>"W"I@77-792IU?;CF4'&F?H=N2W/J]P=MX>_TN''77;+2YO[<[UR6XY>
M'EOIL:Z2ZSV7G.OE6E\R)DOEC(A.,^_PR;0WX79P<#XXLM:Z),BOF?F8:Q+E
M<OY<5@$IY<AHY#8_&[:'P>3T=2 A0T%12PM<OJU':/+\<OVT0W!0U&,"6=3V
M-0.YA<DVB08;" 6ZZ4LQ# 6Z<^V/;%U?![XA=[,>T,K9NO[NUC('.A0WKGXR
MJU]J"P@I>/KIF?O%BW0/;'*7+X/9.7_O:.L8*LZ@OHTT9H4WV71<11R  G%!
M>?8VEGG8H/E@N^O)=\>>'WSI=>N1\YE%L#>\AX/:@H]=7.FDRS776.!YT.C?
M:J<MZLBI=#S2@B?X)C-OS&+J$=;Q]T?:VX%63.GDN KX>D)57650[90A[;[.
MK* -/862=.ZKBEGQ604E5^>IT8'Q.L(=PCCDFQ2]#KZ:,:' ";X(A;UN'Y^4
M1J%X%TPN[2X^Y>#LHWV4\NZG621V=X7LC;W'UXQ#%CHOF0NG\4^X''>*'U4H
M0/4W*^I\-FF[J"-XRS?>1Z$/L>BZ_=R8M^S$V]_;7:A.H3K"L FIL_::RE4$
M#_,&52/NT1[5K(NO>LP;_?C:#B=$OO(X,> *11D4ZRMB+G4!1^>TV^EDM:I2
M+3C9FW.G\-C:#')9&[19^%!YMU897/W0LUJ \G%817B?P]<2Z*_8,#(W%)[D
M#-FP&BDDJ*#)O ;0(+Y(COL.C M"8?98-AM&.C(#K-%P1#GP=@]X]AF$&6JS
MFYIL6-1_?904\(R3#138[%BK$+S<^I=1ZA$'@%IK@JTS;R7&)N),[U<L:&9E
MVW^/[\ITK)CK_&;Y*Q>K:0H \O)3C>-<]JNI4-1"LRVLI4;FUEJ>7N(EY]\Z
M6[98<XXO(U?:)&"P\=S:K5A@(I:P=2EXT)\J</X[6<WV50YBU;BS[[M4 QOV
M%$L_)U<':0N-,["N?+4^YYV<>&A&1G&O"$?F7NU#NYK,%5]<NJ1YA]9*#S,^
M5'TL)27H;5B<1G9G?ATI@V3WO5 T5:COZF=G,@\EB3A)J.D\XJ4X$2/0$&](
M.R_"MW%)A?\$CB(T1*0< UW=$T\MU@\U]N-\>(;'3-MI:]#OOSK/'Y*/>W$#
M[@_<C:%#',!9P(JQ& ?(:N"%'G(K'2#),I@96X\(#WQ3^1C3L0^2TDR:1Q6V
M;?RW"NT>VS_=@#=G^QHOSA1MP3_38V+*/WH]^5)]0&R.!DBDM]-_0;%FA*\)
MV4NDGX:3Y1TSZ!(-J'U%/!\G>R\/!_2[^7O4(W>_,?8:&'CBCW9G+9YZB^W:
M!AW5!-"& YB]3,TNIME$Q6S/1A7OA)-CFM5U$;]LE4N7HK+3 XQ/4QPV!6A<
M?R?]!K01RN6;YQT+@>.F#;R97RMQ*I&U\?O71$77(J,^U7O(T$V"'L@9!XB;
M)7*^<NTW9EQ:($:/L5:F,(,U#[3O%)^ZXNYIUZQ%),NV=3@Z]:^I!>YLY7"L
MOTX.F08OH)]1FFL0N\:\$AJ'&I-"4TQSK>,]:CV6@@C>HQ62?MISDO,]B=KG
M#'1+DG6,?V;J7PC]/!HU6A4Y"Z?<QP^%$&DZK#A5=9)ZF99[6T9$PM<FS'I)
M?N;>Z^MA>]ZODRZI1*)"0%Y6N=HEK[V2\X  TV6_"^M/:M],J?^K=6WA#^[7
MJJYQNJ,H]XG#%<:L,C69M"^/$NY2TH).$6_U6.9WB?"7V[DT)XH+*4_<_!XV
M7N#%"=RB -P]->-77-[K9UZSCK\W&M>&3[ 91YLU"EXL77XN.O+HP-D>>Q:Q
M,SU*L\^*%WJ&W>!O*T%WAF;(.NOE.6K0QH%3?W:V_H-FU<A)F)B%,2C!>/L&
M%%.75MPFO$'#<[3:\S+RE!2C[MR#+:R&-VSOMZ9(K8'5WZ&AKF/:!#!=Q**T
M3YE6%L*J"N,:N@[W/>XVB[8.%K^FM6E5A"3M4S^=F[UXYF?&(_O'>4>]Q Z/
MA<:RXBH<+;I.#*IY)YHTU//<K$R(UC'I6-BH#K;'#'F]I*WH4V@X%\"V6&C@
M2%>+BWV^M]_0S2^5CRA*CH\U7LA'O$VU2@X!GT=7E+'X3@I^^F^M]UK\I_7>
MM_]AO?<?4J")5XP4\  =2D#:J$JL8$_4MN4C*^ H-$H</PCO.SD"H99(&(*.
M_;.S,/01.7_Z[TW!?UG,+5?XIU1I'<\#3#D8@%4$EB37+$8<^)F+^[N72>>G
MG;:1<TQ5!@^XUX$-DUB$%.W/$08;=MV<]1W?B**?P3-QN3@V[*'%"FN7 ^T[
M 8>^"]T+Q$.[ 44,>:*9&8*B3V_MI)%K/2O_-]7>_MMG&6&S,MC<A"KBPGZA
MS/JM.X2;;]_<W[VK>*Q5OE_[&T+:]LK4JE;-[O>\1ED&*5SZ67HA?27)*/D[
MEVV,[1,OCR0%RUCP#7;2?*E"Y!O4MYH4YP!')OF68?1LS(<MQ?L1UDDW5<[*
M290IZ\6>AL\)C,-KKPG1W.F(+UYR]92M5U9O[66Z0EZO5>MH2TW21]NN^N3A
MY5BOH>>). #6XW@QG<Y3"TFR?2(&V8MB%[J3JN^:39\Q^.W^6$E)F6>=$[CF
M4B((V \8OF##:@.(8T 'B%*C(5Z-CQT%VY,734#I37"!# (4V=8M(KBO_F_X
MCH/,SGAG29S3E_\?EW43_D,9[;H9D1F:!Q_'@5&=M>60=65AIRGX?VE?1%?Z
MAVXY:W*'H9AGH0-6R['$->?&A"&#;4JGP\$8@;D0:*B]"">U'44=!.M>,JTI
MNX'#E1>?/:5*O".'O2JJU%DC_CDO,P/CDN,UJYJ4&; /88;BY_,^J(RO\NDM
MHJ((%",D78QSI8[\Q) >21G055+C+Q6?->XBWR^,EX(R\;S3TSDM;0<1?=;4
M'VC<#R^?QM_OCAB%Q1 B"2PHI2$3/)^L.JE.F/U"RM=!SO K#OQ 0!'*MAA0
MTK44.!7 AM4C0L9$Z?*D#'<"]V)Y>F"1[0VC\KQ26VM)EYCG\$_W]AA.G1H?
MZ%/C@&YBGNE!\?6K]U5ZA[[7>G'6/EY/FV]@J?LFX@Y]+&3-95"1Z]A*2*IP
M-5F*Q4B*X%)J&E^O-_I@8CU:3<86,@T@MYRA3Y!XQ$.ZAVNV3X25"IC.ZU>&
M^%Y/LA-"!$C-(,*)A3@LPI;EXLYWPBO=F"K88/TQEO3@AG-2]0/)W2ZS+'_A
MW+,AG1R13^E77"=LF^3*[[!AF.E)^6R,K.K'^/RHI3&<1ZWZ8<D59?A%)]C)
MQ7[5'_B>%?I93Z9 MZ-83K6\5VM]6ZQI)_-LOP&^/:,FH/KIM4O<IFM_"B8_
M#I4!='$E)O_V9F-Y+([*01J+[7\E*OK +NE$A6Z!_?X+QA8?5+^)9(3_Z,1^
MW VIFB$I^&'PDW C?IB1T=%]7-<Y,8CFSW9<W$\_<EMMW]-Q< ]AH=JJ"*;C
M27SQGUU/N#DZ/A*J8L,^@:&S0RN0NU(+-NJA?,4>&"RYR<K&<#N<VD?]*Z:D
M]^"UHNX,N\N,F)DK/==Z-^ -J7$IQY@"K&\(&_AA3"L;)K@!WTO/[<A9R;:X
M\.MU@@\=.QI_Y+23!CSHBC['7US+@62 X4B'TV0H2K3T$.?*T3M4"X:29O'#
M@?)0[#*>TL0W%ODCJR?V#'+2AMP(S0H7%2!WDHZ;#$BO5TG<ZG[J?;E*L5_0
MLVBT5N9%V\S5@T*JWT]^>7<4_T=5WNS;E1PXS=O]E<_H)+%@?M;=9@L1U"D3
M)S,-_BZ7<2/+C@Z@I*[B]^Q4AMQ:_<]=#_YJBLRRI .&)=4_RDOSJ@HBG_F1
MQFZ=^%'^.<!8?]\/53]>=4P!4"L)C&?EHSTK"^@NU+,+8E0/HIQ6W_#>\I]&
M;)B1W".7UUHBP2HO)F>9D9F%5?JSMWO)*\^7Q8LJ"V)L_+P>?'O_\]NE_!]3
M%TX?U#P=0E%^&T@9+!;NRJY:*9#-9,/BW ?ZVS<OG6#PQY $[>5&&7IS ULT
MWVNRV/GXRBQ:&RO6#3O,-RZ>,SYZ/Z=R;9=KFI7@B!NC@:OM ^]D5/;5E!_C
MG\/DZ!( 68\-.^##D+'%G"NW)90XZMC%=VO >+P/6G:\^:T5%K7KCW9$W[(1
MLT^9]'+I";9>_W/U#&YZ*V5;\E#]S%%UN9!$+=8\?K$+UX%OQ/NK;-:L!!]K
M?L?4?2*>D&OKN6=LAFMC01BIH:$O;/JBM29B;ZX' <H&QE,(E'LR0C0BY3'*
MM*HZ?))\[(CE53WK+=F>*)G<O<(78QDY+3>U87ZMQ!#<D>J#].AQ$ZPS4Y[4
M<79%O;]P9EBF<K'7P^U1?8K[_F]9O#<46 )U(P:!'7-VRWTZ8]B%BG3Z<R8;
MMHOD)(R/,5F8+UEN6_>-9WI:/1A]0)D-=H=S.127IT4#WJD+QI>X<W+)XK;/
MWC1K:.KOBUPX8)!<G::G;^P#ORA\>1E;6 TI7ZU;]06T?'Y 6\/].8Q*0="3
M#L*[X;')'VN/ZW!9&NT^\;2]B/%)[B.[#Z'AQN_/C;21<KXC7W+]^<55K(MY
MUH62"QK_'%6YM?"HC_DYA:[^S5<6'N8:?W'*W]/Y<BJ]11'S>J=GPMNW:%_\
MD#:?/UI@ G_@TRX]!7)#^8<\]]H'>Z-%6*F/FN_0AR=+R#*3^*$G#:'?Z9,-
M0W%!LLFC4Z*_CHSUGDH^]V'O)!?'54,;CBNYIT+6+XV=:OO!E\"MKKXYREI>
MH2K+[V=<:)9]8&0B-OQT4TJNYEQR.9\_85^E.A7?1%,[3LF-],Y9-'_K&- _
MJ'1QX]DU04W]]IMO6LY6A<2(["WK&)2Q\!%I3;]G$/5.<'CP+*%^!>8 %U1U
M3*5[UF_[-F7F."CQ.-@X[-U*]5#U@5T1"]YU7?3]+@5&'V,/ICG>9LF,LJ^^
M7I%\8*S(#3.8L["70-URJ[&Q4]VRO1#$JRQ\6EX1O0)RYT%(TM$-/,9#V.6T
M>.E6-OI6G^,[$T^[CNH$X5H''_2J-X=;8&Q-C5[M=CEAUV22K-D',/T=4![:
MQX;)LV%B/14#>0P<YXN4MHF-2GW64FSHELE6=57Q\LYZJX?OUG^+ "W_$P$"
M__\GP,I06A$K;0,Y^+9><;LC'8(1?J]AG8C^Y4V#LAZQB,O=9TH,7ZZN7!/6
MB<1NS8SU30P %)/U[FH.B0;?6Q-R8<_1<MZN!XIQGC*]IZR2NX4-MZP!MX;!
MG_@/==;*2[KG^K_R--UK&XM@98^NK Y;8C,:;3Y**VC>*5PBY;(&'<?FS8G7
MUD<8*B%;MR9Q3,&L6A0GYB^T"G6 II:9HTD]-KKL^%PF+?Q9H:E?<&430E9?
MD_^S^T.7WUV67D[\'=2#M ^VBKG]\_:)22LINB=*(R1;,Y!1.=:)T8-+??UM
MWSW5\)"LSR*__+=>GPG9BU^=EXXQM7D)3O)54N]1./#D?OQJ;4I1?K%/\&>9
M7NOW0=S*L.CF&SN]B=J( HBY1#ID$;N54$PG0HJDU+*R<_C"]%$3?W\QT:EI
MCZ%1L>&?].HSXT-FN6*/;8P:,U*MHP=+B.V@*S 15RT.=%VE#H![G0CT4?@_
M#3>'($D]1LR=!,:13"P7>,:?;PMDPRB"H,U: ANVOXHJ#P83(PB46^YL6-,<
M&Q9@M=.FY?9*,V0(.VU:W%G">II,]>>:+ X\DYL->P\T7/C*AB&(X%^$_^(U
MG&/#@G)V^KJX[[R5?96/'G 8,0L97(W)%NZ7,_/29D/GM@1&9:>Z9( -.YZN
MSI!FWDLRBD $JJEZOA0T<N/)-TUZS2=+2-GW/X?R@D(#D@DQ[<&Z0$B_ ?H^
MR*>W%KL(#SO#XS<Z8[CJ@""]XNL=36]=GU>R845GS[&\\/ITZ IV/Z2S)N<G
M&9K^ZU! LV@)0V8MO$C&?K]M_1YS'E5J:"(NTBC==*<W\R;"AZ7/Y"U7._:4
MZIFE_Y(1-]?Y"_4:07%N>OMUU(*(UJ+Z]I>W!/C*:P0-#>?!ZWJ*K=U567UA
MC!!&_810+8*;N9OR3H7O;>$!I?IM0^4&Q<B'/U\Y1?XRU]RP$<.Z6AH)4KWQ
M!Y\)A[)A#M^G*IY73S]=&]E>PI^I>;K(BHT/7:E@C!+;'D)&V'3M-7Z'2'%>
MKO>IGDLGJ0*ZW<_E%'1O+OSB#.COWI-DIU7^[GW&E^C7W.-N>ZI60Q9J2$G'
M!9 '8[9$4YUH=F"@HCQOWE'OB>&2RP^<AQ::_^MSCTH'&HP;@-_0]-3@MN )
M_\_3CQD&:B^@KV1X:=)XZ9YI"_U"\59?'6Q4.AP\.6Y<OCUZ][KUP[T_3Z^J
M\%MMJ:-7!%Q2'TSRG5"=/[?:%C]?TI4[9O/[Q0I73ZO+H8:;*=$N1?$ZWX$O
M>NJ"5(G!OVO<#X%#"(JZ\V[PMU))TFF**H7.UZBTO[OCD'J%#L&UM_#61].D
M'/A);0W1>.8(';*QW=/T1H;R2/O0IM_&U2I%68WTU#.$ BD6B>KWY%3W;K4^
M!D/=]Y=.\U;L7Y(Q.D9^\S(#WTH8*U-H*Y>:,@^5>]ER]YRS/3!9SN7-:Q+J
M@.8I!.MS-1QM'#-%57K#%,%WG&G3R;"[\$ GZ1-OJ^DIY.F9REDH%_-[A/ZK
M?].;N%]5)>'S3\POL9)9W-;,XIO.>XG*XR;#752+/0,KMMH(<=QL*]K1>;^+
M';A0:+ZFBS%!<-CK2)TODOI))D_$DKP3[#6/';%1>\VKC2<Z"H'<F13X#=MV
M. ]:2B+V@EJ/T\"5[:VP0::K5>*X\UM0@([BQM:K"5%F _5*I=+L?@QF,D7T
M](*H)OOBEFVU"8IQT^U&?/M=9,#M2OU57=!CYPB(#8XNVMR$']HW,Z8WX5TI
MEM):4YU"@O7?.;P6\PY[9?7*;O&>YG;Y>-8Y5BAA/!+@9<.>2H5:.NNCZ+J5
M3YUN!V>BZHZ,M33[>%TRTIKDG?[(_]Y$&9]]#O_N5^FB?/OC>=1@[3H695+!
M%%CR+4;67O'XZTY.V4QY6WKR($9NI[LBO6?1KQ0UI#GY"\NXQ.2G\H5O-(T^
M_3HL;"SX_%IO@W^((!MF-_)]]LLO)&S '?49TJ\7A,;CX2(3<?4K7+4BTBHS
M7UTS1R4_6UN<%7VX[>=TE&7PQZ2HOLR\75[25-M1 I]L OC98!N$HVN>;KCH
MC4DAC9<(1S#.F-^(4TQ-QEVT21_Z$2FTJ:)WX\JE@P+3YK?E\X_&T9_<J('K
MO]26"$L. =-2- Y_R30P#C'6?AZ%^+1HG&A6'G-R:G38UVQ=DRF@21.)IOVA
MT\O=UW2=)^!\325#2U1*I_!SL?*DSO.[;?*S?K3<YUN4:^"CBPW4H((5+]9[
M4XBW\FR?\#?+QLS8=9_C@$5SG':-6#Y^;0TE#]16'LO%2=2Q8<%'+F8[9-WZ
M/H2\:C-K>TK"M.D:ARAALVN>N/Z8P#F9>[HY>\S0SO"#X%6QUJ%1\;'$E4U3
M5KW?2VF!UB?&V2)*^N11B0([&1^+E3(*$ :I)I'H?ZR]4SR4Y'S<-KL!)S-;
M4NY_Y>2N8%2:IJS/JQ-4/!NV9\G6?]BY44;/1)7C:Y,6'*5"T,K \^*.VWP8
MD';AFTG>.2QIG[YGJL<SAG/5$:,+3\!1>9NP;)BZ 93VUAX"J-L(TLEP.!B2
M!M&%GRBD)1O;FNIV8)4-8?T@-'T0YJR* POWM-DP-2&04P[48HY TNYQ&=B6
MC,>!>Z/9,&R_)R3TXZ/6#&%'"5*![U=#<L3:SD&G0-9&:6L$H:YOVTY=F3KS
M*I%% '7XP-OZX^C(+!\^9CR*&4DW8B"!6G'P J9=Q:@IQ_W;L%=*??^7RJ'8
M=^07Q7-71J7O9DG"Y&.']%Z\'.WL$&0IFI!LF$=\:,^Z$3:XH49G583#@8#P
M29U=63+?SN=+68233[2^?G$XQNR"\IZ;,-@NU#<*ZH11>Y:OCK!@Y[/>V+CB
M^5S:@*YJY-;LT1=/I<NQ Q>BT'$%2 O4,YQ3_.(,.ES]L,E\X*S$O!#S>"-5
MT@$09JI3W*)B2RKRB_L?AB6)>'VN/P-?X7[<R7B;#O1^9P(0YOLZBCH/<S0*
M^+-Z,;REX0E=\;2?;^ADYU;"0ZFMSH8[>@&>>LW?0S'%)7/ ]1<'M)'B?G&:
MHE5R0*]4.\&.,"A0 Q1UOH68D^F0W.PS]9:F0]<*82 ELM1E+U7M,9RVX)!T
ML4I01SO!^8W]U<W#/EL7VPVF+&9-S/>GS1N'?+":STK#J((] .4F-HBX?SE7
MKAH^.NRUJ2YL72)='/]9Y'<*7/8N[]Q$!-]/%9.F:C4ZBH3T-Z^W R4H8-$$
M8UK4^UCXA]C\$YZ[:GYNGC!9_VJXT<EGZH6[YW/M3E/G_<+HE1NN^SJ.^QJ]
M$=S6,"%A5,(,+[XW$G)?)B2%(\K@23-6Q\<7M3NYE9!M))2, <H'\6E;:GL_
M56*)DZ+3&'TY#L>#YINYZF13TOVXV$;U<_31!]%)KOUE<X3Q6%0!4XG\DK"_
M$'$Q6%38Z9C:*V: +B%=</TWU0 V4*7AN3H-?%?SL!)^@E_N\Z]V6+<93W5&
M(^@&)&SH,?P?M-S$J&N#R:?FZ+0_+6Z3"_SWN,I(!'2E#(.3*4AQS3)ERE N
M_:S,ZDRI?[G@>TLK6W/<H;<P\5CG]3P=B^,6#E*F="U'DNDD*CFC)E?:)*0W
MB@U[5E_,AE6)$G;C9B+:E0($C[-AMKE1X *!-,3$_D0-1H-[D=3C),O1JLV&
MXVVH77,Y@3X/6SPSVZO?'/PX^7-YV4Q[FN\L01?Q#/YGLP:1+_0N(F:\ZLA5
M;0DCH?AWL[^J>_?./8T3%LG<]^6TZ(2&[BM_P:T9S\9/$7;+) E;0-H-VYFU
M5>P[HUNWA3%;N1\^R^PT 76FWD,1=LVFZ^\("_D<!?+AUVJJ5&?R!%5 O[M2
M@$0V0)97OOE:7MBU+![P4.;1[JSO![UWOWCUUHKG7SAB<?M2,N%>#?T3ZD!@
M>J"AP%1(^%92L;;'*D*IR<OU%G]0HJ=9KIV2@XSLRLB_ H1O*A2S)>D*DWR!
MN*+F(#SZQ@3JD*W'2_K-F=VX^ST21<'?E&+O'I3/X PR5E[T5PL@F)[+=G7F
MSYK\X7XA*CDJOFAYG7D@G\ W-Y[WHE&CP(F7EC] W3GTKH2X^6_%E6:0(A6B
M]U 'PA'C7X"#"C+P6HQT7^$P=FE%?+E3JS2)VV.^^/NPY?W,^O-<7'Y[R:C"
M7I/?E(&#2(E&'8&]YY6$CBLY#GDR^;B"\H\^^V,[D:YT^%NJ&S[?GAC,G-EY
M/<).OI3L.8EG'AP%J.6(_W2+@(:AR3 ;]K]2E=!_Y%CJ"K@7>II-21RLDFSW
M ZYUI\YU/1?2JKKEZIN*=-[[./1-5>]^W-TUU(\/>BB>!K/UM>>H_G1.(>OL
M1!IA"^=8OR7Z,ENN[ZN$F,=R7TG)UBEGQJ-Y$_/9)2SU3FO3&&EU=:WN6.'!
M&[N?:=M$9J<9J>M%M6O#8)>T\1$YF,,. P3*7<3@Y(U2REB>V$9<^'J+^P$U
M7;5;"I5_;<]5Z A;MKXQ/60*VR6\B/I::.R-<5<5$[MSL2HMW8<6&DXX'O\D
MWXOTO3P_!L]UH/R*!%##=*,&+IV<=.9F7F)]D<XM! [:#P'U$XY?Z.*#CF*?
M<A^6]8^7>^?TGI>]+14GHKSVT;7PO<F2I2#MJ-RA/$,1,<D[)IZC^/SH^;YT
MB9G!5=-.WA]](P_L2P<MK,$>AV5==>^_"[3L,2'_9]ZWY\F&<1V>[Y$(PARV
M)+-AFE%$@R EQIW^;]B6P '<+51&#)7 /+)& TKIM0RX8E7Z]9X%JUU5QPHD
M<\UR]GU<OKCTY=L[-LQ# &50:_KS4<%W0<GGPRCZ(1=4J&8[->"(5UA2E;)3
M%$#GT06Y<:$[S>QU<;\DBC$U0/$U-FQ)C[K=V=#5J+ <Z /_XUYQE%H^TQ<D
MFN:UQO_ZZ90-I_:N< R9*4:OF.B,2/JKAXF<T#4?,.MR5]ZL=^&PX2J_L!"1
M'J"QZP/E.GZ&5"5/LV;]4 489^DY1<C=BU%_<FKA#C\^>O<KC;L=:O 2?<D1
MIKQ[(D 7S7?TQ0-7A\<OR!KYQ@-VLIT%EO"6]9*1%[BC.E(05.9^SE3R50I=
MKDCO0S.(VZ>3":K@;J"V!L-'Y?RF2.17E<KR\F#LLEK3;B0G)"WIA;0<I9UZ
MM(E/K8223,Z+] -4WMT.\&!0N&B4J?*M(^U2TA;C9C,H2*^^ZK_V0#3'_%V5
M?CFCKXNQAR_X4KM^U;&N=:?.90^;"KT'25CJ; UXQM 1T90D4&UVXNQQ7ZLQ
MRR67UXIE+5,N*Q9P2H(M85VH&U*Z\XBF2C.]3"$[=7SDDD;1%:DFG16%<[D(
M2]97-,>$5Y(NLOD47T_4M=KX1;,2?Q/G![$N/814;XF&%;KD2@W2OWC-&U3K
MV<@*HEOX'E'J/68P=^K"$Z;.&TM3-%[8<K4K]3SB7,GVB=*P-NX;5D6FS?W:
MF/0N]YWB0\YBUI?+Q'!4,7?WNH]_^0^*6E*Y:E2*4X0.X>(4SHX-L\YO H:"
MRZF6*V0(K#A[J%R-UX[L !#/>ELGEUW)]6;9//>SB?JWKQP-O__A=23S1F+@
M,X,.-&RYNT+^XK,G4=HMXH2'X_<.-(P[J&*NO&SMT+AFM.D\G6SE-#O%=&S\
M@W:$9XSC+CM[ZZ04MZ WG%M,SR67X_U0>R 5'^(C)87OM,(83.AX8O'Y%J1*
MNV]E_9Q-S CAN;AT>&,>E6F4N>^%N^15T=SA0;$*Q.7T>T;B7SD]UK7=G[-.
M0^CRJII/-]WK:G.U:JE_[#7]F0/'&CN/QQ[L;M?,D!$54<L8V]A6?X!8FJ;(
M:;/BU?;2/6NV974CWMB?N1094/8A:K5]+&Q5OHSC307':TY/069!@UDZ+>*)
MR9'BZ)XN*;E:5"_X:8)9PD#(I?K[-#HL; "AD+I7&OSY[RS6_%_S\0/K3NHW
M.5AD/"DM*0M/CCU_^))6V 7#M[6[#UTTZ-*H^#*RLP+I!R4^M?(;P*!0DV>2
M.&4TM>DK9<#P<Z7 V3A'_M'2XH32Z_<.W:K=??YJ]>;/#=9%^R'=M(JT!Z9$
M\^&Q0:O;OSMW4X//)AY]%!F3+ZPE>M#K-*F:FP69XOC;,0$ZUL<E&WVA+Z[V
M55A#A9V)_=I\U$5P<G\++S)MX^1?&?@A952#O=4OY>=]0SKJUWK8,,$B9*=-
M?_,D4WN"9:1'NM3HMO%B$$\A:E266,IBM+NLR-0"D/LKM6!<M:<X9_R:Q?T?
M;R7(VRJ [; @O.FNF;458CHYD[E8MRPS59B8'*L4H37L()+;;S#"C\I\Y/('
M?=>;LF9@V8-<12@T/ER<F&X)>AL*9<A/;)-#%J[<_)\;RNMR$.#FHQHZL=%-
MU0<IB*"BTC2$3*_Q\]BWK'DBOQRIKGJ ]0FZR]?Q,P7NCAEH8^J!ZO"G]<61
MR:6E%1B<U*_ZMK"-7[7BFC>O>GFG'WI:]LI9P$AB\&K;LCD86!1+H3V*L'N4
MJ5A1);)9A3"80+TA[D*;,32]P(%ZM0-=RT7A^G-AV0Z,"NM?^Z/*MIZ$>3X[
M[78B:M?.D_6#0D.MRCK\CW.M@:YHGH.:4O]7]3X%78+HK;<T+_G6AN-1]X1_
M[I[<E[6(V@6)IAPGIGWL@"57[2EX_N^E2\>>')11&,9.QAJ+33DAI>]Q<7#\
M51'"1(:4DJIMDX[S?CY'6Y2S:FM!#\\SA/:_L#Q1E*WND6Y"T-KVW@)Y,J&,
MHQ;WXO_DNVC_7XFOK4P-N@*D1<']+X$ZG0GD 7H@_V? ;O[]Z"0'=B/DE9ZZ
MCS ?8PDI <&46R0=BL"<?'3'">)NHKU.\MPQV:@\\I!T]N.284;OB>=Z?R)1
M(CL!=!I8G@-?M!,B=CKNW!Z_BA]LTRH<4#L_:#$V-#QF4:RDKOKX-J+RQL_3
M$;-K^&'XGP':2[I/&EJVQ]W">1==D6@H*N!])/AYW&Y_?;47"15)K+GD:KYP
MPBCN*VWD.$BI0G[A]\B%U9R 7=7O4@>NX@C_.TT=_K'1 WOP?P!02P,$%
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M)ECDOR39OPOV/^2: GA8F!C&8^$'X, >M3#^"/ ?(.:4^^\0O#=XBB.5KW=
MUB6H(WOWMH=!>=-X.G =R6),WD!\5"3_^%&0XIB\U:U;:"4_<-FL3,STB.'9
M52F_4=PYF"E/DXP,+I)C<F9U\:*QN/+9 T"-$!V(]$ I]4+VXZY"8F6XR#]C
MH-LN;E8CB\F[%F,J,MP)05KJQ^V3VCVT#\XGW[-F0^?7>W9/PI#5:-:])#K@
M.:3>O8/MD@QU47<9@QD1V3ZJN+T^H*20<V/6N&M8K>=E:-N8R<$3<DOEJ 0:
ME_G\#!_%AT0'UH3YNE2<D$VH=0@7*J6+3UMT1X4.Y,II'5@[XP>K;<4JNR$?
M21NX#XL9 &311#IP#9J4+U(/%Z8R.(Q'ZQ$W)"P(=(#;9Y:-U-W\(J3Z2HQ>
M@F1TK,+DJ)E);SI_7:.%ZHG+,/A+J]X9R7FK>YHX ;1>F\QA<M::[S/J*3(D
MME)6R]2H_M6G[N2Z^A"7VE-QH_ 9VZ'T7C/V"00+]0(9V^O*+D$'>N>B&S'[
MQQ5: D2BO:NK"Z\V=3X:3"L\]NO)@_[7UJ8\ 0C]*;3KW@MG&E=8.54SH4-7
M(T\\H5WD AWP@"<O'S!^UO@R0)32W$4Y]>Q'D<NSN?!]-V";?! G^R&X0 W:
MG.1)XY+FZ]U#X+$)#34\J!2\/"[VT*=617Q%TH75['L2Q1.LJ@*3CGB3Y,##
M)DQJE9QB3_>S4WS -[O&*S)0\!>^)@++LM;JX?<,[3^ANE&--B*D/W-6OLYM
M))W[\I>@N"=2Y?VH@';7H>N_VFML<FA<+/@P)"4,#"8C\:5=5:==R'P]%@VU
MI. HF365Q33RF7POQ^6#E=8=BV?=LWRN'#ET?O[8\JK.?+XH2MT6G(0FP*#8
M9[R>Q+:&<F_+,"]R6-U["Q_Y9()^.S(I_OA^M?T?AX6W9&)WCZ*-$RAG]G)I
M!U$?YQ5:"(H@HOK[$,-FL9&S9IHZVVNG"$LGL\4<4XLSH5\&:Q=$+_2Q/^"K
M:).@C4($KH$3WKLPS @=X-K&<8.Q3B.*8VB5,E1HMU6Y]U2]W6KDDG"([WS:
M48) ;P^7L,>UCE<]P0AQ TZJ^MY3&,.G^0Q44($_+ ];/%J7&-<_1?CT6%#^
M_&X(/_B.&,1WEP2?K.F <\%,=XT<4!_Q\%6C:M#"_(-&0B92$ESOW3KWQN)U
M9!_%1T^OT#W0:^!7VHN+>$-E/\2%#^P=V#J^U:.[4%03)0:<+D(EX'\LCC5%
MT XY.8%.HN3SSU@3X==B?*-$90=EKJILK<.(I<(?:._AHG"O)%D"WQH3'A&!
MW;?6>C6XE.H[AH3>0I]FV,NIC]MQ4MDN<V-AT#TWT3:W6,XOLB1G&=A)60V;
M1TB@+E"B]I[^F!,$+]A\7&V8BPMJ<E*96<SIDZ:R6$7S/'@)R%FW5]O+'HQO
MVN5'*?;0]I-%^R3S15"N=,#2TH>865ZV F78BGM:J^[%Q;S#[<C$.NW]:IQV
MRU&&8@9'&"$@%>5FOO<$(TH;P4B"-A4W*'1 $&:2+=T8)?S68MIG/&;K)\=)
MM:%#K^MW=2/=;-WW.QH>K@]$3@T3&]/#\/ HJUV8MS_:A>R2NU0*C1;L!5::
M93)X"N&-K@B5%@%.U =EOQ.>RD_GF=$7\*8=\(0IY&KMKBKH>1%TJ3$J0R&)
M]3M9<<K71ST<[TR?]JLZ_BJ7:^D(6>.,WA4,66?!WGOW.I6COG&OIE5]UQ:<
MGC_?0A;MJ ,%$%S?=Q#1:]>;<:,*SEV!R+N9'^H&8+YM#E\4"$6\4>U/^2Q)
MIFL)(OG0E%;HKAEH,-=A<!CT+7CVNJ;+XWGNJ?X-\SNIF3NC;D)6AY?$;5*+
M[.VM7^E%5)^WFDX@(J,QTMZX^M(>Y&3:1R/0OOR=CUQV/ HW/+Z=(_F8_R"N
MI4ZD\Y#XEJQGLLZL6<;]0XVIEV^E[ZJ!GI1(T)Z,-00O[!YUH9ZH)VM%3AN1
MAN_#'"D)+O9VCV(>WO>55Y%O>#Y8"R#V3P:\L)?$Y\?F\U"-2=.G00M%JB![
MST_$ 2<]2SW76K)FTF)-[-,[1YJTK,I_I2!57C'-['-UP_4SNY.8?I(.A7OH
ML!<(_UK;U0+SN^&LV/F"O&-@TO/O3?XH9T)PSYP 2M(ZGH!/%'$JJ>L(??9J
MW[Q&P7H!X)<.3GS5;&@]&30RY6PBH/U [H;>$3'FMN-DK=5W9"A!<75HU]#+
M"1L3**W>XX?V'4,C2$LAJU,ZUUL:=N5[BBF[L8-U]58"K][J3;.%:\^!QY#W
M6T^398FJJ:4H[.66QA$#01^:N,2C^E=>XT3'L1]'@LZ <.WX?H'/:Y0Q2DT)
M30'S"2)P'<1C=W4Q0W"..W1 %)5@.++V RKR36(C+OEQJ=?*;>?5#^K%@N^4
M-Y_KW>, K,6:K TP9%Q[?K+!P;U[&CA!, O?5@[OAD.H5T=AWD1>D3ZK3/-5
MV(R)B(,33/1,X\MXCL]:7S9SM)?>*-J^)F>MIN[>H)J!/154"#DEGG'QM!CQ
M3+A LHI]-N8YVL"K.[GF-!N*8CE;+N<A[<YU\>1%8AH _8XCV21I=<[5320;
MZ*/R\?)CL7%M$F#RW!ER4Z2JI@?4(U!^IIZUZ%6R@N 9M]>.18$I/R."\.?-
MQFKWJMO403="<-0=>'+^RYL8(1*NVQ*QJ]2YT^IZU*+EN\52C/E\).W3J0KN
M_E3X3KD\1Y>/X,_8:+0UR$INZ</6-?4-)TS@.!LJ]+&$N90[O*?/D SKMQHD
MPU1[=ZWB%?..--U\7!CO6)PHN%@FKL.;\A3N.\R*ZNHU. A*^^'A/(AOYD7H
M@-$&:9=57QD;S^N9]M]^"JRQN]]X'_ZZG;5]^'"X-F32D_!S+8I0,QW+B,^1
MM$.@HHD+^[FV#^DV+ZVDAP,@L6F6*L4IJS::A96SH;XAINM!+R&XQ'SX7@K6
M&S<EB&]:O11 A#-CAOW FJXVSC&J>2 AR=Z>?+6VN3E)TWERT8(C46"OJ#_B
M869PD@6+Q+J']H\-IEDP?;YT[2?9CMB#Y::Z!):@;=*[&+NG6U<QIAI:O^WC
M(^NIZV+%53<E?%M2+4-R?X CXB6\"Q*'D6)P>065A>]],^]B-] MJHM,$I$6
M6;9*52WQ25@S?LI\6$OP\#MQ5X,KWQ,7K-E]R%J4H>;&?#PV&L-,A3>1M>(P
MJE^W;LR*)KB.8^M6YU_$3TG&9H><\7_MF]X75V3BMN7/O$#)9S90I+J2/S4O
MQQIH4O=G=4R]CPH0ND;X>'$7DU5A?%C$L4KUG)_ZE4AI&4UWN?T!"%UP&K^4
M %VM(*GC?ZY!=@6_S\)([W-(6Y91CLVDO:KN[)_1/\Q6?1\<:8CR&"WR#0R*
M_JED4I >[E.P%XX6)+-T(H2IMV@'1FGR*PCVQ8_*]ET2ICV.J@;3,L\DK.HU
MB^W/?#GML_BH0X 8\"1Q?IYYCBI,V^SMHRBWYMN_"0T5).RQ!G+:7D\16;8-
M/\M]B(=M:+)/NQ(Y^1-?0Q5PZX,(WWF%\UP>;8 *>U]X5OZLQY/ >VE6L2G0
M3W72XW.'P]$N9K[;/C4,Y1:C+O1BH'L/%6I)D$C-%'[$%-ARZHVN753IF[%/
M#SK*NI2C90TMK@KE=]:CU7=13F!.=S8V9H)B!&Y=">3^6A5-*26-.OA6M?9Q
M+UD<>K":%)!YJY]SS5 LVWZMB+Q+R$^@ALVG3/ZDV->/5V.DP;8-D[&:0)Q$
M K=S0[1-T0'XY.6<^UH&;K+NAH>\K1X)>;EBYK)%&G;A:'VPBM2";Z"\)EC%
MVQ,M22E1BF\L/+7*E\+*K'3L^$\C%P9=K:LZ$Z%#/7.?@SL,H*3K->0VI C(
M2(7G7!BPI;;<6^5OJ5!'15E8]? 7-G RM=WOP=D\E.;67&=-Y)R4@1#M/?9E
M:=\E\#1!<N\"G@%Y+!3O4T79GG1=]-6Z\*HMTAS?A-:H,TDS/=9KX&G_]NE^
M"E\<5N+'!G@4TCG,@_8!?7SQ2:<&VEWE'^><(;/<D+A>))FC7R.5)*0JS:5]
M)^VX_;'3Q]')F5V4.7"2.,Q\@P[4PSNPDWG#KJ!+T4#0AQM9&.BN:DVUDU-+
M\<_,D]CKJ,$K?8>,,[UFK5M9ORBQ-B#C$/6Q:V/SD+A&'#/,!T\'6+QG]Y$5
M'D[-W;]SM%(Q]''/LS62F=9T =,9WR-VJ6DN%0TL6@_04J#B/"X<SL:WNDOV
MI''^(.:+H4^3?KU^\3%0A>]L2Y8Q^5A]G:1/.B8M(=1A4AS6<=3DG%:_U8 A
MQ 9MN/<2,S7'1X7N:J .\TF"Z037N*FE*&38\UR#_@$S!V)P6\LC4Z7>UYD:
M%QTF'[]SY:@6I 23E[MKQ.A AWEKH"?9M!V)S[6W!$V+G6=6;C/$]JW+8,BN
M^N2RLV4#3VIS<V*]%S[C8<U NG-W_GZ8YZXJVA]TW#5%A<[K[TW$K!J(6L[7
MB( 7\'O%S<5M,FI6O NVSJ>>RS>'GTL25*N>+W!&:E=A)PD;!&PW<GJC%R$-
M,R+9=[>)D'K+22T6+TAKPW'UXTV9"Z>Q=YR'3M,*;0=7#[DM<22>ZR^AA/.5
M>17& T?^2ZCMZEXBSF>WA0Y,ZG4@!+!>PV)?YKXS 'Q2*-[78$=?ARG[FZ7M
M^NSH20>;2T)R1A9$T-]<48-I^X?P *J4*!I!E2;#._,Y- <FTYW)Q7?O9?,<
MO3F85O707'GWR>U'CJ+BW_.4^ANPX%'HZK(;\KFK5Z.,VL0\Z<>/&5S\+;3.
M_,# Y^U#OK '%BK3O??.Y!2FAK^[%G=9]8L$\/.;TGN:+.T3'6!M$T?#/K3)
M?\N3S[*M([L9YO'7?U N;FN9<,^#J\G51QYTM7VWY<[#-'#@Z!P;UCLEEN'U
M;^P[FBUC7A> *:?CCS8@N,$*D\Q.&H?\VW@_J2B!,ST.G++*K_<)\ DQ?;UH
MKTY.MDHX@58;MVJOL!1!BC0\F^%%&\-2)Y5[PN>.)CG&75+N,)2,CY8W4C9
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M%*B\/2O7F,[<)+)ZQC"9JRZR\K@7<\V_EF0.8^\SP#+T'H8'_(6WFESNM L
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MH[YHV^PWM)IR[LH8/B&_8I$/[8H9.?*3&6K\%]>!GTAIVAA68JU-&\R:;^J
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MER88\&#&<-Q4HUU#ZKG:,2K\V5[\\FFR2\9'ERF+DAZE1]0FSM9[M_LOQ2S
MW,0T\^<WHNE ';87(:G8B6!%S?5FTA3'KGO=P0I\(SGSJM*V%YXWU$%S]_F?
M%'9XNZK%//")1QI+22.]KR%S=^K>0[!K_(*)S[?(NCT#M2ZT^F3DS<R:/G[V
MJ$Q%O35QMS/:CC-:+V2:A.RQFE2<[TLH E^3FKH,=,;01J4M5D^]:/*[<D$B
M6G('TLR554<OQ[W[4E&GWV-B5N*)/%$J^4M*]%Y-8&@,-CP/#I;2 8[\F"R'
MS(T+NY8/)PZ<#I7R%?-,GI$P13XT.<XA/BR5_<-J2O!4+2EE-6)^C@.M1=;
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M4.*V&Q"-\P41!K'OM/KM#!D(\R3C4]GG'2S;$RNV(MU.QV_J.-SDMWZ%V!*
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MLJ5= :0<EXMV7P:U!XN;^S.21./*W2P&X^3-G_+/42*TQF:$6,KLFW3W1L&
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MNMRR3X]ISO4ASPBOR"NHY1I<7O]IG"3$=0D-42Q;M19IJ8IN%=5;^VM*(T<
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M!_:ALV:\L[L6X)E%Y,)&A\\N+<ZGE;%=U_1%S;5/_P8JM[K34$V4,.(FY9(
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M=75)@.=92>T4)ND_M&AU)G=S'N0A!>D)W,8 5<[:FEIBQ#QQ>?=UW-3(GX/
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M6I204Q+S]%#.3"A"5CQHH#UZ3/*A5LKX^$]9FHPI[E8X#TB(H_-QPB&7D9V
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M& T]^ _EQ+*8.'GR6_);0HI\@6_\Q97/'M*]V$D%S>^U43WP*#\;6L!T3&^
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MY]7S!Q\_;$QRF/KFAM\BT0KD'\H/4*5Y=AU5F>>#"W4S7_!O</T9QILPKNS
MI7:N"P\]C+G$-18]BA'IR_(+8VGJ!50A:'-/*!+JZ#5PZKMM[?'6[WZ$R,%Z
MU'AD,T7&'(R'*.$\&Y$T]0(6MV7F:.,@/I*G5]RI:ED.]_%E?ULTG>KX6K5L
M<D>I=VZBMEYVM5%NTTI?$SF29-@O!%'?D]6Q&MXD:5+EH'F/9$O"@O)7CD$\
M FI1+7FP74\I_OVXTF:_W^&3I0)]= @=OM3*O4<1C&)W :XEZ.YFDA6KLCB!
M$6?9\AB!'%Z=^FF!*IO)^:3Q2\/D<'0*M"RAGB#'/RJ"S$8JWXHNXC/N3;0-
M)W*4) ,D-9.V L[9B[:T&M[=#^;/LXJ\U]B%,MT<&^L[5]C'LO7/RI630;$)
MD2P[=R!<"-JZ-HQ!L"P[8"!>")TLY@84<Z\#(71C$-K;X;IAT??G'I]J7Z@V
MR+3K_[.S2?-YK[,J/T1DF,M5Y!D!R2*9C,955G? Q;MIC2CZXYQ;:<X1O[X[
MUPP^"E&2LBBP;G'R2/+OWK?Y<<J%\\>W?(;=0TS$,'1$=GVE[6C$:)Y:$(I%
MI*5&!Y 5,;#A[&H_9&!@X>D=[5Z[-9&2QXW>]R>6&,-:D+^4=;?\$()D 52G
MLCA/;G2.<1D&KA0%+/ XMF?-XM9&)SSP)7T](.?MM3/ Y)BT\NSMWK-S.>CE
MI0+N271]L[LN&\&4Y!['=E#4EDE:P PKAS:$W7/= 9FY8')8(>UN0;V>2;Z
M/>6]GFBB)9-!;/B8(67\G' $'HT5&^(]).P>>[3[XZE>,[RLUX?>C:F=W=$W
MM5[I^![K.P$.GOX/MZO_GP<!V$3!#M$[Z:PQ*-R_M8[R>\GW_DUG8T,D_S>"
MADNS]H\6>;"F0'O][/H,*4HD@HZX+CX@*: 3-[P;2M[]G,<#VHH\(B6,_$LD
MCQ\*OFS8H[COX"QR%U$S50@B#PI!<C@S[%?'T_(L\46=N=/=@N;@5&8U>P,\
M=>DOC5':76X!CPUMKI+#[XC;/^LJ]7EWQI)Q>-D]BJ $:%-14ULX3N7\-U&1
MS76SU2__;-]6_-[?S/G^I,_K%5.K<DC=/^ MJIO2_H GK)I(9BPRTX%["IW:
M1I ;OF_&#.E0MM_0_C.=WBG/L_U@H])@U"0A?UU>^^$FI6(4ATIBX\.$(*00
M% 917<6'NYNSL3$T5Y3"AQJ"!&LI+9;3\:MW4,GRP VC'].Q"?%QL?2PH^*"
M'9K^_AY<2<RU^O(:= Z^*2W&QL#7Z564:[S-WK%7V'YK579U&,R#$D&LAK64
M^\&BK!6 <U_FVM(NGG<*6-[9A=Q#KGIP7OF4?9^*Q>,RBTT&^LZ,M<ZC(9Q\
M?A+6"&/&<E[J82-/C]QE;6-]BFS'BJ=\1GR9=[Q1O?ZZ6T_'"M2[J4#=$ AB
M*S**8UC5G',C#2H%7C,2%:P/;PIX%X>7#;*?Z\\S&;''WVM^VD2X-A3:\O**
M;E6BU.L,Z>7QHC\PO')**=<?R+=UPJ! 9:R=B2MBRO!(C82&HB_9'VMJX\W;
M&A)KHP]"R_3GAMF46#/BU,GCHGE_XD"WZP-.-#BQ;W%IP1,2796"+U>O] ZR
M;4Y?&3'T57O+?GX^^9O7I$<G?MP='H/;0@+S=-F0J ;-O'EG@A9@;A&9;1>@
M@,_[9F+[*- D;_>^;X=J\(<VPTRUWM+);7V MG8#I/3=7 ML.\8?2 HJ6%#?
M(SN?9D;2]QC2&J$BK ]6<4%.R.3/S5]2>OV/R<.H&4F"WD'LM! D:=8W6>+\
M@M+\$"WI&C3X\T+M4X4ZV>99&9^)JP17M8_\Q.\ !,;LEJ[FR8J4+K6<!RUG
M^8SQ#+C:([_FAJQG!G7&I20>+U$\F^+KSUAL;=)2V$ON@,D*C+S(%99-)9,E
M'8ARR[:BL^!G=1&Y+RKZI-$'0]*+3"_5(!_V=RLH=J\/VOON308]"7<SB@AE
M*W(R^;4D%5X *W")P4" /*VW#52^ACK3(:H+$CG??OI-'].L'F*$A]B:^7V!
M,GLM\B[%REB"'A%9#G934TQ)AFUC?<IMD4#2Y^D'/[O>DHQB91T%+1UQ'@Q8
MF>/)3C41S%C[8]B/(<K )<=!A!.P3H^SLW<[TT.SO.(/W_."?K0)%=>D??V!
M7W-)QO^HC 8JZ8( >GT\XM^R<;]41#[;[<+W_3>=\ZT\5/^/=IQT,$'2_8\H
MC'<(04ETE@V_C;PZ$>#^;_K<G*S%Y_V&!/O^P%P_9KY8@5\&RBB7ALDT<W[=
M)>X)C(MGRO/AH")NDA"TO9N81$PEH)>OX*B)),U1DNJ\\MA2#L/A'GUV=5K%
MEHU_5FR<:[0ROU&9Z;!/S_=<,UKG!#QH&R*<YM%6R<8QB8]G-HUN=3<:8":U
M#.(\;./<(B,),E6=$-*^B[(2Q/27E1V"(4CY&%,3Q8JA!K:A)J9:+3^A1QJV
MB+>6*!TSU)*]YI66_,PO_4W8#Q./AP0O'95K9=^VA$GA)XAMA'W WY*L)X=@
MGB%\7^9J7Q16CJW=^;PP[?'OVP.%OD6%][.OKH3=W=7M1Q""/.7[!%\)(MA^
M>A\@GP">% C&8+MYFE[T-B"/?G;&,)!^/<V'[E+T<]WUIFO-N)2'EU,7,VUC
M/^1)6FZK*"$>HAU$0YJ// 5,6Q!BYFH[CIZWLK2HRME?=75OT+%)M41HV/GS
M$H6P"4G."=;?RZ,\^J()FX$UUCTK.Z(L[R3[HF0<XN359>4O/V;;G'=#HQLV
M%Y$LQ=6VFVVZS9$#NC\"DAP+]EH[7A6(<1W!B-,@,C_78&#SDMUVFN[>ZHI5
MQ[7+4U^AXF7VGYT@W7HO!@(YB[QD*ZL22.=:8P=-,29 #UVRNYX<AP,;-F"?
M;US11Q9+O%VT< SO?U83'36_]43A-<"2$PVT<Y70^AQ=H(B*D)U<M.D<0%MU
M8O?B'=)T9UF"U\P' 4J_]IQ;JGTZ,R/_ZCLTL>;[]RLE3#VN!KJ/2H[&J@J&
MB1(-_FP;NE@]%:PRF3X-<1F='=7V46#Q4R^X>CY%[;S]Z':UYOT["1W'Q)'<
M S,SU[$S0E"E?/;:PX8+WB297:=^RY2&9SY]'-[4]9U>!J-FD\#]UIH8&SY1
MH(9N&74M4G$%LD<GBUX%/FPQNL7=UGK_7G1R:3QXZZ-"Z2UT8@SY'FHJE;'\
M FK#/8BYRE9/8HARUYUV&8LSTBSH&&?(L"I!]1*6)>^N5L4F.#UIEEN>+*%'
MQI!T+9N$H$GQ%G*Y9;N708,.^QRR$=GZ&[WO9D&K;\HEG7><&[;;OR[*QX""
M,K:3O?%/9D0C_!0-[#2>DN1<JQV%PE T!_>N!A^:IFBD&ZT0@QZU+V?N>!II
M)]Q^!QU!S]KOKBQ3V5>/%T-,=XL6YDUV3NK4'>1-EIUM@L:*Q+%.QYKUL(5$
MJS%-]E0;18%,S3QR)IUKAK[$\6:O/>7MSD->"<3MACJQP39NQD<"*A8>W&?N
M/6B69*??$4/>=,'C\-8$"@ 7Q141J3Y]!Y#IYIW/_BCQ8 $LG%UIY2BAI[VP
MVO;C^>4=W7$Y+9]N97S?+ T*%?_?X/K_A@43;#]E$YF:3C(#6@O1J8RY".LA
M^A2Q7*3-< [SIJ5/==P^^D3;R34[I74;WZ">4"N$#'8,]_N!0$,(JH;SM9Z3
M5/! M1GU6QK!$I0Y=^ %.#UMU.\MZ6OF,KJXZC?T[8^R]Q$7'\163I[[Z0&D
MD&FI."J>O*J)FX6W07B/Z^$3<U1+GFQ@,T[I$4Z&MX65.]'@ZL/!+[T13!=:
M3X_^UFJX7ALE6,B&_+/<>:B$H#^(NP-?/X0#XZ8H@D0'1-H=DAD;BWQ+^^24
M!4\L.GOBBI.QE^WIR3_*C<3+8PE4FM\ X<!NCMG(Y(B-4XE#H/74WY_F=W&/
M99(D^/GDF^ )9 ND0@AJ(N] ^]-FF<5$!DYQL4J@6X60][YOG(6')SZZZ/+]
M55N8Y6?GH5SY*6P_1!IZE$I1P>S]N]6'V5$_ M6D0=2\74@EC#V/&KUGBRGV
M9='W$@=$2RCG=&W*Z3,'FB(N;@+%'[-NRB09\W-(6WF'_EYEZP(X<W+X*8_2
M\3LF%P3_##WJ4P>"^R[6)':Z#?K.N09)??JR1/:,^VYC^US%JMJ7H8KKO(:[
M'4(!].!M#C#.P)CA^R$-EL73&;470I!38_5QDQ4>/7-B3,?3_D<8[)AN201)
M$XW@>+#"^(2&X]R]MJI89;8B<\LMW^+[YG:U6?5HIK'F#8?6\AORS:I2+Y/+
M;W(/\53Y.61J-E'-K"2.))?J6M7? *.=&;QQI'*D;LIL-&D]YY1,[LSOH<-]
MTQO]XI-RSB)NW+$Z[<HYPJ]ZA)_ M9(.C/R!1$)V\_1"\P#GLV/FMB4Y+$'.
MC<^^>Y]Z361SS>(_EY1.5-508]_R^K@0,*#]HX@5;$>9K&ZK\V*7LL]7U*5R
MGC?F=>K&>LM&';]Z9[OX*UDE-9,T$%\T99K\6K*':_UR% Z$%<?VD#1J6>]F
MDN[2XTXV/YRB?!EH#?5"(0/OEU7$=IQ-<YKD=F/*+-4* NFY3'DP4Y9KA5$$
M4F\B+1+RR9V4'0ND _W=R:EVP[3A9\XI%Z6^^\2KBG$_.Y6N7! ?6W7NK L,
M6X5/_>1\!0IHE)<?EB\#@:Q,I+1DJT!*^5G_A/NBZ;%[=8UU9]]@YDY&,:3.
M16A159.F 5F.!]MCJ0VK[:6^F8U=CE F/B/,M6(52</%1D886%[AQ:*VQTPC
M9E6B4>>..U9W/CLY)C9!3@X@TF"E"B(&V/J>7;+TAR4$G0?:B[Q2W6'#J^,:
M(]1:]L[\\F[,K\MZN[_L,M&V45(=6Q!_#K7,!*Q:@W'/H)9W.3Y6YTI?]+90
MOGK\?A^]>9_OK6N?\L5LM1B)GIO__)]=\""=MN7Q2YPK0!<C9CD:(F.M( 1Y
M(5U2DSE3%&;W/*;/2"O:^FSN9:53CDU[.N!::7_J]#Z,MOC%IGQD(8#'EDM'
MA:!3-D*0D1M<"$I$XFCX)3VN/D:%W8YOPS\7)82X\H BRQZN_#)G=G4&\4:V
M30C2*B]3S?KT7=5#,UXZ>%IN_<=&8E[ST;\7SVK_I\5^_J.&L>6Z"4%=K4"D
M8!JVFJC,]:W!*PIZ<6(-071]O#Q0TDQ!#AMQ0C,9W!/THU..CMC+\;HM'U5W
MCK"P&BS2S?9:0ZCZ3L?8+$>'VJKD5_?JSIQ?2UR@7.KI^2? KR9@NUE:X-C
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M#" :65];M$:A:-*_W/OVD"X[3SZR:44,C'D+0U$\L1U9&A^2?5T;#J<<N>H
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MD#&A(I:J%X*\C\/R3]I;O)V7:KGJI*R=6*'&\_99X3&6QQ_?EG_MZXC*Y7!
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MD-UPWX:7OAA)>^NJYN6DOZK-1;&;6NJI."Y^F,[_N&V?1@EN3G/2:7%Q9C;
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M)LB!+S  = Z6RNL[^:J%K:#W#Q]!<,R"^^WK+A-ZI^N47O(AR6=^HG[]:F$
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M%@AN%[KCC_YU#[DK B90*O;J+*DM$$I2*^\KE)OYNXB;]2&;EO_%H?(GA]?
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M"-OM0@L;!KR%GR9&+*"MQC;=&YM"Q:]L="=848]Q+]QA;4"1S;2AOV@,X$,
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MZERGT&11$;\'Z7GQZXABO-,>^;6OX?<1\^:7YFW?<Q(\&?@C7/OU[5S*(^C
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M#I/-IU>K9O:<^1'AT\^+M^[VR[BSGXA)\;[%)_T($7,M0]F?LV!JWRJDV)G
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MV-Y83;SXI%VE^O*7K8@;X5M##^/EYIJYRH&6-3>%=4@C;GAR"TH4C5: ,?Z
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M8=*_L'[_K[9B^ /"+A\*0?_N(Y(:V G!/!@5B:&][EY%AM-NO('O;K-2A<&
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M+$TA/!:GE?M:M]#WA*P.+6YN]7")P]/;EJ:_+91GSEU#68SCZL1X5N[]>GK
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M&B.*PG\$Z\>G;1J ; ]RGN+0%XVQ(HGAM!>D]2.W\I%K14I:)<?2KS2*2'K
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M,6$A8;'_[HO;"FP5$61MNL?/MPO8M)6/?RL?MQ. \<XH^+?C\0'_Y\6WB5]
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M8Z\BXF R+,=^N;5.1)P[0)>;+O*[4E_I5WM4XI2(KN[GC+A :M+^]9<']@D
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M56HW8_?U*TY\M57=<K6UHFT][4CP-#99=3\4P"N %R$]IANG#;.E#EJF:UV
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M]U3:A/L)]<B#KRY^0\U<#2^?^N$;3 F'.V,IWPB_K;$K,UQ@R1_^KS?K5Q.
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MWP6QB]G@P EZ\[#9$-3K *KF"KU9L0AI:+(]UO542[WV5"C^Y/^&! +?KY]
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MLP>'S*S:+*>\.<+$/^[QY4Q7F<YO8Z!R87SM/R91S_V$4?DP'Q*^@]CO^.W
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MYH"P&:93KNU?>4*@G\*2QW!"=6&!;A]+6!"VG'V(BX<EB2(<E 9ODD>;IGG
M@7"R+L,",L299J*Y>S:$PDKT<FS]-,HA*5QQ?N/\W3_V<UI=R*FXW=NW.6^_
M-"O9UY-P_%R<+RDK[?2PEK=JE>^R"D7;3XV&(@]>* P=W'Z&7K>?[^[^M,P
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M>=4.&(;?WA3LI*][WPB8]/A'39%R&EA9L!F-*\G,7;#ZF",V__I5A2[,P"_
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MSFD?YZ<',3-8>Y(X>!8_C0>,3ZYBA>]):9SU'F-'8'*5+(R6$12^:0\<-=I
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M:VBQ^HS^Y9GE]U@86 K40,<:>$!5(P\0<@U%#[9B."N1G#=H&G(0/3U%H*A
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M3K#T]& OW,AB;8MV2NLH7/R4%Q]_<L:P8-EZQ Z<*2LC7!;M,)0GW)0.6>
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ML;=L5[A<U*E,B$C'L%[;^5^Q=EJG3P?W$OH>[UZ[$TN,WU5Y#UA&T4M8H=H
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MQAJ[G[G!TZN!'U8+K*9\_\_R)*6W8!ESH-M-@G<1J'H#5P _R+BI@(R!TQU
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M>R\D_-K?,+8!6,7C:*5(19%%#$9EE$#XE:)IK*,0EFO9\!["MI9P"SJ\!Z_
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MR8YNE!;/3MYW_.[*W$]2#QS< ^N'4=HY:!'9#"^"@;O=4CO5T0-G[KB= I&
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M,WNU#Y\NC[%W!U;2S$C)5M:U#655U*[*F=G<0!^)<'/5H0#<:N#U1]T?Q:G
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MC83<#=LU-:'.+?]?A.;^'R?C_6UB3PE<HC-QRZ&?<+\KG?EZQ&%"-OFG3T>
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M))51-99I^Y7L=ZP5E"Y).U(^0]%Y-/EJI]0Z[=$ C=CK.8HGW.X*(;(\*6#
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M8D29'ZA'U]SP1N"&.CQ0V]5QZW9&'?79N4:';]:JNXYEKK_(;:6F0?XB:$C
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M!R^)7?77G,=E6\+C[;_9ZZ_RB_O_-%O_2PMG"ZNGB)XBZ12A$7-)\B20) 4
MRV15+NZ/_Z8SI+>")[],(FXR>U<@W7H3("%I!3)T7/67$!G8-0K&D**N_Y1<
MF?Z"NXS_:TNY1Q"<K86)#[0C/XG5! ?PJI(WR446+T?S+7'!8XB_T!P:&#BS
M9V/5G^;?M=)?/L+Z2Y5"C:Z^P?_<Z\@:/9(DW7X'Q*\D2NAH#B76<LS$O:5?
M8HQV[UC:C%(Y_N;?5WG5"*2[YN/^OL?]U ^QL>4IW;O>;W,0'I4]PBWD(45J
M>$ZR2%6%QK"JMU,#YO)4*1MM-?T<PC:B- .9)Q-N>YPK+8QNS>\^9(2L:5.U
M<D'6R?JCR7MQ[;H274P4'SG;HY%"-OM5L#-#>"Y(HEH+%,T]FG2-*27GE)H]
M2?J]\YBG4Y'&]TQ'EN)N P5Z!*NV8D9/UAP@?BM%(3@HMI>BVG(:@+;YA"58
MLI2G;MVR@U &7YF)')>OEJ)VI46$!\ $H6_;55\].)*G%.AZXZKS($V2>MH>
M!L?HRC0S :%DO24_3T ;K!/KRL0@ :?$2%_8R8;<LW?"K'+#1$OY/KOCM&9=
M7E>].838@>XKP!A)#7<"[8B3PPZQH/"@.U!HB">AMH&N?-9;\VFBEM:T[S:4
MR?F9R[G>ND<:U!OV?+O@J-KD^%O>L]O*[F-)K-W&H17(Q3!PE^U&C)*X&B/=
MG4.?E":GO/8E,I0?U=L2-DHCPS]-1G8U%1QP&"Q_'[2C":I]QOCD[Y?>FX-)
MD>)'=MK8\:-<C30[<\DH14.TO;LJ>(@9G6RG@;%,BXET4]F5/^[:T-J29%+5
MW9B>:'AE3XDCQ-'PQE+3KC4+A1RD2 4N*)8"W?B;(13@N$6FQ I0)L6U6%R%
M4BW2R- !B_)A-KE^,.G9\S&_7\/J;]HWI<:GRGGMC8G=FU&8#KT,1@,LB2*,
MK\@8_Z=67"[9)]("D/=$1E7T%V#) D=ERKJ D-'RZ&+]&<9+A+Y-0'59\N-C
MPRI%S7K9MG,DHI03I<[B_-W!7?(SY4('C \_;T:>.W\O^NDZ<(1+ %TMB7K<
M^P5/O.S4^*JOG<)B8H+J3]M,;3JY(\TSWMNL*Y*I#\GQRY"2*9(X76(@:6?5
M.)8#<"ZCXXZ%^M0P<E.+$PFZ<:3*Q*\=]Z([0C7'*&/U28_VK%.J7J9J^?:6
MBX]45_UE29W('%ABC$5+%.6%AK[8C^3=GR()6WX1H)(=X[_ZT:^&O"-;W=0B
M$W,_3+\7SX2_UWJMTKFUY(&C4'^]__4<:03$AV.'"%LQ2#Y/4"(FB5"RZB+-
M-.O&1:: >AS;>_[YIY8])1\:5"2"J1__3#;FHMYG>VO;%ZIO5T-LM_CFI;DS
M/;IR=+K!QZ$Z;RBKR<?/Y3K1U!@<?_$]X&CHA=B8MK[C=?8P?=%)Z59!(3A-
M"CM'LDX<V^+-UU2&=FZ3!^")H8MPK:!/EAT^@2FUSJ%NK8LNVQUS87:C:\_K
M[3^S^^^6[Q'[L P8<*J/N0+ASE/OHB3K3;CN"4U>\1(HNG.T\Y8/E(HH.C.'
M4P73/A]4Z>1.S+/OG1^ERO)%(+[/5'@X9_T_PIMI$#"!AGL3)E*U%KB =/[E
M4<%&_B35"*N#N<P?9&48PE0<RRPMUJ'R?J:_< U>6^:F7BZ7[6CHK)\[[)]=
MF&* W\R!@WJ460U "H\57@)?!(% !0.JU,='LAF,0_C4I_)\\SJUCF7/E^BF
MWM)H)<WD/.V;E3VH%R[:/2H!^I?/WH 0^GUVK>&ZKY9TL!H:.@C@+C@-.MHM
M:)2U>6W1E3H@QI4S34B6R!5([AS:%59:]_MJ$G=N;-M<L-_!%D%DG,H!8N[^
MF_JWN)BU4M>9D1JU1-*'K)DKEWZ;%C]>@02QDB12BK'SY1WY1#O#?WM?:F1B
M#(O'?5W"S1[5M9R^6X!Z<>PS79G3F%+Y*,QT[RY8R?Y3\EV$6O>9!.$%=)B
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M[Y!ZPQ0'&90:"];]-J#?0?V[SK[&T8A%[G'Y.2SGP/LWTWN&>V4S72_<=LG
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M@]3=%6$) *[R/K[, I4([NR[V1[^9$X 2/R$ '""S.CB\'(WN:2ZH":J,O#
MA891O9R@K#_SREX>;3LV(M+?WX'I)8+&F!L.0B-W>O)U,)WF#?@;A;=>86;V
M^1;YL8H)U3G^2/0L'+[PQ%0_K7? $B^>Z7;];:-!UNH#GPX(T\-,)0SSW",)
M<QX&&FTB/NLN1RK0L4E6F)NX38W&J1,(^-Y1_,\M,NQCDS=94P$-V6M!=^5*
MQ*.A"C^V1/5"&B&+7APXN'RD<+('TQ#*4)LQ@[C+D]'K(RY%W7<"PF)OEASN
M*Y_TVQRM8')O\XH(QP!3'6Y[^K;3T_G\L<$8HXR)T&+/@6W?,Z1_%7V*\H:O
M&K-U>%AH" [<:9,E ,('L<3F\:ZC-G2;= 8T#*K"=1@R17D0$.!!2],=I4G#
M@QYGNA>5\X+V#4KT;YF=#MACM5J<4L929U?Q;F""$#<Q:FAC,/=XICOO)9XK
MC9A):_33&_U9O*'73-&O/(DA==F8;!R04"IU^\]IC3U3CI#F3>3WV'BQ->O"
MFH87Y-?]4?I1529'VNM>2'[5>VEOW&5G(YQM-7 O2X&- $D<9Z[E4.,^#N*&
M/S;C!R/4;51+.QQ?^T/)J&7EL-W+%-?,/Z\\[Y>3WC],"!PE!L$F$.Q30D=Y
MR;7DE6!"A>^TU%,<(-Q+H.S,46-Z96+#9$2K:QJM+L'.<<VZ_-Z7NP8?WT7L
MT)[:'A.R[18*QU;AY4)#$,E0YC'L)([>UXU(=%#_P#T:3,=GZR@WC$</Z!I%
MEGY@?'VY$OTQQ\6Y-5Z1@5W"FB*IGI)SWQ8G6=^<>(_0&[@.X"0\2"?'#,N5
MK@!+)O<7_@HN&=-^>ZC6KL[1:ZN'Y;9+#Y5MY>AM]@$!0PVR'LT+K:]J[FIW
MQ8_'R6I%VDOX)N;.P823HP4]C[E.J1_D*IK1?!@<JH?L(LB@8:51%BSK/%:D
MVX.%2Y\]8LHZQJHN%W?U1T3J?#2%CE;O=^G:'[1,89[ 3VC/8+,PB#1H>(T/
M6YI)9%QFCE%H%4WI"&:]'RLYNYARPTHDSJY^/I;MGV9=L'W6/)VHB_G,$-L)
M=$#*KZ>(W/VB<]-G ,/T1$Q^ZR6^P*;Q55'V((QC-<C:1X*JVP5<?HC$',PD
M-:W;]EE:8Z/]*DMLCJAFI^Z[&L,XC><JY=(ABS-X_OL2 _ 4QPZI0G=-S.UP
M<"".V#DQF^EW9X\Z=?K<D5J"UD?PXS9TZ#]C<\[T]MDQ'5<50-/*5((!$B]T
MLPP[>R:&[HR_:><>P\)[G='K*6B5F<_Q=>.E7W%OK')7O!<AU^:.GWZ/) $)
MDAP'_K!08(4THNJBG2%KAB]=(0!D9KIME(Z-3PMA0G)_!1QR(3B]T(ICV@[7
M+_J\\P*D(':F _]P*<;>^OV2K.PK%ZG*5A/3TCO!/O>>],M(OSU[Y?)P>R4[
M"/3BP+@VA#%#WA,H_)4Z/5K]4E>KG99/MU2[7?3:"7Z0A<'7/ER[*J#8%JO3
M]I);S+M#I)9 ZB&W,-3/4"7T.$69JQ@C #*T7+LH6N"-SND]K]KOPL!C"3MG
M3A8<P[KG^6IKT/,GM@=G(HI,[K0M38>)LK\='VU@Z+XYZNY-3!DCJTV9DGI*
ME22?AFR565%(%0!-&_-FEB?CZ)*+L'#J_7.XCA*I#^TN?#W^!Y^,7U8[=@V=
M]TW:D.SPYABCQYK5T0=5G,LGNW)5H]CKO&),*'32XE@FB2\^0@S25LA80;KZ
M.:XCTMJ/Q\='!!D,?&WA35$F:+OZM:MV6@V=E=R["DN[BBX2(KD/O'(AX'H8
MJ,O+_#$^--DI .J64WXBI+_GUUN.36N\O/SL@7_/UYN*!Q?'X0"/K'[VF6(R
M 'F> [<]N/Z@55^KIGZZ4R.^1CG&O+>RS#QTJTY/QAE7[^$?2.]O/J,UC*!X
M;\L[L\'.H4')GKY9=ZYN?$S4CB">A=T*YRB!%D)=7PAE6&'B;O M/_F&36__
M  W/=IHYFKO@G_^$(=ZS5I@]<?/H-?'OX2?<PR^$97S.D_GCY;IZ-T6,_SN)
M.V.HSV$-ZHG$2(640I_L:&@B6IH96,Q<[D!O3T98%EF/_1EIUKCED'__O<<O
MPX^;]GQUW[F_0:D7<*CCW1>BAJE][!RPC55&LR](K!R^ .Z;^=2^.^J:*7@_
MQC7!@;PV>$J*X+GAR_;A@+OOXSO8MJ H7ZJ V=T%$>?OXT_ 9+@B3P(]'H7!
M&E2]6T]0+IXXTP_?\/TJ^NUQD^KW_8"NF%S/LX//W$@) L!17/7X?VG?G,H0
M9_ITP1IP'0AM]/MIAU;"C0.LY9N-D(T+7G-1)G&[R8&3;A$6!Y=JJ[:Z:3P-
M/KM16NRR-T$.9<S\UD&\,:T"&E 7,EL:L)+(B]U.PQ6C!C[%C!K3X>GM.7FG
M_-ZX5*2=$OL&1-?FO]2FD*.H!!SGF"^_KP!MG(/>.A\H@R/E7S5D1W^%N:7,
MF5[ #4I_2=J>X_/6K/W;MDL6CCJR+#.^U%<FM'?:GC68T2[)<4:%@1&E7,_1
M"Z,.^J LK2^[]/F0G7.\^<V6EOP=IA6%Y(";(B'7_,Z:WPHP+/PQY<'>P"L.
M&4=+7BS1&#*SVQ?,L?_\V9VY<.!#Z*'J1V[1$Y8SJO/?EW5-E%]HQ)RG6EA<
M46@<<A1';FH3.M@OIAVER93"J&*NSN!Z,*)@:F"F6V;?5<GD&+C!$#>P\/*Y
MBZTWU;US';QMPMP#^D7O]9^9F'W%%B(TZ W<<Y].3!+DQ5@]1Q'IY,N2(RB.
M1W"=Y+].\7Z8H:NJ/T]]GEK,.7=2/'#EN$[0/D?/N+.Y_=Q#PHIU$OV>J$B0
M0FT%G<[-0+8@ [Q!I5+_<*@LP0!TZMD13#^J,ZUM5/U -E'6:>>@F%&]L[ZI
MZKW9W8G8Q\:S1"'N87J;?5JE&I+L8=1B=N4,5 -9V>W99Y/Y Y>"V1B#4;9)
MU<V)*Z,0< B3V'+\P(M/;LWRS6+*(D/H-]#G9EW$":_>0'VP11W+C6#)TA4R
M&0R&G1-+FQ[XLC %?SE8)"3IC86J9V?$GUE+74;;LMVM9^4<]3Y PR 3PIP@
M !A'F5$P4(2UW,$FZ#$+TJL);ZO#U9/S@H]V?LS[D'KK8(R/FV*JJW/PUNMP
M8V%9N\8QYT;PBO5X-01-U,4/C68IRQ6?+YJ#+;7MF>YPI$U"::6%&#QJ4Y^R
M2:F_>9;&!OEXL\Y!T,1LT9Y53X>F\+7#' Q9Z'3#6Z%_<.W&4>',&=\A2ZRZ
M6_.EH];KZV2C7?<+[GIVEK_^I&TITC.%Z=Q(V(AL._*"*=D'F?1@WP$+F"N]
M\YK8KD$=E,>M!:?V0V<"-7;=],XY<Z8K*^U@U.D]^R2B,M9@ZGP21![EP3GD
MP3DU%VC&LDEM#Z1(XATV^Y[^KNX]Y%097J">$YCP6.I+8M=4GXE14*RIAJB$
M-?[\P]L2;AU;C@*HB5IA]A$RZN!B)W8\Z,?9!YY#[:<5";&E;MTX 0+BN]>S
MW&I\+U[:9]?L<=GDA,ER]/"1R)MI;Z$E7POV'>89PK8B;_!EGPI]D\YD-Z/K
MN$=8]LO)#<6G&@9@]-@<YC>_=F9>-KW_:\,)N"*YL5;T]F/G* W# D#9?F9F
MG!'%V<M_)SQYG)T&DE@>'B-<O4L1/D<^FHI.%WL'/$@HU#:JR7<S,RC2>WM+
M+?;R:[$-CI)WD$2^M!)G.Y+#EWXE)$QBS:QK8#Z'1KJK6%'QH_6NGG?R(R+G
MRN'ZM W&Z=*GTWJ#0D[LW?Y*EHY=W,_THN-[B#>@*HW;GH7'03;$["NB;)AK
MM>HY[G?#*O'%[F/9VA:]SQ_L+-LF)G=G3S5^(I4OLYMC@?[(AWYTV CJ<$@Z
M.JSWV,?;*Z]1/=)*I$=1>ZLQH6V+ 9\8,5+GXQEOSQW)63IE4MJ4?WJ5(F1C
MU!K8"]PBBQ5Z$M2N62@Q8_EDM.^+4!O,_(%-$0 *,0BEYA1J3EQYZXTY]DI%
MK<_L)\9L1'=$I]CU$%2@,/*.H+:#R2PLB:*%UN /0S712M/<@TK-/6<,::Y9
M9T>J[=QL7735O4CVU;.RN8I*#>P:L2P)]TV_JFK;A6='\-\.(46IN"Z\!/*J
M .C6T09%9V0]E)&BKA\B/^JJQ[+'O>>;MY_,^>:JGNNV[;-^O/:UO0;U<]!Z
M8<S(,KW83T#W<E0,KX2@-S=MS"QIDW5[#/>_<+-O^]C.[V\Z[*[H2?AD?SRC
M>;@N2:K6I@_7O+R(8XZS6YBIB\9T2D:Z.LELLV]_/$T R 7,%5@4).N^+(H>
M<=5VBF@QC=04JTWN.=J@!7QB-2]6,"?[B(W01 Q\"G[\XP@)HH#:5_V=O*7Q
MU2@\V(!0'I'=>5\N>*)O(NC3J5&Y)J<+06\6,=0\F'0T=!/*F\ LZ,-G^$-O
M\BVL7UV>0:3$VD[="#._J$6J"J!<5-0?\XB26_)]FXQ[H\R=]H.8)NQW!I ^
M) AHV-PA #(QSP-_(XA%ED,]_1!7M@*,<AR*P/^Y3#MZ9').F>Q^<<#XP%"!
M:?"F%3V11)3XZUXH0T@PQ49!.*MJY@&E8;Q;  B3G"I!$2D /(>HP^W.=-A-
MOGYS?<35]Y]?--]:GUXASY-ICZ;I>X\$7JS*4V@ '+(?7;<K8#OQL@C*:!)_
MXQC7ACEY@K6Q\2E8U6,!)^QF8;)B\D>M$C G<I2M6UH?)(NES62K*9VP/"GB
M>>%;$:_U-XZ3(R)"F-M+9Q"9."4[I2KN'I88>3 9Y<0<AZ4>(S:UYD_53+1/
M1,QVK$RDOE%=B6<$$EDP.B:)((TR99GU8M)MZWV145VVXK.->(I!>ZXVW-A7
M)_Z+4F_UDO>>3PQ/WQE V?$I88M0KRZB&A\2!E-MEWU2-*#2TVI56U5VID%!
MJ62,;E!H:$0UCW3U:KRNMV>K%O!KC7WU]W+5-']0 &A88C-S,9T'H>'$+;MR
MV%F@#UV]YW6,O YGH/D.Y$=F3'U6?_V[596-UOU:-GLZYQPTA1G)#BW!_;W.
MAZ$(#VS:;6J0=SQ$+CHHC7'WVO^<XIH^S3SJ.:6=[^>MEG7(87Q7]U?%/UJ\
M.P<PY!M\F2#.#G0_1:F:( ,N!+#,TE!QF,>8<!(5EEHB.XIRKB*=U4:09YM'
M:'DUM*G;.F<2G\<N=?8%<\SXGRCU<8Q<9BLB"U;?W+-P)NY@':&PSR<\8K:^
M91B_#1B QT=<R1F FV^0U7]2*69S0!I8Q682F>ZX1**JG2$3[\$4 #U8"*A"
M@DE$2_WP$.&Z,;>WB#]N@U=FAM54--[_VIP_/;OCA,;;/A.YMH(K8OK#Z/<4
MYN'!B3)V+(O2HY#N>9%ORGI<SPKHBB5+]F0.IOD/7\RF[WET[5%(ZY1RP9V#
M;6%^+MM\SZ<8T;,597H^8*B-PNKJ@5="MAT;JN;K(N\(89+_&ELGF67+H?'Q
M""K/X\2JW'FR?*3[N>!MNV2J?A$"E%9:7@]6H\=@3=\6IS@J2+@;2X$A.O.T
MVI"E\RA: ,B&:;GD1#V=)S,^G;YGLABA=^=:"I!-\GP6>8:T7U6$]GN*DG3X
M[[5VW2\3\CX(0Y+53()*<_<^[;Q6BMK(\L&>6.X:(X;F!#<VA?'?-<=9/[?5
M<XVX'&7B]-;S^'7251N&H3!^IL!@SG[4Y7K>8]0.5A7=IPN;Y@EB.))>+$17
M#9K<.^,W?#/E9'W[K7GRK&;^7EES:+[!@3YXXG4K 7!! (!&N,5&3C"8>QI,
M8.:2;$G8++O=8G$ZNDS#;#NSA%)X(4I943FNCI"QPW^3@6MAXNU-GK[*XI<H
MFZ#4>LSSRBX/;3"WT\;!@%697M"ICH7/,# =4+G&FFN'F.U#JR9QXV/6=9VR
MO1:O1.M=DS1V:#S<N, V_>V4* G>#3U6 W3#4KOS3E XY9X+A&T(I87M?#^S
ML??:?H:KQ:@)_:+^U8KX0-?XBIRW\I]T:+X068>=J+T@A?G-&6QC9O868M+:
M+>BF#OL8*@'#M6)-:Y?VO&G]@YMFER2U5=$9\4'$6=7SO[3#9,!NOO=AI@?O
M/D&8\)]:523DL"(5,M6A\E8O'<0OHG7J69F^4*Y>@8-)7<G,T5L+H/R[V!57
M8U*)AE[5629\=G#"C WA/;&D3.KY_UXZ1T]1-%%J=$B:!=<!)HH,Z*;(V]G'
MG'L4=G7W*_5ZZX7^BA(Z/?R.^9F,FR=WFFN( RN4"1_V<]XCN\L"0&(16<5^
MR4*0]G$H:6RHK(/NQ=@2DSQ==:4SG\[ =X0:B6P(,6B^J5  :=.4?+#"WP$.
M<.#<RR"+H\D?)"I +YX)[2R,(Q$GB)[C:$/X>G!V>?.*FWPMUN(,^1?+[OBT
MQ5%]=ST]?7B,?J)F#C":RY>&<**1&#;L]UJ<"H;6QTB@)IA1)=,$ &V; Z2X
M?4LLRB<\]-G1J&BR93,DG&,S@>(4N.T2.VK1,:R;]M;8=0FR49B%">9,#X8D
M9P\JI!5,?>P!9SI1A8PZT2K B'%!^6*<NF+XB\Q[Z30]"5*_][>U&Q\^2-[P
M17^":$&I16AS7BU!F>L,#M(Q63I;0#,FXC"8S>2O]:WNWX7?W'QY7JG_\>FI
M29(Z>:N-=8[YH=<ZECGCIHF!<L2F5(8]E3A1L)]7S=?F#\$:"WI@V&S$XX76
M;]T!E(EQ&+93:_X=RWXV$RXUM&F?K[=DSK9V-V[74'7RI[W^G.5>(O,H3YM.
M87BPQNEX4LW5\>-,U][!)#+LNA5DXZ3+7)S8)2NP!&'Y=?^%5]I2FMY'UGT>
M(&796L*)KOU.D6VWXD"0F6QA]HG!=@ES1I&Q$7\KTK5SO"G0?K0![H+M?Q%.
MGJMF/ Z;\;W0=LLZUC,@9/:\HP-MZ*?^6'31F<!]?M2 J@OWS[6F]9F<NVL]
M[O7F^7LI>P6U50I#B@(A7JC1$5Z<+STBS!3+S%0LOOU<]47_M2QJ:E\36M6L
MZO4VTN>2X.K,>$LP8LE/:L7').XK.DM45+3Y*3Y;EW>72'V*J4_-1!U_S.\5
M (V#W115)*2'K]\VMAB-P*YOPC^;#U3/GW?2'QMK9A>\>/7Q2<[]LELQ\AK;
MQ&[*W588+ [P9)8+M7/A7:,=(2]521!9AFSJR"(TG")[T=^0?9S95/H,SA[7
MNI6W6=:RU"1/F6R98Q!]7S\HYU49C("A4I>EP%@$J#=(JHFT2CWVBGFLH!*\
MT66;W)I6/AQC++L0'[&]^2PTFE;P5OSRRFN?,B4O+E1H7"N40QLO&VV&'A
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M!SJOR&$3A2O/*T:),KU.?3Q':&5BDAIJE&?7IV3Z+AM4E'M:9BAL\^T])/E
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M*!(.UNCWE.=Q7=A$X6!<YJV6&:P<<N>;[I["Q'8;Z)P4;KY]YMTC V/U^]S
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MA.Z0\I%WG_B]0@!\U5H3 %E# D"^BF.!&7(7 &^LA%5=$Y\H]'0"YG\MVHH
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M+D@NNZNQ:Y9S>OA%"R%L;*YEF^X?NC-KR:]@?%GI<FXHRY6KDDI'7">&+LO
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M8,#]B8D+:[>6, =XV8Q8:$%0GS&LH'MGP=[S*Q*UX0BMU(J,6UI_A -X&W(
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MGL8,<WFY]/5*%XJ:K)K=I3XE#:D??S&YXI9,!U !>(O^I=W_4=H=P>CO1SX
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M\T59S>+O:(*DE3K>:0Y[QTS/.MP)+K[,'3%L$-A(?O;HP[,,9@MM.H!DRQ=
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M7!*^;Y,G3JY9\7C%CNT/_D@*_R.&4U^W+.BOMFKZECO/2,3;H]U[1?:F.<,
MS9< UM=.0ZMS@&NF0V %;E'6<A<'R/"=Y0 Z1=A'X#\_@+V),0RXS'A.D=X8
MML6BX.R%@;[3\PP[>**FA)$T@QD=7#1KX^(SF-6 ZF+"OYLX]*#>D5C1V%"8
M+WF 2YKC?1W,>W1I*A&? M6;Z0^6+\C6WG9;&T)^XJH>XDLRH]I!)_/Q\T.H
MI?-\IV0Y@"<6/^#U0 #' =9JP7T@54D,P>9O1@\:(HY?,X0UFWIO%#$["U.Y
MN\XZK!U+.BP6K/M]YF?75&!@S%@M""-$_0-PO'7ZYXTD^.GN(W0Y #ZZE\7C
MN!@-K5L1UV'?0?(3;-6+_IR;KS!\TCQ>NTE3KIM,6MP&(U4>:2X"DR<"!TCJ
MIJW(I7-:Z+A N;E9VN\/8ZZQ?<&!]_JPLQ5=WM]#QW@A)@XEF8_U;MV5\\%3
MX$2 NJW,NA?30>]_RYYR[-^"C"-SN,7%(@Y0G!L/;?26@+ N(%4A=<9HH?]J
M8$T6-2+:RBWR1I>%8'#FJZD+N'*3Q&^JG?;FGL'1ZLN1F:;EM5QTZ[:KC9!X
M#YK/V+]XZ5'6VZ.]QDYZJ[,6<3.5QQ-UW1?/DW% 6T);*-0+;DAF%##78ZXR
M+)Q?.]$ST??((067P]&F^E[=NB+7=I]5<'Z<>NGSK0</=/=OWKC1_,"*12]J
M'HSDK*TI% [@WW$FAQ9.#\\LI+EFAB#YNUA'V7$L;8<TK;AXY_J.?OUS!\N)
M]C<J=\T\>_3*9@>^V>7K<LYJIO\#DHT+MSWRW531E126?)[O /H,\S1-H3)C
M54;TARCGO$@E??FO[Y5^,CO1<<30YR4?3%OL##KQ?8IE)-_8;=0-,,-?M8$=
MIW'(*VYT[X7NT5@Q]G-BPV7)0.6C]!E2I&3HODNI)P-V<@V?O87"0)^72WIH
MTHSZW._U3Z]CB= 4RR:1AH&V>53PD882.SC%H<0N=%VM7?A A*SU2N3^CVFL
M\RNZ?\VQ_F Y%#S-"CH9&0!.7"Z$@^EI5-*OW_)#]T)DV*GRPXB.7B25\#VO
M7UYIGT!?^;TKSRA/+ RT,\Y+.FSO;GC0"X1[3M.*7U&0/ND?12.6VNXA9XR;
MX5_WPYCY\LY%4V;-'.S1VU['!4)Q6@]_AO-?11_S"K]A<D4]HLL'FY!,V$3U
M[&I<\:SP'&\K#I H,?1).HYD@-SX_=&=M[W\C++2GK5-5JT:5R@\^BJM3N-.
MTNF*NS?%=UTZ_;ADHU2J1J:X]-1GKCOZ">F5X>&978UQ@3(/_\?3:IW(R_C%
M/5O KVOZ.< );4LIRW;F*EA,-Z*A8E7$TG[9V5OX18%6#L"CF;X-'NX4@J7+
MW \[S&J#7M_O'*)<-<E%7X>2CF-N9*%:M=8P*JO*>O9E,1S2ZLDQ7N>:Q;/O
MG2DZ)1(EY__^V=L;JRZ+UCZ^?_KZ5?ZMP'R4'(U)Q[(CD7VMR)!>+HU#-+XJ
MI$CAZE1&X*R.#R-DEB(U*?3:;!P'OO-^V5.FDBHJ68G:F]N\*3SL^;GUV"AL
M)?03.U)+&*K%"E,5)\R]X[I8^][YD3$*2/]"W8ZB: F+D[.>'BX'*J\,9Q>'
M2SA?-@U^#XA%_VD+/+_V)\]^XSV1?I#IQ\<R8H7V#\%&J&6'U.8WG<T@/_CN
M\)KI,VP[$I'#UQY$OTGCJG1&Z&03BYJBZGH^*9RP#6P]E)Y.SM%+W^YYP<KA
M?LB)#<T[-IYQPNS9FJLJP*NYRU/_=>)0=R3E8$7=2;F4T3G3*D0F%,_TN(!Q
M8SSP\*8IE<8B&]*PTA=&>^0:ZYZKX.FG/-TL5&P+FR2=GAM+/#I-&OF<7/MU
M:KOE42XK NOP\IU:#@8==E7@*BP7QCJ/X4PF^<DD=SJI38AMRVV>WXXZ5Y K
M)'ZP=>3 V1+^TSYA#]JK2ZH,;//XZB)VEIC>NW\Y68;9&HC)S1^\533,GR;D
MU6L]F?6R.>TV3,S'FY?, A=[^X2J>D/<(55&#%.1=2Y2E^:/@\1&33KP_O/F
M:R-/X\IS/6X4F"\V#+:VVCS52%DWN'?D4]&M,LQU&,E\[V-6L6/F\1UEE;TY
MD7[]+86'$K9;&3-N]*S+MN!]4*:"W]XSG9,U.YA =*ECGF@H$'<8$$@.NN!I
M<M]&2D#T@Q=K].#[#H6$)K-J;;GV]F[)UWE[S FS'^CK!7#4Z0HC]#09>M#O
M%;S564W?3B>'Z*TUS+9)B=KUN)S%]]S#66.#MB=8@>*&VDE;B'(]#"_R<$4P
MDAQY=ZY6:TUVV]L#YA;FQJU3 [S6%I%'XG+\Y*6'5#PD'Q\>'2)3L:V%*<TI
M6S%Y!>'N#1T]8^'7V>)X[W"G@Y53M5_I@7+#TU_S^ETJ%84QVHPTIB;+GK8[
MFA*L0W8OLK)SZ?>6.F.N.X].G\1^D8C@MPU1?X8=>+7V[,437XY(C6S=QY#]
M@)7Y\KK)/2B_/47[I(*%U%LS=P?E++V1+??NORT-E$[??_1;ZR7.L!_ _+AS
M#K?$+/@95M>T_<A3Y@EKP(%4F/Q;VL @=7@ND[ 0.0KI$ RU!=C'O3?^S&UJ
M4%1#ET5>ABE4=)T#S$FGCIG]FIY[%<)QFD0@2%^ PNHC^I&+4HY+51S@I$[M
M$T-M;"QVQW?K0(NO8.14I"GZ1_97!1Q0[%BPH/E%OY1ZI+&YE^>T1\<#@O]
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M;IO9N=.L)(9=*FLE Z05_%S+L?]OM1P;XLW0ZO^LY7@T[+=K.:9J*3+LR)?
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MT7+Q0_WSX8>%M>W#[K<NE 78%]:,XSJ.&@X&#H1=^A((_YMI@LES/R,[>?/
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MP1]E7_A-.OMGG<#^D1(L*:->D/A) TD,'%36AE\Z-#Z!1C+FO86&ZNL*CW$
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MEO T83.]M+F".PZ@HH)8WT68/^4PXLE591R@$T&.#$+VO?SB%(G/K&B[KWB
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MO//\+)BI+09"&?_43QKNTZ@QT'%/I@8_Q84,9;9B.C+^J'9G5C[_IRRT$;K
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MH1L$I^Y[8.R)%69M)I#L D\&#26+O2."UC6(L.X_>OA%- ,#U,&F\H->+2)
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M)I2)H6)5#5LJ)"VBUBO='JGI9;:_$Q>NH[%L:%%D8<@0J-L4V"X%KN2Z$D^
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MC<,!&C-H)'RJT5DL?E[%V^I][V36G-A:U:GE .%5\ R1+W&&H\6?P"E&."5
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M1%T%[!>\$&<?VK'0M4Q<]^2_:);)XUWMPWM^1RE-B:W+1%U?S+0SUU.4 RF
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M=[E?93,I*V:F]1=R["W[=^K5[8S2*<M1N.ED,*Q(]]XAZ*3I[9TC?%WDB@V
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M(3!$H5];TN-V8<"?J==Y=V5>)X"L>(RR<MI+ZU+^D0TCL9=I6IG="@6WM>/
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MS?*_[(V.-#VKUORDNOV=LP?^@/ZAT[D"99!P!DVF- D);D[\Q!":&+N8ZAX
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M;3^&,!#Y[H3HKG?1BAOC2(\CY2['[F=G65&V0/M%> J7X3';^5JTA\B$KZ?
M%*P/"GK.)&)]-PHBL!9,=>4N<K:K.0$9VQ5C^7^T=V7Q4']_?[)$I+$+,8E2
MH?G9$\U40I(HV9>I$)J8%!F99K)$QA:*4JAL*9.=$C-V0F3/$C,C]"O+=\+X
M:A;/UW/QO)[+Y^9_]UR<B[DXK_.=<\[GO7S/YWR^M>OKDN[8&H>>JU%[7=D=
MRN4+ FEG]HST1:'IQ4I;::%2'4!N([I,9-&4(1'F49LS8<$R;D5&#7[SSPJ=
M3IL[A O:6;(OYJC]>;A'6.E[_Y?P%A5WME,UF+=52):5VX(C3P/GD,DD*=*-
M>\Z-X]]I9&X@I,JR"KXD*C5%D?3M*X:OI99HQ&]'=01>^9@?&H76]IV\Y\[R
M:T8H$,6\2$THVO4&&S81C&9*B#,046LJ".:1!(@I1+[_RII*.%#$P&+/^-PS
M$L)FN"SMU>V2$[?*L;K.4WM]'ZU)U"3VDG:B%*&_?XIZD#B*J!KERJPP.]KL
M8J>K5",9I9)X<W? .6K-T]P)R'F%+=2AC#QY&W GL?9.SZ^RSI)^N:3:TZW_
M!-(NDYJTB;(_4:(@ACF-\$>751"$:EAQ";-U UP3TIOZ\=ZB(@MI"RSI[>D>
MYL!B(VDU6/WIU[W7OC]!7+AP K%U^]8#\CDI"+Q"$U4:7(?FYN<PVA_QX/9O
M8VE\)WC2]R-+X8&FRXE*:EEEK>YDKV+6F=F(@#3_KU'2)WI$DDA-!XF["%8@
MB7,-'+$;ZX/@#,%5YR#[@%XMO)D^YP0U3_8S<_!N >9,];#']$G_&J^K70.!
MSJF/))HNI0PH'13\(TCG(FH16RE,L5AH^%7P) "?L8LAZA&TRZ):VI%%X/EE
MVT!GJQ2O35A\%!CADNHTL#2'54AE_MFO%ZA3"Z^IH*IM7<L1,KO"*F4'L$H7
M!*$?%+"888,1)?:KR@^CU D6$/-[7FUQBNVTWF>P/U1O-/."EG%V\)V6!9:H
MPWJ)SP;)]^!+>"O'M%29<(I72+J.EL-CFT@U0E,B+%J[A(W-4!$O;751#".&
MC^H=&!%7] D;%JU/<;A&/A.TI'U6J][7\<^#N%#6! .W,,NQ!2/8 3PHB'Q3
MOG':B2:@#<?HNNH^$,?2HEO4Q-\.8);N:MI?4"48&-V5;A/JIRUI5JY5G[Z_
M\<J'I2ML)/>8.6,3]L#,D:F#94?P2OEFW /]7(=23ZQ;;30* 8X/&P3?"U6W
MN6U8KS#BK./O^V3<TD75<!(O=K34C_>$Y+,<O56OIL6$OYN@4C6LJF+E7C=2
M?[($C'9Y;C]4W> T&^TQ/>5YKFT^Y]2[C\DPL;<P1QB,4 Y-&Q]T!31;IZO;
M1MLV8?=)@ U-FGL$J(TS4S/,SFU=)A\COLK#9HXGM1;/N8P%A/4,)IP46TIC
M7I#4$[[D#"M;)-&IZ#]Q\'$%_N?9#GYB,K7^/8+]F)>#VLT?P0@0+G".$JX-
M!N',=&8D=*IX02.]K,79M.U['U5H]L0=-I'=MK'(\<0OL^.VJN[P^W(E:/0<
M)<2"!<N]&;5_B'N%$=%')AYA:3[(F6Y!*0]6??H4T?TIX;A+.J[8@") J3O1
MLU3AVWI.;+0?749K+GTX!4%55#QQC"9)<*=+N-OTUV-F4D0G\1@7ZF ^>=HY
M%KYS_*361&>C=O>>+E;YQ5,?]M+GJ.6#!AQ/==O:@9+')49E&O:Q)FJ78";+
MC<4_!?]PV/H@A6,!!8XVR<<VC+_C8PF_*5?1+&P&(80E[JL%'4I!XZ:+TV!$
MVXA;;%Y8Q)7@X+>'.$8OS#T7/KAGF.].3*U_X1P#KK-]P0+.[BE^&Z:<&.?'
MLG)G]34M1U/51NMMBOD]0,"ZUS_]2\BE*TF0"ZFF?=7H]_F0QM2IB%HY_OJQ
M>'DE!^<ER+&%'L.4J$ <0"L:I(RC;<!JEC*CJ#40T3)_,J5]>J?9N0R%L+O6
M+R;%Q9_.QT9$/)6_%N#H$T^NE(8;; ,H5!K@Y\A+IEW?A(V)-"*$2?X<W+@Z
MLZ\))XU/L4<CS+1VLS1;15)L U'(\L]7Z@9":O4F)CJP-R0M-92]3:Z5WN0U
MH%2(0XO0QJD$M>B8&%5)UFK-7:<\^ANJ,>C,^)$V#N8L-TN.O_U58[3/*#GX
MILLIRIYS%578PP)Z%A'3"[^AG@"( 61F]O<M*C.1"1@IOB;A5.:I=(M*5EP;
M7%:'U_Z\\/-A6QU*OJ2%,*7"6B.X\BECUX2L?(?<<M6V#3D&9BR"X=BW5>;:
M%>SG[-PZ,*TG >N-D!:M*<LQ9:TG<.'%_V8E]60>DUBUU\Y8WZAW]Y^>3?LU
MZVV9P91+RM_HXFER1 E*8#4]]WYN#2I^!AY[=RDSG#D]CF2BWC$2W'E'7/*'
M2X(8#]TF)]X=U+<X)*3^WGPF"KMT&,(O#G-^89ISXGHN< ,12?-3T:<7D?U8
MO,Q(/F+B.WA81>S.L%K6A,> [\<D2M0&N=]*]CW]O:/WU9O;WG_BBX4"[]BW
MP6*.O2;7:)XKW<?$)(4<1[>,O .F9U(:NW7<'48N/WYF._S@EW^AUH2N;**J
M2G-$F/0GW]T5SC^S9;>Q.KA2&$A)5BW?IV[#CYX%%S9ATE>!QS1IW"R(+"+X
M4#E6Y)+Z(U?NFZMPY -DUIOI'7M:NU*?2$16P<M__@>2]_YWVYANGP8<^[[)
M,$83UTAQ4WK@&OLXYM30DL&BTR!?*M#);M_<#B43[ZF,$DKU<.RE1\&/SLQ1
M'Y;.1[-'-V'IW6 M!*&F$/ /)JZQZ^5:\*H:;8X%\8_38AP\*#K?J^O\.H)3
M)&?P$1)G"Y5T@VR+>IZ/86P,B,VDEAD2_05Z-3AWPQ^+X,:[$7=L'2T2&W.E
M"'[Y!!2 ZRBMN?YWJ0A7%."4"R1<+]]8U^\L;U-=KW;T[.W2:]WV(DW$$#3V
M>LZ1)7V>Y6ILPBJR(1'T;[L89\$YUE5BI\[9U&(G5@))]J[6)DP-VL-2*UW@
M4X<GQ^ZDVP2$WN'?_HMX3=8"6MB/_OL,@GH1&K^'<)=7 %F#E&\-!$>.&CC0
MTL)'C?#50.^6NZJ4MP&/IDX*7G>C-*0B9;NZ+ _\3DS.RQK?JHU$_%[GO*@)
MQ0H#&%V,9R4OJ<A<&"#HWD$=ZC"XJI9_O<[Y^?8255U^L1,V(%]\W,CK9=0)
M5/IKFC&:GD@#+I+&T]DIK,Q%)!,]T=>>913'*-WFAG=N(RI7?QQ<K *YR)?8
MN[;M5:F>YU[9/+WQH]I5U6G_N?/6BH:KB/NTK:HT1:UH)="[Z2\ND>!=Z(Z?
M=XBS!8S)]79 +68@!"GE9<LO%#]^]D^7:4 .9L,O'O:8KG:U^Q'\S<'2W*U$
MG</H!2N.'G[%&;1E.3._#!&1_44#:A^!G%3&/<M-F'WVFD%=6H][&RYH;C[D
MCO/Y=IWF_0EZCR>??]B$?2MEC[)$R%6;L/&B#E*U0FNVEAU :RH=%\< _.QW
M4RT2+Y2<(GT+ S(/'P@5)(Y\>):8DFEZ_W.C[+:U)W),C#2-_AI=@6FVBZ1*
M\UYR0UF"%ZN^<HF7[03^;6E6RL.Z<2L/@*^J!RQJ)V93TR4J.SLO*I85&68R
M4L!#M0O9,YAHR)PT, +#VL(00.D1G<#Z0(8">)NB&1_BNN0I+91K@3U)%,S<
MN>>4_>M.!KE]X27B1#]F#R3,2/22*1'>1_25I^CK\*2#.>+#9FC&JW<$R_H&
MH+<@WU^)$+A_1*.Z84BAZU.\=\VU5$;6!<5VYJ?'SN& %E^,PI$G?H5TK@$Z
M5E6851NO;8B4;]+F;W\.,3,\-%MLL.UF>XXW-?/V&S=S"4!4?#'^&5F@44[H
M/OSUS]+<K6]GVJ&]<\=:F*N;, &J&G[>XQ/+Z'EA2S$^K:792V2X>AB83?RH
MZWG]5@![<'_,N6V7KQV\0P#'5IQ-H)V6R"M![86(LU+S(4J7>X)5F,L41+31
MY .4Y-\53#0_LLT?^S78Y&/?+'#&[$&*]"W,LO3M+-C?9#(+6BAO-IN73O*>
ME@Q0E>&])FHCX];L) .,LY*CBXXD1809Y<F5C)2=?:13I1>>'EY;\^;1$=\G
M!0(&!"-=JC"IR683YDT:5V>DI* .<U'@LW")W.;?KN]1Z@''-F&QH1+&3L#"
MA8F&SQ'9J#FACX[^WF&GRLO2O84FNT[ UK.TYG-C(=!!?[-BCK%B7]$QR3<G
M_7,$@'JE35A"O6M8WI2;_]_ _'*K?YP;/L2KK8R8>".#=G<K!KY_RWALSH&F
MS8ET%3>.968\![P9?:T2=SI:O?8.%@P1U+UG$ +7_\)8.H^Q#4L&HT.4R^Y#
MES8Z'U8*";,7A;Z*]#]V[L,H0P8%4XYKA">ZQ366(@CF(T%F)U^.GPQCLA@T
MH5]U;:4/*',7@2]O)[]-V.QZD9R'UZ^[@L9/V,>6ZD*Q?I/4=+8J-QY1KM""
M2]IB_K9/)J$T,EHQ=%H0;WIA<-7)/]1]>"34)>2WK_P%@^#8JC(T]5YY+E*;
M\\)'</&8%IGEO @'PIHP>\SV<XS!W';$-591<M47.WO@?1(O]^8F+*AFL/7
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M(U09=*.M'SL<,)R.],FR]@$\^V)*?@RX63TI##,*5(RI/+NL9GK+\UF*1M8
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MP!D@C(WCY=$"<T6VRA?+$([3-V%*;1SSZZI:]74L+XI$^B1H.6];P>_\Z'K
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M5Y<JJ#OU<M_I-P)"L(/VL-WO3>G3"T\XAXF]==0\)GQLZ^7,/;H-[[*W$Q7
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MF#T&Y\-,3,J1_=QED$9D>+@8N$,7Q:^ ]V=7-JRP;H>?B3I5?&3R\&''R .
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MY.H3HBZ</)ZF^.)*%K/R?H[=D>OBQ7$.U#OC,S_I\DQMU@>HA'T,9PDILH^
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M?YE"WU#XR17T?E8 K/*4S0\.Q?"  5]/'O#!!_W;NGTQNA'S&U!+S@N8#^?
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MZE@D]<JX"4VX=4NT;HJ(6->OI'-@UV%!@3A 67#K?_Y;70'>Q/\ 4$L#!!0
M   ( &>! 5G#$@4CRQ\  (HR   4    8FEI8BTR,#(T,#8S,%]G,RYJ<&?M
M>@D\E&W;]V7?&[NL4Y8HX4Y2(4-E2XB*).:6; DI0L9<I61)UI0HDZ6D,-D+
MF2Q#Y9;LH<P,99>98ERX9N:]NK_O?;[G[>YYWOOY?M_R?M_O/OV.F7'.->?U
M_Q_'>1S'_QPX[SE40/R I8TEP,7-!?R*_ "<+\ Z\U/!)[T!;P 97)P18!_
MS?5]?'_D_CYX>;X_\O'R\O#R\_'S_VX"0H*("?#S"XH("@E_'\@K41%AT>^_
M?%_DOWV4FX^'AT]8@%] ^%\>G)> A"!0PWV,ATL5X);@XI'@XK0": 0CW^_P
MN(#_/KBX>7CY^ 40&"+(!=7B"'P>'@0T'X(8>3<:>1_@E>"3W+C-G%_*T5-
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M@%\/F(ACJ,FD*MD'8U$=_J&SI-CE\O>V+UPUZN\<W5JCDG3\,U4DN;#,^)#
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MVC,>H"?N5W'"AONTH>C!0%4EHT^77VVZ9'11*_^2\+\;\?&TD4=]44=AP,7
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M#L?F.'PK(:J;AAYJ&QD=E9+VYT[EK@SRT;J/NH\70G*-UU0>W\E6J*?'O21
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M2"NVG$S4XIE[Y'EM5+JV-L'KAO0655WNRR^!=3'W_L3_)'&&_@U02P,$%
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MRKG'!012.+$K%-[OWKH][!A:=+*=S="H93]&0*$Y.1!\(?8UOFMOS1VF0ZW
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M%Z NRL^9F76;2CUSGR-M\_)C"%8'Y+?*C>?K]*1].?G'"U4?:7TMM.;I,PI
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M5!7MMY!2S9YO(_NR!5((8@=\-TNVE;>]-GVL=?V>I\%_F=RYP_\+4$L#!!0
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MVVM+R=?>0^YTX7Y9AYD@/*@3[H$4&A>_T>T_JDC279?/ ?*W[#B1IVF.X_C
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M3BNIU U:"MC! O8V48.KJ%$M=YNJ=-JP$FPV$OLG&]7T&JSS-OUE(V'N(_U
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MMGN3[@0&O5Y6Y .+WWZ?F0#1IJHEC:.H$S[!0:2GKE6.C'49MT,M!(G8'[+
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M;\WL=[>_8U+G-RN*#$%WR@ IT/$;_2P8_AP9JS69/VC0IR17Q1$8K*[J2+C
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M]\[4+6SPDP!*>C(;<@BEM#KDQX:<5MLL:7G>#_R]E[$@Z*(P?X&."((.SV\
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MBJ?Z#381&"Y#+$8M/"&N=(,KUMV0&#@@#Z)>CXNU.?HN,@IT_D"S JCOL&K
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MN0)22+Y3XJ4& 4H,#?_9,#;$8.0L&U*=!>HO63;D\3SS*1LR6>6*6?N.81A
M[O<(CN(H@\0B*%,HFI^UD<"&/,EDB5:NZK,A&=0,@'@1H ILF?D%/B[\U!AH
MSZ"+-F"^U-N)[@3>X:/1>QBBM.P,#W&)'J*9-CIM=:Q\"55XKM<-%J!EC.=K
MG%LZWGY<V5AP[O:@W27-2"[K@F=.(B7]GGV2.:F>G_:9WD.B+ S?2CRFEN09
MM%S,MI1,[/?:O5D-LVK,T,WXI,(2YACI8$+N6C 45#&L<YE_.\;.(%9R'\,F
MM6-9N\%YD 2@P)O-ZK-3@CC*)39DG?_K)/8\.(I3M"7PY$'0MGC,P-F+?_WK
M<W9()U;(YI;B#V#Q-"N/:L&$@$ZE!FQPU$+EW^]-)M.-%+NQ!P14R#70\7)M
MY#; EK> 4.&T8$/B=-HCECMH-WACP7.=,$I)%[ N%_OWXW\S&N@T1H -^<;I
MS1"$L<XN:<MWPTA/]73 4US@>M=VFX#]>O.K4[WI!]B0E],PFCJ4\?3_W!G1
M#?R5"ZEE0VA2^%JB(*L=4ZX47'T"=>-#IRJPQXTG+UK?D@UYE%X[TK)TM_^U
M$W. ORKZN:3!^J41+4U(W,;<3U;#"J+:0Q]^148D7I&R^1Z1+8AL-D&D>^'-
M\J=+EF 9#(E6ZKKW[I[LR$RY.WXWYC0_5-ZQ@A>;$*9F1COL,JJ2_VXF0)T_
M^@NP[*AJ09^V8!W!*<,NZKI'+")H7@M]O*S(QG V) A<@GK+GWH"67DCWPS\
MS8B-?K9?CM[76*F?[ [Z-_M]R?LO].[!?W;7AF-I6KXL/30/&#)@>]D0776<
M@OP*/XLG\@T-6*W!D")9[>G'.G7.ZNBD?.GE71TLS>UC+#F- 4W?XQ8&1YO7
M?*.K1B1@'&Q(W2%4 (C0/6"G0G/  35?9FJ15H&XJQ_T=QOQ1>3N?!O8>/E(
MRB>3TKL$#R- ?]VEWDN\@SK@$H%]7'OY!50J6\0W_E[NMMDNM[Z<3_\*$K'%
M_Q;,1O7_Y]K%_WV>XJ> .H%G*',U838@DQB:G1N,D8A @S_>4XK=@V[ZQC"W
M(*@T$&3"+)[8&VK#&.:%;UF=HT&5;2 3@"?<)&K#/D7-CVAJTK![EQB1HK4'
M4C11E[7:%NU.O+"_E[=]-L&S3WX#ZD-JXG6AB2O7P>M)<K4\Z8N)6@WRW2EP
M3\FW@Y\L>K3_%<S+KS]C9?]OL7!_W!Z6-)*7W!$FU$#<@S+SS'<K5*DO3\J:
M5<0%!$!&;US8/O>[IU[T7[L1T(7.TJEO?M3Y>BO/)0V1#TV.?,O[(C%C97E*
MC UAR'F' LMF.C!0#KG^22:L4"!/SW #Z0R#_S0X'/AI X@O&T+)JQ8$A[3Y
MSY:LG2__XA.A9A0L*SPW;/,=E%S@D!PX!;9T@ C*H<'9D+/=(!FF28?\R2D$
M-6IQ&]+I4' E5:$,@[L@GP?OR)U*0C#Y+4"6.YS"RSH22[M$Y 8'GH($-O_L
M'* *?OOO/OYW'_^[C__=Q_]X'PL]H?J=.KHW5.<XC$K?E^^R.>WB]?Z03![A
MY:Z>-[^4EO_LP]&&<UL@A'T&BO#!MQBFY$(-RYX570^KV/,47.CR24 ;C':X
MA/G3W#>";,.W&.7)Y;:X@*-[@(+3+/)=UX RC5F_-PP52MFGUP9.;F2:#L*E
M@/!CX)R/"/$8=Z%K 9*X]%IFVXJ$Z&HD8@Z@R8?-TK.0D>/=LR@)\LE!D:,!
MAKCCRE].Z>RWZ1'MAZQB08X7G.J6#NW!756*W%\M94P8U#GHJWKFPHG5)Y_C
M.3H +:>F:ED.W]549H$JHF]\I*YZUS<&UQM:=Y.X<D42[TZDRAED5V#WOL=)
M;E)/'Y4'JQVJ*OS<<8:#[PM28Y5$'0JG!M81M\/<V9"^V(LT9V#DZ!"Q5KL$
M+5G6>[?MS)0AN@6_5^Z S+4UR^1Q'8YN7<1L.2F(PX&)80F@;M(B26FZ5=><
M*3A3T]B]COTRA+DD^P/BI%WU7I<5>90GA+?A8Y#E]0@*U9O@]#D)V*&0#H0"
M7 P7Z),5G+C D7Z[WCE]A4])Z<3%08F;3L<R94]_AMW^P/5#<,QQ*S-WKLJ7
M;H-<6[6+_;RVOX@F:M3M/887GU7U#YX_/ATI_OG"6^/VD;3<[/N%5UW9D%TH
MWI<H_5Z6W)3V/GTL,J:EI=L6M^^$QEY"P-"9.1GWN:7148BYH6_)58[:>3;$
MJR,"X$,YD'>+KIYFQJW PN]KA)9JW1UT:H"+*Y1TWLKY%!E^M=BMIZU3?S%Y
MBY7$PM5\J $SB0UQ1W"AOU?S?2]-XZW;R'E8B/2')YA0$:&E/\[Z5Q@L(P<%
M'NP3-M:"6ST6?Z3\1$^&<8GY KAF\2C<US_;A@:8!C;#3U.P8:IC0B+9RUVJ
MCX?:>P_MBF^62 B%;.V[GBD9 )_MN):/;F%#=NH=0P\ I55\-!=+:N\[EG3O
M\H'1?>K13@+HRXGA.CL5SSW-/3"P*#>\UY6CD%D)>,?N1->C!4N^YU 4)B+]
M4O^X417$8U9E8X>WB([74KH9E_C(9Z?S8ZDOK54OE?1C_;J\\9>["DL-GKS\
M6&YRAC^M\IF8"Q7[=8%PLI&XA^$-VO(RK8%^&F5"^T@2Q47 !$J8>C8,+1>R
MAWUD-(]Q#(NKN.N(P9V^&.6NME#.[  >WF<B3'Z:_@AV&^H490^F ,G3J&U=
M[K:[Q'K)P4WD$?Q$DW)]:.;-Z">[.([*!0B+EVSI_I<W(<-8WV!E-W"[JF5_
ML#H0G'I[W#'[6!*.4T3"19KWN>^'B\J[;_E["@DE^SHK]*2&'KCII2F:[/\!
M_H4->7<'7#7T(*+4Y8D?&Y)J%]M 4'NJO$C]8>0F6\ZA*_C,A>@Z$P%98.U$
M$RJPD6AE[&P_79^QZWOU >3J@GF0OGZWDMH3/_F#[GVP7E'3+V<*X@]QIBB_
MJ3$,%%,A8^:RR96P* )F=IU^@M6A'5O/A@C0[O6*QN[7N;\L8IV:$9Y\]WBK
MO_('MT'TM7VO3IK[UG&28,,YQK?0JJROXH>_&:I-5FO](-BK C-Z-=ISG\0K
MN>6\5K$ ]5X^A6?5B4(,KU9%OI[4V]N]("/$DNVM>A0REQ"Z RO=6>'V9,NI
M+6DQD&TO+G!)T=58^%ZBF(X'&1HB#J/9YR.YR-#0:Q$C=I2D][Z"GP-MS?=-
M$\;YB\;WW<[&'[B^12PX**G:@1FG(S.R$ .4L"$1N.&70UH4OX70Y32/VJ=(
M>U)OR!O],:)99G83P7%C&K9^H_L<AV'8^ [S.^K%00:GQ*%T&'H@G9-61S_F
MCBD-BRX1UA%].8D7B7"W)#H$O6PX^"(J9OC-T>L-QCL$XF]G2G]P@PV_Q)5(
MHCEAXK$,?GP#D5+(B>UO+T-=OJ[V,-?)G\"&%%6S!C%Z1(U[Q-3Y)<>9''3[
M)A1QH4((#CBI,=6/)#^3FK>@>M 06M+?)M70/=ABZSSXHD-"DS757[[%4*=I
MM969DT'QBM.8_42!ZHL?I;TGMTF;ZO+4KAXXFGU:[D#[*U3=6%E9E/H"AO,+
M=^:VH@=W@7V )R8$S4'C(A$)'(:>1O6]CJI)7?TUVH8/W<8=9_S]3_WAF1']
MA,!0GQN]]>/SXM9T7COF)[020ZQGV72!T+VJ_1W%0=(%+H>8A30DZ:D4]U[O
MGK^I&>Y]/93OY46D8HX!UT<LG)FHM[6/U88HC@VIYGB;41&)=#&.&2)3<O9[
M1#V7BCL]=JFE_9+XJ<]S"$G6(!Q6)HH\:=0#\_+F0FHR]G55F3@%C5RCQ"^.
MSUR03>89#7J)D#2:K;42?GHJY[S3M@M<Q$N7M.^]<LYWH[A7>+98>/IRMWJK
MNL@?.<YI(SX<O-OL/^5/G<1A]"NLEFBZX11+E H/T?&1><0('#:[,IV^DWK)
M.L/'3476]FK*D5-).Y_)5=QP<4\_)4<\RO"BA5-AY(Z&&6P?%XL;3J63L'48
MSBGU#:_R0&_2C_E"_J:G0O[[I_P"I8]$:%U#**N*MM[.8HXQ=Q5@^6E"->+J
M]G>IF)"2PBMV)N-VT586$<-G&*CF\:,$I%CL.<@Z<76=F0QS7R"<1L&&8<'0
MO54'LVC;VR$H$W!1YKX9%5:4-WNK]'D^)3SBULF*UWDQ_X4GFC=4? \881.1
MTO2Z(<'O1K-3N4@-\XJRX+7SE.J0@O[6/>EO,XSG+N<NQELHW3;[_/K6#;Z4
M#?7_\8"F;RWT/9XA4%D'B*DI$>3KT[5I@B.\0@[[(\_U5#GDSJBP(=?L,.OW
MWD4(Q<C?J-%RMI)P+C_II;6A08('XUR]Q9!65RBQ<TV9J*/4W=$CGX^I$KDG
M\=YN<D<5R>,*IT?WZ!><_^, IXG.B'BA 01%I#L -5IZ.U#NS#0="TK=<$>-
M19C>?JIZH2>WF]T&TISP@Z \8" !5=Z!:FB1P+8R9^]*?ZHD>=<2MS .4:+$
M]]*"AM.$3I>*WOA8^JWD2^'AI)'KF2T7U2[8/+I@$_4T4U<^X_]+JF%A1&DV
MFPJ<8[YT81;@;D"AD]K0R-(@:0651A&NR%LYJ<;472=\MA4=V)$D3+X@8%Q9
M]'+7EDK@V[,+7+7 ^[78NQA"\6I*)TN)A4>(Z1P5JE_8X3!-T'BDQ^UF69KW
M33%3.;NGW\A'PLQ/I68/9?C6V1KZYVV3>IKH)DPYIIY(B+>(D6G$[4"9OG1-
M=F9!:59-]^YGE:4<@MZ;F%UM$[OC,%)0)*R.^5CN/C+C.XS8!A6(%<-PN1G9
MVWSU*#BHIU2Z3;[<.[4<?:)1I3NBYR6O)&TWU]R@4)2BZ&IZ#WJ?Q4O@)JZ/
M__-]=)[@<-62Q(\K@RU38[>6[D &*V_N47$L-Q#8TLCZIBW3&+L/)8:_"^V;
M:*AP#!F1KW2./-OK]X>(?:"ALLSSPQ<*D_@"4N\4:,Q)\L4A%-$=T*)DAD#R
MJNNWA5LHSC>L#GA*SOL[7B@C<N']IGHAN[>EM^^@9O)#-)7%S04X#9H)F=+5
M/1D/=.3)R;-,NA'*F79MN&/O-"!<TK&#84.YE[,179U+,@W,_>:5[3G9NT2P
MD%Y_B3R7=ZR_,U)04\J"AVJUZKKY,*\'@AL:#)0TU6,?ZXE1I%:^\I(M*=.M
M%Y(O]KR,,$B8)2WL,+UQ[W22Z(^K>PPO,1$&D-/94TDBTL\],]VL6SD+LW;N
M+CG:I=EYYDWL58B@[K^2\?COS__JAVLLEB%6R8:HPEGC%LP&_%@T.A>H:<4M
M&0#S-]B0 0>T#7XE]C&P>/8:;%Z&E?:<$4J.923;X.B@<LIY*;B1MIGC MI
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MLJ@@ 04"@R&XXK!%Q1"0B8B,$#$F7)$M;(K*XD)P81 %HH1E)$!,$*)LN;B
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MOG&L5___I%'T_QR6RJ%_ 5!+ P04    " !G@0%9AVTQ0:65  #@M@  %
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MR;RKKNS^1(IW0<E*(VXR)JK:[X1K7W887BY4I3 R5]("FZ9_,$?COH303X+
M%@34X*67HDB)C+A[F"VBOWL\N97JQ'A9;R;>,Z\^@O*!<,S\SL[.SKG>\@+]
M6*.T.2'4W.N%DE.<>@)''.>SB"$@F*G*^-AF+M(;%4)(7VV@Z?U!B:TC!#)<
MX6_WICSJQZH?[J9&9@ZIM@1MI407!YI#M$Y[?SO]$M5U!BGKCOP\?YSQ;@O#
M[Z^,D-2@%JJ1TS8U.THK?A^PRACR45-ZVY)S_9O5\3.$GR(ZC 3H<80>(Z_C
M*!T.BE/^DGC2B4%BJ&[\1-NU(-4GVVK5?95E> T[[A]!NFK/;AN(U!<D J2V
M$&RPS8+=="(5RRA]**-LQT<_33DW3.0O2RIU.XN;>1V_47J%8W,QZ]1M#JCS
M$!"%IID@1_-VUB2K_?8:4\AVSJ.FHONJR,-IH:[-UV$'Z%@7*\V8O]?%TP;4
M;UI5EWGJ+Q:1KVT\A4&0@G2AIC90ARAL?[1Y<@O;3@G,)<EHR@WD,;FD.EQ%
M%7<)+W>TO[SN"%3_-9P@%987WF.W?X4JM2)TX.[UC!X)__CS3I>Y.3\ M]L$
MF0)K\OTTT=][K8I111<IT)B(J*-5T(O\;V>EGRU\C,N,%,H#2)A ?)J"[HBI
M*EF0E-,'293+B=72A)I,#[R%/\)?3;GRJC-[*OZ:R_<7N65 0-H#ZR/!>=LB
MO,A9J(9=6J$<J$O9H-ZA\/8T4K[<8 '=XF]_&P\5;#F.]D#RJ']3?((^VBW2
MNV0^J![?;QZ,:@I*I7-3M'MA==EUA'2I%3EF85']]:<5&];C1UL>7VAL.LG1
M87"K>5]:ZC*7 JD1%DB $4M8@+=WOR*IOA-"2QP^?<@R'7,/=0#539J$<B&_
M>0#;=DER+"!^C9B#_3O[YSHNL*A,;[!#/>Q3\ZE,8L[2YL@ECL4$F?VMU/N,
M4KHNS0(><K7] WF]O-B_4'Y2:13A2 P($ W<RO_5J6*@]C5345U=Z<V%EE=Q
MSTZ#>"(DUI27D(Y;7NCO0:=#&G)2D=+^>4WIRQ2#>,G$U,.C&ML%1]?.834"
M3+V\X1]&&B=WSRY U!W;4%W0>I%H<3"1%(X5B68:4993'%PHW#5/FQ:TI>>Q
M(?XU-YS/CB3=\S;W,-9W-JW(DG?J>VTMF,F!0^*9ZB"&@)H>)D%2H)PUPW3E
MZU!(A-Z,1JFFGGH[UV8?K\FHN'K5P=CBY-T<0LXJD;U/OS)>(Z6F_2!UZ/[=
M@ ZU'[[6^D5IXB1N'#S[D%4Q-+17[)(L"XC8*=VDBC9KG;JUO;&F3TG$P@#F
M?C^4%%V=_/%OGV:IGH.?L4%!Z.(-1LI7>U.*</J2GGUVUN#"_;.& KM!U,=V
MX-'P-4XRZ@K80,*+TW5C7=,,;-YLHT0\NFZ]KYZU.7;@[)4(+8X^Q0R9K*XK
M:IP3&-_(-/$NR'XD]Z^B>OQLFS,:AAT66IG<:TK4DK=-:^ASSC29410*/_-L
ME;PLW'P? $+_,J>1^\C#_<.2""ZPJF*0Z)HN K\!S[HTV6#RG*906WZ\":=U
MY-:7E[)6&?)+A ]?4J<&@D(I>3M444:Z%A,Z@&2J9%$?DZL*MFWQOOY!#?.,
M9X.M2UH!;9DVB/ZJ9?TQ%M!U 2D/YE")8(%(%RK:77Q4WRR$L%ZD^@1QKMK/
M7A>K^75D"=\3YP_TK4A_?>&ZR%=[)ZWW,N\D"ZAC =C6]*<L@'\+G1) B#K7
M,]GR,R"DW,GO*UO7D_V?"R;@Z4/I]V).6CG>^/L,ZL8"8GOH)RB.?;-%CSWX
MZ-+H>5]<11/ZCWJ%K=?#$5TW;)F=64OV%:B#7G#<JFV4,DT=^;UP/^,-E/L7
M2L94_EZ 8GO39N@AE3-)#UNGGPZL*=W85R,?VQ;S M=Y*SZB:"V#!:BZT711
MTRS@+0M8*5R*-L3XI,_R]B!AC,?UP[C9OJ:C$F-MRF;+*8J=UQ,V!PYI*^*0
M*R=[:5<WSVF_0>>A""]<?'K=1*B]8%$5W65RO7S*U(9@)H\UGFB?Z)'XV#Q>
MEDEY?<WS2:_O<<N8L4']M(7T??"Q'E0C;S**D/O(/=&(;(G=>"(7GA[?+60>
M5")R<MFI89C,KW6/%"^!:'7["+TO4K4"E9XP]6$!W#*,<H0TD981%/F6?FA4
MH]I[KMY<H_&C15KAM#<ON7A_/=LZ%J:.I/3]OS'23 'D9Z@VI:A'4VJ)9%(D
M/^W7>-ELZ_KJH!DV[?E[Y=:D"XTR 7/UT2?W&Q>EL #R98]8C$"'",(,W/85
MIK8344_RYAJ+RN=][:6R=?3;QM0C3LVO"ZG E(29MP13*>Z.-'[F=%$=JBMH
MFM/\.U(3<7:$;EB#.#4:J(>6!NVNM3T]9#%/G;>6)-%T#VR:EGF=C6ONX#T<
M\].=&[Q&8L<<3&W1JB]A.,E8(]LECOG=!5GRL+7L2/7"IQS[EMB3-5\^6(LF
M/Q.H/9R:#.Q5=J$:A]E2$A^ (435?LQ,9&_1?L>^-6.XJN/X=J3Z-+HB6?=8
MTRN7S_@[K_H$N6[/''[_0/TK5(@YAFI8PK#73I"RW#,728V:?)JR/[?8,N2U
MS4(*;UQ/V&9;\MX3CL:A):T;_0IW&/-C Y(S3+Q2^E-4G?TA%#&X>)C1_..Z
M1RPBB(!)8&<92,IE^CE*6.YKPR=0!3 P0)SFOF=R"Y'1T'M%)O4Q[_%E7TY5
M/8Y^!#>C&'D4KDA]R7A-YR6_([QOHDCWVE%.N*&\9OV^.^%6)F]_D131GQCD
M6] B9I\:US6RW@]8^.V(<"#G4?QT!YHN6$E]07%/>0<&SG:&Y^!0:6VP-Z?1
MD>6_I>+/-[ZTF%7,I#P^'#U_>SGH\ /8!Z\V=9HY<\S11BP)0FJS&GYZ(87/
M"I*PL)OW-_UQ7GIWC2H!LX8*IV"Z\BHP! JEU<U#U/>1YNN\Q35W0>4(T6O/
MTZ)WX[NX]TDQY8#M- B5!'ZJ'&*'1S'$#482XA8QG1?,WL/A^GNS]X:R*S5S
M/]T\'#EHXGURMC30[:OAJJIP'#9*WB,?(VYZ&_\1UGT(ML"[ZLQ>>&@[9:Z\
M?2*5O5K72 77A]VC HU4GNK<XNG4NG4\O?OMQNE\ZQMWD.G.@WK4#+O@>[<R
M%JYG2MV\H'/PO>6-A\4B,= 3"&-&-E.#[=P."!01C\/W2H7M*:?W%"A$R6G:
M]4W)F9Y=?)5P_/N/<^V-VUQ%-QP[F,,8 '-K(UH.]:3#%#DH%89[G.VB.=18
M&5$.I^XXI96<SA'F46G)TPM9[ N)[A3])K/<2_>,I*DYH[J<.A0Q:[?"R9N:
M^AVROTHOP$25/C@),6_-+4;5+>*;WL\'K[EOE-#/,Y*UH!+P,>+R*GH!'8_6
M*Y0=#UK?@B7N%>8Y1S=MXHC$NGNOO/6U+$-E5TX?U$IC+X4)136M0^0,S9RN
MPTBC^Y!$.%Q\;^_TSA^)N_8QICI6A1;?&.OHK-V6>O+S9TE.Q3>>#4^V6$ J
MK#&GIR@!+VAZB"+8;:Q2OB"_D23B#^G![[_K]RZTQI2<]"SNV+4$_=3$3,O.
MU-!E8#=QM2& NXDN6F>=/"]I#N-IX#U>"M2Y?/N*$K.F^_<CM&M<Z*ID%K"J
M3;,$F8L!;>*O0>@?\\GME+B4*)4_]J.W$B9]G2ARND?.*1YXRZN:!ZPQU1%A
M8,X":C:=&L2.6;!8X^6>-3^(F'^X]JW@=V>BO-[@&K,)IHX&0Q\M+&7@/]2/
MW#EU),[Q([R).D2QJ*+X>( F-#WDM[VFWGP6P/O1G,2X<"ALRF9LBY;C]N=N
MW0\(_@?W8H:%^&%=SF>FE=2G((5<1$+3);2I@>3$'HB,$SPY0*17;APW1$UY
MD&,P:1%UW$-%.N_DY0ND8Y#!;X2J3$"]R(CQRE24O-&)D6,:(HZ!?VDWP6%B
M>!([</C^+CS<.+:&\ TJ<_&7<UL:.#RN^)=TU/MX]?MK3[\G\\D4BU0C(+3[
M"%D*[^H.R0.GV(O'*<C7DFVQ<T5I#P.\?VA2TZ+NG<X</6]Q<U/LL[CO$7IO
MORKG4A"H9K<6P<8#^ _:J=L0>>; O#99)8D4H#7%%$6+W?"7:M)*G;IL+39_
MAG.W4>4\U[ZNZ# ^K(W07[P45()N0-FAB^,7$MEIT>N0#8DW[<@XPL?KS9]'
MZ!1OZ_XD3)U6<61^BH&Y@ZF"B^&& 'UI'T_85#C;F<P9M6QLMY$,(5]"B?EB
MA#M45Q2.C)OZE.&L2WWE;$DWW#3\@[E[/PZ)B7W7L._##L;C.H_L/I'@H';$
M6G]?'3!2&37-8OYZ%^IPF@4\D\QA/+)D <7)3:>Y)>S_EY($PIJ8+@P.GB_J
M<=<F;S]]5S&GYEH#NU)O37C)(\1I07AW,SKBT&G]!S*WFY("UDA7TR2.']7:
M%],)[(\M<$<%TZS@"K/4DB9&YL_1!D]V*N-L2O9L/V!./>*M-525BLE=BFCM
M"]N-#/O;:GJ9!Y^.%*)#P"JSFF&L2+R"'$4IVX@FD4>-#X)/[AJ9"+V9-=K"
M^OWN$"-7M!*;R(%-Q#3H7ZM,[EC;X[^_&&GF*?<=Z.VLLH^)2142^%X2+2]T
M8O9L-I6B$=SWVE[TOL1^ '@H*559X=LR60!-KUXAN^'<SH[<P/WH_6BI=^_$
MYR^="5?XN13XJGX5[W?L0>WKX ,-+S:.((Z00[I;KA44UC"J?'TKP$<XON*.
M:?$UJS?1&K.G/4X(3P,^DI_>P3UZC!EK3\O?@V'=U 6;9II%;G#XW4RSLM8+
MNQFZ^SSOB1EJ[=]_?/LRQ3*);D9 "^/!'FS+4$=!^4K8 S<_PYT'CY/G9<;K
M/J_"!23$[!H ;\1I\ PYA_35@(J78$K#PWM'<$;^5O0S)6<>?:CMN\"?T5C(
MJSC:6)\&L28S<WF2BE?")J]?K^5;J]$\[$2*YS6_>GE?S"\>]:5!#'A<.CJ@
M30\O4<+(@YX8)N\Z#L$.W";["9OB6, P(:U"&N;=/[04X6;4ISY-]Z19(23)
MJIV-C+*V<PNSY\D>U!LNCXW'C3*TCCS7SEI\F_;MF]NUR\+8ET+>T2;)I/35
M69IQD22["((C.4"U/X6H @8;,/(U5.+H7Y=1!8L;<X4AKZ9>PL.9 JH$'XI'
M(MV,XDFP[,4D2KEKM-O A.%Q_5"%!%S?^N+?1==6K&E:D,;+W2M>%_^.26XI
M Y>G$-K$(@E!'5+0_FD_V,P.97Z%!0366W<,A2H@/BW,[Q^05O5//3'053[R
MSTAAZTC#1(2)9V5'^:.IO)09%R6+W\1H8;WXT_@CP+ZAS/M&)+1C"N(NHQG!
M0:XDA=/5V+B6;D3)Z=66,[^3DY>>:,I;6CZ>Y]7*& @LR[8B19^@%7<LO#C5
M<^RP0BUQ@Q>TZ;;8 AVZ]\)>AJI/M8U?*O(\"//[A C*LXT.ROAP<BTS>*!*
MGZU6B,NX1FB49P_5,?S1C2&MW-"0NYG6OHK'+."Y,3JU5ZZ^Z#J<,=JV3 UF
MH)$RR-&F1_B$-EBY__PABF7"G3132P)>>L6B_^I86]?+.=*/+R,??AKK'EO(
MR"AT[4.1+T-X5MQ/3=%%R74$C][T)-5N1XLIK$ME])9,8(#>GW*@'9VK1XD8
M*SY<'\RK_NJ@@AKG["(9G^@]1:+<P EG_7[FTEXOE^7RNODIS\TAL8&T+L'C
MF<6$%[P''301RD17B*@;O+N_QQAAW+!U3)A:)9FI.=3KNR.ZR!GRELKUS,3Q
M&+F'^AS4ID022IAL\$YIJ"6_G1D.B7PSOR3R@>_,WTFB!X]4NG^@\)CLSP-V
M3V%T24-B)5UQB&*,ISX NPQ[L,KIO7?I4K ZX6;3N?B3*7$!3Q'#ZI5^P(Z;
M)R&HR^X .*K]9(\-'C8$/>#)/ X\[1%$FF^0I_K.A6^?;WARRIA>GV\BHH3
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MJ=4=LG\/"Q!E*OSPEW9D"M!\4AVM6LBX&Y]'!WR,!P23"-9NN7*Z&*&9@ZG
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M3'YE,L05G".C;X#.9%WS1O+[%]4> Y1].-OK1)>EF;7&V;<)S^INNR.OB-0
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MBV]5.AV1+GM-J6!!S2J00^94C:T)U8\,2S35+O7'*'08S8(&?WNOVT26_J+
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M7&*PAAV)NOF)+]ZND\=#Z%ZKES*&ENR,OA5D5]K'S_6F5):XST%X,/R\2GA
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M&$\HFOPPF-/. 8Q_M-XN>_17]P)8_R=9@& $#[;5U( ]"K4I'R3!RXS-9?[
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M3!&:41WQ:V=]QF&[3IB^#"ZZVI$RX"Y&4_]VZWM]G]2)#_$?:@,3#@N1_.>
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M_7GWMR8/GX0=*T,NQBQ$$%=ZH!7K:4H*&E:&K%Z/E_UC]MUD- <0P[:JQ'$
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M?[ID"?Z"*==.6_/D[\V*SE3R]KLV=_1=E;>%=;'QX-3,MT[;%]4I?X4)MB$
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MPI'WB%[M?\?FE=<>L;/^7T%X $& O0<E2.X,%V\B"J!-W?-="@XWEB>_G#U
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M@I5BPV)>>/R_/^CM;1*!35NVM\V5''O]WMINO7@1&3%Q$R8HE@4N"-C0M?<
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MG($--,^)3W=*(C)7[HI=7:=..\TZAGKKKQ=*BB#^IG^2%%/Z:[>.NZ<LMU#
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MR][_3>Q[?TZVVI=INTH3\_B:37#;\7<:T+T@%+D[[1(W%7JO"CJC3=F;P?
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MQC6S,\\EU,OL<2]-/=SQ]97[DY;ISWK_BTG]_U^/"'_F/P!02P,$%     @
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M@9@V&"MZ]DW."3#Y[4K-7:337$C[C"!2TC)A#I\DZEA0WAQ:^.G K,:;M3=
M0 8X]DNSJN%T\,"$D[&@]F-9'UT%<>;&DR2MU2X2=$Y^M8]BX.6(C@V24F\/
M0/F-H.#$Q?NK$V<\ZJLH<NWY9$I<;WFEA>"G+[J3;!':,^ )1'S#>=*Q>=6T
M(B3Z>GWU@+Z0+^V0Q+/*3UZC\PXCVPK!%T"8=D*WX'<">82,+: =#Q^&"'J
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MUZA X5MS0[:4\*QW1C*B#J6JEP/4;T1*26NZR?(%PG7 2?QB(G3U'5$=OT.
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MRS0QMP-/[),>:Y7YA[?H>&!\*8HHAYSIKQJA,_'A6IF$IVSN ??U;M24?$_
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M7U_"U>P#J@H\USX[5>545]?)A=?='6P:<%#Q5C4U>VK:Z#6MOW%)T>7WQ,Z
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M6Y&D&W-/)4D ?H0YF,93GJX7N&R^>ZE<@$,I<+N.EY.=7#\QOJZI30!=A\
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M^KZKB,-L5L+R6(:/QH[X=!G;XPF7CYP[<UF(\&^T<Y3TDO7'= <G(CI\FMS
M_Q;M""!ES99Z)H7=!%)=>63QYXX=>FPI)?C'U/,&_=P!R7#?''^K,FQ%U1HN
M:M:J/__JN0ZQHU>4WJFD5,1X$/1T\]W"&2GTXT06A!<8,4QJ#1".-^YQ1^YU
M]"U(<?=";OO@Y^?IW>.+:D\:EE7QY1\#\AU(TER _&0U(WR-P-X1\-B]P\VP
MWP,J91[RJ: K3RN!/7*]XQ;CE;O>,%LC4[5/!+B\/VG"NT;>X\3@^$A0=156
MR:NPS/6XM,*N*8Z0C3U"DEA&^A3P@2D(A/E0<18>-4>87#C^1N^$['-:N7?]
MGVO.>%2N5"R.K'AT>-R?NW#?QB197ACNH:LUMW4R'J]-2'7:CSISF#*7+I4Z
M/9 HY326W5<UW$\P4*R#<J'V("E/&GP_!73PXYOV^37=<C3033%^YR=0O[.F
M[2#T[)CYL;BA"T*2GW'2HX +W8@&GG*\DF)@VG"BMFM)?L]WL17L08N:-6.U
MLMR1Z*$EB]J1@%X:OA1$3F?H\OES?*H<B>:)[^&<2%7U^N2(1L][-QLN-U45
M!$6JFN 48 Y.2LW#G8WHH&'V)@Z_B)BG6 6O9^/U7AU;IBH-'#L^C*T@C[65
M*7:4K70<EKCD739UUME!Q^&BDGGR/.^&4=R4K_UB_@?CP'?!CN>FIB(MB\-K
M-XRC).?&^JORO[G"2O -L/WT>\"37 ?+4^&TN9%KE*GO156JR<>T7YD2;QIW
MGSQ&>IGV^E#PA9G8;GMA?D"-FE\_?CY)'3BN&/A=69(TNW;-(U_'=6Z:353]
M<MD'\[A&5*5$UEZA.M1;VX* S_A]Y7@V;Q:D>3.ZE,31'B/L#=7@&Q>BI ^+
MAIM'U'X[^C$X*&YW)EJF*9(C^I*UB1\H1!%P/A;$@; /R*R#E7,]&?5V[+Q>
MTV?>E)^MFN:.^$"6XK:]6=Q>^>B*0(BMJ.M#1+I 6/Y:LNY+S.[EN2P$'.XI
M/NREA\G M0S>4)'.;SD4E7466>JWVF_>T(G-KYAI<]=7]S].W!F0#(*<?S!3
M],\_83"QEO3E4W RB#8S@]"3CBQ( PLBYW](_;#)%/OLX]^4@__E 4_&4PS1
M&TH<A*WMINAON_ W\G^&8 ,/X?1H* "=CDF:6-K@D:9*MZ5?ZE+GV2S>2)8/
M7AM/]N/-O*>D+G>0/?R/^WO?7V0_48;R(\<<H&M1H[/(&)ZQL/)]MY:U4W/T
M@\<7;@=#&RJ5]_?%JNN)WMDH+!J03+E3@_TZ_YKQ6E79K"ZQGR"@;"'H\OHV
M.:8IZ8K1Y3K(G@L0SP(GJ]8 1>K^6KYPU!6RE/&6P:/3H?HUO3:)W@TOBX:.
M1G >O%8_49*;&[7W@%?DK8T3669E?5DGF;9+$;C3]!O 8TZ%<64@K&C>9>3E
M2&O^W,J= DU&K(@0/MAVMHI9G6D^-O1M<VSLK0G%AZ_+_$X9PHWWRM"Q6VQ%
MER]</,IS*SRW)^?(\MNX!7'#EUF?1Q[$=2\OZ56',QOFKIT*5(\[^L85(_#N
MHXW(LRN0P$M&(^E\WB7K378M?&FG>FWZ/F<8Y&G[B=Q)@D#&'91*(&P7.WE>
MJ1M$FE?_\4Y+\B02P$[@FZ6APZU69'R8&1.[0ZKJB(>_K=]SM;D=D9=AU^LR
MPF\&B;<F2K1_='TY(]DV%GQ8WU#KOW0(Q["?;\#79L$L*FCQ\-=KPN+<3R7J
M)@7#0\+7^'6$G5OP,2B7"6B8ZKG>&H^)ZF*%-WF66F[N<S+58Q$',@&34X^'
MRXE_*0Y%&N%M7S,F,B8**GJLU,U*XN/BJPD6'1;_,T)2X%T]$=/4^?1 HQ.Y
M\VG*=ZQ094>-+PXC_ZD)/73PW A@S'.8D2#:,V7FE#T>2"OG1R3/XZHW4RT/
M /%4/M+\#>8V*JW\3>JC'3.:?;85*^=ZO!(;O<B&SLI7,)8(NR:L[]AD5>S+
M&QY[SEKDK%S9 7NANUCWR.TEU?!;]KN>6ZXEU:.Z;B[ZU25RSBCX1#N!._V(
MI7>Z?I*);)CN.ZF%*-<[G+M6M,:>08Y^\2[DXJ'? 0K)U3NZZ2Y4I:9+'04/
M^)6<3,S2)N1%WG"(/)-,RXC/TBK;,.H?=OH&0^B?K$RKGL?G@C?WS;:?Z#+^
MO.3/++3-)8<>-@ ,3';FDJ ;_'@*O@/Z!ZC<&U<V[_Y+;S3X9[+<(T'_47"2
M"9+Y04L69/!@.PMR67YM%#2K(J%,]HW,*:":J:Y-UUZV^U*FKQY0$&#[V^=!
M_&0D-T_B/'^*%*SJ!!Q/0W^<P .$Z8#F>!;D8UX,8#()CN"C^?:W8__,,C?Z
M<>$_KWRE,( 4"XZ9%@KP308HO41_[,<"Z=/@&+ZA*;\L+?V%JJ[(XG^"JJ@D
M?O3'5^BH@!N;T=P@O<UG03CH7:LZA_7ASZ'9_]JS3'^^*(8LYC,!D(#17P4O
M,1Z?P:^RP2WJT<L7T$1TBBH\ C]IB&_"GT3-@TYEKG7ZWN]ZC&;3_SET,8/\
M1V?UQ\#$T1EZM"0+$L6T6S"%T<-!_!P<\..1'\]]?]L=]<_2\PKQ#?./J[TT
M\/THE![V#?TX0)-<V4J/0J##_JSLS?5Y\TL7]Y^B!B8)*#-&#/,(W88:F:9(
MU7NJ;(#T.L/=U.5@>3QQ^$"NS&YU(M1@O-8X'$*! UXF=2S(ID -"+>#4:OH
MQBH<.R@!8V0\77(&XYOQ2)F/*=1'@3%#EH18$!)<!4KYCGG,@JPJ>B^Q('LW
MYL=S7W/M9$%"/5!<H!94MZ(!DTY-NE(^$<W8-ZX$X@*<[WK>:;9Z-&D,S@9>
MLS.5P.19Z6)!]L\!4%!%O*)9$ HFK7;NOU?SWZOY[]7\'[(:RQQ*# D6PN3T
M5D$=(IDS=*>[S@K?.UD8,'#>&66-='9I92MW7_TWDX =7EZ>%;PE!/B=5LX#
M+=TZ<D4\(I=E3<.(D%U:\A-, = %1@4TJTI1$S"/W:$Q*0^P2>O9G7I5<9_F
M)#G:(Q>7W]3&B54DM!W9&W=0%_)%W15&,8ZR,GY"TXVIY^6/[/?$G:=6A)$6
M'>?&KT8)175,[&DA?>3,?[^9'SM>RT'+!:0HG<VP8GPD\P <L&T8::3A]E3'
MZ)5%CQE+P3Y6V&+CY-EVW[?6N'7I\.%M_?3[ )F21$-38NBG8$?H7E:O9T-(
M4J0TZHNR%07/YL/V'!W'ZX]SFS[=08;T2]=S#;?3_!@92TNKZ" 8-ZG70TB*
M5T?S6E7QAV(<-JHXC']X[L+T;BVV@([*8W8I*\C!]3I?Z"(/19&HN:A%]57J
MT&Q.$Z#(\#_ >@F\69D)N9!58S]XP,[C*?>I'<@''@4JTH;=,$<8<!H;@CM#
MYPD^JWR>$M\XW)(P@><?/KVE4.KO7?S6U_!6]-F=Q<;)X8E_>(T\:WW&]>Z[
M\_$R;-SWZ<O%3<&35D.7V^1; 2M:"" ^P8(\$=]2^X;F7B43DZ7$JH1%JYZ-
MC)PY][&KNOB%^$VAHSYLHBZ])E9G]#L/J<G=Z^K-S^<,Y+J):"F##9H3*]*W
M%+W5:.;]![=N4O!!\MHZ5SGL7IP@M.]LOY-WY_5.F["W]\UD90:%6NRW=S;@
M1SIIVD 760D>2N#"R9AW%CAREZ58)+[)&K\MI&YH75YJH<8_&NFVE3&ZW7?O
MFK^!88^[CBS9K!])*B\M>SQ35?7AF>C#EG#35R\H>1#1^+KM.'-&Q9J4 "T<
M**=LT6X":CM\DR)J+I([))N%1?O/],IZ*^F6QW]VL'GNPM-4MWLB5.GE.=&=
M]2JPUD)=Y' HV1!>G!.2;4MIB>+!%5*C-WD;RO.%:"G'[G5]#]^(WW_..1@]
M]?XUEPD@1>TAP18/$8. &(I5R\WY*M&D6^9BC!I9C>S;7X1<3N0_U,N6+,2D
MX(E)!QJ1%).6"AKUC$M."YQ'XL39[8]S+T"V?37I+ON?QK6&?Z4E8B@0&NZT
M[Y>WAUE_HW/?R^VP0Y!A O9IPOU%A9.GNP9'QX^]=!9\]*F:*Z]2Z!M;$85
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ML>;H"A=*R8JV*65CO^&R7^U#%/ONZ!Q4L B_7;.RSQK(F/=3:D7.)=,3)MF
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M_."GZ9\+%R=?QI[2>0(Y=B],N-JZ_W0WN4/"/EU%;Q(7O%:20+C5P*,B01W
MB]>@'AN(;V$C8L8(5>?PQQ.3""L?>;@_V(R< .B"VGWH(YPAC7_O$=J/3#'N
MB='HU>YJ77@1OL=]K8VZLM>96_DMWBH[&*NC':*?PW^QUKQ8JMDBD(G\=SX:
M<J_S8"<UJA>J-"KSX7K^^;^'DM*BHJ*,"<PM(.F$I]?Q&\$G#QI+B><PSL@#
MVZ[:O7!N-'9F>T.%&9Y%KDBMKOD#22XVD"F,F^H-ZU9.C/_5O*,GK][U47CS
M>*29*"C]HT01MU@.YYD*1_*:,^ @_E+3I)DY#7KZ;<HVD=]]UJHZP-CX'3[L
MT%./KI301"4T3>*3G#&0<!KJ\K]]?8[#7V%8#G\EXM8KK[*!7RT.' !;S@)U
M!GK80#Q.!NLKPH<O4<;Y(T GPC\JIYH^-,]@29(?IM&,;!]T5?#R7'W];ZML
M9D^H677$#0\.3GP_H5/VX-C7(>_=(V>='Q6M%\0='7V\9'8('27D^?.2S:>+
M]6V7W&KK V!/K1:GI+?KF,>=F9*YK)P.-O!8VYD-+$UB\=+8[I.(7]K$W?@F
M+.L4\@N1)HL^P09*TQ%4>0YO:FSB_F;U8@?MV0#?%S:PDOSM_X$B.9500_RG
M$@(X7Y%8?,D^+*<2+B;_L$ZU?OCPGTJ,M:?E^GC6!"_/Z^L'_Y/![ I%SW.H
MU&UF:U2*4PWB@[ 30TJ[ORXXI^=M.[FN^6*OA/K*-/,EOGVDK?Y23GU],G^C
MVLU^>?8[LFF@#YJ,%.@4GE]C W(LY7E45G=+P?3?J#35S+ZCU]^^+6JVB;XC
M>9M.6[&E"'<I+0'9M#J*(15/O["7SY*&#=2!&B44Q3!2G5QGF>^"%#4J@1E.
M*"XAIZ7<4K.O+SKULF#$67A (/&:GY+SSW+JF0CNN6L].5:JTCDGI:1]U'C$
M8N)-G65)D-D2>B@81\:"=NV\# 1*[9_IVP,,I#7U95'3M-L&U.@$?BNW.'H8
MQ3=1<LR#J3#%,L9V7S"+"[A#B^U?X/O0"#J2=FO=N@B33G7ZC2U<9=GE2:=7
M*TYT*6VY;_2-S@:1<.M+#%ETS)09[/5:X70'&9NL,,]2IR%3FWP[)YN,LFS?
M6]^O?\OM>43K=67E\V>B03_30OC!"Z.],W##1FI_D4Q#;+!RT_<:Y4=!=\PT
M;:P7+AK7'U%/5+^7F]GDY3+6F"4>(.L!I>W/"XZ[$7>3OC-M_%#G[?S95<>E
M\.N.8__7,@FP*]2-W#R&P6/IASDVMZK9] /:A$FLQGPJD3=#4&4^VSWI5&%>
M "=()9*H0R_.>HXUA4_K/KT\ 9)4'QUK30]]OEO)];US)[D+L[\EUS(?LC]
M<T$IY05UZW"1F,DU7YCFRT[9'4&O7?[S(CC8!2U["5"_FV60.0*3 QWLI@HN
M3*KB)F8<WF:&!46HH#\LB8H.RFH$I1\;[);BVN1E UUQVDLE3&EN<DWF&YKV
M %Q1(0K/!D2M<U!J_;*NYJ/M\\+GIM=?G3[>=>O^LXA*7+W? S-IANQGAG4
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M<&UT;C S^J!NL=X5>C4;(.CW=8J#=8Q@S*B)<?>H9 !A!%>Z^K?Y7;6[_TQ
M&%U$I%KAB*M?^L/L834+!;_DZ\>?.4_&O"IX%103_A?>4'$F*B!"R.).4(3@
MH-+86[R:]CYYZQ,'J$'<I-'ND(02OAL?FD$KZE,\7"9S&^]A11K>O]#G]Z^V
MEPV3-WOVA2^#A8=N.N'\<0Q=!^ROVI[6T;D?) .B(LXKY %.=-W3K[,$[_#M
MERUTP;CY?6M+MU+"#W.HVLL83 8)*8RZO<K:P2\HO7W[U+'=.*9\VBE TN.:
MM*/>IRO<:A1']^'<1&XSP<[3UQWO'L@\\QPRBMSWLW6#LLV08M[9J_!L*!0)
MZ7<R"6&JGK9*42TX71^/8C;,1;ZD=P] C4,#-_!%R %<T\RZ,<,*,\GB&:_U
MFH%K_@KQ>7%UKG1+9?3"N&>+OYJR34#AWFEE%W -&8&R[<:(4OF2KU.3[YEI
MO/(OM*ME PT!,1;W(Z>I&YZ4YA-=CI_UCW<MO]/(M25!]Z,0)#:07,,\M @3
M#&@]G!> 6V_US?92;FHW?=9V,_.8].VAH="3.O8.IZ'2K*D2:=9^M .G@QU_
MED PPJBGUI--69(!*BKCG5 PUJ8]H\[R52YA-\Q*HH@V*)"11A7D_ZH4#L^E
MXO *$:-,:5,RY,%VE?4M0W=C$B3Y>?R?BN.[+;*8 .3OW\=AB\?G9][[0X%.
M'M"A?P8JP=2E.O>XAJ0<?4)8ZU7 )NO>Z'R,(\),+-4]OVW.[]2L805!SXG>
M*/BQ1NK*?=<.2F/D3F%YI'^+/E[>2RE$4_&)5(-8^4-CI0@#KETVP#@=H*(^
MW<F#F6U>4)BHA0DCI RJ:BZ,C]GD!,/E#-Z$2'FUS(Y?CKMRK,YF#]=IC-Y'
MVXC'"/Q<V$=K3JZYMHJ41VN\_FGTUZ+W3J-12K1"4__D8-*Q0U=;E$3&*R-.
MU-4TU@F SF?;)R-$)/$F<47]=7?H&:ZQ;NH9&[Y?)8>>/.)6"_X_[>%Y;0@G
M]C=$K5-(QN\+>HA<9K*O#+_],6ZQJP!=QR4-ARY'9Y]GJ"F66^U.C6K-QXL
MD8_^%^^+_E>2-'6&J<3%!@Z'D.H81YJQ?V]-!OUV!8-8H@ ;R#6FSNP]FD/L
M&0<:?O=#;&I7_40]LV$#JB9L@(0XH/DBE?F>J;F'90,)G+0\S+1E SY&6VS
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M.FR/6M2+75FLYSN1X&5W"4H3C_UWR*/=MI@W=;556[DLD22.EN*G1>WE,=C
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M;-Y8^1KW!%B!"5E^^M1FZ7T@^%P!V;F?2'C:'<H\O)<3CI#V;T'*=1Z8G5]
M/>TK<#W7D96\OFAOM(JBE&DV2!\]</<X_O'F#XV'D#(S$>I6%U380(K:@D=R
M^[-4)M1N_WKU,\;;Z:&V2KF51&5\Z,F!P &:_?H6E7L KIL\P#("%1?WO#Q:
MM*Y/;R.%"?/N_<Z_*876G].O>_&E.S\"/>SGS!>-^S<$00>R<58%^&$Q2W;P
M5'%I;??B3QU8.PR5_40U_Y(OCWW X>GTAM?>GKCC(XI^=&MP@L9''NA%9*A
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M==8LTNL[Q;[3G&7T&I'#UB%&G!C1+9B,,X(R[)WL)[&6='M][J954<7HJG:
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MFHA1?12<&!"&,3@V4'F%9[20 P4U(V^XD]T68F@Z57A!'GO&X$BK<W/D_:G
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MN?:9+Y>-(6Y<]6[NVX;'_,RY,M!- 8."+\T.OZVM.*T\CT7?@L0T][5#]],
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MK>ZZ!5#R_V+OO:.:ZM9U\65%0421WJ+2NR)()RH"(B)%Z24BT@5$!8*$!%%
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MCT[TC/BU)K&A1G;<2<P99Z0<E-E3FG=1GN^L/(/BT.R H&^?F#^;GDIEXD<
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M1U1NQ)9A7B7-AI.9,AKQ>OOA%?/+:N/% O.\WY^7M%R.88^\-%?T(#*1CN,
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MIVJB-AT/ET>3?IR)+DVT# Q0EAMNBVLFY>+[81;*?C_D6"L)-'HW%$X1A<=
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M=5B%#W.44$C)>>28P'0NUACKDEBI)B-?J3#]=+3ZR;\VYY7/)TJ\&#:)/;;
M=XXHV'<YQ\G8\!NNZZ5*MH+ME94Q_F.=@0>G+@OST&.OS<6(:NFW-QX\^5(#
ML 5/X2$!:D(@^TTP<1+*/+KPY'CAW<HD9,X!RHJIZ3UY!?'(AT<.73OM?YEU
M1DW@YR<.D(W6)P/:%YM0?,N2Z?WWU<9L+SAN?8D=\XG1%#(V/2)B+M_X^+0;
MY\%3Z]EHPNPT>P,D0@E'9AZ;2E;-:5P-34#C>0]8558?%0Y24>6O<3%_K-//
M]E)"?])&8^JN=I=:W-Y'%?EW<&7*T44BM$&-O?==<9\L-C I)3O-SJW&MC)
MF?UJA-:=? !R'4C[!"7H1PVOX@.#ZO+AIZ:M"O>P0;)'-^N\['I7^2TLCGC\
MN.G=4!.PPB-E.NOO'!R,G<R&?*@,*7>19&LDA?3>23:(-FS7->Q=:.<TP\R=
MLKP:/4/J>&0*9<=^/_ED:R]Y!KMC5[0^B6O$'D*8[X6JL!.F\<+!KN56[*:@
M:Y:%,QN[1Y VOPM',#)<*8@G#P@X<MA?U?+$)YDWS[Z&_MC$A>&.J\@1Q:^
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M.NC6# LPUB+6BFB/+;3:CE')8I-]RA'QG47$]*U5$[N8?WPS?'4I!2_N/I)
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MRVNE]3[1NEP#0+Q[AV"CX>U;: .O].3!M%-()KB>5ME7UPTGQ*VI#BO#=>.
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M]QX:-<M,N&/KW\JZR<NRST*C5T(%FC'JJ'1;S:HPKLR+U+,B?-_QW>U[:P^
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M]=]3*/)+.FW.5G;V$]3H,;K40VU'GVI.4QO'>D.>X(4,[I9L=2D#=TE?@H0
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M\9/^[N1:EO_N0IAWY9FSFW;[%?Z9#6<49+4FD"XY%,KA,QI_)/EG4$8';""
MI^^^)%X(84;M)ODXW-@8I\T*.MU>N&R4K].G8WF\FLV0Q,G1[ UOV-\>(X07
MK??!&EMC'F[(_:(-*QO(>O!HYYVUEKE\2:/%8B7SL;K2,2.M^<U\UY<U&WD2
MJLWEQN%>X2P]83ZAW,-"9+WG[J%W3!19GW#V<+!W/0!BJ0Z(1D+K(#X>+ZQ
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MS2BOS,J[E8MS* J.K8ISKJZDY9S0E6T[S%N!S^U2WI$AV];(XH6>HO.B4!4
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M*/T RB.8 !>9'PE[C6B$AR9>R;B6&JTB\D/O0TU?__;FO-$F=X*"DI$DFMO
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MN[6T)H;D!60-,M<ZODSGD$_:]&8A8G&-1&SW6#**=/F#(&&W)T/01R+W/3%
MM@_GT'<$ OMH9S7_F)J(@*N>(=IVZ9X\_SZ*R5B2)3UQ(DH4<+OZ[^BE<@90
MRS3[\ U6E]%.DOX<=WVV!KM W!U5.EP<E*>QZ^?O\[$LBW8SV@^#H>#Q7=R
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M!G'J)9"RS.=A1@4/0I.-7XOJS.IT5<#'C@FYSW=< %PPP'9\F&WI>E R0D5
M&)'6AR.(2!+"E&8(4BX(P4Q$)(O-,E[.P;0\D/@N<.HY0\XA,CV4 #U]\'F,
MS8@%\&?'A,/DCY'0CAP;/9J+^C!&,+QT5\P>MDV@2$N^H<VF4@Y0(3V?M3IT
M?5O6S?MOCYRJ0H*-HG,M;LHZ5P<X]?MU_I 7ZF.K((R\2) (IC&/(/+3 !)!
M B@P9O)_J?!%;)9F.8>=F8WVP $H6A94;N)Q8 +P+1>FR9FS7H!N"F<I6$T3
M/2.^6JO4<P84:Q=@B_BG+>);_L#[TXA;Y(1< .4L<W06,POGEUP ]SH+Y615
MRUP5O>=LL^;7XJI@7,@0L>$?\R>5T-X_^FQ/.E<H$G&4< %CEB50>JD$8A)Q
M2#')<)9X:<(CH_R4$?F93=_ C-+ '3NPY0>\+GOH:APT@T1+O#4S4;.A:.J%
M[6-T\1K&4Z"99YRL9'>593(COFQFR0J85]DDNU7,,TBW%5:%%5^>'TBY7GF>
M%_$X(3#S> A1AA.89IF 7DR81U/J)5C+Y7JU\LPFI*<%.F+Z^:-]Z4_GCZQE
M,E-H37&,LD<'6;?*'NVOM%CVZ*  X^S1X0_8[<_O_VN3-\^_\>:^E"KWQ+NC
MZ>NOA?QNWN>/-UR^.*F)=WP593$F7L@@]84'D8A\2/P@ADGF^R'/<)#Y1ADD
M;<IS!R0M'Q>@'"B#O)#+2'[,=EY])/4VW5GP,5//C@70\0!V3%R +1M@QX>[
M/==8=$?;K3[=17=:8SA>;K+F"YQC3+YP*D,-59_RX>E3_IGCM3H-^A7GA2IN
M6<4XS&B4!I"R.(/(%Q@23T0P(]3#F/N^(,(L?:I#=O;LZ4=>UW]KZ\A^O),T
MZY_ 6I+E*I?:<0+* O!.H>HMJS8FY@2^&8^#B& $4Z&.^ 7U($XC#Y)4^-0/
M"8LC9&ZGW:%K8:(5JBVHX,<.U)]VJ+(N[:'NSSVVETB6PMG$BKM#S\J [\A?
M@ ]_P$]7ZKB^QT\QT=<\NC;@>E([M=TG2'X'LZT'PF&+K?FLG;%^6SX\5OR>
M%[4,M[KB0ZEGU^(6?Y,_=67H-V6ETD&735/E9-.TQ>CE)RE^6302"KGZW57O
M+*V"F,0)#U0"&S&(,$TA"4D$,?6R.,0HH6:I&\?\S7ZT/^)V*/ANK=5/ (_8
M:XO ]QC<NIM2.55Y>"E @[^9&2S7[U+/MGW'-V1F!O=?SEZ=]T6[94O,)=,J
MG33<C>GY!I<OWMT^Z^#J5*A@;#IG M61E77-W:(&>29H7]KNN<B<FX!71>67
M!5-_J.WE":_;(O0V#YP(00(44LA3GT"$0E4>@F*8!93C% =IF)G5A>I073#=
MWE[E4$=C[5]&C)R;99\"U32Y[@@J0]MX!)DY,^D:@CI/H$_1_$YY<PT8CJ?+
M=1ZVLQCO9!CUA!MIO#[@O/H#KS>2W.Z7;3I^E42("E]:"!%['*(D3&&6LABR
MF!'N>2Q.8J-LH [1F>W%CEIW5?8"",D*>%*\F)D'+03UK(-K7,R,PPB2_L#M
MRX;\@]-&N4*_X5JBK/RG[B)<5<E'>9<?)%R4%0?70LBGW)D0$S0<61 MDHL:
M$!,07MH/HV?-S >G;"4]F$^\K/O*/@WU?_70W)FDLH"?WE]KYH->BS2MM&=)
M8Z:9@R .JPZ/<C]Q>":?Z96(LIWNO%YI$04Y*L"@!<<_8)GO?GA<E\^<?^'5
M4TYY>SGF#:Y5;<W#H_3_VU8-TNU_PPLN\N:#Y'3\+ZKZIJCY*DIH&&=)!)F'
M*41A(O?2Q$>0$^IGU N9'Z2K<=N9TUE')XQI?7M/]MV9K.?H[L7C;X +(;<5
MPS2M&_@U$[G+06I_,PNV'(&;_KKKWI;<<W"A,AV@Y])AQM<I/*YRPFZ86C9K
M[!3(5WEEMZM;]B%9K\NOJIG?A[)Z5VY((S;K2TK5';'Z,Z=<.B,RBGF[J2KY
MQ5W%<9J$F1] 00,$$9=V$N,TD)$&S8*,1+XTCR:1AA'UF=V1@2[8$;X 6P:!
M]*%5ETB6-T E*R] SY5A=Q CN/6LX6P@FAD]U_B9M^>PP<%5WPTCVLLVU+"!
MY56G#*M%S$Q2VX7I'2_P.K^]YQ5^Y)LFI[5T3(;+7A'RY?\)3"D7$*5A ''*
M0IBE2<21+WP:^3K6YQ2AV7,;BC(8DS9HF#8%T+2]<"FV:>KBE<3J>.=TO&3X
M_=#O#><(!KL^<$?@<-3Y34.TR2YO4\\OU]%-0XJ][FTZG[<P1Q\VS:;BG\MG
MO%9'_[OJK-OR#>\,'V?7Q1>LTL W5<DVM%GYB%(<RZ Q1BR&*(H3F)+0AU$0
M(YP@SFB8:=LI&PYF-F =,\^JQJ?G1:4@"5>=UEIV#/39"F -.S<W;&8&L.,&
M;-D956J"VU)&@&!@"5P70#$%K@7HV9H;30.S.3>J=O:T1[?:HGOTBZGJT6K<
M'4,^=NRY:KAY#C23]MAJX>4,]3ER[UGPLQ:R,.U?;JX^?;[\S\O>>< TRR(/
M(XB3P(?R'1#YMY##+(Y9)DCDA9AK&^W]M><^6^^)&=B)%[)KV%-[B0Q39ST=
M&]_PA50&=LU>.CN+I2^EF1$Z+,>D>7GQR'*&XS"O>R;AR$=L>[/0BN.:O^/=
MGU?%ZP!VY84^XIGO0Y^%TG6+$VD I.\&>1KZH1<1$B!BEO[7(3M[<G^;FZFV
M-$W;AVB IY>N<@:(Y;75CBKX<:#_$\@+<"!YY;)UB+[$SCJ':)!<N'&(/@BO
M^X88/.ONNLSV>@'!., X#F&" PI1(.T#85$",Y0F212(A/C^JMF.=;"ZB&!U
M?>/(P(H3US=>78JAY5TQX[48!]<TON?UC,5N92QX&^.O<PO#YO;%F;<N^M*#
MSYLU]ST2^9=5=<G*1[FK?ECC.X-2F2,K+% WHR@#11KZXY-ET'-A5%)S#(=I
M;74'@9F>:D@/_E0LN*O".2&C;4G.L667K,\Y(=J+8IU3G[;;>O\79W=Y<=>V
MPE'];N[SQW>EZF"Z"D/DT0BI<)PS=> 3P8R+%"9!ZD5)*-(LT>HM>I+2S!K;
MTP5CPN#/CK1AM?MQL/0V5R<0F&FLG?3&.^I)R1QMI\?I++J7GA3WY49Z^@&+
M)-J;39T7O*[?E@]$]:B2"W_>NI-73!KE7.1XVSCFDLK=O.+LLF ?Y:_S=3<Z
MH:XW#YSUI\?=)[<3%CXJA[_[W2J)L0S L0=Y@*4]R B!*4XPQ(D7<LY\+\1,
M.T>W*.LS&YC=")1U&]P:#S%;]CUJY!O_LF_'S/8-8H"1'!=@)PD8BS(T&QN$
M::\"C<0!O3S;VIG^@8O1")Q6JO[W?]GW;Y"9_<M^#^P2OW_-[X-9DOF[O)+)
M'/:R'"V7(O\N2.]EX+\/!W9QQ/86S;N\INNRWD@]W V.Y#Y.42 H%)1R5;I*
M(*$A4_.3TH3C.(MY8-;J9I*>B2FQZG&CJ(.6//A-0BB)M\-MS**):<CT(@IG
M,)CMK"/Y1X3!GSIC2(UC"RT9'<47T[06C3&TQ'X99^@]9)ZQN_R**W;[<*>6
M_2B-TE7#'TZYDD>?F^][V9(#MZIE[]W^-U,1!RUU1ZFI2<FLLE*'5UPL(34I
MT#@7-?U!L^]6734'FK)Q_@D_\#ZU$C!$LT U)PU(IOX30)+&,@S%/L]8*./.
M3*OP^#2IF>/$<=M 1=0P":4!U;0^N@7 ].375'9M9=07:VJ/D*N,]@?YTTXW
M-0@LHJ3Z@@[::O"$1?KI4B(4JDE^'TM<]&4_ :&$D(! +U.]KY@(5-LK B/$
M& ^BF)%$_Y;  0(SJZ@B"-KAD(JD00A_" N-1,N9$IKIX+YP-C5>AZ0T2"><
M*:U=T*_Y2LVB\ E))F/E0\\M%]%.<+T7=TY]SBXZ',Z,KPOI- Q33E2G\_W6
MYBN2B23A 8>,8C4YG88P"UD,DS2-2,JQC!:-NB]ITIW9JK0U#'O%SWE9J7J'
MBC_E_"MX*C?TGE=MUSNS$%(75[U@<@:TS"S4J-A#X37BHIL4\6(PA+L0TU!R
M1\&F+M5%PTY#*%X&H*:/V]F3=I(59[6ZEJUJTB\+]AM6<UV:YVOQ&Z[^R=M.
M<KO"E15!<>HE60:YR#!$'J(0AR2!490&TBM!8<B160;*F(?9LU(#1T"]U=;:
MU&W6^J%C2R6MI1H];%FSKC,SAU_/ ,T*J9DIVL>RO12DH!S844#N&!H5KKFS
M2=9@.+).YO07M5/6\+RT6/8+V;8;7LL?RZKK,[4KH*HEX;;QY>%_OI5_JS%M
MJP=V&;@LCFE"A723/"8@2KP88A(+B%5S\S@B'".M0_DYF)O9J]IC%> 1KZVF
M%F4!Z;&/@&;$L&F'88>O3\\L?J^78F8Q]]_'N#)0O8[QS]>-]'9!<R^#T/V'
MW&9IYX3/61=AAZPMW$+8/:BO^P?/0,-VL.D3+S:\:P-4M-.J_YXW]V\W=5,^
MC :2<\8IRK(("H]ZJH,9@23,0D@H4K?2L?R[9S;!5(ONS*:VYZ+SA08^P%?)
M"!@X,1[F;HJLGJF< 2\S*^@(*HM1HT:".YLIJD=UX>&A1E"\GA)J]KB=05&'
MM&TB<]O<IVXGDM:\>N+UK5ST\EM>KZ*(^PB1 $8T22!"&8*$APCZJ9^B4,0I
M84;^G1[9F<W)E_=OP="_^0+X ?2R"[#E;->VJNYG^';, <6=U!W)GZ&)T<1:
MS\*X1]#,P,P(GK'1,</"D<W1)+JHR3$#XJ7%,7S:,F4FOT6CH^*$)B0040:#
M*(N[:NZ,11A2D1"/>'XHO143P[*__,P&1!&S.4(_@H5F<LI:0L/,D[YPYCFE
M@S*X2ACM+[YL-NB@8*]2/8<_9:=0^T64K,MK[T)[CH)8#?&#(:$$(M_'D+!8
M1@)>&*E#KBCQC7;N:7(S*]R+DF:VG<RM$[#;H*>GDNXP,5/1L^ P5EH]*1TI
M\0EBBRJUGN OE5SS*3.E;QL>5,^KW[^L!!,Q"J(0(HR$=,D3"C.Y:T*YG4I'
M/45^$&$=Q=XM.;/R_O[SE^-]MHY).:V =KR;*=GOGZYNW[\#7VXO;]]_.5^;
M7K,\4:39?[A3F/Z'G:Z,EEI$'UZS/GSG#_R+W6;V=Y[?W3=26YZD\MSQ3QM5
M]/$N7V_D[]K>V/7UIJD;&5)(Q;ID_]ATQ7Q2&9(D##B&+,$^1*H_;*;BTS1*
M"9'A:BJ047,.2SZ,-,B\;T?+@$I0/Y:-NG6!UX"6#P^JI*/ER6SKL\5:;T]<
M $$S/1X8 CU'H&-)G:!V_( 10Q>@9_4"['ASMY6>"8ZC/=:6BT4WWS.A>KDK
MG[N<I8^N3IHZ#T =&/2=W:, )2'R&&1(59DQRN3FG4A//0@08R%C-&1FM2 '
MZ<Q>[[$KJNZ2/65[KF9R_7@:)TTG_%S9#7WO5LCAKN6.HD-_>TH@5V[V01K+
M>M=38KYRJB<_;*><K7]>;P]X LRIGS $!?,"Z4ID(<0^5?7C$:)9EDH]-<I(
M[2\_LX_=$;,^!'L!A9[BV0MHIG'ZLAFKVF$1'.G8B\475:[#@KW4JB.?LKR!
MFQ=YPS^J1KTOJRU_K50#..11CQ'FP<SG&40)BZ6O'GO0XSA)TB#U&#6:'W.*
MX,PJUY&'+?W7M<$7H.7!\$;N*0CU%-,E,&:J>AXFYC=S-05U=3GW%+EE[^=J
M"O_JBJ[N<[8'RU7;$V"8FOU>QJO-\^XN[.Z&N1?Y"(?8@SB-E#U($DAPYD,1
M4B_(6!IGQ- -UJ:]J&N<%V!@;#NF'K2L&1<^ZX.K9REF <S,9!R!YGET?7JF
M>_W&PCL[0-:EN_ 9LB$<KX^131>PG%HGUV5]1FQ7%3TZ3PUCZ;&K>N24H 2B
MV"/R;W$"$^PA/TXB$3*M$2RZ!&=V-,;D]UK4GG$"?1)#/?OA$ADSLW$F*.;S
MY30E=352[A2Y9:?(:0K_:G"<[G.6;;O;4;5R[6Y\[2W^]ADW7!7-Y<4F+^[Z
MD[BRJ/M_4MV+"IJO\Z[:90AWL6#<1X3 V(LCB##FD$1,AO]A$/JQ\!)$L9DC
MXHBSV=V4?;* \.8KYP5H[CE0IW9 </DV\!K4#6XV4D&>VQ'!DO7N-A(?Q-S^
MVK!?N*,7J&>LOL-+,;-I6P9!/X]9#0A6C(!]3BZ&"5*SY$0<P^2JC[DCKI9M
M>>X6RE?=T1TO;V>%/_'F+:[O;ZKR*6><O7G^O5:1Y;8,XE*QV-W"C)&?"9$R
M2%&(($)^ K&, *''TS2*$?<\E)F<UNJ3GOF 5@U6H)(3(-;E5S5<K.4'D&?P
MXT;5Y^3%3Z#<%NW@+5MFYM( :3V+. ]^9D9/0:>8 #=CU'X?4-N5.EV>1LW8
MUID#X,B<&1!>U&*9 _+2*%FL,+?=V?H)!$<9YFD,DRA5HUP8A=BC,8S2 /%(
M.GM9&IH$AN8LS!PJOMW:H/;^SR&3\[>Y;(ZA-S8O=K/;H%E<+WM,%C=+W\>A
ML@?(WDPY<I,D);EV\ZQJP)O+@JF^:(\J07S)6-NDI%YE(2<!#RF,:4 @BK,(
M9HF'((U"7W"2H,RL9/LTR9G-T<" #%@4"VW,N&5"55CU;!AW_SB%I)X)<HN/
MF<DY&QJ;?AZ:TKIKX'&*X-(=.S0!.-"B0_=).^,P7*B[%I>4;AXV:S7EL:UY
M>5L^/%;\GA?U-LY3[8UN5:)]=]H3>TE$XTQ9#H8A"GD(TS3E4' >>1F-4Q()
M$\MQ)C\SFY6!.U7".>*O[^NPQ^&023DQP6V6EZ)GA!:$VLQ"6:,,_FQ9!+,<
MVCF"RY&).Y>;1>V?(^A>&D=7RUIT@+V]_G#U[OVGM^_[7J!1F'""O13&@H40
M):F .(UE?)=A@GQ"/(&UVC<>6GQFF[:E9M .]:7XTP;G7*',K,>6D$V?UY>"
M&?1X/4- N_ZNIU^<66O7(P),MG5]^<QR+5V/<+O7SO789RQ=)76.R-D[3II!
MZ^. "1H%D!#"5599.C^"J":+/DFR("$X,ZHK?$5A;G>FHP<404,/Y146FC['
M.1(:>A$CX1P.O#\IB:L-_M7ZRV[9Q\1[M0D?_:"EEC5R:[XOU_*)NNO@WN[H
MJ]BG)$P#!'T_E#MLFB&8^B*%01IQ/T T#A.QZJ?4WQJHW&%R6E_+K/M:OB*J
M_15M21DJWA%X--7O#&GME'!$\/\!'<D+,"VWN2I.2^5*(8]0658MIT5]I9PG
M/F[A^;[+ZZ;*B:K)N/U:]L9?<$]$R.,P$*JGBD !S-(X@)BP$(5^0!"+M-W?
M0Q1FW@A')(&D:> P'H1#PQT^5T@S-7PAGXUG?%!0 _?X7('M?.2QX,W7\G@W
M #-7>4J827_YX(/+.<U3?.]YSI,?M+ST5JIY?JI"Y(X7]/FJ$&7UT)>#E)OF
M8][D=^V/O^%&J?#V5"\*0Q;BR(/2MC#I92/178\+>"@H3H(P"8S&<=LR,K,-
M4FR!$5\78,09P(HUL.,-],S97[RS?1UZGL82()O9P/GP-;_\=R8XKJX)VK*Q
M[(7",\%Z=?7PW/4L2X8?'M?E,^=?>/644][>_'^CVO2H7"4OZFT;/(J[P1&[
M@:<WO,I+^;EZW"<JX)@)%".(_$1 E&%I%07V8.QCP2E)48*-*DH<\S=WYD*Q
M!TG;@NH&/[?-M4>-D"_ ^V^*Z7YX\5O\F#=XK7B] )</JG7,&0V\7+])/8/Z
M'=^/8<C7OIHW<[\:\^KB>0!T567LF+MEJXWG@?95U?%,9&PF &[[M-2WY4U5
ML@UM^O;)0_?2SWS=UO/<EFJV1GU5W*CA5__!<56OPE#=! LX3'#$I067_TE#
M^2-/>)3Y"?)92H9DED;$?!XW%KDN,V,]8@\,?(#;$K0L@)8'DU%\YT&O$9LO
M *?=S;,1CBU\+6=@:+R^[7@\QKAE3WJZWP=LDQ&)BX%NETD8@]^4JM*^!;_J
MP:\&\*L!?/FA;A!57G1S[\"SXM15"L(-7M,S&\\CL>!X1R=8[$^"=+.DV=8R
MGC'=S:W=U?1HN/(3C\_LCN]-'^](ZQF9*8FG+;4C80TM\&LY';<(T!#KK!'K
M+]=<?,CZ$:$.C5D_]E%SI;JM<-M=KZK>R("?M75 NAIUZ-FY2W(ZDN.PJ;Y0
M-P,D_?PI9QN\UE>O@[*?UJUSQ393+ V)^^(^1SHV)9Z5@AU<<#'MFA)GK%J3
MG[,=$%4WE=P=-Y5<6$58NPD.[7"14*0B4A>>>$ 11 D/(6$9@RS)&/)8F/I$
MZVQ0D][,JKE'W7XPRRG0]')"#J$P4U=S%"S&.FG)YFR<TS2UA<<X:8G^>GR3
MWF.63?9P7JEQ+?S-\V\<JZXZRDA_J/A_;50:O?W6BHP1E+$ IJ&Z#( "I'IB
M>]!',>%^C 1%6@WB#6C.K.XCLF!+UTKC=?#3TWK'J)AIOA4@YNWU]$5TU6%/
M@^*R3?;T(7C59\_@43-CP'B^ZIIKO6V[P+?U1:^:6*\8(QDG,8?8"QA$+ VD
M'?!BF":AET0!)=C3:H.E1VYF$] WA>LX "T+%P?ZM^M9 TT IPV!>UC,;,"Y
MB&B; S-!)]QVN5!G!.1?=KJON?PB:F\FZJ#QAD^9!\Y719W+3_9APTVYSFG.
M:S4X_*/F^:7F*O-]6WOB8 @Q!_+M\6,[ IUMU#?7[:FCH=A6(:?.^HM%H ;"
MC@-2D\<LSNFZ*?:M6OQ>Y$W=URVFA&)?T!!ZGAI1%J4<9D&00NZG:8+C)!2^
MI]=W;8**R5?:JH=:1Q;4BB[8*,(&)SM'D-$X'CM?6D.7LQ.S)0A:BC;UJT?D
M-3BA.E]NNY.GUZ_9U1G2M$239T-''EWNS&>:][VSG!,?M8N'?Z_YM7A?-_D#
M;GB]"J.,IU&0P0!C:5%2G\$T\D+H9VE"$ T)XX8MI?<)S&Y,)#EUWYH/!,VB
MVQ=HZ 6R]A*:&9!>M"VEB\X'D&%K_^<L]\4/2^<H7'VQ^**1Z6'!7@:A1SYE
ML8=_X45>5I]*N<RMA(_?E'G1?,F_W7XM/^1/O.](^6[#;[_*/Y^'_PYW%#*>
M4<&Y@('<YZ5FQ@QF"'O0IQ31S$O2)$BT[Z:<Q\O,D6KX<QQ$_P-T/(*62< V
M',AO3V"P4YZ)MX8'L1R*9H9B#[F6,]"R!B1O[;T9Q=VV!:KD#W2L[?ZPNEIS
M)N &+LQRP-NY.HN\ #,?R0UDD[[4F226\[G<8+'GFSE:TJ+.AOWCME2%HY</
MC79QS>B9N2MJMO5'JI!L7. ZE$D;%-B,13V=K;&5TLS6'A?PE'QFM30'A+$K
MH!DOM%S5S 'V]TIE#OV[N3*,DH6J9EH&$,^&JG%\A9D5Q>2;8R+W:3UQ([*9
MUHQH@H'H?,IS6D(K59I8=C'%.BW:6,TT/FVQ ]W=-6_OB[N;HB[^P.NKXLOF
MX:%;N&Z*6[+^4%:7CVNR_H^J]_1TMRG3A>?>R^[NJO;> 'A[KZJ[5$7TC2J8
MEK:_/:=\V>CM#2^XR!L@I"]XN5Y+AZ^HU7=;=4%4Y>V/9=6T'7*!D@R_5(&V
MJLE@>S1^#QI[Z)ROP'"C_1[H._3"SX+3;JLWIK:</V +Q)[38+V(;;7 EP>\
M7K_9U'G!ZWK%$L_#G&8P2WT*419[,$,I@LS'G# OQ5SOZNJ1]9>I!VA)@H&F
MZ>G_/B#3]L2!F&86PTQ"B]/\@W*<<7R_O]["Y_4'A7E]0'_X8^9>P]OR"U]S
M*BUP7]MCX*0?>G8!]QP7\LO4$P8]96-7_:#<IS?B<T4VTQQ;:8TVPRF1K/:[
M@PLNMJ5-B3/>M28_9W$E!!/I[U0?\[IYT3U9]U[(L05FUJB>+E"$+TQ]W>-2
MGU8E)P*;Z=-8UEF:.VO)97<?Y.BJRUT*.278WLV0DQ^V.+K;]EEI5'T:KVC>
MM7KXG-_=-_6GC7(NKT5_O;)>D53XOL\C-3[5@PA1#Z8(^Y (Y#'L\]2/]+LH
MF]&>?1L<F '[W(".G0O0,02NQ7"OVZ28QQ#G:5V?&3W3'?6O!)S!4=M\ -H=
MK3D%TNP(S0Z*R2,SPR67.R*SDW7O2,QRB3.O]5P5CYNF_LB?^#H<NGHB/^1!
MG,(DBB*(>" -<ZP:72<1"YG'$R]%9C5-$]1F+W#ZDM\5N<BIFGGS>U$2=3&J
M'_^N> $_MMR T'!6QQ2 TW;6,2AF=E41[=)_%ST %Z '8(9FV1HBNK['<X#2
M][F_<USDH_=V)AZQ+%8L*MX9D5]Q7J@.>-?%.U[E3U@-<:U7./1C[J4$ABB3
M^LUP G$:$HBSA&0B":.4&$WQ.4%O9F=K1QTH\L-PF+( (QX,ZQM/ *BGZ0YA
M,=/V\Q Q+WW4D]-5+>0):LL61^J)_JI:4O,QJQAL+?]>5NU*H_X*RLU0?2VO
M'Y4?^?Z;<C1J_H'S&YRS59;Y) KB",:<48B\",$LY3'TU9Q G"0"^YY!*&;!
MPLQ&HJ,)>$\4",[!HR1K%#S8(*L5?,V,EVD,-F)GOY?CP!'HX1QX A]4Z=X2
M<!J%9#/#:AN9S0"O:81V!C(G C6;E9>,U\Z0_$78=LY*%H;]ZK?/EQ_?7?6Q
M1AQ&$<E2"B,1)1"AQ(.$^+X,VR*$, _CU-<O<]];>F9#W-,R,!3[@FO84VMQ
MS.QD3\:F!'Q?) .;9BV:G:W2%M',_AR48M*N[#^QG+TXR.F>'3C\"0O][LZ-
M_YZSH0H:WW'5T[9M0OA!LO4;_D=9C28UU"N>IH+'G*C++5+U419!XD<!3%DB
MHC# B9]H]3VSI#^SI=BQH4J6^LZ;=3=P_D'Q MB(&0/MLT!:P^K,BY^9:>I+
M.A0S8 3CM=AVCU4,@98C\&XQ% T,W;QHVEG#'M6O"M7'0U_.8]]-5Q=X[4&9
M-*X6RRYG@>UEWC/39RQCEX-[6W&6-Q\PS=>2\+OR00;Z*Y^F41JG#,8888@8
M#R&F<0*]P(L\Q-+,0UHGGE-$YC[:;$F"@2;XLZ-JV![K(#IZ6;5S938,ADW%
M-<Z>3<GC*&5VD,2B>;(I(5\FQR8_:Z>,:EQE.[DR;W)>#UTQ"]8-R=O]RX>G
M3WG;2F^8?I1$<>8E7@PC/^ 0Q81"S+,,AEF(A9?Y/O&,1K[:,C*S4G<M$]KC
M,=YR NHM*V:*;8VTGO(O@9^9@6CGS>X(7PR-AR[:AD,=7WO__N$/^.E*Y7I4
MC=,,TZ;.A<B1S;%F8U&[="Y8+VW7V>O9)(:*)][WKK\J_L!5KO3XJI!F0/ZZ
M]7LDP=UX/1$&(<<8<L:0M&C2&4G# ,$4^Z% R$>$ZF?ZC4C/G5C:\:(NJPS<
M@($=,/!C/$// F6=+-5<V!EFL?Y*L)EDPN:"SS)3-H+Q:@I&5[&@E?S3.3:C
M%1?,P=E(NI^CLUK!SM7\M2S9UWR]7D5!0A(:2H<Q#BA$*$TA]F2LYPM&XDB(
MA'EJ@GFCYS@.RVI]D[?3FQHS$SH0,7/YMA(S@BEBC,,X\3)UB!Q 0@(,I9,<
M95D4T2 TFE%H)+/]QG&FU(AY68#C3$VI53$]2F 6B@#B*/4PSF@6Q/[JL1U(
M]J7!U1SONY?])1%C!"X X7=Y4:CKYJ4 W7J6L,01"006\GN0D0@B(K_^)!8A
MQ!G._)2)+!.DA^5]<6+JV?F@#"0L(.'2C3\7#+W@QD8\L\W^Y%?=.-IXR;.C
MZ&&[[*+1P$MA7GKWK_[=;HMHN]!R5JNTHYHE=2VNFWM>C7:IE1_&" 4)APGU
M$X@X"V'F$PXY23!! M$D8":F]#3)N0]S>@:Z%'DW*4UJE=IR&VESJ/0]MZR8
M*9D&FGKJYQ8C,\7<AT=15^BT],&5!C+&>JLOK".-UB"XJ*[K _#2"A@\:6D?
MNC&ZW<0YSF[+6_SM[WES?U^N53KA0UD=GH6Z2N(D15&FVI *(ET13^VY7$@C
M0I+$]^)8$*0W9_1<5LS<5(LAHP-CW0!&SE17J;RN-UB^_,ZPJ/:YJJ=%/9H=
M3<>=*_#>\"GI+!O:'=NWI&F-YD3>SD9U'*E+J-_ B)5^&,#Q&= .K=:9H+BR
M9;9L+&OAS@3KE=T[=STS:UA7S:IMXOR9/\IOY+U<5EK>NPH_7&Z:^[)2U=/=
M/7M_%1 9=F+JP3B,9; A(PR(B4@ABW"2"9J**$4Z[I(!S9G]I:[]^8X-T/-Q
M 7:<&#55,(%SVD+-!)*9,6J_:B?P.=DZ4=O^6(@\96KD<B,S(W_:F1@32HM8
M$PO1!\-A\ZC%^4?K?:D.5UC1*!C+ZZYGVU!>Z6.:T3"%GA\+B"*2PA0)!@6A
M,0[B2,956A,)=8C-;!6Z@& @WYXP;ADP2,J?0DSC],(A#F:*/P6!32GNR6^/
M_I&$0TSL#B'.P\;L_$%3V,D3AU-K+'?&H"G-WJF"[C-V0: *)PN)__,[N>RZ
M5!UP=MU;@CC#S&<>#%F60A3@ *89#B&)6!BAR ^P,!P_,47.Y(MK=5=[2]PL
M IN$2"_*<B6VF0W;4@4[LHX'BYL(Z"@JFB2U:.2C(_3+Z$;K&3M5?O_PN"Z?
M.6]]H>Y>4+^YT#2*8M]'$-.4J?(R#V8\BB$A3. HB;U$KQCC)*6Y_9*6E&'B
M]C@L>KKK1%B+J.-XHN-BN+CGOJ7"26$=*?%Q.HMJ\$EQ7ZKOZ0=<5(Y>/N%\
MK8H'5+(#KWG;.FO%&:-"4 ()33E$.)0;L4>E4GO"8U["PB0Q.JS1H#EW]H'>
M<[;I#B&V]*$H*ZA.;D;EC'V7-L/J;QU0]6R 8ZC,K,&KTL]]J-I3G%/XG%G>
M.2GQ+)6<ARE^QZ+-20BFZS.G'[4U&(\5IWD7+I+ IPFE*?0C/U9^NB\M0Q)!
M'/M"F@DO\[G1?8_QXC.;@#$I4^T>(:"KQG9RF>JKAD@6"OF:=V>:-UIZ815[
M+=1K73KP&4L/N2V/_HTW]R7;G:-^*=?L+:ZJ9U5#W>8)5Y@2X:74AY&JK$,I
M9Q#[&84AELH5DRB,0VKD,&L2GEG9^FL"'1^C _\A@PT41X;>M2ZDFL[V#$"9
M:>]Y&)D[W(8"N_*_=<DNZXX;@O'*.S=]_OS"JN&T4F[M;:+N0U[@@BI*M,F?
MVNU_)0@C L4A#((PDM8$$]5[5L TR +! A)&9M<Q#>DO<5A@7TNE Z">[9@1
M%C,3LE]E]>.VAD1ZZS_UQ59;?L".H7FJK@R0F*$$2X?Z=ZO',H!FJCC+9!D[
M@S/$R=?BLFAREJ\WJAO0+L!X_XVN-XPSQ8TJB=AT!SK7XCVN5)5U?<.[HHDN
MYHU%FI* $$@]X4%$1";M$2,P0Q[*B(=$PK3*&.9A;\F<PXC=<;9A8+A3X!'+
M[<#GGFG5\:(K2;++3CA^J7HV\ON]*C,3>NC-/%_L7LS[FR_@+5Y3-5RJS82Z
MSG_, Y0C"^N8N44-\#S OK3/,U&Q[-$A"53\7@T\>^)7!2T?^"?>7(M;_&T5
M4A%'F2]@B)0M3F,*,Q;[D/BACVC@>P3C55,V>*UGBR=H&1G6+45ME=VC#/*6
M-/AQW;:$Q4W7[Z2]J]B4X$U>WO%"1E?T^#U%8RCU+* C@,S,V3XV5STV;;O<
M"R#)JWU%,B!CS!= W<BOH,O*5@WI734#F:"T;$^0TR*_:@VB\8A%!=F'S0-6
M]U#ZX\<0>8F/$@2YD+X8BBF&6>R%,*%ID*84!9H#ZPZL/;,/-1 SJ']Z(?NT
MKIXID9EN#G1LJKI>2&50Q&4OG5W-EKZ49O59A^68+,=Z\<ARU5>'>=TKMCKR
M$<MTLQ!<A8"]"9'6X[-<6HWZ+533H<[C4!'C;FIYO0J]-$(DS*"(U5E.1$*8
M(A+!. H(H\*C6>B;U5S9L#%[+99%UL@*3LVT\\P0&::@!VX&3T'=A%$,@7V.
M+OIDTHBIBZ$/H\,,]1G8N,I6V["P;.;Z#)!>9;'/6<O.4EU^Q16[E<]>?LOK
M59IX GG"AR$7JG</P:K&)(-AR"@F@J;4]TWR0WNKS^R:M+2 (@;^5.0,DS+[
M0.@9#VOQ#%,BVI(9J_A!"1SI[O[:BRKE0;%>:MOA#UEX]Y?ASW[TA1=Y67TJ
M&UZS#?\-/_NJY6;O'@8D8&F893 -*8=(9"',!)-Z%5#&@R#F<::5=]4C-[.B
M*?+>_P =!Z!E 4@>@&0"^!= \6'@2)\&3R-B< J)F7(JRM-@V(07IU$QB#B<
MHF,7A+A R2P\T19Z,F(YO<IR08RV1'MQC?Y3%I;OS7]<7_]Q]9_]5Y+C+$H"
MED 6)"%$J8<AX5$(&8^]U N3T"=$V\KM+3VS1>MI&>CGON :%LI:'#-KU).Q
M,3G[(AF8%VO1[$S)J9=E9B8.,C]I$O:?6$[]#W*ZI^J'/W'F[;"_E]4_KXKV
MU+NNVUSH9ZY&7?)ZE?&0!&G@011B E&41I PU1PDE=J>$B*#"6)Y2>PXU=GS
M$XJT:E3YV!&WO#$V 9M>;.$8"C,SLB5^ 08X>@:VAQ8#$S/<)#LML>L+91,4
MO\^]LM,0'+U>IO&H=?';(Z^:YQOY56GZEL./RGY+(JO$CRB+F =QR*4M2'T,
MTP@',,FB+$@]&?(@P]F^4^1F-P(#\0OPJ,BW-YWYP(!-+Y\I[#R:^0('&"8H
M$6I,O>H![P>0HH!Y299XC&'#*D$GR-EU8>MQN]GB]GZ'VR>GN.D94E=HF%G0
M,X"P*?H[*:&["K_CI)8NYSLI](':O=//V!G'CSDF:IR$*EH-8T28D(&/)]1!
MCD\CF 6(P0P+=>";Q%1=U].O[!BM/7,EQZUZ!*QW],RT=0R"GG):BF:FBQ\U
MY#%6N@.<.]*Q\<J+JM0!D5YJT*&/G%O9^A;7]U(9U1]*(9_P6IUKM.57NVX+
M4<")AZD'PQ@G$!%"89H*)G]4A:LLP)1Q,__"C('9/8XOFX<'7#TKUUIT9<12
M$W%=\Z8&7_/F'CS@9JA2E9]92^<.-/>X )D'&'Y6O?7["DGU:>FP4RE.N^VT
M?^$[P6R+5;7>DY[:SX>]F648EP2_'?!J_S)BIB\Q!;.TS[!#PGDUJ1;Q[U0M
M:@+,\6I0HU4L4J&C%.L'^76[*?.B^4]>E1_RIV$BW+L-O_TJ_WSN_JO^I<^V
M"<0)HD$(.4NE=6.IC  PC:'O4Y8*(HU<HG7K\&Q.9@X/T,_>P:,C^<V,#%*5
M9V&MD:Q="D%#8S5&3?$%6L: X@PH!H8*$""9 QU?PQ_M/ULDA<]"VB"'O!3B
M=BGG^9$W2UJ[0&LRQWT6@>52XBYPV,N@.UG0^JK 0UFTW65N<'5=?6E4#]P_
M\'K#AQL)JY@G'*LT>\PR#R+!,,P$X1!' 4:<,H:\P,P)UJ ZN^?;\= UU+X
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MIZ=K>X)/*Y>M,(8':DH*? '>=>>+YRO+(;8GM&/X>*<BPT\[/=E;;A'%."3
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M_ORQ[)JIO2L?U#UO$F61'V0!3%'$((JC!&+DJ5GS45M[F,1"_Z+K81HS:^]
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M$\C0\K1=V&9JMS9?:[7OUD9-HV6:H\:Q\CLF(7[NDP&M&JYB$8DPBU.(0Y1
M))4$8HX]F,8TY&'$6&+FI1RD,K/V;&E>@"$KU6U;AL5.AQ'24ZVSY393,@N1
M+9JI3HCDK#_J(1H+MSR=$/-U%].I#ULDS/J)M->B'XK3[P1]AY+ZJJ#K#5.;
MZ]NRJ,MUSI1;/6ZN5K]P8M,P]@CU(A@P=0R2AG+_B]59B"=XC+B?XE"KC'$6
M[N8^MVVGH??#S]48WXX]-<^7CA@$I.\,6+<L&N1UG+\MC5S;]WP'ACM_/UWY
M6H!A<%;/[-!JJ08#N_(O8,PPV.ML69O$'0N\)H,\W/=\778)N=%0[*95H,?^
MY57]RS-5J)\=I>/F@G(R+^><Z'()NKGPVLO4S4;$;/.LJV;U&_Z6/VP>AB+
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MZ3_;7;G[3,79*A"1GU 2PR!(L2IO)Y!@SX.$8DZ]A":(:A4%67,PL]IV]%7
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MSW)3ET]/FZ7LTKXC&J=%03,L,Y:;<_)&=T.<,J94R%22$_LF 6]'GUI==^0
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MX0XJJU@\[K:S,#6+Z@U?M[L8/=]-IAV+6*:4:3G"8H))$D2X2-,<%WH_$9*
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M=IX'GW:L#E,]/57+;^N*_\^V6FY2\#PA(4Y3%IC<):V;-(MQJ/(X+O*\H(1
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MXVAB*_R61:1Y-*K13Q/8'GWV^-QV OKA4U/W&]I"Q=]\61CQN6<!9N#_W2<
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MB,_&<6:Q;3GK_>W+L[D3KQ??3U+O;7I_N,]5D:J *BPSQ;2!""),4[W!B&A
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M0F&<!P$F+-6V+(T)IFD4D2*/LEQ:7<:U(3:Q"6N(H75+'CT8^DW;'/V[+0<
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MY,[T4;PG*LXI#[C)K*.8Z-T 9H4(,%52D% 5!8^MJIU:T)HZN-A1-B>0;0-
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M+(%GS"ZK<;:N4,<%NMUAUC!RU8#V810TY_)F]O)[KFQF0?B[%#6S!^1</3/
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M0I3TF,3$.FH('GR5AB8P'G "%SNEO$Q:F$X"!74HHW1.%F]5DXX(S%PDZ9R
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MB?7SSMPG:EA"6Y[0EJEVG]RPA0U?J&,,<"7 !?%A;9\#1Y@M<('0Y7J%"Y:
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M)#(5 C,2:4PD2S E@N%"Y%$J2IDK!IJ@>YK4R/;*$D9[E-$?EC9JB ,/#@P
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M2UFLFKD@UW/9G %6\EH8MMI,):^;IE*.:N^\WG@*O<="8TH[)M"."_3'AH^
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MBY+D-#811%P(3#BAF$4DP47!::2R-,U8!HL@/#D9/90P+TD!^VC[8NKV!9\
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MB8SNBW;S&EIJ75$?L%O)2V3<=/8R:6&*VHK9$AO!'STM2JA^(R\)3-M@Y*2
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M*36.\]B.Z-(%YIQ&N"CCM)"**\9!9TO/T!O9==E2[\<^VYD3T*[1P\BYV8B
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MY;.=2VJ30TOU3<WKZKMJ.U5VO6]*37.>9PRG*F681$F)69E3G'&>%5$<Q;0
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MA'*AW(^:N% <VTMASTTR].U:V9/]/0[0E@5 -..$H4/0%QH9F#'IJ*.._&3
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M;P1 *R,!LCOQ<BN#;??'%5KOB8&^=W+8':9&$*0Z20!9BG$?OT/>YZ=YI-#
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M$"2G64[R-$V=<SSGJ(UL$QKR:$<?]1@ I"/.8N:0M0F)!$S[AT#PF31P%@U
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MBI!D15ID5@E(!R-/; )Z6O89?KMB9Q&AD8PC++,LP"2* DQ#91K91$6:Y4%
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M01UNH!Q,?7:AB;3MQ[7JF5),RPHUACQZKC2L_<_+IS;ZT=JX]H/UFO]D]J7
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M(3WI^#$*LZKTB(C[&CSVJ&/,Z7Q11A,3Z[Z7$54\88+@E&2%WCL7.<ZSC.)
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MNF?SZ]*E-<8HG5<1""\'-\1A@. \>@O>$6J"-M35/L?;?/^PA:#UD7*P;)M
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MMO??"S?I39HF#-_0%2@S&A,!EP,%070";S!^XUZ(%'CFM'JSLQ=(&GC<4VM
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MF%_/DJ.>N:"\!$;+=0OG*;CD)'J8"=T;)XR)M;OX;*-C6.!44.^C@Y<C9=T
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M=@N_X)1RQ'/01'=[96FA[,J0715T:;F56 ]]S)XGJD*;MNTOV+8,"*'!,**
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M\1J<51)G Q;J0ZG,Q/U^\0GU@Y24Z3/OTK<TF5V6_/V-&Y SX21X4*;D74)
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M/:46I' >-^IRK24%C/6L3/@C)YFL?5S_F(IA+TV^ZKYTI J: ]%&PEX&)HU
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M.U\H0B6#N&G?01]TT>#12BCDFJ&/R2@W54IA&(5'/Z]B4JL@N860G 7%M8?
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MX!0\8=XVY\66>TTV3("I P.5HA K"&G!..M=+'72>NMTRS,DO9R+#:.@,/R
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M)R2M;%A%TXVGSJBW#Y/,L@6;YI;O^[>__.W#FY]WVD@RQK2.I(-,<61QA('
M=8(:R6K.O$(YS#C??NZ,V[F=C ]@U=Q2_O1]C6&UN!V"*(FJE*B([%(M3U*
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M5"![1RY>-$:(00?,QT[_SW/TO(]7/(DH.H#65<J(>1\DN7S 0_4$%9-03\%
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MI?G L>3]?>:,-%%(7?OV"K(]+H)'VG9""<D"K=26UH<GPRB;6T%.A8QG(-A
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M0Z: F2"-#%SR6$N1N;2<&U*L1ZGZUB\>(JW8/#=<7B_K\=WY31-\5;>.)IO
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M<G#3F+MS@^7WY=FXG4 Q:I <%003,BB3,A"W%*040K36>WOW3O$CT!G[YD%
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MG[3>*Q79@G.)@U1"VFA1\#*LR<V3KYD73O.)?CF)''I#U'5WJ-W@;*T%4\F
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M&>ICG^&.:R&,#C#5-$.2FV0L#W727U7X.4H(0ELP2BJ!WOID6T?C7G]*_4Z
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M"W@M$D@G4JS9SO3_S6.>3Y+5&Z3VD?\/8<^VPN@B5D7W>[K>UWH3PC@373&
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M-S]<%9&<&I,9F;N&3 ]1IP<'#EXAAZB"TE9+AJGUR^L0NH9A\D6_03022O]
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MA-W;P]K)KAPHO':NMX+84Y.*$:,E/XEQ1]=:TJGU@(@'"1DYNME.T+/67.\
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M4S@[@4RWI^?6TUJQ =$@0I1UQ+CB'NK#*UBG>)*!9],\+O0432.W_.H%/(-
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M3#9J^>2<N#G%FG%\S4#:6^"J[M)'06>'67"&'&M&AD(VQDNC<F/ [4AB)QD
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MV,IEX.VM&4.=LF$PD+LPN[F)=ABC0&!9.:V#'>A3>QQ>:'BQ%^R]PHM],"B
M4%V"6=Y9J2 784@5"T-"'BBA#/ 82VH4)3 YK5YX>+$7"0:$%_L@4@#)^A5*
MX4+)5?5\QS4$Q!,,M,,08.R$]Z22W*4NO?UJRMF,(=[A4"J @MO*87A455H
M*9@&A#H3"QU40#+BI"(.,9GZB/>+1+A'F&OCH2J ;WVC;M8SB0QVP&@AXDT2
M!306&BC.D645H3#Y>P.O(,+=BQ0C(]Q]$,KM5U]WMH5-XV840HOHE"4QK\X
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M8'RAL#1AQZ@D4/G43\:^Q1_'<OH9XH]]>%' .7%71$,2[BM.JW!PQD&SVE=
M*FF!T,Y;)CW1Y)GJY;S*^&,OIO2(/_:!K5P&WH0]M,%$&F@!$[%BAPBFF:QX
MF.PQ*B%(, 235SMYH?''7K#WBC_VP:  0G6)=E%'I49AE^!5,/&)JL*05*6
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M+_0Y?*%]./T,OM ^O"C@3+<Y)XWJL&-120'5T;\LG05:\S <(Z24NH)&I,Z
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M#^G<)-\&P)EK+C[$;+Q%O SO*NK">2^,"*,P;26V0. P;24*[ P'1,%0[P<
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M[]U7U[8S9Z?SU4<]\.\N+6_IH><B06_M9F3"A[!WU%?NNJ.GR_C VL+%,?;
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M89OZ^;EN;[J:QM_?O95"W/\C<=ZAO\.OZ#>_B%^T6KC_^:__!U!+ P04
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MD! Q0&[6LZQ;^*[=SY?OQ;\%]MV_%/X"4$L#!!0    ( &>! 5E\35FE;!4
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M!%Q D81 *J(7-S6/HF5].@]*OW/604EPKB2?3H&[*.AP]%GM@!*<MRH#J:
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M[<N[K8KG;45>&I.)AK"^4I/&^ F,'R* ,(Q5;!5BK3SKHZ_]O%:=Y]A;U I
M(3(^1+T" VT]IQ9V;!8]"3B&FCKRDC;L@LK.1#S(4U&8CW81&N ,,=(;V[8
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M &"W_W_JK2_M&_)?TIOY_P=02P,$%     @ 9X$!6<K(+)6C$0  4U\  !X
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M%"P[3X0V$SGU31A-O9K5K-*J<^3'A3:18&H<UP;6P5Y?9QHE/U;:==G5H"6
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M_P=02P$"% ,4    " !G@0%9'!OWS=_; @!_""L $0              @ $
M    8FEI8BTR,#(T,#8S,"YH=&U02P$"% ,4    " !G@0%9O"R&4"P?   ,
M>0$ $0              @ $.W ( 8FEI8BTR,#(T,#8S,"YX<V102P$"% ,4
M    " !G@0%9%9H#7S4B   76@$ %0              @ %I^P( 8FEI8BTR
M,#(T,#8S,%]C86PN>&UL4$L! A0#%     @ 9X$!67(%"#2)TP  7Y ) !4
M             ( !T1T# &)I:6(M,C R-# V,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( &>! 5FD,L/2H[X  *+T   4              "  8WQ P!B:6EB+3(P
M,C0P-C,P7V<Q+FIP9U!+ 0(4 Q0    ( &>! 5EE"4EGR:   ,S3   5
M          "  6*P! !B:6EB+3(P,C0P-C,P7V<Q,"YJ<&=02P$"% ,4
M" !G@0%9'G+#.<"L   LX@  %0              @ %>404 8FEI8BTR,#(T
M,#8S,%]G,3$N:G!G4$L! A0#%     @ 9X$!68N$7Y*!)@$ ?IH! !4
M         ( !4?X% &)I:6(M,C R-# V,S!?9S$R+FIP9U!+ 0(4 Q0    (
M &>! 5F=+J4FM",! )ZD 0 5              "  04E!P!B:6EB+3(P,C0P
M-C,P7V<Q,RYJ<&=02P$"% ,4    " !G@0%9D+#7KT\L  !K/@  %
M        @ 'L2 @ 8FEI8BTR,#(T,#8S,%]G,BYJ<&=02P$"% ,4    " !G
M@0%9PQ(%(\L?  "*,@  %               @ %M=0@ 8FEI8BTR,#(T,#8S
M,%]G,RYJ<&=02P$"% ,4    " !G@0%9;Q^D J,L  !K/P  %
M    @ %JE0@ 8FEI8BTR,#(T,#8S,%]G-"YJ<&=02P$"% ,4    " !G@0%9
M5$(I)/HL  #I/P  %               @ $_P@@ 8FEI8BTR,#(T,#8S,%]G
M-2YJ<&=02P$"% ,4    " !G@0%9\70WJE2/  !*L   %
M@ %K[P@ 8FEI8BTR,#(T,#8S,%]G-BYJ<&=02P$"% ,4    " !G@0%9AVTQ
M0:65  #@M@  %               @ 'Q?@D 8FEI8BTR,#(T,#8S,%]G-RYJ
M<&=02P$"% ,4    " !G@0%9*7AT@1?5  !5  $ %               @ '(
M% H 8FEI8BTR,#(T,#8S,%]G."YJ<&=02P$"% ,4    " !G@0%9Q?Z(3D;;
M  !N!@$ %               @ $1Z@H 8FEI8BTR,#(T,#8S,%]G.2YJ<&=0
M2P$"% ,4    " !G@0%9DT8LXU)] 0#?E0X %0              @ &)Q0L
M8FEI8BTR,#(T,#8S,%]L86(N>&UL4$L! A0#%     @ 9X$!671#Y$,Z#0$
MVG8, !4              ( !#D,- &)I:6(M,C R-# V,S!?<')E+GAM;%!+
M 0(4 Q0    ( &>! 5F\<!K*[ <  ,XI   6              "  7M0#@!B
M:6EB+3(P,C0V,S!X97@S,3$N:'1M4$L! A0#%     @ 9X$!68N-GOO?!P
M/B@  !8              ( !FU@. &)I:6(M,C R-#8S,'AE>#,Q,BYH=&U0
M2P$"% ,4    " !G@0%9."YXDE@%  "L(   %@              @ &N8 X
M8FEI8BTR,#(T-C,P>&5X,S(Q+FAT;5!+ 0(4 Q0    ( &>! 5E\35FE;!4
M "6%   >              "  3IF#@!E>&AI8FET,3 S+69O<FUO9G!S=6%W
M87)D82YH=&U02P$"% ,4    " !G@0%9(R[7Y_P1  "@7P  '@
M    @ 'B>PX 97AH:6)I=#$P-"UF;W)M;V9R<W5A=V%R9&$N:'1M4$L! A0#
M%     @ 9X$!6<K(+)6C$0  4U\  !X              ( !&HX. &5X:&EB
M:70Q,#4M9F]R;6]F<G-U87=A<F1A+FAT;5!+!08     &0 9 )@&  #YGPX
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>biib-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20240630"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:CompletedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:CompletedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:CurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:CurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityTerminatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:OmnibusEquityPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:OmnibusEquityPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MosunetuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:LenderDisputeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="employee">
        <measure>biib:Employee</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-30" unitRef="shares">145661642</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">145661642</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues contextRef="c-3" decimals="-5" id="f-31" unitRef="usd">1899600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-5" id="f-32" unitRef="usd">1845800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-33" unitRef="usd">3611500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-34" unitRef="usd">3609100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-35" unitRef="usd">444500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-36" unitRef="usd">433400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-5" id="f-37" unitRef="usd">838500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-5" id="f-38" unitRef="usd">832900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-5" id="f-39" unitRef="usd">120800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-5" id="f-40" unitRef="usd">176800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-5" id="f-41" unitRef="usd">305400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-5" id="f-42" unitRef="usd">477000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-5" id="f-43" unitRef="usd">2464900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-5" id="f-44" unitRef="usd">2456000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-45" unitRef="usd">4755400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-5" id="f-46" unitRef="usd">4919000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-15" decimals="-5" id="f-47" unitRef="usd">546000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-16" decimals="-5" id="f-48" unitRef="usd">592700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-49" unitRef="usd">1088200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-17" decimals="-5" id="f-50" unitRef="usd">1255500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-15" decimals="-5" id="f-51" unitRef="usd">513900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-16" decimals="-5" id="f-52" unitRef="usd">584200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-5" id="f-53" unitRef="usd">966800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-17" decimals="-5" id="f-54" unitRef="usd">1154800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-5" id="f-55" unitRef="usd">553800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-16" decimals="-5" id="f-56" unitRef="usd">548000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-57" unitRef="usd">1135300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-17" decimals="-5" id="f-58" unitRef="usd">1153000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-15" decimals="-5" id="f-59" unitRef="usd">86900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-16" decimals="-5" id="f-60" unitRef="usd">52900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-1" decimals="-5" id="f-61" unitRef="usd">165200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-17" decimals="-5" id="f-62" unitRef="usd">103100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing contextRef="c-15" decimals="-5" id="f-63" unitRef="usd">62400000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-16" decimals="-5" id="f-64" unitRef="usd">56900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-1" decimals="-5" id="f-65" unitRef="usd">128000000.0</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-17" decimals="-5" id="f-66" unitRef="usd">114000000.0</biib:Collaborationprofitlosssharing>
    <us-gaap:RestructuringCharges contextRef="c-15" decimals="-5" id="f-67" unitRef="usd">6600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-16" decimals="-5" id="f-68" unitRef="usd">34400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-69" unitRef="usd">18100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-17" decimals="-5" id="f-70" unitRef="usd">44000000.0</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-71" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-16" decimals="-5" id="f-72" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-73" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-17" decimals="-5" id="f-74" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-5" id="f-75" unitRef="usd">-85200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-16" decimals="-5" id="f-76" unitRef="usd">121200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-5" id="f-77" unitRef="usd">-178900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-17" decimals="-5" id="f-78" unitRef="usd">51800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses contextRef="c-15" decimals="-5" id="f-79" unitRef="usd">1766200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-16" decimals="-5" id="f-80" unitRef="usd">1747900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-5" id="f-81" unitRef="usd">3591900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-17" decimals="-5" id="f-82" unitRef="usd">3772600000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-83" unitRef="usd">698700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-84" unitRef="usd">708100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-85" unitRef="usd">1163500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-86" unitRef="usd">1146400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-5" id="f-87" unitRef="usd">115100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-5" id="f-88" unitRef="usd">114800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-89" unitRef="usd">186500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-5" id="f-90" unitRef="usd">165500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-5" id="f-91" unitRef="usd">583600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-5" id="f-92" unitRef="usd">593300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-93" unitRef="usd">977000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-94" unitRef="usd">980900000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-95" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-96" unitRef="usd">1700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-97" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-98" unitRef="usd">1400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-99" unitRef="usd">583600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-100" unitRef="usd">591600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-101" unitRef="usd">977000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-102" unitRef="usd">979500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-103"
      unitRef="usdPerShare">4.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-104"
      unitRef="usdPerShare">4.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-105"
      unitRef="usdPerShare">6.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-106"
      unitRef="usdPerShare">6.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">4.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">4.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">6.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">6.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-5" id="f-111" unitRef="shares">145600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="-5" id="f-112" unitRef="shares">144700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-113" unitRef="shares">145400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="-5" id="f-114" unitRef="shares">144600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-5" id="f-115" unitRef="shares">145900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="-5" id="f-116" unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-117" unitRef="shares">145900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="-5" id="f-118" unitRef="shares">145400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-119" unitRef="usd">583600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-120" unitRef="usd">591600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-121" unitRef="usd">977000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-122" unitRef="usd">979500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-123" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-124" unitRef="usd">-4500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-125" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-126" unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-15" decimals="-5" id="f-127" unitRef="usd">20100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-16" decimals="-5" id="f-128" unitRef="usd">6900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-5" id="f-129" unitRef="usd">34800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-17" decimals="-5" id="f-130" unitRef="usd">-28500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-131" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-132" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-133" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-134" unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-135" unitRef="usd">-5600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-136" unitRef="usd">-3400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-137" unitRef="usd">-27000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-138" unitRef="usd">18700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-5" id="f-139" unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-5" id="f-140" unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-141" unitRef="usd">7700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-5" id="f-142" unitRef="usd">-7900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-5" id="f-143" unitRef="usd">598100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-5" id="f-144" unitRef="usd">590800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-145" unitRef="usd">984700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-5" id="f-146" unitRef="usd">971600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-147" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-148" unitRef="usd">1700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-149" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-150" unitRef="usd">1400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-151" unitRef="usd">598100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-152" unitRef="usd">592500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-153" unitRef="usd">984700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-154" unitRef="usd">973000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-5" id="f-155" unitRef="usd">1908900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-5" id="f-156" unitRef="usd">1049900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-19" decimals="-5" id="f-157" unitRef="usd">2500000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-18" decimals="-5" id="f-158" unitRef="usd">2400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-20" decimals="-5" id="f-159" unitRef="usd">1627100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-21" decimals="-5" id="f-160" unitRef="usd">1664100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-22" decimals="-5" id="f-161" unitRef="usd">451100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-23" decimals="-5" id="f-162" unitRef="usd">435900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-18" decimals="-5" id="f-163" unitRef="usd">2506100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-5" id="f-164" unitRef="usd">2527400000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-18" decimals="-5" id="f-165" unitRef="usd">615300000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-19" decimals="-5" id="f-166" unitRef="usd">1182000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-18" decimals="-5" id="f-167" unitRef="usd">7108500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-19" decimals="-5" id="f-168" unitRef="usd">6859300000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-18" decimals="-5" id="f-169" unitRef="usd">3249300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-19" decimals="-5" id="f-170" unitRef="usd">3309700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-18" decimals="-5" id="f-171" unitRef="usd">389400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-19" decimals="-5" id="f-172" unitRef="usd">420000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-18" decimals="-5" id="f-173" unitRef="usd">8232900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-19" decimals="-5" id="f-174" unitRef="usd">8363000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-18" decimals="-5" id="f-175" unitRef="usd">6227400000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-19" decimals="-5" id="f-176" unitRef="usd">6219200000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-18" decimals="-5" id="f-177" unitRef="usd">915100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-19" decimals="-5" id="f-178" unitRef="usd">928600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-18" decimals="-5" id="f-179" unitRef="usd">681500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-19" decimals="-5" id="f-180" unitRef="usd">745000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-18" decimals="-5" id="f-181" unitRef="usd">26804100000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-19" decimals="-5" id="f-182" unitRef="usd">26844800000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="c-18" decimals="-5" id="f-183" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-19" decimals="-5" id="f-184" unitRef="usd">150000000.0</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-18" decimals="-5" id="f-185" unitRef="usd">281600000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-19" decimals="-5" id="f-186" unitRef="usd">257400000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-18" decimals="-5" id="f-187" unitRef="usd">354500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-19" decimals="-5" id="f-188" unitRef="usd">403300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-189" unitRef="usd">2472100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-190" unitRef="usd">2623600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-191" unitRef="usd">3108200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-192" unitRef="usd">3434300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt contextRef="c-18" decimals="-5" id="f-193" unitRef="usd">6292000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-19" decimals="-5" id="f-194" unitRef="usd">6788200000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-18" decimals="-5" id="f-195" unitRef="usd">590600000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-19" decimals="-5" id="f-196" unitRef="usd">641800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-18" decimals="-5" id="f-197" unitRef="usd">367500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-19" decimals="-5" id="f-198" unitRef="usd">400000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-18" decimals="-5" id="f-199" unitRef="usd">556700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-19" decimals="-5" id="f-200" unitRef="usd">781100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-18" decimals="-5" id="f-201" unitRef="usd">10915000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-19" decimals="-5" id="f-202" unitRef="usd">12045400000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-18" id="f-203" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-19" id="f-204" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-18"
      decimals="3"
      id="f-205"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c-18" decimals="-5" id="f-206" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-19" decimals="-5" id="f-207" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-18"
      decimals="4"
      id="f-208"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue contextRef="c-18" decimals="-5" id="f-209" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-19" decimals="-5" id="f-210" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-18" decimals="-5" id="f-211" unitRef="usd">407500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-19" decimals="-5" id="f-212" unitRef="usd">302500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-5" id="f-213" unitRef="usd">-146000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-5" id="f-214" unitRef="usd">-153700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-18" decimals="-5" id="f-215" unitRef="usd">18604600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-19" decimals="-5" id="f-216" unitRef="usd">17627600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue contextRef="c-18" decimals="-5" id="f-217" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-19" decimals="-5" id="f-218" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-219" unitRef="usd">15889100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-5" id="f-220" unitRef="usd">14799400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-18" decimals="-5" id="f-221" unitRef="usd">26804100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-19" decimals="-5" id="f-222" unitRef="usd">26844800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-223" unitRef="usd">977000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-224" unitRef="usd">980900000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-225" unitRef="usd">306400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-17" decimals="-5" id="f-226" unitRef="usd">229700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-227" unitRef="usd">44400000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-17" decimals="-5" id="f-228" unitRef="usd">36800000</us-gaap:InventoryWriteDown>
    <biib:AmortizationOfInventoryStepUp contextRef="c-1" decimals="-5" id="f-229" unitRef="usd">134200000</biib:AmortizationOfInventoryStepUp>
    <biib:AmortizationOfInventoryStepUp contextRef="c-17" decimals="-5" id="f-230" unitRef="usd">0</biib:AmortizationOfInventoryStepUp>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-231" unitRef="usd">143400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-5" id="f-232" unitRef="usd">147100000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-233" unitRef="usd">-47100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-17" decimals="-5" id="f-234" unitRef="usd">-170900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-1" decimals="-5" id="f-235" unitRef="usd">-61600000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-17" decimals="-5" id="f-236" unitRef="usd">26800000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-5" id="f-237" unitRef="usd">88600000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-17" decimals="-5" id="f-238" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-5" id="f-239" unitRef="usd">-65000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-17" decimals="-5" id="f-240" unitRef="usd">-60500000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-24" decimals="-5" id="f-241" unitRef="usd">-12300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-25" decimals="-5" id="f-242" unitRef="usd">-21800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-26" decimals="-5" id="f-243" unitRef="usd">15100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-5" id="f-244" unitRef="usd">6700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-245" unitRef="usd">188200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-17" decimals="-5" id="f-246" unitRef="usd">65100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-5" id="f-247" unitRef="usd">-115600000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-17" decimals="-5" id="f-248" unitRef="usd">-127100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-5" id="f-249" unitRef="usd">-7700000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-17" decimals="-5" id="f-250" unitRef="usd">-82400000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-5" id="f-251" unitRef="usd">103000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-17" decimals="-5" id="f-252" unitRef="usd">55500000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-253" unitRef="usd">1179000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-5" id="f-254" unitRef="usd">942300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-255" unitRef="usd">79400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-17" decimals="-5" id="f-256" unitRef="usd">137600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-5" id="f-257" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-17" decimals="-5" id="f-258" unitRef="usd">1682200000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-5" id="f-259" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-17" decimals="-5" id="f-260" unitRef="usd">4120300000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-261" unitRef="usd">406800000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-17" decimals="-5" id="f-262" unitRef="usd">788100000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-263" unitRef="usd">103000000.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-17" decimals="-5" id="f-264" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-5" id="f-265" unitRef="usd">84100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-17" decimals="-5" id="f-266" unitRef="usd">21000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-1" decimals="-5" id="f-267" unitRef="usd">57500000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-17" decimals="-5" id="f-268" unitRef="usd">103200000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-5" id="f-269" unitRef="usd">3300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-17" decimals="-5" id="f-270" unitRef="usd">1100000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-271" unitRef="usd">400500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-5" id="f-272" unitRef="usd">-1706500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-273" unitRef="usd">40800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-17" decimals="-5" id="f-274" unitRef="usd">54600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-5" id="f-275" unitRef="usd">650000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-17" decimals="-5" id="f-276" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c-1" decimals="-5" id="f-277" unitRef="usd">0</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c-17" decimals="-5" id="f-278" unitRef="usd">1700000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-5" id="f-279" unitRef="usd">6000000.0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-17" decimals="-5" id="f-280" unitRef="usd">-300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-281" unitRef="usd">-684800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-5" id="f-282" unitRef="usd">-53200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-283" unitRef="usd">894700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-17" decimals="-5" id="f-284" unitRef="usd">-817400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-5" id="f-285" unitRef="usd">-35700000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-5" id="f-286" unitRef="usd">15900000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-5" id="f-287" unitRef="usd">1049900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-5" id="f-288" unitRef="usd">3419300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-5" id="f-289" unitRef="usd">1908900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-5" id="f-290" unitRef="usd">2617800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-5" id="f-291" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-5" id="f-292" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-5" id="f-293" unitRef="shares">169400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-5" id="f-294" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-5" id="f-295" unitRef="usd">329500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-5" id="f-296" unitRef="usd">-160500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-5" id="f-297" unitRef="usd">18021000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-35" decimals="-5" id="f-298" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-5" id="f-299" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-5" id="f-300" unitRef="usd">15213000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-37" decimals="-5" id="f-301" unitRef="usd">583600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-5" id="f-302" unitRef="usd">583600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-5" id="f-303" unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-5" id="f-304" unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-39" decimals="-5" id="f-305" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-40" decimals="-5" id="f-306" unitRef="usd">7900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-15" decimals="-5" id="f-307" unitRef="usd">7900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-39" decimals="-5" id="f-308" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-40" decimals="-5" id="f-309" unitRef="usd">-1800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-5" id="f-310" unitRef="usd">-1800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-40" decimals="-5" id="f-311" unitRef="usd">-72900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-5" id="f-312" unitRef="usd">-72900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-40" decimals="-5" id="f-313" unitRef="usd">1000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-15" decimals="-5" id="f-314" unitRef="usd">1000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="-5" id="f-315" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-5" id="f-316" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-5" id="f-317" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-5" id="f-318" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-5" id="f-319" unitRef="usd">407500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-5" id="f-320" unitRef="usd">-146000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-321" unitRef="usd">18604600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-46" decimals="-5" id="f-322" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-5" id="f-323" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-324" unitRef="usd">15889100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-47" decimals="-5" id="f-325" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-5" id="f-326" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-48" decimals="-5" id="f-327" unitRef="shares">168700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-5" id="f-328" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-5" id="f-329" unitRef="usd">302500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-5" id="f-330" unitRef="usd">-153700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-5" id="f-331" unitRef="usd">17627600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-52" decimals="-5" id="f-332" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-5" id="f-333" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-5" id="f-334" unitRef="usd">14799400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-53" decimals="-5" id="f-335" unitRef="usd">977000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-336" unitRef="usd">977000000.0</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-54" decimals="-5" id="f-337" unitRef="usd">7700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-5" id="f-338" unitRef="usd">7700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-55" decimals="-5" id="f-339" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-56" decimals="-5" id="f-340" unitRef="usd">23600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-1" decimals="-5" id="f-341" unitRef="usd">23600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-55" decimals="-5" id="f-342" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-56" decimals="-5" id="f-343" unitRef="usd">-64400000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-5" id="f-344" unitRef="usd">-64400000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-56" decimals="-5" id="f-345" unitRef="usd">-149000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-346" unitRef="usd">-149000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-56" decimals="-5" id="f-347" unitRef="usd">3200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-1" decimals="-5" id="f-348" unitRef="usd">3200000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="-5" id="f-349" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-5" id="f-350" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-5" id="f-351" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-5" id="f-352" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-5" id="f-353" unitRef="usd">407500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-5" id="f-354" unitRef="usd">-146000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-355" unitRef="usd">18604600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-46" decimals="-5" id="f-356" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-5" id="f-357" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-358" unitRef="usd">15889100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-57" decimals="-5" id="f-359" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-5" id="f-360" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-58" decimals="-5" id="f-361" unitRef="shares">168600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-5" id="f-362" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-5" id="f-363" unitRef="usd">91200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-5" id="f-364" unitRef="usd">-172000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-5" id="f-365" unitRef="usd">16854400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-62" decimals="-5" id="f-366" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-5" id="f-367" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-5" id="f-368" unitRef="usd">13796600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-5" id="f-369" unitRef="usd">-9600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-5" id="f-370" unitRef="usd">13787000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-66" decimals="-5" id="f-371" unitRef="usd">591600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-67" decimals="-5" id="f-372" unitRef="usd">591600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-68" decimals="-5" id="f-373" unitRef="usd">1700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-5" id="f-374" unitRef="usd">593300000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-69" decimals="-5" id="f-375" unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-67" decimals="-5" id="f-376" unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-16" decimals="-5" id="f-377" unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-68" decimals="-5" id="f-378" unitRef="usd">1500000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-16" decimals="-5" id="f-379" unitRef="usd">1500000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-70" decimals="-5" id="f-380" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-71" decimals="-5" id="f-381" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-67" decimals="-5" id="f-382" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-16" decimals="-5" id="f-383" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-70" decimals="-5" id="f-384" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-71" decimals="-5" id="f-385" unitRef="usd">-3800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-67" decimals="-5" id="f-386" unitRef="usd">-3800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-5" id="f-387" unitRef="usd">-3800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-71" decimals="-5" id="f-388" unitRef="usd">-74100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-67" decimals="-5" id="f-389" unitRef="usd">-74100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-16" decimals="-5" id="f-390" unitRef="usd">-74100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-71" decimals="-5" id="f-391" unitRef="usd">100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-67" decimals="-5" id="f-392" unitRef="usd">100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-16" decimals="-5" id="f-393" unitRef="usd">100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-72" decimals="-5" id="f-394" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-5" id="f-395" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-73" decimals="-5" id="f-396" unitRef="shares">168600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-5" id="f-397" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-5" id="f-398" unitRef="usd">170700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-5" id="f-399" unitRef="usd">-172800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-5" id="f-400" unitRef="usd">17446000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-77" decimals="-5" id="f-401" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-77" decimals="-5" id="f-402" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-5" id="f-403" unitRef="usd">14466900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-5" id="f-404" unitRef="usd">-6400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-5" id="f-405" unitRef="usd">14460500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-80" decimals="-5" id="f-406" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-80" decimals="-5" id="f-407" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-81" decimals="-5" id="f-408" unitRef="shares">167900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-81" decimals="-5" id="f-409" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-82" decimals="-5" id="f-410" unitRef="usd">73300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-83" decimals="-5" id="f-411" unitRef="usd">-164900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-84" decimals="-5" id="f-412" unitRef="usd">16466500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-85" decimals="-5" id="f-413" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-85" decimals="-5" id="f-414" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-86" decimals="-5" id="f-415" unitRef="usd">13397900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-87" decimals="-5" id="f-416" unitRef="usd">-9500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-5" id="f-417" unitRef="usd">13388400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-88" decimals="-5" id="f-418" unitRef="usd">979500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-89" decimals="-5" id="f-419" unitRef="usd">979500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-90" decimals="-5" id="f-420" unitRef="usd">1400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-421" unitRef="usd">980900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-91" decimals="-5" id="f-422" unitRef="usd">-7900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-89" decimals="-5" id="f-423" unitRef="usd">-7900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-5" id="f-424" unitRef="usd">-7900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-90" decimals="-5" id="f-425" unitRef="usd">1700000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-17" decimals="-5" id="f-426" unitRef="usd">1700000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-92" decimals="-5" id="f-427" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-93" decimals="-5" id="f-428" unitRef="usd">29400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-89" decimals="-5" id="f-429" unitRef="usd">29400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-17" decimals="-5" id="f-430" unitRef="usd">29400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-92" decimals="-5" id="f-431" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-93" decimals="-5" id="f-432" unitRef="usd">-84000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-89" decimals="-5" id="f-433" unitRef="usd">-84000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-5" id="f-434" unitRef="usd">-84000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-93" decimals="-5" id="f-435" unitRef="usd">-153000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-89" decimals="-5" id="f-436" unitRef="usd">-153000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-17" decimals="-5" id="f-437" unitRef="usd">-153000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-93" decimals="-5" id="f-438" unitRef="usd">1000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-89" decimals="-5" id="f-439" unitRef="usd">1000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-17" decimals="-5" id="f-440" unitRef="usd">1000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-72" decimals="-5" id="f-441" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-5" id="f-442" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-73" decimals="-5" id="f-443" unitRef="shares">168600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-5" id="f-444" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-5" id="f-445" unitRef="usd">170700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-5" id="f-446" unitRef="usd">-172800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-5" id="f-447" unitRef="usd">17446000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-77" decimals="-5" id="f-448" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-77" decimals="-5" id="f-449" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-5" id="f-450" unitRef="usd">14466900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-5" id="f-451" unitRef="usd">-6400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-5" id="f-452" unitRef="usd">14460500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-453">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#x2019;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD and we have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.&lt;/span&gt;&lt;span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Climate-Related Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Enhancement and Standardization of Climate-Related Disclosures for Investors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023 the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock contextRef="c-1" id="f-454">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#x2019;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD and we have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).&lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-455">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-456"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-457">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary contextRef="c-1" decimals="INF" id="f-458" unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-459">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Climate-Related Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Enhancement and Standardization of Climate-Related Disclosures for Investors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023 the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-461">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reata Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS (omaveloxolone), the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of this acquisition, we paid Reata shareholders $172.50 in cash for each issued and outstanding Reata share, which totaled approximately $6.6&#160;billion. In addition, we agreed to pay approximately $983.9&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $590.5&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $983.9&#160;million paid to Reata's equity award holders, we recognized approximately $393.4&#160;million as compensation attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the year ended December 31, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a $1.0 billion term loan under our term loan credit agreement. For additional information on our term loan credit agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Topic 805, Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Price Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition of Reata is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;26, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to Reata shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,602.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of Reata equity compensation pre-acquisition services and related taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents cash consideration transferred of $172.50 per outstanding Reata common stock based on 38.3&#160;million Reata shares outstanding at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preliminary Purchase Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made year-to-date to the amounts initially recorded as of the acquisition date on September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date&lt;br/&gt;(as adjusted)&lt;br/&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,259.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology for SKYCLARYS (U.S.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development (omaveloxolone)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent payable to Blackstone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(300.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(916.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,719.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $4.9&#160;million, deferred tax liability by $4.1&#160;million and goodwill by $9.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Total inventory acquired was&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately $1.3&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be within approximately 3 years from the acquisition date. For the three and six months ended June 30, 2024, amortization from the fair value step-up adjustment was approximately $90.1&#160;million and $134.2&#160;million, respectively, which includes approximately $46.0&#160;million of inventory used for clinical purposes rather than for commercial sale during the second quarter of 2024, and therefore reflected within research and development expense within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intang&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ible assets:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Intangible assets are comprised of $4.2&#160;billion related to SKYCLARYS commercialization rights in the U.S., $2.3&#160;billion of IPR&amp;amp;D related to the omaveloxolone program outside the U.S., which had not yet received regulatory approval in the E.U. as of the acquisition date, $100.0&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $40.0&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing a discount rate of 14.3% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $4.2&#160;billion intangible asset will be amortized over its expected economic life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon SKYCLARYS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;receiving E.U. regulatory approval in February 2024, we began selling the product in certain countries in Europe, and began amortizing the $2.3&#160;billion I&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PR&amp;amp;D asset related to the program outside the U.S. over its expected economic life using an economic consumption model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $121.2&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $473.5&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-related expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acquisition-related expense, primarily comprised of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $28.4&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assumptions in the Allocations of Purchase Price&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he results of operations of Reata, along with the estimated fair values of the assets acquired and liabilities assumed in the Reata acquisition, have been included in our condensed consolidated financial statements since the closing of the Reata acquisition on September 26, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of income taxes. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Human Immunology Biosciences&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, aMR, PMN and IgAN. Felzartamab has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for development in the treatment of PMN and has received ODD in the treatment of antibody-mediated rejection in kidney transplant recipients. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of this acquisition, we made an upfront payment to HI-Bio of approximately $1.15&#160;billion which was funded through available cash on hand. Additionally, we may pay up to $650.0&#160;million in potential milestone payments to the former shareholders of HI-Bio. We expect this transaction to be accounted for as an acquisition of a business and recognized within our condensed consolidated financial statements during the third quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to lead program felzartamab, the HI-Bio pipeline acquired includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial, and the potential for continued development in a range of complement-mediated diseases.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-94"
      decimals="1"
      id="f-462"
      unitRef="usdPerShare">172.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-95" decimals="-8" id="f-463" unitRef="usd">6600000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-96" decimals="-5" id="f-464" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices contextRef="c-95" decimals="-5" id="f-465" unitRef="usd">590500000</biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-96" decimals="-5" id="f-466" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <us-gaap:OperatingExpenses contextRef="c-95" decimals="-5" id="f-467" unitRef="usd">393400000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-95" decimals="-5" id="f-468" unitRef="usd">196400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-95" decimals="-5" id="f-469" unitRef="usd">197000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-97" decimals="-8" id="f-470" unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-471">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition of Reata is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;26, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to Reata shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,602.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of Reata equity compensation pre-acquisition services and related taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents cash consideration transferred of $172.50 per outstanding Reata common stock based on 38.3&#160;million Reata shares outstanding at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.&lt;/span&gt;&lt;/div&gt;September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date&lt;br/&gt;(as adjusted)&lt;br/&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,259.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology for SKYCLARYS (U.S.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development (omaveloxolone)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent payable to Blackstone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(300.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(916.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,719.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $4.9&#160;million, deferred tax liability by $4.1&#160;million and goodwill by $9.0&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-95" decimals="-5" id="f-472" unitRef="usd">6602900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices contextRef="c-95" decimals="-5" id="f-473" unitRef="usd">590500000</biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-95" decimals="-5" id="f-474" unitRef="usd">7193400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-94"
      decimals="1"
      id="f-475"
      unitRef="usdPerShare">172.50</us-gaap:BusinessAcquisitionSharePrice>
    <biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired contextRef="c-94" decimals="-5" id="f-476" unitRef="shares">38300000</biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-98" decimals="-5" id="f-477" unitRef="usd">267300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-98" decimals="-5" id="f-478" unitRef="usd">15900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-98" decimals="-5" id="f-479" unitRef="usd">1259000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-98" decimals="-5" id="f-480" unitRef="usd">53600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-99" decimals="-5" id="f-481" unitRef="usd">4200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-100" decimals="-5" id="f-482" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-101" decimals="-5" id="f-483" unitRef="usd">100000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-102" decimals="-5" id="f-484" unitRef="usd">40000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-98" decimals="-5" id="f-485" unitRef="usd">121200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther contextRef="c-98" decimals="-5" id="f-486" unitRef="usd">106400000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="c-98" decimals="-5" id="f-487" unitRef="usd">159900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability contextRef="c-98" decimals="-5" id="f-488" unitRef="usd">300000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-98" decimals="-5" id="f-489" unitRef="usd">916500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-98" decimals="-5" id="f-490" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet contextRef="c-98" decimals="-5" id="f-491" unitRef="usd">-2500000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-98" decimals="-5" id="f-492" unitRef="usd">6719900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-98" decimals="-5" id="f-493" unitRef="usd">473500000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-98" decimals="-5" id="f-494" unitRef="usd">7193400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther contextRef="c-103" decimals="-5" id="f-495" unitRef="usd">4900000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability contextRef="c-103" decimals="-5" id="f-496" unitRef="usd">-4100000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill contextRef="c-103" decimals="-5" id="f-497" unitRef="usd">-9000000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-94" decimals="-8" id="f-498" unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod contextRef="c-94" id="f-499">P3Y</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod>
    <us-gaap:ProfitLoss contextRef="c-104" decimals="-5" id="f-500" unitRef="usd">-90100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-105" decimals="-5" id="f-501" unitRef="usd">-134200000</us-gaap:ProfitLoss>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-106" decimals="-5" id="f-502" unitRef="usd">46000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-107" decimals="-8" id="f-503" unitRef="usd">4200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-108" decimals="-8" id="f-504" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-109" decimals="-5" id="f-505" unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-110" decimals="-5" id="f-506" unitRef="usd">40000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate contextRef="c-94" decimals="3" id="f-507" unitRef="number">0.143</biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-107" decimals="-8" id="f-508" unitRef="usd">4200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-108" decimals="-8" id="f-509" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:OperatingLeaseArea contextRef="c-94" decimals="0" id="f-510" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-94" id="f-511">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-94" decimals="-5" id="f-512" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-94" id="f-513">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-94" decimals="-5" id="f-514" unitRef="usd">121200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <us-gaap:Goodwill contextRef="c-94" decimals="-5" id="f-515" unitRef="usd">473500000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="c-111" decimals="-5" id="f-516" unitRef="usd">28400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-112" decimals="-7" id="f-517" unitRef="usd">1150000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-113" decimals="-5" id="f-518" unitRef="usd">650000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-519">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sale of Joint Venture Equity Interest in Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $2.3&#160;billion. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing, with approximately $1.3&#160;billion in cash to be deferred over two payments. The first deferred payment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$812.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was received in April 2023 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the second deferred payment of $437.5&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was received in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;three and six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended June 30, 2024, we recognized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; gains&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$1.4&#160;million and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$7.5&#160;million, respectively, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;to reflect the changes in fair value associated with the passage of time related to the second deferred payment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;due to us, which was received in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;three and six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended June 30, 2023, we recognized gains of approximately $2.6&#160;million and $13.7&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the first deferred payment due to us. Additionally, for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;three and six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended June 30, 2023, we recognized gains of approximately $3.6&#160;million and $9.8&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the second deferred payment due to us. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sale of Priority Review Voucher&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $103.0&#160;million upon the closing of the PRV purchase, of which approximately $14.4&#160;million is payable to Ionis. Our net portion of approximately $88.6&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the three and six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-114" decimals="3" id="f-520" unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-115" decimals="-5" id="f-521" unitRef="usd">2300000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture contextRef="c-116" decimals="-8" id="f-522" unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-117" decimals="-8" id="f-523" unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-118" decimals="-5" id="f-524" unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-119" decimals="-5" id="f-525" unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-120" decimals="-5" id="f-526" unitRef="usd">1400000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-121" decimals="-5" id="f-527" unitRef="usd">7500000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-122" decimals="-5" id="f-528" unitRef="usd">2600000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-123" decimals="-5" id="f-529" unitRef="usd">13700000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-124" decimals="-5" id="f-530" unitRef="usd">3600000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-125" decimals="-5" id="f-531" unitRef="usd">9800000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="c-126" decimals="-5" id="f-532" unitRef="usd">103000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:AccountsPayableCurrent contextRef="c-127" decimals="-5" id="f-533" unitRef="usd">14400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-534" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-535" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-536">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2023 Fit for Growth Restructuring Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,000 employees and we expect to incur restructuring charges ranging from approximately $260.0&#160;million to $280.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2023 cost saving initiatives are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Costs:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reata Integration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimate we will incur total integration charges ranging from approximately $35.0&#160;million to $40.0&#160;million, related to severance and employment costs, which are expected to be paid by the end of 2024. These amounts were substantially incurred during 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our Reata integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and spending related to workforce reductions from our 2023 Fit for Growth program and Reata Integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction contextRef="c-128" decimals="-8" id="f-537" unitRef="usd">1000000000</biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="c-129"
      decimals="INF"
      id="f-538"
      unitRef="employee">1000</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-130" decimals="-5" id="f-539" unitRef="usd">260000000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-131" decimals="-5" id="f-540" unitRef="usd">280000000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-541">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2023 cost saving initiatives are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our Reata integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1 contextRef="c-132" decimals="-5" id="f-542" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-132" decimals="-5" id="f-543" unitRef="usd">2000000.0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-132" decimals="-5" id="f-544" unitRef="usd">2000000.0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-133" decimals="-5" id="f-545" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-133" decimals="-5" id="f-546" unitRef="usd">11500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-133" decimals="-5" id="f-547" unitRef="usd">11500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-134" decimals="-5" id="f-548" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-134" decimals="-5" id="f-549" unitRef="usd">2200000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-134" decimals="-5" id="f-550" unitRef="usd">2200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-135" decimals="-5" id="f-551" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-135" decimals="-5" id="f-552" unitRef="usd">500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-135" decimals="-5" id="f-553" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-136" decimals="-5" id="f-554" unitRef="usd">6300000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-136" decimals="-5" id="f-555" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-136" decimals="-5" id="f-556" unitRef="usd">6300000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-137" decimals="-5" id="f-557" unitRef="usd">17800000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-137" decimals="-5" id="f-558" unitRef="usd">16500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-137" decimals="-5" id="f-559" unitRef="usd">34300000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-138" decimals="-5" id="f-560" unitRef="usd">6300000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-138" decimals="-5" id="f-561" unitRef="usd">4200000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-138" decimals="-5" id="f-562" unitRef="usd">10500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-139" decimals="-5" id="f-563" unitRef="usd">17800000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-139" decimals="-5" id="f-564" unitRef="usd">28500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-139" decimals="-5" id="f-565" unitRef="usd">46300000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-140" decimals="-5" id="f-566" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-140" decimals="-5" id="f-567" unitRef="usd">3400000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-140" decimals="-5" id="f-568" unitRef="usd">3400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-141" decimals="-5" id="f-569" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-141" decimals="-5" id="f-570" unitRef="usd">11500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-141" decimals="-5" id="f-571" unitRef="usd">11500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-142" decimals="-5" id="f-572" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-142" decimals="-5" id="f-573" unitRef="usd">7100000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-142" decimals="-5" id="f-574" unitRef="usd">7100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-143" decimals="-5" id="f-575" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-143" decimals="-5" id="f-576" unitRef="usd">500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-143" decimals="-5" id="f-577" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-144" decimals="-5" id="f-578" unitRef="usd">15600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-144" decimals="-5" id="f-579" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-144" decimals="-5" id="f-580" unitRef="usd">15600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-145" decimals="-5" id="f-581" unitRef="usd">24900000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-145" decimals="-5" id="f-582" unitRef="usd">16500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-145" decimals="-5" id="f-583" unitRef="usd">41400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-129" decimals="-5" id="f-584" unitRef="usd">15600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-129" decimals="-5" id="f-585" unitRef="usd">10500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-129" decimals="-5" id="f-586" unitRef="usd">26100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-146" decimals="-5" id="f-587" unitRef="usd">24900000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-146" decimals="-5" id="f-588" unitRef="usd">28500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-146" decimals="-5" id="f-589" unitRef="usd">53400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-147" decimals="-5" id="f-590" unitRef="usd">35000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-148" decimals="-5" id="f-591" unitRef="usd">40000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:SeveranceCosts1 contextRef="c-149" decimals="-5" id="f-592" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-149" decimals="-5" id="f-593" unitRef="usd">1500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-149" decimals="-5" id="f-594" unitRef="usd">1500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-150" decimals="-5" id="f-595" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-150" decimals="-5" id="f-596" unitRef="usd">3300000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-150" decimals="-5" id="f-597" unitRef="usd">3300000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-151" decimals="-5" id="f-598" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-151" decimals="-5" id="f-599" unitRef="usd">3300000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-151" decimals="-5" id="f-600" unitRef="usd">3300000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-152" decimals="-5" id="f-601" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-152" decimals="-5" id="f-602" unitRef="usd">6000000.0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-152" decimals="-5" id="f-603" unitRef="usd">6000000.0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-153" decimals="-5" id="f-604" unitRef="usd">300000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-153" decimals="-5" id="f-605" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-153" decimals="-5" id="f-606" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-154" decimals="-5" id="f-607" unitRef="usd">2500000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-154" decimals="-5" id="f-608" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-154" decimals="-5" id="f-609" unitRef="usd">2500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-155" decimals="-5" id="f-610" unitRef="usd">300000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-155" decimals="-5" id="f-611" unitRef="usd">4800000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-155" decimals="-5" id="f-612" unitRef="usd">5100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-156" decimals="-5" id="f-613" unitRef="usd">2500000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-156" decimals="-5" id="f-614" unitRef="usd">9300000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-156" decimals="-5" id="f-615" unitRef="usd">11800000</us-gaap:RestructuringCharges>
    <biib:OperatingLeaseArea contextRef="c-94" decimals="0" id="f-616" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-94" id="f-617">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-618">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and spending related to workforce reductions from our 2023 Fit for Growth program and Reata Integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-157" decimals="-5" id="f-619" unitRef="usd">75400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-158" decimals="-5" id="f-620" unitRef="usd">35900000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-159" decimals="-5" id="f-621" unitRef="usd">11500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-160" decimals="-5" id="f-622" unitRef="usd">7100000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-159" decimals="-5" id="f-623" unitRef="usd">42200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-160" decimals="-5" id="f-624" unitRef="usd">15600000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-159" decimals="-5" id="f-625" unitRef="usd">-800000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-160" decimals="-5" id="f-626" unitRef="usd">-600000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-161" decimals="-5" id="f-627" unitRef="usd">45500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-162" decimals="-5" id="f-628" unitRef="usd">28000000.0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-163" decimals="-5" id="f-629" unitRef="usd">6600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-164" decimals="-5" id="f-630" unitRef="usd">17800000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-163" decimals="-5" id="f-631" unitRef="usd">11900000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-164" decimals="-5" id="f-632" unitRef="usd">13400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-163" decimals="-5" id="f-633" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-164" decimals="-5" id="f-634" unitRef="usd">100000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-165" decimals="-5" id="f-635" unitRef="usd">40200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-166" decimals="-5" id="f-636" unitRef="usd">32300000</us-gaap:RestructuringReserve>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-637">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;418.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;582.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,149.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;636.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,209.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;429.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;438.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;846.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,052.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,899.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;801.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,845.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in certain international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;418.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;528.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;461.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;418.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;783.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;361.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;893.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;955.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,085.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,225.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,182.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,334.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;770.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;577.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;880.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;958.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;577.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,592.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,018.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,611.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,502.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,106.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in certain international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 25.4% and 12.3% of gross product revenue for the three months ended June 30, 2024, and 25.5% and 12.0% of gross product revenue for the six months ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 27.0% and 9.3% of gross product revenue for the three months ended June 30, 2023, and 27.2% and 8.4% of gross product revenue for the six months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;857.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,355.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,765.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(797.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,058.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(155.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(477.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(643.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;910.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;964.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty revenue on sales of OCREVUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;639.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;832.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Contract Manufacturing, Royalty and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing, royalty and other revenue is summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.336%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract manufacturing, royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Manufacturing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, our share of contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as we are not the principal, as well as royalties we receive from net sales on products related to patents that we have out-licensed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-638">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;418.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;582.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,149.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;636.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,209.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;429.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;438.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;846.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,052.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,899.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;801.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,845.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in certain international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;418.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;528.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;461.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;418.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;783.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;361.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;893.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;955.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,085.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,225.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,182.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,334.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;770.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;577.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;880.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;958.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;577.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,592.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,018.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,611.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,502.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,106.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in certain international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues contextRef="c-167" decimals="-5" id="f-639" unitRef="usd">44100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-168" decimals="-5" id="f-640" unitRef="usd">208100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-169" decimals="-5" id="f-641" unitRef="usd">252200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-170" decimals="-5" id="f-642" unitRef="usd">66500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-171" decimals="-5" id="f-643" unitRef="usd">187700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-172" decimals="-5" id="f-644" unitRef="usd">254200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-173" decimals="-5" id="f-645" unitRef="usd">144200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-174" decimals="-5" id="f-646" unitRef="usd">21600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-175" decimals="-5" id="f-647" unitRef="usd">165800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-176" decimals="-5" id="f-648" unitRef="usd">130300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-177" decimals="-5" id="f-649" unitRef="usd">15900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-178" decimals="-5" id="f-650" unitRef="usd">146200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-179" decimals="-5" id="f-651" unitRef="usd">188300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-180" decimals="-5" id="f-652" unitRef="usd">229700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-181" decimals="-5" id="f-653" unitRef="usd">418000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-182" decimals="-5" id="f-654" unitRef="usd">196800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-183" decimals="-5" id="f-655" unitRef="usd">203600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-184" decimals="-5" id="f-656" unitRef="usd">400400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-185" decimals="-5" id="f-657" unitRef="usd">117200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-186" decimals="-5" id="f-658" unitRef="usd">65600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-187" decimals="-5" id="f-659" unitRef="usd">182800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-188" decimals="-5" id="f-660" unitRef="usd">145900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-189" decimals="-5" id="f-661" unitRef="usd">74400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-190" decimals="-5" id="f-662" unitRef="usd">220300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-191" decimals="-5" id="f-663" unitRef="usd">28200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-192" decimals="-5" id="f-664" unitRef="usd">39900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-193" decimals="-5" id="f-665" unitRef="usd">68100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-194" decimals="-5" id="f-666" unitRef="usd">34100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-195" decimals="-5" id="f-667" unitRef="usd">48000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-196" decimals="-5" id="f-668" unitRef="usd">82100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-197" decimals="-5" id="f-669" unitRef="usd">145400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-198" decimals="-5" id="f-670" unitRef="usd">105500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-199" decimals="-5" id="f-671" unitRef="usd">250900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-200" decimals="-5" id="f-672" unitRef="usd">180000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-201" decimals="-5" id="f-673" unitRef="usd">122400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-202" decimals="-5" id="f-674" unitRef="usd">302400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-203" decimals="-5" id="f-675" unitRef="usd">248700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-204" decimals="-5" id="f-676" unitRef="usd">213500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-205" decimals="-5" id="f-677" unitRef="usd">462200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-206" decimals="-5" id="f-678" unitRef="usd">259900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-207" decimals="-5" id="f-679" unitRef="usd">223200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-208" decimals="-5" id="f-680" unitRef="usd">483100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-209" decimals="-5" id="f-681" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-210" decimals="-5" id="f-682" unitRef="usd">18700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-211" decimals="-5" id="f-683" unitRef="usd">18700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-212" decimals="-5" id="f-684" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-213" decimals="-5" id="f-685" unitRef="usd">23400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-214" decimals="-5" id="f-686" unitRef="usd">23400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-215" decimals="-5" id="f-687" unitRef="usd">582400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-216" decimals="-5" id="f-688" unitRef="usd">567400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-217" decimals="-5" id="f-689" unitRef="usd">1149800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-218" decimals="-5" id="f-690" unitRef="usd">636700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-219" decimals="-5" id="f-691" unitRef="usd">572600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-220" decimals="-5" id="f-692" unitRef="usd">1209300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-221" decimals="-5" id="f-693" unitRef="usd">157300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-222" decimals="-5" id="f-694" unitRef="usd">271800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-223" decimals="-5" id="f-695" unitRef="usd">429100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-224" decimals="-5" id="f-696" unitRef="usd">155800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-225" decimals="-5" id="f-697" unitRef="usd">281300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-226" decimals="-5" id="f-698" unitRef="usd">437100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-227" decimals="-5" id="f-699" unitRef="usd">75600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-228" decimals="-5" id="f-700" unitRef="usd">24400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-229" decimals="-5" id="f-701" unitRef="usd">100000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-230" decimals="-5" id="f-702" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-231" decimals="-5" id="f-703" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-232" decimals="-5" id="f-704" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-233" decimals="-5" id="f-705" unitRef="usd">4600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-234" decimals="-5" id="f-706" unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-235" decimals="-5" id="f-707" unitRef="usd">5000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-236" decimals="-5" id="f-708" unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-237" decimals="-5" id="f-709" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-238" decimals="-5" id="f-710" unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-239" decimals="-5" id="f-711" unitRef="usd">237500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-240" decimals="-5" id="f-712" unitRef="usd">296600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-241" decimals="-5" id="f-713" unitRef="usd">534100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-242" decimals="-5" id="f-714" unitRef="usd">156700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-243" decimals="-5" id="f-715" unitRef="usd">281300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-244" decimals="-5" id="f-716" unitRef="usd">438000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-245" decimals="-5" id="f-717" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-246" decimals="-5" id="f-718" unitRef="usd">117300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-247" decimals="-5" id="f-719" unitRef="usd">117300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-248" decimals="-5" id="f-720" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-249" decimals="-5" id="f-721" unitRef="usd">109200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-250" decimals="-5" id="f-722" unitRef="usd">109200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-251" decimals="-5" id="f-723" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-252" decimals="-5" id="f-724" unitRef="usd">53200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-253" decimals="-5" id="f-725" unitRef="usd">53200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-254" decimals="-5" id="f-726" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-255" decimals="-5" id="f-727" unitRef="usd">58800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-256" decimals="-5" id="f-728" unitRef="usd">58800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-257" decimals="-5" id="f-729" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-258" decimals="-5" id="f-730" unitRef="usd">13100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-259" decimals="-5" id="f-731" unitRef="usd">13100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-260" decimals="-5" id="f-732" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-261" decimals="-5" id="f-733" unitRef="usd">20100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-262" decimals="-5" id="f-734" unitRef="usd">20100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-263" decimals="-5" id="f-735" unitRef="usd">10300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-264" decimals="-5" id="f-736" unitRef="usd">3400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-265" decimals="-5" id="f-737" unitRef="usd">13700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-266" decimals="-5" id="f-738" unitRef="usd">7000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-267" decimals="-5" id="f-739" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-268" decimals="-5" id="f-740" unitRef="usd">7000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-269" decimals="-5" id="f-741" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-270" decimals="-5" id="f-742" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-271" decimals="-5" id="f-743" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-272" decimals="-5" id="f-744" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-273" decimals="-5" id="f-745" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-274" decimals="-5" id="f-746" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-275" decimals="-5" id="f-747" unitRef="usd">11100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-276" decimals="-5" id="f-748" unitRef="usd">187000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-277" decimals="-5" id="f-749" unitRef="usd">198100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-278" decimals="-5" id="f-750" unitRef="usd">7000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-279" decimals="-5" id="f-751" unitRef="usd">188100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-280" decimals="-5" id="f-752" unitRef="usd">195100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-281" decimals="-5" id="f-753" unitRef="usd">14900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-282" decimals="-5" id="f-754" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-283" decimals="-5" id="f-755" unitRef="usd">14900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-284" decimals="-5" id="f-756" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-285" decimals="-5" id="f-757" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-286" decimals="-5" id="f-758" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-287" decimals="-5" id="f-759" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-288" decimals="-5" id="f-760" unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-289" decimals="-5" id="f-761" unitRef="usd">2700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-290" decimals="-5" id="f-762" unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-291" decimals="-5" id="f-763" unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-292" decimals="-5" id="f-764" unitRef="usd">3400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-293" decimals="-5" id="f-765" unitRef="usd">15700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-294" decimals="-5" id="f-766" unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-295" decimals="-5" id="f-767" unitRef="usd">17600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-296" decimals="-5" id="f-768" unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-297" decimals="-5" id="f-769" unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-298" decimals="-5" id="f-770" unitRef="usd">3400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-299" decimals="-5" id="f-771" unitRef="usd">846700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-300" decimals="-5" id="f-772" unitRef="usd">1052900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-3" decimals="-5" id="f-773" unitRef="usd">1899600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-301" decimals="-5" id="f-774" unitRef="usd">801000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-302" decimals="-5" id="f-775" unitRef="usd">1044800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-5" id="f-776" unitRef="usd">1845800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-303" decimals="-5" id="f-777" unitRef="usd">87800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-304" decimals="-5" id="f-778" unitRef="usd">418700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-305" decimals="-5" id="f-779" unitRef="usd">506500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-306" decimals="-5" id="f-780" unitRef="usd">141200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-307" decimals="-5" id="f-781" unitRef="usd">387500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-308" decimals="-5" id="f-782" unitRef="usd">528700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-309" decimals="-5" id="f-783" unitRef="usd">250100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-310" decimals="-5" id="f-784" unitRef="usd">43200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-311" decimals="-5" id="f-785" unitRef="usd">293300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-312" decimals="-5" id="f-786" unitRef="usd">223800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-313" decimals="-5" id="f-787" unitRef="usd">30600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-314" decimals="-5" id="f-788" unitRef="usd">254400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-315" decimals="-5" id="f-789" unitRef="usd">337900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-316" decimals="-5" id="f-790" unitRef="usd">461900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-317" decimals="-5" id="f-791" unitRef="usd">799800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-318" decimals="-5" id="f-792" unitRef="usd">365000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-319" decimals="-5" id="f-793" unitRef="usd">418100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-320" decimals="-5" id="f-794" unitRef="usd">783100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-321" decimals="-5" id="f-795" unitRef="usd">228400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-322" decimals="-5" id="f-796" unitRef="usd">132900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-323" decimals="-5" id="f-797" unitRef="usd">361300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-324" decimals="-5" id="f-798" unitRef="usd">248500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-325" decimals="-5" id="f-799" unitRef="usd">144200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-326" decimals="-5" id="f-800" unitRef="usd">392700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-327" decimals="-5" id="f-801" unitRef="usd">56800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-328" decimals="-5" id="f-802" unitRef="usd">76400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-329" decimals="-5" id="f-803" unitRef="usd">133200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-330" decimals="-5" id="f-804" unitRef="usd">64000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-331" decimals="-5" id="f-805" unitRef="usd">91300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-332" decimals="-5" id="f-806" unitRef="usd">155300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-333" decimals="-5" id="f-807" unitRef="usd">285200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-334" decimals="-5" id="f-808" unitRef="usd">209300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-335" decimals="-5" id="f-809" unitRef="usd">494500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-336" decimals="-5" id="f-810" unitRef="usd">312500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-337" decimals="-5" id="f-811" unitRef="usd">235500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-338" decimals="-5" id="f-812" unitRef="usd">548000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-339" decimals="-5" id="f-813" unitRef="usd">462500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-340" decimals="-5" id="f-814" unitRef="usd">431000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-341" decimals="-5" id="f-815" unitRef="usd">893500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-342" decimals="-5" id="f-816" unitRef="usd">505300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-343" decimals="-5" id="f-817" unitRef="usd">450600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-344" decimals="-5" id="f-818" unitRef="usd">955900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-345" decimals="-5" id="f-819" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-346" decimals="-5" id="f-820" unitRef="usd">37900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-347" decimals="-5" id="f-821" unitRef="usd">37900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-348" decimals="-5" id="f-822" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-349" decimals="-5" id="f-823" unitRef="usd">47500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-350" decimals="-5" id="f-824" unitRef="usd">47500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-351" decimals="-5" id="f-825" unitRef="usd">1085600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-352" decimals="-5" id="f-826" unitRef="usd">1140100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-353" decimals="-5" id="f-827" unitRef="usd">2225700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-354" decimals="-5" id="f-828" unitRef="usd">1182800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-355" decimals="-5" id="f-829" unitRef="usd">1151700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-356" decimals="-5" id="f-830" unitRef="usd">2334500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-357" decimals="-5" id="f-831" unitRef="usd">305800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-358" decimals="-5" id="f-832" unitRef="usd">464600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-359" decimals="-5" id="f-833" unitRef="usd">770400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-360" decimals="-5" id="f-834" unitRef="usd">302500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-361" decimals="-5" id="f-835" unitRef="usd">577900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-362" decimals="-5" id="f-836" unitRef="usd">880400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-363" decimals="-5" id="f-837" unitRef="usd">148600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-364" decimals="-5" id="f-838" unitRef="usd">29400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-365" decimals="-5" id="f-839" unitRef="usd">178000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-230" decimals="-5" id="f-840" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-231" decimals="-5" id="f-841" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-232" decimals="-5" id="f-842" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-366" decimals="-5" id="f-843" unitRef="usd">9000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-367" decimals="-5" id="f-844" unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-368" decimals="-5" id="f-845" unitRef="usd">9600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-236" decimals="-5" id="f-846" unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-237" decimals="-5" id="f-847" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-238" decimals="-5" id="f-848" unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-369" decimals="-5" id="f-849" unitRef="usd">463400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-370" decimals="-5" id="f-850" unitRef="usd">494600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-371" decimals="-5" id="f-851" unitRef="usd">958000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-372" decimals="-5" id="f-852" unitRef="usd">303400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-373" decimals="-5" id="f-853" unitRef="usd">577900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-374" decimals="-5" id="f-854" unitRef="usd">881300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-375" decimals="-5" id="f-855" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-376" decimals="-5" id="f-856" unitRef="usd">236000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-377" decimals="-5" id="f-857" unitRef="usd">236000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-378" decimals="-5" id="f-858" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-379" decimals="-5" id="f-859" unitRef="usd">218200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-380" decimals="-5" id="f-860" unitRef="usd">218200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-381" decimals="-5" id="f-861" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-382" decimals="-5" id="f-862" unitRef="usd">108000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-383" decimals="-5" id="f-863" unitRef="usd">108000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-384" decimals="-5" id="f-864" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-385" decimals="-5" id="f-865" unitRef="usd">113200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-386" decimals="-5" id="f-866" unitRef="usd">113200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-387" decimals="-5" id="f-867" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-388" decimals="-5" id="f-868" unitRef="usd">30900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-389" decimals="-5" id="f-869" unitRef="usd">30900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-390" decimals="-5" id="f-870" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-391" decimals="-5" id="f-871" unitRef="usd">40500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-392" decimals="-5" id="f-872" unitRef="usd">40500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-393" decimals="-5" id="f-873" unitRef="usd">14000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-394" decimals="-5" id="f-874" unitRef="usd">5300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-395" decimals="-5" id="f-875" unitRef="usd">19300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-396" decimals="-5" id="f-876" unitRef="usd">15200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-397" decimals="-5" id="f-877" unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-398" decimals="-5" id="f-878" unitRef="usd">15600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-399" decimals="-5" id="f-879" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-400" decimals="-5" id="f-880" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-401" decimals="-5" id="f-881" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-402" decimals="-5" id="f-882" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-403" decimals="-5" id="f-883" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-404" decimals="-5" id="f-884" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-405" decimals="-5" id="f-885" unitRef="usd">14800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-406" decimals="-5" id="f-886" unitRef="usd">380200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-407" decimals="-5" id="f-887" unitRef="usd">395000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-408" decimals="-5" id="f-888" unitRef="usd">15200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-409" decimals="-5" id="f-889" unitRef="usd">372300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-410" decimals="-5" id="f-890" unitRef="usd">387500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-411" decimals="-5" id="f-891" unitRef="usd">27300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-412" decimals="-5" id="f-892" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-413" decimals="-5" id="f-893" unitRef="usd">27300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-414" decimals="-5" id="f-894" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-415" decimals="-5" id="f-895" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-416" decimals="-5" id="f-896" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-417" decimals="-5" id="f-897" unitRef="usd">1700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-418" decimals="-5" id="f-898" unitRef="usd">3800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-419" decimals="-5" id="f-899" unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-420" decimals="-5" id="f-900" unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-421" decimals="-5" id="f-901" unitRef="usd">4800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-422" decimals="-5" id="f-902" unitRef="usd">5800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-423" decimals="-5" id="f-903" unitRef="usd">29000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-424" decimals="-5" id="f-904" unitRef="usd">3800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-425" decimals="-5" id="f-905" unitRef="usd">32800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-426" decimals="-5" id="f-906" unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-427" decimals="-5" id="f-907" unitRef="usd">4800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-428" decimals="-5" id="f-908" unitRef="usd">5800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-429" decimals="-5" id="f-909" unitRef="usd">1592800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-430" decimals="-5" id="f-910" unitRef="usd">2018700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-911" unitRef="usd">3611500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-431" decimals="-5" id="f-912" unitRef="usd">1502400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-432" decimals="-5" id="f-913" unitRef="usd">2106700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-914" unitRef="usd">3609100000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="c-1"
      decimals="INF"
      id="f-915"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-15"
      decimals="INF"
      id="f-916"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-16"
      decimals="INF"
      id="f-917"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-17"
      decimals="INF"
      id="f-918"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-433"
      decimals="INF"
      id="f-919"
      unitRef="number">0.254</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-434"
      decimals="INF"
      id="f-920"
      unitRef="number">0.123</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-435"
      decimals="INF"
      id="f-921"
      unitRef="number">0.255</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-436"
      decimals="INF"
      id="f-922"
      unitRef="number">0.120</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="c-1"
      decimals="INF"
      id="f-923"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-15"
      decimals="INF"
      id="f-924"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-16"
      decimals="INF"
      id="f-925"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-17"
      decimals="INF"
      id="f-926"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-437" decimals="3" id="f-927" unitRef="number">0.270</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-438" decimals="3" id="f-928" unitRef="number">0.093</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-439"
      decimals="INF"
      id="f-929"
      unitRef="number">0.272</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-440"
      decimals="INF"
      id="f-930"
      unitRef="number">0.084</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="c-1" id="f-931">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;857.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,355.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,765.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(797.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,058.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(155.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(477.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(643.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;910.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-441" decimals="-5" id="f-932" unitRef="usd">173300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-442" decimals="-5" id="f-933" unitRef="usd">857100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-443" decimals="-5" id="f-934" unitRef="usd">31600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-19" decimals="-5" id="f-935" unitRef="usd">1062000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-444" decimals="-5" id="f-936" unitRef="usd">399300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-445" decimals="-5" id="f-937" unitRef="usd">1355200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-446" decimals="-5" id="f-938" unitRef="usd">10600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-1" decimals="-5" id="f-939" unitRef="usd">1765100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-444" decimals="-5" id="f-940" unitRef="usd">-5600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-445" decimals="-5" id="f-941" unitRef="usd">27300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-446" decimals="-5" id="f-942" unitRef="usd">-12700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-1" decimals="-5" id="f-943" unitRef="usd">9000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-444" decimals="-5" id="f-944" unitRef="usd">260100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-445" decimals="-5" id="f-945" unitRef="usd">797800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-446" decimals="-5" id="f-946" unitRef="usd">300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-1" decimals="-5" id="f-947" unitRef="usd">1058200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-444" decimals="-5" id="f-948" unitRef="usd">155800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-445" decimals="-5" id="f-949" unitRef="usd">477000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-446" decimals="-5" id="f-950" unitRef="usd">11100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-1" decimals="-5" id="f-951" unitRef="usd">643900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-447" decimals="-5" id="f-952" unitRef="usd">162300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-448" decimals="-5" id="f-953" unitRef="usd">910200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-449" decimals="-5" id="f-954" unitRef="usd">43500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-18" decimals="-5" id="f-955" unitRef="usd">1116000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="c-1" id="f-956">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;964.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-450" decimals="-5" id="f-957" unitRef="usd">151500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-451" decimals="-5" id="f-958" unitRef="usd">135500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-452" decimals="-5" id="f-959" unitRef="usd">964500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-453" decimals="-5" id="f-960" unitRef="usd">926500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-18" decimals="-5" id="f-961" unitRef="usd">1116000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-19" decimals="-5" id="f-962" unitRef="usd">1062000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock contextRef="c-1" id="f-963">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty revenue on sales of OCREVUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;639.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;832.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <us-gaap:Revenues contextRef="c-454" decimals="-5" id="f-964" unitRef="usd">336300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-455" decimals="-5" id="f-965" unitRef="usd">325500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-456" decimals="-5" id="f-966" unitRef="usd">639000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-457" decimals="-5" id="f-967" unitRef="usd">609100000</us-gaap:Revenues>
    <biib:ShareOfCoPromotionProfits contextRef="c-458" decimals="-5" id="f-968" unitRef="usd">103400000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-459" decimals="-5" id="f-969" unitRef="usd">103600000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-460" decimals="-5" id="f-970" unitRef="usd">190500000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-461" decimals="-5" id="f-971" unitRef="usd">216100000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-458" decimals="-5" id="f-972" unitRef="usd">4800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-459" decimals="-5" id="f-973" unitRef="usd">4300000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-460" decimals="-5" id="f-974" unitRef="usd">9000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-461" decimals="-5" id="f-975" unitRef="usd">7700000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-976" unitRef="usd">444500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-977" unitRef="usd">433400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-5" id="f-978" unitRef="usd">838500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-5" id="f-979" unitRef="usd">832900000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock contextRef="c-1" id="f-980">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing, royalty and other revenue is summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.336%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract manufacturing, royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues contextRef="c-462" decimals="-5" id="f-981" unitRef="usd">100000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-463" decimals="-5" id="f-982" unitRef="usd">183100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-464" decimals="-5" id="f-983" unitRef="usd">252200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-465" decimals="-5" id="f-984" unitRef="usd">490000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-466" decimals="-5" id="f-985" unitRef="usd">20800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-467" decimals="-5" id="f-986" unitRef="usd">-6300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-468" decimals="-5" id="f-987" unitRef="usd">53200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-469" decimals="-5" id="f-988" unitRef="usd">-13000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-5" id="f-989" unitRef="usd">120800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-5" id="f-990" unitRef="usd">176800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-5" id="f-991" unitRef="usd">305400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-5" id="f-992" unitRef="usd">477000000.0</us-gaap:Revenues>
    <biib:ShareOfNonControlingInterestRecognized contextRef="c-470" decimals="2" id="f-993" unitRef="number">0.500</biib:ShareOfNonControlingInterestRecognized>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-994">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;401.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,821.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,926.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,506.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,527.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recorded approximately $1.3&#160;billion of acquired inventory, which includes measurement period adjustments, related to SKYCLARYS as a result of our acquisition of Reata in September 2023. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income when the inventory is sold, which is expected to be within approximately 3 years from the acquisition date. For the three and six months ended June 30, 2024, amortization from the fair value step-up adjustment was approximately $90.1&#160;million and $134.2&#160;million, respectively, which includes approximately $46.0&#160;million of inventory used for clinical purposes rather than for commercial sale during the second quarter of 2024, and therefore reflected within research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-995">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;401.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,821.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,926.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,506.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,527.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-18" decimals="-5" id="f-996" unitRef="usd">401200000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-19" decimals="-5" id="f-997" unitRef="usd">426900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-18" decimals="-5" id="f-998" unitRef="usd">1821200000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-19" decimals="-5" id="f-999" unitRef="usd">1926800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-18" decimals="-5" id="f-1000" unitRef="usd">395000000.0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-19" decimals="-5" id="f-1001" unitRef="usd">255400000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-18" decimals="-5" id="f-1002" unitRef="usd">2617400000</biib:InventoryNetCurrentAndNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-19" decimals="-5" id="f-1003" unitRef="usd">2609100000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:InventoryNet contextRef="c-18" decimals="-5" id="f-1004" unitRef="usd">2506100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-5" id="f-1005" unitRef="usd">2527400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent contextRef="c-18" decimals="-5" id="f-1006" unitRef="usd">111300000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-19" decimals="-5" id="f-1007" unitRef="usd">81700000</us-gaap:InventoryNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-18" decimals="-5" id="f-1008" unitRef="usd">2617400000</biib:InventoryNetCurrentAndNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-19" decimals="-5" id="f-1009" unitRef="usd">2609100000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-94" decimals="-8" id="f-1010" unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod contextRef="c-94" id="f-1011">P3Y</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod>
    <us-gaap:ProfitLoss contextRef="c-104" decimals="-5" id="f-1012" unitRef="usd">-90100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-105" decimals="-5" id="f-1013" unitRef="usd">-134200000</us-gaap:ProfitLoss>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-106" decimals="-5" id="f-1014" unitRef="usd">46000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-1015">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquired and in-licensed rights and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,515.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,595.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,919.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,440.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,739.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13-31 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,548.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,439.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,548.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,429.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,063.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,035.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,028.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,869.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,859.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,340.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,340.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,267.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,035.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,232.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,869.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,363.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2024, amortization and impairment of acquired intangible assets totale&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$86.9 million and $165.2 million, respectively,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;compared to $52.9 million and $103.1 million, respectively, in the prior year comparative periods. The increases were primarily due to amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS. For the three and six months ended June 30, 2024 and 2023, we had no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between 2 to 31 years, with a remaining weighted average useful life of 12 years for acquired and in-licensed rights and patents and 10 years for developed technology and other. In connection with our acquisition of Reata in September 2023 we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately $4.2&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset, with an estimated fair value of approximately $2.3&#160;billion, from IPR&amp;amp;D to completed technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. The carrying value associated with our IPR&amp;amp;D assets as of December 31, 2023, related to the IPR&amp;amp;D programs we acquired in connection with our acquisition of Reata in September 2023, with an estimated fair value of approximately $2.3&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset from IPR&amp;amp;D to completed technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease priority review voucher that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $100.0&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;565.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;660.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;680.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;710.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from Reata acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,227.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ac&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="c-1" id="f-1016">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquired and in-licensed rights and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,515.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,595.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,919.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,440.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,739.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13-31 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,548.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,439.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,548.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,429.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,063.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,035.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,028.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,869.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,859.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,340.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,340.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,267.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,035.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,232.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,869.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,363.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-471" id="f-1017">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-472" id="f-1018">P22Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-473" decimals="-5" id="f-1019" unitRef="usd">10515300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-473" decimals="-5" id="f-1020" unitRef="usd">2595900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-473" decimals="-5" id="f-1021" unitRef="usd">7919400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-474" decimals="-5" id="f-1022" unitRef="usd">8180200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-474" decimals="-5" id="f-1023" unitRef="usd">2440700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-474" decimals="-5" id="f-1024" unitRef="usd">5739500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-475" id="f-1025">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-476" id="f-1026">P31Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-477" decimals="-5" id="f-1027" unitRef="usd">3548600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-477" decimals="-5" id="f-1028" unitRef="usd">3439100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-477" decimals="-5" id="f-1029" unitRef="usd">109500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-478" decimals="-5" id="f-1030" unitRef="usd">3548600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-478" decimals="-5" id="f-1031" unitRef="usd">3429100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-478" decimals="-5" id="f-1032" unitRef="usd">119500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-18" decimals="-5" id="f-1033" unitRef="usd">14063900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-18" decimals="-5" id="f-1034" unitRef="usd">6035000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-18" decimals="-5" id="f-1035" unitRef="usd">8028900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-19" decimals="-5" id="f-1036" unitRef="usd">11728800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-19" decimals="-5" id="f-1037" unitRef="usd">5869800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-19" decimals="-5" id="f-1038" unitRef="usd">5859000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-479" decimals="-5" id="f-1039" unitRef="usd">40000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-479" decimals="-5" id="f-1040" unitRef="usd">40000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-480" decimals="-5" id="f-1041" unitRef="usd">2340000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-480" decimals="-5" id="f-1042" unitRef="usd">2340000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-481" decimals="-5" id="f-1043" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-481" decimals="-5" id="f-1044" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-482" decimals="-5" id="f-1045" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-482" decimals="-5" id="f-1046" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-483" decimals="-5" id="f-1047" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-483" decimals="-5" id="f-1048" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-484" decimals="-5" id="f-1049" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-484" decimals="-5" id="f-1050" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-18" decimals="-5" id="f-1051" unitRef="usd">14267900000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-18" decimals="-5" id="f-1052" unitRef="usd">6035000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-18" decimals="-5" id="f-1053" unitRef="usd">8232900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-19" decimals="-5" id="f-1054" unitRef="usd">14232800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-19" decimals="-5" id="f-1055" unitRef="usd">5869800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-19" decimals="-5" id="f-1056" unitRef="usd">8363000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-15" decimals="-5" id="f-1057" unitRef="usd">86900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-1" decimals="-5" id="f-1058" unitRef="usd">165200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-16" decimals="-5" id="f-1059" unitRef="usd">52900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-17" decimals="-5" id="f-1060" unitRef="usd">103100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-17" decimals="-5" id="f-1061" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-16" decimals="-5" id="f-1062" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="-5" id="f-1063" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-15" decimals="-5" id="f-1064" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-485" id="f-1065">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-486" id="f-1066">P31Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife contextRef="c-473" id="f-1067">P12Y</biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife>
    <biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife contextRef="c-477" id="f-1068">P10Y</biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-107" decimals="-8" id="f-1069" unitRef="usd">4200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-108" decimals="-8" id="f-1070" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-108" decimals="-8" id="f-1071" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-109" decimals="-5" id="f-1072" unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1073">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;565.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;660.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;680.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;710.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-18" decimals="-5" id="f-1074" unitRef="usd">185000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-18" decimals="-5" id="f-1075" unitRef="usd">565000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-18" decimals="-5" id="f-1076" unitRef="usd">660000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-18" decimals="-5" id="f-1077" unitRef="usd">680000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-18" decimals="-5" id="f-1078" unitRef="usd">710000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-18" decimals="-5" id="f-1079" unitRef="usd">720000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1080">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from Reata acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,227.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-19" decimals="-5" id="f-1081" unitRef="usd">6219200000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-5" id="f-1082" unitRef="usd">9000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-1" decimals="-5" id="f-1083" unitRef="usd">-800000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill contextRef="c-18" decimals="-5" id="f-1084" unitRef="usd">6227400000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-18" decimals="INF" id="f-1085" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1087">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,816.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,513.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,506.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;660.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Denali, Sangamo and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value as of June 30, 2024 and December 31, 2023. In addition, there have been no changes to our valuation techniques as of June 30, 2024 and December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Level 3 Assets and Liabilities Held at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of assets or liabilities into or out of Level 3 as of June 30, 2024 and December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial Instruments Not Carried at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 Term Loan 364-day tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 Term Loan three-year tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,718.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,747.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,721.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,746.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,275.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,018.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;969.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current portion of notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,448.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,292.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,788.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,448.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,292.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,287.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,938.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of June 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of June 30, 2024, compared to December 31, 2023, are primarily related to increases in U.S. treasury yields partially offset by a decrease in credit spreads used to value our Senior Notes since December 31, 2023. For additional information related to our Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1086">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,816.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,513.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,506.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;660.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-487" decimals="-5" id="f-1088" unitRef="usd">1449700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-488" decimals="-5" id="f-1089" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-489" decimals="-5" id="f-1090" unitRef="usd">1449700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-490" decimals="-5" id="f-1091" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-487" decimals="-5" id="f-1092" unitRef="usd">302700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-488" decimals="-5" id="f-1093" unitRef="usd">302700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-489" decimals="-5" id="f-1094" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-490" decimals="-5" id="f-1095" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-487" decimals="-5" id="f-1096" unitRef="usd">23400000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-488" decimals="-5" id="f-1097" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-489" decimals="-5" id="f-1098" unitRef="usd">23400000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-490" decimals="-5" id="f-1099" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-487" decimals="-5" id="f-1100" unitRef="usd">38500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-488" decimals="-5" id="f-1101" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-489" decimals="-5" id="f-1102" unitRef="usd">38500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-490" decimals="-5" id="f-1103" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:DerivativeAssets contextRef="c-18" decimals="-5" id="f-1104" unitRef="usd">1800000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-488" decimals="-5" id="f-1105" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-489" decimals="-5" id="f-1106" unitRef="usd">1800000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-490" decimals="-5" id="f-1107" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-487" decimals="-5" id="f-1108" unitRef="usd">1816100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-488" decimals="-5" id="f-1109" unitRef="usd">302700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-489" decimals="-5" id="f-1110" unitRef="usd">1513400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-490" decimals="-5" id="f-1111" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-487" decimals="-5" id="f-1112" unitRef="usd">18600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-488" decimals="-5" id="f-1113" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-489" decimals="-5" id="f-1114" unitRef="usd">18600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-490" decimals="-5" id="f-1115" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-487" decimals="-5" id="f-1116" unitRef="usd">18600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-488" decimals="-5" id="f-1117" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-489" decimals="-5" id="f-1118" unitRef="usd">18600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-490" decimals="-5" id="f-1119" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-491" decimals="-5" id="f-1120" unitRef="usd">610700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-492" decimals="-5" id="f-1121" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-493" decimals="-5" id="f-1122" unitRef="usd">610700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-494" decimals="-5" id="f-1123" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-491" decimals="-5" id="f-1124" unitRef="usd">416800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-492" decimals="-5" id="f-1125" unitRef="usd">416800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-493" decimals="-5" id="f-1126" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-494" decimals="-5" id="f-1127" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-495" decimals="-5" id="f-1128" unitRef="usd">430000000.0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-496" decimals="-5" id="f-1129" unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-497" decimals="-5" id="f-1130" unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-498" decimals="-5" id="f-1131" unitRef="usd">430000000.0</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-491" decimals="-5" id="f-1132" unitRef="usd">11900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-492" decimals="-5" id="f-1133" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-493" decimals="-5" id="f-1134" unitRef="usd">11900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-494" decimals="-5" id="f-1135" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-491" decimals="-5" id="f-1136" unitRef="usd">37500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-492" decimals="-5" id="f-1137" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-493" decimals="-5" id="f-1138" unitRef="usd">37500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-494" decimals="-5" id="f-1139" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-491" decimals="-5" id="f-1140" unitRef="usd">1506900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-492" decimals="-5" id="f-1141" unitRef="usd">416800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-493" decimals="-5" id="f-1142" unitRef="usd">660100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-494" decimals="-5" id="f-1143" unitRef="usd">430000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-491" decimals="-5" id="f-1144" unitRef="usd">31600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-492" decimals="-5" id="f-1145" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-493" decimals="-5" id="f-1146" unitRef="usd">31600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-494" decimals="-5" id="f-1147" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-491" decimals="-5" id="f-1148" unitRef="usd">31600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-492" decimals="-5" id="f-1149" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-493" decimals="-5" id="f-1150" unitRef="usd">31600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-494" decimals="-5" id="f-1151" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-499"
      decimals="3"
      id="f-1152"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AssetImpairmentCharges contextRef="c-15" decimals="INF" id="f-1153" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-1154" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-1155">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 Term Loan 364-day tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 Term Loan three-year tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,718.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,747.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,721.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,746.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,275.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,018.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;969.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current portion of notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,448.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,292.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,788.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,448.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,292.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,287.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,938.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of June 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-500" decimals="-5" id="f-1156" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-500" decimals="-5" id="f-1157" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-501" decimals="-5" id="f-1158" unitRef="usd">150000000.0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-501" decimals="-5" id="f-1159" unitRef="usd">150000000.0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-502" decimals="-5" id="f-1160" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-502" decimals="-5" id="f-1161" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-503" decimals="-5" id="f-1162" unitRef="usd">150000000.0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-503" decimals="-5" id="f-1163" unitRef="usd">150000000.0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-504" decimals="-5" id="f-1164" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-504" decimals="-5" id="f-1165" unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-505" decimals="-5" id="f-1166" unitRef="usd">500000000.0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-505" decimals="-5" id="f-1167" unitRef="usd">500000000.0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-506" decimals="-5" id="f-1168" unitRef="usd">1718700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-506" decimals="-5" id="f-1169" unitRef="usd">1747600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-507" decimals="-5" id="f-1170" unitRef="usd">1721500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-508" decimals="-5" id="f-1171" unitRef="usd">1746600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-509" decimals="-5" id="f-1172" unitRef="usd">1275900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-509" decimals="-5" id="f-1173" unitRef="usd">1494300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-510" decimals="-5" id="f-1174" unitRef="usd">1279300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-511" decimals="-5" id="f-1175" unitRef="usd">1493800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-512" decimals="-5" id="f-1176" unitRef="usd">1018800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-512" decimals="-5" id="f-1177" unitRef="usd">1100800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-513" decimals="-5" id="f-1178" unitRef="usd">1089700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-514" decimals="-5" id="f-1179" unitRef="usd">1100700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-515" decimals="-5" id="f-1180" unitRef="usd">969300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-515" decimals="-5" id="f-1181" unitRef="usd">1474700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-516" decimals="-5" id="f-1182" unitRef="usd">1049000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-517" decimals="-5" id="f-1183" unitRef="usd">1474300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-518" decimals="-5" id="f-1184" unitRef="usd">466200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-518" decimals="-5" id="f-1185" unitRef="usd">474600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-519" decimals="-5" id="f-1186" unitRef="usd">498200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-520" decimals="-5" id="f-1187" unitRef="usd">472800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-521" decimals="-5" id="f-1188" unitRef="usd">5448900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-521" decimals="-5" id="f-1189" unitRef="usd">6292000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-522" decimals="-5" id="f-1190" unitRef="usd">6137700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-522" decimals="-5" id="f-1191" unitRef="usd">6788200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-18" decimals="-5" id="f-1192" unitRef="usd">5448900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-18" decimals="-5" id="f-1193" unitRef="usd">6292000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-19" decimals="-5" id="f-1194" unitRef="usd">6287700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-19" decimals="-5" id="f-1195" unitRef="usd">6938200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-97" decimals="-8" id="f-1196" unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-523" decimals="-3" id="f-1197" unitRef="usd">500000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-524" decimals="-3" id="f-1198" unitRef="usd">500000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-1199">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of our money market funds approximates fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable equity securities, classified as available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(497.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(497.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;948.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(542.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(563.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.747%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,275.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,682.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of December 31, 2023, we have sold all of our marketable debt securities. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized losses for the three and six months ended June 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, our strategic investment portfolio was comprised of investments totaling $352.3 million which are included in investments and other assets in our condensed consolidated balance sheets. As of December 31, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023, our strategic investment portfolio was comprised of investments totaling $460.7 million which are included in other current assets and investments and other assets within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our strategic investment portfolio as of June 30, 2024, was primarily due to the decrease in the fair value of our investment in Sage common stock as well as the sale of a portion of our Denali and Sangamo common stock during 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-1200">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-525" decimals="-5" id="f-1201" unitRef="usd">1449700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-526" decimals="-5" id="f-1202" unitRef="usd">610700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-18" decimals="-5" id="f-1203" unitRef="usd">1449700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-19" decimals="-5" id="f-1204" unitRef="usd">610700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-1205">The following tables summarize our marketable equity securities, classified as available-for-sale:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(497.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(497.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;948.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(542.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(563.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-527" decimals="-5" id="f-1206" unitRef="usd">800200000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-527" decimals="-5" id="f-1207" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-527" decimals="-5" id="f-1208" unitRef="usd">497500000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-527" decimals="-5" id="f-1209" unitRef="usd">302700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-18" decimals="-5" id="f-1210" unitRef="usd">800200000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-18" decimals="-5" id="f-1211" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-18" decimals="-5" id="f-1212" unitRef="usd">497500000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-18" decimals="-5" id="f-1213" unitRef="usd">302700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-528" decimals="-5" id="f-1214" unitRef="usd">31600000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-528" decimals="-5" id="f-1215" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-528" decimals="-5" id="f-1216" unitRef="usd">21000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-528" decimals="-5" id="f-1217" unitRef="usd">10600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-529" decimals="-5" id="f-1218" unitRef="usd">948300000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-529" decimals="-5" id="f-1219" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-529" decimals="-5" id="f-1220" unitRef="usd">542100000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-529" decimals="-5" id="f-1221" unitRef="usd">406200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-19" decimals="-5" id="f-1222" unitRef="usd">979900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-19" decimals="-5" id="f-1223" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-19" decimals="-5" id="f-1224" unitRef="usd">563100000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-19" decimals="-5" id="f-1225" unitRef="usd">416800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="c-1" id="f-1226">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.747%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,275.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,682.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-16" decimals="-5" id="f-1227" unitRef="usd">1275500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-17" decimals="-5" id="f-1228" unitRef="usd">1682200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-16" decimals="-5" id="f-1229" unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-17" decimals="-5" id="f-1230" unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-16" decimals="-5" id="f-1231" unitRef="usd">-1400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-17" decimals="-5" id="f-1232" unitRef="usd">-2100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio contextRef="c-530" decimals="-5" id="f-1233" unitRef="usd">352300000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio contextRef="c-531" decimals="-5" id="f-1234" unitRef="usd">460700000</biib:StrategicInvestmentPortfolio>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-1235">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts and foreign currency options in effect as of June 30, 2024 and December 31, 2023, had durations of 1 to 15 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,420.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,658.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the net unrealized gains of approximately $3.4&#160;million to be settled over the next 15 months, of which approximately $1.9&#160;million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2024 and December 31, 2023, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,199.3 million and $1,301.5 million as of June 30, 2024 and December 31, 2023, respectively. Net losses of $5.7 million and $30.0 million related to these contracts were recorded as a component of other (income) expense, net for the three and six months ended June 30, 2024, respectively, compared to net losses of $7.2 million and $5.4 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-532" id="f-1236">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-533" id="f-1237">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-534" id="f-1238">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-535" id="f-1239">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="c-1" id="f-1240">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,420.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,658.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-536" decimals="-5" id="f-1241" unitRef="usd">1420300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-537" decimals="-5" id="f-1242" unitRef="usd">1169000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-538" decimals="-5" id="f-1243" unitRef="usd">69600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-539" decimals="-5" id="f-1244" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-540" decimals="-5" id="f-1245" unitRef="usd">142400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-541" decimals="-5" id="f-1246" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-542" decimals="-5" id="f-1247" unitRef="usd">26200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-543" decimals="-5" id="f-1248" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-544" decimals="-5" id="f-1249" unitRef="usd">1658500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-545" decimals="-5" id="f-1250" unitRef="usd">1169000000</us-gaap:DerivativeNotionalAmount>
    <biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock contextRef="c-1" id="f-1251">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock>
    <biib:UnrealizedGainOnDerivatives contextRef="c-1" decimals="-5" id="f-1252" unitRef="usd">12900000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedGainOnDerivatives contextRef="c-17" decimals="-5" id="f-1253" unitRef="usd">0</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedLossOnDerivatives contextRef="c-1" decimals="-5" id="f-1254" unitRef="usd">9500000</biib:UnrealizedLossOnDerivatives>
    <biib:UnrealizedLossOnDerivatives contextRef="c-17" decimals="-5" id="f-1255" unitRef="usd">34800000</biib:UnrealizedLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-5" id="f-1256" unitRef="usd">3400000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-17" decimals="-5" id="f-1257" unitRef="usd">-34800000</us-gaap:UnrealizedGainLossOnDerivatives>
    <biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months contextRef="c-18" decimals="-5" id="f-1258" unitRef="usd">3400000</biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months contextRef="c-18" decimals="-5" id="f-1259" unitRef="usd">1900000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1260">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-546" decimals="-5" id="f-1261" unitRef="usd">7600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-547" decimals="-5" id="f-1262" unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-548" decimals="-5" id="f-1263" unitRef="usd">900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-549" decimals="-5" id="f-1264" unitRef="usd">-1000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-550" decimals="-5" id="f-1265" unitRef="usd">-4900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-551" decimals="-5" id="f-1266" unitRef="usd">1400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-552" decimals="-5" id="f-1267" unitRef="usd">-700000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-553" decimals="-5" id="f-1268" unitRef="usd">-800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-554" decimals="-5" id="f-1269" unitRef="usd">10500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-555" decimals="-5" id="f-1270" unitRef="usd">20000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-556" decimals="-5" id="f-1271" unitRef="usd">1100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-557" decimals="-5" id="f-1272" unitRef="usd">600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-558" decimals="-5" id="f-1273" unitRef="usd">-7000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-559" decimals="-5" id="f-1274" unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-560" decimals="-5" id="f-1275" unitRef="usd">-1900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-561" decimals="-5" id="f-1276" unitRef="usd">-2900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeNotionalAmount contextRef="c-562" decimals="-5" id="f-1277" unitRef="usd">1199300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-563" decimals="-5" id="f-1278" unitRef="usd">1301500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-15" decimals="-5" id="f-1279" unitRef="usd">-5700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-1" decimals="-5" id="f-1280" unitRef="usd">-30000000.0</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-16" decimals="-5" id="f-1281" unitRef="usd">7200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-17" decimals="-5" id="f-1282" unitRef="usd">5400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-1283">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-564" decimals="-5" id="f-1284" unitRef="usd">17600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-565" decimals="-5" id="f-1285" unitRef="usd">300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-566" decimals="-5" id="f-1286" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-567" decimals="-5" id="f-1287" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-568" decimals="-5" id="f-1288" unitRef="usd">8300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-569" decimals="-5" id="f-1289" unitRef="usd">26500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-570" decimals="-5" id="f-1290" unitRef="usd">5800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-571" decimals="-5" id="f-1291" unitRef="usd">11600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-572" decimals="-5" id="f-1292" unitRef="usd">10300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-573" decimals="-5" id="f-1293" unitRef="usd">5100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-1294">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,537.4 million and $2,402.5 million as of June 30, 2024 and December 31, 2023, respectively. For the three and six months ended June 30, 2024, depreciation expense totaled $71.9 million and $141.2 million, respectively, compared to $64.5 million and $126.6 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we built a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility includes 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of December 31, 2023, we had approximately $728.8 million capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of this facility (the first manufacturing suite) received a GMP multi-product license from the SWISSMEDIC and was placed into service. The second manufacturing suite, which was also licensed to operate by the SWISSMEDIC, became operational in the first quarter of 2024, resulting in approximately $717.3&#160;million of fixed assets being placed into service. Solothurn has been approved for the manufacture of LEQEMBI by the FDA.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-18" decimals="-5" id="f-1295" unitRef="usd">2537400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-19" decimals="-5" id="f-1296" unitRef="usd">2402500000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-1297" unitRef="usd">71900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1298" unitRef="usd">141200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-5" id="f-1299" unitRef="usd">64500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-17" decimals="-5" id="f-1300" unitRef="usd">126600000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="c-574"
      decimals="INF"
      id="f-1301"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="c-575"
      decimals="INF"
      id="f-1302"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="c-576"
      decimals="INF"
      id="f-1303"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross contextRef="c-577" decimals="-5" id="f-1304" unitRef="usd">728800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-578" decimals="-5" id="f-1305" unitRef="usd">717300000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1306">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;6100 Legacy Drive Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $121.2&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <biib:OperatingLeaseArea contextRef="c-94" decimals="0" id="f-1307" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-94" id="f-1308">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-94" decimals="-5" id="f-1309" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-94" id="f-1310">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-94" decimals="-5" id="f-1311" unitRef="usd">121200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1312">Credit Agreement&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement (2023 Term Loan). On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid $350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion of the three-year tranche being subsequently repaid during the second quarter of 2024. As of June 30, 2024, the 2023 Term Loan was paid in full. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-579" decimals="-3" id="f-1313" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-97" decimals="-8" id="f-1314" unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-523" decimals="-3" id="f-1315" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-524" decimals="-3" id="f-1316" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-580" decimals="-3" id="f-1317" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths contextRef="c-581" decimals="-5" id="f-1318" unitRef="usd">350000000</us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-582" decimals="-5" id="f-1319" unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-583" decimals="-5" id="f-1320" unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-584" decimals="-5" id="f-1321" unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1322">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and six months ended June 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in AOCI, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(147.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(141.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(172.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(172.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(172.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from AOCI:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-585" decimals="INF" id="f-1323" unitRef="usd">5000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-586" decimals="-8" id="f-1324" unitRef="usd">2100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1325">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in AOCI, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(147.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(141.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(172.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(172.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(172.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-587" decimals="-5" id="f-1326" unitRef="usd">-10300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-588" decimals="-5" id="f-1327" unitRef="usd">-2700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-589" decimals="-5" id="f-1328" unitRef="usd">-147500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-5" id="f-1329" unitRef="usd">-160500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-590" decimals="-5" id="f-1330" unitRef="usd">22300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-591" decimals="-5" id="f-1331" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-592" decimals="-5" id="f-1332" unitRef="usd">-5600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-15" decimals="-5" id="f-1333" unitRef="usd">16700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-590" decimals="-5" id="f-1334" unitRef="usd">-2200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-591" decimals="-5" id="f-1335" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-592" decimals="-5" id="f-1336" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-15" decimals="-5" id="f-1337" unitRef="usd">-2200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-590" decimals="-5" id="f-1338" unitRef="usd">20100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-591" decimals="-5" id="f-1339" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-592" decimals="-5" id="f-1340" unitRef="usd">-5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-5" id="f-1341" unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-593" decimals="-5" id="f-1342" unitRef="usd">9800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-594" decimals="-5" id="f-1343" unitRef="usd">-2700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-595" decimals="-5" id="f-1344" unitRef="usd">-153100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-5" id="f-1345" unitRef="usd">-146000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-596" decimals="-5" id="f-1346" unitRef="usd">-25000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-597" decimals="-5" id="f-1347" unitRef="usd">-2600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-598" decimals="-5" id="f-1348" unitRef="usd">-126100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-5" id="f-1349" unitRef="usd">-153700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-599" decimals="-5" id="f-1350" unitRef="usd">37700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-600" decimals="-5" id="f-1351" unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-601" decimals="-5" id="f-1352" unitRef="usd">-27000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-1" decimals="-5" id="f-1353" unitRef="usd">10600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-599" decimals="-5" id="f-1354" unitRef="usd">-2900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-600" decimals="-5" id="f-1355" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-601" decimals="-5" id="f-1356" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-1" decimals="-5" id="f-1357" unitRef="usd">-2900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-599" decimals="-5" id="f-1358" unitRef="usd">34800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-600" decimals="-5" id="f-1359" unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-601" decimals="-5" id="f-1360" unitRef="usd">-27000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-5" id="f-1361" unitRef="usd">7700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-593" decimals="-5" id="f-1362" unitRef="usd">9800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-594" decimals="-5" id="f-1363" unitRef="usd">-2700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-595" decimals="-5" id="f-1364" unitRef="usd">-153100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-5" id="f-1365" unitRef="usd">-146000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-602" decimals="-5" id="f-1366" unitRef="usd">-10000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-603" decimals="-5" id="f-1367" unitRef="usd">-20300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-604" decimals="-5" id="f-1368" unitRef="usd">-600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-605" decimals="-5" id="f-1369" unitRef="usd">-141100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-65" decimals="-5" id="f-1370" unitRef="usd">-172000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-606" decimals="-5" id="f-1371" unitRef="usd">-5500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-607" decimals="-5" id="f-1372" unitRef="usd">10200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-608" decimals="-5" id="f-1373" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-609" decimals="-5" id="f-1374" unitRef="usd">-3400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-16" decimals="-5" id="f-1375" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-606" decimals="-5" id="f-1376" unitRef="usd">1000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-607" decimals="-5" id="f-1377" unitRef="usd">-3300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-608" decimals="-5" id="f-1378" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-609" decimals="-5" id="f-1379" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-16" decimals="-5" id="f-1380" unitRef="usd">-2300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-606" decimals="-5" id="f-1381" unitRef="usd">-4500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-607" decimals="-5" id="f-1382" unitRef="usd">6900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-608" decimals="-5" id="f-1383" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-609" decimals="-5" id="f-1384" unitRef="usd">-3400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-16" decimals="-5" id="f-1385" unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-610" decimals="-5" id="f-1386" unitRef="usd">-14500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-611" decimals="-5" id="f-1387" unitRef="usd">-13400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-612" decimals="-5" id="f-1388" unitRef="usd">-400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-613" decimals="-5" id="f-1389" unitRef="usd">-144500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-5" id="f-1390" unitRef="usd">-172800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-614" decimals="-5" id="f-1391" unitRef="usd">-15700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-615" decimals="-5" id="f-1392" unitRef="usd">15100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-616" decimals="-5" id="f-1393" unitRef="usd">-1100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-617" decimals="-5" id="f-1394" unitRef="usd">-163200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-28" decimals="-5" id="f-1395" unitRef="usd">-164900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-618" decimals="-5" id="f-1396" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-619" decimals="-5" id="f-1397" unitRef="usd">-10100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-620" decimals="-5" id="f-1398" unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-621" decimals="-5" id="f-1399" unitRef="usd">18700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-17" decimals="-5" id="f-1400" unitRef="usd">9100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-618" decimals="-5" id="f-1401" unitRef="usd">1400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-619" decimals="-5" id="f-1402" unitRef="usd">-18400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-620" decimals="-5" id="f-1403" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-621" decimals="-5" id="f-1404" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-17" decimals="-5" id="f-1405" unitRef="usd">-17000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-618" decimals="-5" id="f-1406" unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-619" decimals="-5" id="f-1407" unitRef="usd">-28500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-620" decimals="-5" id="f-1408" unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-621" decimals="-5" id="f-1409" unitRef="usd">18700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-5" id="f-1410" unitRef="usd">-7900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-610" decimals="-5" id="f-1411" unitRef="usd">-14500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-611" decimals="-5" id="f-1412" unitRef="usd">-13400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-612" decimals="-5" id="f-1413" unitRef="usd">-400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-613" decimals="-5" id="f-1414" unitRef="usd">-144500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-5" id="f-1415" unitRef="usd">-172800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="c-1" id="f-1416">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from AOCI:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-622" decimals="-5" id="f-1417" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-623" decimals="-5" id="f-1418" unitRef="usd">-1300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-624" decimals="-5" id="f-1419" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-625" decimals="-5" id="f-1420" unitRef="usd">-1800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-622" decimals="-5" id="f-1421" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-623" decimals="-5" id="f-1422" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-624" decimals="-5" id="f-1423" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-625" decimals="-5" id="f-1424" unitRef="usd">400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues contextRef="c-626" decimals="-5" id="f-1425" unitRef="usd">7600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-627" decimals="-5" id="f-1426" unitRef="usd">2400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-628" decimals="-5" id="f-1427" unitRef="usd">10500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-629" decimals="-5" id="f-1428" unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c-626" decimals="-5" id="f-1429" unitRef="usd">4900000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-627" decimals="-5" id="f-1430" unitRef="usd">-1400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-628" decimals="-5" id="f-1431" unitRef="usd">7000000.0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-629" decimals="-5" id="f-1432" unitRef="usd">-900000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-626" decimals="-5" id="f-1433" unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-627" decimals="-5" id="f-1434" unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-628" decimals="-5" id="f-1435" unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-629" decimals="-5" id="f-1436" unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-626" decimals="-5" id="f-1437" unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-627" decimals="-5" id="f-1438" unitRef="usd">-400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-628" decimals="-5" id="f-1439" unitRef="usd">-500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-629" decimals="-5" id="f-1440" unitRef="usd">-2300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-630" decimals="-5" id="f-1441" unitRef="usd">2200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-631" decimals="-5" id="f-1442" unitRef="usd">2300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-632" decimals="-5" id="f-1443" unitRef="usd">2900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-633" decimals="-5" id="f-1444" unitRef="usd">17000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1445">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;583.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;591.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1446">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;583.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;591.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-1447" unitRef="usd">583600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-1448" unitRef="usd">591600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-1449" unitRef="usd">977000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-1450" unitRef="usd">979500000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-5"
      id="f-1451"
      unitRef="shares">145600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-16"
      decimals="-5"
      id="f-1452"
      unitRef="shares">144700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1453" unitRef="shares">145400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-17"
      decimals="-3"
      id="f-1454"
      unitRef="shares">144600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-634"
      decimals="-5"
      id="f-1455"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-635"
      decimals="-5"
      id="f-1456"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-636"
      decimals="-5"
      id="f-1457"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-637"
      decimals="-5"
      id="f-1458"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-638"
      decimals="-5"
      id="f-1459"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-639"
      decimals="-5"
      id="f-1460"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-640"
      decimals="-5"
      id="f-1461"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-641"
      decimals="-5"
      id="f-1462"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-15"
      decimals="-5"
      id="f-1463"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-16"
      decimals="-5"
      id="f-1464"
      unitRef="shares">800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-5" id="f-1465" unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-17"
      decimals="-5"
      id="f-1466"
      unitRef="shares">800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-15"
      decimals="-5"
      id="f-1467"
      unitRef="shares">145900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-16"
      decimals="-5"
      id="f-1468"
      unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1469" unitRef="shares">145900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-17"
      decimals="-3"
      id="f-1470"
      unitRef="shares">145400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1471">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.269%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2024 Omnibus Equity Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024 our shareholders approved the 2024 Omnibus Equity Plan for share-based awards to our prospective and current employees, non-employee directors, officers or consultants. Awards granted from the 2024 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2024 Omnibus Equity Plan consist of 3.7 million shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) on the date that our shareholders approved the 2024 Omnibus Equity Plan, plus shares that were subject to awards under the 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) that remain unissued upon the cancellation, surrender, exchange, termination or forfeiture of such awards. The 2024 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a 1.5-to-1 ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not made any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan since our shareholders approved the 2024 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan in the future, except that unused shares under the 2017 Omnibus Equity Plan have been carried over for use under the 2024 Omnibus Equity Plan. Awards outstanding under the 2017 Omnibus Equity Plan and the Directors Plan as of the date our shareholders approved the 2024 Omnibus Equity Plan will remain outstanding and subject to the terms and conditions of the 2017 Omnibus Equity Plan and the Directors Plan, as applicable, and the relevant award agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2024 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024 our shareholders approved the 2024 ESPP. The 2024 ESPP, which became effective on July 1, 2024, replaced the 2015 ESPP, which expired on June 30, 2024. The maximum number of shares of our common stock that may be purchased under the 2024 ESPP is 2.5 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1472">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.269%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-642" decimals="-5" id="f-1473" unitRef="usd">27300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-643" decimals="-5" id="f-1474" unitRef="usd">27900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-644" decimals="-5" id="f-1475" unitRef="usd">54700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-645" decimals="-5" id="f-1476" unitRef="usd">59200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-646" decimals="-5" id="f-1477" unitRef="usd">45600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-647" decimals="-5" id="f-1478" unitRef="usd">48400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-648" decimals="-5" id="f-1479" unitRef="usd">89600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-649" decimals="-5" id="f-1480" unitRef="usd">98500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-15" decimals="-5" id="f-1481" unitRef="usd">72900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-16" decimals="-5" id="f-1482" unitRef="usd">76300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-5" id="f-1483" unitRef="usd">144300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-17" decimals="-5" id="f-1484" unitRef="usd">157700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-15" decimals="-5" id="f-1485" unitRef="usd">2300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-16" decimals="-5" id="f-1486" unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1487" unitRef="usd">5600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-17" decimals="-5" id="f-1488" unitRef="usd">5900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-15" decimals="-5" id="f-1489" unitRef="usd">70600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-16" decimals="-5" id="f-1490" unitRef="usd">73700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-1" decimals="-5" id="f-1491" unitRef="usd">138700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-17" decimals="-5" id="f-1492" unitRef="usd">151800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-15" decimals="-5" id="f-1493" unitRef="usd">13400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-16" decimals="-5" id="f-1494" unitRef="usd">13300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-5" id="f-1495" unitRef="usd">26300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-17" decimals="-5" id="f-1496" unitRef="usd">28000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-650" decimals="-5" id="f-1497" unitRef="usd">57200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-651" decimals="-5" id="f-1498" unitRef="usd">60400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-652" decimals="-5" id="f-1499" unitRef="usd">112400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-653" decimals="-5" id="f-1500" unitRef="usd">123800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-1501">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-654" decimals="-5" id="f-1502" unitRef="usd">58300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-655" decimals="-5" id="f-1503" unitRef="usd">59900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-656" decimals="-5" id="f-1504" unitRef="usd">115600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-657" decimals="-5" id="f-1505" unitRef="usd">121600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-658" decimals="-5" id="f-1506" unitRef="usd">11700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-659" decimals="-5" id="f-1507" unitRef="usd">9800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-660" decimals="-5" id="f-1508" unitRef="usd">22200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-661" decimals="-5" id="f-1509" unitRef="usd">19300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-662" decimals="-5" id="f-1510" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-663" decimals="-5" id="f-1511" unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-664" decimals="-5" id="f-1512" unitRef="usd">6300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-665" decimals="-5" id="f-1513" unitRef="usd">6800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-666" decimals="-5" id="f-1514" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-667" decimals="-5" id="f-1515" unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-668" decimals="-5" id="f-1516" unitRef="usd">-2000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-669" decimals="-5" id="f-1517" unitRef="usd">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-670" decimals="-5" id="f-1518" unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-671" decimals="-5" id="f-1519" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-672" decimals="-5" id="f-1520" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-673" decimals="-5" id="f-1521" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-674" decimals="-5" id="f-1522" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-675" decimals="-5" id="f-1523" unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-676" decimals="-5" id="f-1524" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-677" decimals="-5" id="f-1525" unitRef="usd">3500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-15" decimals="-5" id="f-1526" unitRef="usd">72900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-16" decimals="-5" id="f-1527" unitRef="usd">76300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-5" id="f-1528" unitRef="usd">144300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-17" decimals="-5" id="f-1529" unitRef="usd">157700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-15" decimals="-5" id="f-1530" unitRef="usd">2300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-16" decimals="-5" id="f-1531" unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1532" unitRef="usd">5600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-17" decimals="-5" id="f-1533" unitRef="usd">5900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-15" decimals="-5" id="f-1534" unitRef="usd">70600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-16" decimals="-5" id="f-1535" unitRef="usd">73700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-1" decimals="-5" id="f-1536" unitRef="usd">138700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-17" decimals="-5" id="f-1537" unitRef="usd">151800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-678"
      decimals="-5"
      id="f-1538"
      unitRef="shares">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <biib:RatioOfNumberOfSharesReservedUnderPlan
      contextRef="c-679"
      decimals="1"
      id="f-1539"
      unitRef="number">1.5</biib:RatioOfNumberOfSharesReservedUnderPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-680"
      decimals="-5"
      id="f-1540"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1541">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased inventory valuation step-up and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2024, compared to the same periods in 2023, the changes in our effective tax rates include the impact of changes in jurisdictional profit mix, including non-cash tax effects of changes in the value of our equity investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in our effective tax rate for the six months ended June 30, 2024, also reflects the resolution of an uncertain tax matter during the first quarter of 2023 related to tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decrease by up to approximately $25.0&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1542">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased inventory valuation step-up and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-15" decimals="3" id="f-1543" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-16" decimals="3" id="f-1544" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1545" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-17" decimals="3" id="f-1546" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-15" decimals="3" id="f-1547" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-16" decimals="3" id="f-1548" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1549" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-17" decimals="3" id="f-1550" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-15" decimals="3" id="f-1551" unitRef="number">-0.062</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-16" decimals="3" id="f-1552" unitRef="number">-0.047</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1553" unitRef="number">-0.052</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-17" decimals="3" id="f-1554" unitRef="number">-0.050</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-15" decimals="3" id="f-1555" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-16" decimals="3" id="f-1556" unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1557" unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-17" decimals="3" id="f-1558" unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-15" decimals="3" id="f-1559" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-16" decimals="3" id="f-1560" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-1" decimals="3" id="f-1561" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-17" decimals="3" id="f-1562" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-15" decimals="3" id="f-1563" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-16" decimals="3" id="f-1564" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-1" decimals="3" id="f-1565" unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-17" decimals="3" id="f-1566" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-15" decimals="3" id="f-1567" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-16" decimals="3" id="f-1568" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1569" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-17" decimals="3" id="f-1570" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-15" decimals="3" id="f-1571" unitRef="number">0.165</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-16" decimals="3" id="f-1572" unitRef="number">0.162</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1573" unitRef="number">0.160</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-17" decimals="3" id="f-1574" unitRef="number">0.144</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-18" decimals="-5" id="f-1575" unitRef="usd">25000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-1576">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other (Income) Expense, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(156.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(105.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(121.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(51.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(105.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $51.4&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $27.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $117.7&#160;million, partially offset by a decrease in the fair value of Sangamo common stock of approximately $10.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the six months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $68.3&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $17.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the six months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $78.0&#160;million, partially offset by a decrease in the fair value of Sangamo and Ionis common stock of approximately $47.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;964.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata related accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;689.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,472.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $556.7 million and $781.1 million as of June 30, 2024 and December 31, 2023, respectively, and included accrued income taxes totaling $191.7 million and $403.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c-1" id="f-1577">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(156.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(105.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(121.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(51.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest contextRef="c-15" decimals="-5" id="f-1578" unitRef="usd">20100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-16" decimals="-5" id="f-1579" unitRef="usd">75900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-5" id="f-1580" unitRef="usd">37500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-17" decimals="-5" id="f-1581" unitRef="usd">156800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c-15" decimals="-5" id="f-1582" unitRef="usd">61300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-16" decimals="-5" id="f-1583" unitRef="usd">49100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-1584" unitRef="usd">130500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-17" decimals="-5" id="f-1585" unitRef="usd">111600000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-15" decimals="-5" id="f-1586" unitRef="usd">-30700000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-16" decimals="-5" id="f-1587" unitRef="usd">105400000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-1" decimals="-5" id="f-1588" unitRef="usd">-61300000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-17" decimals="-5" id="f-1589" unitRef="usd">27700000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-15" decimals="-5" id="f-1590" unitRef="usd">-11300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-16" decimals="-5" id="f-1591" unitRef="usd">-8700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-1592" unitRef="usd">-20700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-17" decimals="-5" id="f-1593" unitRef="usd">-19400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-5" id="f-1594" unitRef="usd">-2000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-5" id="f-1595" unitRef="usd">-2300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-1596" unitRef="usd">-3900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-5" id="f-1597" unitRef="usd">-1700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-5" id="f-1598" unitRef="usd">-85200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-16" decimals="-5" id="f-1599" unitRef="usd">121200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-5" id="f-1600" unitRef="usd">-178900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-17" decimals="-5" id="f-1601" unitRef="usd">51800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-1602">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(105.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $51.4&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $27.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $117.7&#160;million, partially offset by a decrease in the fair value of Sangamo common stock of approximately $10.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the six months ended June 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage and Sangamo common stock of approximately $68.3&#160;million, partially offset by an increase in the fair value of Denali common stock of approximately $17.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the six months ended June 30, 2023, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sage common stock of approximately $78.0&#160;million, partially offset by a decrease in the fair value of Sangamo and Ionis common stock of approximately $47.4&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-15" decimals="-5" id="f-1603" unitRef="usd">30400000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-16" decimals="-5" id="f-1604" unitRef="usd">-106500000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-5" id="f-1605" unitRef="usd">61000000.0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-17" decimals="-5" id="f-1606" unitRef="usd">-28400000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-15" decimals="-5" id="f-1607" unitRef="usd">600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-16" decimals="-5" id="f-1608" unitRef="usd">-700000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-5" id="f-1609" unitRef="usd">5500000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-17" decimals="-5" id="f-1610" unitRef="usd">900000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-15" decimals="-5" id="f-1611" unitRef="usd">29800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-16" decimals="-5" id="f-1612" unitRef="usd">-105800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-1613" unitRef="usd">55500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-17" decimals="-5" id="f-1614" unitRef="usd">-29300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-681" decimals="-5" id="f-1615" unitRef="usd">51400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-682" decimals="-5" id="f-1616" unitRef="usd">27000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-683" decimals="-5" id="f-1617" unitRef="usd">117700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-684" decimals="-5" id="f-1618" unitRef="usd">10900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-685" decimals="-5" id="f-1619" unitRef="usd">68300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-686" decimals="-5" id="f-1620" unitRef="usd">17600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-687" decimals="-5" id="f-1621" unitRef="usd">78000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-688" decimals="-5" id="f-1622" unitRef="usd">47400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-1623">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;964.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata related accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;689.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,472.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-452" decimals="-5" id="f-1624" unitRef="usd">964500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-453" decimals="-5" id="f-1625" unitRef="usd">926500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1626" unitRef="usd">228300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1627" unitRef="usd">335100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <biib:Collaborationexpensesaccrual contextRef="c-18" decimals="-5" id="f-1628" unitRef="usd">319400000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual contextRef="c-19" decimals="-5" id="f-1629" unitRef="usd">214600000</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-18" decimals="-5" id="f-1630" unitRef="usd">193000000.0</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-19" decimals="-5" id="f-1631" unitRef="usd">191500000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1632" unitRef="usd">77400000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1633" unitRef="usd">117500000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1634" unitRef="usd">689500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1635" unitRef="usd">838400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1636" unitRef="usd">2472100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1637" unitRef="usd">2623600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-18" decimals="-5" id="f-1638" unitRef="usd">556700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-19" decimals="-5" id="f-1639" unitRef="usd">781100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-18" decimals="-5" id="f-1640" unitRef="usd">191700000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-19" decimals="-5" id="f-1641" unitRef="usd">403200000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-1642">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 19:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Genentech, Inc. (Roche Group)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt"&gt;U.S.:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt"&gt;Canada:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCREVUS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0&#160;million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LUNSUMIO (mosunetuzumab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for 30.0% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;COLUMVI (glofitamab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024 Roche announced that COLUMVI, in combination with chemotherapy GemOx (glofitamab-gxbm), demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Formulas&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN and LUNSUMIO Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0&#160;million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After LUNSUMIO Approval until the First Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First Threshold Date until the Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;First Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Second Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $350.0&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was 35.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0&#160;million of operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Second GAZYVA Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was 35.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2023 we accrued a $31.0&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. As of December 31, 2023, we paid approximately $16.0 million of the $31.0&#160;million payable. The remaining portion was subsequently paid in January 2024. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the six months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LEQEMBI (lecanemab) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in Japan (September 2023), China (January 2024), South Korea (May 2024), Hong Kong (July 2024) and Israel (July 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization of LEQEMBI in the U.S., we began recognizing our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated statements of income, as we are not the principal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of LEQEMBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the LEQEMBI Collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Eisai related to the agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s discussed above were approximately $10.3&#160;million and $1.4&#160;million as of June 30, 2024 and December 31, 2023, respectively. Amounts payable to Eisai related to the agreements discussed above were $171.8&#160;million and $118.4&#160;million as of June 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD and potential treatment of MDD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. In July 2024 we and Sage announced that the Phase 2 KINETIC 2 dose-range study of BIIB124 did not meet its endpoints. Based on these results, we discontinued our further development of BIIB124 for the potential treatment in essential tremor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. ZURZUVAE for PPD became commercially available in the U.S. during the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. The CRL stated that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies would be needed. We and Sage are continuing to seek feedback from the FDA and evaluating next steps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. During the fourth quarter of 2023 we accrued a milestone payment due to Sage of $75.0&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2024, we recognized net profit-sharing expense of approximately $6.5 million and $11.5 million, respectively, to reflect Sage's 50.0% share of net collaboration results in the U.S. for ZURZUVAE for PPD, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to the Sage collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Sage collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease (LRRK2 Collaboration) and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transport Vehicle technology. In July 2024 we terminated our license with Denali for the ATV-enabled anti-amyloid beta program. This termination also results in the termination of the exclusive option agreement, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to the Denali collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2024, we recorded approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$8.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.6&#160;million and $2.8 million, respectively, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2024 we accrued a $15.0 million milestone upon the FDA approval of OPUVIZ in the U.S., which was recognized in intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $165.0 million in additional development, regulatory and sales-based milestones. The timing of the commercial launch of OPUVIZ in the U.S. is subject to ongoing litigation involving our collaborator, Samsung Bioepis, in which the court has entered a preliminary injunction against us and Samsung Bioepis restraining the offer for sale or sale of OPUVIZ in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 c&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million by August 2024, and obtained an option to acquire exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2024 we exercised our option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years. In connection with this exercise, we paid Samsung Bioepis an option exercise fee of $60.0&#160;million in July 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;income. For the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended June 30, 2024, we recognized net profit-sharing expense of approximately $55.9&#160;million and $116.5&#160;million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $56.9 million and $114.0 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufacturing, royalty and other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Samsung Bioepis related to the agreements di&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;scussed above were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$19.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $9.9&#160;million as of June 30, 2024 and December 31, 2023, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$93.6&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$73.7&#160;million as of June 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2023 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-689"
      decimals="INF"
      id="f-1643"
      unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-690"
      decimals="INF"
      id="f-1644"
      unitRef="number">0.240</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage contextRef="c-691" decimals="-5" id="f-1645" unitRef="usd">900000000</biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage>
    <biib:Reductioninroyaltyrate
      contextRef="c-691"
      decimals="INF"
      id="f-1646"
      unitRef="number">0.500</biib:Reductioninroyaltyrate>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-692"
      decimals="INF"
      id="f-1647"
      unitRef="number">0.030</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:PeriodOfCollaborationAgreement contextRef="c-691" id="f-1648">P11Y</biib:PeriodOfCollaborationAgreement>
    <biib:PercentageOfFutureDevelopmentCosts
      contextRef="c-693"
      decimals="INF"
      id="f-1649"
      unitRef="number">0.300</biib:PercentageOfFutureDevelopmentCosts>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="c-694"
      decimals="INF"
      id="f-1650"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-695" decimals="-5" id="f-1651" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-695" decimals="-5" id="f-1652" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionProfitSharingFormulaTableTextBlock contextRef="c-1" id="f-1653">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After LUNSUMIO Approval until the First Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First Threshold Date until the Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-695" decimals="-5" id="f-1654" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-695" decimals="-5" id="f-1655" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="c-694"
      decimals="INF"
      id="f-1656"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-694"
      decimals="INF"
      id="f-1657"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour
      contextRef="c-694"
      decimals="INF"
      id="f-1658"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="c-696" decimals="-5" id="f-1659" unitRef="usd">500000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne contextRef="c-696" decimals="-5" id="f-1660" unitRef="usd">150000000</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
    <biib:SalesTriggerGrossSalesThreshold contextRef="c-696" decimals="-5" id="f-1661" unitRef="usd">350000000</biib:SalesTriggerGrossSalesThreshold>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-695"
      decimals="INF"
      id="f-1662"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-695"
      decimals="INF"
      id="f-1663"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-695" decimals="-5" id="f-1664" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-695" decimals="-5" id="f-1665" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PretaxProfitSharingFormulaTableTextBlock contextRef="c-1" id="f-1666">Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-695" decimals="-5" id="f-1667" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-695" decimals="-5" id="f-1668" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="c-695"
      decimals="INF"
      id="f-1669"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-695"
      decimals="INF"
      id="f-1670"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="c-696" decimals="-5" id="f-1671" unitRef="usd">500000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-695"
      decimals="INF"
      id="f-1672"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:AccruedPaymentToTerminationAgreement contextRef="c-697" decimals="-5" id="f-1673" unitRef="usd">31000000</biib:AccruedPaymentToTerminationAgreement>
    <biib:PaymentsMadeToTerminationAgreement contextRef="c-698" decimals="-5" id="f-1674" unitRef="usd">16000000</biib:PaymentsMadeToTerminationAgreement>
    <biib:AccruedPaymentToTerminationAgreement contextRef="c-697" decimals="-5" id="f-1675" unitRef="usd">31000000</biib:AccruedPaymentToTerminationAgreement>
    <biib:ShareOfNonControlingInterestRecognized
      contextRef="c-470"
      decimals="2"
      id="f-1676"
      unitRef="number">0.500</biib:ShareOfNonControlingInterestRecognized>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock contextRef="c-1" id="f-1677">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of LEQEMBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the LEQEMBI Collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration contextRef="c-699" decimals="-5" id="f-1678" unitRef="usd">90600000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-700" decimals="-5" id="f-1679" unitRef="usd">86200000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-701" decimals="-5" id="f-1680" unitRef="usd">177900000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-702" decimals="-5" id="f-1681" unitRef="usd">194100000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-699" decimals="-5" id="f-1682" unitRef="usd">45400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-700" decimals="-5" id="f-1683" unitRef="usd">43000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-701" decimals="-5" id="f-1684" unitRef="usd">89000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-702" decimals="-5" id="f-1685" unitRef="usd">97000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-703" decimals="-5" id="f-1686" unitRef="usd">137700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-704" decimals="-5" id="f-1687" unitRef="usd">17100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-705" decimals="-5" id="f-1688" unitRef="usd">311600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-706" decimals="-5" id="f-1689" unitRef="usd">27600000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-703" decimals="-5" id="f-1690" unitRef="usd">68900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-704" decimals="-5" id="f-1691" unitRef="usd">8500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-705" decimals="-5" id="f-1692" unitRef="usd">155800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-706" decimals="-5" id="f-1693" unitRef="usd">13800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AccountsReceivableFromCollaborator contextRef="c-707" decimals="-5" id="f-1694" unitRef="usd">10300000</biib:AccountsReceivableFromCollaborator>
    <biib:AccountsReceivableFromCollaborator contextRef="c-698" decimals="-5" id="f-1695" unitRef="usd">1400000</biib:AccountsReceivableFromCollaborator>
    <biib:AccountsPayableToCollaborator contextRef="c-707" decimals="-5" id="f-1696" unitRef="usd">171800000</biib:AccountsPayableToCollaborator>
    <biib:AccountsPayableToCollaborator contextRef="c-698" decimals="-5" id="f-1697" unitRef="usd">118400000</biib:AccountsPayableToCollaborator>
    <biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock contextRef="c-1" id="f-1698">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-708" decimals="-5" id="f-1699" unitRef="usd">16500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-709" decimals="-5" id="f-1700" unitRef="usd">14300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-710" decimals="-5" id="f-1701" unitRef="usd">33100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-711" decimals="-5" id="f-1702" unitRef="usd">32600000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-708" decimals="-5" id="f-1703" unitRef="usd">8300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-709" decimals="-5" id="f-1704" unitRef="usd">7100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-710" decimals="-5" id="f-1705" unitRef="usd">16600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-711" decimals="-5" id="f-1706" unitRef="usd">16300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="c-712" decimals="-5" id="f-1707" unitRef="usd">75000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:Collaborationprofitlosssharing contextRef="c-713" decimals="-5" id="f-1708" unitRef="usd">6500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-714" decimals="-5" id="f-1709" unitRef="usd">11500000</biib:Collaborationprofitlosssharing>
    <biib:ShareOfNetProfitFromSageTherapeuticsPercent contextRef="c-18" decimals="2" id="f-1710" unitRef="number">0.500</biib:ShareOfNetProfitFromSageTherapeuticsPercent>
    <biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock contextRef="c-1" id="f-1711">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to the Sage collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Sage collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-715" decimals="-5" id="f-1712" unitRef="usd">9600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-716" decimals="-5" id="f-1713" unitRef="usd">52100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-717" decimals="-5" id="f-1714" unitRef="usd">21200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-718" decimals="-5" id="f-1715" unitRef="usd">86900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-715" decimals="-5" id="f-1716" unitRef="usd">4800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-716" decimals="-5" id="f-1717" unitRef="usd">26100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-717" decimals="-5" id="f-1718" unitRef="usd">10600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-718" decimals="-5" id="f-1719" unitRef="usd">43500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-719" decimals="-5" id="f-1720" unitRef="usd">26900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-720" decimals="-5" id="f-1721" unitRef="usd">60100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-721" decimals="-5" id="f-1722" unitRef="usd">54500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-722" decimals="-5" id="f-1723" unitRef="usd">98300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-719" decimals="-5" id="f-1724" unitRef="usd">13500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-720" decimals="-5" id="f-1725" unitRef="usd">30000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-721" decimals="-5" id="f-1726" unitRef="usd">27300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-722" decimals="-5" id="f-1727" unitRef="usd">49100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock contextRef="c-1" id="f-1728">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to the Denali collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-723" decimals="-5" id="f-1729" unitRef="usd">15400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-724" decimals="-5" id="f-1730" unitRef="usd">22100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-725" decimals="-5" id="f-1731" unitRef="usd">29600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-726" decimals="-5" id="f-1732" unitRef="usd">38700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-723" decimals="-5" id="f-1733" unitRef="usd">9300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-724" decimals="-5" id="f-1734" unitRef="usd">13200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-725" decimals="-5" id="f-1735" unitRef="usd">17800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-726" decimals="-5" id="f-1736" unitRef="usd">23200000</biib:Expensereflectedwithinstatementsofincome>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-727" decimals="-5" id="f-1737" unitRef="usd">8500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-728" decimals="-5" id="f-1738" unitRef="usd">16000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-729" decimals="-5" id="f-1739" unitRef="usd">2600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-730" decimals="-5" id="f-1740" unitRef="usd">2800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:ContingentCommercializedRightsNumberOfProducts
      contextRef="c-731"
      decimals="INF"
      id="f-1741"
      unitRef="product">2</biib:ContingentCommercializedRightsNumberOfProducts>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-731"
      decimals="INF"
      id="f-1742"
      unitRef="number">0.450</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:AccruedMilestonePayments contextRef="c-732" decimals="-5" id="f-1743" unitRef="usd">15000000.0</biib:AccruedMilestonePayments>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-733" decimals="-5" id="f-1744" unitRef="usd">165000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborativeArrangementTermExtension contextRef="c-733" id="f-1745">P5Y</biib:CollaborativeArrangementTermExtension>
    <biib:ContractOptionExerciseFee contextRef="c-733" decimals="-5" id="f-1746" unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <biib:CollaborativeArrangementTermExtension contextRef="c-733" id="f-1747">P5Y</biib:CollaborativeArrangementTermExtension>
    <biib:CollaborativeArrangementContractOptionExerciseFeePaid contextRef="c-733" decimals="-5" id="f-1748" unitRef="usd">60000000</biib:CollaborativeArrangementContractOptionExerciseFeePaid>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-733"
      decimals="INF"
      id="f-1749"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing contextRef="c-734" decimals="-5" id="f-1750" unitRef="usd">55900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-735" decimals="-5" id="f-1751" unitRef="usd">116500000</biib:Collaborationprofitlosssharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-733"
      decimals="INF"
      id="f-1752"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing contextRef="c-736" decimals="-5" id="f-1753" unitRef="usd">56900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-737" decimals="-5" id="f-1754" unitRef="usd">114000000.0</biib:Collaborationprofitlosssharing>
    <us-gaap:AccountsReceivableNet contextRef="c-738" decimals="-5" id="f-1755" unitRef="usd">19000000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-739" decimals="-5" id="f-1756" unitRef="usd">9900000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-738" decimals="-5" id="f-1757" unitRef="usd">93600000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-739" decimals="-5" id="f-1758" unitRef="usd">73700000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-1759">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2007 we consolidated the results of Neurimmune as we determined we were the primary beneficiary because we had the power through the collaboration to direct the activities that most significantly impacted the entity's economic performance and we were required to fund 100.0% of the research and development costs incurred in support of the collaboration. The collaboration and license agreement with Neurimmune was for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023 we notified Neurimmune of our decision to terminate the Neurimmune Agreement. Subsequent to the termination, we reconsidered our relationship with Neurimmune and determined that we were no longer the primary beneficiary of the variable interest entity. As a result, we recorded a net gain on the deconsolidation of Neurimmune of approximately $3.0&#160;million, which was recorded in other (income) expense, net within our consolidated statements of income for the year ended December 31, 2023, included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024 and December 31, 2023, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $22.8 million and $16.4 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="c-740"
      decimals="INF"
      id="f-1760"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-740" decimals="-5" id="f-1761" unitRef="usd">3000000</us-gaap:DeconsolidationGainOrLossAmount>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="c-18" decimals="-5" id="f-1762" unitRef="usd">22800000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="c-19" decimals="-5" id="f-1763" unitRef="usd">16400000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-1764">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. If an estimate of the possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Loss Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are defendants in three securities actions, one filed by Nadia Shash and Amjad Khan in November 2020 in the District Court and related to ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022 in the District Court and related to ADUHELM and one filed by Thomas Allen Gray in the U.S. District Court for the District of Colorado related to statements about our compliance controls, 2023 earnings guidance and other matters. All allege violations of federal securities laws under 15 U.S.C. &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seek declarations of the actions as class actions and monetary relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and members of the Board of Directors are named as defendants in three derivative actions, one filed by The Booth Family Trust in February 2022 in the District Court, one filed by Elaine Wang in July 2022 in the District Court and one filed by Jonathan Blaufarb in July 2024 in the U.S. District Court for the District of Colorado. The Booth and Wang actions relate to ADUHELM and other matters, and the Blaufarb action relates to statements about our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#xa7;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#x2019; fees and costs payable to the plaintiffs. The Booth and Wang actions are stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, the Technical Boards of Appeal of the European Patent Office upheld the validity of Fresenius Kabi Deutschland GmbH's (Fresenius Kabi's) European Patent 3 145 488 (the EP '488 Patent), which expires in May 2035. In June 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of the EP &#x2018;488 Patent. In March 2024 the D&#xfc;sseldorf Regional Court dismissed Fresenius Kabi's claim of infringement of the German counterpart of the EP '488 Patent and Fresenius Kabi has appealed to the Higher Regional Court of D&#xfc;sseldorf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $200.0 million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed suit against us in the High Court of Justice of England and Wales on one of the previously asserted claims, seeking payment of $49.9&#160;million, interest and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Humana Patient Assistance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the District Court dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had alleged violations of the federal RICO Act and state laws. In December 2023 Humana appealed to the United States Court of Appeals for the First Circuit and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California, alleging that it is owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs. We estimate that the royalties claimed total approximately $88.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lender Dispute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2024, BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP filed suit against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement with Reata and seeking payment of approximately $23.2&#160;million, plus interest, costs and attorneys' fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received subpoenas from the SEC seeking information relating to ADUHELM and its launch. We have also received subpoenas from the DOJ and SEC seeking information relating to our business operations in several foreign countries. The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TYSABRI Biosimilar Patent Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#xa7;262, seeking a declaratory judgment of patent infringement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Annulment Proceedings in the General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 Mylan Ireland filed an action in the General Court of the European Union to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-741" decimals="-5" id="f-1765" unitRef="usd">200000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-742" decimals="-5" id="f-1766" unitRef="usd">49900000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-743" decimals="-5" id="f-1767" unitRef="usd">88300000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-744" decimals="-5" id="f-1768" unitRef="usd">23200000</us-gaap:LossContingencyDamagesSoughtValue>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-15" id="f-1769">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-15" id="f-1770">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-15" id="f-1771">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-15" id="f-1772">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
